>>>>> MMI
text_000N_47274|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|10/6|
text_000N_47274|MMI|5.18|RNA, Small Interfering|C1099354|[nnon,phsu]|["siRNA"-tx-1-"siRNA"-noun-0]|TX|4/5|
text_000N_47274|MMI|5.18|Small Interfering RNA [EPC]|C4722296|[phsu]|["siRNA"-tx-1-"siRNA"-noun-0]|TX|4/5|
text_000N_47274|MMI|3.71|Response to treatment|C0521982|[clna]|["Response to treatment"-tx-1-"response to treatment"-noun-0]|TX|17/11,38/9|
text_000N_47274|MMI|3.44|afatinib|C2987648|[orch,phsu]|["AFATINIB"-tx-1-"afatinib"-noun-0]|TX|29/8|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Activation action|C1879547|[acty]|["Activate"-tx-1-"activate"-verb-0]|TX|14/8|
text_000N_47289|MMI|5.18|PRKAA1 wt Allele|C3890397|[gngm]|["AMPK"-tx-1-"AMPK"-noun-0]|TX|23/4|
text_000N_47289|MMI|5.18|activate - Data Operation|C3853838|[ftcn]|["activate"-tx-1-"activate"-verb-0]|TX|14/8|
text_000N_47289|MMI|5.18|activate biological process|C1515877|[ftcn]|["Activate"-tx-1-"activate"-verb-0]|TX|14/8|
text_000N_47289|MMI|5.18|sorafenib|C1516119|[orch,phsu]|["SORAFENIB"-tx-1-"sorafenib"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Miller Fisher Syndrome|C0393799|[dsyn]|["Miller Fisher Syndrome"-tx-1-"Miller-Fisher syndrome"-noun-0]|TX|7/22|
text_000N_47304|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|41/2|
text_000N_47304|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|41/2|
text_000N_47304|MMI|5.18|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|30/10|
text_000N_47304|MMI|3.61|A variant NOS|C4740192|[imft]|["A variant NOS"-tx-1-"a variant"-noun-0]|TX|47/9|
text_000N_47304|MMI|3.46|Guillain-Barre Syndrome|C0018378|[dsyn]|["Guillain-Barre"-tx-1-"Guillain-Barr√©"-noun-0]|TX|60/14|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.61|Integral Membrane Proteins|C0021699|[aapp]|["Transmembrane Protein"-tx-1-"transmembrane proteins"-noun-0]|TX|29/22|
text_000N_47320|MMI|3.49|Adenylate Cyclase|C0001492|[aapp,enzy]|["Cyclases, Adenylyl"-tx-1-"adenylyl cyclases"-noun-0]|TX|4/17|
text_000N_47320|MMI|3.46|All of the Time|C3812891|[fndg]|["Always"-tx-1-"always"-adv-0]|TX|22/6|
text_000N_47320|MMI|3.46|Always (frequency)|C2003902|[tmco]|["Always"-tx-1-"always"-adv-0]|TX|22/6|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|Albinism, Oculocutaneous|C0078918|[cgab]|["ALBINISM, OCULOCUTANEOUS"-tx-1-"oculocutaneous albinism"-noun-0]|TX|5/23|
text_000N_47334|MMI|5.18|Autosomal recessive inheritance|C0441748|[genf]|["Autosomal Recessive Inheritance"-tx-1-"autosomal recessive inheritance"-noun-0]|TX|37/31|
text_000N_47334|MMI|5.18|Show|C1547282|[anim]|["Show"-tx-1-"show"-verb-0]|TX|29/4|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|propofol|C0033487|[orch,phsu]|["PROPOFOL"-tx-1-"Propofol"-noun-0]|TX|3/8|
text_000N_47349|MMI|3.61|short-term|C0443303|[tmco]|["Short-term"-tx-1-"short-term"-adj-0]|TX|21/10|
text_000N_47349|MMI|3.56|Sedated state|C0235195|[fndg]|["Sedation"-tx-1-"sedation"-noun-0]|TX|32/8|
text_000N_47349|MMI|3.56|Sedation|C5400562|[fndg]|["Sedation"-tx-1-"sedation"-noun-0]|TX|32/8|
text_000N_47349|MMI|3.56|Sedation procedure|C0344106|[topp]|["Sedation"-tx-1-"sedation"-noun-0]|TX|32/8|
text_000N_47349|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|12/4|
<<<<< MMI
>>>>> MMI
text_000N_47363|AA|iNKT|invariant natural killer T cells|1|4|9|32|70:4
text_000N_47363|MMI|3.59|FATE1 gene|C1539479|[gngm]|["FATE"-tx-1-"fate"-noun-0]|TX|81/4|
text_000N_47363|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47363|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47363|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47363|MMI|3.55|Invariant Natural Killer T-Cells|C2350467|[cell]|["Invariant Natural Killer T-Cells"-tx-1-"invariant natural killer T cells"-noun-0]|TX|36/32|
text_000N_47363|MMI|3.44|Staphylococcal Protein A|C0038164|[aapp,imft,irda]|["a protein"-tx-1-"a proteins"-noun-0]|TX|9/1,24/8|
text_000N_47363|MMI|3.43|Tetum Language|C2959953|[lang]|["TET"-tx-1-"TET"-noun-0]|TX|20/3|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.68|Disorders of Porphyrin Metabolism|C0032708|[dsyn]|["Porphyrias"-tx-1-"porphyrias"-noun-0]|TX|14/10|
text_000N_47377|MMI|3.56|Hereditary|C0439660|[ftcn]|["INHERITED"-tx-1-"inherited"-verb-0]|TX|25/9|
text_000N_47377|MMI|3.56|Patterns|C0449774|[spco]|["Pattern"-tx-1-"pattern"-noun-0]|TX|52/7|
text_000N_47377|MMI|3.50|Cutaneous|C0221912|[spco]|["Cutaneous"-tx-1-"cutaneous"-adj-0]|TX|4/9|
text_000N_47377|MMI|3.50|Cutaneous (intended site)|C4521174|[spco]|["Cutaneous"-tx-1-"cutaneous"-adj-0]|TX|4/9|
text_000N_47377|MMI|3.50|Cutaneous Route of Drug Administration|C1522447|[ftcn]|["CUTANEOUS"-tx-1-"cutaneous"-adj-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|MYC protein, human|C1454487|[aapp,bacs]|["MYC"-tx-1-"myc"-noun-0]|TX|3/3|
text_000N_47392|MMI|5.18|Tumor Suppressor Genes|C0079427|[gngm]|["Tumour suppressor gene"-tx-1-"tumour suppressor gene"-noun-0]|TX|9/22|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|AIDSVAX|C0675907|[imft,phsu]|["ALVAC-HIV"-tx-1-"ALVAC-HIV"-noun-0]|TX|4/9|
text_000N_47406|MMI|3.63|Clinical Trials|C0008976|[resa]|["Trial"-tx-1-"trial"-noun-0]|TX|59/5|
text_000N_47406|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47406|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47406|MMI|3.48|HIV prevention|C0150413|[topp]|["HIV prevention"-tx-1-"HIV prevention"-noun-0]|TX|28/14|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|27/15|
text_000N_47420|MMI|3.68|KLF10 gene|C1537488|[gngm]|["TIEG1"-tx-1-"TIEG1"-noun-0]|TX|16/5|
text_000N_47420|MMI|3.59|Apoptosis|C0162638|[celf]|["APOPTOSIS"-tx-1-"apoptosis"-noun-0]|TX|43/9|
text_000N_47420|MMI|3.59|Apoptosis Pathway|C4759886|[cnce]|["Apoptosis"-tx-1-"apoptosis"-noun-0]|TX|43/9|
text_000N_47420|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|8/7|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.64|Adenocarcinoma of large intestine|C1319315|[neop]|["Colorectal Adenocarcinoma"-tx-1-"colorectal adenocarcinoma"-noun-0]|TX|59/25|
text_000N_47435|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|43/15|
text_000N_47435|MMI|3.54|Alteration|C1515926|[idcn]|["Alteration"-tx-1-"alterations"-noun-0]|TX|4/11|
text_000N_47435|MMI|3.44|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|34/8|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|Mitochondria|C0026237|[celc]|["Mitochondria"-tx-1-"mitochondria"-noun-0]|TX|4/12|
text_000N_47450|MMI|3.62|cytoneme|C1523679|[celc]|["membrane nanotube"-tx-1-"membrane nanotubes"-noun-0]|TX|30/18|
text_000N_47450|MMI|3.57|Pass (indicator)|C2828386|[fndg]|["Pass"-tx-1-"pass"-verb-0]|TX|17/4|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Homologous Gene|C1334043|[gngm]|["Homolog"-tx-1-"homolog"-noun-0]|TX|96/7|
text_000N_43235|MMI|3.60|ERCC6 wt Allele|C1707866|[gngm]|["CSB"-tx-1-"CSB"-noun-0]|TX|91/3|
text_000N_43235|MMI|3.60|Kashubian Language|C4724271|[lang]|["CSB"-tx-1-"CSB"-noun-0]|TX|91/3|
text_000N_43235|MMI|3.53|Delta (difference)|C1705241|[qnco]|["*Difference"-tx-1-"differences"-noun-0]|TX|25/11|
text_000N_43235|MMI|3.53|Different|C1705242|[qlco]|["Difference"-tx-1-"differences"-noun-0]|TX|25/11|
text_000N_43235|MMI|3.48|protein B|C0377800|[aapp,rcpt]|["protein B"-tx-1-"protein B"-noun-0]|TX|80/9|
text_000N_43235|MMI|3.46|Genetic Syndrome Associated with Congenital Heart Defect|C5238705|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|71/8|
text_000N_43235|MMI|3.46|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|57/5|
text_000N_43235|MMI|3.46|Syndrome|C0039082|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|71/8|
text_000N_43235|MMI|3.46|cocaine|C0009170|[hops,orch,phsu]|["COCAINE"-tx-1-"Cocaine"-noun-0]|TX|63/7|
text_000N_43235|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_43235|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_43235|MMI|3.43|Function (attribute)|C0542341|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|14/10|
text_000N_43235|MMI|3.43|Functional|C0205245|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|14/10|
text_000N_43235|MMI|3.43|Functional Relationship|C2700217|[cnce]|["Functional"-tx-1-"functional"-adj-0]|TX|14/10|
text_000N_43235|MMI|3.43|Memory for Designs Test|C0025262|[diap]|["MFD"-tx-1-"Mfd"-noun-0]|TX|45/3|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|3.61|Anosmia|C0003126|[fndg]|["ANOSMIA"-tx-1-"anosmia"-noun-0]|TX|20/7|
text_000N_43275|MMI|3.61|Anosmia, CTCAE|C4552990|[fndg]|["Anosmia"-tx-1-"anosmia"-noun-0]|TX|20/7|
text_000N_43275|MMI|3.55|Architecture|C0003737|[ocdi]|["Architecture"-tx-1-"architecture"-noun-0]|TX|60/12|
text_000N_43275|MMI|3.55|Disruption|C0332453|[ftcn]|["Disruption"-tx-1-"disruption"-noun-0]|TX|38/10|
text_000N_43275|MMI|3.55|Nuclear (incident type)|C4554581|[qlco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|52/7|
text_000N_43275|MMI|3.55|Nuclear (nucleus)|C0521447|[spco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|52/7|
text_000N_43275|MMI|3.52|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|28/6|
text_000N_43275|MMI|3.52|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|28/6|
text_000N_43275|MMI|3.50|COVID-19|C5203670|[dsyn]|["COVID 19"-tx-1-"covid-19"-noun-0]|TX|3/8|
text_000N_43275|MMI|3.50|COVID19 (document)|C5243469|[inpr]|["COVID-19"-tx-1-"covid-19"-noun-0]|TX|3/8|
text_000N_43275|MMI|3.47|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-adj-0]|TX|12/7|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Arteriosclerosis|C0003850|[dsyn]|["ATHEROSCLEROSIS"-tx-1-"atherosclerosis"-noun-0]|TX|25/15|
text_000N_43303|MMI|5.18|Atherosclerosis|C0004153|[dsyn]|["ATHEROSCLEROSIS"-tx-1-"atherosclerosis"-noun-0]|TX|25/15|
text_000N_43303|MMI|5.18|metformin|C0025598|[orch,phsu]|["METFORMIN"-tx-1-"metformin"-noun-0]|TX|5/9|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Cytokeratin|C0010803|[aapp]|["Cytokeratin"-tx-1-"cytokeratin"-noun-0]|TX|3/11|
text_000N_43331|MMI|5.18|Tumor Markers|C0041365|[bacs]|["Tumor Marker"-tx-1-"tumor marker"-noun-0]|TX|17/12|
<<<<< MMI
>>>>> MMI
text_000N_43358|AA|CMT2D|cause Charcot-Marie-Tooth Disease Type 2D|1|5|13|41|94:5
text_000N_43358|MMI|7.19|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0,"gene mutations"-tx-1-"mutations gene"-noun-0]|TX|5/9;5/9,27/4|
text_000N_43358|MMI|5.18|Container status - Identified|C1550043|[fndg]|["Identified"-tx-1-"identified"-verb-0]|TX|37/10|
text_000N_43358|MMI|5.18|Identified|C0205396|[qlco]|["Identified"-tx-1-"identified"-verb-0]|TX|37/10|
text_000N_43358|MMI|5.18|Microfilaria sp identified|C0552545|[lbtr]|["Identified"-tx-1-"identified"-verb-0]|TX|37/10|
text_000N_43358|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|48/2|
text_000N_43358|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|48/2|
text_000N_43358|MMI|5.18|Treponema identified|C0370079|[lbtr]|["Identified"-tx-1-"identified"-verb-0]|TX|37/10|
text_000N_43358|MMI|3.91|Charcot-Marie-Tooth disease, Type 2D|C1832274|[dsyn]|["Charcot-Marie-Tooth Disease Type 2D"-tx-1-"Charcot-Marie-Tooth Disease Type 2D"-noun-0]|TX|57/35|
text_000N_43358|MMI|3.59|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|51/5|
text_000N_43358|MMI|3.59|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|51/5|
text_000N_43358|MMI|3.56|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|5/9|
text_000N_43358|MMI|3.46|GARS gene|C5240554|[gngm]|["GARS gene"-tx-1-"GARS gene"-noun-0]|TX|22/9|
text_000N_43358|MMI|3.43|Family lepisosteidae - gar|C0327763|[fish]|["Gar"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|GARS1 gene|C1414988|[gngm]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|GARS1 wt Allele|C4318453|[gngm]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|GART gene|C1414989|[gngm]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|GART protein, human|C1530787|[aapp,enzy]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|GART wt Allele|C4283928|[gngm]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|Glycine-tRNA Ligase, human|C4320088|[aapp,enzy]|["GARS"-tx-1-"GARS"-noun-0]|TX|22/4|
text_000N_43358|MMI|3.43|phosphoribosylamine-glycine ligase activity|C1150722|[moft]|["GAR"-tx-1-"GARS"-noun-0]|TX|22/4|
<<<<< MMI
>>>>> MMI
text_000N_43386|AA|TCA|tricarboxylic acid|1|3|3|18|27:3
text_000N_43386|MMI|5.18|Citric Acid Cycle|C0008858|[moft]|["Tricarboxylic Acid Cycle"-tx-1-"tricarboxylic acid cycle"-noun-0]|TX|7/18,32/5|
text_000N_43386|MMI|3.59|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|38/8|
text_000N_43386|MMI|3.59|Inflammation|C0021368|[patf]|["INFLAMMATION"-tx-1-"inflammation"-noun-0]|TX|50/12|
text_000N_43386|MMI|3.59|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|38/8|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|3.64|Congestive heart failure|C0018802|[dsyn]|["Heart failure"-tx-1-"heart failure"-noun-0]|TX|23/13|
text_000N_40839|MMI|3.64|Heart Failure, CTCAE|C4554158|[fndg]|["Heart Failure"-tx-1-"heart failure"-noun-0]|TX|23/13|
text_000N_40839|MMI|3.64|Heart failure|C0018801|[dsyn]|["HEART FAILURE"-tx-1-"heart failure"-noun-0]|TX|23/13|
text_000N_40839|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
text_000N_40839|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|10.42|GAA gene|C1414899|[gngm]|["ALPHA-GLUCOSIDASE, ACID"-tx-1-"acid alpha-glucosidase"-noun-0,"Pompe disease"-tx-1-"Pompe disease"-noun-0]|TX|3/22;49/13|
text_000N_40886|MMI|5.18|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|30/6|
text_000N_40886|MMI|5.18|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|30/6|
text_000N_40886|MMI|5.18|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|30/6|
text_000N_40886|MMI|5.18|Etiology|C1314792|[ftcn]|["Causes"-tx-1-"causes"-verb-0]|TX|42/6|
text_000N_40886|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["causes"-tx-1-"causes"-verb-0]|TX|42/6|
text_000N_40886|MMI|5.18|Generalized glycogen storage disease of infants|C0342751|[dsyn]|["Pompe disease"-tx-1-"Pompe disease"-noun-0]|TX|49/13|
text_000N_40886|MMI|5.18|Glycogen storage disease type II|C0017921|[dsyn]|["POMPE DISEASE"-tx-1-"Pompe disease"-noun-0]|TX|49/13|
text_000N_40886|MMI|5.18|Mutant|C0596988|[comd]|["Mutant"-tx-1-"mutant"-noun-0]|TX|68/6|
text_000N_40886|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"causes"-verb-0]|TX|42/6|
text_000N_40886|MMI|5.18|lysosomal alpha glucosidase|C1706105|[aapp,phsu]|["Acid alpha glucosidase"-tx-1-"acid alpha-glucosidase"-noun-0]|TX|3/22|
<<<<< MMI
>>>>> MMI
text_000N_40913|AA|ARG|Abelson-related gene|1|3|5|20|31:3
text_000N_40913|MMI|3.61|Protein-Serine-Threonine Kinases|C0072402|[aapp,enzy]|["Serine Kinase"-tx-1-"serine kinase"-noun-0]|TX|54/13|
text_000N_40913|MMI|3.56|Encode (action)|C2700640|[acty]|["Encode"-tx-1-"encode"-verb-0]|TX|41/6|
text_000N_40913|MMI|3.55|ABL2 gene|C0812381|[gngm]|["ABELSON-RELATED GENE"-tx-1-"Abelson-related gene"-noun-0]|TX|9/20|
text_000N_40913|MMI|3.55|ABL2 wt Allele|C1706108|[gngm]|["Abelson Related Gene"-tx-1-"Abelson-related gene"-noun-0]|TX|9/20|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Mucosal-Associated Invariant T-Cell|C3891065|[cell]|["MAIT Cells"-tx-1-"MAIT cells"-noun-0]|TX|3/10|
text_000N_40941|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_40941|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_40941|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_40941|MMI|3.46|Multiple Myeloma|C0026764|[neop]|["MULTIPLE MYELOMA"-tx-1-"multiple myeloma"-noun-0]|TX|29/16|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Dietary Selenium|C2348282|[elii]|["Selenium"-tx-1-"selenium"-noun-0]|TX|22/8|
text_000N_40972|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|31/4|
text_000N_40972|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|31/4|
text_000N_40972|MMI|5.18|Selenium supplement|C0521939|[inch,phsu]|["Selenium"-tx-1-"selenium"-noun-0]|TX|22/8|
text_000N_40972|MMI|5.18|Selenoproteins|C0074302|[aapp,bacs]|["Selenoproteins"-tx-1-"selenoproteins"-noun-0]|TX|3/14|
text_000N_40972|MMI|5.18|selenium|C0036581|[bacs,elii,phsu]|["SELENIUM"-tx-1-"selenium"-noun-0]|TX|22/8|
text_000N_40972|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|38/4|
text_000N_40972|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|38/4|
text_000N_40972|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|38/4|
text_000N_40972|MMI|3.48|Prevention of Prostate Cancer|C0281413|[topp]|["Prostate Cancer Prevention"-tx-1-"prostate cancer prevention"-noun-0]|TX|46/26|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Determined by|C0521095|[qlco]|["Determined"-tx-1-"determined"-verb-0]|TX|28/10|
text_000N_40999|MMI|3.68|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|16/6|
text_000N_40999|MMI|3.68|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|16/6|
text_000N_40999|MMI|3.50|Gorilla <Western Gorilla>|C0018090|[mamm]|["Gorilla"-tx-1-"gorilla"-noun-0]|TX|8/7|
text_000N_40999|MMI|3.50|Gorilla <genus>|C1095850|[mamm]|["Gorilla"-tx-1-"gorilla"-noun-0]|TX|8/7|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|collagen|C0009325|[aapp,phsu]|["Collagen"-tx-1-"collagen"-noun-0]|TX|3/8|
text_000N_173087|MMI|3.68|NR4A2 protein, human|C1142652|[aapp,bacs]|["human protein"-tx-1-"human protein"-noun-0]|TX|30/13|
text_000N_173087|MMI|3.47|Abundance|C2346714|[qlco]|["Abundant"-tx-1-"abundant"-adj-0]|TX|21/8|
text_000N_173087|MMI|3.47|Most|C0205393|[qnco]|["Most"-tx-1-"most"-adv-0]|TX|16/4|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Coronary Artery Bypass Surgery|C0010055|[topp]|["Coronary Artery Bypass Grafting"-tx-1-"coronary artery bypass grafting"-noun-0]|TX|66/31|
text_000N_173104|MMI|5.18|Following|C0332282|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|56/9|
text_000N_173104|MMI|5.18|Result|C1274040|[ftcn]|["Outcome"-tx-1-"outcome"-noun-0]|TX|48/7|
text_000N_173104|MMI|5.18|Status post|C0231290|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|56/9|
text_000N_173104|MMI|3.59|Administration occupational activities|C0001554|[ocac]|["Administration"-tx-1-"administration"-noun-0]|TX|5/14|
text_000N_173104|MMI|3.59|Administration procedure|C1533734|[topp]|["Administration"-tx-1-"administration"-noun-0]|TX|5/14|
text_000N_173104|MMI|3.59|Agent Administration|C2348003|[hlca]|["Administration"-tx-1-"administration"-noun-0]|TX|5/14|
text_000N_173104|MMI|3.45|liothyronine|C0041014|[aapp,horm,phsu]|["Triiodothyronine"-tx-1-"triiodothyronine"-noun-0]|TX|23/16|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.56|Behavior|C0004927|[bhvr]|["Behaviour, NOS"-tx-1-"behaviour"-noun-0]|TX|55/9|
text_000N_173120|MMI|3.56|Behavior:-:Point in time:^Patient:-|C2707008|[clna]|["Behavior"-tx-1-"behaviour"-noun-0]|TX|55/9|
text_000N_173120|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_173120|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_173120|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_173120|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_173120|MMI|3.48|Pituitary Adenoma|C0032000|[neop]|["Adenoma of Pituitary"-tx-1-"of pituitary adenomas"-noun-0]|TX|65/21|
text_000N_173120|MMI|3.46|Matrix Metalloproteinases|C0623362|[aapp,enzy]|["Matrix Metalloproteinases"-tx-1-"matrix metalloproteinases"-noun-0]|TX|24/25|
text_000N_173120|MMI|3.43|In addition to|C0332287|[ftcn]|["With"-tx-1-"with"-prep-0]|TX|50/4|
text_000N_173120|MMI|3.43|With - dosing instruction fragment|C1705690|[inpr]|["With"-tx-1-"with"-prep-0]|TX|50/4|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|13/4|
text_000N_173136|MMI|5.18|GHRL gene|C1825346|[gngm]|["GHRELIN"-tx-1-"ghrelin"-noun-0]|TX|5/7|
text_000N_173136|MMI|5.18|GHRL protein, human|C1870739|[aapp,horm]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|5/7|
text_000N_173136|MMI|5.18|Ghrelin Measurement|C3813179|[lbpr]|["GHRELIN"-tx-1-"ghrelin"-noun-0]|TX|5/7|
text_000N_173136|MMI|5.18|Lenomorelin|C4722442|[orch,phsu]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|5/7|
text_000N_173136|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|13/4|
text_000N_173136|MMI|5.18|ghrelin|C0911014|[aapp,horm]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|5/7|
text_000N_173136|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|20/4|
text_000N_173136|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|20/4|
text_000N_173136|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|20/4|
text_000N_173136|MMI|3.46|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischemic stroke"-noun-0]|TX|28/15|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|JTV519|C0754680|[orch,phsu]|["JTV519"-tx-1-"JTV519"-noun-0]|TX|3/6|
text_000N_173151|MMI|3.56|Administration of prophylactic drug or medicament|C0420172|[topp]|["Drug Prevention"-tx-1-"drug prevention"-noun-0]|TX|29/4,42/10|
text_000N_173151|MMI|3.42|Cardiac Arrhythmia|C0003811|[dsyn]|["Arrhythmias"-tx-1-"arrhythmias"-noun-0]|TX|56/11|
text_000N_173151|MMI|3.42|Potential|C3245505|[qlco]|["Potential"-tx-1-"potential"-adj-0]|TX|19/9|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|3.58|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|15/7|
text_000N_173167|MMI|3.47|Blood - brain barrier anatomy|C0005854|[bpoc]|["Blood-Brain Barrier"-tx-1-"blood brain barrier"-noun-0]|TX|27/19|
text_000N_173167|MMI|3.47|Blood - brain barrier function|C1305865|[ortf]|["Blood-brain barrier"-tx-1-"blood brain barrier"-noun-0]|TX|27/19|
text_000N_173167|MMI|3.42|Astrocytes|C0004112|[cell]|["Astrocytes"-tx-1-"astrocytes"-noun-0]|TX|4/10|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Regenerating muscle fiber|C0034964|[cell]|["muscle regeneration"-tx-1-"muscle regeneration"-noun-0]|TX|3/19|
text_000N_173183|MMI|3.57|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
text_000N_173183|MMI|3.57|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
text_000N_173183|MMI|3.57|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
text_000N_173183|MMI|3.57|Use of|C1524063|[ftcn]|["Use of"-tx-1-"use of"-noun-0]|TX|53/6|
text_000N_173183|MMI|3.48|Mice, Inbred mdx|C0206535|[mamm]|["mdx Mice"-tx-1-"mdx mice"-noun-0]|TX|35/8|
text_000N_173183|MMI|3.46|Mesenchymal Stem Cells|C1257975|[cell]|["Mesenchymal Stem Cells"-tx-1-"mesenchymal stem cells"-noun-0]|TX|68/22|
text_000N_173183|MMI|3.42|In addition to|C0332287|[ftcn]|["With"-tx-1-"with"-prep-0]|TX|44/4|
text_000N_173183|MMI|3.42|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-adj-0]|TX|60/7|
text_000N_173183|MMI|3.42|With - dosing instruction fragment|C1705690|[inpr]|["With"-tx-1-"with"-prep-0]|TX|44/4|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Depressive Symptoms|C0086132|[sosy]|["Depressive Symptoms"-tx-1-"depressive symptoms"-noun-0]|TX|26/19|
text_000N_173199|MMI|5.18|simvastatin|C0074554|[orch,phsu]|["SIMVASTATIN"-tx-1-"simvastatin"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Melioidosis|C0025229|[dsyn]|["MELIOIDOSIS"-tx-1-"Melioidosis"-noun-0]|TX|3/11|
text_000N_173214|MMI|3.59|Burkholderia pseudomallei|C0033819|[bact]|["BURKHOLDERIA PSEUDOMALLEI"-tx-1-"Burkholderia pseudomallei"-noun-0]|TX|39/25|
text_000N_173214|MMI|3.55|Bacteria|C0004611|[bact]|["Bacterium"-tx-1-"bacterium"-noun-0]|TX|29/9|
text_000N_173214|MMI|3.55|Bacteria present|C4038931|[fndg]|["Bacterium"-tx-1-"bacterium"-noun-0]|TX|29/9|
text_000N_173214|MMI|3.52|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|15/6|
text_000N_173214|MMI|3.52|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|15/6|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Glucocorticoid Receptor|C0034809|[aapp,rcpt]|["Glucocorticoid Receptor"-tx-1-"glucocorticoid receptor"-noun-0]|TX|7/23|
text_000N_173230|MMI|5.18|NR3C1 gene|C1334899|[gngm]|["GLUCOCORTICOID RECEPTOR"-tx-1-"glucocorticoid receptor"-noun-0]|TX|7/23|
text_000N_173230|MMI|5.18|NR3C1 protein, human|C1370369|[aapp,rcpt]|["Glucocorticoid Receptor"-tx-1-"glucocorticoid receptor"-noun-0]|TX|7/23|
text_000N_173230|MMI|5.18|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|33/20|
text_000N_173230|MMI|5.18|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|33/20|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)|C3469521|[dsyn]|["FANCONI ANEMIA"-tx-1-"Fanconi anemia"-noun-0]|TX|3/14|
text_000N_173245|MMI|5.18|Fanconi Anemia|C0015625|[dsyn]|["Fanconi anaemia"-tx-1-"Fanconi anemia"-noun-0]|TX|3/14|
text_000N_173245|MMI|3.61|Entity|C1551338|[enty]|["Entity"-tx-1-"entity"-noun-0]|TX|82/6|
text_000N_173245|MMI|3.57|Presentation|C0449450|[idcn]|["Presented"-tx-1-"presented"-verb-0]|TX|18/9|
text_000N_173245|MMI|3.47|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|74/7|
text_000N_173245|MMI|3.47|Genetic Heterogeneity|C0242960|[orga]|["Heterogeneous"-tx-1-"heterogeneous"-adj-0]|TX|60/13|
text_000N_173245|MMI|3.47|Heterogeneity|C0019409|[qlco]|["Heterogeneous"-tx-1-"heterogeneous"-adj-0]|TX|60/13|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.56|Emotional hypersensitivity|C0520946|[fndg]|["Hypersensitivity"-tx-1-"hypersensitivity"-noun-0]|TX|3/16|
text_000N_173260|MMI|3.56|Hypersensitivity|C0020517|[patf]|["Hypersensitivity"-tx-1-"hypersensitivity"-noun-0]|TX|3/16|
text_000N_173260|MMI|3.49|DNA Crosslinking Agent|C1511666|[chvf]|["DNA Crosslinking Agent"-tx-1-"DNA crosslinking agents"-noun-0]|TX|23/23|
text_000N_173260|MMI|3.46|FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)|C3469521|[dsyn]|["FANCONI ANEMIA"-tx-1-"Fanconi anemia"-noun-0]|TX|61/14|
text_000N_173260|MMI|3.46|Fanconi Anemia|C0015625|[dsyn]|["Fanconi anaemia"-tx-1-"Fanconi anemia"-noun-0]|TX|61/14|
<<<<< MMI
>>>>> MMI
text_000N_173276|AA|AU|adenine uridine|1|2|3|15|55:2
text_000N_173276|AA|UTR|untranslated region|1|3|3|19|111:3
text_000N_173276|MMI|7.06|adenine|C0001407|[bacs,nnon]|["ADENINE"-tx-1-"AU"-noun-0,"ADENINE"-tx-1-"adenine"-noun-0]|TX|126/2;38/7|
text_000N_173276|MMI|7.06|uridine|C0041984|[nnon,phsu]|["URIDINE"-tx-1-"AU"-noun-0,"URIDINE"-tx-1-"uridine"-noun-0]|TX|126/2;46/7|
text_000N_173276|MMI|5.18|RNA-Binding Proteins|C0085177|[aapp,bacs]|["RNA-Binding Proteins"-tx-1-"RNA binding Proteins"-noun-0]|TX|3/20|
text_000N_173276|MMI|5.18|are unit of measure|C1551058|[qnco]|["Are"-tx-1-"AREs"-noun-0]|TX|74/4|
text_000N_173276|MMI|5.18|cellular response to DNA damage stimulus|C1155291|[celf]|["DNA damage response"-tx-1-"DNA Damage Response"-noun-0]|TX|148/19|
text_000N_173276|MMI|3.59|Balloon Catheter Rated Burst Pressure|C4723642|[qnco]|["RBP"-tx-1-"RBPs"-noun-0]|TX|129/4|
text_000N_173276|MMI|3.59|RENBP gene|C1419339|[gngm]|["RBP"-tx-1-"RBPs"-noun-0]|TX|129/4|
text_000N_173276|MMI|3.59|Retinol Binding Protein Measurement|C1446172|[lbpr]|["RBP"-tx-1-"RBPs"-noun-0]|TX|129/4|
text_000N_173276|MMI|3.59|SUGP1 gene|C1425671|[gngm]|["RBP"-tx-1-"RBPs"-noun-0]|TX|129/4|
text_000N_173276|MMI|3.58|Untranslated Regions|C0600680|[nnon]|["Untranslated Region"-tx-1-"untranslated region"-noun-0]|TX|90/19|
text_000N_173276|MMI|3.55|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|30/4|
text_000N_173276|MMI|3.55|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|30/4|
text_000N_173276|MMI|3.55|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|64/8|
text_000N_173276|MMI|3.55|Wealthy|C0699759|[qlco]|["Rich"-tx-1-"rich"-adj-0]|TX|59/4|
text_000N_173276|MMI|3.42|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-prep-0]|TX|80/2|
text_000N_173276|MMI|3.42|Present|C0150312|[fndg]|["In"-tx-1-"in"-prep-0]|TX|80/2|
text_000N_173276|MMI|3.42|Within|C0332285|[spco]|["In"-tx-1-"in"-prep-0]|TX|80/2|
text_000N_173276|MMI|3.40|RNA, Messenger|C0035696|[bacs,nnon]|["mRNA"-tx-1-"mRNAs"-noun-0]|TX|119/5|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Toxin|C0040549|[bacs,hops]|["Toxin"-tx-1-"toxin"-noun-0]|TX|7/5|
text_000N_173291|MMI|5.18|Toxin (disposition)|C4522020|[qlco]|["Toxin"-tx-1-"toxin"-noun-0]|TX|7/5|
text_000N_173291|MMI|3.59|Clostridium botulinum|C0009055|[bact]|["CLOSTRIDIUM BOTULINUM"-tx-1-"Clostridium botulinum"-noun-0]|TX|25/21|
text_000N_173291|MMI|3.55|All of the Time|C3812891|[fndg]|["Always"-tx-1-"always"-adv-0]|TX|47/6|
text_000N_173291|MMI|3.55|Always (frequency)|C2003902|[tmco]|["Always"-tx-1-"always"-adv-0]|TX|47/6|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|3.63|BTK gene|C1412841|[gngm]|["BTK"-tx-1-"BTK"-noun-0]|TX|23/3|
text_000N_97283|MMI|3.63|BTK protein, human|C1528376|[aapp,enzy]|["BTK"-tx-1-"BTK"-noun-0]|TX|23/3|
text_000N_97283|MMI|3.63|Bruton's Tyrosine Kinase Measurement|C5237447|[lbpr]|["BTK"-tx-1-"BTK"-noun-0]|TX|23/3|
text_000N_97283|MMI|3.59|Autoimmune Diseases|C0004364|[dsyn]|["autoimmunity"-tx-1-"autoimmunity"-noun-0]|TX|41/12|
text_000N_97283|MMI|3.59|Autoimmune state|C0004368|[patf]|["Autoimmunity"-tx-1-"autoimmunity"-noun-0]|TX|41/12|
text_000N_97283|MMI|3.53|Protein Tyrosine Kinase|C0033681|[aapp,enzy]|["Tyrosine Kinase"-tx-1-"tyrosine kinase"-noun-0]|TX|7/15|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|nivolumab|C3657270|[aapp,imft,phsu]|["NIVOLUMAB"-tx-1-"nivolumab"-noun-0]|TX|3/9|
text_000N_97301|MMI|3.66|Non-Small Cell Lung Carcinoma|C0007131|[neop]|["Non-Small Cell Cancer of Lung"-tx-1-[111,102,32,78,111,110,8211,83,109,97,108,108,45,67,101,108,108,32,76,117,110,103,32,67,97,110,99,101,114]-noun-0]|TX|32/29|
text_000N_97301|MMI|3.54|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-1]|TX|13/4|
text_000N_97301|MMI|3.54|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97301|MMI|3.54|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|RET protein, human|C0389252|[aapp,rcpt]|["RET"-tx-1-"RET"-noun-0]|TX|3/3|
text_000N_97316|MMI|3.68|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|17/4|
text_000N_97316|MMI|3.68|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|17/4|
text_000N_97316|MMI|3.68|Major|C0205164|[qlco]|["Major"-tx-1-"major"-noun-0]|TX|11/5|
text_000N_97316|MMI|3.68|Major <insect>|C4318856|[euka]|["Major"-tx-1-"major"-noun-0]|TX|11/5|
text_000N_97316|MMI|3.68|Severe (severity modifier)|C0205082|[fndg]|["Major"-tx-1-"major"-noun-0]|TX|11/5|
text_000N_97316|MMI|3.68|US Military Commissioned Officer O4|C4521762|[clas]|["Major"-tx-1-"major"-noun-0]|TX|11/5|
text_000N_97316|MMI|3.64|HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1|C3888239|[fndg]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|34/20|
text_000N_97316|MMI|3.64|Hirschsprung Disease|C0019569|[dsyn]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|34/20|
text_000N_97316|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
text_000N_97316|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|trastuzumab|C0728747|[aapp,imft,phsu]|["TRASTUZUMAB"-tx-1-"trastuzumab"-noun-0]|TX|57/11|
text_000N_97331|MMI|3.64|Favorable Response|C4054987|[fndg]|["FAVORABLE RESPONSE"-tx-1-"favorable response"-noun-0]|TX|35/18|
text_000N_97331|MMI|3.63|Expression (foundation metadata concept)|C3854321|[idcn]|["Expression"-tx-1-"expression"-noun-0]|TX|16/10|
text_000N_97331|MMI|3.63|Expression procedure|C0185117|[topp]|["Expression"-tx-1-"expression"-noun-0]|TX|16/10|
text_000N_97331|MMI|3.57|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.57|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.57|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.57|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.57|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.57|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_97331|MMI|3.48|ERBB2 gene|C0242957|[gngm]|["HER-2"-tx-1-"HER2"-noun-0]|TX|5/4|
text_000N_97331|MMI|3.48|ERBB2 protein, human|C1702024|[aapp,enzy,rcpt]|["HER2"-tx-1-"HER2"-noun-0]|TX|5/4|
text_000N_97331|MMI|3.48|HER-2-neu peptide vaccine|C0879250|[aapp,imft,phsu]|["HER-2"-tx-1-"HER2"-noun-0]|TX|5/4|
text_000N_97331|MMI|3.48|Human Epidermal Growth Factor Receptor 2 Measurement|C3810543|[lbpr]|["HER2"-tx-1-"HER2"-noun-0]|TX|5/4|
text_000N_97331|MMI|3.48|Oncogene ErbB2|C3853888|[gngm]|["HER -2"-tx-1-"HER2"-noun-0]|TX|5/4|
text_000N_97331|MMI|3.48|erbB-2 Receptor|C0069515|[aapp,enzy,rcpt]|["her-2"-tx-1-"HER2"-noun-0]|TX|5/4|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|STAT3 Measurement|C4721493|[lbpr]|["STAT3"-tx-1-"STAT3"-noun-0]|TX|3/5|
text_000N_97347|MMI|5.18|STAT3 gene|C1367307|[gngm]|["STAT3"-tx-1-"STAT3"-noun-0]|TX|3/5|
text_000N_97347|MMI|5.18|STAT3 protein, human|C1530116|[aapp,bacs]|["STAT3"-tx-1-"STAT3"-noun-0]|TX|3/5|
text_000N_97347|MMI|5.18|Stat3 protein|C0253050|[aapp,bacs]|["stat3"-tx-1-"STAT3"-noun-0]|TX|3/5|
text_000N_97347|MMI|3.55|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"autophagy"-noun-0]|TX|54/9|
text_000N_97347|MMI|3.55|Conditional|C1701901|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
text_000N_97347|MMI|3.55|Dependent - ability|C0851827|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
text_000N_97347|MMI|3.55|Dependent for Toilet Use|C4321395|[inpr]|["dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
text_000N_97347|MMI|3.55|Dependent for bathing|C0429986|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
text_000N_97347|MMI|3.55|Dependent for dressing|C0429964|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
text_000N_97347|MMI|3.55|EIF2AK2 gene|C1539341|[gngm]|["EIF2AK2"-tx-1-"EIF2AK2"-noun-0]|TX|21/7|
text_000N_97347|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_97347|MMI|3.55|Metabolic Suppression|C0301625|[orgf]|["Suppression"-tx-1-"suppression"-noun-0]|TX|39/11|
text_000N_97347|MMI|3.55|Percentage suppression|C0439181|[qnco]|["% suppression"-tx-1-"suppression"-noun-0]|TX|39/11|
text_000N_97347|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_97347|MMI|3.55|Psychological suppression|C0728721|[menp]|["suppression"-tx-1-"suppression"-noun-0]|TX|39/11|
text_000N_97347|MMI|3.55|Visual Suppression|C0221103|[patf]|["Suppression"-tx-1-"suppression"-noun-0]|TX|39/11|
text_000N_97347|MMI|3.55|dependent|C3244310|[ftcn]|["dependent"-tx-1-"dependent"-adj-0]|TX|29/9|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|3.52|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|26/7|
text_000N_97362|MMI|3.52|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|26/7|
text_000N_97362|MMI|3.42|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"free"-adj-0]|TX|21/4|
text_000N_97362|MMI|3.42|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"free"-adj-0]|TX|21/4|
text_000N_97362|MMI|3.42|Genome|C0017428|[gngm]|["Genomes"-tx-1-"genomes"-noun-0]|TX|47/7|
text_000N_97362|MMI|3.42|Jumping Genes|C1257902|[gngm]|["TRANSPOSON"-tx-1-"transposon"-noun-0]|TX|10/10|
text_000N_97362|MMI|3.42|Mammals|C0024660|[mamm]|["Mammalian"-tx-1-"mammalian"-adj-0]|TX|37/9|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|5.18|Daprodustat|C4519188|[orch,phsu]|["DAPRODUSTAT"-tx-1-"Daprodustat"-noun-0]|TX|3/11|
text_000N_97378|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_97378|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_97378|MMI|3.45|Anemia|C0002871|[dsyn]|["ANEMIA"-tx-1-"anemia"-noun-0]|TX|29/6|
text_000N_97378|MMI|3.45|Anemia, CTCAE|C4554633|[fndg]|["Anemia"-tx-1-"anemia"-noun-0]|TX|29/6|
text_000N_97378|MMI|3.45|Genus Anemia|C1000483|[plnt]|["Anemia"-tx-1-"anemia"-noun-0]|TX|29/6|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|5.18|Cholinergic Receptors|C0034792|[aapp,rcpt]|["Acetylcholine receptor"-tx-1-"acetylcholine receptor"-noun-0]|TX|40/22|
text_000N_97394|MMI|5.18|Curare|C0010463|[hops,orch,phsu]|["Curare"-tx-1-"Curare"-noun-0]|TX|5/6|
text_000N_97394|MMI|3.59|Function (attribute)|C0542341|[ftcn]|["Function"-tx-1-"function"-verb-0]|TX|12/8|
text_000N_97394|MMI|3.59|Function Axis|C0700205|[orga]|["FUNCTION"-tx-1-"function"-verb-0]|TX|12/8|
text_000N_97394|MMI|3.59|Mathematical Operator|C1705273|[inpr]|["Function"-tx-1-"function"-verb-0]|TX|12/8|
text_000N_97394|MMI|3.59|Stimulation (motivation)|C1948023|[npop]|["Stimulating"-tx-1-"stimulating"-noun-0]|TX|24/11|
text_000N_97394|MMI|3.59|physiological aspects|C0031843|[phsf]|["function"-tx-1-"function"-verb-0]|TX|12/8|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|3.68|Signal Transduction|C0037083|[celf]|["Signaling"-tx-1-"signaling"-noun-0]|TX|10/9|
text_000N_97409|MMI|3.68|biological signaling|C3537152|[biof]|["signalling"-tx-1-"signaling"-noun-0]|TX|10/9|
text_000N_97409|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|27/4|
text_000N_97409|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|27/4|
text_000N_97409|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|27/4|
text_000N_97409|MMI|3.50|IL18 gene|C1334109|[gngm]|["IL18"-tx-1-"IL18"-noun-0]|TX|5/4|
text_000N_97409|MMI|3.50|Interleukin-18|C0383327|[aapp,imft]|["IL18"-tx-1-"IL18"-noun-0]|TX|5/4|
text_000N_97409|MMI|3.50|interleukin 18 protein, human|C3849701|[aapp,imft]|["IL18"-tx-1-"IL18"-noun-0]|TX|5/4|
text_000N_97409|MMI|3.44|Thymus <angiosperm>|C1015036|[plnt]|["Thymus"-tx-1-"thymus"-noun-0]|TX|35/6|
text_000N_97409|MMI|3.44|Thymus Gland|C0040113|[bpoc]|["THYMUS"-tx-1-"thymus"-noun-0]|TX|35/6|
<<<<< MMI
>>>>> MMI
text_000N_97424|AA|RA|Rheumatoid Arthritis|1|2|3|20|64:2
text_000N_97424|MMI|5.18|methotrexate|C0025677|[orch,phsu]|["METHOTREXATE"-tx-1-"methotrexate"-noun-0]|TX|3/12|
text_000N_97424|MMI|3.58|Rheumatoid Arthritis|C0003873|[dsyn]|["RHEUMATOID ARTHRITIS"-tx-1-"Rheumatoid Arthritis"-noun-0]|TX|42/20|
text_000N_97424|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|16/4,39/2|
text_000N_97424|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_97424|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
<<<<< MMI
>>>>> MMI
text_000N_97440|MMI|5.18|apremilast|C1678805|[orch,phsu]|["APREMILAST"-tx-1-"Apremilast"-noun-0]|TX|3/10|
text_000N_97440|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_97440|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_97440|MMI|3.46|Behcet Syndrome|C0004943|[dsyn]|["Beh√ßet Syndrome"-tx-1-"Beh√ßet Syndrome"-noun-0]|TX|28/6,37/8|
<<<<< MMI
>>>>> MMI
text_000N_97456|MMI|5.18|Cell Invasion|C2699153|[patf]|["Invasion"-tx-1-"invasion"-noun-0]|TX|3/8|
text_000N_97456|MMI|5.18|Tumor Cell Invasion|C1269955|[neop]|["Invasion"-tx-1-"invasion"-noun-0]|TX|3/8|
text_000N_97456|MMI|3.55|1 (finding)|C5201140|[fndg]|["One"-tx-1-"one"-noun-0]|TX|27/3|
text_000N_97456|MMI|3.55|One|C0205447|[qnco]|["ONE"-tx-1-"one"-noun-0]|TX|27/3|
text_000N_97456|MMI|3.44|Secondary Malignant Neoplasm|C3266877|[neop]|["Metastasis Cancer"-tx-1-"metastasis cancer"-noun-0]|TX|16/10,51/6|
text_000N_97456|MMI|3.44|Secondary Neoplasm|C2939419|[neop]|["Metastasis cancer"-tx-1-"metastasis cancer"-noun-0]|TX|16/10,51/6|
<<<<< MMI
>>>>> MMI
text_000N_97471|MMI|5.18|Chemokine (C-X-C Motif) Ligand 7 Measurement|C5235138|[lbpr]|["CXCL7"-tx-1-"CXCL7"-noun-0]|TX|3/5|
text_000N_97471|MMI|5.18|PPBP gene|C1335239|[gngm]|["CXCL7"-tx-1-"CXCL7"-noun-0]|TX|3/5|
text_000N_97471|MMI|5.18|PPBP wt Allele|C1705594|[gngm]|["CXCL7"-tx-1-"CXCL7"-noun-0]|TX|3/5|
text_000N_97471|MMI|5.18|chemokine|C0282554|[aapp,imft]|["Chemokine"-tx-1-"chemokine"-noun-0]|TX|11/9|
<<<<< MMI
>>>>> MMI
text_000N_97487|MMI|3.68|Has property|C1292721|[ftcn]|["properties"-tx-1-"properties"-noun-0]|TX|30/10|
text_000N_97487|MMI|3.68|Property (attribute)|C0871161|[qlco]|["properties"-tx-1-"properties"-noun-0]|TX|30/10|
text_000N_97487|MMI|3.45|Amyloidogenesis|C1706803|[comd]|["Amyloidogenesis"-tx-1-"amyloidogenic"-adj-0]|TX|16/13|
<<<<< MMI
>>>>> MMI
text_000N_97502|MMI|5.18|CTCF gene|C1422163|[gngm]|["CTCF Gene"-tx-1-"CTCF gene"-noun-0]|TX|23/9|
text_000N_97502|MMI|5.18|Contain (action)|C2700400|[acty]|["Contain"-tx-1-"contain"-verb-0]|TX|13/7|
text_000N_97502|MMI|5.18|Containing (qualifier)|C0332256|[ftcn]|["contain"-tx-1-"contain"-verb-0]|TX|13/7|
text_000N_97502|MMI|5.18|Nematodes|C1704319|[euka]|["Nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
text_000N_97502|MMI|5.18|Nematodes <beetle>|C1947962|[euka]|["Nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
text_000N_97502|MMI|5.18|Phylum Nematoda|C0027581|[euka]|["nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
<<<<< MMI
>>>>> MMI
text_000N_97518|MMI|5.18|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|60/29|
text_000N_97518|MMI|5.18|Clinical Trial Data|C4684601|[inpr]|["Clinical Trial Data"-tx-1-"clinical trial data"-noun-0]|TX|5/19|
text_000N_97518|MMI|5.18|Support, device|C0183683|[medd]|["Support, NOS"-tx-1-"support"-verb-0]|TX|25/7|
text_000N_97518|MMI|5.18|Supportive assistance|C1521721|[cnce]|["Support"-tx-1-"support"-verb-0]|TX|25/7|
text_000N_97518|MMI|3.64|Use of|C1524063|[ftcn]|["Use of"-tx-1-"use of"-noun-0]|TX|37/6|
text_000N_97518|MMI|3.44|minocycline|C0026187|[antb,orch]|["Minocyclin"-tx-1-"minocycline"-noun-0]|TX|44/11|
<<<<< MMI
>>>>> MMI
text_000N_14856|MMI|7.06|FGF13 gene|C1414598|[gngm]|["FGF13"-tx-1-"FGF13"-noun-0,"FHF2"-tx-1-"FHF2"-noun-0]|TX|36/5;16/4|
text_000N_14856|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|43/15|
text_000N_14856|MMI|3.59|Encephalopathies|C0085584|[dsyn]|["ENCEPHALOPATHY"-tx-1-"encephalopathy"-noun-0]|TX|59/14|
text_000N_14856|MMI|3.59|Encephalopathy, CTCAE 3.0|C1963101|[fndg]|["Encephalopathy"-tx-1-"encephalopathy"-noun-0]|TX|59/14|
text_000N_14856|MMI|3.59|Encephalopathy, CTCAE 5.0|C4554030|[fndg]|["Encephalopathy"-tx-1-"encephalopathy"-noun-0]|TX|59/14|
text_000N_14856|MMI|3.59|FGF13 protein, human|C1313752|[aapp,bacs]|["FGF13"-tx-1-"FGF13"-noun-0]|TX|36/5|
text_000N_14856|MMI|3.59|Known|C0205309|[qlco]|["Known"-tx-1-"known"-verb-0]|TX|27/5|
text_000N_14856|MMI|3.59|Variant|C0205419|[qlco]|["variants"-tx-1-"variants"-noun-0]|TX|4/8|
text_000N_14856|MMI|3.59|fibroblast growth factor 13|C0665690|[aapp,bacs]|["FGF13"-tx-1-"FGF13"-noun-0]|TX|36/5|
text_000N_14856|MMI|3.45|FGF13 wt Allele|C3890231|[gngm]|["FHF2"-tx-1-"FHF2"-noun-0]|TX|16/4|
<<<<< MMI
>>>>> MMI
text_000N_14887|MMI|5.18|Semagacestat|C2713560|[orch,phsu]|["SEMAGACESTAT"-tx-1-"Semagacestat"-noun-0]|TX|3/12|
text_000N_14887|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_14887|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_14887|MMI|3.48|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|30/19|
text_000N_14887|MMI|3.48|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|30/19|
<<<<< MMI
>>>>> MMI
text_000N_14910|MMI|3.43|Joint deviation|C0427243|[fndg]|["Joint variants"-tx-1-"joint variants"-noun-0]|TX|18/5,51/8|
text_000N_14910|MMI|3.42|Inference|C0679201|[menp]|["Inference"-tx-1-"inference"-noun-0]|TX|33/9|
text_000N_14910|MMI|3.42|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|46/4|
text_000N_14910|MMI|3.42|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|46/4|
<<<<< MMI
>>>>> MMI
text_000N_14932|MMI|3.56|Antidote|C0003295|[phsu]|["Antidotes"-tx-1-"antidotes"-noun-0]|TX|23/9|
text_000N_14932|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_14932|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_14932|MMI|3.43|Entity Determiner - specific|C1552740|[inpr]|["specific"-tx-1-"specific"-adj-0]|TX|14/8|
text_000N_14932|MMI|3.43|Specific qualifier value|C0205369|[qlco]|["Specific"-tx-1-"specific"-adj-0]|TX|14/8|
text_000N_14932|MMI|3.43|dabigatran|C2348066|[orch,phsu]|["DABIGATRAN"-tx-1-"dabigatran"-noun-0]|TX|37/10|
<<<<< MMI
>>>>> MMI
text_000N_14957|MMI|3.68|Feb.|C3843933|[tmco]|["Feb."-tx-1-"Feb"-noun-0]|TX|6/3|
text_000N_14957|MMI|3.63|Gangliosides|C0017082|[orch,phsu]|["Gangliosides"-tx-1-"gangliosides"-noun-0]|TX|32/12|
text_000N_14957|MMI|3.54|Target|C1521840|[ftcn]|["Target"-tx-1-"target"-noun-0]|TX|47/6|
text_000N_14957|MMI|3.54|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"target"-noun-0]|TX|47/6|
text_000N_14957|MMI|3.48|Brain|C0006104|[bpoc]|["BRAIN"-tx-1-"brain"-noun-0]|TX|26/5|
text_000N_14957|MMI|3.48|Head>Brain|C4266577|[bpoc]|["Brain"-tx-1-"brain"-noun-0]|TX|26/5|
text_000N_14957|MMI|3.48|Major|C0205164|[qlco]|["Major"-tx-1-"major"-adj-0]|TX|20/5|
text_000N_14957|MMI|3.48|Major <insect>|C4318856|[euka]|["Major"-tx-1-"major"-adj-0]|TX|20/5|
text_000N_14957|MMI|3.48|Severe (severity modifier)|C0205082|[fndg]|["Major"-tx-1-"major"-adj-0]|TX|20/5|
text_000N_14957|MMI|3.48|US Military Commissioned Officer O4|C4521762|[clas]|["Major"-tx-1-"major"-adj-0]|TX|20/5|
text_000N_14957|MMI|3.45|Alzheimer's disease treatment|C1979617|[topp]|["Alzheimer's disease treatment"-tx-1-"treatment Alzheimer's disease"-noun-0]|TX|62/9,75/19|
<<<<< MMI
>>>>> MMI
text_000N_14980|MMI|3.55|Polyadenylation|C0949765|[moft]|["Polyadenylation"-tx-1-"polyadenylation"-noun-0]|TX|21/15|
text_000N_14980|MMI|3.43|Alternative|C1523987|[qlco]|["Alternative"-tx-1-"alternative"-adj-0]|TX|9/11|
text_000N_14980|MMI|3.43|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|54/11|
text_000N_14980|MMI|3.43|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|54/11|
text_000N_14980|MMI|3.43|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|54/11|
text_000N_14980|MMI|3.43|Gene Mutant|C0678941|[gngm]|["alternative"-tx-1-"alternative"-adj-0]|TX|9/11|
text_000N_14980|MMI|3.43|Zebrafish|C0043457|[fish]|["Zebrafish"-tx-1-"zebrafish"-noun-0]|TX|44/9|
text_000N_14980|MMI|3.43|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|54/11|
<<<<< MMI
>>>>> MMI
text_000N_15004|MMI|3.60|Vaccine allergy|C0571550|[dsyn]|["allergy vaccine"-tx-1-"vaccine allergy"-noun-0]|TX|11/7,30/7|
text_000N_15004|MMI|3.56|Vaccine [APC]|C5399710|[phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|11/7|
text_000N_15004|MMI|3.56|Vaccines|C0042210|[aapp,imft,phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|11/7|
text_000N_15004|MMI|3.46|Allergy to peanuts|C0559470|[dsyn]|["Peanut Allergy"-tx-1-"peanut allergy"-noun-0]|TX|23/14|
text_000N_15004|MMI|3.43|Arachis hypogaea|C0030736|[plnt]|["Peanut"-tx-1-"peanut"-noun-0]|TX|23/6|
text_000N_15004|MMI|3.43|Peanuts - dietary|C0949399|[food]|["PEANUT"-tx-1-"peanut"-noun-0]|TX|23/6|
<<<<< MMI
>>>>> MMI
text_000N_15028|MMI|10.42|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0,"condition"-tx-1-"condition"-noun-0]|TX|11/7;22/9|
text_000N_15028|MMI|5.18|Condition|C0348080|[qlco]|["Condition"-tx-1-"condition"-noun-0]|TX|22/9|
text_000N_15028|MMI|5.18|Condition Domain|C4722256|[inpr]|["CONDITION"-tx-1-"condition"-noun-0]|TX|22/9|
text_000N_15028|MMI|5.18|Condition:Find:Pt:^Patient:Nom|C3864998|[clna]|["Condition"-tx-1-"condition"-noun-0]|TX|22/9|
text_000N_15028|MMI|5.18|Exploding head syndrome|C3163857|[dsyn]|["Exploding head syndrome"-tx-1-"Exploding Head Syndrome"-noun-0]|TX|39/23|
text_000N_15028|MMI|5.18|Logical Condition|C1705253|[cnce]|["Condition"-tx-1-"condition"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.98|Call (Instruction)|C1947967|[ftcn]|["Call"-tx-1-"called"-verb-0]|TX|32/6|
text_000N_15028|MMI|3.98|Decision|C0679006|[menp]|["Call"-tx-1-"called"-verb-0]|TX|32/6|
<<<<< MMI
>>>>> MMI
text_000N_15051|MMI|5.18|OTOL1 gene|C3148557|[gngm]|["otolin 1"-tx-1-"Otolin-1"-noun-0]|TX|3/8|
text_000N_15051|MMI|5.18|otolin-1|C1121041|[aapp]|["otolin-1"-tx-1-"Otolin-1"-noun-0]|TX|3/8|
text_000N_15051|MMI|3.68|Matrix|C4050026|[orch,phsu]|["Matrix"-tx-1-"matrix"-noun-0]|TX|14/6|
text_000N_15051|MMI|3.68|Matrix (unit of presentation)|C4319583|[qnco]|["Matrix"-tx-1-"matrix"-noun-0]|TX|14/6|
text_000N_15051|MMI|3.68|Matrix Array|C1704640|[spco]|["Matrix"-tx-1-"matrix"-noun-0]|TX|14/6|
text_000N_15051|MMI|3.68|Matrix Dosing Unit|C4724180|[qnco]|["Matrix"-tx-1-"matrix"-noun-0]|TX|14/6|
text_000N_15051|MMI|3.68|Matrix substance|C1706515|[bdsu]|["Matrix"-tx-1-"matrix"-noun-0]|TX|14/6|
text_000N_15051|MMI|3.68|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|21/7|
<<<<< MMI
>>>>> MMI
text_000N_15074|MMI|3.60|Seizures|C0036572|[sosy]|["Seizures"-tx-1-"seizures"-noun-0]|TX|39/8|
text_000N_15074|MMI|3.52|Lupus Erythematosus, Systemic|C0024141|[dsyn]|["SYSTEMIC LUPUS ERYTHEMATOSIS"-tx-1-"Systemic Lupus Erythematosus"-noun-0]|TX|4/28|
text_000N_15074|MMI|3.52|Systemic Lupus Erythematosus Pathway|C2984317|[cnce]|["Systemic lupus erythematosus"-tx-1-"Systemic Lupus Erythematosus"-noun-0]|TX|4/28|
text_000N_15074|MMI|3.46|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|33/5|
text_000N_15074|MMI|3.46|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|33/5|
<<<<< MMI
>>>>> MMI
text_000N_15098|MMI|5.18|Frequently|C0332183|[tmco]|["Often"-tx-1-"often"-adv-0]|TX|28/5|
text_000N_15098|MMI|5.18|Often - answer to question|C4050225|[inpr]|["Often"-tx-1-"often"-adv-0]|TX|28/5|
text_000N_15098|MMI|3.68|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|19/8|
<<<<< MMI
>>>>> MMI
text_000N_15123|MMI|5.18|APP gene|C1364818|[gngm]|["Alzheimer disease"-tx-1-"Alzheimer Disease"-noun-0]|TX|72/17|
text_000N_15123|MMI|5.18|Alzheimer's Disease|C0002395|[dsyn]|["ALZHEIMER DISEASE"-tx-1-"Alzheimer Disease"-noun-0]|TX|72/17|
text_000N_15123|MMI|5.18|Relate - vinyl resin|C0163712|[orch]|["relates"-tx-1-"relates"-verb-0]|TX|27/7|
text_000N_15123|MMI|5.18|Research Activities|C0242481|[resa]|["Research"-tx-1-"research"-verb-0]|TX|13/8|
text_000N_15123|MMI|5.18|research|C0035168|[resa]|["Research"-tx-1-"research"-verb-0]|TX|13/8|
text_000N_15123|MMI|3.56|Function (attribute)|C0542341|[ftcn]|["Function"-tx-1-"function"-noun-0]|TX|39/8|
text_000N_15123|MMI|3.56|Function Axis|C0700205|[orga]|["FUNCTION"-tx-1-"function"-noun-0]|TX|39/8|
text_000N_15123|MMI|3.56|Mathematical Operator|C1705273|[inpr]|["Function"-tx-1-"function"-noun-0]|TX|39/8|
text_000N_15123|MMI|3.56|physiological aspects|C0031843|[phsf]|["function"-tx-1-"function"-noun-0]|TX|39/8|
text_000N_15123|MMI|3.43|Notch|C1235660|[bsoj]|["Notch"-tx-1-"Notch"-noun-0]|TX|51/5|
text_000N_15123|MMI|3.43|Signal Transduction|C0037083|[celf]|["Signaling"-tx-1-"Signaling"-noun-0]|TX|57/9|
text_000N_15123|MMI|3.43|biological signaling|C3537152|[biof]|["signalling"-tx-1-"Signaling"-noun-0]|TX|57/9|
<<<<< MMI
>>>>> MMI
text_000N_15147|MMI|5.18|Microtubules|C0026046|[celc]|["Microtubules"-tx-1-"microtubules"-noun-0]|TX|4/12|
text_000N_15147|MMI|3.59|Marked|C1706089|[qlco]|["Marked"-tx-1-"marked"-verb-0]|TX|17/6|
text_000N_15147|MMI|3.59|Massive|C0522501|[qlco]|["Marked"-tx-1-"marked"-verb-0]|TX|17/6|
<<<<< MMI
>>>>> MMI
text_000N_15172|MMI|4.12|Germ-Line Mutation|C0206530|[genf]|["Germline Variant"-tx-1-"germline variants"-noun-0]|TX|5/17|
text_000N_15172|MMI|3.64|Colorectal Cancer Pathway|C2984278|[cnce]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_15172|MMI|3.64|Colorectal Carcinoma|C0009402|[neop]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_15172|MMI|3.64|Malignant neoplasm of colon and/or rectum|C4722085|[neop]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_15172|MMI|3.64|NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|C3542412|[inpr]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_15172|MMI|3.57|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-verb-0]|TX|28/10|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|CTCF gene|C1422163|[gngm]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|34/4|
text_000N_43303|MMI|5.18|CTCF protein, human|C1456335|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|34/4|
text_000N_43303|MMI|5.18|CTGF protein, human|C1137457|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|34/4|
text_000N_43303|MMI|5.18|Circadian Rhythm Pathway KEGG|C1522723|[biof]|["Circadian Rhythm"-tx-1-"circadian rhythm"-noun-0]|TX|48/16|
text_000N_43303|MMI|5.18|Circadian Rhythms|C0008810|[orgf]|["Circadian rhythm"-tx-1-"circadian rhythm"-noun-0]|TX|48/16|
text_000N_43303|MMI|5.18|Follow|C4281991|[ftcn]|["Follow"-tx-1-"follow"-verb-0]|TX|39/6|
text_000N_43303|MMI|5.18|Follow - dosing instruction imperative|C1719822|[inpr]|["Follow"-tx-1-"follow"-verb-0]|TX|39/6|
text_000N_43303|MMI|5.18|Followed by|C0332283|[tmco]|["follow"-tx-1-"follow"-verb-0]|TX|39/6|
text_000N_43303|MMI|3.57|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_43303|MMI|3.57|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_43303|MMI|3.57|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_43303|MMI|3.57|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|9/11|
text_000N_43303|MMI|3.44|PARP1 gene|C1538577|[gngm]|["PARP1"-tx-1-"PARP1"-noun-0]|TX|24/5|
text_000N_43303|MMI|3.44|PARP1 protein, human|C1567710|[aapp,enzy]|["PARP1"-tx-1-"PARP1"-noun-0]|TX|24/5|
text_000N_43303|MMI|3.44|PARP1 wt Allele|C1709384|[gngm]|["PARP-1"-tx-1-"PARP1"-noun-0]|TX|24/5|
text_000N_43303|MMI|3.44|TIPARP gene|C1428200|[gngm]|["PARP-1"-tx-1-"PARP1"-noun-0]|TX|24/5|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Istiratumab|C5139900|[aapp,imft,phsu]|["ISTIRATUMAB"-tx-1-"istiratumab"-noun-0]|TX|7/11|
text_000N_40999|MMI|3.64|Malignant neoplasm of pancreas|C0346647|[neop]|["Pancreatic Cancer"-tx-1-"Pancreatic Cancer"-noun-0]|TX|31/17|
text_000N_40999|MMI|3.64|Pancreatic Cancer Pathway|C2984259|[ftcn]|["Pancreatic cancer"-tx-1-"Pancreatic Cancer"-noun-0]|TX|31/17|
text_000N_40999|MMI|3.64|Pancreatic carcinoma|C0235974|[neop]|["PANCREATIC CANCER"-tx-1-"Pancreatic Cancer"-noun-0]|TX|31/17|
text_000N_40999|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|22/4|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Detected (finding)|C0442726|[fndg]|["detect"-tx-1-"detect"-verb-0]|TX|7/6|
text_000N_47320|MMI|5.18|Dosing Days to Detection|C3891454|[tmco]|["DETECT"-tx-1-"detect"-verb-0]|TX|7/6|
text_000N_47320|MMI|5.18|Use of|C1524063|[ftcn]|["Using"-tx-1-"using"-verb-0]|TX|37/5|
text_000N_47320|MMI|3.59|Asymmetric Chest Appearance|C5238639|[fndg]|["Asymmetry"-tx-1-"asymmetries"-noun-0]|TX|25/11|
text_000N_47320|MMI|3.59|Asymmetry (qualifier value)|C0332514|[spco]|["Asymmetry"-tx-1-"asymmetries"-noun-0]|TX|25/11|
text_000N_47320|MMI|3.57|Protein Domain|C1514562|[amas]|["Signature"-tx-1-"signatures"-noun-0]|TX|84/10|
text_000N_47320|MMI|3.57|Routine Signature|C1705596|[idcn]|["Signature"-tx-1-"signatures"-noun-0]|TX|84/10|
text_000N_47320|MMI|3.57|Signature|C1519316|[inpr]|["Signature"-tx-1-"signatures"-noun-0]|TX|84/10|
text_000N_47320|MMI|3.48|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|14/3|
text_000N_47320|MMI|3.48|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|14/3|
text_000N_47320|MMI|3.48|Genomic Orientation|C1704972|[spco]|["Strand"-tx-1-"strand"-noun-0]|TX|18/6|
text_000N_47320|MMI|3.48|Nucleic Acid Strand|C1704973|[nnon]|["Strand"-tx-1-"strand"-noun-0]|TX|18/6|
text_000N_47320|MMI|3.46|*Relative|C1547039|[qnco]|["*Relative"-tx-1-"relative"-noun-0]|TX|56/8|
text_000N_47320|MMI|3.46|Abundance|C2346714|[qlco]|["Abundance"-tx-1-"abundance"-noun-0]|TX|65/9|
text_000N_47320|MMI|3.46|Dinucleoside Phosphates|C0012476|[nnon]|["dinucleotide"-tx-1-"dinucleotide"-noun-0]|TX|43/12|
text_000N_47320|MMI|3.46|Genome|C0017428|[gngm]|["Genomic"-tx-1-"genomic"-adj-0]|TX|76/7|
text_000N_47320|MMI|3.46|Genomics|C0887950|[bmod]|["genomic"-tx-1-"genomic"-adj-0]|TX|76/7|
text_000N_47320|MMI|3.46|Relative|C0205345|[qlco]|["Relative"-tx-1-"relative"-noun-0]|TX|56/8|
text_000N_47320|MMI|3.46|Relative (related person)|C0080103|[famg]|["RELATIVE"-tx-1-"relative"-noun-0]|TX|56/8|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Carcinogenesis|C0596263|[neop]|["Oncogenesis"-tx-1-"oncogenesis"-noun-0]|TX|25/11|
text_000N_47274|MMI|5.18|Neoplastic Cell Transformation|C0007621|[neop]|["Oncogenesis"-tx-1-"oncogenesis"-noun-0]|TX|25/11|
text_000N_47274|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|17/7|
text_000N_47274|MMI|5.18|saracatinib|C2828242|[orch,phsu]|["SARACATINIB"-tx-1-"saracatinib"-noun-0]|TX|5/11|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Acupuncture procedure|C0394664|[topp]|["Acupuncture"-tx-1-"acupuncture"-noun-0]|TX|4/11|
text_000N_47289|MMI|5.18|Acupuncture therapy discipline|C0001299|[bmod]|["Acupuncture"-tx-1-"acupuncture"-noun-0]|TX|4/11|
text_000N_47289|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|16/5|
text_000N_47289|MMI|5.18|Hematoma, Epidural, Spinal|C0877172|[patf]|["Spinal epidural haematoma"-tx-1-"spinal epidural hematoma"-noun-0]|TX|22/24|
text_000N_47289|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|16/5|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|G-Quadruplexes|C1517336|[nusq]|["G Quadruplexes"-tx-1-"G-quadruplexes"-noun-0]|TX|4/14|
text_000N_47334|MMI|3.68|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|32/4|
text_000N_47334|MMI|3.68|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|32/4|
text_000N_47334|MMI|3.59|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|49/12|
text_000N_47334|MMI|3.59|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|49/12|
text_000N_47334|MMI|3.59|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|49/12|
text_000N_47334|MMI|3.59|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|49/12|
text_000N_47334|MMI|3.59|Target|C1521840|[ftcn]|["Target"-tx-1-"targets"-verb-0]|TX|37/7|
text_000N_47334|MMI|3.59|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"targets"-verb-0]|TX|37/7|
text_000N_47334|MMI|3.50|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.50|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.50|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|23/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|3.68|Qualitative form|C0348078|[qlco]|["shape"-tx-1-"shape"-noun-0]|TX|14/5|
text_000N_47349|MMI|3.68|Shapes|C0332479|[spco]|["Shape"-tx-1-"shape"-noun-0]|TX|14/5|
text_000N_47349|MMI|3.68|With shape|C0522512|[spco]|["Shape"-tx-1-"shape"-noun-0]|TX|14/5|
text_000N_47349|MMI|3.68|subharmonic aided pressure estimation|C4724253|[diap]|["SHAPE"-tx-1-"shape"-noun-0]|TX|14/5|
text_000N_47349|MMI|3.59|Population Group|C1257890|[popg]|["Population"-tx-1-"populations"-noun-0]|TX|32/11|
text_000N_47349|MMI|3.59|geographic population|C0032659|[qnco]|["Populations"-tx-1-"populations"-noun-0]|TX|32/11|
text_000N_47349|MMI|3.50|Promoter|C0086860|[bacs,nnon]|["Promoter"-tx-1-"promoter"-noun-0]|TX|5/8|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"autophagy"-noun-0]|TX|23/9|
text_000N_47392|MMI|5.18|D Vitamin|C3537249|[phsu]|["Vitamin D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
text_000N_47392|MMI|5.18|Induce (action)|C0205263|[ftcn]|["Induce"-tx-1-"induce"-verb-0]|TX|15/6|
text_000N_47392|MMI|5.18|Vitamin D Drug Class|C3714503|[phsu,vita]|["VITAMIN D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
text_000N_47392|MMI|5.18|Vitamin D [EPC]|C2936842|[vita]|["Vitamin D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
text_000N_47392|MMI|5.18|Vitamin D3 measurement|C0523979|[lbpr]|["Vitamin D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
text_000N_47392|MMI|5.18|ergocalciferol|C0014695|[orch,phsu,vita]|["Vitamin D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
text_000N_47392|MMI|5.18|vitamin D|C0042866|[phsu,vita]|["VITAMIN D"-tx-1-"Vitamin D"-noun-0]|TX|5/9|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|avelumab|C4055417|[aapp,imft,phsu]|["AVELUMAB"-tx-1-"avelumab"-noun-0]|TX|3/8|
text_000N_47406|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_47406|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_47406|MMI|3.48|Bladder Cancer Pathway|C2984270|[cnce]|["Bladder cancer"-tx-1-"bladder cancer"-noun-0]|TX|26/14|
text_000N_47406|MMI|3.48|Bladder Neoplasm|C0005695|[neop]|["Bladder cancer"-tx-1-"bladder cancer"-noun-0]|TX|26/14|
text_000N_47406|MMI|3.48|Carcinoma of bladder|C0699885|[neop]|["Bladder Cancer"-tx-1-"bladder cancer"-noun-0]|TX|26/14|
text_000N_47406|MMI|3.48|Childhood Bladder Carcinoma|C3899675|[neop]|["Bladder Cancer"-tx-1-"bladder cancer"-noun-0]|TX|26/14|
text_000N_47406|MMI|3.48|Malignant neoplasm of urinary bladder|C0005684|[neop]|["BLADDER CANCER"-tx-1-"bladder cancer"-noun-0]|TX|26/14|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|32/6|
text_000N_47420|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|32/6|
text_000N_47420|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|32/6|
text_000N_47420|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|24/7|
text_000N_47420|MMI|3.68|Deregulation|C1880287|[acty]|["Deregulation"-tx-1-"deregulation"-noun-0]|TX|11/12|
text_000N_47420|MMI|3.50|SCRIB gene|C1539732|[gngm]|["SCRIB"-tx-1-"SCRIB"-noun-0]|TX|5/5|
<<<<< MMI
>>>>> MMI
text_000N_47435|AA|DCM|Dilated Cardiomyopathy|1|3|3|22|79:3
text_000N_47435|MMI|10.42|DES gene|C1413980|[gngm]|["DESMIN"-tx-1-"desmin"-noun-0,"intermediate filament protein"-tx-1-"intermediate filament protein"-noun-0]|TX|3/6;13/29|
text_000N_47435|MMI|5.18|DES protein, human|C5441700|[aapp,bacs]|["Desmin"-tx-1-"desmin"-noun-0]|TX|3/6|
text_000N_47435|MMI|5.18|Desmin|C0011696|[aapp,bacs]|["Desmin"-tx-1-"desmin"-noun-0]|TX|3/6|
text_000N_47435|MMI|5.18|GFAP gene|C1415042|[gngm]|["intermediate filament protein"-tx-1-"intermediate filament protein"-noun-0]|TX|13/29|
text_000N_47435|MMI|5.18|Intermediate Filament Proteins|C0021769|[aapp,bacs]|["Intermediate Filament Protein"-tx-1-"intermediate filament protein"-noun-0]|TX|13/29|
text_000N_47435|MMI|5.18|desmin location|C1325785|[celc]|["desmin"-tx-1-"desmin"-noun-0]|TX|3/6|
text_000N_47435|MMI|3.64|Cardiomyopathy, Dilated|C0007193|[dsyn]|["Cardiomyopathy, Dilated"-tx-1-"Dilated Cardiomyopathy"-noun-0]|TX|55/22|
text_000N_47435|MMI|3.64|Dilated Cardiomyopathy Pathway|C2984282|[ftcn]|["Dilated cardiomyopathy"-tx-1-"Dilated Cardiomyopathy"-noun-0]|TX|55/22|
text_000N_47435|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|43/8|
text_000N_47435|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Abdominal Pain|C0000737|[sosy]|["ABDOMINAL PAIN"-tx-1-"abdominal pain"-noun-0]|TX|3/14|
text_000N_47377|MMI|5.18|Abdominal Pain, CTCAE 5|C4554323|[fndg]|["Abdominal Pain"-tx-1-"abdominal pain"-noun-0]|TX|3/14|
text_000N_47377|MMI|3.56|Symptom:Find:Pt:^Patient:Nom|C3854129|[clna]|["Symptom"-tx-1-"symptom"-noun-0]|TX|27/7|
text_000N_47377|MMI|3.56|Symptoms|C1457887|[sosy]|["Symptom"-tx-1-"symptom"-noun-0]|TX|27/7|
text_000N_47377|MMI|3.43|Autistic Disorder|C0004352|[mobd]|["AUTISM"-tx-1-"autism"-noun-0]|TX|38/6|
text_000N_47377|MMI|3.43|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|20/6|
text_000N_47377|MMI|3.43|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|20/6|
text_000N_47377|MMI|3.43|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|20/6|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.56|Effect|C1280500|[qlco]|["Effects"-tx-1-"effects"-noun-0]|TX|19/7|
text_000N_47450|MMI|3.46|Adipose tissue|C0001527|[tisu]|["Fat Tissue"-tx-1-"fat tissue"-noun-0]|TX|30/10|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|atenolol|C0004147|[orch,phsu]|["ATENOLOL"-tx-1-"atenolol"-noun-0]|TX|3/8|
text_000N_43331|MMI|3.59|CYP2D6 gene|C1332830|[gngm]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|27/6|
text_000N_43331|MMI|3.59|Cytochrome P-450 CYP2D6|C0057223|[aapp,enzy]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|27/6|
text_000N_43331|MMI|3.59|Cytochrome P450 2D6, human|C3887685|[aapp,enzy]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|27/6|
text_000N_43331|MMI|3.59|Metabolic Process, Cellular|C1524026|[celf]|["Metabolized"-tx-1-"metabolized"-verb-0]|TX|12/11|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.68|Disruption|C0332453|[ftcn]|["Disruption"-tx-1-"disruption"-noun-0]|TX|8/10|
text_000N_47304|MMI|3.59|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.59|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.59|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|27/7|
text_000N_47304|MMI|3.59|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.59|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.59|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.59|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|19/4|
text_000N_47304|MMI|3.50|Transverse abdominal diameter|C4082312|[qnco]|["TAD"-tx-1-"TAD"-noun-0]|TX|4/3|
text_000N_47304|MMI|3.50|Treatment Assignment Description|C5237014|[inpr]|["TAD"-tx-1-"TAD"-noun-0]|TX|4/3|
text_000N_47304|MMI|3.50|aminoglutethimide/danazol/hydrocortisone/tamoxifen|C0280090|[topp]|["TAD"-tx-1-"TAD"-noun-0]|TX|4/3|
<<<<< MMI
>>>>> MMI
text_000N_43275|AA|GRB|genomic regulatory block|1|3|5|24|31:3
text_000N_43275|AA|GRBs|genomic regulatory blocks|1|4|5|25|31:4
text_000N_43275|MMI|3.63|(City) Block|C1706084|[geoa]|["Block"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Genome|C0017428|[gngm]|["Genomic"-tx-1-"genomic"-adj-0]|TX|4/7|
text_000N_43275|MMI|3.63|Genomics|C0887950|[bmod]|["genomic"-tx-1-"genomic"-adj-0]|TX|4/7|
text_000N_43275|MMI|3.63|Obstruction|C0028778|[patf]|["blocks"-tx-1-"blocks"-verb-0]|TX|23/6|
text_000N_43275|MMI|3.63|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-adj-0]|TX|12/10|
text_000N_43275|MMI|3.63|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-adj-0]|TX|12/10|
text_000N_43275|MMI|3.57|Different|C1705242|[qlco]|["Different"-tx-1-"different"-adj-0]|TX|41/9|
text_000N_43275|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|37/3|
text_000N_43275|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|37/3|
text_000N_43275|MMI|3.44|Tietz syndrome|C0391816|[dsyn]|["TADS"-tx-1-"TADs"-noun-0]|TX|56/4|
text_000N_43275|MMI|3.44|Transverse abdominal diameter|C4082312|[qnco]|["TAD"-tx-1-"TADs"-noun-0]|TX|56/4|
text_000N_43275|MMI|3.44|Treatment Assignment Description|C5237014|[inpr]|["TAD"-tx-1-"TADs"-noun-0]|TX|56/4|
text_000N_43275|MMI|3.44|aminoglutethimide/danazol/hydrocortisone/tamoxifen|C0280090|[topp]|["TAD"-tx-1-"TADs"-noun-0]|TX|56/4|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|lasmiditan|C4519199|[orch,phsu]|["LASMIDITAN"-tx-1-"Lasmiditan"-noun-0]|TX|3/10|
text_000N_43386|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_43386|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_43386|MMI|3.45|Migraine Disorders|C0149931|[dsyn]|["MIGRAINE"-tx-1-"migraine"-noun-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_40839|AA|AML|Acute myeloid leukemia|1|3|5|22|45:3
text_000N_40839|MMI|5.18|KAT2A gene|C1415020|[gngm]|["KAT2A"-tx-1-"KAT2A"-noun-0]|TX|3/5|
text_000N_40839|MMI|3.68|Acute Myeloid Leukemia Pathway|C2984331|[cnce]|["Acute myeloid leukemia"-tx-1-"Acute myeloid leukemia"-noun-0]|TX|21/22|
text_000N_40839|MMI|3.68|Leukemia, Myelocytic, Acute|C0023467|[neop]|["Acute myeloid leukaemia"-tx-1-"Acute myeloid leukemia"-noun-0]|TX|21/22|
text_000N_40839|MMI|3.68|NCI CTEP SDC Acute Myeloid Leukemia Sub-Category Terminology|C3541370|[inpr]|["Acute Myeloid Leukemia"-tx-1-"Acute myeloid leukemia"-noun-0]|TX|21/22|
text_000N_40839|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_40839|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.75|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|13/20|
text_000N_40913|MMI|3.75|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|13/20|
text_000N_40913|MMI|3.50|Chromatin|C0008546|[aapp]|["Chromatin"-tx-1-"chromatin"-noun-0]|TX|36/9|
text_000N_40913|MMI|3.50|chromatin location|C1325550|[celc]|["chromatin"-tx-1-"chromatin"-noun-0]|TX|36/9|
<<<<< MMI
>>>>> MMI
text_000N_40941|AA|CD|Crohn's disease|1|2|3|15|20:2
text_000N_40941|MMI|5.18|Crohn Disease|C0010346|[dsyn]|["Crohns Disease"-tx-1-"Crohn's disease"-noun-0]|TX|3/15|
text_000N_40941|MMI|3.60|Food Consumption|C2983605|[fndg]|["Consumption of food"-tx-1-"consumption of food"-noun-0]|TX|38/14,66/4|
text_000N_40941|MMI|3.55|Refrigerated Specimen|C2347927|[qlco]|["REFRIGERATED"-tx-1-"refrigerated"-adj-0]|TX|53/12|
text_000N_40941|MMI|3.52|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|24/6|
text_000N_40941|MMI|3.52|Links List|C1517892|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|24/6|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|dasatinib|C1455147|[orch,phsu]|["DASATINIB"-tx-1-"dasatinib"-noun-0]|TX|3/9|
text_000N_40972|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|13/9,27/9|
text_000N_40972|MMI|3.43|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|40/12|
text_000N_40972|MMI|3.43|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|40/12|
text_000N_40972|MMI|3.43|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|40/12|
text_000N_40972|MMI|3.43|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|40/12|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Retroviridae|C0035366|[virs]|["Retroviruses"-tx-1-"retroviruses"-noun-0]|TX|4/12|
text_000N_40886|MMI|3.64|Gene Therapy Agent|C1517496|[phsu]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|26/12|
text_000N_40886|MMI|3.64|gene therapy|C0017296|[topp]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|26/12|
text_000N_40886|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|17/4|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|3.54|Genome|C0017428|[gngm]|["Genomic"-tx-1-"genomic"-noun-0]|TX|25/7|
text_000N_173136|MMI|3.54|Genomics|C0887950|[bmod]|["genomic"-tx-1-"genomic"-noun-0]|TX|25/7|
text_000N_173136|MMI|3.51|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|33/7|
text_000N_173136|MMI|3.51|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|33/7|
text_000N_173136|MMI|3.44|Budding Yeast Measurement|C3814776|[lbpr]|["Budding Yeast"-tx-1-"budding yeast"-noun-0]|TX|48/13|
text_000N_173136|MMI|3.44|Saccharomycetales|C0014181|[fngs]|["Budding yeast"-tx-1-"budding yeast"-noun-0]|TX|48/13|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Complete Trisomy 21 Syndrome|C4521042|[dsyn]|["Down Syndrome"-tx-1-"Downs syndrome"-noun-0]|TX|3/14|
text_000N_173120|MMI|5.18|Down Syndrome|C0013080|[dsyn]|["Downs Syndrome"-tx-1-"Downs syndrome"-noun-0]|TX|3/14|
text_000N_173120|MMI|3.59|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|18/15|
text_000N_173120|MMI|3.56|Risk Reduction|C1137094|[inbe]|["Risk Decrease"-tx-1-"decreased risk"-noun-0]|TX|34/14|
text_000N_173120|MMI|3.55|Childhood Leukemia|C1332977|[neop]|["Leukemia"-tx-1-"leukemia"-noun-0]|TX|52/8|
text_000N_173120|MMI|3.55|leukemia|C0023418|[neop]|["LEUKEMIA"-tx-1-"leukemia"-noun-0]|TX|52/8|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|3.56|Present|C0150312|[fndg]|["PRESENT"-tx-1-"present"-noun-0]|TX|12/7|
text_000N_173151|MMI|3.56|Presentation|C0449450|[idcn]|["Present"-tx-1-"present"-noun-0]|TX|12/7|
text_000N_173151|MMI|3.56|Radial-Femoral Lag Present|C5238858|[fndg]|["Present"-tx-1-"present"-noun-0]|TX|12/7|
text_000N_173151|MMI|3.43|Mediator of activation protein|C1363844|[aapp,bacs]|["Mediator"-tx-1-"Mediator"-noun-0]|TX|3/8|
text_000N_173151|MMI|3.41|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|29/9|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Finding|C0243095|[fndg]|["Find"-tx-1-"find"-verb-0]|TX|6/4|
text_000N_173104|MMI|3.57|Bacteriophages|C0004651|[virs]|["Bacteriophages"-tx-1-"bacteriophages"-noun-0]|TX|11/14|
text_000N_173104|MMI|3.44|Gastrointestinal tract structure|C0017189|[bdsy]|["Gut"-tx-1-"gut"-noun-0]|TX|33/3|
text_000N_173104|MMI|3.44|Gut|C0699819|[bpoc]|["Gut"-tx-1-"gut"-noun-0]|TX|33/3|
text_000N_173104|MMI|3.44|Intestines|C0021853|[bpoc]|["Gut"-tx-1-"gut"-noun-0]|TX|33/3|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|RNA|C0035668|[nnon]|["RNA"-tx-1-"RNA"-noun-0]|TX|3/3|
text_000N_173199|MMI|5.18|Ribonucleic Acid Measurement|C4319105|[lbpr]|["RNA"-tx-1-"RNA"-noun-0]|TX|3/3|
text_000N_173199|MMI|3.68|Hybrids|C0020205|[orgm]|["Hybrids"-tx-1-"hybrids"-noun-0]|TX|11/7|
text_000N_173199|MMI|3.59|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|57/7|
text_000N_173199|MMI|3.59|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|57/7|
text_000N_173199|MMI|3.59|Abnormally high|C1299351|[qlco]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|Form:Finding:Point in time:{Setting}:Document:{Role}|C4255237|[clna]|["Form"-tx-1-"form"-verb-0]|TX|34/4|
text_000N_173199|MMI|3.59|Formation|C1522492|[ftcn]|["Form"-tx-1-"form"-verb-0]|TX|34/4|
text_000N_173199|MMI|3.59|High|C0205250|[qlco]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|High (finding)|C5200928|[fndg]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|High Level|C4321237|[fndg]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|High Mitosis-Karyorrhexis Index|C3889660|[inpr]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|IPSS Risk Category High|C4522209|[inpr]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|IPSS-R Risk Category High|C5202936|[fndg]|["High"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|Manufactured form|C0376315|[mnob]|["Form"-tx-1-"form"-verb-0]|TX|34/4|
text_000N_173199|MMI|3.59|Qualitative form|C0348078|[qlco]|["Form"-tx-1-"form"-verb-0]|TX|34/4|
text_000N_173199|MMI|3.59|Value Above Reference Range|C2700149|[inpr]|["HIGH"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.59|high - ActExposureLevelCode|C3887512|[idcn]|["high"-tx-1-"high"-adj-0]|TX|42/4|
text_000N_173199|MMI|3.50|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|7/3|
text_000N_173199|MMI|3.50|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|7/3|
text_000N_173199|MMI|3.48|G-Series Nerve Agent GC|C5203019|[hops]|["GC"-tx-1-"GC"-noun-0]|TX|54/2|
text_000N_173199|MMI|3.48|GBA wt Allele|C3537453|[gngm]|["GC"-tx-1-"GC"-noun-0]|TX|54/2|
text_000N_173199|MMI|3.48|GC, vitamin D binding protein, human|C4281799|[aapp,bacs]|["Gc"-tx-1-"GC"-noun-0]|TX|54/2|
text_000N_173199|MMI|3.48|IPSS Risk Category Low|C4522223|[inpr]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|IPSS-R Risk Category Low|C5203106|[fndg]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|Low Level|C4321351|[fndg]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|Low Mitosis-Karyorrhexis Index|C3890211|[qnco]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|Malignant Germ Cell International Collaborative Risk Classification, Low|C5444026|[clas]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|low|C0205251|[qlco]|["Low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|low confidentiality|C1550472|[inpr]|["low"-tx-1-"low"-adj-0]|TX|50/3|
text_000N_173199|MMI|3.48|low exposure|C4048187|[qlco]|["low"-tx-1-"low"-adj-0]|TX|50/3|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|3.63|Decision Support Systems, Management|C0011112|[inpr]|["Decision Support Systems, Management"-tx-1-"Decision support systems management"-noun-0]|TX|14/24,56/10|
text_000N_173214|MMI|3.44|Chronic pain|C0150055|[sosy]|["Chronic Pain"-tx-1-"chronic pain"-noun-0]|TX|43/12|
text_000N_173214|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_173214|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|3.60|Disease Marker|C1511983|[idcn]|["marker disease"-tx-1-"marker disease"-noun-0]|TX|23/6,34/7|
text_000N_173167|MMI|3.46|NEFL gene|C1417668|[gngm]|["neurofilament light"-tx-1-"neurofilament light"-noun-0]|TX|3/19|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|ELAV-like protein 1|C0388204|[aapp,imft]|["Protein, HuR"-tx-1-"HuR protein"-noun-0]|TX|5/11|
text_000N_173230|MMI|3.68|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"process"-noun-0]|TX|39/7|
text_000N_173230|MMI|3.68|Process|C1522240|[phpr]|["Process"-tx-1-"process"-noun-0]|TX|39/7|
text_000N_173230|MMI|3.68|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"process"-noun-0]|TX|39/7|
text_000N_173230|MMI|3.68|bony process|C1184743|[bpoc]|["Process"-tx-1-"process"-noun-0]|TX|39/7|
text_000N_173230|MMI|3.50|RNA Splicing|C0035687|[genf]|["Splicing"-tx-1-"splicing"-adj-0]|TX|30/8|
text_000N_173230|MMI|3.50|nuclear mRNA cis splicing, via spliceosome|C2610186|[genf]|["splicing"-tx-1-"splicing"-adj-0]|TX|30/8|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Sumoylation|C1157990|[moft]|["Sumoylation"-tx-1-"SUMOylation"-noun-0]|TX|3/11|
text_000N_47363|MMI|3.64|Post-Translational Protein Processing|C0033666|[moft]|["Post Translational Modification"-tx-1-"post-translational modification"-noun-0]|TX|17/31|
text_000N_47363|MMI|3.43|Eukaryota|C0684063|[euka]|["Eukaryotes"-tx-1-"eukaryotes"-noun-0]|TX|52/10|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Leukemia, Myelocytic, Acute|C0023467|[neop]|["AML"-tx-1-"AML"-noun-0]|TX|41/3|
text_000N_43358|MMI|3.56|Social Role|C0035820|[socb]|["Roles"-tx-1-"roles"-noun-0]|TX|10/5|
text_000N_43358|MMI|3.43|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|28/9|
text_000N_43358|MMI|3.43|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|28/9|
text_000N_43358|MMI|3.43|cohesins|C0907709|[aapp,bacs]|["cohesin"-tx-1-"cohesin"-noun-0]|TX|20/7|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Pacritinib|C3467842|[orch,phsu]|["PACRITINIB"-tx-1-"pacritinib"-noun-0]|TX|3/10|
text_000N_173183|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|14/9,28/9|
text_000N_173183|MMI|3.43|Myelofibrosis|C0026987|[neop]|["MYELOFIBROSIS"-tx-1-"myelofibrosis"-noun-0]|TX|41/13|
text_000N_173183|MMI|3.43|Myelofibrosis Assessment|C4722417|[diap]|["Myelofibrosis"-tx-1-"myelofibrosis"-noun-0]|TX|41/13|
text_000N_173183|MMI|3.43|Primary Myelofibrosis|C0001815|[neop]|["MYELOFIBROSIS"-tx-1-"myelofibrosis"-noun-0]|TX|41/13|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|7.11|Exons|C0015295|[bacs,nnon]|["Exon"-tx-1-"exon"-noun-0]|TX|[3/4],[33/4]|
text_000N_173087|MMI|7.11|Variant Exon|C5401401|[nnon]|["exon"-tx-1-"exon"-noun-0]|TX|[3/4],[33/4]|
text_000N_173087|MMI|3.68|Does skip|C0560435|[fndg]|["skipping"-tx-1-"skipping"-noun-0]|TX|8/8|
text_000N_173087|MMI|3.57|Correlation|C1707520|[qlco]|["Correlated"-tx-1-"correlated"-verb-0]|TX|17/10|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Cephalopoda|C0324027|[euka]|["Cephalopods"-tx-1-"cephalopods"-noun-0]|TX|3/11|
text_000N_173245|MMI|5.18|Edit|C0868955|[ocac]|["Editing"-tx-1-"editing"-verb-0]|TX|23/7|
text_000N_173245|MMI|5.18|RNA|C0035668|[nnon]|["RNA"-tx-1-"RNA"-noun-0]|TX|19/3|
text_000N_173245|MMI|5.18|Ribonucleic Acid Measurement|C4319105|[lbpr]|["RNA"-tx-1-"RNA"-noun-0]|TX|19/3|
text_000N_173245|MMI|5.18|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-verb-0]|TX|15/3|
text_000N_173245|MMI|5.18|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-verb-0]|TX|15/3|
text_000N_173245|MMI|5.18|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-verb-0]|TX|15/3|
text_000N_173245|MMI|3.60|Less Than|C0439092|[qnco]|["Less Than"-tx-1-"less than"-adv-0]|TX|31/4,47/4|
text_000N_173245|MMI|3.56|Frequently|C0332183|[tmco]|["Frequently"-tx-1-"frequently"-adv-0]|TX|36/10|
text_000N_173245|MMI|3.56|Species|C1705920|[clas]|["Species"-tx-1-"species"-noun-0]|TX|58/7|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|Cardiovascular Diseases|C0007222|[dsyn]|["Cardiovascular Disease"-tx-1-"cardiovascular disease"-noun-0]|TX|63/22|
text_000N_173260|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|32/15|
text_000N_173260|MMI|3.57|Consumption of goods|C0009830|[acty]|["Consumption"-tx-1-"consumption"-noun-0]|TX|7/11|
text_000N_173260|MMI|3.57|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|51/8|
text_000N_173260|MMI|3.57|biologic consumption|C1947907|[phsf]|["Consumption"-tx-1-"consumption"-noun-0]|TX|7/11|
text_000N_173260|MMI|3.44|Cacao Plant|C0006622|[plnt]|["chocolate"-tx-1-"chocolate"-noun-0]|TX|22/9|
text_000N_173260|MMI|3.44|Chocolate|C0008299|[food]|["Chocolate"-tx-1-"chocolate"-noun-0]|TX|22/9|
text_000N_173260|MMI|3.44|Chocolate Flavor|C1337204|[food]|["CHOCOLATE"-tx-1-"chocolate"-noun-0]|TX|22/9|
text_000N_173260|MMI|3.44|Theobroma cacao, cocoa, chocolate|C0939909|[phsu]|["chocolate"-tx-1-"chocolate"-noun-0]|TX|22/9|
<<<<< MMI
>>>>> MMI
text_000N_173291|AA|MSC|Mesenchymal stem cells|1|3|5|22|28:3
text_000N_173291|MMI|3.61|Multipotent Stem Cells|C1136335|[cell]|["Multipotent cell"-tx-1-"multipotent cells"-noun-0]|TX|33/17|
text_000N_173291|MMI|3.52|Mesenchymal Stem Cells|C1257975|[cell]|["Mesenchymal Stem Cells"-tx-1-"Mesenchymal stem cells"-noun-0]|TX|4/22|
<<<<< MMI
>>>>> MMI
text_000N_14856|MMI|5.18|OSTN gene|C1428912|[gngm]|["MUSCLIN"-tx-1-"Musclin"-noun-0]|TX|3/7|
text_000N_14856|MMI|3.68|Peptides|C0030956|[aapp,phsu]|["Peptide"-tx-1-"peptide"-noun-0]|TX|23/7|
text_000N_14856|MMI|3.50|Cell secretion|C1327616|[celf]|["Secretory"-tx-1-"secretory"-adj-0]|TX|13/9|
<<<<< MMI
>>>>> MMI
text_000N_14887|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|57/9|
text_000N_14887|MMI|3.45|Small Molecule|C1328819|[orch]|["Small Molecule"-tx-1-"small molecule"-noun-0]|TX|10/14|
text_000N_14887|MMI|3.43|Migraine Disorders|C0149931|[dsyn]|["MIGRAINE"-tx-1-"migraine"-noun-0]|TX|70/8|
text_000N_14887|MMI|3.43|Preposition For|C0521125|[qlco]|["For"-tx-1-"for"-prep-0]|TX|49/3|
text_000N_14887|MMI|3.43|WWOX wt Allele|C4321252|[gngm]|["FOR"-tx-1-"for"-prep-0]|TX|49/3|
text_000N_14887|MMI|3.43|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_14887|MMI|3.43|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_14887|MMI|3.43|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_14887|MMI|3.43|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|37/11|
<<<<< MMI
>>>>> MMI
text_000N_14910|AA|TG2|transglutaminase-2|1|3|3|18|64:3
text_000N_14910|MMI|5.18|Celiac Disease|C0007570|[dsyn]|["Coeliac disease"-tx-1-"celiac disease"-noun-0]|TX|3/14|
text_000N_14910|MMI|3.57|Protein Glutamine gamma Glutamyltransferase 2|C5444761|[aapp,enzy]|["Transglutaminase II"-tx-1-"transglutaminase-2"-noun-0]|TX|44/18|
text_000N_14910|MMI|3.57|TGM2 gene|C1420714|[gngm]|["TRANSGLUTAMINASE 2"-tx-1-"transglutaminase-2"-noun-0]|TX|44/18|
text_000N_14910|MMI|3.57|transglutaminase 2|C0529334|[aapp,enzy]|["transglutaminase 2"-tx-1-"transglutaminase-2"-noun-0]|TX|44/18|
text_000N_14910|MMI|3.54|CDISC Events Class|C3541888|[clas]|["EVENTS"-tx-1-"events"-noun-0]|TX|79/6|
text_000N_14910|MMI|3.54|Conditional|C1701901|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.54|Dependent - ability|C0851827|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.54|Dependent for Toilet Use|C4321395|[inpr]|["dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.54|Dependent for bathing|C0429986|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.54|Dependent for dressing|C0429964|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.54|Event|C0441471|[evnt]|["Events"-tx-1-"events"-noun-0]|TX|79/6|
text_000N_14910|MMI|3.54|Event Unit|C4724244|[qnco]|["EVENTS"-tx-1-"events"-noun-0]|TX|79/6|
text_000N_14910|MMI|3.54|Gliadin|C0017622|[aapp,bacs]|["Gliadin"-tx-1-"gliadin"-noun-0]|TX|28/7|
text_000N_14910|MMI|3.54|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-adj-0]|TX|36/7|
text_000N_14910|MMI|3.54|dependent|C3244310|[ftcn]|["dependent"-tx-1-"dependent"-adj-0]|TX|69/9|
text_000N_14910|MMI|3.51|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|18/6|
text_000N_14910|MMI|3.51|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|18/6|
<<<<< MMI
>>>>> MMI
text_000N_43303|AA|FPGA|field-programmable gate array|1|4|7|29|35:4
text_000N_43303|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|62/2|
text_000N_43303|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|62/2|
text_000N_43303|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|57/4|
text_000N_43303|MMI|3.63|Problems - What subject filter|C1546466|[idcn]|["Problems"-tx-1-"problems"-noun-0]|TX|90/8|
text_000N_43303|MMI|3.60|Technology|C0039421|[ocdi]|["Technology"-tx-1-"technology"-noun-0]|TX|41/10|
text_000N_43303|MMI|3.53|Sequence Alignment|C0080143|[mbrt]|["Sequence Alignment"-tx-1-"sequence alignment"-noun-0]|TX|71/18|
text_000N_43303|MMI|3.46|Array|C1510941|[spco]|["Array"-tx-1-"array"-noun-0]|TX|28/5|
text_000N_43303|MMI|3.46|Field|C1521738|[cnce]|["Field"-tx-1-"field"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.46|Force Field|C2349184|[cnce]|["Field"-tx-1-"field"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.46|In the Field|C3539073|[spco]|["FIELD"-tx-1-"field"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.46|Knowledge Field|C2346620|[cnce]|["Field"-tx-1-"field"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.41|Gated|C4266464|[fndg]|["Gated"-tx-1-"gate"-noun-0]|TX|23/4|
<<<<< MMI
>>>>> MMI
text_000N_14932|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|59/8|
text_000N_14932|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|59/8|
text_000N_14932|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14932|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14932|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14932|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14932|MMI|3.48|TERT Promoter Mutation|C5205374|[comd]|["TERT Promoter Mutation"-tx-1-"TERT promoter mutation"-noun-0]|TX|32/22|
text_000N_14932|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|71/12|
text_000N_14932|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|71/12|
text_000N_14932|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|71/12|
text_000N_14932|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|71/12|
text_000N_14932|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|84/8|
text_000N_14932|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_14932|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_14957|MMI|3.64|Complicated malaria|C2747816|[dsyn]|["Severe Malaria"-tx-1-"severe Malaria"-noun-0]|TX|48/14|
text_000N_14957|MMI|3.56|Persons|C0027361|[popg]|["People"-tx-1-"people"-noun-0]|TX|4/6|
text_000N_14957|MMI|3.50|Blood group O (finding)|C0427625|[fndg]|["Blood Group O"-tx-1-"blood group O"-noun-0]|TX|16/13|
<<<<< MMI
>>>>> MMI
text_000N_14980|MMI|5.18|Plagiocephaly|C0265529|[cgab]|["Plagiocephaly"-tx-1-"plagiocephaly"-noun-0]|TX|51/13|
text_000N_14980|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14980|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14980|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14980|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_14980|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_14980|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_14980|MMI|3.43|FGFR3 protein, human|C0527057|[aapp,enzy,rcpt]|["FGFR3"-tx-1-"FGFR3"-noun-0]|TX|32/5|
text_000N_14980|MMI|3.43|Mutation|C0026882|[genf]|["Mutation"-tx-1-"mutation"-noun-0]|TX|38/8|
text_000N_14980|MMI|3.43|Mutation Abnormality|C1705285|[comd]|["Mutation"-tx-1-"mutation"-noun-0]|TX|38/8|
<<<<< MMI
>>>>> MMI
text_000N_15004|MMI|4.12|Tumor Antigens|C0041361|[aapp,imft]|["tumor-specific antigen"-tx-1-"tumour specific antigens"-noun-0]|TX|4/24|
text_000N_15004|MMI|3.60|Protein coding gene|C3839127|[gngm]|["Protein coding gene"-tx-1-"protein coding genes"-noun-0]|TX|52/20|
text_000N_15004|MMI|3.55|Known|C0205309|[qlco]|["Known"-tx-1-"known"-adj-0]|TX|46/5|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Poly ADP Ribosylation|C4331020|[moft]|["Poly ADP Ribosylation"-tx-1-"poly ADP ribosylation"-noun-0]|TX|3/4,9/3,14/12|
text_000N_40999|MMI|3.64|Transcriptional Regulation|C1158770|[genf]|["Transcriptional Control"-tx-1-"transcriptional control"-noun-0]|TX|40/23|
text_000N_40999|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|28/8|
text_000N_40999|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["Malignant tumour"-tx-1-"malignant tumor"-noun-0]|TX|43/15|
text_000N_173276|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Tumour, malignant"-tx-1-"malignant tumor"-noun-0]|TX|43/15|
text_000N_173276|MMI|3.81|Mesenchymal hamartoma of liver|C1333971|[neop]|["Hepatic Mesenchymal Hamartoma"-tx-1-"Hepatic mesenchymal hamartoma"-noun-0]|TX|3/29|
text_000N_173276|MMI|3.47|Usual|C3538928|[qlco]|["Usually"-tx-1-"usually"-adv-0]|TX|33/7|
text_000N_173276|MMI|3.47|Usually|C3888388|[fndg]|["Usually"-tx-1-"usually"-adv-0]|TX|33/7|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Chemotherapy|C3665472|[topp]|["CHEMOTHERAPY"-tx-1-"chemotherapy"-noun-0]|TX|34/12|
text_000N_47274|MMI|5.18|Chemotherapy Regimen|C0392920|[topp]|["Chemotherapy, NOS"-tx-1-"chemotherapy"-noun-0]|TX|34/12|
text_000N_47274|MMI|5.18|Pharmacotherapy|C0013216|[topp]|["Chemotherapy"-tx-1-"chemotherapy"-noun-0]|TX|34/12|
text_000N_47274|MMI|5.18|pharmacotherapeutic|C0013217|[ftcn]|["chemotherapy"-tx-1-"chemotherapy"-noun-0]|TX|34/12|
text_000N_47274|MMI|3.59|Cell secretion|C1327616|[celf]|["Secreted"-tx-1-"secreted"-verb-0]|TX|10/8|
text_000N_47274|MMI|3.59|Disease Response|C1704632|[fndg]|["RESPONSE"-tx-1-"response"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.59|Response (communication)|C2911692|[menp]|["Response"-tx-1-"response"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.59|Response (statement)|C1706817|[inpr]|["Response"-tx-1-"response"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.59|Response process|C0871261|[orga]|["Response"-tx-1-"response"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.59|Responsive Disease|C5236984|[fndg]|["response"-tx-1-"response"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.59|Secreted|C4554416|[lbtr]|["Secreted"-tx-1-"secreted"-verb-0]|TX|10/8|
<<<<< MMI
>>>>> MMI
text_000N_15028|MMI|5.18|ocrelizumab|C1882138|[aapp,imft,phsu]|["OCRELIZUMAB"-tx-1-"ocrelizumab"-noun-0]|TX|3/11|
text_000N_15028|MMI|3.58|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|15/9,29/9|
text_000N_15028|MMI|3.45|Multiple Sclerosis|C0026769|[dsyn]|["MULTIPLE SCLEROSIS"-tx-1-"multiple sclerosis"-noun-0]|TX|42/18|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.68|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|12/4|
text_000N_47420|MMI|3.68|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|12/4|
text_000N_47420|MMI|3.50|TFRC gene|C1420708|[gngm]|["TFR1"-tx-1-"TFR1"-noun-0]|TX|7/4|
text_000N_47420|MMI|3.50|TFRC protein, human|C0108801|[aapp,rcpt]|["TFR1"-tx-1-"TFR1"-noun-0]|TX|7/4|
text_000N_47420|MMI|3.50|TFRC wt Allele|C1705610|[gngm]|["TFR1"-tx-1-"TFR1"-noun-0]|TX|7/4|
text_000N_47420|MMI|3.45|Erythropoiesis|C0014819|[ortf]|["Erythropoiesis"-tx-1-"erythropoiesis"-noun-0]|TX|33/14|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|9/9|
text_000N_43235|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|9/9|
text_000N_43235|MMI|3.59|Polyneuropathy|C0152025|[dsyn]|["POLYNEUROPATHY"-tx-1-"polyneuropathy"-noun-0]|TX|29/14|
text_000N_43235|MMI|3.55|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|19/6|
text_000N_43235|MMI|3.55|Links List|C1517892|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|19/6|
text_000N_43235|MMI|3.50|PDXK gene|C1418446|[gngm]|["PDXK"-tx-1-"PDXK"-noun-0]|TX|4/4|
<<<<< MMI
>>>>> MMI
text_000N_15051|MMI|5.18|SOX10 Transcription Factor|C1571654|[aapp,bacs]|["SOX10"-tx-1-"SOX10"-noun-0]|TX|3/5|
text_000N_15051|MMI|5.18|SOX10 gene|C1420317|[gngm]|["SOX10"-tx-1-"SOX10"-noun-0]|TX|3/5|
text_000N_15051|MMI|3.60|Melanoma Cell|C1513095|[cell]|["Melanoma Cell"-tx-1-"melanoma cells"-noun-0]|TX|22/14|
text_000N_15051|MMI|3.57|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|9/9|
text_000N_15051|MMI|3.57|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|9/9|
<<<<< MMI
>>>>> MMI
text_000N_47392|AA|miR-21|MicroRNA-21|3|6|3|11|18:6
text_000N_47392|MMI|5.18|MIR21 gene|C1537719|[gngm]|["microRNA 21"-tx-1-"MicroRNA-21"-noun-0]|TX|5/11|
text_000N_47392|MMI|3.64|Cardiovascular Diseases|C0007222|[dsyn]|["Cardiovascular Disease"-tx-1-"cardiovascular disease"-noun-0]|TX|40/22|
text_000N_47392|MMI|3.57|Contribution|C1880177|[acty]|["Contribute"-tx-1-"contribute"-verb-0]|TX|26/10|
<<<<< MMI
>>>>> MMI
text_000N_15074|MMI|5.18|Hereditary Diseases|C0019247|[dsyn]|["Genetic Disease"-tx-1-"genetic disease"-noun-0]|TX|24/15|
text_000N_15074|MMI|5.18|Tuberous Sclerosis|C0041341|[neop]|["Sclerosis, Tuberous"-tx-1-"Tuberous Sclerosis"-noun-0]|TX|3/18|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|9/9|
text_000N_47334|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|9/9|
text_000N_47334|MMI|3.59|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|19/6|
text_000N_47334|MMI|3.59|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|19/6|
text_000N_47334|MMI|3.59|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|19/6|
text_000N_47334|MMI|3.50|BRAF gene|C0812241|[gngm]|["BRAF"-tx-1-"BRAF"-noun-0]|TX|4/4|
text_000N_47334|MMI|3.50|BRAF protein, human|C1259929|[aapp,bacs]|["BRAF"-tx-1-"BRAF"-noun-0]|TX|4/4|
text_000N_47334|MMI|3.50|Proto-Oncogene Proteins B-raf|C0104940|[aapp,enzy]|["b-raf"-tx-1-"BRAF"-noun-0]|TX|4/4|
text_000N_47334|MMI|3.45|Melanocytic neoplasm|C1302746|[neop]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|29/8|
text_000N_47334|MMI|3.45|Melanoma Pathway|C2984289|[ftcn]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|29/8|
text_000N_47334|MMI|3.45|NCI CTEP SDC Melanoma Sub-Category Terminology|C3539018|[inpr]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|29/8|
text_000N_47334|MMI|3.45|melanoma|C0025202|[neop]|["MELANOMA"-tx-1-"melanoma"-noun-0]|TX|29/8|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.58|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|9/7|
text_000N_47289|MMI|3.47|RISC-loading complex|C2753334|[celc]|["RISC-loading complex"-tx-1-"RISC loading complex"-noun-0]|TX|21/20|
text_000N_47289|MMI|3.42|DICER1 gene|C1333218|[gngm]|["Dicer"-tx-1-"Dicer"-noun-0]|TX|3/5|
text_000N_47289|MMI|3.42|DICER1 protein, human|C1309483|[aapp,enzy]|["Dicer"-tx-1-"Dicer"-noun-0]|TX|3/5|
text_000N_47289|MMI|3.42|DICER1 wt Allele|C1707615|[gngm]|["DICER"-tx-1-"Dicer"-noun-0]|TX|3/5|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|12/4|
text_000N_47349|MMI|5.18|JARID2 gene|C1416528|[gngm]|["JARID2"-tx-1-"Jarid2"-noun-0]|TX|5/6|
text_000N_47349|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|12/4|
text_000N_47349|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_47349|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_47349|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_47349|MMI|3.45|Embryonic Development|C0013936|[ortf]|["Embryo Development"-tx-1-"embryo development"-noun-0]|TX|33/18|
text_000N_47349|MMI|3.43|Early|C1279919|[tmco]|["Early"-tx-1-"early"-adj-0]|TX|27/5|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|3.68|XRN1 gene|C1538124|[gngm]|["XRN1"-tx-1-"Xrn1"-noun-0]|TX|15/4|
text_000N_47406|MMI|3.68|XRN1 protein, human|C1173619|[aapp,enzy]|["XRN1"-tx-1-"Xrn1"-noun-0]|TX|15/4|
text_000N_47406|MMI|3.55|Component (part)|C1705248|[cnce]|["Component"-tx-1-"component"-noun-0]|TX|22/9|
text_000N_47406|MMI|3.55|Component object|C0449432|[mnob]|["Component"-tx-1-"component"-noun-0]|TX|22/9|
text_000N_47406|MMI|3.55|Drug Product Component|C5552856|[phsu]|["Component"-tx-1-"component"-noun-0]|TX|22/9|
text_000N_47406|MMI|3.50|Exonuclease|C0015296|[aapp,enzy]|["Exonuclease"-tx-1-"exonuclease"-noun-0]|TX|3/11|
text_000N_47406|MMI|3.43|Human body|C0242821|[humn]|["bodies"-tx-1-"bodies"-noun-0]|TX|41/6|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Intraoperative Radiation Therapy|C0338240|[topp]|["Intraoperative Radiotherapy"-tx-1-"intraoperative radiotherapy"-noun-0]|TX|3/27|
text_000N_47320|MMI|3.58|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|31/4,50/2|
text_000N_47320|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|53/12|
text_000N_47320|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|53/12|
text_000N_47320|MMI|3.56|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|53/12|
text_000N_47320|MMI|3.56|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|53/12|
text_000N_47320|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.68|Organization Name|C1552679|[inpr]|["Organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.68|Organization administrative structures|C0029246|[orgt]|["Organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.68|Organized|C1300196|[ftcn]|["Organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.68|Physiologic Organization|C0029237|[phsf]|["Organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.68|Professional Organization or Group|C1522486|[prog]|["Organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.68|organizational|C0220885|[qlco]|["organization"-tx-1-"organization"-noun-0]|TX|54/12|
text_000N_43331|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43331|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43331|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43331|MMI|3.50|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|47/6|
text_000N_43331|MMI|3.50|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|47/6|
text_000N_43331|MMI|3.43|Data Transcription|C4554264|[acty]|["transcription"-tx-1-"transcription"-noun-0]|TX|20/13|
text_000N_43331|MMI|3.43|Factory|C0442614|[mnob]|["factories"-tx-1-"factories"-noun-0]|TX|34/9|
text_000N_43331|MMI|3.43|Transcription, Genetic|C0040649|[genf]|["Transcription"-tx-1-"transcription"-noun-0]|TX|20/13|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.75|RNA, Guide|C0082774|[bacs,nnon]|["Guide RNA"-tx-1-"guide RNA"-noun-0]|TX|11/9|
text_000N_47450|MMI|3.64|Human cells|C0427861|[lbtr]|["Human cells"-tx-1-"human cells"-noun-0]|TX|34/11|
text_000N_47450|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|26/4|
text_000N_47450|MMI|3.48|Singular|C0205171|[qnco]|["SINGLE"-tx-1-"single"-adj-0]|TX|4/6|
text_000N_47450|MMI|3.48|Unmarried|C0087136|[fndg]|["single"-tx-1-"single"-adj-0]|TX|4/6|
text_000N_47450|MMI|3.48|Unmarried person|C0037179|[popg]|["Single"-tx-1-"single"-adj-0]|TX|4/6|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|3.68|Protein Overexpression|C1514559|[genf]|["Overexpression"-tx-1-"overexpression"-noun-0]|TX|10/14|
text_000N_43386|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|25/15|
text_000N_43386|MMI|3.56|Better|C0332272|[qlco]|["Better"-tx-1-"better"-adj-0]|TX|41/6|
text_000N_43386|MMI|3.56|Better than Others|C4522046|[fndg]|["Better"-tx-1-"better"-adj-0]|TX|41/6|
text_000N_43386|MMI|3.56|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|56/8|
text_000N_43386|MMI|3.56|Improved - answer to question|C4084203|[fndg]|["Better"-tx-1-"better"-adj-0]|TX|41/6|
text_000N_43386|MMI|3.56|Patients|C0030705|[podg]|["*^patient"-tx-1-"patient"-noun-0]|TX|48/7|
text_000N_43386|MMI|3.56|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|56/8|
text_000N_43386|MMI|3.50|METTL1 gene|C1417124|[gngm]|["METTL1"-tx-1-"METTL1"-noun-0]|TX|3/6|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Megakaryocytopoiesis|C0522310|[ortf]|["Megakaryopoiesis"-tx-1-"megakaryopoiesis"-noun-0]|TX|30/16|
text_000N_40886|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_40886|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_40886|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_40886|MMI|3.46|GTF2I gene|C1415347|[gngm]|["TFII-I"-tx-1-"TFII-I"-noun-0]|TX|20/6|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|lucatumumab|C2980061|[aapp,imft,phsu]|["LUCATUMUMAB"-tx-1-"lucatumumab"-noun-0]|TX|5/11|
text_000N_40913|MMI|3.59|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|17/4|
text_000N_40913|MMI|3.59|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|17/4|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Contain (action)|C2700400|[acty]|["Contains"-tx-1-"contains"-verb-0]|TX|25/8|
text_000N_40972|MMI|5.18|Containing (qualifier)|C0332256|[ftcn]|["contains"-tx-1-"contains"-verb-0]|TX|25/8|
text_000N_40972|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Human cells|C0427861|[lbtr]|["Human cells"-tx-1-"human cells"-noun-0]|TX|72/11|
text_000N_40972|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Treating|C1522326|[ftcn]|["Treated"-tx-1-"treated"-verb-0]|TX|64/7|
text_000N_40972|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_40972|MMI|3.68|Data Set|C0150098|[inpr]|["Dataset"-tx-1-"data set"-noun-0]|TX|16/8|
text_000N_40972|MMI|3.68|Silo (dataset)|C1706233|[inpr]|["Dataset"-tx-1-"data set"-noun-0]|TX|16/8|
text_000N_40972|MMI|3.56|Data|C1511726|[idcn]|["Data"-tx-1-"data"-noun-0]|TX|50/4|
text_000N_40972|MMI|3.56|Data (eukaryote)|C3714741|[euka]|["Data"-tx-1-"data"-noun-0]|TX|50/4|
text_000N_40972|MMI|3.56|Data call receiving device|C3245479|[medd]|["data"-tx-1-"data"-noun-0]|TX|50/4|
text_000N_40972|MMI|3.46|Gene Expression|C0017262|[genf]|["Gene Expression"-tx-1-"gene expression"-noun-0]|TX|34/15|
text_000N_40972|MMI|3.46|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"gene expression"-noun-0]|TX|34/15|
text_000N_40972|MMI|3.43|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|59/4|
text_000N_40972|MMI|3.43|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|59/4|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.68|HOXA11 gene|C1415654|[gngm]|["HOXA11"-tx-1-"HOXA11"-noun-0]|TX|15/6|
text_000N_47377|MMI|3.68|Homeobox Protein Hox-A11|C3273497|[aapp]|["HOXA11"-tx-1-"HOXA11"-noun-0]|TX|15/6|
text_000N_47377|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|22/15|
text_000N_47377|MMI|3.64|Endometrial Diseases|C1720816|[dsyn]|["Endometrial Disease"-tx-1-"endometrial disease"-noun-0]|TX|38/19|
text_000N_47377|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.64|DNA Repair|C0012899|[genf]|["DNA Repair"-tx-1-"DNA repair"-noun-0]|TX|32/10|
text_000N_47435|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
text_000N_47435|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
text_000N_47435|MMI|3.53|DNA-Directed DNA Polymerase|C0012892|[aapp,enzy]|["DNA Polymerase"-tx-1-"DNA polymerase"-noun-0]|TX|3/14|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|doxorubicin|C0013089|[antb,orch]|["Doxorubicine"-tx-1-"Doxorubicin"-noun-0]|TX|3/11|
text_000N_47304|MMI|3.82|Cardiotoxicity|C0876994|[inpo]|["Cardiotoxicity"-tx-1-"cardiotoxic"-adj-0]|TX|15/11|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Oxidative Stress|C0242606|[comd]|["Oxidative Stress"-tx-1-"oxidative stress"-noun-0]|TX|3/16|
text_000N_43275|MMI|3.57|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|20/8|
text_000N_43275|MMI|3.57|Expression (foundation metadata concept)|C3854321|[idcn]|["Expression"-tx-1-"expression"-noun-0]|TX|37/10|
text_000N_43275|MMI|3.57|Expression procedure|C0185117|[topp]|["Expression"-tx-1-"expression"-noun-0]|TX|37/10|
text_000N_43275|MMI|3.57|FOXO Family|C3899164|[aapp]|["FoxO"-tx-1-"FOXO"-noun-0]|TX|32/4|
text_000N_43275|MMI|3.57|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|20/8|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Viral|C0521026|[ftcn]|["viruses"-tx-1-"viruses"-noun-0]|TX|4/7|
text_000N_43358|MMI|5.18|Virus|C0042776|[virs]|["VIRUSES"-tx-1-"viruses"-noun-0]|TX|4/7|
text_000N_43358|MMI|3.57|Subacute thyroiditis|C0040149|[dsyn]|["Subacute Thyroiditis"-tx-1-"subacute thyroiditis"-noun-0]|TX|46/20|
text_000N_43358|MMI|3.54|Etiology|C1314792|[ftcn]|["Etiology"-tx-1-"etiology"-noun-0]|TX|28/8|
text_000N_43358|MMI|3.54|Etiology aspects|C0015127|[ftcn]|["etiology"-tx-1-"etiology"-noun-0]|TX|28/8|
text_000N_43358|MMI|3.54|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|40/5|
text_000N_43358|MMI|3.54|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|12/8|
text_000N_43358|MMI|3.54|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|12/8|
text_000N_43358|MMI|3.54|Science of Etiology|C1524003|[cnce]|["Etiology"-tx-1-"etiology"-noun-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|3.68|FBXW7 gene|C1333533|[gngm]|["FBW7"-tx-1-"Fbw7"-noun-0]|TX|11/4|
text_000N_40839|MMI|3.68|FBXW7 wt Allele|C1704938|[gngm]|["FBW7"-tx-1-"Fbw7"-noun-0]|TX|11/4|
text_000N_40839|MMI|3.57|Type A|C4264487|[clas]|["Type A"-tx-1-"a type"-noun-0]|TX|16/1,22/4|
text_000N_40839|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|3/7|
text_000N_40839|MMI|3.47|PRKN gene|C1418270|[gngm]|["E3 ubiquitin ligase"-tx-1-"E3 ubiquitin ligase"-noun-0]|TX|30/19|
text_000N_40839|MMI|3.47|ubiquitin-protein ligase|C0077678|[aapp,enzy]|["E3 Ubiquitin Ligase"-tx-1-"E3 ubiquitin ligase"-noun-0]|TX|30/19|
text_000N_40839|MMI|3.42|Kit Ligand, human|C3887684|[aapp,bacs]|["SCF"-tx-1-"SCF"-noun-0]|TX|18/3|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Ethyol|C0591467|[orch,phsu]|["Ethyol"-tx-1-"ethyol"-noun-0]|TX|118/6|
text_000N_40941|MMI|3.57|Finding of protein concentration, dipstick|C1304757|[lbtr]|["concentration protein"-tx-1-"concentration protein"-noun-0]|TX|9/13,26/7|
text_000N_40941|MMI|3.57|Protein concentration, test strip measurement|C0427716|[lbpr]|["concentration protein"-tx-1-"concentration protein"-noun-0]|TX|9/13,26/7|
text_000N_40941|MMI|3.56|Aftercare|C0001758|[hlca]|["After Administration"-tx-1-"after administration"-noun-0]|TX|50/5,60/14|
text_000N_40941|MMI|3.42|Hypothalamic inhibiting factor|C0301821|[horm,orch]|["HIF"-tx-1-"HIF"-noun-0]|TX|34/3|
text_000N_40941|MMI|3.42|Hypoxia Inducible Factor Family|C3811709|[aapp]|["HIF"-tx-1-"HIF"-noun-0]|TX|34/3|
text_000N_40941|MMI|3.42|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|41/8|
text_000N_40941|MMI|3.42|Prodrugs|C0033262|[chvf]|["Prodrug"-tx-1-"prodrug"-noun-0]|TX|97/7|
text_000N_40941|MMI|3.42|amifostine|C0015020|[orch,phsu]|["AMIFOSTINE"-tx-1-"amifostine"-noun-0]|TX|105/10|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Keutel syndrome|C1855607|[dsyn]|["KEUTEL SYNDROME"-tx-1-"Keutel syndrome"-noun-0]|TX|3/15|
text_000N_173104|MMI|3.75|Hereditary Diseases|C0019247|[dsyn]|["Genetic Disorder"-tx-1-"genetic disorder"-noun-0]|TX|28/16|
text_000N_173104|MMI|3.48|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|21/6|
text_000N_173104|MMI|3.48|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|21/6|
text_000N_173104|MMI|3.48|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|21/6|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|vemurafenib|C3192263|[orch,phsu]|["VEMURAFENIB"-tx-1-"vemurafenib"-noun-0]|TX|3/11|
text_000N_173151|MMI|3.64|Malignant neoplasm of thyroid|C0007115|[neop]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|24/14|
text_000N_173151|MMI|3.64|NCI CTEP SDC Thyroid Cancer Sub-Category Terminology|C3541337|[inpr]|["Thyroid Cancer"-tx-1-"thyroid cancer"-noun-0]|TX|24/14|
text_000N_173151|MMI|3.64|Papillary Thyroid Carcinoma Pathway|C2984307|[cnce]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|24/14|
text_000N_173151|MMI|3.64|Thyroid Neoplasm|C0040136|[neop]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|24/14|
text_000N_173151|MMI|3.64|Thyroid carcinoma|C0549473|[neop]|["Cancer, Thyroid"-tx-1-"thyroid cancer"-noun-0]|TX|24/14|
text_000N_173151|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|15/4|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|3.64|Carcinoma of lung|C0684249|[neop]|["LUNG CANCER"-tx-1-"lung cancer"-noun-0]|TX|57/11|
text_000N_173136|MMI|3.64|Malignant neoplasm of lung|C0242379|[neop]|["Lung Cancer"-tx-1-"lung cancer"-noun-0]|TX|57/11|
text_000N_173136|MMI|3.64|Primary malignant neoplasm of lung|C1306460|[neop]|["Lung cancer"-tx-1-"lung cancer"-noun-0]|TX|57/11|
text_000N_173136|MMI|3.62|Cancer Risk|C0596244|[qnco]|["Cancer Risk"-tx-1-"risk cancer"-noun-0]|TX|48/4,62/6|
text_000N_173136|MMI|3.57|Chest>Lung|C4037972|[blor]|["Lung"-tx-1-"lung"-noun-0]|TX|57/4|
text_000N_173136|MMI|3.57|Lung|C0024109|[bpoc]|["LUNG"-tx-1-"lung"-noun-0]|TX|57/4|
text_000N_173136|MMI|3.57|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-verb-0]|TX|48/4|
text_000N_173136|MMI|3.57|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-verb-0]|TX|48/4|
text_000N_173136|MMI|3.56|Radiation Oncology specialty|C0243005|[bmod]|["Radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|5/12|
text_000N_173136|MMI|3.56|Therapeutic radiology procedure|C1522449|[topp]|["RADIOTHERAPY"-tx-1-"radiotherapy"-noun-0]|TX|5/12|
text_000N_173136|MMI|3.56|radiotherapeutic|C0034619|[inpr]|["radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|5/12|
text_000N_173136|MMI|3.46|Hodgkin Disease|C0019829|[neop]|["HODGKIN DISEASE"-tx-1-"Hodgkin disease"-noun-0]|TX|22/15|
text_000N_173136|MMI|3.43|Increase|C0442805|[ftcn]|["increases"-tx-1-"increases"-noun-0]|TX|38/9|
text_000N_173136|MMI|3.43|Increased|C0205217|[qnco]|["Increases"-tx-1-"increases"-noun-0]|TX|38/9|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|HSD17B6 gene|C1537381|[gngm]|["oxidoreductase"-tx-1-"oxidoreductase"-noun-0]|TX|12/14|
text_000N_173230|MMI|5.18|MICAL1 gene|C1537694|[gngm]|["MICAL"-tx-1-"Mical"-noun-0]|TX|3/5|
text_000N_173230|MMI|5.18|Oxidoreductase|C0030016|[aapp,enzy]|["Oxidoreductase"-tx-1-"oxidoreductase"-noun-0]|TX|12/14|
text_000N_173230|MMI|5.18|Oxidoreductase (disposition)|C4521991|[qlco]|["Oxidoreductase"-tx-1-"oxidoreductase"-noun-0]|TX|12/14|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|RNA, Circular|C0073432|[nnon]|["circRNAs"-tx-1-"circRNAs"-noun-0]|TX|4/8|
text_000N_173087|MMI|5.18|ribonuclease R|C0658605|[aapp,enzy]|["RNase R"-tx-1-"RNase R"-noun-0]|TX|43/7|
text_000N_173087|MMI|3.59|Antimicrobial Susceptibility Result|C2827758|[lbtr]|["SUSCEPTIBLE"-tx-1-"susceptible"-adj-0]|TX|13/11|
text_000N_173087|MMI|3.59|Predisposition -- attribute|C0220898|[orga]|["Susceptible"-tx-1-"susceptible"-adj-0]|TX|13/11|
text_000N_173087|MMI|3.59|Susceptible|C0231204|[ftcn]|["Susceptible"-tx-1-"susceptible"-adj-0]|TX|13/11|
text_000N_173087|MMI|3.45|Catabolism|C0699900|[orgf]|["Degradation"-tx-1-"degradation"-noun-0]|TX|28/11|
text_000N_173087|MMI|3.45|Material Degradation|C1881707|[fndg]|["Degradation"-tx-1-"degradation"-noun-0]|TX|28/11|
text_000N_173087|MMI|3.45|degradation aspects|C0243125|[orgf]|["degradation"-tx-1-"degradation"-noun-0]|TX|28/11|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Hypercholesterolemia|C0020443|[dsyn]|["High cholesterol"-tx-1-"high cholesterol"-noun-0]|TX|51/16|
text_000N_173183|MMI|5.18|Hypercholesterolemia result|C1522133|[fndg]|["High Cholesterol"-tx-1-"high cholesterol"-noun-0]|TX|51/16|
text_000N_173183|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|42/2|
text_000N_173183|MMI|5.18|Therapeutic procedure|C0087111|[topp]|["TREAT"-tx-1-"treat"-verb-0]|TX|45/5|
text_000N_173183|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|42/2|
text_000N_173183|MMI|5.18|Treating|C1522326|[ftcn]|["Treat"-tx-1-"treat"-verb-0]|TX|45/5|
text_000N_173183|MMI|5.18|Treatment intent|C1292734|[ftcn]|["treat"-tx-1-"treat"-verb-0]|TX|45/5|
text_000N_173183|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|37/4|
text_000N_173183|MMI|5.18|telomestatin|C0968242|[orch]|["telomestatin"-tx-1-"telomestatin"-noun-0]|TX|3/12|
text_000N_173183|MMI|3.63|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|32/4|
text_000N_173183|MMI|3.63|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|32/4|
text_000N_173183|MMI|3.48|3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (disposition)|C4521898|[qlco]|["Statin"-tx-1-"statin"-noun-0]|TX|25/6|
text_000N_173183|MMI|3.48|EEF1A2 gene|C1414273|[gngm]|["statin"-tx-1-"statin"-noun-0]|TX|25/6|
text_000N_173183|MMI|3.48|Hydroxymethylglutaryl-CoA Reductase Inhibitors|C0360714|[orch,phsu]|["Statin"-tx-1-"statin"-noun-0]|TX|25/6|
text_000N_173183|MMI|3.48|New|C0205314|[qlco]|["Novel"-tx-1-"novel"-adj-0]|TX|19/5|
text_000N_173183|MMI|3.48|literary novel|C0679622|[inpr]|["novel"-tx-1-"novel"-adj-0]|TX|19/5|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.68|Aneuploidy|C0002938|[comd]|["Aneuploidy"-tx-1-"aneuploidy"-noun-0]|TX|10/10|
text_000N_173120|MMI|3.59|Non-invasive|C0205303|[ftcn]|["Non-invasive"-tx-1-"non-invasive"-noun-0]|TX|38/12|
text_000N_173120|MMI|3.59|Prenatal Testing|C1456692|[hlca]|["Prenatal Testing"-tx-1-"prenatal testing"-noun-0]|TX|51/16|
text_000N_173120|MMI|3.55|Detected (finding)|C0442726|[fndg]|["Detected"-tx-1-"detected"-verb-1]|TX|24/8|
text_000N_173120|MMI|3.55|Detection|C1511790|[topp]|["Detected"-tx-1-"detected"-verb-0]|TX|24/8|
text_000N_173120|MMI|3.50|Fetal|C0521457|[ftcn]|["Foetal"-tx-1-"fetal"-adj-0]|TX|4/5|
text_000N_173120|MMI|3.50|Fetus|C0015965|[emst]|["Fetal"-tx-1-"fetal"-adj-0]|TX|4/5|
text_000N_173120|MMI|3.50|Prenatal care|C0033052|[hlca]|["Fetal"-tx-1-"fetal"-adj-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_15098|MMI|5.18|Chlorotoxin|C0293227|[aapp,hops,phsu]|["CHLOROTOXIN"-tx-1-"chlorotoxin"-noun-0]|TX|3/11|
text_000N_15098|MMI|5.18|Peptides|C0030956|[aapp,phsu]|["Peptide"-tx-1-"peptide"-noun-0]|TX|17/7|
<<<<< MMI
>>>>> MMI
text_000N_15123|MMI|3.75|Cerebrovascular accident|C0038454|[dsyn]|["Stroke Syndrome"-tx-1-"stroke syndrome"-noun-0]|TX|12/15|
text_000N_15123|MMI|3.75|Paralytic stroke|C1263853|[dsyn]|["Stroke syndrome"-tx-1-"stroke syndrome"-noun-0]|TX|12/15|
text_000N_15123|MMI|3.68|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|37/7|
text_000N_15123|MMI|3.50|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|30/6|
text_000N_15123|MMI|3.50|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|30/6|
text_000N_15123|MMI|3.50|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|30/6|
text_000N_15123|MMI|3.48|Airplanes|C0683901|[mnob]|["aeroplane"-tx-1-"airplane"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_15147|MMI|3.68|4f|C0450379|[inpr]|["4f"-tx-1-"4F"-noun-0]|TX|5/2|
text_000N_15147|MMI|3.63|Peptides|C0030956|[aapp,phsu]|["Peptide"-tx-1-"peptide"-noun-0]|TX|24/7|
text_000N_15147|MMI|3.50|Per Liter|C3642217|[qnco]|["/L"-tx-1-"L"-noun-0]|TX|3/1|
text_000N_15147|MMI|3.48|APOE gene|C1412481|[gngm]|["APOE"-tx-1-"apoE"-noun-0]|TX|11/4|
text_000N_15147|MMI|3.48|ApoE protein, human|C4308468|[aapp,bacs]|["Apo-E"-tx-1-"apoE"-noun-0]|TX|11/4|
text_000N_15147|MMI|3.48|Apolipoprotein E|C0003595|[aapp,bacs]|["ApoE"-tx-1-"apoE"-noun-0]|TX|11/4|
text_000N_15147|MMI|3.48|Apolipoproteins E measurement (procedure)|C0523511|[lbpr]|["APOE"-tx-1-"apoE"-noun-0]|TX|11/4|
text_000N_15147|MMI|3.48|mimetics|C0920591|[bmod]|["mimetic"-tx-1-"mimetic"-adj-0]|TX|16/7|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|3.64|Colorectal Cancer Pathway|C2984278|[cnce]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|34/17|
text_000N_173167|MMI|3.64|Colorectal Carcinoma|C0009402|[neop]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|34/17|
text_000N_173167|MMI|3.64|Malignant neoplasm of colon and/or rectum|C4722085|[neop]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|34/17|
text_000N_173167|MMI|3.64|NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|C3542412|[inpr]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|34/17|
text_000N_173167|MMI|3.59|Inactivation|C0544461|[ftcn]|["Inactivation"-tx-1-"inactivation"-noun-0]|TX|5/12|
text_000N_173167|MMI|3.57|Assisted (qualifier value)|C1269765|[qlco]|["Help"-tx-1-"help"-verb-0]|TX|26/4|
text_000N_173167|MMI|3.57|Help document|C1552861|[inpr]|["help"-tx-1-"help"-verb-0]|TX|26/4|
text_000N_173167|MMI|3.45|CYLD gene|C1413850|[gngm]|["CYLD"-tx-1-"CYLD"-noun-0]|TX|21/4|
text_000N_173167|MMI|3.45|CYLD protein, human|C2985250|[aapp,enzy]|["CYLD"-tx-1-"CYLD"-noun-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_15172|MMI|5.18|apremilast|C1678805|[orch,phsu]|["APREMILAST"-tx-1-"Apremilast"-noun-0]|TX|3/10|
text_000N_15172|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_15172|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_15172|MMI|3.46|Behcet Syndrome|C0004943|[dsyn]|["Beh√ßet Syndrome"-tx-1-"Behcet syndrome"-noun-0]|TX|28/6,37/8|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Nerinetide|C5418474|[orch,phsu]|["NERINETIDE"-tx-1-"nerinetide"-noun-0]|TX|3/10|
text_000N_173291|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173291|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173291|MMI|3.48|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischaemic stroke"-noun-0]|TX|28/16|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|DNA Methylation|C0376452|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_47363|MMI|5.18|DNA Methylation Analysis|C1880239|[mbrt]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_47363|MMI|5.18|DNA Methylation [PE]|C3536933|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_47363|MMI|3.64|Gene Expression|C0017262|[genf]|["Gene Expression"-tx-1-"gene expression"-noun-0]|TX|70/15|
text_000N_47363|MMI|3.64|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"gene expression"-noun-0]|TX|70/15|
text_000N_47363|MMI|3.61|Epigenetic Process|C1516924|[genf]|["Epigenetic Modification"-tx-1-"epigenetic modification"-noun-0]|TX|22/23|
text_000N_47363|MMI|3.60|covalent chromatin modification|C1156198|[genf]|["chromatin modification"-tx-1-"modification chromatin"-noun-0]|TX|33/12,49/9|
text_000N_47363|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|59/7|
text_000N_47363|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|59/7|
text_000N_47363|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|19/2|
text_000N_47363|MMI|3.43|Chromatin|C0008546|[aapp]|["Chromatin"-tx-1-"chromatin"-noun-0]|TX|49/9|
text_000N_47363|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|19/2|
text_000N_47363|MMI|3.43|chromatin location|C1325550|[celc]|["chromatin"-tx-1-"chromatin"-noun-0]|TX|49/9|
text_000N_47363|MMI|3.43|study of epigenetics|C1655731|[bmod]|["Epigenetic"-tx-1-"epigenetic"-adj-0]|TX|22/10|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Depressed mood|C0344315|[mobd]|["depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depression - recess|C4085311|[qlco]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depression Scale (BASC-2)|C4049644|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depression Subordinate Domain|C4084909|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depression Visual Analogue Scale|C4553827|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depression motion|C0460137|[ftcn]|["Depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Depressive disorder|C0011581|[mobd]|["Depression"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|5.18|Mental Depression|C0011570|[mobd]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|3/10|
text_000N_173245|MMI|3.59|Brain Neoplasms|C0006118|[neop]|["Tumour of brain"-tx-1-"of brain tumor"-noun-0]|TX|45/14|
text_000N_173245|MMI|3.57|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|14/15|
text_000N_173245|MMI|3.57|Prognosis bad|C0278252|[fndg]|["Poor prognosis"-tx-1-"poor prognosis"-noun-0]|TX|30/14|
text_000N_173245|MMI|3.54|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|60/8|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.61|MicroRNAs|C1101610|[bacs,nnon]|["miRNAs"-tx-1-"miRNAs"-noun-0]|TX|32/6|
text_000N_173260|MMI|3.60|Blood^Patient|C5187159|[bdsu]|["Blood^Patient"-tx-1-"patients blood"-noun-0]|TX|54/8,64/5|
text_000N_173260|MMI|3.57|Detected (finding)|C0442726|[fndg]|["Detected"-tx-1-"detected"-verb-0]|TX|42/8|
text_000N_173260|MMI|3.57|Detection|C1511790|[topp]|["Detected"-tx-1-"detected"-verb-0]|TX|42/8|
text_000N_173260|MMI|3.50|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|4/19|
text_000N_173260|MMI|3.50|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|4/19|
text_000N_173260|MMI|3.47|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-adj-0]|TX|24/7|
text_000N_173260|MMI|3.47|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-adj-0]|TX|24/7|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Empyema, Subdural|C0038539|[dsyn]|["Empyema, Subdural"-tx-1-"subdural empyema"-noun-0]|TX|3/16|
text_000N_43235|MMI|3.57|Complication|C0009566|[patf]|["Complication"-tx-1-"complication"-noun-0]|TX|22/12|
text_000N_43235|MMI|3.57|Complication (attribute)|C2362589|[idcn]|["Complication"-tx-1-"complication"-noun-0]|TX|22/12|
text_000N_43235|MMI|3.44|Sinusitis|C0037199|[dsyn]|["SINUSITIS"-tx-1-"sinusitis"-noun-0]|TX|38/9|
text_000N_43235|MMI|3.44|Sinusitis, CTCAE|C4553555|[fndg]|["Sinusitis"-tx-1-"sinusitis"-noun-0]|TX|38/9|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|NADPH Oxidase 5|C4319656|[aapp]|["NADPH Oxidase 5"-tx-1-"NADPH oxidase 5"-noun-0]|TX|3/15|
text_000N_40999|MMI|5.18|NOX5 gene|C1423017|[gngm]|["NADPH OXIDASE 5"-tx-1-"NADPH oxidase 5"-noun-0]|TX|3/15|
text_000N_40999|MMI|3.59|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|19/9|
text_000N_40999|MMI|3.59|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|19/9|
text_000N_40999|MMI|3.59|Rodent|C0035804|[mamm]|["Rodents"-tx-1-"rodents"-noun-0]|TX|32/7|
<<<<< MMI
>>>>> MMI
text_000N_43303|AA|HRQoL|health-related quality of life|1|5|9|30|141:5
text_000N_43303|MMI|5.18|Monitor Device|C0181904|[medd]|["Monitors"-tx-1-"monitors"-noun-0]|TX|88/8|
text_000N_43303|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|59/4|
text_000N_43303|MMI|3.68|5 Days|C1442466|[tmco]|["5D"-tx-1-"5D"-noun-0]|TX|45/2|
text_000N_43303|MMI|3.68|Equal|C0205163|[qlco]|["EQ"-tx-1-"EQ"-noun-0]|TX|42/2|
text_000N_43303|MMI|3.68|Equivalent Weight|C0439185|[qnco]|["eq"-tx-1-"EQ"-noun-0]|TX|42/2|
text_000N_43303|MMI|3.68|Instrument - device|C0348000|[mnob]|["Instrument"-tx-1-"instrument"-noun-0]|TX|72/10|
text_000N_43303|MMI|3.68|Patient-Reported Survey Instrument|C4554108|[inpr]|["instrument"-tx-1-"instrument"-noun-0]|TX|72/10|
text_000N_43303|MMI|3.65|Health evaluation|C0175637|[hlca]|["Health assessment"-tx-1-"Health Assessment"-noun-0]|TX|23/17|
text_000N_43303|MMI|3.65|Medical Examination|C0582103|[hlca]|["Health Assessment"-tx-1-"Health Assessment"-noun-0]|TX|23/17|
text_000N_43303|MMI|3.64|Health-Related Quality Of Life|C4279947|[idcn]|["Health-Related Quality Of Life"-tx-1-"health-related quality of life"-noun-0]|TX|109/30|
text_000N_43303|MMI|3.63|Assessed|C1516048|[acty]|["Assessment"-tx-1-"assessment"-noun-0]|TX|181/10|
text_000N_43303|MMI|3.63|Evaluation procedure|C1261322|[hlca]|["Assessment"-tx-1-"assessment"-noun-0]|TX|181/10|
text_000N_43303|MMI|3.50|Simple|C0205352|[qlco]|["Simple"-tx-1-"simple"-adj-0]|TX|65/6|
text_000N_43303|MMI|3.48|+5|C0728893|[qnco]|["+5"-tx-1-"5"-integer-0]|TX|170/1|
text_000N_43303|MMI|3.48|5+|C5425955|[fndg]|["5+"-tx-1-"5"-integer-0]|TX|170/1|
text_000N_43303|MMI|3.48|>5|C0439084|[qnco]|[">5"-tx-1-"5"-integer-0]|TX|170/1|
text_000N_43303|MMI|3.48|PSA Level Less than Five|C4084795|[fndg]|["<5"-tx-1-"5"-integer-0]|TX|170/1|
text_000N_43303|MMI|3.48|Question (inquiry)|C1522634|[inpr]|["Question"-tx-1-"question"-noun-0]|TX|172/8|
text_000N_43303|MMI|3.46|DIMENSION (pharmacologic substance)|C4761422|[orch,phsu]|["DIMENSION"-tx-1-"Dimension"-noun-0]|TX|13/9|
text_000N_43303|MMI|3.46|Dimensions|C0439534|[qnco]|["Dimension"-tx-1-"Dimension"-noun-0]|TX|13/9|
text_000N_43303|MMI|3.46|EuroQOL (assessment scale)|C0451150|[inpr]|["EuroQOL"-tx-1-"EuroQol"-noun-0]|TX|3/7|
text_000N_43303|MMI|3.43|Chronic disease|C0008679|[dsyn]|["Chronic Disease"-tx-1-"chronic disease"-noun-0]|TX|151/15|
text_000N_43303|MMI|3.43|Widespread Disease|C0849867|[dsyn]|["General disease"-tx-1-"general disease"-noun-0]|TX|101/7,159/7|
text_000N_43303|MMI|3.42|Chronic graft-versus-host disease|C0867389|[dsyn]|["Chronic"-tx-1-"chronic"-noun-0]|TX|151/7|
text_000N_43303|MMI|3.42|General medical service|C3812897|[hlca]|["General"-tx-1-"general"-noun-0]|TX|101/7|
text_000N_43303|MMI|3.42|Generalized|C0205246|[spco]|["General"-tx-1-"general"-noun-0]|TX|101/7|
text_000N_43303|MMI|3.42|Safety Reporting Documentation|C3891294|[inpr]|["General"-tx-1-"general"-noun-0]|TX|101/7|
text_000N_43303|MMI|3.42|US Military Commissioned Officer O10|C4521767|[clas]|["General"-tx-1-"general"-noun-0]|TX|101/7|
text_000N_43303|MMI|3.42|chronic|C0205191|[tmco]|["CHRONIC"-tx-1-"chronic"-noun-0]|TX|151/7|
<<<<< MMI
>>>>> MMI
text_000N_14856|MMI|5.18|vortioxetine|C3661282|[orch,phsu]|["VORTIOXETINE"-tx-1-"vortioxetine"-noun-0]|TX|3/12|
text_000N_14856|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|16/9,30/9|
text_000N_14856|MMI|3.43|Depressed mood|C0344315|[mobd]|["depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depression - recess|C4085311|[qlco]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depression Scale (BASC-2)|C4049644|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depression Subordinate Domain|C4084909|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depression Visual Analogue Scale|C4553827|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depression motion|C0460137|[ftcn]|["Depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Depressive disorder|C0011581|[mobd]|["Depression"-tx-1-"depression"-noun-0]|TX|43/10|
text_000N_14856|MMI|3.43|Mental Depression|C0011570|[mobd]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|43/10|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|palbociclib|C3853822|[orch,phsu]|["PALBOCICLIB"-tx-1-"palbociclib"-noun-0]|TX|3/11|
text_000N_47420|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47420|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47420|MMI|3.45|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|29/12|
text_000N_47420|MMI|3.45|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|29/12|
text_000N_47420|MMI|3.45|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|29/12|
text_000N_47420|MMI|3.45|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|29/12|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Thyroid Hormone Receptor|C0034843|[aapp,rcpt]|["Thyroid Hormone Receptors"-tx-1-"thyroid hormone receptors"-noun-0]|TX|3/25|
text_000N_47274|MMI|3.64|Brain Injuries|C0270611|[inpo]|["Brain Injury"-tx-1-"brain injury"-noun-0]|TX|42/12|
text_000N_47274|MMI|3.57|Change -- procedure|C4319952|[topp]|["Change"-tx-1-"change"-verb-0]|TX|29/6|
text_000N_47274|MMI|3.57|Changed status|C0443172|[qnco]|["change"-tx-1-"change"-verb-0]|TX|29/6|
text_000N_47274|MMI|3.57|Changing|C0392747|[ftcn]|["Change"-tx-1-"change"-verb-0]|TX|29/6|
text_000N_47274|MMI|3.57|Delta (difference)|C1705241|[qnco]|["Change"-tx-1-"change"-verb-0]|TX|29/6|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Cortical Spreading Depression|C0038050|[clna]|["Cortical Spreading Depression"-tx-1-"cortical spreading depression"-noun-0]|TX|5/29|
text_000N_40913|MMI|5.18|Following|C0332282|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|63/9|
text_000N_40913|MMI|5.18|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischemic stroke"-noun-0]|TX|73/15|
text_000N_40913|MMI|5.18|Status post|C0231290|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|63/9|
text_000N_40913|MMI|3.57|Ischemic|C0475224|[ftcn]|["Ischemic"-tx-1-"ischemic"-adj-0]|TX|45/8|
text_000N_40913|MMI|3.57|Specimen Appearance Assessment|C5553941|[lbpr]|["APPEAR"-tx-1-"appear"-verb-0]|TX|35/6|
text_000N_40913|MMI|3.57|TSPAN33 gene|C1823520|[gngm]|["PENUMBRA"-tx-1-"penumbra"-noun-0]|TX|54/8|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|selumetinib|C2980074|[orch,phsu]|["SELUMETINIB"-tx-1-"Selumetinib"-noun-0]|TX|3/11|
text_000N_173199|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173199|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173199|MMI|3.50|Low grade glioma|C1997217|[neop]|["Low Grade Glioma"-tx-1-"low-grade glioma"-noun-0]|TX|29/16|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|adalimumab|C1122087|[aapp,imft,phsu]|["ADALIMUMAB"-tx-1-"adalimumab"-noun-0]|TX|3/10|
text_000N_173276|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173276|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173276|MMI|3.48|Hidradenitis Suppurativa|C0162836|[dsyn]|["Hidradenitis Suppurativa"-tx-1-"hidradenitis suppurativa"-noun-0]|TX|28/24|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|panitumumab|C0879427|[aapp,imft,phsu]|["PANITUMUMAB"-tx-1-"Panitumumab"-noun-0]|TX|5/11|
text_000N_47289|MMI|3.55|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_47289|MMI|3.55|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_47289|MMI|3.50|Biliary Tract Cancer|C0750952|[neop]|["Cancer of Biliary Tract"-tx-1-"of biliary tract cancer"-noun-0]|TX|34/23|
text_000N_47289|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|58/8|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|ADARB2 gene|C1412217|[gngm]|["ADAR3"-tx-1-"Adar3"-noun-0]|TX|3/5|
text_000N_47304|MMI|5.18|Memory|C0025260|[menp]|["Memory"-tx-1-"memory"-noun-0]|TX|34/6|
text_000N_47304|MMI|5.18|Memory Device|C1706377|[mnob]|["Memory"-tx-1-"memory"-noun-0]|TX|34/6|
text_000N_47304|MMI|5.18|Memory G-code|C4282129|[inpr]|["Memory"-tx-1-"memory"-noun-0]|TX|34/6|
text_000N_47304|MMI|5.18|Memory observations|C0700327|[fndg]|["memory"-tx-1-"memory"-noun-0]|TX|34/6|
text_000N_47304|MMI|3.59|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_47304|MMI|3.59|Knowledge acquisition|C0013621|[edac]|["learning"-tx-1-"learning"-noun-0]|TX|21/8|
text_000N_47304|MMI|3.59|Learning|C0023185|[menp]|["Learning"-tx-1-"learning"-noun-0]|TX|21/8|
text_000N_47304|MMI|3.59|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
<<<<< MMI
>>>>> MMI
text_000N_47334|AA|TLR|Toll-like receptor|1|3|5|18|25:3
text_000N_47334|AA|TLRs|Toll-like receptors|1|4|5|19|25:4
text_000N_47334|MMI|5.18|Toll-like receptors|C0670896|[aapp,rcpt]|["Toll-Like Receptors"-tx-1-"Toll-like receptors"-noun-0]|TX|4/19|
text_000N_47334|MMI|3.59|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-verb-0]|TX|31/7|
text_000N_47334|MMI|3.55|Microorganism|C0445623|[orgm]|["Microbe"-tx-1-"microbes"-noun-0]|TX|42/8|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|10.42|NEFL gene|C1417668|[gngm]|["NFL"-tx-1-"NfL"-noun-0,"neurofilament light chain"-tx-1-"neurofilament light chain"-noun-0]|TX|3/3;8/25|
text_000N_47320|MMI|10.42|NEFL protein, human|C1455438|[aapp,bacs]|["NF-L"-tx-1-"NfL"-noun-0,"Neurofilament Light Chain"-tx-1-"neurofilament light chain"-noun-0]|TX|3/3;8/25|
text_000N_47320|MMI|5.18|NEFL wt Allele|C2981619|[gngm]|["NFL"-tx-1-"NfL"-noun-0]|TX|3/3|
text_000N_47320|MMI|5.18|Neurofilament-L|C1518285|[celc]|["NF-L"-tx-1-"NfL"-noun-0]|TX|3/3|
text_000N_47320|MMI|3.57|Biological Markers|C0005516|[clna]|["Biomarker"-tx-1-"biomarker"-noun-0]|TX|37/9|
text_000N_47320|MMI|3.44|Nerve Degeneration|C0027746|[comd]|["Neurodegeneration"-tx-1-"neurodegeneration"-noun-0]|TX|50/17|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|30/5|
text_000N_47349|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|36/15|
text_000N_47349|MMI|3.68|Characteristics|C1521970|[qlco]|["Features"-tx-1-"features"-noun-0]|TX|13/8|
text_000N_47349|MMI|3.50|Chromatin|C0008546|[aapp]|["Chromatin"-tx-1-"chromatin"-noun-0]|TX|3/9|
text_000N_47349|MMI|3.50|chromatin location|C1325550|[celc]|["chromatin"-tx-1-"chromatin"-noun-0]|TX|3/9|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.64|Aurora Kinase B|C1439287|[aapp,enzy]|["Kinase, Aurora B"-tx-1-"aurora B kinase"-noun-0]|TX|30/15|
text_000N_47392|MMI|3.63|RNF2 gene|C1419419|[gngm]|["RING1B"-tx-1-"ring1B"-noun-0]|TX|71/6|
text_000N_47392|MMI|3.63|RNF2 protein, human|C1455461|[aapp,bacs]|["RING1b"-tx-1-"ring1B"-noun-0]|TX|71/6|
text_000N_47392|MMI|3.63|RNF2 wt Allele|C4723865|[gngm]|["RING1B"-tx-1-"ring1B"-noun-0]|TX|71/6|
text_000N_47392|MMI|3.55|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_47392|MMI|3.55|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_47392|MMI|3.48|Polycomb|C0083956|[aapp,bacs]|["Polycomb"-tx-1-"polycomb"-noun-0]|TX|54/8|
text_000N_47392|MMI|3.48|Polycomb-Group Proteins|C1623167|[aapp,bacs]|["Polycomb"-tx-1-"polycomb"-noun-0]|TX|54/8|
text_000N_47392|MMI|3.48|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|63/7|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|4.25|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["LONG NON-CODING RNA"-tx-1-"long non coding RNAs"-noun-0]|TX|4/20|
text_000N_47406|MMI|4.25|RNA, Long Untranslated|C3494264|[bacs,nnon]|["RNA, Long Non-Coding"-tx-1-"long non coding RNAs"-noun-0]|TX|4/20|
text_000N_47406|MMI|3.98|Protein coding gene|C3839127|[gngm]|["Protein coding gene"-tx-1-"protein coding genes"-noun-0]|TX|53/20|
text_000N_47406|MMI|3.68|Conserved Sequence|C0009802|[nusq]|["Conserved Sequence"-tx-1-"conserved sequence"-noun-0]|TX|28/9,41/8|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|CTCF gene|C1422163|[gngm]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|4/4|
text_000N_43331|MMI|5.18|CTCF protein, human|C1456335|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|4/4|
text_000N_43331|MMI|5.18|CTCFL gene|C1424110|[gngm]|["BORIS"-tx-1-"BORIS"-noun-0]|TX|13/5|
text_000N_43331|MMI|5.18|CTCFL wt Allele|C3812165|[gngm]|["BORIS"-tx-1-"BORIS"-noun-0]|TX|13/5|
text_000N_43331|MMI|5.18|CTGF protein, human|C1137457|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|4/4|
text_000N_43331|MMI|5.18|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|53/6|
text_000N_43331|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|53/6|
text_000N_43331|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|53/6|
text_000N_43331|MMI|3.57|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|31/6|
text_000N_43331|MMI|3.57|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|31/6|
text_000N_43331|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|19/8|
text_000N_43331|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|19/8|
text_000N_43331|MMI|3.57|Regulation|C0851285|[gora]|["Regulation"-tx-1-"regulation"-noun-0]|TX|38/10|
text_000N_43331|MMI|3.57|Regulation of biological process|C1327622|[biof]|["Regulation"-tx-1-"regulation"-noun-0]|TX|38/10|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|RNA, Circular|C0073432|[nnon]|["circRNAs"-tx-1-"circRNAs"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|baricitinib|C4044947|[orch,phsu]|["BARICITINIB"-tx-1-"baricitinib"-noun-0]|TX|3/11|
text_000N_47435|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47435|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47435|MMI|3.48|Rheumatoid Arthritis|C0003873|[dsyn]|["RHEUMATOID ARTHRITIS"-tx-1-"rheumatoid arthritis"-noun-0]|TX|29/20|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.81|Magnetic Resonance Imaging|C0024485|[diap]|["Imaging, Magnetic Resonance"-tx-1-"magnetic resonance imaging"-noun-0]|TX|11/26|
text_000N_47377|MMI|3.61|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-noun-0]|TX|3/7|
text_000N_47377|MMI|3.61|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-noun-0]|TX|3/7|
text_000N_47377|MMI|3.61|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-noun-0]|TX|3/7|
text_000N_47377|MMI|3.54|Aspects of disease screening|C0220909|[ftcn]|["screening"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|Athletes|C0238703|[prog]|["Athletes"-tx-1-"athletes"-noun-0]|TX|86/8|
text_000N_47377|MMI|3.54|Athletes <Butterfly>|C3714533|[euka]|["Athletes"-tx-1-"athletes"-noun-0]|TX|86/8|
text_000N_47377|MMI|3.54|Before|C0332152|[tmco]|["Pre"-tx-1-"pre"-adj-0]|TX|55/3|
text_000N_47377|MMI|3.54|Before values|C0740175|[qlco]|["Pre"-tx-1-"pre"-adj-0]|TX|55/3|
text_000N_47377|MMI|3.54|Disease Screening|C1710031|[diap]|["Screening"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|Indicated|C1444656|[fndg]|["Indicated"-tx-1-"indicated"-verb-0]|TX|38/9|
text_000N_47377|MMI|3.54|Participation|C0679823|[ftcn]|["Participation"-tx-1-"participation"-adj-0]|TX|59/13|
text_000N_47377|MMI|3.54|Pure Spanish horse breed (organism)|C3669034|[mamm]|["PRE"-tx-1-"pre"-adj-0]|TX|55/3|
text_000N_47377|MMI|3.54|Screening|C1710032|[hlca]|["Screening"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|Screening Study|C2348164|[resa]|["SCREENING"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|Screening procedure|C0220908|[diap]|["Screening"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|Trial Screening|C1710477|[resa]|["SCREENING"-tx-1-"screening"-noun-0]|TX|73/9|
text_000N_47377|MMI|3.54|photoreactivating enzyme activity|C2257086|[genf]|["PRE"-tx-1-"pre"-adj-0]|TX|55/3|
text_000N_47377|MMI|3.54|research subject screening|C1698960|[resa]|["screening"-tx-1-"screening"-noun-0]|TX|73/9|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|7.70|PTK2 protein, human|C1565427|[aapp,enzy]|["FAK"-tx-1-"FAK"-noun-0,"Focal Adhesion Kinase"-tx-1-"Focal Adhesion Kinase"-noun-0]|TX|15/3;20/21|
text_000N_43275|MMI|5.18|Focal Adhesion Kinase 1|C0059239|[aapp,enzy]|["focal adhesion kinase"-tx-1-"Focal Adhesion Kinase"-noun-0]|TX|20/21|
text_000N_43275|MMI|5.18|Focal Adhesion Protein-Tyrosine Kinases|C1565434|[aapp,enzy]|["Focal Adhesion Kinase"-tx-1-"Focal Adhesion Kinase"-noun-0]|TX|20/21|
text_000N_43275|MMI|5.18|PTK2 gene|C1366894|[gngm]|["FOCAL ADHESION KINASE"-tx-1-"Focal Adhesion Kinase"-noun-0]|TX|20/21|
text_000N_43275|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Age|C0001779|[orga]|["Chronological Age"-tx-1-"chronological age"-noun-0]|TX|4/17|
text_000N_40886|MMI|3.61|Telomere Length|C4331397|[qnco]|["Telomere Length"-tx-1-"telomere length"-noun-0]|TX|48/15|
text_000N_40886|MMI|3.56|Measured|C0444706|[qlco]|["measuring"-tx-1-"measuring"-adj-0]|TX|38/9|
text_000N_40886|MMI|3.56|Measured from|C0449770|[qnco]|["measuring"-tx-1-"measuring"-adj-0]|TX|38/9|
text_000N_40886|MMI|3.56|Percent of Predicted Value|C1882327|[qnco]|["%{Predicted}"-tx-1-"predicted"-verb-0]|TX|25/9|
text_000N_40886|MMI|3.56|Prediction|C0681842|[idcn]|["Predicted"-tx-1-"predicted"-verb-0]|TX|25/9|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|3.76|YEAST FACTOR|C1860230|[gngm]|["YEAST FACTOR"-tx-1-"yeast factor"-noun-0]|TX|7/5,32/6|
text_000N_173214|MMI|3.68|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|18/20|
text_000N_173214|MMI|3.68|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|18/20|
text_000N_173214|MMI|3.64|Hypocupremia|C0268070|[dsyn]|["Copper deficiency"-tx-1-"copper deficiency"-noun-0]|TX|52/17|
text_000N_173214|MMI|3.61|Data Transcription|C4554264|[acty]|["transcription"-tx-1-"transcription"-noun-0]|TX|18/13|
text_000N_173214|MMI|3.61|Transcription, Genetic|C0040649|[genf]|["Transcription"-tx-1-"transcription"-noun-0]|TX|18/13|
text_000N_173214|MMI|3.57|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-verb-0]|TX|39/7|
text_000N_173214|MMI|3.47|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_173214|MMI|3.47|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_173214|MMI|3.47|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_173214|MMI|3.47|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_173214|MMI|3.47|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
<<<<< MMI
>>>>> MMI
text_000N_14887|MMI|5.18|Smallpox|C0037354|[dsyn]|["SMALLPOX"-tx-1-"small pox"-noun-0]|TX|4/9|
text_000N_14887|MMI|5.18|Smallpox Viruses|C0037356|[virs]|["Smallpox"-tx-1-"small pox"-noun-0]|TX|4/9|
text_000N_14887|MMI|3.57|World|C2700280|[popg]|["World"-tx-1-"world"-noun-0]|TX|39/5|
<<<<< MMI
>>>>> MMI
text_000N_14910|MMI|5.18|armodafinil|C1701455|[orch,phsu]|["ARMODAFINIL"-tx-1-"armodafinil"-noun-0]|TX|5/11|
text_000N_14910|MMI|3.57|Fatigue|C0015672|[sosy]|["FATIGUE"-tx-1-"fatigue"-noun-0]|TX|25/7|
text_000N_14910|MMI|3.57|Fatigue Subordinate Domain|C4050243|[inpr]|["Fatigue"-tx-1-"fatigue"-noun-0]|TX|25/7|
text_000N_14910|MMI|3.57|Fatigue, CTCAE 5.0|C4554645|[fndg]|["Fatigue"-tx-1-"fatigue"-noun-0]|TX|25/7|
text_000N_14910|MMI|3.57|Feel Fatigue|C3463815|[inpr]|["Fatigue"-tx-1-"fatigue"-noun-0]|TX|25/7|
text_000N_14910|MMI|3.44|Glioblastoma Multiforme Pathway|C2984291|[ftcn]|["Glioma"-tx-1-"glioma"-noun-0]|TX|36/6|
text_000N_14910|MMI|3.44|Glioma|C0017638|[neop]|["GLIOMA"-tx-1-"glioma"-noun-0]|TX|36/6|
text_000N_14910|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|tirilazad|C0245179|[orch,phsu]|["TIRILAZAD"-tx-1-"tirilazad"-noun-0]|TX|3/9|
text_000N_173230|MMI|3.57|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|13/9,27/9|
text_000N_173230|MMI|3.47|Subarachnoid Hemorrhage, Aneurysmal|C0751530|[patf]|["Subarachnoid Hemorrhage, Aneurysmal"-tx-1-"aneurysmal subarachnoid haemorrhage"-noun-0]|TX|40/35|
<<<<< MMI
>>>>> MMI
text_000N_14932|MMI|3.54|Diversity|C1880371|[qlco]|["Diversity"-tx-1-"diversity"-noun-0]|TX|25/9|
text_000N_14932|MMI|3.43|Drosophila suzukii|C1002114|[euka]|["Drosophila suzukii"-tx-1-"Drosophila suzukii"-noun-0]|TX|42/18|
text_000N_14932|MMI|3.42|Abnormally high|C1299351|[qlco]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|High|C0205250|[qlco]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|High (finding)|C5200928|[fndg]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|High Level|C4321237|[fndg]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|High Mitosis-Karyorrhexis Index|C3889660|[inpr]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|IPSS Risk Category High|C4522209|[inpr]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|IPSS-R Risk Category High|C5202936|[fndg]|["High"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|Nucleotides|C0028630|[nnon]|["Nucleotide"-tx-1-"nucleotide"-noun-0]|TX|14/10|
text_000N_14932|MMI|3.42|Species|C1705920|[clas]|["Species"-tx-1-"species"-noun-0]|TX|61/7|
text_000N_14932|MMI|3.42|Value Above Reference Range|C2700149|[inpr]|["HIGH"-tx-1-"high"-adj-0]|TX|9/4|
text_000N_14932|MMI|3.42|high - ActExposureLevelCode|C3887512|[idcn]|["high"-tx-1-"high"-adj-0]|TX|9/4|
<<<<< MMI
>>>>> MMI
text_000N_14980|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|26/6|
text_000N_14980|MMI|5.18|Proton Pump Inhibitors|C0358591|[phsu]|["Inhibitors, Proton Pump"-tx-1-"proton pump inhibitors"-noun-0]|TX|3/22|
text_000N_14980|MMI|5.18|Proton Pump Inhibitors [MoA]|C1384478|[moft]|["Proton Pump Inhibitors"-tx-1-"proton pump inhibitors"-noun-0]|TX|3/22|
text_000N_14980|MMI|5.18|Proton pump inhibitors for peptic ulcer and GORD|C3540020|[phsu]|["Proton pump inhibitors"-tx-1-"proton pump inhibitors"-noun-0]|TX|3/22|
text_000N_14980|MMI|3.68|Biological Absorption|C2347023|[orgf]|["Absorption"-tx-1-"absorption"-noun-0]|TX|43/10|
text_000N_14980|MMI|3.68|Energy Absorption|C2825050|[phpr]|["Absorption"-tx-1-"absorption"-noun-0]|TX|43/10|
text_000N_14980|MMI|3.68|Material Absorption|C2347080|[phpr]|["Absorption"-tx-1-"absorption"-noun-0]|TX|43/10|
text_000N_14980|MMI|3.68|Pharmacokinetics: Absorption|C2698776|[bmod]|["ABSORPTION"-tx-1-"absorption"-noun-0]|TX|43/10|
text_000N_14980|MMI|3.68|Process of absorption|C0000854|[npop]|["Absorption"-tx-1-"absorption"-noun-0]|TX|43/10|
text_000N_14980|MMI|3.50|levothyroxine|C0040165|[aapp,horm,phsu]|["Thyroxine"-tx-1-"thyroxine"-noun-0]|TX|33/9|
<<<<< MMI
>>>>> MMI
text_000N_15004|MMI|5.18|OSTN gene|C1428912|[gngm]|["OSTEOCRIN"-tx-1-"osteocrin"-noun-0]|TX|3/9|
text_000N_15004|MMI|3.57|Skeletal bone|C0262950|[bpoc]|["BONE"-tx-1-"bone"-noun-0]|TX|42/4|
text_000N_15004|MMI|3.57|XXX bone|C1442209|[bpoc]|["Bone"-tx-1-"bone"-noun-0]|TX|42/4|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Subacute Sclerosing Panencephalitis|C0038522|[dsyn]|["PANENCEPHALITIS, SUBACUTE SCLEROSING"-tx-1-"subacute sclerosing panencephalitis"-noun-0]|TX|3/35|
text_000N_173104|MMI|3.61|Measles Vaccine|C0025010|[imft,phsu]|["Measles Vaccine"-tx-1-"Measles vaccine"-noun-0]|TX|53/15|
text_000N_173104|MMI|3.61|Vaccine product containing only Measles morbillivirus antigen (medicinal product)|C5240001|[phsu]|["Measles vaccine"-tx-1-"Measles vaccine"-noun-0]|TX|53/15|
text_000N_173104|MMI|3.53|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|39/6|
text_000N_173104|MMI|3.53|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|39/6|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Achondroplasia|C0001080|[cgab]|["ACHONDROPLASIA"-tx-1-"Achondroplasia"-noun-0]|TX|3/14|
text_000N_40839|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|18/15|
text_000N_40839|MMI|3.64|Deafness|C0011053|[fndg]|["hearing loss"-tx-1-"hearing loss"-noun-0]|TX|34/12|
text_000N_40839|MMI|3.64|Hearing Loss|C3887873|[fndg]|["Hearing Loss"-tx-1-"hearing loss"-noun-0]|TX|34/12|
text_000N_40839|MMI|3.64|Hearing Loss, Partial|C0018772|[fndg]|["hearing loss"-tx-1-"hearing loss"-noun-0]|TX|34/12|
text_000N_40839|MMI|3.64|hearing impairment|C1384666|[dsyn]|["HEARING LOSS"-tx-1-"hearing loss"-noun-0]|TX|34/12|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|7.70|SETMAR gene|C1419974|[gngm]|["METNASE"-tx-1-"Metnase"-noun-0,"SETMAR"-tx-1-"SETMAR"-noun-0]|TX|24/7;16/6|
text_000N_40941|MMI|5.18|SETMAR protein, human|C1723767|[aapp,enzy]|["Metnase"-tx-1-"Metnase"-noun-0]|TX|24/7|
text_000N_40941|MMI|3.68|Concept model domain|C3541951|[inpr]|["Domain"-tx-1-"domain"-noun-0]|TX|47/6|
text_000N_40941|MMI|3.68|Domain (area of knowledge)|C1880389|[ftcn]|["Domain"-tx-1-"domain"-noun-0]|TX|47/6|
text_000N_40941|MMI|3.68|Superkingdom (taxonomic category)|C1883221|[cnce]|["Domain"-tx-1-"domain"-noun-0]|TX|47/6|
text_000N_40941|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|8/7|
text_000N_40941|MMI|3.50|Transposase|C0076934|[aapp,enzy]|["Transposase"-tx-1-"transposase"-noun-0]|TX|35/11|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|indinavir|C0376637|[orch,phsu]|["INDINAVIR"-tx-1-"indinavir"-noun-0]|TX|3/9|
text_000N_47450|MMI|3.57|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|13/9,27/9|
text_000N_47450|MMI|3.47|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|40/29|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Radiosurgery|C0085203|[topp]|["Radiosurgery"-tx-1-"radiosurgery"-noun-0]|TX|4/12|
text_000N_173151|MMI|3.56|Dysembryoplastic neuroepithelial tumor|C1266177|[neop]|["DNET"-tx-1-"DNET"-noun-0]|TX|33/4|
text_000N_173151|MMI|3.56|Neoplasms|C0027651|[neop]|["Tumors"-tx-1-"tumors"-noun-0]|TX|38/6|
text_000N_173151|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|20/4|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.59|High|C0205250|[qlco]|["Higher"-tx-1-"higher"-adj-0]|TX|35/6|
text_000N_173291|MMI|3.59|Induce (action)|C0205263|[ftcn]|["Induction"-tx-1-"induction"-noun-0]|TX|3/9|
text_000N_173291|MMI|3.59|Induction Clinical Trial Setting|C4722132|[hcro,mnob]|["INDUCTION"-tx-1-"induction"-noun-0]|TX|3/9|
text_000N_173291|MMI|3.59|Induction Therapy|C5202807|[topp]|["Induction"-tx-1-"induction"-noun-0]|TX|3/9|
text_000N_173291|MMI|3.59|Induction procedure|C0857127|[topp]|["induction"-tx-1-"induction"-noun-0]|TX|3/9|
text_000N_173291|MMI|3.45|Interferon|C3652465|[aapp,imft,phsu]|["Interferon"-tx-1-"interferon"-noun-0]|TX|16/10|
text_000N_173291|MMI|3.45|Interferons|C0021747|[aapp,imft]|["INTERFERON"-tx-1-"interferon"-noun-0]|TX|16/10|
text_000N_173291|MMI|3.45|Males|C0086582|[orga]|["Males"-tx-1-"males"-noun-0]|TX|45/5|
text_000N_173291|MMI|3.45|human leukocyte interferon|C0733470|[aapp,imft,phsu]|["Interferon"-tx-1-"interferon"-noun-0]|TX|16/10|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|27/9|
text_000N_43358|MMI|3.78|Artificial Cells|C2936320|[mnob]|["Artificial Cells"-tx-1-"artificial cells"-noun-0]|TX|4/10,21/5|
text_000N_43358|MMI|3.75|Blood Cells|C0005773|[cell]|["Blood Cells"-tx-1-"blood cells"-noun-0]|TX|15/11|
text_000N_43358|MMI|3.63|Cell Count|C0007584|[lbpr]|["CELLS"-tx-1-"cells"-noun-0]|TX|21/5|
text_000N_43358|MMI|3.63|Cells|C0007634|[cell]|["Cells"-tx-1-"cells"-noun-0]|TX|21/5|
text_000N_43358|MMI|3.53|Blood Substitutes|C0005836|[phsu]|["Artificial Blood"-tx-1-"artificial blood"-noun-0]|TX|4/16|
text_000N_43358|MMI|3.48|Artificial (qualifier value)|C2004457|[qlco]|["Artificial"-tx-1-"artificial"-noun-0]|TX|4/10|
text_000N_43358|MMI|3.48|Blood|C0005767|[bdsu]|["Blood"-tx-1-"blood"-noun-0]|TX|15/5|
text_000N_43358|MMI|3.48|Blood specimen|C0178913|[bdsu]|["Blood"-tx-1-"blood"-noun-0]|TX|15/5|
text_000N_43358|MMI|3.48|In Blood|C0005768|[bdsu]|["BLOOD"-tx-1-"blood"-noun-0]|TX|15/5|
text_000N_43358|MMI|3.48|peripheral blood|C0229664|[bdsu]|["BLOOD"-tx-1-"blood"-noun-0]|TX|15/5|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|PTEN gene|C0694888|[gngm]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_173136|MMI|5.18|PTEN protein, human|C1430988|[aapp,enzy]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_173136|MMI|5.18|Phosphatase and Tensin Homolog Measurement|C4553405|[lbpr]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_173136|MMI|5.18|Tumor Suppressor Gene Indicator|C5400960|[ftcn]|["tumor suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|10/17|
text_000N_173136|MMI|5.18|Tumor Suppressor Genes|C0079427|[gngm]|["Tumor Suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|10/17|
text_000N_173136|MMI|5.18|tumor suppressor activity|C1325410|[celf]|["tumor suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|10/17|
<<<<< MMI
>>>>> MMI
text_000N_14957|MMI|5.18|Human Embryonic Stem Cells|C1171346|[cell]|["hESC"-tx-1-"hESC"-noun-0]|TX|5/4|
text_000N_14957|MMI|3.62|Age related macular degeneration|C0242383|[dsyn]|["Age related macular degeneration"-tx-1-"age-related macular degeneration"-noun-0]|TX|43/32|
text_000N_14957|MMI|3.54|Test Administration|C0237455|[edac]|["Test Treatment"-tx-1-"tested treatment"-noun-0]|TX|15/6,30/9|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Cell Differentiation process|C0007589|[celf]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|52/15|
text_000N_40972|MMI|5.18|Differentiation|C2945687|[ftcn]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|52/15|
text_000N_40972|MMI|5.18|Histopathologic Grade differentiation|C1511938|[clna]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|52/15|
text_000N_40972|MMI|5.18|T-Cell Development|C1515126|[celf]|["T cell development"-tx-1-"T-cell development"-noun-0]|TX|29/18|
text_000N_40972|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40972|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40972|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40972|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_40972|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-verb-0]|TX|48/8|
text_000N_173087|MMI|5.18|Report (document)|C0684224|[inpr]|["Reported"-tx-1-"reported"-verb-0]|TX|36/8|
text_000N_173087|MMI|5.18|Reported|C4319718|[ftcn]|["Reported"-tx-1-"reported"-verb-0]|TX|36/8|
text_000N_173087|MMI|5.18|Reporting|C0700287|[hlca]|["Reported"-tx-1-"reported"-verb-0]|TX|36/8|
text_000N_173087|MMI|5.18|Saccharomyces cerevisiae|C0036025|[fngs]|["Saccharomyces cerevisae"-tx-1-"Saccharomyces cerevisiae"-noun-0]|TX|84/24|
text_000N_173087|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|45/2|
text_000N_173087|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|45/2|
text_000N_173087|MMI|3.59|Protein Overexpression|C1514559|[genf]|["Overexpression"-tx-1-"overexpression"-noun-0]|TX|4/14|
text_000N_173087|MMI|3.57|Life Span|C0870809|[grpa]|["Lifespan"-tx-1-"lifespan"-noun-0]|TX|57/8|
text_000N_173087|MMI|3.57|Longevity|C0023980|[tmco]|["Lifespan"-tx-1-"lifespan"-noun-0]|TX|57/8|
text_000N_173087|MMI|3.48|Budding Yeast Measurement|C3814776|[lbpr]|["Budding Yeast"-tx-1-"budding yeast"-noun-0]|TX|69/13|
text_000N_173087|MMI|3.48|Saccharomycetales|C0014181|[fngs]|["Budding yeast"-tx-1-"budding yeast"-noun-0]|TX|69/13|
text_000N_173087|MMI|3.45|Sirtuins|C1136177|[aapp,enzy]|["Sirtuins"-tx-1-"sirtuins"-noun-0]|TX|22/8|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.61|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|37/14|
text_000N_43235|MMI|3.60|At risk|C1444641|[qlco]|["At risk"-tx-1-"at risk"-noun-0]|TX|34/2,47/4|
text_000N_43235|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|4/8|
text_000N_43235|MMI|3.56|Increase|C0442805|[ftcn]|["INCREASED"-tx-1-"increased"-noun-0]|TX|37/9|
text_000N_43235|MMI|3.56|Increased|C0205217|[qnco]|["Increased"-tx-1-"increased"-noun-0]|TX|37/9|
text_000N_43235|MMI|3.56|Increased (finding)|C5236002|[fndg]|["Increased"-tx-1-"increased"-noun-0]|TX|37/9|
text_000N_43235|MMI|3.48|FBN1 gene|C1414542|[gngm]|["Marfan syndrome"-tx-1-"marfan syndrome"-noun-0]|TX|18/15|
text_000N_43235|MMI|3.48|Family history of Marfan syndrome|C4040152|[fndg]|["Marfan syndrome"-tx-1-"marfan syndrome"-noun-0]|TX|18/15|
text_000N_43235|MMI|3.48|Marfan Syndrome|C0024796|[dsyn]|["MARFAN'S SYNDROME"-tx-1-"marfan syndrome"-noun-0]|TX|18/15|
text_000N_43235|MMI|3.43|AT genotype|C4554368|[fndg]|["AT"-tx-1-"at"-prep-0]|TX|34/2|
text_000N_43235|MMI|3.43|Apnea Time|C4764186|[qnco]|["AT"-tx-1-"at"-prep-0]|TX|34/2|
text_000N_43235|MMI|3.43|At|C1516077|[spco]|["At"-tx-1-"at"-prep-0]|TX|34/2|
text_000N_43235|MMI|3.43|Cardiac Arrhythmia|C0003811|[dsyn]|["Arrhythmias"-tx-1-"arrhythmias"-noun-0]|TX|55/11|
text_000N_43235|MMI|3.43|GATM wt Allele|C4049625|[gngm]|["AT"-tx-1-"at"-prep-0]|TX|34/2|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|TMPO wt Allele|C3541334|[gngm]|["LAP2"-tx-1-"LAP2"-noun-0]|TX|24/4|
text_000N_40999|MMI|3.68|ERBB2 Interacting Protein, Human|C1447765|[aapp,bacs]|["Erbin"-tx-1-"Erbin"-noun-0]|TX|17/5|
text_000N_40999|MMI|3.68|ERBIN gene|C1333352|[gngm]|["ERBIN"-tx-1-"Erbin"-noun-0]|TX|17/5|
text_000N_40999|MMI|3.50|Falco columbarius|C0254121|[bird]|["Merlin"-tx-1-"Merlin"-noun-0]|TX|34/6|
text_000N_40999|MMI|3.50|NF2 gene|C0085114|[gngm]|["MERLIN"-tx-1-"Merlin"-noun-0]|TX|34/6|
text_000N_40999|MMI|3.50|NF2 protein, human|C5197349|[aapp,bacs]|["Merlin"-tx-1-"Merlin"-noun-0]|TX|34/6|
text_000N_40999|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|8/8|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.56|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|22/4|
text_000N_47420|MMI|3.56|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|22/4|
text_000N_47420|MMI|3.43|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_47420|MMI|3.43|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_47420|MMI|3.43|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_47420|MMI|3.43|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_47420|MMI|3.43|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|13/8|
text_000N_47420|MMI|3.43|Medical Device Emits Smoke|C1881674|[fndg]|["Smoking"-tx-1-"smoking"-adj-0]|TX|5/7|
text_000N_47420|MMI|3.43|Smoking|C0037369|[inbe]|["SMOKING"-tx-1-"smoking"-adj-0]|TX|5/7|
text_000N_47420|MMI|3.43|Tobacco smoking behavior|C0453996|[inbe]|["Smoking"-tx-1-"smoking"-adj-0]|TX|5/7|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|MAC lymphadenitis|C0858195|[dsyn]|["Mycobacterium tuberculosis"-tx-1-"Mycobacterium tuberculosis"-noun-0]|TX|60/26|
text_000N_173167|MMI|5.18|Mycobacterium Tuberculosis Measurement|C4317078|[lbpr]|["Mycobacterium tuberculosis"-tx-1-"Mycobacterium tuberculosis"-noun-0]|TX|60/26|
text_000N_173167|MMI|5.18|Mycobacterium avium|C0026913|[bact]|["MYCOBACTERIUM AVIUM"-tx-1-"Mycobacterium avium"-noun-0]|TX|3/19|
text_000N_173167|MMI|5.18|Mycobacterium tuberculosis|C0026926|[bact]|["MYCOBACTERIUM TUBERCULOSIS"-tx-1-"Mycobacterium tuberculosis"-noun-0]|TX|60/26|
text_000N_173167|MMI|3.57|Antimicrobial Susceptibility Result|C2827758|[lbtr]|["SUSCEPTIBLE"-tx-1-"susceptible"-adj-0]|TX|28/11|
text_000N_173167|MMI|3.57|Predisposition -- attribute|C0220898|[orga]|["Susceptible"-tx-1-"susceptible"-adj-0]|TX|28/11|
text_000N_173167|MMI|3.57|Susceptible|C0231204|[ftcn]|["Susceptible"-tx-1-"susceptible"-adj-0]|TX|28/11|
text_000N_173167|MMI|3.44|Antibiotic throat preparations|C3540706|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics|C0003232|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE|C3540707|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics for systemic use|C3540704|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics, Antitubercular|C0003237|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics, Gynecological|C3540708|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antibiotics, ophthalmologic|C3540710|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Antifungal Antibiotics, Topical|C3540705|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
text_000N_173167|MMI|3.44|Less Than|C0439092|[qnco]|["Less"-tx-1-"less"-adv-0]|TX|23/4|
text_000N_173167|MMI|3.44|Smaller|C0547044|[qlco]|["Less"-tx-1-"less"-adv-0]|TX|23/4|
text_000N_173167|MMI|3.44|antibiotics, intestinal|C3540709|[antb]|["Antibiotics"-tx-1-"antibiotics"-noun-0]|TX|43/11|
<<<<< MMI
>>>>> MMI
text_000N_15028|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_15028|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-pron-0]|TX|9/3|
text_000N_15028|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-pron-0]|TX|9/3|
text_000N_15028|MMI|3.43|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-adj-0]|TX|13/8|
text_000N_15028|MMI|3.43|Non-alcoholic Fatty Liver Disease|C0400966|[dsyn]|["NAFLD"-tx-1-"NAFLD"-noun-0]|TX|36/5|
<<<<< MMI
>>>>> MMI
text_000N_173183|AA|LAF|Logic Alignment Free|1|3|5|20|26:3
text_000N_173183|MMI|3.63|Alignment|C1706765|[qnco]|["Alignment"-tx-1-"Alignment"-noun-0]|TX|10/9|
text_000N_173183|MMI|3.63|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"Free"-adj-0]|TX|20/4|
text_000N_173183|MMI|3.63|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"Free"-adj-0]|TX|20/4|
text_000N_173183|MMI|3.63|Logic|C0023963|[idcn]|["Logic"-tx-1-"Logic"-noun-0]|TX|4/5|
text_000N_173183|MMI|3.61|Genome, Bacterial|C0085238|[gngm]|["Bacterial genomes"-tx-1-"bacterial genomes"-noun-0]|TX|43/17|
text_000N_173183|MMI|3.56|Classification|C0008902|[clas]|["Classification"-tx-1-"classification"-noun-0]|TX|61/14|
text_000N_173183|MMI|3.56|Classification of information|C0678229|[ocac]|["classification"-tx-1-"classification"-noun-0]|TX|61/14|
text_000N_173183|MMI|3.56|Taxonomic|C0008903|[ftcn]|["classification"-tx-1-"classification"-noun-0]|TX|61/14|
text_000N_173183|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|34/4|
<<<<< MMI
>>>>> MMI
text_000N_15051|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|33/15|
text_000N_15051|MMI|3.64|Genes, Developmental|C0017340|[gngm]|["Genes, Developmental"-tx-1-"developmental genes"-noun-0]|TX|49/19|
text_000N_15051|MMI|3.63|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|24/8|
<<<<< MMI
>>>>> MMI
text_000N_15074|MMI|6.95|XPC gene|C1421540|[gngm]|["RAD4"-tx-1-"Rad4"-noun-0,"XPC"-tx-1-"XPC"-noun-0]|TX|3/4;8/3|
text_000N_15074|MMI|3.59|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|33/7|
text_000N_15074|MMI|3.47|DNA Damage|C0012860|[comd]|["DNA Damage"-tx-1-"DNA damage"-noun-0]|TX|14/10|
text_000N_15074|MMI|3.45|DNA Repair Protein Complementing XP-C Cells|C3273670|[aapp]|["XPC"-tx-1-"XPC"-noun-0]|TX|8/3|
text_000N_15074|MMI|3.45|XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C|C2752147|[cgab,dsyn]|["XPC"-tx-1-"XPC"-noun-0]|TX|8/3|
text_000N_15074|MMI|3.45|XPC wt Allele|C3273669|[gngm]|["RAD4"-tx-1-"Rad4"-noun-0]|TX|3/4|
text_000N_15074|MMI|3.43|Esthesia|C0036658|[ortf]|["sense"-tx-1-"sensing"-adj-0]|TX|25/7|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|74/7|
text_000N_47363|MMI|4.12|Epigenetic Process|C1516924|[genf]|["Epigenetic Modification"-tx-1-"epigenetic modifications"-noun-0]|TX|4/24|
text_000N_47363|MMI|3.64|circulatory system development|C3156319|[biof]|["CARDIOVASCULAR development"-tx-1-"cardiovascular development"-noun-0]|TX|43/26|
<<<<< MMI
>>>>> MMI
text_000N_173245|AA|PrEP|prophylaxis|1|4|1|11|79:4
text_000N_173245|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|17/9|
text_000N_173245|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|HIV Infections|C0019693|[dsyn]|["HIV Infection"-tx-1-"HIV infection"-noun-1]|TX|38/13|
text_000N_173245|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|PREVENT (product)|C0309872|[phsu]|["PREVENT"-tx-1-"prevent"-verb-0]|TX|30/7|
text_000N_173245|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|12/4|
text_000N_173245|MMI|5.18|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|12/4|
text_000N_173245|MMI|5.18|Pre-Exposure Prophylaxis|C3850098|[topp]|["Pre-Exposure Prophylaxis"-tx-1-"Pre-exposure prophylaxis"-noun-0]|TX|53/24|
text_000N_173245|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|27/2|
text_000N_173245|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|27/2|
text_000N_173245|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173245|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173245|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
text_000N_173245|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173245|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|86/3|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.67|Na-K ATPase inhibitor|C1569720|[aapp,bacs]|["Na-K ATPase inhibitor"-tx-1-"inhibitors Na K ATPase"-noun-0]|TX|17/10,31/2,35/1,38/6|
text_000N_173260|MMI|3.43|Cardenolides|C0007143|[orch]|["Cardenolides"-tx-1-"cardenolides"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|MFN2 gene|C1424611|[gngm]|["MITOFUSIN 2"-tx-1-"mitofusin 2"-noun-0]|TX|3/11|
text_000N_173120|MMI|5.18|Mitofusin-2|C3816215|[aapp,enzy]|["Mitofusin-2"-tx-1-"mitofusin 2"-noun-0]|TX|3/11|
text_000N_173120|MMI|3.57|receptor|C0597357|[aapp,rcpt]|["Receptor"-tx-1-"receptor"-noun-0]|TX|17/8|
text_000N_173120|MMI|3.44|PARK2 protein, human|C1311470|[aapp,enzy]|["Parkin"-tx-1-"parkin"-noun-0]|TX|30/6|
text_000N_173120|MMI|3.44|PRKN gene|C1418270|[gngm]|["PARKIN"-tx-1-"parkin"-noun-0]|TX|30/6|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|STAT4 gene|C1335874|[gngm]|["STAT4"-tx-1-"Stat4"-noun-0]|TX|3/5|
text_000N_173276|MMI|5.18|STAT4 protein, human|C1530119|[aapp,bacs]|["STAT4"-tx-1-"Stat4"-noun-0]|TX|3/5|
text_000N_173276|MMI|5.18|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|11/20|
text_000N_173276|MMI|5.18|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|11/20|
<<<<< MMI
>>>>> MMI
text_000N_15098|MMI|5.18|MECP2 gene|C1417098|[gngm]|["Rett syndrome"-tx-1-"Rett syndrome"-noun-0]|TX|57/13|
text_000N_15098|MMI|5.18|Rett Syndrome|C0035372|[dsyn]|["Rett's syndrome"-tx-1-"Rett syndrome"-noun-0]|TX|57/13|
text_000N_15098|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involvement"-tx-1-"involvement"-noun-0]|TX|13/11|
text_000N_15098|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_15098|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_15098|MMI|3.43|CYRIB protein, human|C5196828|[aapp,bacs]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|FAM49B wt Allele|C3812159|[gngm]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|IGKV1-16 gene|C1416177|[gngm]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|INRG Stage L1|C4524638|[fndg]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|L1 innervation|C1179698|[blor]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|L1 level|C0446432|[blor]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|Long Interspersed Nucleotide Element-1|C0600472|[bacs,nnon]|["L1"-tx-1-"L1"-noun-0]|TX|28/2|
text_000N_15098|MMI|3.43|Retrotransposition|C1514925|[genf]|["Retrotransposition"-tx-1-"retrotransposition"-noun-0]|TX|31/18|
<<<<< MMI
>>>>> MMI
text_000N_15123|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|37/15|
text_000N_15123|MMI|3.59|Sepsis|C0243026|[dsyn]|["SEPSIS"-tx-1-"sepsis"-noun-0]|TX|53/6|
text_000N_15123|MMI|3.59|Sepsis (Invertebrate)|C1090821|[euka]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|53/6|
text_000N_15123|MMI|3.59|Sepsis, CTCAE|C4552837|[fndg]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|53/6|
text_000N_15123|MMI|3.59|Septicemia|C0036690|[dsyn]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|53/6|
text_000N_15123|MMI|3.56|Organism|C0029235|[orgm]|["Organisms"-tx-1-"organisms"-noun-0]|TX|4/9|
text_000N_15123|MMI|3.43|Genus|C1708235|[clas]|["Genus"-tx-1-"genus"-noun-0]|TX|21/5|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|PLN gene|C1418650|[gngm]|["PHOSPHOLAMBAN"-tx-1-"phospholamban"-noun-0]|TX|3/13|
text_000N_43386|MMI|5.18|phospholamban|C0070876|[aapp,enzy]|["phospholamban"-tx-1-"phospholamban"-noun-0]|TX|3/13|
text_000N_43386|MMI|3.58|ATPase inhibitory protein|C0052610|[aapp,phsu]|["ATPase inhibitory protein"-tx-1-"inhibitory protein ATPase"-noun-0]|TX|30/18,59/6|
text_000N_43386|MMI|3.42|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-adj-0]|TX|19/10|
text_000N_43386|MMI|3.42|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-adj-0]|TX|19/10|
<<<<< MMI
>>>>> MMI
text_000N_14856|MMI|5.18|NADPH Oxidase|C0068355|[aapp,enzy]|["NADPH Oxidase"-tx-1-"NADPH oxidase"-noun-0]|TX|4/13|
text_000N_14856|MMI|5.18|NADPH Oxidase Complex|C5552912|[aapp,enzy]|["NADPH-Oxidase"-tx-1-"NADPH oxidase"-noun-0]|TX|4/13|
text_000N_14856|MMI|5.18|NADPH oxidase activity|C1151146|[moft]|["NADPH oxidase"-tx-1-"NADPH oxidase"-noun-0]|TX|4/13|
text_000N_14856|MMI|5.18|diphenyleneiodonium|C0058381|[orch,phsu]|["diphenyleneiodonium"-tx-1-"diphenylene iodonium"-noun-0]|TX|47/20|
text_000N_14856|MMI|3.59|acetovanillone|C0050465|[orch,phsu]|["Apocynin"-tx-1-"apocynin"-noun-0]|TX|34/8|
text_000N_14856|MMI|3.59|inhibited|C0311403|[qlco]|["Inhibited"-tx-1-"inhibited"-verb-0]|TX|21/9|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|3.60|BRCA Mutation Analysis|C4687424|[lbpr]|["BRCA Mutation Analysis"-tx-1-"BRCA mutation analysis"-noun-0]|TX|11/22|
text_000N_47274|MMI|3.42|Greeks|C0337806|[popg]|["GREEK"-tx-1-"Greek"-noun-0]|TX|41/5|
text_000N_47274|MMI|3.42|Population Group|C1257890|[popg]|["Population"-tx-1-"population"-noun-0]|TX|47/10|
text_000N_47274|MMI|3.42|geographic population|C0032659|[qnco]|["Population"-tx-1-"population"-noun-0]|TX|47/10|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Pigmentation|C0031911|[orga]|["Pigmentation"-tx-1-"pigmentation"-noun-0]|TX|32/12|
text_000N_47304|MMI|5.18|Structure showing abnormal deposition of pigment (morphologic abnormality)|C3665492|[patf]|["Pigmentation"-tx-1-"pigmentation"-noun-0]|TX|32/12|
text_000N_47304|MMI|3.68|Palmitoylation|C0598435|[moft]|["Palmitoylation"-tx-1-"palmitoylation"-noun-0]|TX|10/14|
text_000N_47304|MMI|3.50|MC1R gene|C1417061|[gngm]|["MC1R"-tx-1-"MC1R"-noun-0]|TX|5/4|
text_000N_47304|MMI|3.50|Melanocyte-Stimulating Hormone Receptor, human|C4082292|[aapp,rcpt]|["MC1R"-tx-1-"MC1R"-noun-0]|TX|5/4|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.54|1 (finding)|C5201140|[fndg]|["One"-tx-1-"one"-noun-0]|TX|10/3|
text_000N_40913|MMI|3.54|One|C0205447|[qnco]|["ONE"-tx-1-"one"-noun-0]|TX|10/3|
text_000N_40913|MMI|3.44|Mobius Syndrome|C0221060|[dsyn]|["M√∂bius Syndrome"-tx-1-"Moebius syndrome"-noun-0]|TX|40/16|
text_000N_40913|MMI|3.42|Autistic Disorder|C0004352|[mobd]|["AUTISM"-tx-1-"autism"-noun-0]|TX|3/6|
text_000N_40913|MMI|3.42|Characteristics|C1521970|[qlco]|["Characteristics"-tx-1-"characteristics"-noun-0]|TX|21/15|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|37/3|
text_000N_173199|MMI|5.18|tocilizumab|C1609165|[aapp,imft,phsu]|["TOCILIZUMAB"-tx-1-"Tocilizumab"-noun-0]|TX|0/11|
text_000N_173199|MMI|3.78|Antibodies, Anti-Idiotypic|C0003242|[aapp,imft]|["anti antibody"-tx-1-"anti antibody"-noun-0]|TX|18/4,27/8|
<<<<< MMI
>>>>> MMI
text_000N_15147|MMI|5.18|Alpers Syndrome (disorder)|C0205710|[dsyn]|["Alpers Disease"-tx-1-"Alpers disease"-noun-0]|TX|3/14|
text_000N_15147|MMI|3.59|Autosomal recessive inheritance|C0441748|[genf]|["Autosomal Recessive"-tx-1-"autosomal recessive"-noun-0]|TX|34/19|
text_000N_15147|MMI|3.55|Hereditary|C0439660|[ftcn]|["INHERITED"-tx-1-"inherited"-verb-0]|TX|18/9|
text_000N_15147|MMI|3.55|Mode|C1513371|[ftcn]|["Mode"-tx-1-"mode"-noun-0]|TX|54/4|
text_000N_15147|MMI|3.55|Population Mode|C2347637|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|54/4|
text_000N_15147|MMI|3.55|Sample Mode|C2348146|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|54/4|
text_000N_15147|MMI|3.55|Statistical Mode|C1705738|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|54/4|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.72|Thyroid Hormone Resistance Syndrome|C2940786|[dsyn]|["Thyroid Hormone Resistance Syndrome"-tx-1-"thyroid hormone resistance syndrome"-noun-0]|TX|61/35|
text_000N_47289|MMI|3.60|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|36/9|
text_000N_47289|MMI|3.60|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|36/9|
text_000N_47289|MMI|3.57|Thyroid Hormone Receptor Alpha-1|C0919489|[aapp,rcpt]|["Thyroid Hormone Receptor Alpha-1"-tx-1-"thyroid hormone receptor alpha1"-noun-0]|TX|4/31|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.63|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|21/7|
text_000N_47334|MMI|3.48|Memory|C0025260|[menp]|["Memory"-tx-1-"memory"-noun-0]|TX|14/6|
text_000N_47334|MMI|3.48|Memory Device|C1706377|[mnob]|["Memory"-tx-1-"memory"-noun-0]|TX|14/6|
text_000N_47334|MMI|3.48|Memory G-code|C4282129|[inpr]|["Memory"-tx-1-"memory"-noun-0]|TX|14/6|
text_000N_47334|MMI|3.48|Memory observations|C0700327|[fndg]|["memory"-tx-1-"memory"-noun-0]|TX|14/6|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|tocilizumab|C1609165|[aapp,imft,phsu]|["TOCILIZUMAB"-tx-1-"tocilizumab"-noun-0]|TX|4/11|
text_000N_47320|MMI|3.64|COVID-19|C5203670|[dsyn]|["COVID 19"-tx-1-"Covid-19"-noun-0]|TX|38/8|
text_000N_47320|MMI|3.64|COVID19 (document)|C5243469|[inpr]|["COVID-19"-tx-1-"Covid-19"-noun-0]|TX|38/8|
text_000N_47320|MMI|3.57|Assessed|C1516048|[acty]|["Assessed"-tx-1-"assessed"-verb-0]|TX|21/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|APLN gene|C1538915|[gngm]|["APELIN"-tx-1-"Apelin"-noun-0]|TX|3/6|
text_000N_47349|MMI|5.18|APLN protein, human|C1454315|[aapp,bacs]|["Apelin"-tx-1-"Apelin"-noun-0]|TX|3/6|
text_000N_47349|MMI|5.18|Apelin|C3542402|[aapp,bacs]|["Apelin"-tx-1-"Apelin"-noun-0]|TX|3/6|
text_000N_47349|MMI|5.18|Usual|C3538928|[qlco]|["Usually"-tx-1-"usually"-adv-0]|TX|10/7|
text_000N_47349|MMI|5.18|Usually|C3888388|[fndg]|["Usually"-tx-1-"usually"-adv-0]|TX|10/7|
text_000N_47349|MMI|3.59|Decreased|C0205216|[qnco]|["Decreased"-tx-1-"decreased"-verb-0]|TX|18/9|
text_000N_47349|MMI|3.59|Decreasing|C0442797|[fndg]|["Decreased"-tx-1-"decreased"-verb-0]|TX|18/9|
text_000N_47349|MMI|3.59|Diabetes|C0011847|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|31/8|
text_000N_47349|MMI|3.59|Diabetes Mellitus|C0011849|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|31/8|
text_000N_47349|MMI|3.59|Reduced|C0392756|[fndg]|["DECREASED"-tx-1-"decreased"-verb-0]|TX|18/9|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|7.77|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-verb-0,"Associated with"-tx-1-"associated with"-verb-0]|TX|66/10;38/15|
text_000N_47435|MMI|5.18|Neuropathy|C0442874|[dsyn]|["NEUROPATHY"-tx-1-"neuropathy"-noun-0]|TX|77/10|
text_000N_47435|MMI|3.59|Amyloidosis|C0002726|[dsyn]|["AMYLOIDOSIS"-tx-1-"amyloidosis"-noun-0]|TX|54/11|
text_000N_47435|MMI|3.45|Prealbumin|C0032923|[aapp,bacs]|["Transthyretin"-tx-1-"transthyretin"-noun-0]|TX|21/13|
text_000N_47435|MMI|3.45|Prealbumin measurement|C0337441|[lbpr]|["Transthyretin"-tx-1-"transthyretin"-noun-0]|TX|21/13|
text_000N_47435|MMI|3.45|TTR gene|C1421224|[gngm]|["TRANSTHYRETIN"-tx-1-"transthyretin"-noun-0]|TX|21/13|
text_000N_47435|MMI|3.45|TTR protein, human|C5196842|[aapp,bacs]|["Transthyretin"-tx-1-"transthyretin"-noun-0]|TX|21/13|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_43331|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_43331|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_43331|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_43331|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_43331|MMI|3.59|Exosomes|C2350332|[celc]|["Exosomes"-tx-1-"exosomes"-noun-0]|TX|26/8|
text_000N_43331|MMI|3.43|Fractional Area Change|C4068466|[qnco]|["FAC"-tx-1-"FACS"-noun-0]|TX|40/4|
<<<<< MMI
>>>>> MMI
text_000N_15172|MMI|5.18|LTF gene|C1416933|[gngm]|["LACTOTRANSFERRIN"-tx-1-"lactotransferrin"-noun-0]|TX|3/16|
text_000N_15172|MMI|5.18|LTF protein, human|C1435815|[aapp,bacs]|["Lactotransferrin"-tx-1-"lactotransferrin"-noun-0]|TX|3/16|
text_000N_15172|MMI|5.18|Lactoferrin measurement|C0523737|[lbpr]|["Lactotransferrin"-tx-1-"lactotransferrin"-noun-0]|TX|3/16|
text_000N_15172|MMI|5.18|Tumor Suppressor Gene Indicator|C5400960|[ftcn]|["tumor suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|22/17|
text_000N_15172|MMI|5.18|Tumor Suppressor Genes|C0079427|[gngm]|["Tumor Suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|22/17|
text_000N_15172|MMI|5.18|lactoferrin|C0022942|[aapp,bacs]|["Lactotransferrin"-tx-1-"lactotransferrin"-noun-0]|TX|3/16|
text_000N_15172|MMI|5.18|tumor suppressor activity|C1325410|[celf]|["tumor suppressor"-tx-1-"tumour suppressor"-noun-0]|TX|22/17|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|7.33|Gene Locus|C1708726|[spco]|["Gene Locus"-tx-1-"gene locus"-noun-0,"Locus"-tx-1-"locus"-noun-0]|TX|17/10;22/5|
text_000N_47392|MMI|7.01|SRY gene|C1420418|[gngm]|["SRY"-tx-1-"Sry"-noun-0,"SRY Gene"-tx-1-"Sry gene"-noun-0]|TX|13/3;13/8|
text_000N_47392|MMI|3.61|Genomic Identifier|C1708233|[cnce]|["locus"-tx-1-"locus"-noun-0]|TX|22/5|
text_000N_47392|MMI|3.57|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"free"-adj-0]|TX|28/4|
text_000N_47392|MMI|3.57|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"free"-adj-0]|TX|28/4|
text_000N_47392|MMI|3.50|Genes, sry|C0949635|[gngm]|["sry Gene"-tx-1-"Sry gene"-noun-0]|TX|13/8|
text_000N_47392|MMI|3.48|Repetitive Region|C0086908|[nusq]|["Repetitive Sequences"-tx-1-"repetitive sequences"-noun-0]|TX|36/20|
text_000N_47392|MMI|3.47|House mice|C0025914|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|7/5|
text_000N_47392|MMI|3.47|Laboratory mice|C0025929|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|7/5|
text_000N_47392|MMI|3.47|Mus|C0026809|[mamm]|["MOUSE"-tx-1-"mouse"-noun-0]|TX|7/5|
text_000N_47392|MMI|3.47|Mus sp.|C1331371|[mamm]|["Mouse, NOS"-tx-1-"mouse"-noun-0]|TX|7/5|
text_000N_47392|MMI|3.47|SRY protein, human|C1566703|[aapp,bacs]|["SRY"-tx-1-"Sry"-noun-0]|TX|13/3|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|3.68|Geographic state|C1301808|[geoa]|["State"-tx-1-"state"-noun-0]|TX|66/5|
text_000N_43275|MMI|3.68|State|C1442792|[ftcn]|["State"-tx-1-"state"-noun-0]|TX|66/5|
text_000N_43275|MMI|3.68|US State|C3148680|[geoa]|["State"-tx-1-"state"-noun-0]|TX|66/5|
text_000N_43275|MMI|3.56|Observation Method - algorithm|C1553907|[ftcn]|["algorithm"-tx-1-"algorithm"-noun-0]|TX|13/9|
text_000N_43275|MMI|3.56|algorithm|C0002045|[inpr]|["Algorithm"-tx-1-"algorithm"-noun-0]|TX|13/9|
text_000N_43275|MMI|3.50|Chromatin|C0008546|[aapp]|["Chromatin"-tx-1-"chromatin"-noun-0]|TX|56/9|
text_000N_43275|MMI|3.50|chromatin location|C1325550|[celc]|["chromatin"-tx-1-"chromatin"-noun-0]|TX|56/9|
text_000N_43275|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_43275|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_43275|MMI|3.43|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancer"-noun-0]|TX|27/8|
text_000N_43275|MMI|3.43|Identification (Psychology)|C0020792|[menp]|["Identification"-tx-1-"identification"-noun-0]|TX|36/14|
text_000N_43275|MMI|3.43|Identified|C0205396|[qlco]|["Identification"-tx-1-"identification"-noun-0]|TX|36/14|
text_000N_43275|MMI|3.43|Material Identification|C4520791|[ftcn]|["Identification"-tx-1-"identification"-noun-0]|TX|36/14|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|10.42|HRC gene|C1415718|[gngm]|["HISTIDINE-RICH CALCIUM-BINDING PROTEIN"-tx-1-"Histidine-Rich Calcium Binding protein"-noun-0,"HRC"-tx-1-"HRC"-noun-0]|TX|7/38;47/3|
text_000N_40886|MMI|5.18|Heart Diseases|C0018799|[dsyn]|["Cardiac Disease"-tx-1-"cardiac disease"-noun-0]|TX|79/15|
text_000N_40886|MMI|3.59|Cardiac Arrhythmia|C0003811|[dsyn]|["Arrhythmias"-tx-1-"arrhythmias"-noun-0]|TX|63/11|
text_000N_40886|MMI|3.59|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|52/7|
text_000N_40886|MMI|3.59|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|52/7|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Activation action|C1879547|[acty]|["Activate"-tx-1-"activate"-verb-0]|TX|12/8|
text_000N_47406|MMI|5.18|ESN364|C4547456|[orch,phsu]|["ESN364"-tx-1-"ESN364"-noun-0]|TX|5/6|
text_000N_47406|MMI|5.18|activate - Data Operation|C3853838|[ftcn]|["activate"-tx-1-"activate"-verb-0]|TX|12/8|
text_000N_47406|MMI|5.18|activate biological process|C1515877|[ftcn]|["Activate"-tx-1-"activate"-verb-0]|TX|12/8|
text_000N_47406|MMI|5.18|hypothalamic pituitary gonadal axis|C0814030|[bpoc]|["Hypothalamic-pituitary-gonadal axis"-tx-1-"hypothalamic-pituitary-gonadal axis"-noun-0]|TX|25/35|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|3.68|Vaccine [APC]|C5399710|[phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|66/7|
text_000N_40839|MMI|3.68|Vaccines|C0042210|[aapp,imft,phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|66/7|
text_000N_40839|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_40839|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_40839|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_40839|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_40839|MMI|3.48|Guillain-Barre Syndrome|C0018378|[dsyn]|["Guillain Barr√© Syndrome"-tx-1-[71,117,105,108,108,97,105,110,8211,66,97,114,114,233,32,115,121,110,100,114,111,109,101]-noun-0]|TX|32/23|
text_000N_40839|MMI|3.48|Guillain-Barre Syndrome, CTCAE|C4552840|[fndg]|["Guillain-Barre syndrome"-tx-1-[71,117,105,108,108,97,105,110,8211,66,97,114,114,233,32,115,121,110,100,114,111,109,101]-noun-0]|TX|32/23|
text_000N_40839|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_40839|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|3.68|ASPN gene|C1423015|[gngm]|["ASPORIN"-tx-1-"Asporin"-noun-0]|TX|15/7|
text_000N_40941|MMI|3.59|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|34/7|
text_000N_40941|MMI|3.59|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|23/7|
text_000N_40941|MMI|3.59|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|23/7|
text_000N_40941|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|sacituzumab govitecan|C4086837|[aapp,imft,phsu]|["SACITUZUMAB GOVITECAN"-tx-1-"sacituzumab govitecan"-noun-0]|TX|3/21|
text_000N_173230|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|25/9|
text_000N_173230|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|25/9|
text_000N_173230|MMI|3.48|Breast Carcinoma|C0678222|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|39/13|
text_000N_173230|MMI|3.48|Childhood Breast Carcinoma|C3897071|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|39/13|
text_000N_173230|MMI|3.48|Malignant neoplasm of breast|C0006142|[neop]|["BREAST CANCER"-tx-1-"breast cancer"-noun-0]|TX|39/13|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Wnt Proteins|C0753137|[aapp,bacs]|["Wnt Protein"-tx-1-"Wnt protein"-noun-0]|TX|7/11|
text_000N_173214|MMI|3.72|Modified By|C0205349|[qlco]|["Modified By"-tx-1-"modified by"-verb-0]|TX|19/11|
text_000N_173214|MMI|3.59|NOTUM gene|C1835953|[gngm]|["NOTUM"-tx-1-"notum"-noun-0]|TX|31/5|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|ADCY7 gene|C1412226|[gngm]|["ADCY7"-tx-1-"ADCY7"-noun-0]|TX|42/5|
text_000N_47450|MMI|5.18|Ulcerative Colitis|C0009324|[dsyn]|["COLITIS, ULCERATIVE"-tx-1-"ulcerative colitis"-noun-0]|TX|52/18|
text_000N_47450|MMI|3.57|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47450|MMI|3.57|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47450|MMI|3.57|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47450|MMI|3.57|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47450|MMI|3.44|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47450|MMI|3.44|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47450|MMI|3.42|Alteration|C1515926|[idcn]|["Alteration"-tx-1-"alterations"-noun-0]|TX|27/11|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|3.68|Adverse Event Emergency Room Visit|C3810541|[fndg]|["ER"-tx-1-"ER"-noun-0]|TX|15/2|
text_000N_173151|MMI|3.68|Environmental and Social Factors Domain|C5400108|[inpr]|["ER"-tx-1-"ER"-noun-0]|TX|15/2|
text_000N_173151|MMI|3.68|Estrogen Receptor Family, human|C5441529|[aapp,rcpt]|["ER"-tx-1-"ER"-noun-0]|TX|15/2|
text_000N_173151|MMI|3.68|Estrogen Receptor Measurement|C3811131|[lbpr]|["ER"-tx-1-"ER"-noun-0]|TX|15/2|
text_000N_173151|MMI|3.57|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|23/8|
text_000N_173151|MMI|3.57|United States Food and Drug Administration|C0041714|[hcro]|["FDA"-tx-1-"FDA"-noun-0]|TX|39/3|
text_000N_173151|MMI|3.50|amantadine|C0002403|[orch,phsu]|["Amantidine"-tx-1-"amantadine"-noun-0]|TX|4/10|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|Progesterone [EPC]|C2757070|[phsu]|["Progesterone"-tx-1-"progesterone"-noun-0]|TX|3/12|
text_000N_47420|MMI|5.18|Traumatic Brain Injury|C0876926|[inpo]|["Traumatic Brain Injury"-tx-1-"traumatic brain injury"-noun-0]|TX|57/22|
text_000N_47420|MMI|5.18|progesterone|C0033308|[horm,orch,phsu]|["PROGESTERONE"-tx-1-"progesterone"-noun-0]|TX|3/12|
text_000N_47420|MMI|3.75|Based on clinical data|C5426732|[fndg]|["Based on clinical data"-tx-1-"based on clinical data"-noun-0]|TX|80/17,104/4|
text_000N_47420|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|16/9,30/9|
text_000N_47420|MMI|3.56|Clinical Trials|C0008976|[resa]|["Trial"-tx-1-"trial"-noun-0]|TX|98/5|
text_000N_47420|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.72|Modified By|C0205349|[qlco]|["Modified By"-tx-1-"modified by"-verb-0]|TX|32/11|
text_000N_173104|MMI|3.68|MAOA gene|C1417001|[gngm]|["MAOA"-tx-1-"MAOA"-noun-0]|TX|12/4|
text_000N_173104|MMI|3.68|MAOA protein, human|C3657721|[aapp,enzy]|["MAOA"-tx-1-"MAOA"-noun-0]|TX|12/4|
text_000N_173104|MMI|3.68|MAOA wt Allele|C3891068|[gngm]|["MAO-A"-tx-1-"MAOA"-noun-0]|TX|12/4|
text_000N_173104|MMI|3.68|Monoamine Oxidase A|C0026455|[aapp,enzy]|["MAO-A"-tx-1-"MAOA"-noun-0]|TX|12/4|
text_000N_173104|MMI|3.68|methaqualone|C0025627|[orch,phsu]|["MAOA"-tx-1-"MAOA"-noun-0]|TX|12/4|
text_000N_173104|MMI|3.59|Methylation|C0025723|[moft]|["Methylation"-tx-1-"methylation"-noun-0]|TX|44/11|
text_000N_173104|MMI|3.59|Protein methylation|C1159269|[moft]|["Methylation"-tx-1-"methylation"-noun-0]|TX|44/11|
text_000N_173104|MMI|3.50|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|7/4|
text_000N_173104|MMI|3.50|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|7/4|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|10.42|MicroRNAs|C1101610|[bacs,nnon]|["MicroRNA"-tx-1-"microRNA"-noun-0,"miRNA"-tx-1-"miRNA"-noun-0]|TX|3/8;12/5|
text_000N_173136|MMI|5.18|29+|C3843708|[fndg]|["29+"-tx-1-"29"-integer-0]|TX|19/2|
text_000N_173136|MMI|3.55|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173136|MMI|3.55|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173136|MMI|3.55|DESI1 gene|C3470073|[gngm]|["POST"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173136|MMI|3.55|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173136|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
text_000N_173136|MMI|3.55|Ischemic|C0475224|[ftcn]|["Ischemic"-tx-1-"ischemic"-adj-0]|TX|39/8|
text_000N_173136|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
text_000N_173136|MMI|3.55|Post|C0687676|[tmco]|["Post"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173136|MMI|3.55|Post Device|C1704687|[mnob]|["Post"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173136|MMI|3.55|SLC35G1 gene|C3469826|[gngm]|["POST"-tx-1-"post"-adj-0]|TX|34/4|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Neuralgia|C0027796|[sosy]|["Pain, Neuropathic"-tx-1-"neuropathic pain"-noun-0]|TX|20/16|
text_000N_173291|MMI|5.18|Neuropathic pain|C3714625|[fndg]|["Neuropathic Pain"-tx-1-"neuropathic pain"-noun-0]|TX|20/16|
text_000N_173291|MMI|5.18|T lymphocyte count|C1167909|[lbpr]|["T-Cells"-tx-1-"T-Cells"-noun-0]|TX|3/7|
text_000N_173291|MMI|5.18|T-Lymphocyte|C0039194|[cell]|["Cells, T"-tx-1-"T-Cells"-noun-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Amnesia|C0002622|[mobd]|["Memory loss"-tx-1-"memory loss"-noun-0]|TX|19/11|
text_000N_43358|MMI|5.18|Memory Loss|C0751295|[sosy]|["MEMORY LOSS"-tx-1-"memory loss"-noun-0]|TX|19/11|
text_000N_43358|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|11/7|
<<<<< MMI
>>>>> MMI
text_000N_14887|MMI|5.18|FTY-720|C0388088|[orch,phsu]|["FTY720"-tx-1-"FTY720"-noun-0]|TX|4/6|
text_000N_14887|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|49/6|
text_000N_14887|MMI|3.55|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|49/6|
text_000N_14887|MMI|3.55|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|49/6|
text_000N_14887|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|17/10|
text_000N_14887|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
text_000N_14887|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|36/9|
<<<<< MMI
>>>>> MMI
text_000N_14910|MMI|5.18|LUM gene|C1416936|[gngm]|["LUMICAN"-tx-1-"lumican"-noun-0]|TX|3/7|
text_000N_14910|MMI|5.18|LUM protein, human|C1701537|[aapp,bacs]|["Lumican"-tx-1-"lumican"-noun-0]|TX|3/7|
text_000N_14910|MMI|5.18|lumican|C0126273|[aapp]|["Lumican"-tx-1-"lumican"-noun-0]|TX|3/7|
text_000N_14910|MMI|5.18|secretory protein|C0597427|[aapp,bacs]|["Secreted protein"-tx-1-"secreted protein"-noun-0]|TX|13/16|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|resveratrol|C0073096|[orch,phsu]|["RESVERATROL"-tx-1-"resveratrol"-noun-0]|TX|5/11|
text_000N_40999|MMI|3.50|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|24/7|
text_000N_40999|MMI|3.50|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|24/7|
text_000N_40999|MMI|3.50|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|24/7|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|SOSTDC1 gene|C1427738|[gngm]|["WISE"-tx-1-"wise"-adj-0]|TX|44/4|
text_000N_47363|MMI|5.18|SOSTDC1 wt Allele|C4321265|[gngm]|["WISE"-tx-1-"wise"-adj-0]|TX|44/4|
text_000N_47363|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|85/3|
text_000N_47363|MMI|3.68|Alanine Aminotransferase 1, human|C3887708|[aapp,enzy]|["Alanine Aminotransferase"-tx-1-"alanine amino transferase"-noun-0]|TX|58/25|
text_000N_47363|MMI|3.68|Alanine Transaminase|C0001899|[aapp,enzy]|["Alanine Aminotransferase"-tx-1-"alanine amino transferase"-noun-0]|TX|58/25|
text_000N_47363|MMI|3.68|D-Alanine Transaminase|C0057041|[aapp,enzy]|["Alanine amino transferase"-tx-1-"alanine amino transferase"-noun-0]|TX|58/25|
text_000N_47363|MMI|3.68|GPT gene|C1415274|[gngm]|["alanine aminotransferase"-tx-1-"alanine amino transferase"-noun-0]|TX|58/25|
text_000N_47363|MMI|3.56|Abbreviations|C0000723|[inpr]|["Abbreviation"-tx-1-"abbreviation"-noun-0]|TX|11/12|
text_000N_47363|MMI|3.56|Known|C0205309|[qlco]|["Known"-tx-1-"known"-verb-0]|TX|49/5|
text_000N_47363|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|8/2|
text_000N_47363|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|8/2|
text_000N_47363|MMI|3.43|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|31/6|
text_000N_47363|MMI|3.43|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|31/6|
text_000N_47363|MMI|3.43|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|31/6|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.63|Survivors|C0206194|[podg]|["Survivors"-tx-1-"survivors"-noun-0]|TX|65/9|
text_000N_47377|MMI|3.61|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|12/14|
text_000N_47377|MMI|3.53|Childhood Leukemia|C1332977|[neop]|["Childhood Leukemia"-tx-1-"childhood leukemia"-noun-0]|TX|46/18|
text_000N_47377|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47377|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47377|MMI|3.43|Meningioma|C0025286|[neop]|["MENINGIOMAS"-tx-1-"meningiomas"-noun-0]|TX|31/11|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|CD56 Expressing Cell Measurement|C3539926|[lbpr]|["CD56"-tx-1-"CD56"-noun-0]|TX|3/4|
text_000N_43303|MMI|5.18|NCAM1 Positive|C4288706|[lbtr]|["CD56+"-tx-1-"CD56"-noun-0]|TX|3/4|
text_000N_43303|MMI|5.18|Neural Cell Adhesion Molecule 1, Human|C4281806|[aapp,bacs]|["CD56"-tx-1-"CD56"-noun-0]|TX|3/4|
text_000N_43303|MMI|3.56|Useful|C3827682|[qlco]|["Useful"-tx-1-"useful"-adj-0]|TX|8/6|
text_000N_43303|MMI|3.46|Ewings sarcoma|C0553580|[neop]|["Ewings Sarcoma"-tx-1-"Ewing sarcoma"-noun-0]|TX|18/13|
text_000N_43303|MMI|3.46|Ewings sarcoma-primitive neuroectodermal tumor (PNET)|C0684337|[neop]|["sarcoma, Ewing's"-tx-1-"Ewing sarcoma"-noun-0]|TX|18/13|
text_000N_43303|MMI|3.46|NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology|C3541889|[inpr]|["Ewing Sarcoma"-tx-1-"Ewing sarcoma"-noun-0]|TX|18/13|
text_000N_43303|MMI|3.43|Forecast of outcome|C0033325|[hlca]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|32/9|
text_000N_43303|MMI|3.43|Prognosis:Find:Pt:^Patient:Nom|C3854082|[clna]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|32/9|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Ubiquitin|C0041538|[aapp,bacs]|["Ubiquitinated"-tx-1-"ubiquitinated"-verb-0]|TX|24/13|
text_000N_40972|MMI|3.68|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|15/8|
text_000N_40972|MMI|3.45|Phagocytosis Pathway|C2984574|[ftcn]|["Phagosome"-tx-1-"phagosomal"-adj-0]|TX|4/10|
text_000N_40972|MMI|3.45|Phagosomes|C0031310|[celc]|["Phagosomes"-tx-1-"phagosomal"-adj-0]|TX|4/10|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|sarcoma treatment|C0748506|[topp]|["sarcoma treatment"-tx-1-"sarcoma treatment"-noun-0]|TX|35/17|
text_000N_43235|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43235|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43235|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_43235|MMI|3.44|regorafenib|C2980094|[orch,phsu]|["REGORAFENIB"-tx-1-"regorafenib"-noun-0]|TX|19/11|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|ASCII Encoding Version for Read Group QC|C5552849|[inpr]|["encoding"-tx-1-"encoding"-verb-0]|TX|19/8|
text_000N_173276|MMI|5.18|Encode (action)|C2700640|[acty]|["Encoding"-tx-1-"encoding"-verb-0]|TX|19/8|
text_000N_173276|MMI|5.18|MIME encoding|C1547699|[idcn]|["Encoding"-tx-1-"encoding"-verb-0]|TX|19/8|
text_000N_173276|MMI|5.18|SDHAF2 gene|C2240298|[gngm]|["SDHAF2 Gene"-tx-1-"SDHAF2 gene"-noun-0]|TX|7/11|
text_000N_173276|MMI|5.18|Staphylococcal Protein A|C0038164|[aapp,imft,irda]|["a protein"-tx-1-"a protein"-noun-0]|TX|28/9|
text_000N_173276|MMI|3.43|SDHA gene|C1419906|[gngm]|["SDHA"-tx-1-"SDHA"-noun-0]|TX|67/4|
text_000N_173276|MMI|3.43|Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial|C3541238|[aapp,enzy]|["SDHA"-tx-1-"SDHA"-noun-0]|TX|67/4|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Cariprazine Measurement|C5553909|[lbpr]|["Cariprazine"-tx-1-"cariprazine"-noun-0]|TX|3/11|
text_000N_173087|MMI|5.18|cariprazine|C2936870|[orch,phsu]|["CARIPRAZINE"-tx-1-"cariprazine"-noun-0]|TX|3/11|
text_000N_173087|MMI|3.58|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|15/9,29/9|
text_000N_173087|MMI|3.45|Bipolar Disorder|C0005586|[mobd]|["Bipolar Disorder"-tx-1-"bipolar disorder"-noun-0]|TX|42/16|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|3.65|gut hormone|C0684155|[horm]|["gut hormones"-tx-1-"gut hormones"-noun-0]|TX|33/12|
text_000N_173167|MMI|3.49|Exercise|C0015259|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|5/17|
text_000N_173167|MMI|3.49|Physical activity|C0026606|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|5/17|
text_000N_173167|MMI|3.46|Influence|C4054723|[cnce]|["Influence"-tx-1-"influence"-noun-0]|TX|23/9|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|44/7|
text_000N_173120|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|34/2|
text_000N_173120|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|34/2|
text_000N_173120|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|29/4|
text_000N_173120|MMI|5.18|Zinc Finger Nucleases|C4505322|[aapp,enzy]|["Zinc Finger Nucleases"-tx-1-"zinc finger nucleases"-noun-0]|TX|4/21|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|GRPR gene|C1415314|[gngm]|["GRPR"-tx-1-"GRPR"-noun-0]|TX|34/4|
text_000N_173260|MMI|5.18|GRPR protein, human|C5441747|[aapp,rcpt]|["GRPR"-tx-1-"GRPR"-noun-0]|TX|34/4|
text_000N_173260|MMI|5.18|NMBR gene|C1334884|[gngm]|["NMBR"-tx-1-"NMBR"-noun-0]|TX|43/4|
text_000N_173260|MMI|5.18|Neuromedin-B Receptor, Human|C5234938|[aapp,rcpt]|["NMBR"-tx-1-"NMBR"-noun-0]|TX|43/4|
text_000N_173260|MMI|3.75|Bombesin Receptor|C0053917|[aapp,rcpt]|["Receptors, Bombesin"-tx-1-"bombesin receptors"-noun-0]|TX|14/18|
text_000N_173260|MMI|3.62|G-Protein-Coupled Receptors|C0682972|[aapp,rcpt]|["G-Protein-Coupled Receptors"-tx-1-"G-protein-coupled-receptors"-noun-0]|TX|74/27|
text_000N_173260|MMI|3.48|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|8/5|
text_000N_173260|MMI|3.43|Malignant neoplasm of lung|C0242379|[neop]|["Lung Cancers"-tx-1-"lung-cancers"-noun-0]|TX|105/12|
text_000N_173260|MMI|3.42|Frequently|C0332183|[tmco]|["Frequently"-tx-1-"frequently"-adv-0]|TX|49/10|
text_000N_173260|MMI|3.40|Protein Overexpression|C1514559|[genf]|["overexpress"-tx-1-"overexpressed"-adj-0]|TX|60/13|
<<<<< MMI
>>>>> MMI
text_000N_14932|MMI|5.18|Changed status|C0443172|[qnco]|["Changed"-tx-1-"changed"-verb-0]|TX|28/7|
text_000N_14932|MMI|5.18|Changing|C0392747|[ftcn]|["Changed"-tx-1-"changed"-verb-0]|TX|28/7|
text_000N_14932|MMI|5.18|Rotavirus Vaccines|C0597418|[aapp,imft,phsu]|["Rotavirus Vaccines"-tx-1-"rotavirus vaccines"-noun-0]|TX|9/18|
text_000N_14932|MMI|3.63|Genotype|C0017431|[orga]|["Genotypes"-tx-1-"genotypes"-noun-0]|TX|62/9|
text_000N_14932|MMI|3.48|Main|C1542147|[qlco]|["Predominant"-tx-1-"predominant"-adj-0]|TX|40/11|
text_000N_14932|MMI|3.48|Rotavirus|C0035870|[virs]|["ROTAVIRUS"-tx-1-"rotavirus"-noun-0]|TX|52/9|
text_000N_14932|MMI|3.48|Rotavirus Measurement|C5400556|[lbpr]|["Rotavirus"-tx-1-"rotavirus"-noun-0]|TX|52/9|
text_000N_14932|MMI|3.48|rotavirus, live, tetravalent vaccine|C3536964|[imft,phsu]|["rotavirus"-tx-1-"rotavirus"-noun-0]|TX|52/9|
<<<<< MMI
>>>>> MMI
text_000N_14980|MMI|5.18|SLC22A3 gene|C1420138|[gngm]|["SLC22A3"-tx-1-"SLC22A3"-noun-0]|TX|3/7|
text_000N_14980|MMI|3.57|Brain|C0006104|[bpoc]|["BRAIN"-tx-1-"brain"-noun-0]|TX|28/5|
text_000N_14980|MMI|3.57|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|11/9|
text_000N_14980|MMI|3.57|Head>Brain|C4266577|[bpoc]|["Brain"-tx-1-"brain"-noun-0]|TX|28/5|
text_000N_14980|MMI|3.57|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|11/9|
<<<<< MMI
>>>>> MMI
text_000N_15004|MMI|7.70|Quantitative Trait Loci|C0597336|[gngm]|["QTL"-tx-1-"QTLs"-noun-0,"Quantitative Trait Loci"-tx-1-"Quantitative Trait Loci"-noun-0]|TX|58/4;5/23|
text_000N_15004|MMI|7.36|RNA Splicing|C0035687|[genf]|["Splicing"-tx-1-"splicing"-adj-0,"Splicing"-tx-1-"splicing"-noun-0]|TX|[39/8],[49/8];[39/8],[49/8]|
text_000N_15004|MMI|7.36|nuclear mRNA cis splicing, via spliceosome|C2610186|[genf]|["splicing"-tx-1-"splicing"-adj-0,"splicing"-tx-1-"splicing"-noun-0]|TX|[39/8],[49/8];[39/8],[49/8]|
text_000N_15004|MMI|5.18|Affecting|C0392760|[ftcn]|["Affecting"-tx-1-"affecting"-verb-0]|TX|29/9|
text_000N_15004|MMI|5.18|Involvement with|C1314939|[ftcn]|["Affecting"-tx-1-"affecting"-verb-0]|TX|29/9|
text_000N_15004|MMI|3.59|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|79/7|
text_000N_15004|MMI|3.55|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|69/6|
text_000N_15004|MMI|3.55|Links List|C1517892|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|69/6|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|CpG Islands|C0282523|[bacs,nnon]|["CpG Islands"-tx-1-"CpG islands"-noun-0]|TX|4/11|
text_000N_47274|MMI|3.57|Close|C3810854|[fndg]|["Close"-tx-1-"close"-adj-0]|TX|24/5|
text_000N_47274|MMI|3.57|Closed|C0587267|[ftcn]|["Close"-tx-1-"close"-adj-0]|TX|24/5|
text_000N_47274|MMI|3.48|Genes, Housekeeping|C1334046|[gngm]|["House-keeping Genes"-tx-1-"housekeeping genes"-noun-0]|TX|33/18|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.75|Exercise|C0015259|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|11/17|
text_000N_47304|MMI|3.75|Physical activity|C0026606|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|11/17|
text_000N_47304|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|29/15|
text_000N_47304|MMI|3.59|Longevity|C0023980|[tmco]|["Longevity"-tx-1-"longevity"-noun-0]|TX|45/9|
text_000N_47304|MMI|3.48|With intensity|C0522510|[qlco]|["Intense"-tx-1-"intense"-adj-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Mitochondria|C0026237|[celc]|["Mitochondria"-tx-1-"mitochondria"-noun-0]|TX|4/12|
text_000N_47320|MMI|3.56|CEL gene|C1413336|[gngm]|["CELL"-tx-1-"cell"-adj-0]|TX|31/4|
text_000N_47320|MMI|3.56|CELP gene|C1413337|[gngm]|["CELL"-tx-1-"cell"-adj-0]|TX|31/4|
text_000N_47320|MMI|3.56|Cell (compartment)|C1948049|[spco]|["Cell"-tx-1-"cell"-adj-0]|TX|31/4|
text_000N_47320|MMI|3.56|Cell Device|C1704653|[medd]|["Cell"-tx-1-"cell"-adj-0]|TX|31/4|
text_000N_47320|MMI|3.56|Cells|C0007634|[cell]|["Cell"-tx-1-"cell"-adj-0]|TX|31/4|
text_000N_47320|MMI|3.56|Transfer Ability|C4319192|[inpr]|["Transfer"-tx-1-"transfer"-verb-0]|TX|17/8|
text_000N_47320|MMI|3.56|Transfer Technique|C1705822|[ftcn]|["Transfer"-tx-1-"transfer"-verb-0]|TX|17/8|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|liothyronine|C0041014|[aapp,horm,phsu]|["Triiodothyronine"-tx-1-"triiodothyronine"-noun-0]|TX|5/16|
text_000N_47334|MMI|3.68|Na(+)-K(+)-Exchanging ATPase|C0001479|[aapp,enzy]|["Sodium-Potassium Pump"-tx-1-"sodium potassium pump"-noun-0]|TX|47/21|
text_000N_47334|MMI|3.50|Erythrocytes|C0014792|[cell]|["Red Blood Cell"-tx-1-"red blood cell"-noun-0]|TX|32/14|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|dichlorphenamide|C0012086|[orch,phsu]|["Diclofenamid"-tx-1-"dichlorphenamide"-noun-0]|TX|3/16|
text_000N_43386|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|20/9|
text_000N_43386|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|20/9|
text_000N_43386|MMI|3.48|Familial Periodic Paralysis|C0030443|[dsyn]|["PERIODIC PARALYSIS"-tx-1-"periodic paralysis"-noun-0]|TX|34/18|
text_000N_43386|MMI|3.48|periodic paralysis (finding)|C1279412|[dsyn]|["Periodic paralysis"-tx-1-"periodic paralysis"-noun-0]|TX|34/18|
<<<<< MMI
>>>>> MMI
text_000N_40913|AA|HGSOCs|high-grade serous ovarian carcinoma|1|6|9|35|111:6
text_000N_40913|MMI|3.84|High grade serous carcinoma|C3839280|[neop]|["High grade serous carcinoma"-tx-1-"high-grade serous carcinoma"-noun-0]|TX|74/17,100/9|
text_000N_40913|MMI|3.60|Ovarian|C0205065|[bpoc]|["Ovarian"-tx-1-"ovarian"-noun-0]|TX|92/7|
text_000N_40913|MMI|3.59|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|25/15|
text_000N_40913|MMI|3.56|Deletion (action)|C1880274|[acty]|["Deletion"-tx-1-"deletion"-noun-0]|TX|3/8|
text_000N_40913|MMI|3.56|Deletion Mutation|C1511760|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|3/8|
text_000N_40913|MMI|3.56|Gene Deletion Abnormality|C1442161|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|3/8|
text_000N_40913|MMI|3.55|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|48/8|
text_000N_40913|MMI|3.55|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|60/8|
text_000N_40913|MMI|3.55|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|48/8|
text_000N_40913|MMI|3.52|Long|C0205166|[qlco]|["LONG"-tx-1-"longer"-adj-0]|TX|41/6|
text_000N_40913|MMI|3.52|Long Heart Murmur|C5238697|[fndg]|["Long"-tx-1-"longer"-adj-0]|TX|41/6|
text_000N_40913|MMI|3.52|Long Variable|C1706317|[qlco]|["Long"-tx-1-"longer"-adj-0]|TX|41/6|
text_000N_40913|MMI|3.43|6q24|C1521572|[celc]|["6q24"-tx-1-"6q24"-noun-0]|TX|15/4|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Ixodes|C0282511|[euka]|["Ixodes"-tx-1-"Ixodes"-noun-0]|TX|3/6|
text_000N_43275|MMI|3.57|Species|C1705920|[clas]|["Species"-tx-1-"species"-noun-0]|TX|12/7|
text_000N_43275|MMI|3.44|Ticks|C0040203|[euka]|["Tick"-tx-1-"tick"-noun-0]|TX|23/4|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|33/9|
text_000N_43331|MMI|3.61|Libraries|C0023621|[mnob,orgt]|["Libraries"-tx-1-"libraries"-noun-0]|TX|23/9|
text_000N_43331|MMI|3.59|Implemented|C4520547|[ftcn]|["Implemented"-tx-1-"implemented"-verb-0]|TX|43/11|
text_000N_43331|MMI|3.59|Java (geographic location)|C0205803|[geoa]|["Java"-tx-1-"JAVA"-noun-0]|TX|58/4|
text_000N_43331|MMI|3.59|Java Programming Language|C2349992|[inpr]|["Java"-tx-1-"JAVA"-noun-0]|TX|58/4|
text_000N_43331|MMI|3.47|Graph - visual representation|C0681493|[inpr]|["Graph"-tx-1-"graph"-noun-0]|TX|10/5|
text_000N_43331|MMI|3.47|Kernel|C1881303|[inpr]|["Kernel"-tx-1-"kernel"-noun-0]|TX|16/6|
text_000N_43331|MMI|3.47|Mathematical Graph|C2698021|[cnce]|["Graph"-tx-1-"graph"-noun-0]|TX|10/5|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|35/5|
text_000N_173183|MMI|5.18|Insomnia, CTCAE 3.0|C1963237|[fndg]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|41/8|
text_000N_173183|MMI|5.18|Insomnia, CTCAE 5.0|C4554626|[fndg]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|41/8|
text_000N_173183|MMI|5.18|Levoxyl|C0721346|[aapp,phsu]|["Levoxyl"-tx-1-"Levoxyl"-noun-0]|TX|4/7|
text_000N_173183|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|35/5|
text_000N_173183|MMI|5.18|Sleep Quality Question|C4082202|[inpr]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|41/8|
text_000N_173183|MMI|5.18|Sleeplessness|C0917801|[sosy]|["INSOMNIA"-tx-1-"insomnia"-noun-0]|TX|41/8|
text_000N_173183|MMI|5.18|levothyroxine sodium|C0079691|[aapp,horm,phsu]|["Laevothyroxine sodium"-tx-1-"levothyroxine sodium"-noun-0]|TX|13/20|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|9/6|
text_000N_47289|MMI|5.18|CALCIUM HOMEOSTASIS|C3653518|[phsu]|["CALCIUM HOMEOSTASIS"-tx-1-"calcium homeostasis"-noun-0]|TX|16/19|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Melanocytic neoplasm|C1302746|[neop]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|58/8|
text_000N_47349|MMI|5.18|Melanoma Pathway|C2984289|[ftcn]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|58/8|
text_000N_47349|MMI|5.18|NCI CTEP SDC Melanoma Sub-Category Terminology|C3539018|[inpr]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|58/8|
text_000N_47349|MMI|5.18|melanoma|C0025202|[neop]|["MELANOMA"-tx-1-"melanoma"-noun-0]|TX|58/8|
text_000N_47349|MMI|5.18|pembrolizumab|C3658706|[aapp,imft,phsu]|["Lambrolizumab"-tx-1-"lambrolizumab"-noun-0]|TX|3/13|
text_000N_47349|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|17/9,31/9|
text_000N_47349|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|44/8|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Athletes|C0238703|[prog]|["Athletes"-tx-1-"athletes"-noun-0]|TX|46/8|
text_000N_173199|MMI|5.18|Athletes <Butterfly>|C3714533|[euka]|["Athletes"-tx-1-"athletes"-noun-0]|TX|46/8|
text_000N_173199|MMI|3.56|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|9/8|
text_000N_173199|MMI|3.43|Brain natriuretic peptide measurement|C1095989|[lbpr]|["BNP"-tx-1-"BNP"-noun-0]|TX|5/3|
text_000N_173199|MMI|3.43|NPPB gene|C1417808|[gngm]|["BNP"-tx-1-"BNP"-noun-0]|TX|5/3|
text_000N_173199|MMI|3.43|NPPB wt Allele|C2982014|[gngm]|["BNP"-tx-1-"BNP"-noun-0]|TX|5/3|
text_000N_173199|MMI|3.43|nesiritide|C0054015|[aapp,horm,phsu]|["BNP"-tx-1-"BNP"-noun-0]|TX|5/3|
text_000N_173199|MMI|3.42|Exercise intensity|C3669170|[qlco]|["Exercise Intensity"-tx-1-"intensive exercise"-noun-0]|TX|24/18|
text_000N_173199|MMI|3.42|Exercise intensity:Type:Pt:^Patient:Ord|C3669171|[clna]|["Exercise intensity"-tx-1-"intensive exercise"-noun-0]|TX|24/18|
<<<<< MMI
>>>>> MMI
text_000N_47435|AA|HDL-R|HDL-receptor|3|5|3|12|84:5
text_000N_47435|MMI|10.42|PCSK9 gene|C1426592|[gngm]|["PCSK9"-tx-1-"PCSK9"-noun-0,"proprotein convertase subtilisin/kexin type 9"-tx-1-"Proprotein convertase subtilisin/kexin type 9"-noun-0]|TX|5/5;12/45|
text_000N_47435|MMI|10.42|PCSK9 protein, human|C1174937|[aapp,enzy]|["PCSK9"-tx-1-"PCSK9"-noun-0,"Proprotein Convertase Subtilisin/Kexin Type 9"-tx-1-"Proprotein convertase subtilisin/kexin type 9"-noun-0]|TX|5/5;12/45|
text_000N_47435|MMI|5.18|Proprotein Convertase Subtilisin/Kexin Type 9 Measurement|C4050316|[lbpr]|["PCSK9"-tx-1-"PCSK9"-noun-0]|TX|5/5|
text_000N_47435|MMI|3.64|high density lipoprotein receptors|C0062151|[aapp,rcpt]|["HDL receptor"-tx-1-"HDL-receptor"-noun-0]|TX|70/12|
text_000N_47435|MMI|3.64|high-density lipoprotein receptor activity|C2611277|[moft]|["HDL receptor"-tx-1-"HDL-receptor"-noun-0]|TX|70/12|
text_000N_47435|MMI|3.57|Binding (Molecular Function)|C1167622|[moft]|["binds"-tx-1-"binds"-verb-0]|TX|59/5|
text_000N_47435|MMI|3.57|Binding action|C1145667|[acty]|["binds"-tx-1-"binds"-verb-0]|TX|59/5|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.60|de novo Mutation|C2985439|[comd]|["de novo Mutation"-tx-1-"de novo mutations"-noun-0]|TX|4/17|
text_000N_173245|MMI|3.57|Responsible to (attribute)|C1273518|[fndg]|["Responsible"-tx-1-"responsible"-adj-0]|TX|45/11|
text_000N_173245|MMI|3.48|Neurodevelopmental Disorders|C1535926|[mobd]|["Neurodevelopmental Disorders"-tx-1-"neurodevelopmental disorders"-noun-0]|TX|61/28|
text_000N_173245|MMI|3.43|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|36/8|
text_000N_173245|MMI|3.43|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-noun-0]|TX|25/10|
text_000N_173245|MMI|3.43|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-noun-0]|TX|25/10|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Autistic Disorder|C0004352|[mobd]|["AUTISM"-tx-1-"autism"-noun-0]|TX|29/6|
text_000N_47406|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47406|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47406|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47406|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_47406|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_47406|MMI|3.44|TBR1 gene|C1420602|[gngm]|["TBR1"-tx-1-"TBR1"-noun-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Weaver syndrome|C0265210|[dsyn]|["Weaver's syndrome"-tx-1-"Weaver syndrome"-noun-0]|TX|3/15|
text_000N_40941|MMI|3.59|Similarity|C2348205|[qlco]|["Similar"-tx-1-"similar"-adj-0]|TX|19/7|
text_000N_40941|MMI|3.45|NSD1 wt Allele|C2698423|[gngm]|["SOTOS"-tx-1-"Sotos"-noun-0]|TX|30/5|
<<<<< MMI
>>>>> MMI
text_000N_40839|AA|ACE|angiotensin-converting-enzyme|1|3|5|29|34:3
text_000N_40839|AA|ARB|angiotensin receptor blocker|1|3|5|28|85:3
text_000N_40839|AA|ARBs|angiotensin receptor blockers|1|4|5|29|85:4
text_000N_40839|MMI|5.18|Angiotensin II receptor antagonist|C0521942|[phsu]|["Angiotensin Receptor Blockers"-tx-1-"angiotensin receptor blockers"-noun-0]|TX|54/29|
text_000N_40839|MMI|5.18|Angiotensin Receptor Antagonists|C0815017|[phsu]|["Angiotensin Receptor Blockers"-tx-1-"angiotensin receptor blockers"-noun-0]|TX|54/29|
text_000N_40839|MMI|5.18|Angiotensin-Converting Enzyme Inhibitors|C0003015|[phsu]|["Angiotensin converting enzyme--Inhibitors"-tx-1-"angiotensin-converting-enzyme inhibitors"-noun-0]|TX|3/29,39/10|
text_000N_40839|MMI|5.18|Angiotensin-Converting Enzyme Inhibitors [MoA]|C2757044|[moft]|["Angiotensin-converting Enzyme Inhibitors"-tx-1-"angiotensin-converting-enzyme inhibitors"-noun-0]|TX|3/29,39/10|
text_000N_40839|MMI|5.18|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-verb-0]|TX|91/8|
text_000N_40839|MMI|3.55|Probability|C0033204|[qnco]|["Likelihood"-tx-1-"likelihood"-noun-0]|TX|104/10|
text_000N_40839|MMI|3.45|COVID-19|C5203670|[dsyn]|["COVID 19"-tx-1-"COVID-19"-noun-0]|TX|125/8|
text_000N_40839|MMI|3.45|COVID19 (document)|C5243469|[inpr]|["COVID-19"-tx-1-"COVID-19"-noun-0]|TX|125/8|
text_000N_40839|MMI|3.43|Borg Category-Ratio 10 Perceived Exertion Score 5|C4050466|[fndg]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Epidermal cGVHD Score 4|C4761449|[fndg]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Intensity and Distress 5|C5203119|[fndg]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Severe (severity modifier)|C0205082|[fndg]|["SEVERE"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Severe Extremity Pain|C4050465|[fndg]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Severe Hallucination|C4722466|[fndg]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
text_000N_40839|MMI|3.43|Severe dysplasia|C0334048|[comd]|["Severe"-tx-1-"severe"-adj-0]|TX|118/6|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|7/3|
text_000N_173214|MMI|5.18|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|7/3|
text_000N_173214|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Negation|C1518422|[ftcn]|["Not"-tx-1-"not"-adv-0]|TX|19/3|
text_000N_173214|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|RNA|C0035668|[nnon]|["RNA"-tx-1-"RNA"-noun-0]|TX|12/3|
text_000N_173214|MMI|5.18|Ribonucleic Acid Measurement|C4319105|[lbpr]|["RNA"-tx-1-"RNA"-noun-0]|TX|12/3|
text_000N_173214|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|35/3|
text_000N_173214|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|35/3|
text_000N_173214|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
text_000N_173214|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|35/3|
text_000N_173214|MMI|5.18|methylate|C0746574|[phsu]|["methylated"-tx-1-"methylated"-verb-0]|TX|23/10|
text_000N_173214|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-1]|TX|35/3|
<<<<< MMI
>>>>> MMI
text_000N_14856|MMI|5.18|Whole Exome Sequencing|C3640077|[mbrt]|["Sequencing, Whole Exome"-tx-1-"whole exome sequencing"-noun-0]|TX|4/22|
text_000N_14856|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|55/8|
text_000N_14856|MMI|3.57|Performed|C0884358|[ftcn]|["PERFORMED"-tx-1-"performed"-verb-0]|TX|32/9|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.68|Exercise|C0015259|[dora]|["Exercise"-tx-1-"exercise"-noun-0]|TX|56/8|
text_000N_43358|MMI|3.68|Exercise Pain Management|C1522704|[topp]|["Exercise"-tx-1-"exercise"-noun-0]|TX|56/8|
text_000N_43358|MMI|3.56|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|12/8|
text_000N_43358|MMI|3.50|With intensity|C0522510|[qlco]|["Intense"-tx-1-"intense"-adj-0]|TX|48/7|
text_000N_43358|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43358|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43358|MMI|3.43|Ultrasonic|C0220934|[ftcn]|["ultrasound"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.43|Ultrasonic Shockwave|C0041621|[npop]|["ultrasound"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.43|Ultrasonics (sound)|C1456803|[npop]|["Ultrasound"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.43|Ultrasonography|C0041618|[diap]|["ULTRASOUND"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.43|Urological ultrasound|C1315081|[diap]|["Ultrasound"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.43|ultrasound device|C1875843|[medd]|["ULTRASOUND"-tx-1-"ultrasound"-noun-0]|TX|24/10|
text_000N_43358|MMI|3.41|COMETT gene|C5240570|[gngm]|["COMET"-tx-1-"comets"-noun-0]|TX|35/6|
text_000N_43358|MMI|3.41|Comet Assay|C0751980|[mbrt]|["COMET"-tx-1-"comets"-noun-0]|TX|35/6|
text_000N_43358|MMI|3.41|Comet Scoring Engine|C2347828|[inpr]|["Comet"-tx-1-"comets"-noun-0]|TX|35/6|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|methylate|C0746574|[phsu]|["methylated"-tx-1-"methylated"-verb-0]|TX|43/10|
text_000N_47392|MMI|3.63|Molecule|C0567416|[sbst]|["Molecules"-tx-1-"molecules"-noun-0]|TX|18/9|
text_000N_47392|MMI|3.53|RNA, Messenger|C0035696|[bacs,nnon]|["Messenger RNA"-tx-1-"messenger RNA"-noun-0]|TX|4/13|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|nimodipine|C0028094|[orch,phsu]|["NIMODIPINE"-tx-1-"nimodipine"-noun-0]|TX|3/10|
text_000N_47450|MMI|3.61|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|92/8|
text_000N_47450|MMI|3.56|Prevention Study|C1706420|[resa]|["PREVENTION"-tx-1-"prevention"-noun-0]|TX|30/10|
text_000N_47450|MMI|3.56|Prophylactic treatment|C0199176|[topp]|["Prevention"-tx-1-"prevention"-noun-0]|TX|30/10|
text_000N_47450|MMI|3.56|Recommendation|C0034866|[idcn]|["Recommended"-tx-1-"recommended"-verb-0]|TX|14/11|
text_000N_47450|MMI|3.56|Vasospasm|C0085616|[patf]|["VASOSPASM"-tx-1-"vasospasm"-noun-0]|TX|44/9|
text_000N_47450|MMI|3.56|prevention aspects|C2700409|[qlco]|["prevention"-tx-1-"prevention"-noun-0]|TX|30/10|
text_000N_47450|MMI|3.55|Subarachnoid Hemorrhage, Aneurysmal|C0751530|[patf]|["Subarachnoid Hemorrhage, Aneurysmal"-tx-1-"aneurysmal subarachnoid hemorrhage"-noun-0]|TX|57/34|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|7.09|Copy (object)|C1948062|[mnob]|["Copy"-tx-1-"copy"-noun-0]|TX|[55/4],[73/4]|
text_000N_40886|MMI|7.09|Replicate|C1883725|[acty]|["Copy"-tx-1-"copy"-noun-0]|TX|[55/4],[73/4]|
text_000N_40886|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Complete Trisomy 21 Syndrome|C4521042|[dsyn]|["Down Syndrome"-tx-1-"Down's syndrome"-noun-0]|TX|0/15|
text_000N_40886|MMI|5.18|Down Syndrome|C0013080|[dsyn]|["Downs Syndrome"-tx-1-"Down's syndrome"-noun-0]|TX|0/15|
text_000N_40886|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Individual|C0237401|[popg]|["Individual"-tx-1-"individual"-noun-0]|TX|31/10|
text_000N_40886|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Occur (action)|C1709305|[acty]|["Occur"-tx-1-"occurs"-verb-0]|TX|16/6|
text_000N_40886|MMI|5.18|Occurrence Indicator|C4284875|[ftcn]|["OCCUR"-tx-1-"occurs"-verb-0]|TX|16/6|
text_000N_40886|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Persons|C0027361|[popg]|["Individual"-tx-1-"individual"-noun-0]|TX|31/10|
text_000N_40886|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|96/3|
text_000N_40886|MMI|3.58|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|63/7|
text_000N_40886|MMI|3.50|Supernumerary|C1883702|[qnco]|["Extra"-tx-1-"extra"-adj-0]|TX|49/5|
text_000N_40886|MMI|3.44|Chromosomes, Human, Pair 21|C0008664|[celc]|["Chromosome 21"-tx-1-"chromosome 21"-noun-0]|TX|81/13|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.54|Methods|C0025663|[ftcn]|["Methods"-tx-1-"methods"-noun-0]|TX|10/7|
text_000N_40999|MMI|3.54|Methods aspects|C0025664|[ftcn]|["METHODS"-tx-1-"methods"-noun-0]|TX|10/7|
text_000N_40999|MMI|3.54|Techniques|C0449851|[ftcn]|["Methods"-tx-1-"methods"-noun-0]|TX|10/7|
text_000N_40999|MMI|3.43|Chromatin Immunoprecipitation Sequencing|C3831111|[mbrt]|["ChIP-Seq"-tx-1-"ChIP-seq"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.42|High|C0205250|[qlco]|["Highly"-tx-1-"highly"-adv-0]|TX|33/6|
text_000N_40999|MMI|3.42|Libraries|C0023621|[mnob,orgt]|["Libraries"-tx-1-"libraries"-noun-0]|TX|61/9|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.61|Choice Behavior|C0008300|[inbe]|["choice"-tx-1-"choice"-noun-0]|TX|64/6|
text_000N_173104|MMI|3.61|Choose (action)|C1707391|[acty]|["Choice"-tx-1-"choice"-noun-0]|TX|64/6|
text_000N_173104|MMI|3.56|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|11/4|
text_000N_173104|MMI|3.56|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|11/4|
text_000N_173104|MMI|3.55|DNA Repair Pathway|C1511689|[cnce]|["DNA Repair Pathway"-tx-1-"DNA repair pathway"-noun-0]|TX|45/18|
text_000N_173104|MMI|3.43|Gene Physical Location|C1517493|[spco]|["position"-tx-1-"position"-noun-0]|TX|32/8|
text_000N_173104|MMI|3.43|Nuclear (incident type)|C4554581|[qlco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|24/7|
text_000N_173104|MMI|3.43|Nuclear (nucleus)|C0521447|[spco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|24/7|
text_000N_173104|MMI|3.43|Position of phenotypic abnormality|C4019252|[spco]|["Position"-tx-1-"position"-noun-0]|TX|32/8|
text_000N_173104|MMI|3.43|Positioning Attribute|C0733755|[spco]|["Position"-tx-1-"position"-noun-0]|TX|32/8|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Proteasome Inhibitor [EPC]|C3537238|[phsu]|["Proteasome Inhibitor"-tx-1-"Proteasome inhibitor"-noun-0]|TX|16/20|
text_000N_173151|MMI|5.18|Proteasome Inhibitors [MoA]|C2266856|[moft]|["Proteasome Inhibitor"-tx-1-"Proteasome inhibitor"-noun-0]|TX|16/20|
text_000N_173151|MMI|5.18|Proteasome inhibitor|C1443643|[phsu]|["Proteasome Inhibitor"-tx-1-"Proteasome inhibitor"-noun-0]|TX|16/20|
text_000N_173151|MMI|5.18|Proteasome inhibitor (disposition)|C4521476|[qlco]|["Proteasome inhibitor"-tx-1-"Proteasome inhibitor"-noun-0]|TX|16/20|
text_000N_173151|MMI|5.18|bortezomib|C1176309|[orch,phsu]|["BORTEZOMIB"-tx-1-"bortezomib"-noun-0]|TX|3/10|
text_000N_173151|MMI|5.18|proteasome inhibitor therapy|C4724205|[topp]|["proteasome inhibitor"-tx-1-"Proteasome inhibitor"-noun-0]|TX|16/20|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Abdomen>Pancreas|C4037927|[bpoc]|["Pancreas"-tx-1-"pancreas"-noun-0]|TX|71/8|
text_000N_173230|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|22/4|
text_000N_173230|MMI|5.18|Pancreas|C0030274|[bpoc]|["PANCREAS"-tx-1-"pancreas"-noun-0]|TX|71/8|
text_000N_173230|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|22/4|
text_000N_173230|MMI|5.18|liothyronine|C0041014|[aapp,horm,phsu]|["Triiodothyronine"-tx-1-"triiodothyronine"-noun-0]|TX|5/16|
text_000N_173230|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|40/4|
text_000N_173230|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|40/4|
text_000N_173230|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|40/4|
text_000N_173230|MMI|3.45|Insulin Secretion|C1256369|[celf]|["Insulin Secretion"-tx-1-"insulin secretion"-noun-0]|TX|48/17|
text_000N_173230|MMI|3.43|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-adj-0]|TX|29/10|
text_000N_173230|MMI|3.43|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-adj-0]|TX|29/10|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Acid reflux|C4317146|[fndg]|["reflux"-tx-1-"reflux"-noun-0]|TX|44/6|
text_000N_173291|MMI|5.18|Reflux|C0232483|[patf]|["Reflux"-tx-1-"reflux"-noun-0]|TX|44/6|
text_000N_173291|MMI|3.57|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173291|MMI|3.57|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173291|MMI|3.57|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173291|MMI|3.57|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173291|MMI|3.44|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_173291|MMI|3.44|Bruxism|C0006325|[mobd]|["BRUXISM"-tx-1-"bruxism"-noun-0]|TX|32/7|
text_000N_173291|MMI|3.44|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_14957|MMI|5.18|amiodarone|C0002598|[orch,phsu]|["AMIODARONE"-tx-1-"amiodarone"-noun-0]|TX|3/10|
text_000N_14957|MMI|3.72|Cardiac depressant drug, NOS|C0301380|[phsu]|["anti arrhythmic drug"-tx-1-"anti-arrhythmic drug"-noun-0]|TX|24/20|
text_000N_14957|MMI|3.49|Canadian Cardiovascular Society Grading Scale Class I|C2698967|[fndg]|["Class I"-tx-1-"class I"-noun-0]|TX|16/7|
text_000N_14957|MMI|3.49|Class 1|C0441885|[clas]|["Class I"-tx-1-"class I"-noun-0]|TX|16/7|
text_000N_14957|MMI|3.49|New York Heart Association Classification - Class I|C1319793|[inpr]|["Class I"-tx-1-"class I"-noun-0]|TX|16/7|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.68|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.68|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.68|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.68|Juice|C1268568|[food]|["Juice"-tx-1-"juice"-noun-0]|TX|13/5|
text_000N_40972|MMI|3.50|Annona x atemoya|C1079976|[plnt]|["atemoya"-tx-1-"atemoya"-noun-0]|TX|5/7|
text_000N_40972|MMI|3.50|CYP1A2 gene|C1332826|[gngm]|["CYP1A2"-tx-1-"CYP1A2"-noun-0]|TX|31/6|
text_000N_40972|MMI|3.50|CYP1A2 protein, human|C1620185|[aapp,enzy]|["CYP1A2"-tx-1-"CYP1A2"-noun-0]|TX|31/6|
text_000N_40972|MMI|3.50|Cytochrome P-450 CYP1A2|C0207509|[aapp,enzy]|["CYP1A2"-tx-1-"CYP1A2"-noun-0]|TX|31/6|
<<<<< MMI
>>>>> MMI
text_000N_15028|MMI|5.18|Dual-Specificity Phosphatases|C1956000|[aapp,enzy]|["Phosphatase, Dual-Specificity"-tx-1-"dual specificity phosphatase"-noun-0]|TX|18/28|
text_000N_15028|MMI|3.63|Acute Promyelocytic Leukemia|C0023487|[neop]|["M3"-tx-1-"M3"-noun-0]|TX|11/2|
text_000N_15028|MMI|3.63|Cubic Meter|C1300554|[qnco]|["m3"-tx-1-"M3"-noun-0]|TX|11/2|
text_000N_15028|MMI|3.63|M3 Mental Health Checklist|C3484373|[inpr]|["M3"-tx-1-"M3"-noun-0]|TX|11/2|
text_000N_15028|MMI|3.63|M3 modifier|C5444851|[fndg]|["M3"-tx-1-"M3"-noun-0]|TX|11/2|
text_000N_15028|MMI|3.63|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Carpal Tunnel Syndrome|C0007286|[dsyn]|["CARPAL TUNNEL SYNDROME"-tx-1-"carpal tunnel syndrome"-noun-0]|TX|3/22|
text_000N_47274|MMI|3.60|Type A|C4264487|[clas]|["Type A"-tx-1-"a type"-noun-0]|TX|26/6|
text_000N_47274|MMI|3.46|Nerve Entrapment|C0917811|[dsyn]|["Nerve Entrapment"-tx-1-"nerve entrapment"-noun-0]|TX|36/16|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|AGO2 gene|C1414333|[gngm]|["AGO2"-tx-1-"AGO2"-noun-0]|TX|3/4|
text_000N_47289|MMI|5.18|EIF2C2 protein, human|C1144026|[aapp,bacs]|["AGO2"-tx-1-"AGO2"-noun-0]|TX|3/4|
text_000N_47289|MMI|3.59|Cytokinesis|C0010813|[celf]|["Cytokinesis"-tx-1-"cytokinesis"-noun-0]|TX|19/11|
text_000N_47289|MMI|3.59|Cytokinesis of the fertilized ovum|C1330957|[celf]|["cytokinesis"-tx-1-"cytokinesis"-noun-0]|TX|19/11|
text_000N_47289|MMI|3.59|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|8/7|
text_000N_47289|MMI|3.59|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|8/7|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|lenvatinib|C2986924|[orch,phsu]|["LENVATINIB"-tx-1-"lenvatinib"-noun-0]|TX|3/10|
text_000N_47304|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47304|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47304|MMI|3.48|Malignant neoplasm of thyroid|C0007115|[neop]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|28/14|
text_000N_47304|MMI|3.48|NCI CTEP SDC Thyroid Cancer Sub-Category Terminology|C3541337|[inpr]|["Thyroid Cancer"-tx-1-"thyroid cancer"-noun-0]|TX|28/14|
text_000N_47304|MMI|3.48|Papillary Thyroid Carcinoma Pathway|C2984307|[cnce]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|28/14|
text_000N_47304|MMI|3.48|Thyroid Neoplasm|C0040136|[neop]|["Thyroid cancer"-tx-1-"thyroid cancer"-noun-0]|TX|28/14|
text_000N_47304|MMI|3.48|Thyroid carcinoma|C0549473|[neop]|["Cancer, Thyroid"-tx-1-"thyroid cancer"-noun-0]|TX|28/14|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Diabetes Mellitus, Insulin-Dependent|C0011854|[dsyn]|["Type I Diabetes"-tx-1-"type 1 diabetes"-noun-0]|TX|51/15|
text_000N_47320|MMI|5.18|Peroxisome Proliferator-Activated Receptor Gamma, human|C3887582|[aapp,rcpt]|["PPARG"-tx-1-"PPARG"-noun-0]|TX|41/5|
text_000N_47320|MMI|3.56|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|11/4|
text_000N_47320|MMI|3.56|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|11/4|
text_000N_47320|MMI|3.44|A variant NOS|C4740192|[imft]|["A variant NOS"-tx-1-"a variants"-noun-0]|TX|9/1,29/8|
text_000N_47320|MMI|3.43|Infrequent|C0521114|[tmco]|["Rare"-tx-1-"rare"-adj-0]|TX|24/4|
text_000N_47320|MMI|3.43|Rare|C0522498|[qlco]|["Rare"-tx-1-"rare"-adj-0]|TX|24/4|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|NSD 1015|C0069105|[orch,phsu]|["NSD 1015"-tx-1-"NSD-1015"-noun-0]|TX|3/8|
text_000N_47349|MMI|3.54|Inhibitor|C1999216|[bacs]|["INHIBITOR"-tx-1-"inhibitor"-noun-0]|TX|15/9|
text_000N_47349|MMI|3.51|Aromatic-L-Amino-Acid Decarboxylases|C1412028|[aapp,enzy]|["aromatic L aminoacid decarboxylase"-tx-1-"Aromatic L-Amino Acid Decarboxylase"-noun-0]|TX|28/35|
text_000N_47349|MMI|3.51|DDC gene|C1413943|[gngm]|["AROMATIC L-AMINO ACID DECARBOXYLASE"-tx-1-"Aromatic L-Amino Acid Decarboxylase"-noun-0]|TX|28/35|
text_000N_47349|MMI|3.51|DDC protein, human|C4042618|[aapp,enzy]|["Aromatic L-Amino Acid Decarboxylase"-tx-1-"Aromatic L-Amino Acid Decarboxylase"-noun-0]|TX|28/35|
text_000N_47349|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|12/2|
text_000N_47349|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|12/2|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|8/9|
text_000N_47363|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|8/9|
text_000N_47363|MMI|3.61|HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1|C3888239|[fndg]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|40/20|
text_000N_47363|MMI|3.61|Hirschsprung Disease|C0019569|[dsyn]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|40/20|
text_000N_47363|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|18/8|
text_000N_47363|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|18/8|
text_000N_47363|MMI|3.56|Syndromic|C5453017|[qlco]|["Syndromic"-tx-1-"syndromic"-adj-0]|TX|30/9|
text_000N_47363|MMI|3.50|BBS2 gene|C1412747|[gngm]|["BBS"-tx-1-"BBS"-noun-0]|TX|4/3|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|ADP-Ribosylation|C0596043|[moft]|["ADP Ribosylation"-tx-1-"ADP-ribosylation"-noun-0]|TX|3/16|
text_000N_47377|MMI|5.18|Post-Translational Protein Processing|C0033666|[moft]|["PTM"-tx-1-"PTM"-noun-0]|TX|22/3|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Progeria|C0033300|[dsyn]|["PROGERIA"-tx-1-"progeria"-noun-0]|TX|3/8|
text_000N_47406|MMI|3.59|Autosomal recessive inheritance|C0441748|[genf]|["Autosomal Recessive"-tx-1-"autosomal recessive"-noun-0]|TX|25/19|
text_000N_47406|MMI|3.59|Genes, Recessive|C0017361|[gngm]|["Recessive Gene"-tx-1-"recessive gene"-noun-0]|TX|35/14|
text_000N_47406|MMI|3.55|Autosome|C0596142|[celc]|["Autosomal"-tx-1-"autosomal"-noun-0]|TX|25/9|
text_000N_47406|MMI|3.55|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|45/4|
text_000N_47406|MMI|3.55|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|45/4|
text_000N_47406|MMI|3.52|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|12/6|
text_000N_47406|MMI|3.52|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|12/6|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|R-Loop Structures|C5197762|[nnon]|["R-Loops"-tx-1-"R-loops"-noun-0]|TX|3/7|
text_000N_47392|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|16/2|
text_000N_47392|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|16/2|
text_000N_47392|MMI|3.59|DNA Replication|C0598312|[genf]|["DNA Replication"-tx-1-"DNA replication"-noun-0]|TX|36/15|
text_000N_47392|MMI|3.59|DNA Replication Pathway|C2984261|[ftcn]|["DNA replication"-tx-1-"DNA replication"-noun-0]|TX|36/15|
text_000N_47392|MMI|3.57|Site of|C2945843|[spco]|["Site of"-tx-1-"sites of"-noun-0]|TX|27/8|
text_000N_47392|MMI|3.55|Form:Finding:Point in time:{Setting}:Document:{Role}|C4255237|[clna]|["Form"-tx-1-"form"-verb-0]|TX|19/4|
text_000N_47392|MMI|3.55|Formation|C1522492|[ftcn]|["Form"-tx-1-"form"-verb-0]|TX|19/4|
text_000N_47392|MMI|3.55|Manufactured form|C0376315|[mnob]|["Form"-tx-1-"form"-verb-0]|TX|19/4|
text_000N_47392|MMI|3.55|Qualitative form|C0348078|[qlco]|["Form"-tx-1-"form"-verb-0]|TX|19/4|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.68|minichromosomes|C5001826|[nusq]|["minichromosomes"-tx-1-"minichromosomes"-noun-0]|TX|17/15|
text_000N_47420|MMI|3.59|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"free"-adj-0]|TX|33/4|
text_000N_47420|MMI|3.59|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"free"-adj-0]|TX|33/4|
text_000N_47420|MMI|3.45|Hepadnaviridae|C0019132|[virs]|["Hepadnaviruses"-tx-1-"hepadnaviral"-adj-0]|TX|4/12|
text_000N_47420|MMI|3.45|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosomes"-tx-1-"nucleosomes"-noun-0]|TX|41/11|
<<<<< MMI
>>>>> MMI
text_000N_43235|AA|miR|microRNA|1|3|1|8|14:3
text_000N_43235|MMI|5.18|MicroRNAs|C1101610|[bacs,nnon]|["MicroRNA"-tx-1-"microRNA"-noun-0]|TX|4/8|
text_000N_43235|MMI|3.58|DNA Methylation|C0376452|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|37/15|
text_000N_43235|MMI|3.58|DNA Methylation Analysis|C1880239|[mbrt]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|37/15|
text_000N_43235|MMI|3.58|DNA Methylation [PE]|C3536933|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|37/15|
text_000N_43235|MMI|3.55|Promoter|C0086860|[bacs,nnon]|["promoters"-tx-1-"promoters"-noun-0]|TX|62/9|
text_000N_43235|MMI|3.55|Regulation|C0851285|[gora]|["Regulated"-tx-1-"regulated"-verb-0]|TX|19/9|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|43/6|
text_000N_43275|MMI|5.18|Burning Mouth Syndrome|C0006430|[dsyn]|["Burning Mouth Syndrome"-tx-1-"burning mouth syndrome"-noun-0]|TX|5/22|
text_000N_43275|MMI|3.63|Woman|C0043210|[popg]|["Women"-tx-1-"women"-noun-0]|TX|66/5|
text_000N_43275|MMI|3.48|DESI1 gene|C3470073|[gngm]|["POST"-tx-1-"post"-noun-0]|TX|50/4|
text_000N_43275|MMI|3.48|Post|C0687676|[tmco]|["Post"-tx-1-"post"-noun-0]|TX|50/4|
text_000N_43275|MMI|3.48|Post Device|C1704687|[mnob]|["Post"-tx-1-"post"-noun-0]|TX|50/4|
text_000N_43275|MMI|3.48|SLC35G1 gene|C3469826|[gngm]|["POST"-tx-1-"post"-noun-0]|TX|50/4|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|Carmustine Implant|C0796325|[clnd]|["Carmustine Wafers"-tx-1-"carmustine wafers"-noun-0]|TX|3/17|
text_000N_47435|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|29/8|
text_000N_47435|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|29/8|
text_000N_47435|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|41/12|
text_000N_47435|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|41/12|
text_000N_47435|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|41/12|
text_000N_47435|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|41/12|
text_000N_47435|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|54/8|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|xaliproden|C1138235|[orch]|["XALIPRODEN"-tx-1-"xaliproden"-noun-0]|TX|5/10|
text_000N_43303|MMI|3.56|Forecast of outcome|C0033325|[hlca]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|24/9|
text_000N_43303|MMI|3.56|Prognosis:Find:Pt:^Patient:Nom|C3854082|[clna]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|24/9|
text_000N_43303|MMI|3.50|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|37/29|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|cabergoline|C0107994|[orch,phsu]|["CABERGOLINE"-tx-1-"cabergoline"-noun-0]|TX|3/11|
text_000N_47450|MMI|3.58|Nelson Syndrome|C0027577|[neop]|["Nelson's syndrome"-tx-1-"Nelson's syndrome"-noun-0]|TX|41/17|
text_000N_47450|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|15/4,34/2|
text_000N_47450|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_47450|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.55|Bias (Epidemiology)|C0005346|[idcn]|["Bias"-tx-1-"bias"-noun-0]|TX|20/4|
text_000N_47334|MMI|3.55|Bias genus|C1504315|[bird]|["Bias"-tx-1-"bias"-noun-0]|TX|20/4|
text_000N_47334|MMI|3.55|Biases|C0242568|[idcn]|["Bias"-tx-1-"bias"-noun-0]|TX|20/4|
text_000N_47334|MMI|3.43|A pattern|C4699190|[fndg]|["A pattern"-tx-1-"a patterns"-noun-0]|TX|9/1,44/8|
text_000N_47334|MMI|3.42|Base Sequence|C0004793|[nusq]|["Sequence"-tx-1-"sequence"-noun-0]|TX|11/8|
text_000N_47334|MMI|3.42|DNA Sequence|C0162326|[nusq]|["Sequence"-tx-1-"sequence"-noun-0]|TX|11/8|
text_000N_47334|MMI|3.42|Digestion|C0012238|[orgf]|["Digestion"-tx-1-"digestion"-noun-0]|TX|34/9|
text_000N_47334|MMI|3.42|Protein Digestion (research activity)|C2349986|[resa]|["Digestion"-tx-1-"digestion"-noun-0]|TX|34/9|
text_000N_47334|MMI|3.42|RNA Sequence|C0162327|[nusq]|["Sequence"-tx-1-"sequence"-noun-0]|TX|11/8|
text_000N_47334|MMI|3.42|Sequence|C1519249|[ftcn]|["Sequence"-tx-1-"sequence"-noun-0]|TX|11/8|
text_000N_47334|MMI|3.42|Sequence - TransmissionRelationshipTypeCode|C3853789|[inpr]|["sequence"-tx-1-"sequence"-noun-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Lifestyle changes|C0870811|[socb]|["Lifestyle changes"-tx-1-"life style changes"-noun-0]|TX|4/18|
text_000N_43331|MMI|5.18|Oxidative Stress|C0242606|[comd]|["Oxidative Stress"-tx-1-"oxidative stress"-noun-0]|TX|30/16|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|AZD3759|C3896908|[orch,phsu]|["AZD3759"-tx-1-"AZD3759"-noun-0]|TX|5/7|
text_000N_43358|MMI|5.18|Blood - brain barrier anatomy|C0005854|[bpoc]|["Blood-Brain Barrier"-tx-1-"blood brain barrier"-noun-0]|TX|23/19|
text_000N_43358|MMI|5.18|Blood - brain barrier function|C1305865|[ortf]|["Blood-brain barrier"-tx-1-"blood brain barrier"-noun-0]|TX|23/19|
text_000N_43358|MMI|5.18|Traverse|C2828360|[cnce]|["Cross"-tx-1-"cross"-verb-0]|TX|13/5|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|ASCII Encoding Version for Read Group QC|C5552849|[inpr]|["encoding"-tx-1-"encoding"-verb-0]|TX|10/8|
text_000N_43386|MMI|5.18|Encode (action)|C2700640|[acty]|["Encoding"-tx-1-"encoding"-verb-0]|TX|10/8|
text_000N_43386|MMI|5.18|FKBP4 gene|C1414626|[gngm]|["FKBP52"-tx-1-"FKBP52"-noun-0]|TX|3/6|
text_000N_43386|MMI|5.18|MIME encoding|C1547699|[idcn]|["Encoding"-tx-1-"encoding"-verb-0]|TX|10/8|
text_000N_43386|MMI|5.18|Molecular Chaperones|C0243041|[aapp,bacs]|["Chaperone"-tx-1-"chaperone"-noun-0]|TX|21/9|
text_000N_43386|MMI|5.18|tacrolimus binding protein 4|C0209554|[aapp,enzy]|["FKBP52"-tx-1-"FKBP52"-noun-0]|TX|3/6|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Pseudovaginal Perineoscrotal Hypospadias|C0268297|[dsyn]|["Steroid 5a-reductase deficiency"-tx-1-"steroid 5A-Reductase deficiency"-noun-0]|TX|5/31|
text_000N_40839|MMI|3.59|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|37/4|
text_000N_40839|MMI|3.59|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|37/4|
text_000N_40839|MMI|3.59|Hermaphroditism|C0019269|[dsyn]|["HERMAPHRODITISM"-tx-1-"hermaphroditism"-noun-0]|TX|45/15|
text_000N_40839|MMI|3.59|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|37/4|
text_000N_40839|MMI|3.59|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|37/4|
text_000N_40839|MMI|3.59|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|37/4|
text_000N_40839|MMI|3.59|True Hermaphroditism (disorder)|C0266361|[dsyn]|["HERMAPHRODITISM"-tx-1-"hermaphroditism"-noun-0]|TX|45/15|
text_000N_40839|MMI|3.59|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|37/4|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Archaea|C0003732|[arch]|["Archaea"-tx-1-"archaea"-noun-0]|TX|7/7|
text_000N_40886|MMI|5.18|Possess|C3154893|[idcn]|["Possess"-tx-1-"possess"-verb-0]|TX|15/7|
text_000N_40886|MMI|5.18|Possessed|C0850310|[mobd]|["possess"-tx-1-"possess"-verb-0]|TX|15/7|
text_000N_40886|MMI|3.64|Replication Origin|C0242961|[nusq]|["Origin of Replication"-tx-1-"origins of replication"-noun-0]|TX|32/10,47/11|
text_000N_40886|MMI|3.43|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|43/3|
text_000N_40886|MMI|3.43|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|43/3|
text_000N_40886|MMI|3.43|Numerous|C0439064|[qnco]|["MULTIPLE"-tx-1-"multiple"-adj-0]|TX|23/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Adenovirus Vector|C1510800|[nnon]|["Adenoviral Vector"-tx-1-"adenoviral vector"-noun-0]|TX|21/17|
text_000N_40941|MMI|5.18|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-verb-0]|TX|14/3|
text_000N_40941|MMI|5.18|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-verb-0]|TX|14/3|
text_000N_40941|MMI|5.18|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-verb-0]|TX|14/3|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Hyperviscosity syndrome|C0221030|[dsyn]|["HYPERVISCOSITY SYNDROME"-tx-1-"hyperviscosity syndrome"-noun-0]|TX|38/23|
text_000N_40972|MMI|3.63|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|21/8|
text_000N_40972|MMI|3.53|Multiple Myeloma|C0026764|[neop]|["MULTIPLE MYELOMA"-tx-1-"multiple myeloma"-noun-0]|TX|4/16|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.63|RNA|C0035668|[nnon]|["rnas"-tx-1-"RNAs"-noun-0]|TX|19/4|
text_000N_40913|MMI|3.48|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancer"-noun-0]|TX|10/8|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Creation of ventriculo-peritoneal shunt|C0162702|[topp]|["Ventriculo peritoneal Shunt"-tx-1-"ventriculoperitoneal shunt"-noun-0]|TX|5/26|
text_000N_40999|MMI|5.18|Hydrocephalus, Normal Pressure|C0020258|[dsyn]|["Hydrocephalus, Normal Pressure"-tx-1-"normal pressure hydrocephalus"-noun-0]|TX|40/29|
text_000N_40999|MMI|5.18|Ventriculoperitoneal catheter|C0175662|[medd]|["Ventriculoperitoneal shunt"-tx-1-"ventriculoperitoneal shunt"-noun-0]|TX|5/26|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.68|neonatal development|C0870945|[phpr]|["neonatal development"-tx-1-"neonatal development"-noun-0]|TX|48/20|
text_000N_173087|MMI|3.64|Use of|C1524063|[ftcn]|["Use of"-tx-1-"use of"-noun-0]|TX|9/6|
text_000N_173087|MMI|3.47|IMPACT gene|C1825598|[gngm]|["IMPACT"-tx-1-"impact"-noun-0]|TX|41/6|
text_000N_173087|MMI|3.47|Impact|C4049986|[qlco]|["Impact"-tx-1-"impact"-noun-0]|TX|41/6|
text_000N_173087|MMI|3.47|Patient currently pregnant|C0549206|[fndg]|["Pregnancy"-tx-1-"pregnancy"-noun-0]|TX|31/9|
text_000N_173087|MMI|3.47|Pregnancy|C0032961|[orgf]|["PREGNANCY"-tx-1-"pregnancy"-noun-0]|TX|31/9|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|apremilast|C1678805|[orch,phsu]|["APREMILAST"-tx-1-"apremilast"-noun-0]|TX|3/10|
text_000N_173104|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173104|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173104|MMI|3.48|Arthritis, Psoriatic|C0003872|[dsyn]|["ARTHRITIS, PSORIATIC"-tx-1-"psoriatic arthritis"-noun-0]|TX|28/19|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Caucasian|C0007457|[popg]|["Caucasians"-tx-1-"Caucasians"-noun-0]|TX|69/10|
text_000N_173120|MMI|5.18|Caucasians|C0043157|[popg]|["CAUCASIANS"-tx-1-"Caucasians"-noun-0]|TX|69/10|
text_000N_173120|MMI|5.18|UGT1A1 gene|C0537026|[gngm]|["UGT1A1"-tx-1-"UGT1A1"-noun-0]|TX|7/6|
text_000N_173120|MMI|5.18|UGT1A1 protein, human|C1567723|[aapp,enzy]|["UGT1A1"-tx-1-"UGT1A1"-noun-0]|TX|7/6|
text_000N_173120|MMI|3.68|Genetic Polymorphism|C0032529|[genf]|["POLYMORPHISM"-tx-1-"polymorphism"-noun-0]|TX|17/12|
text_000N_173120|MMI|3.68|Polymorphism|C1882417|[qlco]|["Polymorphism"-tx-1-"polymorphism"-noun-0]|TX|17/12|
text_000N_173120|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|30/15|
text_000N_173120|MMI|3.57|Disease Response|C1704632|[fndg]|["RESPONSE"-tx-1-"response"-noun-0]|TX|57/8|
text_000N_173120|MMI|3.57|Response (communication)|C2911692|[menp]|["Response"-tx-1-"response"-noun-0]|TX|57/8|
text_000N_173120|MMI|3.57|Response (statement)|C1706817|[inpr]|["Response"-tx-1-"response"-noun-0]|TX|57/8|
text_000N_173120|MMI|3.57|Response process|C0871261|[orga]|["Response"-tx-1-"response"-noun-0]|TX|57/8|
text_000N_173120|MMI|3.57|Responsive Disease|C5236984|[fndg]|["response"-tx-1-"response"-noun-0]|TX|57/8|
text_000N_173120|MMI|3.57|irinotecan|C0123931|[orch,phsu]|["IRINOTECAN"-tx-1-"irinotecan"-noun-0]|TX|46/10|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|rhamnose|C0035417|[bacs,orch]|["RHAMNOSE"-tx-1-"Rhamnose"-noun-0]|TX|5/8|
text_000N_173136|MMI|3.57|Effect|C1280500|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173136|MMI|3.57|Effect, Appearance|C2348382|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173136|MMI|3.57|Outcome of Therapy|C1518681|[fndg]|["effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173136|MMI|3.44|Aging|C0001811|[orgf]|["Ageing"-tx-1-"aging"-noun-0]|TX|33/5|
text_000N_173136|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|19/3|
text_000N_173136|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|19/3|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|FBN1 gene|C1414542|[gngm]|["Marfan syndrome"-tx-1-"Marfan syndrome"-noun-0]|TX|3/15|
text_000N_173151|MMI|5.18|Family history of Marfan syndrome|C4040152|[fndg]|["Marfan syndrome"-tx-1-"Marfan syndrome"-noun-0]|TX|3/15|
text_000N_173151|MMI|5.18|Marfan Syndrome|C0024796|[dsyn]|["MARFAN'S SYNDROME"-tx-1-"Marfan syndrome"-noun-0]|TX|3/15|
text_000N_173151|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|19/15|
text_000N_173151|MMI|3.57|Rupture|C3203359|[inpo]|["RUPTURE"-tx-1-"rupture"-noun-0]|TX|43/7|
text_000N_173151|MMI|3.51|Chorda|C1011714|[plnt]|["Chorda"-tx-1-"chordal"-adj-0]|TX|35/7|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|7.20|TRIM37 gene|C1417503|[gngm]|["TRIM37"-tx-1-"TRIM37"-noun-0,"TRIM37 Gene"-tx-1-"TRIM37 gene"-noun-0]|TX|5/6;5/11|
text_000N_173167|MMI|5.18|Etiology|C1314792|[ftcn]|["Causes"-tx-1-"causes"-verb-0]|TX|26/6|
text_000N_173167|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["causes"-tx-1-"causes"-verb-0]|TX|26/6|
text_000N_173167|MMI|5.18|Mulibrey Nanism|C0524582|[dsyn]|["MULIBREY NANISM"-tx-1-"Mulibrey nanism"-noun-0]|TX|33/15|
text_000N_173167|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"causes"-verb-0]|TX|26/6|
text_000N_173167|MMI|3.75|Gene Mutant|C0678941|[gngm]|["Gene Mutation"-tx-1-"gene mutation"-noun-0]|TX|12/13|
text_000N_173167|MMI|3.75|Gene Mutation|C0596611|[genf]|["Gene Mutation"-tx-1-"gene mutation"-noun-0]|TX|12/13|
text_000N_173167|MMI|3.63|Mutation|C0026882|[genf]|["Mutation"-tx-1-"mutation"-noun-0]|TX|17/8|
text_000N_173167|MMI|3.63|Mutation Abnormality|C1705285|[comd]|["Mutation"-tx-1-"mutation"-noun-0]|TX|17/8|
text_000N_173167|MMI|3.48|TRIM37 protein, human|C1122524|[aapp,enzy]|["TRIM37"-tx-1-"TRIM37"-noun-0]|TX|5/6|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|3.56|Present|C0150312|[fndg]|["PRESENT"-tx-1-"present"-noun-0]|TX|9/7|
text_000N_173183|MMI|3.56|Presentation|C0449450|[idcn]|["Present"-tx-1-"present"-noun-0]|TX|9/7|
text_000N_173183|MMI|3.56|Radial-Femoral Lag Present|C5238858|[fndg]|["Present"-tx-1-"present"-noun-0]|TX|9/7|
text_000N_173183|MMI|3.43|Actins|C0001271|[aapp,bacs]|["Actin"-tx-1-"actin"-noun-0]|TX|3/5|
text_000N_173183|MMI|3.43|Atomic Nucleus|C4724279|[elii]|["Nucleus"-tx-1-"nucleus"-noun-0]|TX|24/7|
text_000N_173183|MMI|3.43|Cell Nucleus|C0007610|[celc]|["NUCLEUS"-tx-1-"nucleus"-noun-0]|TX|24/7|
<<<<< MMI
>>>>> MMI
text_000N_173199|AA|ARM|anesthesia-resistant memory|1|3|5|27|50:3
text_000N_173199|MMI|5.18|Drosophila <basidiomycetes>|C4554050|[fngs]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|58/10|
text_000N_173199|MMI|5.18|Drosophila <flies,subgenus>|C1504613|[euka]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|58/10|
text_000N_173199|MMI|5.18|Drosophila <fruit fly, genus>|C0013138|[euka]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|58/10|
text_000N_173199|MMI|3.56|Essential|C0205224|[qlco]|["Essential"-tx-1-"essential"-adj-0]|TX|7/9|
text_000N_173199|MMI|3.50|anesthesia-resistant memory|C1154342|[menp]|["anesthesia-resistant memory"-tx-1-"anesthesia-resistant memory"-noun-0]|TX|21/27|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|3.54|Computer software|C0037585|[inpr,mnob]|["Software"-tx-1-"software"-noun-0]|TX|13/8|
text_000N_173214|MMI|3.43|Image Processing|C0178706|[mcha]|["Image Analysis"-tx-1-"analysis images"-noun-0]|TX|36/8,53/6|
text_000N_173214|MMI|3.43|Image analysis (procedure)|C0200765|[lbpr]|["Image analysis"-tx-1-"analysis images"-noun-0]|TX|36/8,53/6|
text_000N_173214|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173214|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173214|MMI|3.42|Automated (qualifier value)|C0205554|[ftcn]|["Automated"-tx-1-"automated"-adj-0]|TX|26/9|
text_000N_173214|MMI|3.42|Fish (substance)|C4521129|[food]|["Fish"-tx-1-"FISH"-noun-0]|TX|48/4|
text_000N_173214|MMI|3.42|Fish Flavor|C2700184|[food]|["FISH"-tx-1-"FISH"-noun-0]|TX|48/4|
text_000N_173214|MMI|3.42|Fishes|C0016163|[fish]|["FISH"-tx-1-"FISH"-noun-0]|TX|48/4|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Membrane Transport Proteins|C0596902|[aapp,bacs]|["transporter"-tx-1-"transporter"-noun-0]|TX|67/11|
text_000N_173230|MMI|5.18|Transporter device|C3854146|[medd]|["Transporter"-tx-1-"transporter"-noun-0]|TX|67/11|
text_000N_173230|MMI|5.18|uric acid|C0041980|[bacs,orch]|["URIC ACID"-tx-1-"uric acid"-noun-0]|TX|90/9|
text_000N_173230|MMI|3.98|Excretory function|C0221102|[phsf]|["excrete"-tx-1-"excreting"-verb-0]|TX|80/9|
text_000N_173230|MMI|3.75|atp binding|C1148923|[moft]|["ATP binding"-tx-1-"ATP-Binding"-noun-0]|TX|22/11|
text_000N_173230|MMI|3.68|Gram per Deciliter|C0439267|[qnco]|["g%"-tx-1-"G"-noun-0]|TX|54/1|
text_000N_173230|MMI|3.68|Member Organization|C2698041|[prog]|["Member"-tx-1-"member"-noun-0]|TX|57/6|
text_000N_173230|MMI|3.68|Percent Administered Dose Recovered Per Gram|C5557119|[qnco]|["%/g"-tx-1-"G"-noun-0]|TX|54/1|
text_000N_173230|MMI|3.68|member|C0680022|[popg]|["Member"-tx-1-"member"-noun-0]|TX|57/6|
text_000N_173230|MMI|3.63|Cassette (physical object)|C0450240|[medd]|["Cassette"-tx-1-"Cassette"-noun-0]|TX|34/8|
text_000N_173230|MMI|3.63|Cassette Device|C1706210|[mnob]|["Cassette"-tx-1-"Cassette"-noun-0]|TX|34/8|
text_000N_173230|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
text_000N_173230|MMI|3.50|Subfamily|C1711207|[clas]|["Subfamily"-tx-1-"subfamily"-noun-0]|TX|44/9|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Proton Therapy|C0436226|[topp]|["Therapy, Proton Beam"-tx-1-"proton beam therapy"-noun-0]|TX|3/19|
text_000N_173245|MMI|3.58|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|23/4,42/2|
text_000N_173245|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|Adult Craniopharyngioma|C0278875|[neop]|["Craniopharyngioma"-tx-1-"craniopharyngioma"-noun-0]|TX|45/17|
text_000N_173245|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|Childhood Craniopharyngioma|C0278652|[neop]|["Craniopharyngioma"-tx-1-"craniopharyngioma"-noun-0]|TX|45/17|
text_000N_173245|MMI|3.56|Craniopharyngioma|C0010276|[neop]|["CRANIOPHARYNGIOMA"-tx-1-"craniopharyngioma"-noun-0]|TX|45/17|
text_000N_173245|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173245|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|amantadine|C0002403|[orch,phsu]|["Amantidine"-tx-1-"amantadine"-noun-0]|TX|3/10|
text_000N_173260|MMI|3.58|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|14/9,28/9|
text_000N_173260|MMI|3.43|Disease|C0012634|[dsyn]|["Disorders"-tx-1-"disorders"-noun-0]|TX|41/9|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|modafinil|C0066677|[orch,phsu]|["MODAFINIL"-tx-1-"modafinil"-noun-0]|TX|4/9|
text_000N_173276|MMI|3.60|Test Administration|C0237455|[edac]|["Test Treatment"-tx-1-"tested treatment"-noun-0]|TX|14/6,39/9|
text_000N_173276|MMI|3.57|Schizophrenia|C0036341|[mobd]|["SCHIZOPHRENIA"-tx-1-"schizophrenia"-noun-0]|TX|25/13|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|perampanel|C2698764|[orch,phsu]|["PERAMPANEL"-tx-1-"perampanel"-noun-0]|TX|7/10|
text_000N_173291|MMI|3.68|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|30/29|
text_000N_173291|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|7.19|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0,"gene mutations"-tx-1-"mutations gene"-noun-0]|TX|4/9;4/9,28/4|
text_000N_97283|MMI|6.93|STXBP1 gene|C1420506|[gngm]|["STXBP1"-tx-1-"STXBP1"-noun-0,"STXBP1 gene"-tx-1-"STXBP1 gene"-noun-0]|TX|21/6;21/11|
text_000N_97283|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|33/15|
text_000N_97283|MMI|3.59|Epilepsy|C0014544|[dsyn]|["EPILEPSY"-tx-1-"epilepsy"-noun-0]|TX|49/8|
text_000N_97283|MMI|3.56|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|3.63|induced genetic mutation|C0678940|[genf]|["induced Mutations"-tx-1-"induced mutations"-noun-0]|TX|37/17|
text_000N_97301|MMI|3.60|Electromagnetic Radiation|C0034519|[npop]|["Radiation"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.60|Radiation|C0851346|[npop]|["Radiation"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.60|Radiation Ionizing Radiotherapy|C1524020|[topp]|["Radiation"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.60|Radiotherapy Research|C1524021|[resa]|["Radiation"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.60|Therapeutic radiology procedure|C1522449|[topp]|["RADIATION"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.60|Unit of radiation dose|C0560559|[qnco]|["Radiation"-tx-1-"radiation"-noun-0]|TX|27/9|
text_000N_97301|MMI|3.48|Comet Assay|C0751980|[mbrt]|["Comet Assay"-tx-1-"comet assay"-noun-0]|TX|7/11|
text_000N_97301|MMI|3.46|Measurement|C0242485|[ftcn]|["Measure"-tx-1-"measure"-noun-0]|TX|19/7|
text_000N_97301|MMI|3.46|Measures|C0079809|[qnco]|["Measure"-tx-1-"measure"-noun-0]|TX|19/7|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|Reduced|C0392756|[fndg]|["Reduced"-tx-1-"reduced"-verb-0]|TX|4/7|
text_000N_97316|MMI|3.68|Cigarette|C0677453|[mnob]|["Cigarettes"-tx-1-"cigarettes"-noun-0]|TX|21/10|
text_000N_97316|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|32/9|
text_000N_97316|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|32/9|
text_000N_97316|MMI|3.50|nicotine|C0028040|[hops,orch]|["NICOTINE"-tx-1-"nicotine"-noun-0]|TX|12/8|
text_000N_97316|MMI|3.48|Cessation of smoking|C0085134|[inbe]|["Smoking Cessation"-tx-1-"smoking cessation"-noun-0]|TX|46/17|
text_000N_97316|MMI|3.48|Smoking cessation therapy|C1095963|[topp]|["smoking cessation"-tx-1-"smoking cessation"-noun-0]|TX|46/17|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|3.61|Pharmacotherapy|C0013216|[topp]|["Pharmacological Treatment"-tx-1-"pharmacological treatment"-noun-0]|TX|3/25|
text_000N_97331|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|59/9|
text_000N_97331|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|59/9|
text_000N_97331|MMI|3.46|Cardiovascular event|C1320716|[fndg]|["cardiovascular events"-tx-1-"cardiovascular events"-noun-0]|TX|81/21|
text_000N_97331|MMI|3.46|Subclinical hypothyroidism|C0271790|[dsyn]|["Hypothyroidism, subclinical"-tx-1-"subclinical hypothyroidism"-noun-0]|TX|32/26|
text_000N_97331|MMI|3.43|Reduced|C0392756|[fndg]|["reducing"-tx-1-"reducing"-noun-0]|TX|72/8|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|Malignant neoplasm of kidney|C0740457|[neop]|["Renal Cancer"-tx-1-"renal cancer"-noun-0]|TX|19/12|
text_000N_97347|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|11/7|
text_000N_97347|MMI|5.18|Renal carcinoma|C1378703|[neop]|["Renal Cancer"-tx-1-"renal cancer"-noun-0]|TX|19/12|
text_000N_97347|MMI|5.18|UBE4B gene|C1421297|[gngm]|["UBE4B"-tx-1-"UBE4B"-noun-0]|TX|5/5|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|Cerebral Hemorrhage|C2937358|[patf]|["Intracerebral haemorrhage"-tx-1-"intracerebral hemorrhage"-noun-0]|TX|50/24|
text_000N_97362|MMI|5.18|Cocaine user|C0239076|[fndg]|["COCAINE USE"-tx-1-"cocaine use"-noun-0]|TX|3/11|
text_000N_97362|MMI|5.18|cocaine use|C3496069|[mobd]|["cocaine use"-tx-1-"cocaine use"-noun-0]|TX|3/11|
text_000N_97362|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|15/15|
text_000N_97362|MMI|3.64|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|31/14|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.98|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|4/9|
text_000N_97378|MMI|3.44|Operator gene|C0314621|[gngm]|["gene promoters"-tx-1-"gene promoters"-noun-0]|TX|48/14|
text_000N_97378|MMI|3.44|Gene Targeting|C0242613|[mbrt]|["Gene Targeting"-tx-1-"targeting gene"-noun-0]|TX|35/9,48/4|
text_000N_97378|MMI|3.42|Promoter|C0086860|[bacs,nnon]|["promoters"-tx-1-"promoters"-noun-0]|TX|53/9|
text_000N_97378|MMI|3.42|Target|C1521840|[ftcn]|["Targeting"-tx-1-"targeting"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Antibiotics|C0003232|[antb]|["Antibiotic"-tx-1-"antibiotic"-noun-0]|TX|15/10|
text_000N_47289|MMI|5.18|colistin|C0009316|[aapp,antb]|["COLISTIN"-tx-1-"colistin"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Hereditary|C0439660|[ftcn]|["Heritable"-tx-1-"heritable"-adj-0]|TX|32/9|
text_000N_47304|MMI|4.12|Epigenetic Process|C1516924|[genf]|["Epigenetic Modification"-tx-1-"epigenetic modifications"-noun-0]|TX|4/24|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.63|Escape (mental process)|C0870509|[menp]|["escape"-tx-1-"escape"-noun-0]|TX|27/6|
text_000N_47377|MMI|3.57|Changing|C0392747|[ftcn]|["Altered"-tx-1-"altered"-verb-0]|TX|34/7|
text_000N_47377|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|54/8|
text_000N_47377|MMI|3.57|diabetic|C0241863|[fndg]|["DIABETIC"-tx-1-"diabetic"-noun-0]|TX|45/8|
text_000N_47377|MMI|3.48|Albumins|C0001924|[aapp,bacs]|["Albumen"-tx-1-"albumin"-noun-0]|TX|19/7|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|3.68|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|17/8|
text_000N_47349|MMI|3.59|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|31/4|
text_000N_47349|MMI|3.59|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|31/4|
text_000N_47349|MMI|3.55|Proline measurement|C0523852|[lbpr]|["Proline"-tx-1-"prolines"-noun-0]|TX|39/8|
text_000N_47349|MMI|3.55|proline|C0033382|[aapp,bacs]|["PROLINE"-tx-1-"prolines"-noun-0]|TX|39/8|
text_000N_47349|MMI|3.50|Cyclophilins|C0917877|[aapp,enzy,rcpt]|["Cyclophilins"-tx-1-"cyclophilins"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Patient currently pregnant|C0549206|[fndg]|["Pregnancy"-tx-1-"pregnancy"-noun-0]|TX|3/9|
text_000N_47363|MMI|5.18|Pregnancy|C0032961|[orgf]|["PREGNANCY"-tx-1-"pregnancy"-noun-0]|TX|3/9|
text_000N_47363|MMI|3.68|Communicable Diseases|C0009450|[dsyn]|["Infection, NOS"-tx-1-"infection"-noun-0]|TX|51/9|
text_000N_47363|MMI|3.68|Infection|C3714514|[patf]|["INFECTION"-tx-1-"infection"-noun-0]|TX|51/9|
text_000N_47363|MMI|3.57|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|27/4|
text_000N_47363|MMI|3.57|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|27/4|
text_000N_47363|MMI|3.50|H1N1|C0580264|[inpr]|["H1N1"-tx-1-"H1N1"-noun-0]|TX|46/4|
text_000N_47363|MMI|3.44|Additional|C1524062|[ftcn]|["Additional"-tx-1-"additional"-adj-0]|TX|16/10|
text_000N_47363|MMI|3.44|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|13/2|
text_000N_47363|MMI|3.44|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|13/2|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Semagacestat|C2713560|[orch,phsu]|["SEMAGACESTAT"-tx-1-"Semagacestat"-noun-0]|TX|3/12|
text_000N_47406|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_47406|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_47406|MMI|3.47|Alzheimer's disease treatment|C1979617|[topp]|["Alzheimer's disease treatment"-tx-1-"treatment Alzheimer's disease"-noun-0]|TX|30/9,43/19|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|DNA-Binding Protein SATB1|C2699550|[aapp,rcpt]|["SATB1"-tx-1-"Satb1"-noun-0]|TX|3/5|
text_000N_43235|MMI|5.18|SATB1 gene|C1419822|[gngm]|["SATB1"-tx-1-"Satb1"-noun-0]|TX|3/5|
text_000N_43235|MMI|5.18|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|11/20|
text_000N_43235|MMI|5.18|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|11/20|
<<<<< MMI
>>>>> MMI
text_000N_47274|AA|STAT3|signal transducer and activator of transcription-3|1|5|13|50|55:5
text_000N_47274|MMI|6.93|Tumor Angiogenesis|C1519670|[neop]|["Tumor Angiogenesis"-tx-1-"tumor angiogenesis"-noun-0,"angiogenesis"-tx-1-"angiogenesis"-noun-0]|TX|75/18;81/12|
text_000N_47274|MMI|6.93|Tumor Progression|C0178874|[neop]|["Progression"-tx-1-"progression"-noun-0,"Tumour progression"-tx-1-"tumor progression"-noun-0]|TX|94/11;75/5,94/11|
text_000N_47274|MMI|5.18|STAT3 Measurement|C4721493|[lbpr]|["Signal Transducer and Activator of Transcription 3"-tx-1-"signal transducer and activator of transcription-3"-noun-0]|TX|3/50|
text_000N_47274|MMI|5.18|STAT3 gene|C1367307|[gngm]|["SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3"-tx-1-"signal transducer and activator of transcription-3"-noun-0]|TX|3/50|
text_000N_47274|MMI|5.18|STAT3 protein, human|C1530116|[aapp,bacs]|["Signal Transducer and Activator of Transcription 3"-tx-1-"signal transducer and activator of transcription-3"-noun-0]|TX|3/50|
text_000N_47274|MMI|5.18|Stat3 protein|C0253050|[aapp,bacs]|["Signal Transducer and Activator of Transcription 3"-tx-1-"signal transducer and activator of transcription-3"-noun-0]|TX|3/50|
text_000N_47274|MMI|3.56|Critical|C1511545|[qlco]|["Critical"-tx-1-"critical"-adj-0]|TX|62/8|
text_000N_47274|MMI|3.46|neoplasm angiogenesis|C1537032|[neop]|["Tumour angiogenesis"-tx-1-"tumor angiogenesis"-noun-0]|TX|75/18|
text_000N_47274|MMI|3.43|Angiogenic Process|C0302600|[ortf]|["Angiogenesis"-tx-1-"angiogenesis"-noun-0]|TX|81/12|
text_000N_47274|MMI|3.43|Cancer Progression|C1947901|[patf]|["progression"-tx-1-"progression"-noun-0]|TX|94/11|
text_000N_47274|MMI|3.43|Disease Progression|C0242656|[patf]|["Progression"-tx-1-"progression"-noun-0]|TX|94/11|
text_000N_47274|MMI|3.43|Progression|C0449258|[ftcn]|["Progression"-tx-1-"progression"-noun-0]|TX|94/11|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Whole Genome Sequencing|C3640076|[mbrt]|["Sequencing, Whole Genome"-tx-1-"whole genome sequencing"-noun-0]|TX|4/23|
text_000N_47320|MMI|3.59|Mitochondrial Diseases|C0751651|[dsyn]|["Disease, Mitochondrial"-tx-1-"mitochondrial disease"-noun-0]|TX|53/21|
text_000N_47320|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|31/4,50/2|
text_000N_47320|MMI|3.55|Date of diagnosis|C2316983|[tmco]|["Diagnosis"-tx-1-"diagnosis"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.55|Diagnosis|C0011900|[diap]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.55|Diagnosis Code|C1550350|[inpr]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.55|Diagnosis Study|C1704656|[resa]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.55|Disease|C0012634|[dsyn]|["Diagnosis"-tx-1-"diagnosis"-noun-0]|TX|40/9|
text_000N_47320|MMI|3.55|diagnosis aspect|C1704338|[ftcn]|["diagnosis"-tx-1-"diagnosis"-noun-0]|TX|40/9|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|CADASIL Syndrome|C0751587|[dsyn]|["CADASIL Syndrome"-tx-1-"cadasil syndrome"-noun-0]|TX|151/16|
text_000N_47420|MMI|5.18|Off Study|C1518546|[qlco]|["Study"-tx-1-"studies"-verb-0]|TX|10/7|
text_000N_47420|MMI|5.18|Room of building - Study|C0557651|[mnob]|["Study"-tx-1-"studies"-verb-0]|TX|10/7|
text_000N_47420|MMI|5.18|Scientific Study|C0947630|[resa]|["studies"-tx-1-"studies"-verb-0]|TX|10/7|
text_000N_47420|MMI|5.18|Study|C2603343|[resa]|["Study"-tx-1-"studies"-verb-0]|TX|10/7|
text_000N_47420|MMI|3.98|Representation (action)|C1882932|[acty]|["Represent"-tx-1-"representing"-noun-0]|TX|18/12|
text_000N_47420|MMI|3.68|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|138/7|
text_000N_47420|MMI|3.58|Neurodegenerative Disorders|C0524851|[dsyn]|["Neurodegenerative Diseases"-tx-1-"neurodegenerative diseases"-noun-0]|TX|69/26|
text_000N_47420|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involvement"-tx-1-"involvement"-noun-0]|TX|35/11|
text_000N_47420|MMI|3.44|Complete Trisomy 21 Syndrome|C4521042|[dsyn]|["Down Syndrome"-tx-1-"Down syndrome"-noun-0]|TX|104/13|
text_000N_47420|MMI|3.44|Down Syndrome|C0013080|[dsyn]|["Downs Syndrome"-tx-1-"Down syndrome"-noun-0]|TX|104/13|
text_000N_47420|MMI|3.43|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|56/9|
text_000N_47420|MMI|3.43|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|56/9|
text_000N_47420|MMI|3.43|Notch|C1235660|[bsoj]|["Notch"-tx-1-"Notch"-noun-0]|TX|50/5|
text_000N_47420|MMI|3.42|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-prep-0]|TX|66/2|
text_000N_47420|MMI|3.42|Present|C0150312|[fndg]|["In"-tx-1-"in"-prep-0]|TX|66/2|
text_000N_47420|MMI|3.42|Within|C0332285|[spco]|["In"-tx-1-"in"-prep-0]|TX|66/2|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|7.19|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0,"gene mutations"-tx-1-"mutations gene"-noun-0]|TX|5/9;5/9,27/4|
text_000N_47435|MMI|6.93|ZEB2 gene|C1423021|[gngm]|["ZEB2"-tx-1-"ZEB2"-noun-0,"ZEB2 Gene"-tx-1-"ZEB2 gene"-noun-0]|TX|22/4;22/9|
text_000N_47435|MMI|3.56|Genetic Syndrome Associated with Congenital Heart Defect|C5238705|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|56/8|
text_000N_47435|MMI|3.56|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|50/5|
text_000N_47435|MMI|3.56|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|5/9|
text_000N_47435|MMI|3.56|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|37/5|
text_000N_47435|MMI|3.56|Syndrome|C0039082|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|56/8|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.68|Family history of sudden cardiac death (situation)|C2825161|[fndg]|["Sudden cardiac death"-tx-1-"sudden cardiac death"-noun-0]|TX|44/20|
text_000N_47450|MMI|3.68|Sudden Cardiac Death|C0085298|[patf]|["SUDDEN CARDIAC DEATH"-tx-1-"sudden cardiac death"-noun-0]|TX|44/20|
text_000N_47450|MMI|3.63|Variant|C0205419|[qlco]|["Variant"-tx-1-"variant"-noun-0]|TX|20/7|
text_000N_47450|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|28/15|
text_000N_47450|MMI|3.56|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|68/8|
text_000N_47450|MMI|3.48|HRC gene|C1415718|[gngm]|["HRC"-tx-1-"HRC"-noun-0]|TX|7/3|
text_000N_47450|MMI|3.46|Cardiomyopathy, Dilated|C0007193|[dsyn]|["Cardiomyopathy, Dilated"-tx-1-"dilated cardiomyopathy"-noun-0]|TX|82/22|
text_000N_47450|MMI|3.46|Dilated Cardiomyopathy Pathway|C2984282|[ftcn]|["Dilated cardiomyopathy"-tx-1-"dilated cardiomyopathy"-noun-0]|TX|82/22|
text_000N_47450|MMI|3.43|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-prep-0]|TX|65/2|
text_000N_47450|MMI|3.43|Present|C0150312|[fndg]|["In"-tx-1-"in"-prep-0]|TX|65/2|
text_000N_47450|MMI|3.43|Within|C0332285|[spco]|["In"-tx-1-"in"-prep-0]|TX|65/2|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|celecoxib|C0538927|[orch,phsu]|["CELECOXIB"-tx-1-"celecoxib"-noun-0]|TX|3/9|
text_000N_43275|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43275|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43275|MMI|3.50|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|27/29|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|AMOT gene|C1425094|[gngm]|["AMOT"-tx-1-"Amot"-noun-0]|TX|26/4|
text_000N_47392|MMI|3.68|TLN1 gene|C1420760|[gngm]|["TALIN"-tx-1-"Talin"-noun-0]|TX|16/5|
text_000N_47392|MMI|3.68|Talin|C0085182|[aapp,bacs]|["Talin"-tx-1-"Talin"-noun-0]|TX|16/5|
text_000N_47392|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|7/8|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|28/9|
text_000N_43303|MMI|5.18|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|28/9|
text_000N_43303|MMI|5.18|protamines|C0033603|[aapp,bacs,phsu]|["Protamines"-tx-1-"protamines"-noun-0]|TX|4/10|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.68|Resolution|C2699488|[cnce]|["Resolution"-tx-1-"resolution"-noun-0]|TX|49/10|
text_000N_43331|MMI|3.68|Resolution Property|C1706463|[qnco]|["Resolution"-tx-1-"resolution"-noun-0]|TX|49/10|
text_000N_43331|MMI|3.68|physiologic resolution|C1514893|[patf]|["Resolution"-tx-1-"resolution"-noun-0]|TX|49/10|
text_000N_43331|MMI|3.61|METHOD:*|C5445274|[fndg]|["METHOD:*"-tx-1-"method"-noun-0]|TX|19/6|
text_000N_43331|MMI|3.61|Methods|C0025663|[ftcn]|["Method"-tx-1-"method"-noun-0]|TX|19/6|
text_000N_43331|MMI|3.61|Techniques|C0449851|[ftcn]|["Method"-tx-1-"method"-noun-0]|TX|19/6|
text_000N_43331|MMI|3.61|Test Method|C0871511|[lbpr]|["METHOD"-tx-1-"method"-noun-0]|TX|19/6|
text_000N_43331|MMI|3.47|Micro (prefix)|C3811161|[cnce]|["Micro"-tx-1-"Micro"-noun-0]|TX|8/5|
text_000N_43331|MMI|3.47|Microbiology - Laboratory Class|C4049106|[inpr]|["MICRO"-tx-1-"Micro"-noun-0]|TX|8/5|
text_000N_43331|MMI|3.47|Microbiology procedure|C0085672|[lbpr]|["MICRO"-tx-1-"Micro"-noun-0]|TX|8/5|
text_000N_43331|MMI|3.47|Microscopic (qualifier value)|C0205288|[qlco]|["Micro"-tx-1-"Micro"-noun-0]|TX|8/5|
text_000N_43331|MMI|3.47|Palmyra Atoll|C4053562|[geoa]|["XL"-tx-1-"XL"-noun-0]|TX|16/2|
text_000N_43331|MMI|3.47|Unit Of Measure Prefix - micro|C1553035|[qnco]|["Micro"-tx-1-"Micro"-noun-0]|TX|8/5|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|cabotegravir|C4310385|[aapp,phsu]|["CABOTEGRAVIR"-tx-1-"Cabotegravir"-noun-0]|TX|3/12|
text_000N_43358|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_43358|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_43358|MMI|3.48|HIV prevention|C0150413|[topp]|["HIV prevention"-tx-1-"HIV prevention"-noun-0]|TX|30/14|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|3.81|Ischemic congestive cardiomyopathy|C1960867|[dsyn]|["Ischemic Dilated Cardiomyopathy"-tx-1-"ischemic dilated cardiomyopathy"-noun-1]|TX|55/31|
text_000N_43386|MMI|3.68|Deferred|C0205421|[tmco]|["Delayed"-tx-1-"delayed"-noun-0]|TX|3/7|
text_000N_43386|MMI|3.68|Delayed Capillary Refill Time|C4718438|[fndg]|["Delayed"-tx-1-"delayed"-noun-0]|TX|3/7|
text_000N_43386|MMI|3.68|Delayed Release Mechanism of Action|C4723815|[ftcn]|["Delayed"-tx-1-"delayed"-noun-0]|TX|3/7|
text_000N_43386|MMI|3.68|Delayed Testing|C3272602|[qlco]|["Delayed"-tx-1-"delayed"-noun-0]|TX|3/7|
text_000N_43386|MMI|3.68|Enhance (action)|C2349975|[acty]|["Enhancement"-tx-1-"enhancement"-noun-0]|TX|11/11|
text_000N_43386|MMI|3.68|Enhancement Description|C2985765|[inpr]|["Enhancement"-tx-1-"enhancement"-noun-0]|TX|11/11|
text_000N_43386|MMI|3.68|Refractive surgery enhancement|C1627358|[topp]|["Enhancement"-tx-1-"enhancement"-noun-0]|TX|11/11|
text_000N_43386|MMI|3.68|Views delayed|C1545665|[clna]|["Delayed"-tx-1-"delayed"-noun-0]|TX|3/7|
text_000N_43386|MMI|3.59|Document completion status - Documented|C1609436|[inpr]|["Documented"-tx-1-"documented"-verb-0]|TX|23/10|
text_000N_43386|MMI|3.59|Documented|C1301725|[hlca]|["Documented"-tx-1-"documented"-verb-0]|TX|23/10|
text_000N_43386|MMI|3.59|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|37/8|
text_000N_43386|MMI|3.47|Negation|C1518422|[ftcn]|["Non"-tx-1-"non"-adj-0]|TX|51/3|
<<<<< MMI
>>>>> MMI
text_000N_40839|AA|FFPE|formalin fixed and paraffin embedded|1|4|9|36|85:4
text_000N_40839|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_40839|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_40839|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_40839|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_40839|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_40839|MMI|3.60|Formalin-Fixed Paraffin-Embedded|C4684951|[lbpr]|["Formalin-Fixed Paraffin-Embedded"-tx-1-"formalin fixed paraffin embedded"-noun-0]|TX|46/14,65/17|
text_000N_40839|MMI|3.54|Body tissue|C0040300|[tisu]|["TISSUE"-tx-1-"tissue"-noun-0]|TX|91/6|
text_000N_40839|MMI|3.54|Proteome|C0751973|[aapp,bacs]|["Proteome"-tx-1-"proteome"-noun-0]|TX|32/8|
text_000N_40839|MMI|3.54|Tissue Specimen Code|C1547928|[inpr]|["Tissue"-tx-1-"tissue"-noun-0]|TX|91/6|
text_000N_40839|MMI|3.54|Tissue specimen|C1292533|[tisu]|["Tissue"-tx-1-"tissue"-noun-0]|TX|91/6|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|pentoxifylline|C0030899|[orch,phsu]|["Pentoxyphylline"-tx-1-"Pentoxifylline"-noun-0]|TX|7/14|
text_000N_40886|MMI|3.62|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|47/29|
text_000N_40886|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|25/4,44/2|
text_000N_40886|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_40886|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|deflazacort|C0057258|[orch,phsu]|["DEFLAZACORT"-tx-1-"deflazacort"-noun-0]|TX|5/11|
text_000N_47334|MMI|3.61|Adverse effects|C0879626|[patf]|["Side effects"-tx-1-"side effects"-noun-0]|TX|27/12|
text_000N_47334|MMI|3.61|Adverse event|C0877248|[patf]|["side effects"-tx-1-"side effects"-noun-0]|TX|27/12|
text_000N_47334|MMI|3.61|aspects of adverse effects|C0001688|[ftcn]|["side effects"-tx-1-"side effects"-noun-0]|TX|27/12|
text_000N_47334|MMI|3.43|More|C0205172|[qnco]|["More"-tx-1-"more"-adv-0]|TX|22/4|
text_000N_47334|MMI|3.43|prednisone|C0032952|[horm,orch,phsu]|["PREDNISONE"-tx-1-"prednisone"-noun-0]|TX|45/10|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Exosomes|C2350332|[celc]|["Exosomes"-tx-1-"exosomes"-noun-0]|TX|4/8|
text_000N_40913|MMI|3.59|Detected (finding)|C0442726|[fndg]|["Detected"-tx-1-"detected"-verb-0]|TX|16/8|
text_000N_40913|MMI|3.59|Detection|C1511790|[topp]|["Detected"-tx-1-"detected"-verb-0]|TX|16/8|
text_000N_40913|MMI|3.59|In Urine|C0042037|[ftcn]|["URINE"-tx-1-"urine"-noun-0]|TX|28/5|
text_000N_40913|MMI|3.59|Portion of urine|C2963137|[bdsu]|["Urine"-tx-1-"urine"-noun-0]|TX|28/5|
text_000N_40913|MMI|3.59|Urine|C0042036|[bdsu]|["URINE"-tx-1-"urine"-noun-0]|TX|28/5|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|TP53 gene|C0079419|[gngm]|["P53"-tx-1-"p53"-noun-0]|TX|3/3|
text_000N_40941|MMI|5.18|TP53 protein, human|C0146283|[aapp,bacs]|["P53"-tx-1-"p53"-noun-0]|TX|3/3|
text_000N_40941|MMI|5.18|TP53 wt Allele|C1705526|[gngm]|["p53"-tx-1-"p53"-noun-0]|TX|3/3|
text_000N_40941|MMI|5.18|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["TRANSCRIPTION FACTOR"-tx-1-"transcription factor"-noun-0]|TX|9/20|
text_000N_40941|MMI|5.18|transcription factor activity|C1148759|[genf]|["transcription factor"-tx-1-"transcription factor"-noun-0]|TX|9/20|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Glycoproteins|C0017968|[aapp,bacs]|["Glycoprotein"-tx-1-"glycoprotein"-noun-0]|TX|32/12|
text_000N_40972|MMI|3.85|LOXL2 gene|C1416899|[gngm]|["LYSYL OXIDASE-LIKE 2"-tx-1-"lysyl oxidase-like 2"-noun-0]|TX|9/20|
text_000N_40972|MMI|3.46|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|3/5|
<<<<< MMI
>>>>> MMI
text_000N_40999|AA|ApoE|Apolipoprotein E|1|4|3|16|23:4
text_000N_40999|MMI|5.18|ApoE protein, human|C4308468|[aapp,bacs]|["Apolipoprotein E"-tx-1-"Apolipoprotein E"-noun-0]|TX|5/16|
text_000N_40999|MMI|5.18|Apolipoprotein E|C0003595|[aapp,bacs]|["Apolipoprotein E"-tx-1-"Apolipoprotein E"-noun-0]|TX|5/16|
text_000N_40999|MMI|3.63|*Activity (kind of quantity)|C1561536|[idcn]|["*Activity"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Active|C0205177|[qlco]|["Activity"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Activities|C0441655|[acty]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Activity (animal life circumstance)|C3668946|[fndg]|["Activity"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Biochemical Activity|C3897134|[qnco]|["Activity"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|FDA Establishment Activity Terminology|C4049939|[inpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Percent Activity|C0439167|[qnco]|["% Activity"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.63|Physical Activity Measurement|C4049938|[lbpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|52/8|
text_000N_40999|MMI|3.53|Anti-Inflammatory Agents|C0003209|[phsu]|["Antiinflammatory"-tx-1-"anti-inflammatory"-adj-0]|TX|34/17|
text_000N_40999|MMI|3.53|Anti-inflammatory effect|C1515999|[qlco]|["Anti-inflammatory"-tx-1-"anti-inflammatory"-adj-0]|TX|34/17|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.63|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|19/9|
text_000N_173104|MMI|3.57|Importance Rating Score 0|C4084912|[inpr]|["Important"-tx-1-"important"-adj-0]|TX|29/9|
text_000N_173104|MMI|3.57|Important|C3898777|[qlco]|["Important"-tx-1-"important"-adj-0]|TX|29/9|
text_000N_173104|MMI|3.48|Normal development|C1821244|[fndg]|["Normal development"-tx-1-"normal development"-noun-0]|TX|43/18|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|metoprolol|C0025859|[orch,phsu]|["METOPROLOL"-tx-1-"metoprolol"-noun-0]|TX|3/10|
text_000N_173136|MMI|3.59|CYP2D6 gene|C1332830|[gngm]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|29/6|
text_000N_173136|MMI|3.59|Cytochrome P-450 CYP2D6|C0057223|[aapp,enzy]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|29/6|
text_000N_173136|MMI|3.59|Cytochrome P450 2D6, human|C3887685|[aapp,enzy]|["CYP2D6"-tx-1-"CYP2D6"-noun-0]|TX|29/6|
text_000N_173136|MMI|3.59|Metabolic Process, Cellular|C1524026|[celf]|["Metabolized"-tx-1-"metabolized"-verb-0]|TX|14/11|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.68|SIRT2 gene|C1420071|[gngm]|["SIRT2"-tx-1-"SIRT2"-noun-0]|TX|16/5|
text_000N_173087|MMI|3.68|SIRT2 protein, human|C1258492|[aapp,enzy]|["SIRT2"-tx-1-"SIRT2"-noun-0]|TX|16/5|
text_000N_173087|MMI|3.68|Sirtuin 2|C2720168|[aapp,enzy]|["Sirt2"-tx-1-"SIRT2"-noun-0]|TX|16/5|
text_000N_173087|MMI|3.64|Cervix carcinoma|C0302592|[neop]|["CERVICAL CANCER"-tx-1-"cervical cancer"-noun-0]|TX|41/15|
text_000N_173087|MMI|3.64|Malignant tumor of cervix|C0007847|[neop]|["Cervical cancer"-tx-1-"cervical cancer"-noun-0]|TX|41/15|
text_000N_173087|MMI|3.64|NCI CTEP SDC Cervical Cancer Sub-Category Terminology|C3539064|[inpr]|["Cervical Cancer"-tx-1-"cervical cancer"-noun-0]|TX|41/15|
text_000N_173087|MMI|3.64|cervical cancer|C4048328|[neop]|["Cervical Cancer"-tx-1-"cervical cancer"-noun-0]|TX|41/15|
text_000N_173087|MMI|3.57|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-verb-0]|TX|27/10|
text_000N_173087|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|8/7|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|3.79|Changing|C0392747|[ftcn]|["Altered"-tx-1-"alter"-verb-0]|TX|36/5|
text_000N_173151|MMI|3.68|Anatomy, Regional|C0002812|[bmod]|["Topology"-tx-1-"topology"-noun-0]|TX|49/8|
text_000N_173151|MMI|3.56|Body part inversion|C0021945|[anab]|["Inversion"-tx-1-"inversion"-noun-0]|TX|12/9|
text_000N_173151|MMI|3.56|Chromosome inversion|C0021943|[comd]|["Inversion"-tx-1-"inversion"-noun-0]|TX|12/9|
text_000N_173151|MMI|3.56|Inversion|C2349984|[ftcn]|["Inversion"-tx-1-"inversion"-noun-0]|TX|12/9|
text_000N_173151|MMI|3.56|Inversion Mutation Abnormality|C1705687|[comd]|["Inversion"-tx-1-"inversion"-noun-0]|TX|12/9|
text_000N_173151|MMI|3.50|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|42/6|
text_000N_173151|MMI|3.50|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|42/6|
text_000N_173151|MMI|3.44|Site of|C2945843|[spco]|["Site of"-tx-1-"of sites"-noun-0]|TX|22/2,30/5|
text_000N_173151|MMI|3.43|CRISPR Therapeutics|C5552831|[orgt]|["CRISPR"-tx-1-"CRISPR"-noun-0]|TX|5/6|
text_000N_173151|MMI|3.43|CTCF gene|C1422163|[gngm]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|25/4|
text_000N_173151|MMI|3.43|CTCF protein, human|C1456335|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|25/4|
text_000N_173151|MMI|3.43|CTGF protein, human|C1137457|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|25/4|
text_000N_173151|MMI|3.43|Clustered Regularly Interspaced Short Palindromic Repeats|C3658200|[nnon]|["CRISPR"-tx-1-"CRISPR"-noun-0]|TX|5/6|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|vorinostat|C0672708|[orch,phsu]|["VORINOSTAT"-tx-1-"vorinostat"-noun-0]|TX|3/10|
text_000N_173167|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173167|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173167|MMI|3.45|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|28/12|
text_000N_173167|MMI|3.45|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|28/12|
text_000N_173167|MMI|3.45|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|28/12|
text_000N_173167|MMI|3.45|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|28/12|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Artificial nanoparticles|C1450054|[mnob]|["Nanoparticles"-tx-1-"nanoparticles"-noun-0]|TX|4/13|
text_000N_173120|MMI|5.18|Diagnostic Imaging|C0011923|[diap]|["Imaging"-tx-1-"imaging"-adj-0]|TX|40/7|
text_000N_173120|MMI|5.18|Imaging Techniques|C0079595|[diap]|["Imaging"-tx-1-"imaging"-adj-0]|TX|40/7|
text_000N_173120|MMI|3.59|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Stress Granules|C5442023|[celc]|["Stress Granules"-tx-1-"stress granules"-noun-0]|TX|4/15|
text_000N_173183|MMI|3.60|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"Amyotrophic Lateral Sclerosis"-noun-0]|TX|52/29|
text_000N_173183|MMI|3.54|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
text_000N_173183|MMI|3.54|Pathogenesis|C0699748|[patf]|["Pathogenesis"-tx-1-"pathogenesis"-noun-0]|TX|36/12|
text_000N_173183|MMI|3.54|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Malignant neoplasm of prostate|C0376358|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|48/15|
text_000N_173199|MMI|5.18|NCI CTEP SDC Prostate Cancer Sub-Category Terminology|C3541264|[inpr]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|48/15|
text_000N_173199|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|12/7|
text_000N_173199|MMI|5.18|Prostate Cancer Pathway|C2984325|[cnce]|["Prostate cancer"-tx-1-"prostate cancer"-noun-0]|TX|48/15|
text_000N_173199|MMI|5.18|Prostate carcinoma|C0600139|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|48/15|
text_000N_173199|MMI|3.68|63|C4319614|[qnco]|["63"-tx-1-"63"-integer-0]|TX|8/2|
text_000N_173199|MMI|3.68|Urban Cluster|C5552707|[geoa]|["UC"-tx-1-"Uc"-noun-0]|TX|5/2|
text_000N_173199|MMI|3.66|Sensitive|C0332324|[ftcn]|["Sensitive to"-tx-1-"sensitivity to"-noun-0]|TX|20/14|
text_000N_173199|MMI|3.45|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173199|MMI|3.45|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|3.68|Adverse Event Emergency Room Visit|C3810541|[fndg]|["ER"-tx-1-"ER"-noun-0]|TX|14/2|
text_000N_173214|MMI|3.68|Environmental and Social Factors Domain|C5400108|[inpr]|["ER"-tx-1-"ER"-noun-0]|TX|14/2|
text_000N_173214|MMI|3.68|Estrogen Receptor Family, human|C5441529|[aapp,rcpt]|["ER"-tx-1-"ER"-noun-0]|TX|14/2|
text_000N_173214|MMI|3.68|Estrogen Receptor Measurement|C3811131|[lbpr]|["ER"-tx-1-"ER"-noun-0]|TX|14/2|
text_000N_173214|MMI|3.58|First Treatment Date|C5235902|[tmco]|["First Treatment"-tx-1-"first treatment"-noun-0]|TX|21/5,36/9|
text_000N_173214|MMI|3.50|amantadine|C0002403|[orch,phsu]|["Amantidine"-tx-1-"amantadine"-noun-0]|TX|3/10|
text_000N_173214|MMI|3.43|Akinesia|C0085623|[fndg]|["AKINESIA"-tx-1-"akinesia"-noun-0]|TX|50/8|
text_000N_173214|MMI|3.43|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-adj-0]|TX|27/8|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|29/9|
text_000N_173245|MMI|3.63|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|22/6|
text_000N_173245|MMI|3.63|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|22/6|
text_000N_173245|MMI|3.53|Apis mellifera|C0323351|[euka]|["Apis mellifera"-tx-1-"Apis mellifera"-noun-0]|TX|7/14|
text_000N_173245|MMI|3.53|Apis mellifera preparation|C0939871|[orch,phsu]|["Apis Mellifera"-tx-1-"Apis mellifera"-noun-0]|TX|7/14|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.56|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|19/5|
text_000N_47289|MMI|3.56|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|19/5|
text_000N_47289|MMI|3.44|Genes, vif|C0079429|[gngm]|["Genes, A"-tx-1-"a genetic"-adj-0]|TX|9/9|
text_000N_47289|MMI|3.43|Craniosynostosis|C0010278|[dsyn]|["Craniostenosis"-tx-1-"craniostenosis"-noun-0]|TX|28/14|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|10.42|NEB gene|C1417656|[gngm]|["NEB"-tx-1-"NEB"-noun-0,"NEBULIN"-tx-1-"nebulin"-noun-0]|TX|28/3;33/7|
text_000N_173260|MMI|5.18|ACTA1 gene|C1412136|[gngm]|["ACTA1"-tx-1-"ACTA1"-noun-0]|TX|4/5|
text_000N_173260|MMI|5.18|ACTC1 gene|C1825843|[gngm]|["ACTIN, ALPHA"-tx-1-"alpha actin"-noun-0]|TX|11/11|
text_000N_173260|MMI|5.18|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|42/5|
text_000N_173260|MMI|5.18|alpha-Actin|C0002240|[aapp,bacs]|["alpha-Actin"-tx-1-"alpha actin"-noun-0]|TX|11/11|
text_000N_173260|MMI|5.18|mitotic nuclear membrane disassembly|C1155733|[celf]|["NEB"-tx-1-"NEB"-noun-0]|TX|28/3|
text_000N_173260|MMI|5.18|nebulin|C0068477|[aapp]|["Nebulin"-tx-1-"nebulin"-noun-0]|TX|33/7|
text_000N_173260|MMI|3.64|Myopathies, Nemaline|C0206157|[dsyn]|["Nemaline Myopathy"-tx-1-"nemaline myopathy"-noun-0]|TX|59/17|
text_000N_173260|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|48/7|
text_000N_173260|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|48/7|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|RAD9A gene|C1419245|[gngm]|["RAD9"-tx-1-"Rad9"-noun-0]|TX|5/4|
text_000N_173276|MMI|5.18|RAD9A wt Allele|C3814527|[gngm]|["RAD9"-tx-1-"Rad9"-noun-0]|TX|5/4|
text_000N_173276|MMI|5.18|Saccharomyces cerevisiae|C0036025|[fngs]|["S cerevisiae"-tx-1-"in cerevisiae"-noun-0]|TX|29/2,34/10|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.54|1 (finding)|C5201140|[fndg]|["One"-tx-1-"one"-noun-0]|TX|24/3|
text_000N_47304|MMI|3.54|One|C0205447|[qnco]|["ONE"-tx-1-"one"-noun-0]|TX|24/3|
text_000N_47304|MMI|3.44|Mowat-Wilson syndrome|C1856113|[dsyn]|["MOWAT-WILSON SYNDROME"-tx-1-"Mowat-Wilson syndrome"-noun-0]|TX|58/21|
text_000N_47304|MMI|3.43|HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1|C3888239|[fndg]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|3/20|
text_000N_47304|MMI|3.43|Hirschsprung Disease|C0019569|[dsyn]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|3/20|
text_000N_47304|MMI|3.42|Characteristics|C1521970|[qlco]|["Characteristics"-tx-1-"characteristics"-noun-0]|TX|35/15|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.57|RETINAL NONATTACHMENT, NONSYNDROMIC CONGENITAL|C1857299|[cgab]|["NCRNA"-tx-1-"ncRNAs"-noun-0]|TX|49/6|
text_000N_173291|MMI|3.57|RNA, Untranslated|C0887909|[nnon]|["ncRNA"-tx-1-"ncRNAs"-noun-0]|TX|49/6|
text_000N_173291|MMI|3.46|Candidate|C4527371|[cnce]|["Candidate"-tx-1-"candidate"-noun-0]|TX|39/9|
text_000N_173291|MMI|3.46|Drosophila <basidiomycetes>|C4554050|[fngs]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|4/10|
text_000N_173291|MMI|3.46|Drosophila <flies,subgenus>|C1504613|[euka]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|4/10|
text_000N_173291|MMI|3.46|Drosophila <fruit fly, genus>|C0013138|[euka]|["Drosophila"-tx-1-"Drosophila"-noun-0]|TX|4/10|
text_000N_173291|MMI|3.46|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|30/8|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|ofatumumab|C1832027|[aapp,imft,phsu]|["OFATUMUMAB"-tx-1-"ofatumumab"-noun-0]|TX|3/10|
text_000N_97283|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_97283|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_97283|MMI|3.48|Multiple Sclerosis|C0026769|[dsyn]|["MULTIPLE SCLEROSIS"-tx-1-"multiple sclerosis"-noun-0]|TX|28/18|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Endometriosis|C0014175|[dsyn]|["ENDOMETRIOSIS"-tx-1-"endometriosis"-noun-0]|TX|54/13|
text_000N_97301|MMI|5.18|Irritable Bowel Syndrome|C0022104|[dsyn]|["IRRITABLE BOWEL SYNDROME"-tx-1-"irritable bowel syndrome"-noun-0]|TX|3/24|
text_000N_97301|MMI|3.57|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|33/6|
text_000N_97301|MMI|3.57|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|33/6|
text_000N_97301|MMI|3.57|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|33/6|
text_000N_97301|MMI|3.44|More|C0205172|[qnco]|["More"-tx-1-"more"-adv-0]|TX|28/4|
text_000N_97301|MMI|3.44|Woman|C0043210|[popg]|["Women"-tx-1-"women"-noun-0]|TX|43/5|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|6.96|Linear|C0205132|[spco]|["Linear"-tx-1-"linear"-adj-0]|TX|[13/6],[29/6]|
text_000N_97316|MMI|3.68|DNA Sequence|C0162326|[nusq]|["Sequences"-tx-1-"sequences"-noun-0]|TX|103/9|
text_000N_97316|MMI|3.68|Duration (temporal concept)|C0449238|[tmco]|["TIME"-tx-1-"time"-noun-0]|TX|20/4|
text_000N_97316|MMI|3.68|Time|C0040223|[tmco]|["TIME"-tx-1-"time"-noun-0]|TX|20/4|
text_000N_97316|MMI|3.68|Time (foundation metadata concept)|C3541383|[inpr]|["Time"-tx-1-"time"-noun-0]|TX|20/4|
text_000N_97316|MMI|3.54|Observation Method - algorithm|C1553907|[ftcn]|["algorithm"-tx-1-"algorithm"-noun-0]|TX|42/9|
text_000N_97316|MMI|3.54|algorithm|C0002045|[inpr]|["Algorithm"-tx-1-"algorithm"-noun-0]|TX|42/9|
text_000N_97316|MMI|3.50|Biological Challenge Agent|C4761518|[chvf]|["BIOLOGICAL"-tx-1-"biological"-adj-0]|TX|92/10|
text_000N_97316|MMI|3.50|Biopharmaceuticals|C4553887|[bacs,phsu]|["Biological"-tx-1-"biological"-adj-0]|TX|92/10|
text_000N_97316|MMI|3.50|biological|C0205460|[qlco]|["Biological"-tx-1-"biological"-adj-0]|TX|92/10|
text_000N_97316|MMI|3.50|biology (field)|C0005532|[bmod]|["Biological"-tx-1-"biological"-adj-0]|TX|92/10|
text_000N_97316|MMI|3.42|Computation (action)|C1880157|[acty]|["Computation"-tx-1-"computation"-noun-0]|TX|60/11|
text_000N_97316|MMI|3.42|Space - property|C1883067|[spco]|["Space"-tx-1-"space"-noun-0]|TX|36/5|
text_000N_97316|MMI|3.40|Term (lexical)|C1705313|[idcn]|["Word"-tx-1-"words"-noun-0]|TX|83/5|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|ABCE1 gene|C1412092|[gngm]|["ABCE1"-tx-1-"ABCE1"-noun-0]|TX|3/5|
text_000N_173230|MMI|3.60|ribosome recycling|C3546431|[moft]|["ribosome recycling"-tx-1-"ribosomal recycling"-noun-0]|TX|21/19|
text_000N_173230|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_173230|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Anti-PRL-3 Monoclonal Antibody PRL3-zumab|C4726559|[aapp,imft,phsu]|["PRL3 zumab"-tx-1-"PRL3-zumab"-noun-0]|TX|4/10|
text_000N_47349|MMI|5.18|In Vitro Route of Administration|C2827718|[ftcn]|["In Vitro"-tx-1-"in vitro"-adj-0]|TX|42/8|
text_000N_47349|MMI|5.18|In Vitro [Publication Type]|C0021135|[inpr]|["In Vitro"-tx-1-"in vitro"-adj-0]|TX|42/8|
text_000N_47349|MMI|5.18|In Vivo|C1515655|[spco]|["In Vivo"-tx-1-"in vivo"-adj-0]|TX|55/7|
text_000N_47349|MMI|5.18|in vitro|C1533691|[qlco]|["In Vitro"-tx-1-"in vitro"-adj-0]|TX|42/8|
text_000N_47349|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|15/7|
text_000N_47349|MMI|3.75|Tumor cells, malignant|C0334227|[cell]|["cancer cells"-tx-1-"cancer cells"-noun-0]|TX|29/12|
text_000N_47349|MMI|3.48|PTP4A3 gene|C1419090|[gngm]|["PRL3"-tx-1-"PRL3"-noun-0]|TX|23/4|
text_000N_47349|MMI|3.48|PTP4A3 wt Allele|C4723884|[gngm]|["PRL3"-tx-1-"PRL3"-noun-0]|TX|23/4|
text_000N_47349|MMI|3.48|SMR3B gene|C1539794|[gngm]|["PRL3"-tx-1-"PRL3"-noun-0]|TX|23/4|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Cardiovascular Risk|C4324389|[fndg]|["Cardiovascular Risk"-tx-1-"cardiovascular risk"-noun-0]|TX|25/19|
text_000N_47363|MMI|5.18|Prudent Diet|C5200691|[inbe]|["Prudent Diet"-tx-1-"prudent diet"-noun-0]|TX|5/12|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|MVA 85A|C2933874|[imft,phsu]|["MVA85A"-tx-1-"MVA85A"-noun-0]|TX|4/6|
text_000N_47377|MMI|3.59|Immune response|C0020964|[ortf]|["Immunity"-tx-1-"immunity"-noun-0]|TX|18/8|
text_000N_47377|MMI|3.59|Immune status|C5234945|[phsf]|["Immunity"-tx-1-"immunity"-noun-0]|TX|18/8|
text_000N_47377|MMI|3.45|Smallpox|C0037354|[dsyn]|["SMALLPOX"-tx-1-"smallpox"-noun-0]|TX|35/8|
text_000N_47377|MMI|3.45|Smallpox Viruses|C0037356|[virs]|["Smallpox"-tx-1-"smallpox"-noun-0]|TX|35/8|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|10.42|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|[15/2],[37/2]|
text_000N_47406|MMI|10.42|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|[15/2],[37/2]|
text_000N_47406|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_47406|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_47406|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_47406|MMI|5.18|Pseudopodia|C0033827|[celc]|["Pseudopodia"-tx-1-"pseudopodia"-noun-0]|TX|25/11|
text_000N_47406|MMI|5.18|Purifying|C1998793|[ftcn]|["Purify"-tx-1-"purify"-verb-0]|TX|18/6|
text_000N_47406|MMI|3.57|Analysis|C0936012|[resa]|["ANALYSIS"-tx-1-"analysis"-noun-0]|TX|62/8|
text_000N_47406|MMI|3.57|Analysis of substances|C0002778|[lbpr]|["Analysis"-tx-1-"analysis"-noun-0]|TX|62/8|
text_000N_47406|MMI|3.57|Proteomics|C0872252|[bmod]|["proteomic"-tx-1-"proteomic"-adj-0]|TX|52/9|
text_000N_47406|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|43/4|
text_000N_47406|MMI|3.57|analysis aspect|C1524024|[ftcn]|["analysis"-tx-1-"analysis"-noun-0]|TX|62/8|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.59|Thyroid Hormone Receptor|C0034843|[aapp,rcpt]|["Thyroid Hormone Receptors"-tx-1-"receptors thyroid hormones"-noun-0]|TX|26/9,40/16|
text_000N_43235|MMI|3.58|Plasma membrane|C0007603|[celc]|["Plasma Membrane"-tx-1-"plasma membrane"-noun-0]|TX|10/15|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|tranexamic acid|C0040613|[orch,phsu]|["TRANEXAMIC ACID"-tx-1-"Tranexamic acid"-noun-0]|TX|3/15|
text_000N_43275|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|19/9|
text_000N_43275|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|19/9|
text_000N_43275|MMI|3.48|Cerebral Hemorrhage|C2937358|[patf]|["Intracerebral haemorrhage"-tx-1-"intracerebral haemorrhage"-noun-0]|TX|33/25|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|50000|C4319613|[qnco]|["50000"-tx-1-"50000"-integer-0]|TX|61/5|
text_000N_43303|MMI|3.54|Count|C0750480|[qnco]|["NUMBER"-tx-1-"number"-noun-0]|TX|7/6|
text_000N_43303|MMI|3.54|Count of entities|C0449788|[qnco]|["Number"-tx-1-"number"-noun-0]|TX|7/6|
text_000N_43303|MMI|3.54|Numbers|C0237753|[qnco]|["*Number"-tx-1-"number"-noun-0]|TX|7/6|
text_000N_43303|MMI|3.42|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|41/9|
text_000N_43303|MMI|3.42|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|27/5|
text_000N_43303|MMI|3.42|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|41/9|
text_000N_43303|MMI|3.42|Nuclear (incident type)|C4554581|[qlco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|33/7|
text_000N_43303|MMI|3.42|Nuclear (nucleus)|C0521447|[spco]|["Nuclear"-tx-1-"nuclear"-adj-0]|TX|33/7|
text_000N_43303|MMI|3.42|described|C1552738|[idcn]|["described"-tx-1-"described"-adj-0]|TX|17/9|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|selinexor|C3852671|[orch,phsu]|["SELINEXOR"-tx-1-"Selinexor"-noun-0]|TX|3/9|
text_000N_43358|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43358|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43358|MMI|3.48|Multiple Myeloma|C0026764|[neop]|["MULTIPLE MYELOMA"-tx-1-"multiple myeloma"-noun-0]|TX|27/16|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.58|Sex Characteristics|C0036866|[orga]|["Sex Differences"-tx-1-"sex differences"-noun-0]|TX|10/15|
text_000N_47320|MMI|3.40|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"processes"-noun-0]|TX|50/9|
text_000N_47320|MMI|3.40|Process|C1522240|[phpr]|["Process"-tx-1-"processes"-noun-0]|TX|50/9|
text_000N_47320|MMI|3.40|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"processes"-noun-0]|TX|50/9|
text_000N_47320|MMI|3.40|bony process|C1184743|[bpoc]|["Process"-tx-1-"processes"-noun-0]|TX|50/9|
text_000N_47320|MMI|3.40|Cancer Gene Mutation|C1516197|[comd]|["Oncogene Mutation"-tx-1-"oncogenic mutational"-adj-0]|TX|29/20|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|NTN1 gene|C1334908|[gngm]|["NETRIN 1"-tx-1-"Netrin-1"-noun-0]|TX|3/8|
text_000N_47392|MMI|5.18|NTN1 protein, human|C1442814|[aapp,bacs]|["Netrin 1"-tx-1-"Netrin-1"-noun-0]|TX|3/8|
text_000N_47392|MMI|5.18|netrin-1|C0258174|[aapp,bacs]|["Netrin 1"-tx-1-"Netrin-1"-noun-0]|TX|3/8|
text_000N_47392|MMI|5.18|secretory protein|C0597427|[aapp,bacs]|["Secreted protein"-tx-1-"secreted protein"-noun-0]|TX|14/16|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|Acid reflux|C4317146|[fndg]|["Gastroesophageal Reflux"-tx-1-"gastro esophageal reflux"-noun-0]|TX|3/24|
text_000N_97331|MMI|5.18|Gastroesophageal reflux disease|C0017168|[dsyn]|["gastrooesophageal reflux"-tx-1-"gastro esophageal reflux"-noun-0]|TX|3/24|
text_000N_97331|MMI|5.18|Infantile Gastroesophageal Reflux|C3813607|[fndg]|["Gastroesophageal Reflux"-tx-1-"gastro esophageal reflux"-noun-0]|TX|3/24|
text_000N_97331|MMI|3.68|Burning Mouth Syndrome|C0006430|[dsyn]|["Burning Mouth Syndrome"-tx-1-"burning mouth syndrome"-noun-0]|TX|39/22|
text_000N_97331|MMI|3.56|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|28/7|
text_000N_97331|MMI|3.56|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|28/7|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_47450|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_47450|MMI|3.82|Feasibility|C5235660|[qlco]|["Feasibility"-tx-1-"feasible"-adj-0]|TX|6/8|
text_000N_47450|MMI|3.56|Proteome|C0751973|[aapp,bacs]|["Proteome"-tx-1-"proteome"-noun-0]|TX|41/8|
text_000N_47450|MMI|3.43|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|53/5|
text_000N_47450|MMI|3.43|Compleat Liquid Nutrition|C0725685|[food]|["COMPLEAT"-tx-1-"complete"-adj-0]|TX|32/8|
text_000N_47450|MMI|3.43|Complete|C0205197|[qlco]|["COMPLETE"-tx-1-"complete"-adj-0]|TX|32/8|
text_000N_47450|MMI|3.43|Complete Pharyngeal Contraction|C4283785|[fndg]|["Complete"-tx-1-"complete"-adj-0]|TX|32/8|
text_000N_47450|MMI|3.43|Data operation - complete|C3853530|[ftcn]|["complete"-tx-1-"complete"-adj-0]|TX|32/8|
text_000N_47450|MMI|3.43|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|53/5|
text_000N_47450|MMI|3.43|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|53/5|
text_000N_47450|MMI|3.43|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|53/5|
text_000N_47450|MMI|3.43|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|53/5|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Human cells|C0427861|[lbtr]|["Human cells"-tx-1-"human cells"-noun-0]|TX|40/11|
text_000N_43331|MMI|5.18|PER3 gene|C1418466|[gngm]|["PER3"-tx-1-"PER3"-noun-0]|TX|3/4|
text_000N_43331|MMI|3.57|Activation action|C1879547|[acty]|["Activation"-tx-1-"activation"-noun-0]|TX|26/10|
text_000N_43331|MMI|3.57|Requirement|C1514873|[ftcn]|["Required"-tx-1-"required"-verb-0]|TX|8/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|9/6|
text_000N_40941|MMI|5.18|Pet Animal|C0031268|[anim]|["Pets"-tx-1-"pets"-noun-0]|TX|4/4|
text_000N_40941|MMI|5.18|Pet Health|C1456682|[grpa]|["Pets"-tx-1-"pets"-noun-0]|TX|4/4|
text_000N_40941|MMI|3.50|Infant|C0021270|[aggp]|["INFANT"-tx-1-"infant"-noun-0]|TX|16/6|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|3.61|Statistical Technique|C1710191|[resa]|["Statistical Methods"-tx-1-"statistical methods"-noun-0]|TX|14/19|
text_000N_47274|MMI|3.51|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|79/7|
text_000N_47274|MMI|3.51|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|79/7|
text_000N_47274|MMI|3.43|Chromatin Immunoprecipitation Sequencing|C3831111|[mbrt]|["ChIP-Seq"-tx-1-"ChIP-seq"-noun-0]|TX|111/8|
text_000N_47274|MMI|3.43|histone modification|C1156199|[moft]|["Histone Modification"-tx-1-"histone modification"-noun-0]|TX|90/20|
text_000N_47274|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_47274|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_47274|MMI|3.42|Data|C1511726|[idcn]|["Data"-tx-1-"data"-noun-0]|TX|120/4|
text_000N_47274|MMI|3.42|Data (eukaryote)|C3714741|[euka]|["Data"-tx-1-"data"-noun-0]|TX|120/4|
text_000N_47274|MMI|3.42|Data call receiving device|C3245479|[medd]|["data"-tx-1-"data"-noun-0]|TX|120/4|
text_000N_47274|MMI|3.42|Different|C1705242|[qlco]|["Differential"-tx-1-"differential"-adj-0]|TX|66/12|
text_000N_47274|MMI|3.42|Differential - view|C4554467|[spco]|["Differential"-tx-1-"differential"-adj-0]|TX|66/12|
text_000N_47274|MMI|3.42|Differential quality|C0443199|[qlco]|["Differential"-tx-1-"differential"-adj-0]|TX|66/12|
text_000N_47274|MMI|3.41|Normalize (activity)|C1882115|[resa]|["Normalize"-tx-1-"normalizing"-adj-0]|TX|38/11|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|7.40|Ubiquitination|C1519751|[moft]|["Ubiquitination"-tx-1-"ubiquitination"-noun-0]|TX|[46/14],[70/14]|
text_000N_47420|MMI|5.18|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|13/7|
text_000N_47420|MMI|3.68|5'-Inosinic acid, 2'-deoxy-2'-fluoro-, homopolymer|C0071360|[nnon]|["poly"-tx-1-"poly"-noun-0]|TX|65/4|
text_000N_47420|MMI|3.68|Mono (ethnic group)|C1551432|[popg]|["Mono"-tx-1-"mono"-noun-0]|TX|41/4|
text_000N_47420|MMI|3.68|Mono language|C1551969|[lang]|["Mono"-tx-1-"mono"-noun-0]|TX|41/4|
text_000N_47420|MMI|3.68|POLY|C0747726|[cnce]|["POLY"-tx-1-"poly"-noun-0]|TX|65/4|
text_000N_47420|MMI|3.68|Poly A|C0032400|[nnon]|["poly"-tx-1-"poly"-noun-0]|TX|65/4|
text_000N_47420|MMI|3.68|Polysexuality|C5552797|[orga]|["Poly"-tx-1-"poly"-noun-0]|TX|65/4|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|IRF6 gene|C1416474|[gngm]|["LPS"-tx-1-"LPS"-noun-0]|TX|3/3|
text_000N_47435|MMI|5.18|IRF6 wt Allele|C2697656|[gngm]|["LPS"-tx-1-"LPS"-noun-0]|TX|3/3|
text_000N_47435|MMI|5.18|Lipopolysaccharides|C0023810|[orch]|["LPS"-tx-1-"LPS"-noun-0]|TX|3/3|
text_000N_47435|MMI|5.18|Van der Woude syndrome|C0175697|[dsyn]|["LPS"-tx-1-"LPS"-noun-0]|TX|3/3|
text_000N_47435|MMI|3.68|Multiplicative Product|C1704444|[qnco]|["Product"-tx-1-"product"-noun-0]|TX|19/7|
text_000N_47435|MMI|3.68|Pharmacologic Substance|C1254351|[phsu]|["Product"-tx-1-"product"-noun-0]|TX|19/7|
text_000N_47435|MMI|3.68|product|C1514468|[enty]|["Product"-tx-1-"product"-noun-0]|TX|19/7|
text_000N_47435|MMI|3.50|Microorganism|C0445623|[orgm]|["Microbial"-tx-1-"microbial"-adj-0]|TX|9/9|
<<<<< MMI
>>>>> MMI
text_000N_47334|AA|PDO|Patient-derived organoid|1|3|5|24|31:3
text_000N_47334|AA|PDOs|Patient-derived organoids|1|4|5|25|31:4
text_000N_47334|MMI|6.95|Patients|C0030705|[podg]|["*^patient"-tx-1-"Patient"-adj-0,"*^patient"-tx-1-"patient"-noun-0]|TX|4/7;50/7|
text_000N_47334|MMI|3.63|Organoids|C0029250|[tisu]|["Organoids"-tx-1-"organoids"-noun-0]|TX|20/9|
text_000N_47334|MMI|3.54|Clinical Response|C4055223|[fndg]|["Clinical Response"-tx-1-"responses clinic"-noun-0]|TX|58/9,75/6|
text_000N_47334|MMI|3.48|Derivation|C1441547|[qlco]|["DERIVED"-tx-1-"derived"-adj-0]|TX|12/7|
text_000N_47334|MMI|3.48|Derived value|C3245521|[idcn]|["Derived"-tx-1-"derived"-adj-0]|TX|12/7|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|25/15|
text_000N_43386|MMI|3.68|Protein Overexpression|C1514559|[genf]|["Overexpression"-tx-1-"overexpression"-noun-0]|TX|10/14|
text_000N_43386|MMI|3.59|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|41/7|
text_000N_43386|MMI|3.50|human MUC1 protein|C1612111|[aapp,imft,irda]|["Mucin"-tx-1-"mucin"-noun-0]|TX|4/5|
text_000N_43386|MMI|3.50|mucins|C0026682|[aapp,bacs]|["Mucin"-tx-1-"mucin"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|temsirolimus|C1707080|[orch,phsu]|["TEMSIROLIMUS"-tx-1-"temsirolimus"-noun-0]|TX|5/12|
text_000N_40839|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_40839|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_40839|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_40839|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_40839|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_40839|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_40839|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|51/8|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|3.75|Exercise|C0015259|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|11/17|
text_000N_40886|MMI|3.75|Physical activity|C0026606|[dora]|["Physical Activity"-tx-1-"physical activity"-noun-0]|TX|11/17|
text_000N_40886|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|29/15|
text_000N_40886|MMI|3.59|Longevity|C0023980|[tmco]|["Longevity"-tx-1-"longevity"-noun-0]|TX|45/9|
text_000N_40886|MMI|3.48|With intensity|C0522510|[qlco]|["Intense"-tx-1-"intense"-adj-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|52/8|
text_000N_40913|MMI|5.18|alemtuzumab|C0383429|[aapp,imft,phsu]|["ALEMTUZUMAB"-tx-1-"alemtuzumab"-noun-0]|TX|3/11|
text_000N_40913|MMI|3.72|T-Cell Prolymphocytic Leukemia|C2363142|[neop]|["T-cell prolymphocytic leukaemia"-tx-1-"T-cell prolymphocytic leukemia"-noun-0]|TX|76/30|
text_000N_40913|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40913|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40913|MMI|3.55|Diagnosis|C0011900|[diap]|["Diagnosed"-tx-1-"diagnosed"-verb-0]|TX|61/9|
text_000N_40913|MMI|3.48|Remission Induction|C0035052|[topp]|["Induction, Remission"-tx-1-"remission induction"-noun-0]|TX|29/19|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20|C4759928|[fndg]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|3/7|
text_000N_173136|MMI|5.18|Obesity|C0028754|[dsyn]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|3/7|
text_000N_173136|MMI|5.18|Obesity, CTCAE|C1963185|[fndg]|["Obesity"-tx-1-"obesity"-noun-0]|TX|3/7|
text_000N_173136|MMI|3.64|Impaired cognition|C0338656|[mobd]|["Cognitive decline"-tx-1-"cognitive decline"-noun-0]|TX|22/17|
text_000N_173136|MMI|3.64|Mental deterioration|C0234985|[mobd]|["Cognitive decline"-tx-1-"cognitive decline"-noun-0]|TX|22/17|
text_000N_173136|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|11/7|
text_000N_173136|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|11/7|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Diabetes|C0011847|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|17/8|
text_000N_40999|MMI|5.18|Diabetes Mellitus|C0011849|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|17/8|
text_000N_40999|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|11/5|
text_000N_40999|MMI|5.18|Hydroxymethylglutaryl-CoA Reductase Inhibitors|C0360714|[orch,phsu]|["Statins"-tx-1-"statins"-noun-0]|TX|3/7|
text_000N_40999|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|11/5|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|thiotepa|C0039871|[hops,orch,phsu]|["Thio-Tepa"-tx-1-"thiotepa"-noun-0]|TX|4/8|
text_000N_173104|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|Childhood Osteosarcoma|C1332986|[neop]|["Osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|45/12|
text_000N_173104|MMI|3.56|NCI CTEP SDC Osteosarcoma Sub-Category Terminology|C3541899|[inpr]|["Osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|45/12|
text_000N_173104|MMI|3.56|Osteosarcoma|C0029463|[neop]|["OSTEOSARCOMA"-tx-1-"osteosarcoma"-noun-0]|TX|45/12|
text_000N_173104|MMI|3.56|Osteosarcoma of bone|C0585442|[neop]|["osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|45/12|
text_000N_173104|MMI|3.56|RB1 gene|C0694889|[gngm]|["osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|45/12|
text_000N_173104|MMI|3.56|Recommendation|C0034866|[idcn]|["Recommended"-tx-1-"recommended"-verb-0]|TX|16/11|
text_000N_173104|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
text_000N_173104|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|32/9|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.65|Sequencing Data|C4727174|[inpr]|["Sequencing Data"-tx-1-"sequencing data"-noun-0]|TX|57/15|
text_000N_173120|MMI|3.54|Scientific Equipment|C2827396|[mnob]|["Tool"-tx-1-"tools"-noun-0]|TX|10/5|
text_000N_173120|MMI|3.54|Tool, device (physical object)|C0336791|[mnob]|["Tool"-tx-1-"tools"-noun-0]|TX|10/5|
text_000N_173120|MMI|3.46|Did you read|C4722184|[inpr]|["Read"-tx-1-"read"-adj-0]|TX|52/4|
text_000N_173120|MMI|3.46|Long|C0205166|[qlco]|["LONG"-tx-1-"long"-adj-0]|TX|47/4|
text_000N_173120|MMI|3.46|Long Heart Murmur|C5238697|[fndg]|["Long"-tx-1-"long"-adj-0]|TX|47/4|
text_000N_173120|MMI|3.46|Long Variable|C1706317|[qlco]|["Long"-tx-1-"long"-adj-0]|TX|47/4|
text_000N_173120|MMI|3.46|Nucleotide Sequence Read|C4723641|[lbpr]|["Read"-tx-1-"read"-adj-0]|TX|52/4|
text_000N_173120|MMI|3.46|Processing (action)|C1709694|[acty]|["Processing"-tx-1-"processing"-adj-0]|TX|36/10|
text_000N_173120|MMI|3.46|Reading (activity)|C0034754|[dora]|["Read"-tx-1-"read"-adj-0]|TX|52/4|
text_000N_173120|MMI|3.46|Reading (datum presentation)|C1705179|[cnce]|["read"-tx-1-"read"-adj-0]|TX|52/4|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|3.68|FDA Approval|C2700205|[inpr]|["FDA Approval"-tx-1-"FDA approval"-noun-0]|TX|25/12|
text_000N_173167|MMI|3.47|Receive|C1514756|[qlco]|["RECEIVED"-tx-1-"received"-adj-0]|TX|16/8|
text_000N_173167|MMI|3.47|ruxolitinib|C2931926|[orch,phsu]|["RUXOLITINIB"-tx-1-"ruxolitinib"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|Hold (action)|C1948035|[acty]|["Hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_97347|MMI|5.18|Hold - dosing instruction fragment|C1553387|[inpr]|["Hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_97347|MMI|5.18|hold - Data Operation|C3853841|[ftcn]|["hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_97347|MMI|5.18|teplizumab|C2743673|[aapp,imft,phsu]|["TEPLIZUMAB"-tx-1-"teplizumab"-noun-0]|TX|5/10|
text_000N_97347|MMI|3.57|promise|C1555307|[idcn]|["promise"-tx-1-"promise"-noun-0]|TX|21/7|
text_000N_97347|MMI|3.48|How to Prevent Diabetes|C1659987|[topp]|["Diabetes Prevention"-tx-1-"diabetes prevention"-noun-0]|TX|33/19|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|tocilizumab|C1609165|[aapp,imft,phsu]|["TOCILIZUMAB"-tx-1-"Tocilizumab"-noun-0]|TX|3/11|
text_000N_97362|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_97362|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_97362|MMI|3.50|Giant Cell Arteritis|C0039483|[dsyn]|["ARTERITIS, GIANT CELL"-tx-1-"Giant-Cell Arteritis"-noun-0]|TX|29/20|
text_000N_97362|MMI|3.50|Temporal Arteritis|C1956391|[dsyn]|["Giant cell arteritis"-tx-1-"Giant-Cell Arteritis"-noun-0]|TX|29/20|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Mass Spectrometers (device)|C0183396|[medd]|["Mass Spectrometer"-tx-1-"mass spectrometer"-noun-0]|TX|67/17|
text_000N_173087|MMI|3.68|Lipidomics|C4727082|[bmod]|["Lipidomics"-tx-1-"lipidomics"-noun-0]|TX|11/10|
text_000N_173087|MMI|3.55|Infusion procedures|C0574032|[topp]|["Infusion"-tx-1-"infusion"-noun-0]|TX|33/8|
text_000N_173087|MMI|3.55|Infusion route|C1827465|[ftcn]|["Infusion"-tx-1-"infusion"-noun-0]|TX|33/8|
text_000N_173087|MMI|3.50|Shotguns|C0037003|[mnob]|["Shotgun"-tx-1-"shotgun"-noun-0]|TX|3/7|
text_000N_173087|MMI|3.44|Lipid A|C0023767|[imft,orch]|["Lipid A"-tx-1-"a lipid"-noun-0]|TX|45/7|
text_000N_173087|MMI|3.42|Biospecimen|C2347026|[bdsu]|["Sample"-tx-1-"sample"-noun-0]|TX|53/6|
text_000N_173087|MMI|3.42|Direct (qualifier)|C1947931|[qlco]|["Direct"-tx-1-"direct"-adj-0]|TX|26/6|
text_000N_173087|MMI|3.42|Direct type of relationship|C0439851|[qlco]|["Direct"-tx-1-"direct"-adj-0]|TX|26/6|
text_000N_173087|MMI|3.42|Nucleotide Sequence Sample Name|C5551027|[inpr]|["Sample"-tx-1-"sample"-noun-0]|TX|53/6|
text_000N_173087|MMI|3.42|Specimen|C0370003|[sbst]|["Sample"-tx-1-"sample"-noun-0]|TX|53/6|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|5.18|thalidomide|C0039736|[hops,orch,phsu]|["THALIDOMIDE"-tx-1-"thalidomide"-noun-0]|TX|3/11|
text_000N_97378|MMI|3.58|Drug used|C0449889|[ftcn]|["used drug"-tx-1-"used drug"-noun-0]|TX|15/4,43/4|
text_000N_97378|MMI|3.49|Immunomodulation|C1963758|[topp]|["Immunomodulations"-tx-1-"immunomodulatory"-noun-0]|TX|26/16|
text_000N_97378|MMI|3.49|Immunoregulation|C0678889|[orgf]|["Immunomodulation"-tx-1-"immunomodulatory"-noun-0]|TX|26/16|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|58/19|
text_000N_173151|MMI|5.18|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|58/19|
text_000N_173151|MMI|3.68|mimetics|C0920591|[bmod]|["mimetics"-tx-1-"mimetics"-noun-0]|TX|9/8|
text_000N_173151|MMI|3.57|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|24/10|
text_000N_173151|MMI|3.57|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.57|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_173151|MMI|3.50|APOE gene|C1412481|[gngm]|["APOE"-tx-1-"apoE"-noun-0]|TX|4/4|
text_000N_173151|MMI|3.50|ApoE protein, human|C4308468|[aapp,bacs]|["Apo-E"-tx-1-"apoE"-noun-0]|TX|4/4|
text_000N_173151|MMI|3.50|Apolipoprotein E|C0003595|[aapp,bacs]|["ApoE"-tx-1-"apoE"-noun-0]|TX|4/4|
text_000N_173151|MMI|3.50|Apolipoproteins E measurement (procedure)|C0523511|[lbpr]|["APOE"-tx-1-"apoE"-noun-0]|TX|4/4|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Post-Traumatic Stress Disorder|C0038436|[mobd]|["Posttraumatic stress disorder"-tx-1-"Post Traumatic Stress Disorder"-noun-1]|TX|78/30|
text_000N_47289|MMI|5.18|Scientific Study|C0947630|[resa]|["studies"-tx-1-"studies"-noun-0]|TX|5/7|
text_000N_47289|MMI|3.98|Show|C1547282|[anim]|["Show"-tx-1-"shown"-verb-0]|TX|13/5|
text_000N_47289|MMI|3.55|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|36/4|
text_000N_47289|MMI|3.55|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-noun-0]|TX|36/4|
text_000N_47289|MMI|3.45|DNA Methylation|C0376452|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|49/15|
text_000N_47289|MMI|3.45|DNA Methylation Analysis|C1880239|[mbrt]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|49/15|
text_000N_47289|MMI|3.45|DNA Methylation [PE]|C3536933|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|49/15|
text_000N_47289|MMI|3.44|Chief Complaint Occurs Without Pattern|C5238675|[fndg]|["No pattern"-tx-1-"no patterns"-noun-0]|TX|33/2,65/8|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|3.68|EPRS1 gene|C1414437|[gngm]|["EPRS"-tx-1-"EPRS"-noun-0]|TX|14/4|
text_000N_97283|MMI|3.50|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
text_000N_97283|MMI|3.50|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
text_000N_97283|MMI|3.50|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|FTO gene|C1970415|[gngm]|["FTO"-tx-1-"FTO"-noun-0]|TX|4/3|
text_000N_173199|MMI|5.18|FTO protein, human|C2351322|[aapp,enzy]|["FTO"-tx-1-"FTO"-noun-0]|TX|4/3|
text_000N_173199|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|8/7|
text_000N_173199|MMI|3.63|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|34/11|
text_000N_173199|MMI|3.63|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|34/11|
text_000N_173199|MMI|3.63|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|34/11|
text_000N_173199|MMI|3.63|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|34/11|
text_000N_173199|MMI|3.53|Malignant neoplasm of pancreas|C0346647|[neop]|["Pancreatic Cancer"-tx-1-"pancreatic cancer"-noun-0]|TX|16/17|
text_000N_173199|MMI|3.53|Pancreatic Cancer Pathway|C2984259|[ftcn]|["Pancreatic cancer"-tx-1-"pancreatic cancer"-noun-0]|TX|16/17|
text_000N_173199|MMI|3.53|Pancreatic carcinoma|C0235974|[neop]|["PANCREATIC CANCER"-tx-1-"pancreatic cancer"-noun-0]|TX|16/17|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|golimumab|C2353893|[aapp,imft,phsu]|["GOLIMUMAB"-tx-1-"golimumab"-noun-0]|TX|3/9|
text_000N_173183|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_173183|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_173183|MMI|3.48|Ulcerative Colitis|C0009324|[dsyn]|["COLITIS, ULCERATIVE"-tx-1-"ulcerative colitis"-noun-0]|TX|27/18|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Percutaneous Coronary Intervention|C1532338|[topp]|["Intervention, Percutaneous Coronary"-tx-1-"percutaneous coronary intervention"-noun-0]|TX|56/34|
text_000N_173214|MMI|5.18|trimetazidine|C0041037|[orch,phsu]|["TRIMETAZIDINE"-tx-1-"trimetazidine"-noun-0]|TX|5/13|
text_000N_173214|MMI|3.64|myocardial injury|C0746730|[inpo]|["myocardial injury"-tx-1-"myocardial injury"-noun-0]|TX|32/17|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.62|Animal genome|C0314610|[gngm]|["Animal genome"-tx-1-"animal genomes"-noun-0]|TX|32/14|
text_000N_173245|MMI|3.57|Present|C0150312|[fndg]|["PRESENT"-tx-1-"present"-verb-0]|TX|21/7|
text_000N_173245|MMI|3.57|Presentation|C0449450|[idcn]|["Present"-tx-1-"present"-verb-0]|TX|21/7|
text_000N_173245|MMI|3.57|Radial-Femoral Lag Present|C5238858|[fndg]|["Present"-tx-1-"present"-verb-0]|TX|21/7|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|28/15|
text_000N_47304|MMI|3.59|Glioma|C0017638|[neop]|["GLIOMAS"-tx-1-"gliomas"-noun-0]|TX|44/7|
text_000N_47304|MMI|3.51|Histone H3|C0019647|[aapp,bacs]|["Histone H3"-tx-1-"histone H3"-noun-0]|TX|3/7,19/2|
text_000N_47304|MMI|3.50|GDC Histone Variant Terminology|C5204161|[inpr]|["histone_variant"-tx-1-"histone variant"-noun-0]|TX|3/15|
text_000N_47304|MMI|3.50|Histone Variant|C5447907|[aapp]|["Histone Variant"-tx-1-"histone variant"-noun-0]|TX|3/15|
text_000N_47304|MMI|3.47|Variant|C0205419|[qlco]|["Variant"-tx-1-"variant"-noun-0]|TX|11/7|
text_000N_47304|MMI|3.47|influenza A virus H3 subtype|C2959654|[virs]|["H3"-tx-1-"H3"-noun-0]|TX|19/2|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|3.64|Alternative Splicing|C0002345|[genf]|["Alternative Splicing"-tx-1-"alternative splicing"-noun-0]|TX|59/20|
text_000N_173276|MMI|3.56|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|46/8|
text_000N_173276|MMI|3.56|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_173276|MMI|3.56|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_173276|MMI|3.44|Vertebrates|C0042567|[vtbt]|["Vertebrates"-tx-1-"vertebrates"-noun-0]|TX|83/11|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|solanezumab|C2935150|[aapp,imft,phsu]|["SOLANEZUMAB"-tx-1-"Solanezumab"-noun-0]|TX|3/11|
text_000N_40972|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40972|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40972|MMI|3.48|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|29/19|
text_000N_40972|MMI|3.48|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|29/19|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|enasidenib|C4519428|[orch,phsu]|["ENASIDENIB"-tx-1-"enasidenib"-noun-0]|TX|4/10|
text_000N_173260|MMI|3.60|Acute Myeloid Leukemia Pathway|C2984331|[cnce]|["Acute myeloid leukemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|44/22|
text_000N_173260|MMI|3.60|Leukemia, Myelocytic, Acute|C0023467|[neop]|["Acute myeloid leukaemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|44/22|
text_000N_173260|MMI|3.60|NCI CTEP SDC Acute Myeloid Leukemia Sub-Category Terminology|C3541370|[inpr]|["Acute Myeloid Leukemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|44/22|
text_000N_173260|MMI|3.55|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|18/4,41/2|
text_000N_173260|MMI|3.54|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_173260|MMI|3.54|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Cryptococcus neoformans|C0010416|[fngs]|["CRYPTOCOCCUS NEOFORMANS"-tx-1-"Cryptococcus neoformans"-noun-0]|TX|3/23|
text_000N_47363|MMI|5.18|Infection by Cryptococcus neoformans|C0010414|[dsyn]|["cryptococcus neoformans"-tx-1-"Cryptococcus neoformans"-noun-0]|TX|3/23|
text_000N_47363|MMI|3.63|Individual|C0237401|[popg]|["Individual"-tx-1-"individuals"-noun-0]|TX|93/11|
text_000N_47363|MMI|3.63|Persons|C0027361|[popg]|["Individual"-tx-1-"individuals"-noun-0]|TX|93/11|
text_000N_47363|MMI|3.55|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|38/5|
text_000N_47363|MMI|3.55|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|38/5|
text_000N_47363|MMI|3.50|Immunocompromised Host|C0085393|[fndg]|["Immunocompromised"-tx-1-"immunocompromised"-adj-0]|TX|75/17|
text_000N_47363|MMI|3.45|Skin Diseases, Infectious|C0037278|[dsyn]|["Infection of skin"-tx-1-"of skin infections"-noun-0]|TX|44/2,56/15|
text_000N_47363|MMI|3.42|Bed Status - Isolated|C1548221|[idcn]|["Isolated"-tx-1-"isolated"-adj-0]|TX|47/8|
text_000N_47363|MMI|3.42|Frequently|C0332183|[tmco]|["Frequent"-tx-1-"frequent"-adj-0]|TX|29/8|
text_000N_47363|MMI|3.42|Isolated|C0205409|[ftcn]|["Isolated"-tx-1-"isolated"-adj-0]|TX|47/8|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Apoptosis|C0162638|[celf]|["APOPTOSIS"-tx-1-"apoptosis"-noun-0]|TX|17/9|
text_000N_47377|MMI|5.18|Apoptosis Pathway|C4759886|[cnce]|["Apoptosis"-tx-1-"apoptosis"-noun-0]|TX|17/9|
text_000N_47377|MMI|5.18|Beans (food)|C0004896|[food]|["Beans"-tx-1-"beans"-noun-0]|TX|4/5|
text_000N_47377|MMI|5.18|Induce (action)|C0205263|[ftcn]|["Induce"-tx-1-"induce"-verb-0]|TX|10/6|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Janus kinase inhibitor|C3854325|[phsu]|["JAK Inhibitor"-tx-1-"JAK inhibitor"-noun-0]|TX|17/13|
text_000N_43275|MMI|5.18|tofacitinib|C2930696|[orch,phsu]|["TOFACITINIB"-tx-1-"tofacitinib"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|3.42|Phosphotransferases|C0031727|[aapp,enzy]|["Kinases"-tx-1-"kinases"-noun-0]|TX|44/7|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Diseases of mitral valve|C0026265|[dsyn]|["MITRAL VALVE DISEASE"-tx-1-"mitral valve disease"-noun-0]|TX|55/20|
text_000N_43235|MMI|5.18|Mitral Valve Disease, CTCAE|C4553832|[fndg]|["Mitral Valve Disease"-tx-1-"mitral valve disease"-noun-0]|TX|55/20|
text_000N_43235|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43235|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43235|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43235|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43235|MMI|3.46|Malignant Carcinoid Syndrome|C0024586|[dsyn]|["CARCINOID SYNDROME"-tx-1-"carcinoid syndrome"-noun-0]|TX|32/18|
text_000N_43235|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43235|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|enlimomab|C1258935|[imft]|["enlimomab"-tx-1-"Enlimomab"-noun-0]|TX|3/9|
text_000N_47349|MMI|3.62|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|13/9,34/9|
text_000N_47349|MMI|3.44|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|27/6|
text_000N_47349|MMI|3.44|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|27/6|
text_000N_47349|MMI|3.44|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|27/6|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|CTSL gene|C1332807|[gngm]|["CATHEPSIN L"-tx-1-"cathepsin L"-noun-0]|TX|3/11|
text_000N_47392|MMI|5.18|CTSL protein, human|C1310906|[aapp,enzy]|["Cathepsin L"-tx-1-"cathepsin L"-noun-0]|TX|3/11|
text_000N_47392|MMI|5.18|Cathepsin L|C0054871|[aapp,enzy]|["Cathepsin L"-tx-1-"cathepsin L"-noun-0]|TX|3/11|
text_000N_47392|MMI|3.59|Active|C0205177|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|15/6|
text_000N_47392|MMI|3.59|Active License|C3888249|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|15/6|
text_000N_47392|MMI|3.59|Active State|C0679217|[idcn]|["Active"-tx-1-"active"-adj-0]|TX|15/6|
text_000N_47392|MMI|3.59|Pet is as Active as it Has Been|C5238549|[inpr]|["active"-tx-1-"active"-adj-0]|TX|15/6|
text_000N_47392|MMI|3.59|active (HL7 RoleLink)|C3853793|[idcn]|["active"-tx-1-"active"-adj-0]|TX|15/6|
text_000N_47392|MMI|3.45|Endosomes|C0034850|[celc]|["Endosomes"-tx-1-"endosomes"-noun-0]|TX|25/9|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|12/4|
text_000N_43358|MMI|5.18|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["LincRNAs"-tx-1-"lincRNAs"-noun-0]|TX|3/8|
text_000N_43358|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|12/4|
text_000N_43358|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_43358|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_43358|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_43358|MMI|3.43|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|33/6|
text_000N_43358|MMI|3.43|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|27/5|
text_000N_43358|MMI|3.43|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|33/6|
text_000N_43358|MMI|3.43|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|33/6|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|3.68|Inhibitor|C1999216|[bacs]|["INHIBITOR"-tx-1-"inhibitor"-noun-0]|TX|16/9|
text_000N_40941|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|26/9|
text_000N_40941|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|26/9|
text_000N_40941|MMI|3.50|2019 novel coronavirus|C5203676|[virs]|["SARS-CoV-2"-tx-1-"SARS-CoV-2"-noun-0]|TX|44/10|
text_000N_40941|MMI|3.50|Severe Acute Respiratory Syndrome Coronavirus 2 Measurement|C5401247|[lbpr]|["SARS-CoV-2"-tx-1-"SARS-CoV-2"-noun-0]|TX|44/10|
text_000N_40941|MMI|3.50|apilimod|C2983891|[orch,phsu]|["APILIMOD"-tx-1-"apilimod"-noun-0]|TX|7/8|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Levels (qualifier value)|C0441889|[qlco]|["Levels"-tx-1-"levels"-noun-0]|TX|36/6|
text_000N_43303|MMI|5.18|MACROH2A1 gene|C1415407|[gngm]|["MACRO H2A"-tx-1-"macro-H2A"-noun-0]|TX|25/9|
text_000N_43303|MMI|5.18|MACROH2A1 wt Allele|C3814451|[gngm]|["MACRO H2A"-tx-1-"macro-H2A"-noun-0]|TX|25/9|
text_000N_43303|MMI|3.63|Core Histone Macro-H2A|C2987130|[aapp,bacs]|["mH2A"-tx-1-"mH2A"-noun-0]|TX|19/4|
text_000N_43303|MMI|3.59|Cell Differentiation process|C0007589|[celf]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|57/15|
text_000N_43303|MMI|3.59|Decrease|C0547047|[qnco]|["Decrease"-tx-1-"decrease"-verb-0]|TX|43/8|
text_000N_43303|MMI|3.59|Differentiation|C2945687|[ftcn]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|57/15|
text_000N_43303|MMI|3.59|Histopathologic Grade differentiation|C1511938|[clna]|["Differentiation"-tx-1-"differentiation"-noun-0]|TX|57/15|
text_000N_43303|MMI|3.59|Reduced|C0392756|[fndg]|["Decrease"-tx-1-"decrease"-verb-0]|TX|43/8|
text_000N_43303|MMI|3.53|GDC Histone Variant Terminology|C5204161|[inpr]|["histone_variant"-tx-1-"histone variant"-noun-0]|TX|3/15|
text_000N_43303|MMI|3.53|Histone Variant|C5447907|[aapp]|["Histone Variant"-tx-1-"histone variant"-noun-0]|TX|3/15|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Hold (action)|C1948035|[acty]|["Hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_47320|MMI|5.18|Hold - dosing instruction fragment|C1553387|[inpr]|["Hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_47320|MMI|5.18|hold - Data Operation|C3853841|[ftcn]|["hold"-tx-1-"hold"-verb-0]|TX|16/4|
text_000N_47320|MMI|5.18|nintedanib|C2930789|[orch,phsu]|["NINTEDANIB"-tx-1-"nintedanib"-noun-0]|TX|5/10|
text_000N_47320|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|46/15|
text_000N_47320|MMI|3.64|Systemic Scleroderma|C0036421|[dsyn]|["SCLEROSIS, SYSTEMIC"-tx-1-"systemic sclerosis"-noun-0]|TX|62/18|
text_000N_47320|MMI|3.57|promise|C1555307|[idcn]|["promise"-tx-1-"promise"-noun-0]|TX|21/7|
text_000N_47320|MMI|3.48|Lung diseases|C0024115|[dsyn]|["Disease, Lung"-tx-1-"lung disease"-noun-0]|TX|33/12|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.68|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.68|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|58/9|
text_000N_47420|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47420|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47420|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_47420|MMI|3.50|Adult Medulloblastoma|C0278876|[neop]|["Medulloblastoma"-tx-1-"medulloblastoma"-noun-0]|TX|42/15|
text_000N_47420|MMI|3.50|Childhood Medulloblastoma|C0278510|[neop]|["Medulloblastoma"-tx-1-"medulloblastoma"-noun-0]|TX|42/15|
text_000N_47420|MMI|3.50|Medulloblastoma|C0025149|[neop]|["MEDULLOBLASTOMA"-tx-1-"medulloblastoma"-noun-0]|TX|42/15|
text_000N_47420|MMI|3.50|Medulloblastoma, Not Otherwise Specified|C4330668|[neop]|["Medulloblastoma, NOS"-tx-1-"medulloblastoma"-noun-0]|TX|42/15|
text_000N_47420|MMI|3.48|Proton Therapy|C0436226|[topp]|["Therapy, Proton Beam"-tx-1-"proton beam therapy"-noun-0]|TX|19/19|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.68|Elements|C0013879|[elii]|["Elements"-tx-1-"Elements"-noun-0]|TX|24/8|
text_000N_47435|MMI|3.57|Importance Rating Score 0|C4084912|[inpr]|["Important"-tx-1-"important"-adj-0]|TX|41/9|
text_000N_47435|MMI|3.57|Important|C3898777|[qlco]|["Important"-tx-1-"important"-adj-0]|TX|41/9|
text_000N_47435|MMI|3.44|Phylogeny|C0031797|[idcn]|["Phylogenomics"-tx-1-"phylogenomics"-noun-0]|TX|54/13|
text_000N_47435|MMI|3.44|Research Activities|C0242481|[resa]|["Research"-tx-1-"research"-noun-0]|TX|68/8|
text_000N_47435|MMI|3.44|research|C0035168|[resa]|["Research"-tx-1-"research"-noun-0]|TX|68/8|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|eculizumab|C1541483|[aapp,imft,phsu]|["ECULIZUMAB"-tx-1-"eculizumab"-noun-0]|TX|3/10|
text_000N_47274|MMI|3.62|Myasthenia gravis treatment|C1979765|[topp]|["Myasthenia gravis treatment"-tx-1-"treatment myasthenia gravis"-noun-0]|TX|23/9,36/17|
text_000N_47274|MMI|3.55|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|14/4|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|41/9|
text_000N_47450|MMI|3.75|DNA Synthesis Inhibitors|C0376566|[bacs,phsu]|["Replication Inhibitors"-tx-1-"replication inhibitors"-noun-0]|TX|18/22|
text_000N_47450|MMI|3.48|Hepatitis C|C0019196|[dsyn]|["HCV"-tx-1-"HCV"-noun-0]|TX|14/3|
text_000N_47450|MMI|3.48|hepatitis C virus|C0220847|[virs]|["HCV"-tx-1-"HCV"-noun-0]|TX|14/3|
<<<<< MMI
>>>>> MMI
text_000N_43331|AA|LSD1|Lysine-specific demethylase 1|1|4|7|29|34:4
text_000N_43331|MMI|5.18|KDM1A gene|C1428785|[gngm]|["LYSINE-SPECIFIC DEMETHYLASE 1"-tx-1-"Lysine-specific demethylase 1"-noun-0]|TX|3/29|
text_000N_43331|MMI|3.56|Oxygen supplies regulator|C4281746|[medd]|["Regulator"-tx-1-"regulator"-noun-0]|TX|51/9|
text_000N_43331|MMI|3.56|Regulator|C1704735|[cnce]|["Regulator"-tx-1-"regulator"-noun-0]|TX|51/9|
text_000N_43331|MMI|3.56|Regulators (device)|C0182953|[mnob]|["Regulator"-tx-1-"regulator"-noun-0]|TX|51/9|
text_000N_43331|MMI|3.43|Critical|C1511545|[qlco]|["Critical"-tx-1-"critical"-adj-0]|TX|42/8|
text_000N_43331|MMI|3.43|Hematopoiesis|C0018951|[ortf]|["Hematopoiesis"-tx-1-"hematopoiesis"-noun-0]|TX|64/13|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|Alzheimer's disease treatment|C1979617|[topp]|["Alzheimer's disease treatment"-tx-1-"Alzheimer's disease treatment"-noun-0]|TX|57/29|
text_000N_47334|MMI|3.78|Antibodies, Anti-Idiotypic|C0003242|[aapp,imft]|["anti antibody"-tx-1-"anti antibody"-noun-0]|TX|14/4,27/8|
text_000N_47334|MMI|3.59|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|36/8|
text_000N_47334|MMI|3.59|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|48/4|
text_000N_47334|MMI|3.59|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|48/4|
text_000N_47334|MMI|3.48|APP protein, human|C0611285|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-adj-0]|TX|19/7|
text_000N_47334|MMI|3.48|Amyloid|C0002716|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-adj-0]|TX|19/7|
text_000N_47334|MMI|3.48|Amyloid Proteins|C1456454|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-adj-0]|TX|19/7|
text_000N_47334|MMI|3.48|Amyloid deposition|C0011560|[patf]|["Amyloid"-tx-1-"amyloid"-adj-0]|TX|19/7|
text_000N_47334|MMI|3.48|Amyloidosis|C0002726|[dsyn]|["AMYLOID"-tx-1-"amyloid"-adj-0]|TX|19/7|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Secondary Glioblastoma|C1519214|[neop]|["Secondary Glioblastoma"-tx-1-"secondary glioblastoma"-noun-0]|TX|4/22|
text_000N_43386|MMI|3.64|Brain irradiation|C0852224|[diap]|["Brain irradiation"-tx-1-"brain irradiation"-noun-0]|TX|40/17|
text_000N_43386|MMI|3.54|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|30/6|
text_000N_43386|MMI|3.54|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|30/6|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|vemurafenib|C3192263|[orch,phsu]|["VEMURAFENIB"-tx-1-"vemurafenib"-noun-0]|TX|3/11|
text_000N_40839|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40839|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40839|MMI|3.50|Hairy Cell Leukemia|C0023443|[neop]|["Hairy cell leukaemia"-tx-1-"hairy-cell leukemia"-noun-0]|TX|29/19|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|7.70|RNA, Circular|C0073432|[nnon]|["circRNA"-tx-1-"CircRNA"-noun-0,"circRNA"-tx-1-"circRNA"-noun-0]|TX|3/7;85/7|
text_000N_40886|MMI|7.46|Exons|C0015295|[bacs,nnon]|["Exon"-tx-1-"exon"-noun-0]|TX|[40/4],[70/4]|
text_000N_40886|MMI|7.46|Variant Exon|C5401401|[nnon]|["exon"-tx-1-"exon"-noun-0]|TX|[40/4],[70/4]|
text_000N_40886|MMI|7.36|Introns|C0021920|[bacs,nnon]|["Intron"-tx-1-"intron"-noun-0]|TX|[46/6],[78/6]|
text_000N_40886|MMI|5.18|Formation|C1522492|[ftcn]|["Forming"-tx-1-"forming"-verb-0]|TX|62/7|
text_000N_40886|MMI|5.18|Formed|C0205431|[ftcn]|["Forming"-tx-1-"forming"-verb-0]|TX|62/7|
text_000N_40886|MMI|3.58|Dorsal|C0205095|[spco]|["Back of"-tx-1-"back of"-adj-0]|TX|23/4,37/2|
text_000N_40886|MMI|3.55|RNA Splicing|C0035687|[genf]|["Splicing"-tx-1-"splicing"-noun-0]|TX|28/8|
text_000N_40886|MMI|3.55|nuclear mRNA cis splicing, via spliceosome|C2610186|[genf]|["splicing"-tx-1-"splicing"-noun-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|propranolol|C0033497|[orch,phsu]|["PROPRANOLOL"-tx-1-"propranolol"-noun-0]|TX|3/11|
text_000N_40913|MMI|3.59|Infantile hemangioma|C4317089|[neop]|["Infantile Hemangioma"-tx-1-"infantile hemangioma"-noun-0]|TX|37/20|
text_000N_40913|MMI|3.59|Strawberry nevus of skin|C0206733|[neop]|["Infantile hemangioma"-tx-1-"infantile hemangioma"-noun-0]|TX|37/20|
text_000N_40913|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|15/4,34/2|
text_000N_40913|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_40913|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Bioprinting|C3494251|[mbrt]|["Bioprinting"-tx-1-"bioprinting"-noun-0]|TX|6/11|
text_000N_40999|MMI|5.18|Bone Diseases|C0005940|[dsyn]|["Bone disease"-tx-1-"bone disease"-noun-0]|TX|59/12|
text_000N_40999|MMI|3.64|Regenerative Medicine|C1257974|[bmod]|["Regenerative Medicine"-tx-1-"regenerative medicine"-noun-0]|TX|29/21|
text_000N_40999|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_173104|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_173104|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_173104|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_173104|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_173104|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_173104|MMI|3.44|MRPL53 gene|C1424483|[gngm]|["MRPL53"-tx-1-"MRPL53"-noun-0]|TX|20/6|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|Antibiotics|C0003232|[antb]|["Antibiotic"-tx-1-"antibiotic"-noun-0]|TX|15/10|
text_000N_173136|MMI|5.18|zolpidem|C0078839|[orch,phsu]|["ZOLPIDEM"-tx-1-"zolpidem"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|DNA-Binding Protein SATB1|C2699550|[aapp,rcpt]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_173151|MMI|5.18|SATB1 gene|C1419822|[gngm]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_173151|MMI|3.50|T-Cell Development|C1515126|[celf]|["T cell Maturation"-tx-1-"T-cell maturation"-noun-0]|TX|23/17|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Whole Transcriptome Sequencing|C4086963|[mbrt]|["RNAseq"-tx-1-"RNASeq"-noun-0]|TX|4/6|
text_000N_173167|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|14/4,36/2|
text_000N_173167|MMI|3.55|Analysis|C0936012|[resa]|["ANALYSIS"-tx-1-"analysis"-noun-0]|TX|27/8|
text_000N_173167|MMI|3.55|Analysis of substances|C0002778|[lbpr]|["Analysis"-tx-1-"analysis"-noun-0]|TX|27/8|
text_000N_173167|MMI|3.55|RNA Transcript|C1519595|[nnon]|["Transcripts"-tx-1-"transcripts"-noun-0]|TX|47/11|
text_000N_173167|MMI|3.55|analysis aspect|C1524024|[ftcn]|["analysis"-tx-1-"analysis"-noun-0]|TX|27/8|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Child|C0008059|[aggp]|["Children"-tx-1-"children"-noun-0]|TX|53/8|
text_000N_173183|MMI|5.18|Offspring|C0680063|[famg]|["Children"-tx-1-"children"-noun-0]|TX|53/8|
text_000N_173183|MMI|5.18|amoxicillin|C0002645|[antb,orch]|["Amoxycillin"-tx-1-"amoxicillin"-noun-0]|TX|3/11|
text_000N_173183|MMI|3.58|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|15/4,34/2|
text_000N_173183|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|Malnutrition|C0162429|[dsyn]|["MALNUTRITION"-tx-1-"malnutrition"-noun-0]|TX|37/12|
text_000N_173183|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173183|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Brain Neoplasms|C0006118|[neop]|["Brain tumour"-tx-1-"brain tumor"-noun-0]|TX|48/11|
text_000N_173230|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173230|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173230|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173230|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173230|MMI|3.46|Bornavirus|C0949883|[virs]|["Bornavirus"-tx-1-"borna virus"-noun-0]|TX|32/11|
text_000N_173230|MMI|3.46|borna virus|C0599614|[virs]|["borna virus"-tx-1-"borna virus"-noun-0]|TX|32/11|
text_000N_173230|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_173230|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Gene Expression|C0017262|[genf]|["Gene Expression"-tx-1-"gene expression"-noun-0]|TX|27/15|
text_000N_173120|MMI|5.18|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"gene expression"-noun-0]|TX|27/15|
text_000N_173120|MMI|5.18|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-verb-0]|TX|18/8|
text_000N_173120|MMI|3.68|Exons|C0015295|[bacs,nnon]|["Exons"-tx-1-"exons"-noun-0]|TX|12/5|
text_000N_173120|MMI|3.50|Circular|C1282913|[spco]|["Circular"-tx-1-"circular"-adj-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Genomics|C0887950|[bmod]|["Genomics"-tx-1-"genomics"-noun-0]|TX|53/8|
text_000N_173199|MMI|3.55|Application procedure|C0185125|[topp]|["applications"-tx-1-"applications"-noun-0]|TX|20/12|
text_000N_173199|MMI|3.45|Deep Learning|C4704761|[mcha]|["Deep Learning"-tx-1-"deep learning"-noun-0]|TX|36/13|
text_000N_173199|MMI|3.43|Current (present time)|C0521116|[tmco]|["Currently"-tx-1-"currently"-adv-0]|TX|10/9|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Philadelphia Chromosome|C0031526|[patf]|["Philadelphia Chromosome"-tx-1-"Philadelphia chromosome"-noun-0]|TX|7/23|
text_000N_173245|MMI|3.55|Fused structure|C0332466|[ftcn]|["Fusion"-tx-1-"fusion"-noun-0]|TX|33/6|
text_000N_173245|MMI|3.55|Fusion procedure|C1293131|[topp]|["Fusion"-tx-1-"fusion"-noun-0]|TX|33/6|
text_000N_173245|MMI|3.55|Gene Fusion|C0178648|[mbrt]|["Fusion"-tx-1-"fusion"-noun-0]|TX|33/6|
text_000N_173245|MMI|3.43|Chromosomes, Human, Pair 1|C0008651|[celc]|["Chromosome 1"-tx-1-"chromosomes 1"-noun-0]|TX|57/13|
text_000N_173245|MMI|3.43|part of|C1292711|[spco]|["part of"-tx-1-"parts of"-noun-0]|TX|48/8|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|nintedanib|C2930789|[orch,phsu]|["NINTEDANIB"-tx-1-"nintedanib"-noun-0]|TX|3/10|
text_000N_47304|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47304|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47304|MMI|3.50|Idiopathic Pulmonary Fibrosis|C1800706|[dsyn]|["FIBROSIS, IDIOPATHIC PULMONARY"-tx-1-"Idiopathic Pulmonary Fibrosis"-noun-0]|TX|28/29|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|3.88|Allelic phase|C4255410|[celf]|["Allelic phase"-tx-1-"allele phasing"-noun-0]|TX|5/14|
text_000N_40972|MMI|3.88|Allelic phase:Type:Point in time:^Patient:Nominal|C4255505|[clna]|["Allelic phase"-tx-1-"allele phasing"-noun-0]|TX|5/14|
text_000N_40972|MMI|3.55|Utilities (organization)|C0582205|[orgt]|["utility"-tx-1-"utility"-noun-0]|TX|45/7|
text_000N_40972|MMI|3.55|Utility (animal life circumstance)|C3669222|[ftcn]|["Utility"-tx-1-"utility"-noun-0]|TX|45/7|
text_000N_40972|MMI|3.43|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|71/8|
text_000N_40972|MMI|3.38|Phylogenetic Analysis|C1519068|[resa]|["Phylogenetics"-tx-1-"phylogenetic"-adj-0]|TX|32/12|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Increase|C0442805|[ftcn]|["increases"-tx-1-"increases"-verb-0]|TX|33/9|
text_000N_173291|MMI|5.18|Increased|C0205217|[qnco]|["Increases"-tx-1-"increases"-verb-0]|TX|33/9|
text_000N_173291|MMI|3.63|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|55/4|
text_000N_173291|MMI|3.63|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|55/4|
text_000N_173291|MMI|3.57|Electromagnetic Radiation|C0034519|[npop]|["Radiation"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.57|Radiation|C0851346|[npop]|["Radiation"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.57|Radiation Ionizing Radiotherapy|C1524020|[topp]|["Radiation"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.57|Radiotherapy Research|C1524021|[resa]|["Radiation"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.57|Therapeutic radiology procedure|C1522449|[topp]|["RADIATION"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.57|Unit of radiation dose|C0560559|[qnco]|["Radiation"-tx-1-"radiation"-noun-0]|TX|5/9|
text_000N_173291|MMI|3.53|Brain Neoplasms|C0006118|[neop]|["Brain tumour"-tx-1-"brain tumor"-noun-0]|TX|43/11|
text_000N_173291|MMI|3.48|Tinea Capitis|C0040250|[dsyn]|["TINEA CAPITIS"-tx-1-"tinea capitis"-noun-0]|TX|19/13|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|21/15|
text_000N_47289|MMI|3.63|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|11/9|
text_000N_47289|MMI|3.59|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_47289|MMI|3.59|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_47289|MMI|3.59|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_47289|MMI|3.59|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|37/11|
text_000N_47289|MMI|3.50|Shadow|C0332554|[ftcn]|["Shadow"-tx-1-"shadow"-adj-0]|TX|4/6|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|3.68|Green urine|C0239778|[fndg]|["GREEN URINE"-tx-1-"green urine"-noun-0]|TX|19/11|
text_000N_43275|MMI|3.47|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|13/5|
text_000N_43275|MMI|3.47|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|13/5|
text_000N_43275|MMI|3.47|propofol|C0033487|[orch,phsu]|["PROPOFOL"-tx-1-"propofol"-noun-0]|TX|4/8|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Transcription Activator-Like Effector Nucleases|C4277678|[aapp,enzy]|["TALEN"-tx-1-"TALEN"-noun-0]|TX|3/5|
text_000N_47377|MMI|3.64|Stem cells|C0038250|[cell]|["Stem Cells"-tx-1-"stem cells"-noun-0]|TX|23/10|
text_000N_47377|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|15/4|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Structure of petrous part of temporal bone|C0031266|[bpoc]|["Petrous Bone"-tx-1-"petrous bone"-noun-0]|TX|7/12|
text_000N_173214|MMI|3.61|DNA, Ancient|C3272455|[bacs,nnon]|["Ancient DNA"-tx-1-"ancient DNA"-noun-0]|TX|28/11|
text_000N_173214|MMI|3.56|Sampling|C0870078|[idcn]|["Sampling"-tx-1-"sampling"-noun-0]|TX|40/8|
text_000N_173214|MMI|3.56|Sampling - Surgical action|C0441621|[diap]|["Sampling"-tx-1-"sampling"-noun-0]|TX|40/8|
text_000N_173214|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|20/4|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|benralizumab|C2982078|[aapp,imft,phsu]|["BENRALIZUMAB"-tx-1-"Benralizumab"-noun-0]|TX|3/12|
text_000N_173276|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_173276|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_173276|MMI|3.50|Chronic Spontaneous Urticaria|C0578870|[dsyn]|["Chronic Spontaneous Urticaria"-tx-1-"Chronic Spontaneous Urticaria"-noun-0]|TX|30/29|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Herceptin|C0338204|[aapp,imft,phsu]|["Herceptin"-tx-1-"Herceptin"-noun-0]|TX|40/9|
text_000N_173087|MMI|3.63|trastuzumab|C0728747|[aapp,imft,phsu]|["TRASTUZUMAB"-tx-1-"Trastuzumab"-noun-0]|TX|27/11|
text_000N_173087|MMI|3.54|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-noun-0]|TX|64/3|
text_000N_173087|MMI|3.54|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-noun-0]|TX|64/3|
text_000N_173087|MMI|3.54|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-noun-0]|TX|64/3|
text_000N_173087|MMI|3.53|Monoclonal Antibodies|C0003250|[aapp,imft]|["Monoclonal Antibody"-tx-1-"monoclonal antibody"-noun-0]|TX|7/19|
text_000N_173087|MMI|3.53|Monoclonal Antibody [EPC]|C5203232|[phsu]|["Monoclonal Antibody"-tx-1-"monoclonal antibody"-noun-0]|TX|7/19|
text_000N_173087|MMI|3.46|Malignant neoplasm of prostate|C0376358|[neop]|["Cancer of the Prostate"-tx-1-"of the prostate cancer"-noun-0]|TX|51/2,71/3,88/15|
text_000N_173087|MMI|3.46|Prostate carcinoma|C0600139|[neop]|["Cancer of the Prostate"-tx-1-"of the prostate cancer"-noun-0]|TX|51/2,71/3,88/15|
text_000N_173087|MMI|3.42|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|Potential|C3245505|[qlco]|["Potential"-tx-1-"potential"-adj-0]|TX|54/9|
text_000N_173087|MMI|3.42|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
text_000N_173087|MMI|3.42|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|75/9|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|34/2|
text_000N_173260|MMI|5.18|Therapeutic procedure|C0087111|[topp]|["TREAT"-tx-1-"treat"-verb-0]|TX|37/5|
text_000N_173260|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|34/2|
text_000N_173260|MMI|5.18|Treating|C1522326|[ftcn]|["Treat"-tx-1-"treat"-verb-0]|TX|37/5|
text_000N_173260|MMI|5.18|Treatment intent|C1292734|[ftcn]|["treat"-tx-1-"treat"-verb-0]|TX|37/5|
text_000N_173260|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|29/4|
text_000N_173260|MMI|5.18|ferric carboxymaltose|C2001867|[orch,phsu]|["FERRIC CARBOXYMALTOSE"-tx-1-"ferric carboxymaltose"-noun-0]|TX|4/21|
text_000N_173260|MMI|3.55|Anemia|C0002871|[dsyn]|["ANEMIA"-tx-1-"anemia"-noun-0]|TX|43/6|
text_000N_173260|MMI|3.55|Anemia, CTCAE|C4554633|[fndg]|["Anemia"-tx-1-"anemia"-noun-0]|TX|43/6|
text_000N_173260|MMI|3.55|Genus Anemia|C1000483|[plnt]|["Anemia"-tx-1-"anemia"-noun-0]|TX|43/6|
text_000N_173260|MMI|3.48|Idiopathic chronic inflammatory bowel disease|C0267374|[dsyn]|["Inflammatory bowel disease"-tx-1-"inflammatory bowel disease"-noun-0]|TX|53/26|
text_000N_173260|MMI|3.48|Inflammatory Bowel Diseases|C0021390|[dsyn]|["INFLAMMATORY BOWEL DISEASE"-tx-1-"inflammatory bowel disease"-noun-0]|TX|53/26|
text_000N_173260|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|80/8|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Detected (finding)|C0442726|[fndg]|["detect"-tx-1-"detect"-verb-0]|TX|18/6|
text_000N_97283|MMI|5.18|Dosing Days to Detection|C3891454|[tmco]|["DETECT"-tx-1-"detect"-verb-0]|TX|18/6|
text_000N_97283|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97283|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97283|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97283|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_97283|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_97283|MMI|3.59|BIRC5 protein, human|C1571495|[aapp,bacs]|["survivin protein, human"-tx-1-"survivin protein human"-noun-0]|TX|25/16,63/5|
text_000N_97283|MMI|3.56|Normal Expression|C5447948|[fndg]|["Normal Expression"-tx-1-"expression normal"-noun-0]|TX|42/10,56/6|
text_000N_97283|MMI|3.42|Adult|C0001675|[aggp]|["ADULT"-tx-1-"adult"-noun-0]|TX|69/5|
text_000N_97283|MMI|3.42|Body tissue|C0040300|[tisu]|["Tissues"-tx-1-"tissues"-noun-0]|TX|75/7|
text_000N_97283|MMI|3.42|Legal Adult|C1706450|[popg]|["Adult"-tx-1-"adult"-noun-0]|TX|69/5|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Fatigue|C0015672|[sosy]|["FATIGUE"-tx-1-"fatigue"-verb-0]|TX|3/7|
text_000N_47349|MMI|5.18|Fatigue Subordinate Domain|C4050243|[inpr]|["Fatigue"-tx-1-"fatigue"-verb-0]|TX|3/7|
text_000N_47349|MMI|5.18|Fatigue, CTCAE 5.0|C4554645|[fndg]|["Fatigue"-tx-1-"fatigue"-verb-0]|TX|3/7|
text_000N_47349|MMI|5.18|Feel Fatigue|C3463815|[inpr]|["Fatigue"-tx-1-"fatigue"-verb-0]|TX|3/7|
text_000N_47349|MMI|5.18|Receive|C1514756|[qlco]|["RECEIVING"-tx-1-"receiving"-verb-0]|TX|33/9|
text_000N_47349|MMI|3.59|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|Prevalent|C5204628|[qlco]|["Prevalent"-tx-1-"prevalent"-adj-0]|TX|11/9|
text_000N_47349|MMI|3.59|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.59|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|43/9|
text_000N_47349|MMI|3.45|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|57/12|
text_000N_47349|MMI|3.45|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|57/12|
text_000N_47349|MMI|3.45|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|57/12|
text_000N_47349|MMI|3.45|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|57/12|
text_000N_47349|MMI|3.45|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|24/8|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|leuprolide acetate|C0700596|[aapp,horm,phsu]|["Leuprorelin Acetate"-tx-1-"leuprorelin acetate"-noun-0]|TX|4/19|
text_000N_47406|MMI|3.68|Antiandrogen therapy|C0279492|[topp]|["Androgen Deprivation Therapy"-tx-1-"androgen deprivation therapy"-noun-0]|TX|35/28|
text_000N_47406|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|27/4|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|94/5|
text_000N_97301|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|100/15|
text_000N_97301|MMI|3.60|Autosomal dominant inheritance|C0443147|[genf]|["Autosomal dominant form"-tx-1-"autosomal dominant form"-noun-0]|TX|3/18,35/4|
text_000N_97301|MMI|3.59|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|77/9|
text_000N_97301|MMI|3.59|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|77/9|
text_000N_97301|MMI|3.57|collagen|C0009325|[aapp,phsu]|["Collagen"-tx-1-"collagen"-noun-0]|TX|116/8|
text_000N_97301|MMI|3.57|production|C0033268|[ocac]|["Production"-tx-1-"production"-noun-0]|TX|125/10|
text_000N_97301|MMI|3.55|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|67/6|
text_000N_97301|MMI|3.55|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|67/6|
text_000N_97301|MMI|3.44|Osteogenesis Imperfecta|C0029434|[dsyn]|["OSTEOGENESIS IMPERFECTA"-tx-1-"Osteogenesis imperfecta"-noun-0]|TX|43/23|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|IL2RA protein, human|C1700887|[aapp,rcpt]|["CD25"-tx-1-"CD25"-noun-0]|TX|16/4|
text_000N_97316|MMI|5.18|Regulatory T-Lymphocytes|C0039198|[cell]|["T-Cells, Regulatory"-tx-1-"regulatory T cells"-noun-0]|TX|24/18|
text_000N_97316|MMI|3.68|CD4 Expressing Cell Count|C3541261|[lbpr]|["CD4"-tx-1-"CD4"-noun-0]|TX|10/3|
text_000N_97316|MMI|3.68|T-Cell Surface Glycoprotein CD4, human|C4048280|[aapp,bacs]|["CD4"-tx-1-"CD4"-noun-0]|TX|10/3|
text_000N_97316|MMI|3.55|Oxygen supplies regulator|C4281746|[medd]|["Regulator"-tx-1-"regulator"-noun-0]|TX|54/9|
text_000N_97316|MMI|3.55|Regulator|C1704735|[cnce]|["Regulator"-tx-1-"regulator"-noun-0]|TX|54/9|
text_000N_97316|MMI|3.55|Regulators (device)|C0182953|[mnob]|["Regulator"-tx-1-"regulator"-noun-0]|TX|54/9|
text_000N_97316|MMI|3.44|Immune response|C0020964|[ortf]|["Immune Response"-tx-1-"immune response"-noun-0]|TX|71/15|
text_000N_97316|MMI|3.42|BRAF Gene Rearrangement|C4727483|[comd]|["Positive"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|Positive|C1446409|[fndg]|["Positive"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|Positive Charge|C2825490|[qlco]|["Positive"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|Positive Finding|C1514241|[fndg]|["POSITIVE"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|Positive Lymph Node|C0746319|[fndg]|["Positive"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|Positive Number|C3812269|[qnco]|["Positive"-tx-1-"positive"-adj-0]|TX|45/8|
text_000N_97316|MMI|3.42|percent positive cells|C0439178|[qnco]|["% Positive"-tx-1-"positive"-adj-0]|TX|45/8|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosomes"-tx-1-"nucleosomes"-noun-0]|TX|4/11|
text_000N_43235|MMI|3.68|Replication Origin|C0242961|[nusq]|["DNA Replication Origins"-tx-1-"DNA replication origins"-noun-0]|TX|30/23|
text_000N_43235|MMI|3.53|Gene Physical Location|C1517493|[spco]|["position"-tx-1-"positioned"-verb-0]|TX|16/10|
text_000N_43235|MMI|3.53|Position of phenotypic abnormality|C4019252|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|16/10|
text_000N_43235|MMI|3.53|Positioning Attribute|C0733755|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|16/10|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|IVIG Given for Kawasaki Disease|C5238760|[fndg]|["IVIG"-tx-1-"IVIG"-noun-0]|TX|4/4|
text_000N_40941|MMI|5.18|immunoglobulins, intravenous|C0085297|[aapp,imft,phsu]|["IVIG"-tx-1-"IVIG"-noun-0]|TX|4/4|
text_000N_40941|MMI|3.64|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|24/15|
text_000N_40941|MMI|3.64|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|24/15|
text_000N_40941|MMI|3.62|Alzheimer's disease treatment|C1979617|[topp]|["Alzheimer's disease treatment"-tx-1-"treatment Alzheimer's disease"-noun-0]|TX|48/9,61/19|
text_000N_40941|MMI|3.57|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|14/6|
text_000N_40941|MMI|3.57|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|14/6|
text_000N_40941|MMI|3.43|Preposition For|C0521125|[qlco]|["For"-tx-1-"for"-prep-0]|TX|40/3|
text_000N_40941|MMI|3.43|WWOX wt Allele|C4321252|[gngm]|["FOR"-tx-1-"for"-prep-0]|TX|40/3|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|lubeluzole|C0385965|[orch,phsu]|["LUBELUZOLE"-tx-1-"Lubeluzole"-noun-0]|TX|7/10|
text_000N_97331|MMI|3.59|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischemic stroke"-noun-0]|TX|43/15|
text_000N_97331|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|21/4,40/2|
text_000N_97331|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_97331|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.64|Bladder Cancer Pathway|C2984270|[cnce]|["Bladder cancer"-tx-1-"bladder cancer"-noun-0]|TX|52/14|
text_000N_47392|MMI|3.64|Bladder Neoplasm|C0005695|[neop]|["Bladder cancer"-tx-1-"bladder cancer"-noun-0]|TX|52/14|
text_000N_47392|MMI|3.64|Carcinoma of bladder|C0699885|[neop]|["Bladder Cancer"-tx-1-"bladder cancer"-noun-0]|TX|52/14|
text_000N_47392|MMI|3.64|Childhood Bladder Carcinoma|C3899675|[neop]|["Bladder Cancer"-tx-1-"bladder cancer"-noun-0]|TX|52/14|
text_000N_47392|MMI|3.64|Malignant neoplasm of urinary bladder|C0005684|[neop]|["BLADDER CANCER"-tx-1-"bladder cancer"-noun-0]|TX|52/14|
text_000N_47392|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|43/4|
text_000N_47392|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.50|Bacillus Calmette-Guerin|C0085957|[bact]|["Bacillus Calmette Guerin"-tx-1-"Bacillus Calmette Guerin"-noun-0]|TX|18/24|
<<<<< MMI
>>>>> MMI
text_000N_97347|AA|TAM|transcription-associated mutagenesis|1|3|5|36|41:3
text_000N_97347|MMI|3.63|Mutagenesis Procedure|C3146302|[lbpr]|["Mutagenesis"-tx-1-"mutagenesis"-noun-0]|TX|28/11|
text_000N_97347|MMI|3.63|Mutagenesis Process|C0079866|[moft]|["Mutagenesis"-tx-1-"mutagenesis"-noun-0]|TX|28/11|
text_000N_97347|MMI|3.61|Gene Expression|C0017262|[genf]|["Gene Expression"-tx-1-"gene expression"-noun-0]|TX|57/15|
text_000N_97347|MMI|3.61|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"gene expression"-noun-0]|TX|57/15|
text_000N_97347|MMI|3.56|Levels (qualifier value)|C0441889|[qlco]|["Levels"-tx-1-"levels"-noun-0]|TX|73/6|
text_000N_97347|MMI|3.56|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|46/7|
text_000N_97347|MMI|3.56|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|46/7|
text_000N_97347|MMI|3.48|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-adj-0]|TX|17/10|
text_000N_97347|MMI|3.48|Data Transcription|C4554264|[acty]|["transcription"-tx-1-"transcription"-noun-0]|TX|3/13|
text_000N_97347|MMI|3.48|Transcription, Genetic|C0040649|[genf]|["Transcription"-tx-1-"transcription"-noun-0]|TX|3/13|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|Hypofractionated radiation therapy|C1831786|[topp]|["Hypofractionated Radiotherapy"-tx-1-"hypofractionated radiotherapy"-noun-0]|TX|5/29|
text_000N_97362|MMI|3.57|Benefit|C0814225|[qnco]|["Benefit"-tx-1-"benefit"-noun-0]|TX|46/7|
text_000N_97362|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|42/3|
text_000N_97362|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|42/3|
text_000N_97362|MMI|3.44|Dipinacoline glutamate|C0058409|[aapp]|["DiPG"-tx-1-"DIPG"-noun-0]|TX|58/4|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|16/5|
text_000N_43303|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|16/5|
text_000N_43303|MMI|5.18|Trichomegaly|C0854699|[fndg]|["TRICHOMEGALY"-tx-1-"trichomegaly"-noun-0]|TX|22/12|
text_000N_43303|MMI|5.18|panitumumab|C0879427|[aapp,imft,phsu]|["PANITUMUMAB"-tx-1-"Panitumumab"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|3.59|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_47274|MMI|3.59|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_47274|MMI|3.59|WDHD1 gene|C1427963|[gngm]|["CTF4"-tx-1-"CTF4"-noun-0]|TX|26/4|
text_000N_47274|MMI|3.56|CHTF18 gene|C1425513|[gngm]|["CTF18"-tx-1-"CTF18"-noun-0]|TX|35/5|
text_000N_47274|MMI|3.50|sister chromatid cohesion|C1155633|[celf]|["sister chromatid cohesion"-tx-1-"sister chromatid cohesion"-noun-0]|TX|48/25|
<<<<< MMI
>>>>> MMI
text_000N_47420|AA|AB|Ameloblastoma|1|2|1|13|18:2
text_000N_47420|MMI|5.18|Ameloblastoma|C0002448|[neop]|["AMELOBLASTOMA"-tx-1-"Ameloblastoma"-noun-0]|TX|3/13|
text_000N_47420|MMI|3.75|Benign Neoplasm|C0086692|[neop]|["Tumour, benign"-tx-1-"benign tumor"-noun-0]|TX|31/12|
text_000N_47420|MMI|3.57|Brain|C0006104|[bpoc]|["BRAIN"-tx-1-"brain"-noun-0]|TX|61/5|
text_000N_47420|MMI|3.57|Head>Brain|C4266577|[bpoc]|["Brain"-tx-1-"brain"-noun-0]|TX|61/5|
text_000N_47420|MMI|3.54|Occur (action)|C1709305|[acty]|["Occur"-tx-1-"occurring"-verb-0]|TX|44/9|
text_000N_47420|MMI|3.54|Occurrence Indicator|C4284875|[ftcn]|["OCCUR"-tx-1-"occurring"-verb-0]|TX|44/9|
text_000N_47420|MMI|3.48|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|24/6|
text_000N_47420|MMI|3.48|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|24/6|
text_000N_47420|MMI|3.48|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|24/6|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Contain (action)|C2700400|[acty]|["Contain"-tx-1-"contain"-verb-0]|TX|17/7|
text_000N_47320|MMI|5.18|Containing (qualifier)|C0332256|[ftcn]|["contain"-tx-1-"contain"-verb-0]|TX|17/7|
text_000N_47320|MMI|5.18|CpG Islands|C0282523|[bacs,nnon]|["CpG Islands"-tx-1-"CpG islands"-noun-0]|TX|25/11|
text_000N_47320|MMI|5.18|Genome, Plant|C0242965|[gngm]|["Plant Genomes"-tx-1-"plant genomes"-noun-0]|TX|3/13|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|JNK Pathway|C1621396|[moft]|["JNK Pathway"-tx-1-"JNK pathway"-noun-0]|TX|7/11|
text_000N_47435|MMI|3.64|Liver Regeneration|C0023907|[ortf]|["Liver Regeneration"-tx-1-"liver regeneration"-noun-0]|TX|36/18|
text_000N_47435|MMI|3.64|Liver regeneration disorder|C1318485|[dsyn]|["Liver regeneration"-tx-1-"liver regeneration"-noun-0]|TX|36/18|
text_000N_47435|MMI|3.57|Activation action|C1879547|[acty]|["ACTIVATED"-tx-1-"activated"-verb-0]|TX|19/9|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|7.06|Duplication (finding)|C0332597|[fndg]|["duplications"-tx-1-"duplications"-noun-0]|TX|[17/12],[62/12]|
text_000N_47450|MMI|5.18|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|78/5|
text_000N_47450|MMI|5.18|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|78/5|
text_000N_47450|MMI|5.18|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|78/5|
text_000N_47450|MMI|5.18|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|78/5|
text_000N_47450|MMI|5.18|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|78/5|
text_000N_47450|MMI|3.63|Entire|C0439751|[qnco]|["Whole"-tx-1-"whole"-noun-0]|TX|4/5|
text_000N_47450|MMI|3.63|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|10/6|
text_000N_47450|MMI|3.63|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|10/6|
text_000N_47450|MMI|3.49|Divergence|C0443204|[spco]|["Divergence"-tx-1-"divergent"-adj-0]|TX|35/9|
text_000N_47450|MMI|3.43|Intellectual scale|C0349674|[inpr]|["Scale"-tx-1-"scale"-adj-0]|TX|56/5|
text_000N_47450|MMI|3.43|More|C0205172|[qnco]|["More"-tx-1-"more"-adv-0]|TX|30/4|
text_000N_47450|MMI|3.43|SCALE:*|C5444316|[fndg]|["SCALE:*"-tx-1-"scale"-adj-0]|TX|56/5|
text_000N_47450|MMI|3.43|Scaling|C1947916|[acty]|["Scale"-tx-1-"scale"-adj-0]|TX|56/5|
text_000N_47450|MMI|3.43|Small|C0700321|[qnco]|["SMALL"-tx-1-"small"-adj-0]|TX|50/5|
text_000N_47450|MMI|3.43|Weight measurement scales|C0175659|[medd]|["Scale"-tx-1-"scale"-adj-0]|TX|56/5|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Body Site Modifier - Lower|C1548802|[blor]|["Lower"-tx-1-"lowers"-verb-0]|TX|36/6|
text_000N_43358|MMI|5.18|Cholesterol level test result|C0428466|[lbtr]|["cholesterol levels"-tx-1-"cholesterol levels"-noun-0]|TX|43/18|
text_000N_43358|MMI|5.18|Cholesterol measurement test|C0201950|[lbpr]|["cholesterol levels"-tx-1-"cholesterol levels"-noun-0]|TX|43/18|
text_000N_43358|MMI|5.18|Evidence|C3887511|[idcn]|["Evidence"-tx-1-"evidence"-verb-0]|TX|9/8|
text_000N_43358|MMI|5.18|Lower (action)|C2003888|[acty]|["Lower"-tx-1-"lowers"-verb-0]|TX|36/6|
text_000N_43358|MMI|5.18|Lower - spatial qualifier|C0441994|[spco]|["lowers"-tx-1-"lowers"-verb-0]|TX|36/6|
text_000N_43358|MMI|5.18|tomato juice|C0452460|[food]|["TOMATO JUICE"-tx-1-"tomato juice"-noun-0]|TX|23/12|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|3.54|Work|C0043227|[ocac]|["Work"-tx-1-"work"-noun-0]|TX|26/4|
text_000N_43386|MMI|3.43|Oncotype DX Breast Cancer Assay|C1709318|[lbpr]|["Oncotype DX"-tx-1-"Oncotype DX"-noun-0]|TX|9/11|
text_000N_43386|MMI|3.43|Paraffin Embedded Tissue|C1519524|[tisu]|["Paraffin Embedded Tissue"-tx-1-"paraffin embedded tissues"-noun-0]|TX|36/25|
text_000N_43386|MMI|3.42|Blood Products Laboratory Testing|C3831328|[lbpr]|["Test"-tx-1-"test"-noun-0]|TX|21/4|
text_000N_43386|MMI|3.42|Laboratory Procedures|C0022885|[lbpr]|["Test"-tx-1-"test"-noun-0]|TX|21/4|
text_000N_43386|MMI|3.42|Test - temporal region|C4318744|[blor]|["Test"-tx-1-"test"-noun-0]|TX|21/4|
text_000N_43386|MMI|3.42|Test Result|C0456984|[lbtr]|["Test"-tx-1-"test"-noun-0]|TX|21/4|
text_000N_43386|MMI|3.42|Testing|C0039593|[ftcn]|["Test"-tx-1-"test"-noun-0]|TX|21/4|
text_000N_43386|MMI|3.42|Tests (qualifier value)|C0392366|[inpr]|["test"-tx-1-"test"-noun-0]|TX|21/4|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|postmenopausal syndrome|C0747771|[dsyn]|["postmenopausal symptoms"-tx-1-"postmenopausal symptoms"-noun-0]|TX|71/23|
text_000N_47363|MMI|3.56|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|14/15|
text_000N_47363|MMI|3.56|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|14/15|
text_000N_47363|MMI|3.44|evening primrose oil|C0700602|[orch,phsu]|["EVENING PRIMROSE OIL"-tx-1-"evening primrose oil"-noun-0]|TX|47/20|
text_000N_47363|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_47363|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_47363|MMI|3.42|Effect|C1280500|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|37/6|
text_000N_47363|MMI|3.42|Effect, Appearance|C2348382|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|37/6|
text_000N_47363|MMI|3.42|Outcome of Therapy|C1518681|[fndg]|["effect"-tx-1-"effect"-noun-0]|TX|37/6|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|PLN gene|C1418650|[gngm]|["PHOSPHOLAMBAN"-tx-1-"phospholamban"-noun-0]|TX|3/13|
text_000N_47334|MMI|5.18|phospholamban|C0070876|[aapp,enzy]|["phospholamban"-tx-1-"phospholamban"-noun-0]|TX|3/13|
text_000N_47334|MMI|3.68|Cyclic AMP-Dependent Protein Kinases|C0010531|[aapp,enzy]|["Protein Kinase A"-tx-1-"Protein kinase A"-noun-0]|TX|35/16|
text_000N_47334|MMI|3.68|Protein Kinase A, human|C5441746|[aapp,enzy]|["Protein Kinase A"-tx-1-"Protein kinase A"-noun-0]|TX|35/16|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Occur (action)|C1709305|[acty]|["Occur"-tx-1-"occur"-verb-0]|TX|14/5|
text_000N_43331|MMI|5.18|Occurrence Indicator|C4284875|[ftcn]|["OCCUR"-tx-1-"occur"-verb-0]|TX|14/5|
text_000N_43331|MMI|5.18|RNA Splicing|C0035687|[genf]|["Splicing"-tx-1-"splicing"-noun-0]|TX|5/8|
text_000N_43331|MMI|5.18|nuclear mRNA cis splicing, via spliceosome|C2610186|[genf]|["splicing"-tx-1-"splicing"-noun-0]|TX|5/8|
text_000N_43331|MMI|3.68|AQP1 gene|C1412491|[gngm]|["CO"-tx-1-"co"-adv-0]|TX|20/2|
text_000N_43331|MMI|3.68|AQP1 wt Allele|C5551158|[gngm]|["CO"-tx-1-"co"-adv-0]|TX|20/2|
text_000N_43331|MMI|3.68|Colombia|C3245499|[geoa]|["CO"-tx-1-"co"-adv-0]|TX|20/2|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Athletes|C0238703|[prog]|["Athletes"-tx-1-"athletes"-noun-0]|TX|56/8|
text_000N_40839|MMI|5.18|Athletes <Butterfly>|C3714533|[euka]|["Athletes"-tx-1-"athletes"-noun-0]|TX|56/8|
text_000N_40839|MMI|5.18|Long QT Syndrome|C0023976|[dsyn]|["Long Q-T syndrome"-tx-1-"long QT syndrome"-noun-0]|TX|3/16|
text_000N_40839|MMI|5.18|Prolonged QT interval|C0151878|[fndg]|["Long QT syndrome"-tx-1-"long QT syndrome"-noun-0]|TX|3/16|
text_000N_40839|MMI|3.55|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|22/5|
text_000N_40839|MMI|3.55|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|22/5|
text_000N_40839|MMI|3.48|Family history of sudden cardiac death (situation)|C2825161|[fndg]|["Sudden cardiac death"-tx-1-"sudden cardiac death"-noun-0]|TX|32/20|
text_000N_40839|MMI|3.48|Sudden Cardiac Death|C0085298|[patf]|["SUDDEN CARDIAC DEATH"-tx-1-"sudden cardiac death"-noun-0]|TX|32/20|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|105/3|
text_000N_40886|MMI|3.68|Ligands|C0023688|[chem]|["Ligands"-tx-1-"ligands"-noun-0]|TX|4/7|
text_000N_40886|MMI|3.68|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|27/4|
text_000N_40886|MMI|3.68|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|27/4|
text_000N_40886|MMI|3.64|Drug Development|C0872152|[bmod]|["Pharmaceutical Development"-tx-1-"pharmaceutical development"-noun-0]|TX|44/26|
text_000N_40886|MMI|3.57|Target|C1521840|[ftcn]|["Target"-tx-1-"targets"-verb-0]|TX|32/7|
text_000N_40886|MMI|3.57|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"targets"-verb-0]|TX|32/7|
text_000N_40886|MMI|3.55|Induce (action)|C0205263|[ftcn]|["Induction"-tx-1-"induction"-noun-0]|TX|84/9|
text_000N_40886|MMI|3.55|Induction Clinical Trial Setting|C4722132|[hcro,mnob]|["INDUCTION"-tx-1-"induction"-noun-0]|TX|84/9|
text_000N_40886|MMI|3.55|Induction Therapy|C5202807|[topp]|["Induction"-tx-1-"induction"-noun-0]|TX|84/9|
text_000N_40886|MMI|3.55|Induction procedure|C0857127|[topp]|["induction"-tx-1-"induction"-noun-0]|TX|84/9|
text_000N_40886|MMI|3.50|AHR protein, human|C1312385|[aapp,rcpt]|["AHR"-tx-1-"AhR"-noun-0]|TX|0/3|
text_000N_40886|MMI|3.50|Attractive|C2346874|[qlco]|["Attractive"-tx-1-"attractive"-adj-0]|TX|16/10|
text_000N_40886|MMI|3.50|How Often Felt Attractive|C4553644|[inpr]|["Attractive"-tx-1-"attractive"-adj-0]|TX|16/10|
text_000N_40886|MMI|3.45|Due to|C0678226|[ftcn]|["Due To"-tx-1-"due to"-prep-0]|TX|71/6|
text_000N_40886|MMI|3.43|CYP1A1 gene|C0919425|[gngm]|["CYP1A1"-tx-1-"Cyp1a1"-noun-0]|TX|97/6|
text_000N_40886|MMI|3.43|Cytochrome P-450 CYP1A1|C0059735|[aapp,enzy]|["CYP1A1"-tx-1-"Cyp1a1"-noun-0]|TX|97/6|
<<<<< MMI
>>>>> MMI
text_000N_40913|AA|RAPT|Risk Assessment and Prediction Tool|1|4|9|35|98:4
text_000N_40913|MMI|7.54|Prediction|C0681842|[idcn]|["Predicted"-tx-1-"predicted"-verb-0,"Prediction"-tx-1-"Prediction"-noun-0]|TX|41/9;81/10|
text_000N_40913|MMI|5.18|Body Fluid Discharge|C0012621|[bdsu]|["Discharge"-tx-1-"discharge"-verb-0]|TX|4/9|
text_000N_40913|MMI|5.18|Clinical Status Ordinal Scale Outcome 1|C5401119|[fndg]|["Discharge"-tx-1-"discharge"-verb-0]|TX|4/9|
text_000N_40913|MMI|5.18|Discharge, body substance|C2926602|[sosy]|["Discharge"-tx-1-"discharge"-verb-0]|TX|4/9|
text_000N_40913|MMI|5.18|Patient Discharge|C0030685|[hlca]|["Discharge"-tx-1-"discharge"-verb-0]|TX|4/9|
text_000N_40913|MMI|5.18|Percent of Predicted Value|C1882327|[qnco]|["%{Predicted}"-tx-1-"predicted"-verb-0]|TX|41/9|
text_000N_40913|MMI|5.18|Use of|C1524063|[ftcn]|["Using"-tx-1-"using"-verb-0]|TX|51/5|
text_000N_40913|MMI|3.98|Destination|C0079220|[spco]|["Destination"-tx-1-"destinations"-noun-0]|TX|14/12|
text_000N_40913|MMI|3.98|Target|C1521840|[ftcn]|["Destination"-tx-1-"destinations"-noun-0]|TX|14/12|
text_000N_40913|MMI|3.63|CDISC SDTM Risk Assessment Terminology|C3539808|[inpr]|["Risk Assessment"-tx-1-"Risk Assessment"-noun-0]|TX|61/15|
text_000N_40913|MMI|3.63|Health Risk Assessment|C0679809|[hlca]|["Risk Assessment"-tx-1-"Risk Assessment"-noun-0]|TX|61/15|
text_000N_40913|MMI|3.63|Risk Assessment|C0086930|[hlca]|["Risk Assessment"-tx-1-"Risk Assessment"-noun-0]|TX|61/15|
text_000N_40913|MMI|3.60|Scientific Equipment|C2827396|[mnob]|["Tool"-tx-1-"Tool"-noun-0]|TX|92/4|
text_000N_40913|MMI|3.60|Tool, device (physical object)|C0336791|[mnob]|["Tool"-tx-1-"Tool"-noun-0]|TX|92/4|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.56|Component (part)|C1705248|[cnce]|["Component"-tx-1-"component"-noun-0]|TX|10/9|
text_000N_40999|MMI|3.56|Component object|C0449432|[mnob]|["Component"-tx-1-"component"-noun-0]|TX|10/9|
text_000N_40999|MMI|3.56|Drug Product Component|C5552856|[phsu]|["Component"-tx-1-"component"-noun-0]|TX|10/9|
text_000N_40999|MMI|3.43|replisome|C1325592|[celc]|["replisome"-tx-1-"replisome"-noun-0]|TX|27/9|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|% release (qualifier value)|C0439180|[qnco]|["% release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Ability|C0085732|[orga]|["Able"-tx-1-"able"-adj-0]|TX|27/4|
text_000N_173104|MMI|5.18|Able (finding)|C1299581|[fndg]|["Able"-tx-1-"able"-adj-0]|TX|27/4|
text_000N_173104|MMI|5.18|Discharge (release)|C0680255|[hlca]|["release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Extracellular Vesicles|C3894683|[celc]|["Extracellular Vesicles"-tx-1-"extracellular vesicles"-noun-0]|TX|43/22|
text_000N_173104|MMI|5.18|Gram Positive Bacteria Measurement|C4722271|[lbpr]|["Gram Positive Bacteria"-tx-1-"Gram positive bacteria"-noun-0]|TX|4/22|
text_000N_173104|MMI|5.18|Gram-Positive Bacteria|C0018154|[bact]|["Gram positive bacteria"-tx-1-"Gram positive bacteria"-noun-0]|TX|4/22|
text_000N_173104|MMI|5.18|Patient Discharge|C0030685|[hlca]|["Release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Release (procedure)|C1963578|[topp]|["Release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Release - action (qualifier value)|C1283071|[ftcn]|["Release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Release Determination|C4521542|[resa]|["Release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|Released (action)|C0391871|[ftcn]|["Release"-tx-1-"release"-verb-0]|TX|35/7|
text_000N_173104|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|32/2|
text_000N_173104|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|32/2|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|3.63|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|26/8|
text_000N_173136|MMI|3.48|Interferons|C0021747|[aapp,imft]|["Interferons"-tx-1-"interferons"-noun-0]|TX|4/11|
text_000N_173136|MMI|3.48|Recombinant Interferon|C1522537|[aapp,imft,phsu]|["Interferons"-tx-1-"interferons"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Cell secretion|C1327616|[celf]|["Secreted"-tx-1-"secreted"-verb-0]|TX|23/8|
text_000N_173151|MMI|5.18|Secreted|C4554416|[lbtr]|["Secreted"-tx-1-"secreted"-verb-0]|TX|23/8|
text_000N_173151|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Fetal Hemoglobin|C0015936|[aapp,bacs]|["Foetal haemoglobin"-tx-1-"fetal hemoglobin"-noun-0]|TX|39/16|
text_000N_173167|MMI|5.18|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-verb-0]|TX|20/7|
text_000N_173167|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|28/2|
text_000N_173167|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|28/2|
text_000N_173167|MMI|4.12|Adult|C0001675|[aggp]|["Human, Adult"-tx-1-"adult humans"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|DNA Breaks, Double-Stranded|C1511667|[comd]|["DNA double strand Breaks"-tx-1-"DNA double-strand breaks"-noun-0]|TX|3/24|
text_000N_173230|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|28/4|
text_000N_173230|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|28/4|
text_000N_173230|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|42/4|
text_000N_173230|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|42/4|
text_000N_173230|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|42/4|
text_000N_173230|MMI|3.43|Carcinogenesis|C0596263|[neop]|["Carcinogenesis"-tx-1-"carcinogenesis"-noun-0]|TX|50/14|
text_000N_173230|MMI|3.39|Etiology|C1314792|[ftcn]|["Causality"-tx-1-"causal"-adj-0]|TX|35/6|
text_000N_173230|MMI|3.39|Etiology aspects|C0015127|[ftcn]|["causality"-tx-1-"causal"-adj-0]|TX|35/6|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|5.18|Etiology|C1314792|[ftcn]|["Causes"-tx-1-"causes"-verb-0]|TX|21/6|
text_000N_97378|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["causes"-tx-1-"causes"-verb-0]|TX|21/6|
text_000N_97378|MMI|5.18|Respiratory Tract Infections|C0035243|[dsyn]|["RESPIRATORY INFECTION"-tx-1-"respiratory infection"-noun-0]|TX|30/21|
text_000N_97378|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"causes"-verb-0]|TX|21/6|
text_000N_97378|MMI|5.18|Yersinia pestis|C0043408|[bact]|["YERSINIA PESTIS"-tx-1-"Yersinia pestis"-noun-0]|TX|5/15|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Sumoylation|C1157990|[moft]|["Sumoylation"-tx-1-"sumoylation"-noun-0]|TX|3/11|
text_000N_40972|MMI|3.59|Myogenesis|C0596997|[celf]|["Myogenesis"-tx-1-"myogenesis"-noun-0]|TX|29/10|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Pseudogenes|C0033799|[gngm]|["Pseudogenes"-tx-1-"pseudogenes"-noun-0]|TX|4/11|
text_000N_173120|MMI|3.61|Protein Family|C1335532|[aapp,bacs]|["Protein Family"-tx-1-"protein families"-noun-0]|TX|43/16|
text_000N_173120|MMI|3.56|Do Housework Question|C4282144|[inpr]|["Housekeeping"-tx-1-"housekeeping"-noun-0]|TX|30/12|
text_000N_173120|MMI|3.56|Enrich (product)|C0359583|[food]|["enriched"-tx-1-"enriched"-verb-0]|TX|16/8|
text_000N_173120|MMI|3.56|Housekeeping|C0020053|[ocac]|["Housekeeping"-tx-1-"housekeeping"-noun-0]|TX|30/12|
<<<<< MMI
>>>>> MMI
text_000N_47289|AA|G6PD|Glucose-6-phosphate dehydrogenase|1|4|7|33|39:4
text_000N_47289|MMI|5.18|Deficiency of glucose-6-phosphate dehydrogenase|C2939465|[dsyn]|["Glucose-6-Phosphate Dehydrogenase Deficiency"-tx-1-"Glucose-6-phosphate dehydrogenase deficiency"-noun-0]|TX|4/33,45/10|
text_000N_47289|MMI|5.18|X-linked inheritance|C0241764|[genf]|["X-Linked Inheritance"-tx-1-"X-linked inheritance"-noun-0]|TX|59/20|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Istiratumab|C5139900|[aapp,imft,phsu]|["ISTIRATUMAB"-tx-1-"istiratumab"-noun-0]|TX|3/11|
text_000N_43275|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_43275|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_43275|MMI|3.48|Malignant neoplasm of pancreas|C0346647|[neop]|["Pancreatic Cancer"-tx-1-"pancreatic cancer"-noun-0]|TX|29/17|
text_000N_43275|MMI|3.48|Pancreatic Cancer Pathway|C2984259|[ftcn]|["Pancreatic cancer"-tx-1-"pancreatic cancer"-noun-0]|TX|29/17|
text_000N_43275|MMI|3.48|Pancreatic carcinoma|C0235974|[neop]|["PANCREATIC CANCER"-tx-1-"pancreatic cancer"-noun-0]|TX|29/17|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|3.58|Facultative anaerobic bacteria|C1532741|[bact]|["Facultative anaerobic bacteria"-tx-1-"bacteria facultative anaerobes"-noun-0]|TX|4/8,38/21|
text_000N_173183|MMI|3.44|Clostridium|C0009054|[bact]|["Genus Clostridium"-tx-1-"genus Clostridium"-noun-0]|TX|20/17|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|sonidegib|C3886731|[orch,phsu]|["SONIDEGIB"-tx-1-"sonidegib"-noun-0]|TX|3/9|
text_000N_173199|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_173199|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_173199|MMI|3.50|Basal Cell Carcinoma Pathway|C2984322|[ftcn]|["Basal cell carcinoma"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
text_000N_173199|MMI|3.50|Basal cell carcinoma|C0007117|[neop]|["BASAL CELL CARCINOMA"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
text_000N_173199|MMI|3.50|Experimental Organism Basal Cell Carcinoma|C3811653|[neop]|["Basal Cell Carcinoma"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
text_000N_173199|MMI|3.50|NCI CTEP SDC Basal Cell Carcinoma Sub-Category Terminology|C3540686|[inpr]|["Basal Cell Carcinoma"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
text_000N_173199|MMI|3.50|Skin Basal Cell Carcinoma|C4721806|[neop]|["BASAL CELL CARCINOMA"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
text_000N_173199|MMI|3.50|Tissue Type Code - Basal cell carcinoma|C1547219|[inpr]|["Basal cell carcinoma"-tx-1-"basal cell carcinoma"-noun-0]|TX|27/20|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Paroxetine measurement|C1266689|[lbpr]|["Paroxetine"-tx-1-"paroxetine"-noun-0]|TX|3/10|
text_000N_47304|MMI|5.18|paroxetine|C0070122|[orch,phsu]|["PAROXETINE"-tx-1-"paroxetine"-noun-0]|TX|3/10|
text_000N_47304|MMI|3.57|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|14/9,28/9|
text_000N_47304|MMI|3.47|Premenstrual Dysphoric Disorder|C0520676|[mobd]|["Premenstrual Dysphoric Disorder"-tx-1-"premenstrual dysphoric disorder"-noun-0]|TX|41/31|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|SAFE-Biopharma Standard|C4684764|[inpr]|["SAFE"-tx-1-"safe"-adj-0]|TX|6/4|
text_000N_47377|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|11/2|
text_000N_47377|MMI|5.18|Take|C1515187|[hlca]|["Take"-tx-1-"take"-verb-0]|TX|14/4|
text_000N_47377|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|11/2|
text_000N_47377|MMI|3.59|isotretinoin|C0022265|[orch,phsu]|["ISOTRETINOIN"-tx-1-"isotretinoin"-noun-0]|TX|19/12|
text_000N_47377|MMI|3.45|Patient currently pregnant|C0549206|[fndg]|["Pregnancy"-tx-1-"pregnancy"-noun-0]|TX|39/9|
text_000N_47377|MMI|3.45|Pregnancy|C0032961|[orgf]|["PREGNANCY"-tx-1-"pregnancy"-noun-0]|TX|39/9|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.59|Calcium Channel|C0006685|[aapp,bacs]|["Calcium Channel"-tx-1-"calcium channel"-noun-0]|TX|38/15|
text_000N_173291|MMI|3.55|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|21/4|
text_000N_173291|MMI|3.55|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|21/4|
text_000N_173291|MMI|3.55|S-Adenosylmethionine Measurement|C5400560|[lbpr]|["SAMe"-tx-1-"same"-adj-0]|TX|33/4|
text_000N_173291|MMI|3.55|Same|C0445247|[qlco]|["SAME"-tx-1-"same"-adj-0]|TX|33/4|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Typical Antipsychotic|C2917392|[phsu]|["Typical Antipsychotic"-tx-1-"typical antipsychotic"-adj-0]|TX|18/21|
text_000N_173245|MMI|5.18|pimavanserin|C1722267|[orch,phsu]|["PIMAVANSERIN"-tx-1-"pimavanserin"-noun-0]|TX|3/12|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|5.18|DNA-Binding Protein SATB1|C2699550|[aapp,rcpt]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_97394|MMI|5.18|SATB1 gene|C1419822|[gngm]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_97394|MMI|3.98|Gene Physical Location|C1517493|[spco]|["position"-tx-1-"positioned"-verb-0]|TX|9/10|
text_000N_97394|MMI|3.98|Position of phenotypic abnormality|C4019252|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|9/10|
text_000N_97394|MMI|3.98|Positioning Attribute|C0733755|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|9/10|
text_000N_97394|MMI|3.65|AT Rich Sequence|C0004130|[bacs,nnon]|["Sequences, AT Rich"-tx-1-"AT-rich sequences"-noun-0]|TX|29/17|
text_000N_97394|MMI|3.56|Close|C3810854|[fndg]|["Close"-tx-1-"close"-adj-0]|TX|20/5|
text_000N_97394|MMI|3.56|Closed|C0587267|[ftcn]|["Close"-tx-1-"close"-adj-0]|TX|20/5|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|6.92|Amblyomma americanum|C0323498|[euka]|["Amblyomma americanum"-tx-1-"Amblyomma americanum"-noun-0,"Lone Star tick"-tx-1-"Lone Star Tick"-noun-0]|TX|31/20;16/14|
text_000N_173214|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|57/5|
text_000N_173214|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|57/5|
text_000N_173214|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|74/2|
text_000N_173214|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|74/2|
text_000N_173214|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|106/3|
text_000N_173214|MMI|5.18|victim|C0680681|[popg]|["victim"-tx-1-"victim"-noun-0]|TX|67/6|
text_000N_173214|MMI|3.57|Allergic|C0700624|[ftcn]|["Allergic"-tx-1-"allergic"-adj-0]|TX|84/8|
text_000N_173214|MMI|3.54|Bite (event)|C4721998|[evnt]|["Bite"-tx-1-"bite"-noun-0]|TX|2/4|
text_000N_173214|MMI|3.54|Bite brandname of antibiotic|C5401490|[antb]|["Bite"-tx-1-"bite"-noun-0]|TX|2/4|
text_000N_173214|MMI|3.54|Dental Occlusion|C0011382|[ortf]|["Bite"-tx-1-"bite"-noun-0]|TX|2/4|
text_000N_173214|MMI|3.54|bite injury|C0005658|[inpo]|["Bite"-tx-1-"bite"-noun-0]|TX|2/4|
text_000N_173214|MMI|3.48|Red Meat|C0452848|[food]|["Red Meat"-tx-1-"red meat"-noun-0]|TX|96/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|7.17|Therapeutic procedure|C0087111|[topp]|["Therapeutic"-tx-1-"therapeutic"-noun-0,"Treatment"-tx-1-"treatment"-noun-0]|TX|4/11;96/9|
text_000N_47349|MMI|5.18|Following|C0332282|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|86/9|
text_000N_47349|MMI|5.18|Status post|C0231290|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|86/9|
text_000N_47349|MMI|3.57|Levels (qualifier value)|C0441889|[qlco]|["Levels"-tx-1-"levels"-noun-0]|TX|16/6|
text_000N_47349|MMI|3.57|Milk (body substance)|C0026131|[bdsu]|["BREAST MILK"-tx-1-"breast milk"-noun-0]|TX|55/11|
text_000N_47349|MMI|3.57|Milk, Human|C0026140|[bdsu]|["BREAST MILK"-tx-1-"breast milk"-noun-0]|TX|55/11|
text_000N_47349|MMI|3.57|Therapeutic|C0302350|[ftcn]|["Therapeutic"-tx-1-"therapeutic"-noun-0]|TX|4/11|
text_000N_47349|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|96/9|
text_000N_47349|MMI|3.54|Breast Feeding|C0006147|[orgf]|["Nursing"-tx-1-"nursing"-adj-0]|TX|70/7|
text_000N_47349|MMI|3.54|Discipline of Nursing|C0028677|[bmod]|["NURSING"-tx-1-"nursing"-adj-0]|TX|70/7|
text_000N_47349|MMI|3.54|Mother (person)|C0026591|[famg]|["Mothers"-tx-1-"mothers"-noun-0]|TX|78/7|
text_000N_47349|MMI|3.54|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|42/5|
text_000N_47349|MMI|3.54|nursing therapy|C0028678|[topp]|["nursing"-tx-1-"nursing"-adj-0]|TX|70/7|
text_000N_47349|MMI|3.50|Idiopathic chronic inflammatory bowel disease|C0267374|[dsyn]|["Inflammatory bowel disease"-tx-1-"Inflammatory bowel disease"-noun-0]|TX|110/26|
text_000N_47349|MMI|3.50|Inflammatory Bowel Diseases|C0021390|[dsyn]|["INFLAMMATORY BOWEL DISEASE"-tx-1-"Inflammatory bowel disease"-noun-0]|TX|110/26|
text_000N_47349|MMI|3.44|vedolizumab|C2742797|[aapp,imft,phsu]|["VEDOLIZUMAB"-tx-1-"Vedolizumab"-noun-0]|TX|27/11|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|20/15|
text_000N_47406|MMI|3.59|Arthritis|C0003864|[dsyn]|["ARTHRITIS"-tx-1-"arthritis"-noun-0]|TX|36/9|
text_000N_47406|MMI|3.59|Arthritis, CTCAE|C4552845|[fndg]|["Arthritis"-tx-1-"arthritis"-noun-0]|TX|36/9|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|Give - dosing instruction imperative|C1947971|[ftcn]|["Give"-tx-1-"give"-verb-0]|TX|13/4|
text_000N_173276|MMI|3.68|Long Terminal Repeat|C0023978|[nnon]|["LTR"-tx-1-"LTR"-noun-0]|TX|9/3|
text_000N_173276|MMI|3.57|Relational and Item-Specific Encoding Task|C4321377|[inpr]|["RiSE"-tx-1-"rise"-noun-0]|TX|18/4|
text_000N_173276|MMI|3.50|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_173276|MMI|3.50|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_173276|MMI|3.50|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_173276|MMI|3.50|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_173276|MMI|3.50|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_173276|MMI|3.48|DNA, Circular|C0012925|[bacs,nnon]|["Circular DNA"-tx-1-"circular DNA"-noun-0]|TX|26/12|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|8/9|
text_000N_43235|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|8/9|
text_000N_43235|MMI|3.64|Cardiomyopathy, Dilated|C0007193|[dsyn]|["Cardiomyopathy, Dilated"-tx-1-"dilated cardiomyopathy"-noun-0]|TX|26/22|
text_000N_43235|MMI|3.64|Dilated Cardiomyopathy Pathway|C2984282|[ftcn]|["Dilated cardiomyopathy"-tx-1-"dilated cardiomyopathy"-noun-0]|TX|26/22|
text_000N_43235|MMI|3.57|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.57|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.57|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.57|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.57|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.57|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|18/4|
text_000N_43235|MMI|3.50|PLN gene|C1418650|[gngm]|["PLN"-tx-1-"PLN"-noun-0]|TX|4/3|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|3.61|collagen|C0009325|[aapp,phsu]|["Collagen"-tx-1-"collagen"-noun-0]|TX|30/8|
text_000N_97409|MMI|3.50|LOX gene|C1334349|[gngm]|["LYSYL OXIDASE"-tx-1-"Lysyl oxidase"-noun-0]|TX|3/13|
text_000N_97409|MMI|3.50|LOX protein, human|C4743246|[aapp,enzy]|["Lysyl Oxidase"-tx-1-"Lysyl oxidase"-noun-0]|TX|3/13|
text_000N_97409|MMI|3.50|Protein-Lysine 6-Oxidase|C0024375|[aapp,enzy]|["Lysyl oxidase"-tx-1-"Lysyl oxidase"-noun-0]|TX|3/13|
text_000N_97409|MMI|3.47|Cross link|C0178576|[npop]|["crosslinking"-tx-1-"crosslinking"-adj-0]|TX|17/12|
text_000N_97409|MMI|3.47|Crosslinking Process|C5237922|[phpr]|["Crosslinking"-tx-1-"crosslinking"-adj-0]|TX|17/12|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Selenium deficiency|C0238421|[dsyn]|["SELENIUM DEFICIENCY"-tx-1-"selenium deficiency"-noun-0]|TX|3/19|
text_000N_43303|MMI|3.68|Autoimmune Thyroid Disease Pathway|C2984319|[ftcn]|["Autoimmune thyroid disease"-tx-1-"autoimmune thyroid disease"-noun-0]|TX|35/26|
text_000N_43303|MMI|3.68|Autoimmune thyroid disease|C0178468|[dsyn]|["Autoimmune thyroid disease"-tx-1-"autoimmune thyroid disease"-noun-0]|TX|35/26|
text_000N_43303|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|23/8|
text_000N_43303|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|23/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|EPO protein, human|C2976467|[aapp,bacs]|["Erythropoietin"-tx-1-"Erythropoietin"-noun-0]|TX|3/14|
text_000N_40941|MMI|5.18|Erythropoietin|C0014822|[aapp,horm,phsu]|["Erythropoietin"-tx-1-"Erythropoietin"-noun-0]|TX|3/14|
text_000N_40941|MMI|5.18|Recombinant Erythropoietin|C0376541|[aapp,phsu]|["ERYTHROPOIETIN"-tx-1-"Erythropoietin"-noun-0]|TX|3/14|
text_000N_40941|MMI|5.18|epoetin alfa|C0357126|[aapp,phsu]|["ERYTHROPOIETIN"-tx-1-"Erythropoietin"-noun-0]|TX|3/14|
text_000N_40941|MMI|5.18|erythropoietin activity|C1755594|[moft]|["erythropoietin"-tx-1-"Erythropoietin"-noun-0]|TX|3/14|
text_000N_40941|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|18/9|
text_000N_40941|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|18/9|
text_000N_40941|MMI|3.45|Preterm Infant|C4048294|[aggp]|["Preterm Infants"-tx-1-"Preterm Infants"-noun-0]|TX|51/15|
text_000N_40941|MMI|3.43|Neuroprotection|C0598958|[celf]|["Neuroprotection"-tx-1-"neuroprotection"-noun-0]|TX|32/15|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|PTX3 gene|C1419131|[gngm]|["PENTRAXIN 3"-tx-1-"Pentraxin 3"-noun-0]|TX|4/11|
text_000N_173087|MMI|5.18|PTX3 protein|C0174234|[aapp,bacs]|["pentraxin 3"-tx-1-"Pentraxin 3"-noun-0]|TX|4/11|
text_000N_173087|MMI|5.18|PTX3 protein, human|C1571040|[aapp,bacs]|["Pentraxin-3"-tx-1-"Pentraxin 3"-noun-0]|TX|4/11|
text_000N_173087|MMI|3.55|Result|C1274040|[ftcn]|["Outcome"-tx-1-"outcomes"-noun-0]|TX|24/8|
text_000N_173087|MMI|3.45|Sepsis|C0243026|[dsyn]|["SEPSIS"-tx-1-"sepsis"-noun-0]|TX|36/6|
text_000N_173087|MMI|3.45|Sepsis (Invertebrate)|C1090821|[euka]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|36/6|
text_000N_173087|MMI|3.45|Sepsis, CTCAE|C4552837|[fndg]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|36/6|
text_000N_173087|MMI|3.45|Septicemia|C0036690|[dsyn]|["Sepsis"-tx-1-"sepsis"-noun-0]|TX|36/6|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|Alu Elements|C0002358|[bacs,nnon]|["Alu Elements"-tx-1-"Alu elements"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|% release (qualifier value)|C0439180|[qnco]|["% release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Bacteria|C0004611|[bact]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|3/8|
text_000N_97331|MMI|5.18|Bacteria present|C4038931|[fndg]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|3/8|
text_000N_97331|MMI|5.18|Discharge (release)|C0680255|[hlca]|["release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Extracellular Vesicles|C3894683|[celc]|["Extracellular Vesicles"-tx-1-"extracellular vesicles"-noun-0]|TX|20/22|
text_000N_97331|MMI|5.18|Patient Discharge|C0030685|[hlca]|["Release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Percent of Bacteria|C2347473|[qnco]|["% Bacteria"-tx-1-"bacteria"-noun-0]|TX|3/8|
text_000N_97331|MMI|5.18|Release (procedure)|C1963578|[topp]|["Release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Release - action (qualifier value)|C1283071|[ftcn]|["Release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Release Determination|C4521542|[resa]|["Release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|Released (action)|C0391871|[ftcn]|["Release"-tx-1-"release"-verb-0]|TX|12/7|
text_000N_97331|MMI|5.18|bacteria aspects|C1510439|[ftcn]|["bacteria"-tx-1-"bacteria"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|RUNX2 gene|C1419771|[gngm]|["RUNX2"-tx-1-"RUNX2"-noun-0]|TX|5/5|
text_000N_97362|MMI|5.18|RUNX2 protein, human|C1529564|[aapp,bacs]|["RUNX2"-tx-1-"RUNX2"-noun-0]|TX|5/5|
text_000N_97362|MMI|5.18|astrocyte differentiation|C1657435|[celf]|["astrocyte differentiation"-tx-1-"astrocyte differentiation"-noun-0]|TX|19/25|
text_000N_97362|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|11/7|
text_000N_97362|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|11/7|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|27/5|
text_000N_97301|MMI|5.18|Only - dosing instruction fragment|C1720467|[inpr]|["Only"-tx-1-"only"-adv-0]|TX|22/4|
text_000N_97301|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|27/5|
text_000N_97301|MMI|5.18|Singular|C0205171|[qnco]|["Only"-tx-1-"only"-adv-0]|TX|22/4|
text_000N_97301|MMI|3.59|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|3/9|
text_000N_97301|MMI|3.59|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|3/9|
text_000N_97301|MMI|3.59|Phenotype|C0031437|[orga]|["Phenotypes"-tx-1-"phenotypes"-noun-0]|TX|33/10|
text_000N_97301|MMI|3.45|Epilepsy|C0014544|[dsyn]|["EPILEPSY"-tx-1-"epilepsy"-noun-0]|TX|49/8|
text_000N_97301|MMI|3.45|KCNT2 gene|C1425837|[gngm]|["KCNT2"-tx-1-"KCNT2"-noun-0]|TX|16/5|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|RASA2 gene|C1419278|[gngm]|["RASA2"-tx-1-"RASA2"-noun-0]|TX|3/5|
text_000N_97347|MMI|5.18|Ras GTPase-Activating Protein 2, Human|C5444597|[aapp,bacs]|["RASA2"-tx-1-"RASA2"-noun-0]|TX|3/5|
text_000N_97347|MMI|3.59|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_97347|MMI|3.59|Melanocytic neoplasm|C1302746|[neop]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|21/8|
text_000N_97347|MMI|3.59|Melanoma Pathway|C2984289|[ftcn]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|21/8|
text_000N_97347|MMI|3.59|NCI CTEP SDC Melanoma Sub-Category Terminology|C3539018|[inpr]|["Melanoma"-tx-1-"melanoma"-noun-0]|TX|21/8|
text_000N_97347|MMI|3.59|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_97347|MMI|3.59|melanoma|C0025202|[neop]|["MELANOMA"-tx-1-"melanoma"-noun-0]|TX|21/8|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.55|Conditional|C1701901|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.55|Dependent - ability|C0851827|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.55|Dependent for Toilet Use|C4321395|[inpr]|["dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.55|Dependent for bathing|C0429986|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.55|Dependent for dressing|C0429964|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.55|dependent|C3244310|[ftcn]|["dependent"-tx-1-"dependent"-adj-0]|TX|34/9|
text_000N_47320|MMI|3.42|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancer"-noun-0]|TX|17/8|
text_000N_47320|MMI|3.42|LDB1 gene|C1416809|[gngm]|["LDB1"-tx-1-"LDB1"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.42|LDB1 protein, human|C1433433|[aapp,bacs]|["LDB1"-tx-1-"LDB1"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.42|LDB2 gene|C1416810|[gngm]|["LDB1"-tx-1-"LDB1"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.42|LDB2 wt Allele|C3811096|[gngm]|["LDB1"-tx-1-"LDB1"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.42|Mediate|C0086597|[socb]|["mediated"-tx-1-"mediated"-adj-0]|TX|8/8|
text_000N_47320|MMI|3.42|Mediator brand of benfluorex hydrochloride|C0127400|[orch,phsu]|["Mediated"-tx-1-"mediated"-adj-0]|TX|8/8|
text_000N_47320|MMI|3.42|cohesins|C0907709|[aapp,bacs]|["cohesin"-tx-1-"cohesin"-noun-0]|TX|47/7|
text_000N_47320|MMI|3.40|Loop|C0445022|[spco]|["Loop"-tx-1-"looping"-adj-0]|TX|26/7|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|5.18|rucaparib|C3661315|[orch,phsu]|["RUCAPARIB"-tx-1-"rucaparib"-noun-0]|TX|3/9|
text_000N_97424|MMI|3.61|Cancer Therapeutic Procedure|C0920425|[topp]|["Cancer Treatment"-tx-1-"cancer treatment"-noun-0]|TX|30/16|
text_000N_97424|MMI|3.61|Carcinoma, Ovarian Epithelial|C4721610|[neop]|["Ovarian Cancer"-tx-1-"ovarian cancer"-noun-0]|TX|22/14|
text_000N_97424|MMI|3.61|Malignant neoplasm of ovary|C1140680|[neop]|["OVARIAN CANCER"-tx-1-"ovarian cancer"-noun-0]|TX|22/14|
text_000N_97424|MMI|3.61|ovarian neoplasm|C0919267|[neop]|["ovarian cancer"-tx-1-"ovarian cancer"-noun-0]|TX|22/14|
text_000N_97424|MMI|3.60|Ovarian Treatment|C0851682|[topp]|["Ovarian Treatment"-tx-1-"ovarian treatment"-noun-0]|TX|22/7,37/9|
text_000N_97424|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_97424|MMI|3.56|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_97424|MMI|3.56|Ovarian|C0205065|[bpoc]|["Ovarian"-tx-1-"ovarian"-noun-0]|TX|22/7|
text_000N_97424|MMI|3.56|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|30/6|
text_000N_97424|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|13/4|
text_000N_97424|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
text_000N_97424|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|37/9|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|ATAC-Seq|C4744539|[mbrt]|["ATAC-Seq"-tx-1-"ATAC-Seq"-noun-0]|TX|4/8|
text_000N_47274|MMI|3.61|Single Cell Specimen|C5554878|[cell]|["Single Cell"-tx-1-"single-cell"-adj-0]|TX|28/11|
text_000N_47274|MMI|3.56|Employed|C0557351|[fndg]|["Employed"-tx-1-"employed"-verb-0]|TX|16/8|
text_000N_47274|MMI|3.56|Employed:Find:Pt:^Patient:Ord|C5551697|[clna]|["Employed"-tx-1-"employed"-verb-0]|TX|16/8|
text_000N_47274|MMI|3.56|Employment|C0014003|[qlco]|["Employed"-tx-1-"employed"-verb-0]|TX|16/8|
text_000N_47274|MMI|3.56|Mode|C1513371|[ftcn]|["Mode"-tx-1-"mode"-noun-0]|TX|40/4|
text_000N_47274|MMI|3.56|Population Mode|C2347637|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|40/4|
text_000N_47274|MMI|3.56|Sample Mode|C2348146|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|40/4|
text_000N_47274|MMI|3.56|Statistical Mode|C1705738|[qnco]|["Mode"-tx-1-"mode"-noun-0]|TX|40/4|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Cannabis Smoking|C0006873|[inbe]|["Marihuana USE"-tx-1-"marijuana use"-noun-0]|TX|3/13|
text_000N_47304|MMI|5.18|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|52/6|
text_000N_47304|MMI|5.18|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|52/6|
text_000N_47304|MMI|5.18|Marijuana Smoking|C0024810|[inbe]|["MARIJUANA USE"-tx-1-"marijuana use"-noun-0]|TX|3/13|
text_000N_47304|MMI|5.18|Marijuana Use|C4316909|[mobd]|["Marijuana Use"-tx-1-"marijuana use"-noun-0]|TX|3/13|
text_000N_47304|MMI|5.18|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|52/6|
text_000N_47304|MMI|5.18|marihuana use|C3160814|[mobd]|["marihuana use"-tx-1-"marijuana use"-noun-0]|TX|3/13|
text_000N_47304|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|17/15|
text_000N_47304|MMI|3.64|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|33/14|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.68|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|12/7|
text_000N_47334|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|23/15|
text_000N_47334|MMI|3.61|X Chromosome|C0043292|[celc]|["X Chromosome"-tx-1-"X Chromosome"-noun-0]|TX|43/12|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Interferon|C3652465|[aapp,imft,phsu]|["Interferon"-tx-1-"interferon"-noun-0]|TX|8/10|
text_000N_47363|MMI|5.18|Interferons|C0021747|[aapp,imft]|["INTERFERON"-tx-1-"interferon"-noun-0]|TX|8/10|
text_000N_47363|MMI|5.18|Protein Domain|C1514562|[amas]|["Signature"-tx-1-"signature"-noun-0]|TX|25/9|
text_000N_47363|MMI|5.18|Routine Signature|C1705596|[idcn]|["Signature"-tx-1-"signature"-noun-0]|TX|25/9|
text_000N_47363|MMI|5.18|Signature|C1519316|[inpr]|["Signature"-tx-1-"signature"-noun-0]|TX|25/9|
text_000N_47363|MMI|5.18|human leukocyte interferon|C0733470|[aapp,imft,phsu]|["Interferon"-tx-1-"interferon"-noun-0]|TX|8/10|
text_000N_47363|MMI|3.57|Exist|C2987476|[qlco]|["Exist"-tx-1-"exist"-verb-0]|TX|35/5|
text_000N_47363|MMI|3.57|Lupus Erythematosus, Systemic|C0024141|[dsyn]|["SLE NOS"-tx-1-"SLE"-noun-0]|TX|45/3|
text_000N_47363|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|49/8|
text_000N_47363|MMI|3.57|Systematic Light Exposure|C4724445|[topp]|["sLE"-tx-1-"SLE"-noun-0]|TX|45/3|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|CDH17 gene|C1413274|[gngm]|["cadherin"-tx-1-"cadherin"-noun-0]|TX|3/8|
text_000N_47289|MMI|5.18|Cadherins|C0006631|[aapp,bacs]|["Cadherin"-tx-1-"cadherin"-noun-0]|TX|3/8|
text_000N_47289|MMI|3.63|Biological Markers|C0005516|[clna]|["marker"-tx-1-"marker"-noun-0]|TX|30/6|
text_000N_47289|MMI|3.63|Marker|C5445211|[qlco]|["Marker"-tx-1-"marker"-noun-0]|TX|30/6|
text_000N_47289|MMI|3.53|Plasma membrane|C0007603|[celc]|["Plasma Membrane"-tx-1-"plasma membrane"-noun-0]|TX|14/15|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|ziconotide|C0211011|[aapp,phsu]|["ZICONOTIDE"-tx-1-"ziconotide"-noun-0]|TX|5/10|
text_000N_47377|MMI|3.59|Calcium Channel|C0006685|[aapp,bacs]|["Calcium Channels"-tx-1-"calcium channels"-noun-0]|TX|31/16|
text_000N_47377|MMI|3.55|*Type - Kind of quantity|C1547052|[qnco]|["*Type"-tx-1-"type"-noun-0]|TX|26/4|
text_000N_47377|MMI|3.55|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|16/4|
text_000N_47377|MMI|3.55|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|16/4|
text_000N_47377|MMI|3.55|GDC Type Terminology|C5202910|[inpr]|["TYPE"-tx-1-"type"-noun-0]|TX|26/4|
text_000N_47377|MMI|3.55|Organism by Type|C5552723|[clas]|["TYPE"-tx-1-"type"-noun-0]|TX|26/4|
text_000N_47377|MMI|3.55|Type - attribute|C0332307|[qlco]|["TYPE"-tx-1-"type"-noun-0]|TX|26/4|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.68|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_47392|MMI|3.68|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_47392|MMI|3.68|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_47392|MMI|3.57|Astronauts|C0242688|[prog]|["Astronauts"-tx-1-"astronauts"-noun-0]|TX|4/10|
text_000N_47392|MMI|3.46|American College of Cardiology/American Heart Association Lesion Complexity Score C|C3272283|[fndg]|["High Risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|Disease Risk Index High Risk|C5238223|[inpr]|["High Risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|Drug Accumulation Greater than 5|C5399772|[fndg]|["High risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|High Risk Acute Leukemia|C4050568|[fndg]|["High Risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|High risk|C4319571|[fndg]|["HIGH RISK"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|High risk of|C0332167|[fndg]|["high risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|IPSS-R Risk Category High|C5202936|[fndg]|["High Risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
text_000N_47392|MMI|3.46|International Prognostic Index High Risk Group|C5202937|[fndg]|["High Risk"-tx-1-"higher risk"-adj-0]|TX|18/11|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Carcinogenesis|C0596263|[neop]|["Tumorigenesis"-tx-1-"tumorigenesis"-noun-0]|TX|40/13|
text_000N_47406|MMI|5.18|Neoplastic Cell Transformation|C0007621|[neop]|["Tumorigenesis"-tx-1-"tumorigenesis"-noun-0]|TX|40/13|
text_000N_47406|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|32/7|
text_000N_47406|MMI|3.68|LINC-PINT gene|C3811619|[gngm]|["LINC-PINT"-tx-1-"LINC-PINT"-noun-0]|TX|22/9|
text_000N_47406|MMI|3.47|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|9/5|
text_000N_47406|MMI|3.47|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["lncRNA"-tx-1-"lncRNA"-noun-0]|TX|15/6|
text_000N_47406|MMI|3.47|RNA, Long Untranslated|C3494264|[bacs,nnon]|["lncRNA"-tx-1-"lncRNA"-noun-0]|TX|15/6|
<<<<< MMI
>>>>> MMI
text_000N_47420|AA|AVP|Arginine Vasopressin Peptide|1|3|5|28|70:3
text_000N_47420|MMI|5.18|Autistic Disorder|C0004352|[mobd]|["AUTISM"-tx-1-"autism"-noun-0]|TX|3/6|
text_000N_47420|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_47420|MMI|5.18|Thinking, function|C0039869|[menp]|["Thought"-tx-1-"thought"-verb-0]|TX|10/7|
text_000N_47420|MMI|5.18|Thought|C4319827|[idcn]|["Thought"-tx-1-"thought"-verb-0]|TX|10/7|
text_000N_47420|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_47420|MMI|3.59|Recombinant Vasopressin|C1527128|[aapp,horm,phsu]|["Arginine Vasopressin"-tx-1-"Arginine Vasopressin"-noun-0]|TX|40/20|
text_000N_47420|MMI|3.59|argipressin|C0003779|[aapp,horm,phsu]|["Arginine vasopressin"-tx-1-"Arginine Vasopressin"-noun-0]|TX|40/20|
text_000N_47420|MMI|3.59|human AVP protein|C1098706|[aapp,bacs]|["Arginine-Vasopressin"-tx-1-"Arginine Vasopressin"-noun-0]|TX|40/20|
text_000N_47420|MMI|3.55|Peptides|C0030956|[aapp,phsu]|["Peptide"-tx-1-"Peptide"-noun-0]|TX|61/7|
text_000N_47420|MMI|3.55|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|24/7|
text_000N_47420|MMI|3.55|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|24/7|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|10.42|IGF1 gene|C1334089|[gngm]|["IGFI"-tx-1-"IGF-I"-noun-0,"insulin like growth factor 1"-tx-1-"insulin-like growth factor-I"-noun-0]|TX|33/5;3/28|
text_000N_47435|MMI|10.42|IGF1 protein, human|C3712803|[aapp,bacs]|["IGF1"-tx-1-"IGF-I"-noun-0,"Insulin-Like Growth Factor I"-tx-1-"insulin-like growth factor-I"-noun-0]|TX|33/5;3/28|
text_000N_47435|MMI|10.42|Insulin-Like Growth Factor I|C0021665|[aapp,bacs]|["IGF-1"-tx-1-"IGF-I"-noun-0,"Insulin-like growth factor 1"-tx-1-"insulin-like growth factor-I"-noun-0]|TX|33/5;3/28|
text_000N_47435|MMI|10.42|Somatomedin-C measurement|C0202220|[lbpr]|["IGF1"-tx-1-"IGF-I"-noun-0,"Insulin-like Growth Factor-1"-tx-1-"insulin-like growth factor-I"-noun-0]|TX|33/5;3/28|
text_000N_47435|MMI|5.18|Ability|C0085732|[orga]|["Able"-tx-1-"able"-adj-0]|TX|40/4|
text_000N_47435|MMI|5.18|Able (finding)|C1299581|[fndg]|["Able"-tx-1-"able"-adj-0]|TX|40/4|
text_000N_47435|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|48/6|
text_000N_47435|MMI|5.18|IGF1 wt Allele|C1708414|[gngm]|["IGFI"-tx-1-"IGF-I"-noun-0]|TX|33/5|
text_000N_47435|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|45/2|
text_000N_47435|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|45/2|
text_000N_47435|MMI|3.56|Protein Biosynthesis|C0597295|[moft]|["Protein Synthesis"-tx-1-"protein synthesis"-noun-0]|TX|62/17|
text_000N_47435|MMI|3.56|tendon formation|C3271475|[ortf]|["tendon synthesis"-tx-1-"tendon synthesis"-noun-0]|TX|55/6,70/9|
text_000N_47435|MMI|3.54|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|62/7|
text_000N_47435|MMI|3.45|Ehlers-Danlos Syndrome|C0013720|[dsyn]|["EHLERS-DANLOS SYNDROME"-tx-1-"Ehlers-Danlos syndrome"-noun-0]|TX|91/22|
text_000N_47435|MMI|3.45|Family History of Ehlers-Danlos Syndrome|C5238700|[fndg]|["Ehlers-Danlos syndrome"-tx-1-"Ehlers-Danlos syndrome"-noun-0]|TX|91/22|
text_000N_47435|MMI|3.42|Classic Histology|C4321286|[clas]|["Classic"-tx-1-"classic"-adj-0]|TX|83/7|
text_000N_47435|MMI|3.42|Conventional|C0439858|[qlco]|["Classic"-tx-1-"classic"-adj-0]|TX|83/7|
text_000N_47435|MMI|3.42|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|114/8|
text_000N_47435|MMI|3.42|Tendon structure|C0039508|[bpoc]|["TENDON"-tx-1-"tendon"-noun-0]|TX|55/6|
text_000N_47435|MMI|3.42|classic behavior|C0439658|[qlco]|["Classic"-tx-1-"classic"-adj-0]|TX|83/7|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|pregabalin|C0657912|[aapp,phsu]|["PREGABALIN"-tx-1-"pregabalin"-noun-0]|TX|3/10|
text_000N_47450|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47450|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47450|MMI|3.45|Sciatica|C0036396|[sosy]|["SCIATICA"-tx-1-"sciatica"-noun-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.63|Law (view)|C4554596|[spco]|["Law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.63|Law - Document|C1947938|[inpr]|["Law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.63|Law Profession|C1947939|[ocdi]|["Law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.63|Legal system|C0728724|[rnlw]|["law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.63|Rules of conduct|C0023150|[rnlw]|["Law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.63|aspects of laws|C0220866|[rnlw]|["Law"-tx-1-"law"-noun-0]|TX|28/3|
text_000N_43235|MMI|3.44|Genome|C0017428|[gngm]|["Genomes"-tx-1-"genomes"-noun-0]|TX|68/7|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|58/6|
text_000N_43275|MMI|5.18|Infant|C0021270|[aggp]|["INFANT"-tx-1-"infant"-noun-0]|TX|92/6|
text_000N_43275|MMI|5.18|Labor (Childbirth)|C0022864|[orgf]|["Labour"-tx-1-"labor"-noun-0]|TX|52/5|
text_000N_43275|MMI|5.18|Work|C0043227|[ocac]|["Labor"-tx-1-"labor"-noun-0]|TX|52/5|
text_000N_43275|MMI|3.65|Analgesia, Epidural|C0002769|[topp]|["Epidural Pain management"-tx-1-"epidural pain management"-noun-0]|TX|5/8,29/15|
text_000N_43275|MMI|3.65|Anesthesia and Analgesia|C0002905|[topp]|["anesthesia Pain management"-tx-1-"anesthesia pain management"-noun-0]|TX|14/10,29/15|
text_000N_43275|MMI|3.61|Apgar Score|C0003533|[orga]|["Apgar Score"-tx-1-"Apgar score"-noun-0]|TX|69/11|
text_000N_43275|MMI|3.61|Score^2 minutes post birth:Function:Point in time:^Patient:Ordinal:Apgar|C0489254|[clna]|["Apgar Score"-tx-1-"Apgar score"-noun-0]|TX|69/11|
text_000N_43275|MMI|3.56|Anesthesia procedures|C0002903|[topp]|["anaesthesia"-tx-1-"anesthesia"-noun-0]|TX|14/10|
text_000N_43275|MMI|3.56|Anesthesia substance|C4049933|[phsu]|["Anesthesia"-tx-1-"anesthesia"-noun-0]|TX|14/10|
text_000N_43275|MMI|3.56|Anesthesiology|C0002930|[bmod]|["Anaesthesia"-tx-1-"anesthesia"-noun-0]|TX|14/10|
text_000N_43275|MMI|3.56|Dental anesthesia|C0002912|[topp]|["Anesthesia"-tx-1-"anesthesia"-noun-0]|TX|14/10|
text_000N_43275|MMI|3.56|Medication administration: epidural|C0812144|[topp]|["epidural"-tx-1-"epidural"-noun-0]|TX|5/8|
text_000N_43275|MMI|3.56|Spinal epidural space|C0228134|[bsoj]|["Epidural"-tx-1-"epidural"-noun-0]|TX|5/8|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|PTPN22 gene|C1419102|[gngm]|["PTPN22 Gene"-tx-1-"PTPN22 gene"-noun-0]|TX|7/11|
text_000N_43303|MMI|3.56|Biological Markers|C0005516|[clna]|["Biomarker"-tx-1-"biomarker"-noun-0]|TX|21/9|
text_000N_43303|MMI|3.46|Rheumatoid Arthritis|C0003873|[dsyn]|["RHEUMATOID ARTHRITIS"-tx-1-"Rheumatoid Arthritis"-noun-0]|TX|35/20|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.60|Deficiency|C0011155|[ftcn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
text_000N_43331|MMI|3.60|Malnutrition|C0162429|[dsyn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
text_000N_43331|MMI|3.60|deficiency aspects|C1623416|[qlco]|["deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
text_000N_43331|MMI|3.59|Anemia|C0002871|[dsyn]|["ANEMIA"-tx-1-"anemia"-noun-0]|TX|54/6|
text_000N_43331|MMI|3.59|Anemia, CTCAE|C4554633|[fndg]|["Anemia"-tx-1-"anemia"-noun-0]|TX|54/6|
text_000N_43331|MMI|3.59|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.59|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.59|Genus Anemia|C1000483|[plnt]|["Anemia"-tx-1-"anemia"-noun-0]|TX|54/6|
text_000N_43331|MMI|3.59|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.59|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.59|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.59|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|46/4|
text_000N_43331|MMI|3.57|SLC11A2 gene|C1420089|[gngm]|["DIVALENT METAL TRANSPORTER 1"-tx-1-"divalent metal transporter 1"-noun-0]|TX|6/28|
text_000N_43331|MMI|3.57|solute carrier family 11- (proton-coupled divalent metal ion transporters), member 2|C0288148|[aapp,bacs]|["divalent metal transporter-1"-tx-1-"divalent metal transporter 1"-noun-0]|TX|6/28|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Vocimagene amiretrorepvec|C2984522|[virs]|["VOCIMAGENE AMIRETROREPVEC"-tx-1-"vocimagene amiretrorepvec"-noun-0]|TX|3/25|
text_000N_43358|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_43358|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_43358|MMI|3.52|Recurrent Malignant Glioma|C4684861|[neop]|["Recurrent High-Grade Glioma"-tx-1-"recurrent high-grade glioma"-noun-0]|TX|43/27|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.55|Biological Markers|C0005516|[clna]|["marker"-tx-1-"marker"-noun-0]|TX|12/6|
text_000N_47320|MMI|3.55|Marker|C5445211|[qlco]|["Marker"-tx-1-"marker"-noun-0]|TX|12/6|
text_000N_47320|MMI|3.50|Gram per Deciliter|C0439267|[qnco]|["g%"-tx-1-"g"-adj-0]|TX|3/1|
text_000N_47320|MMI|3.50|Percent Administered Dose Recovered Per Gram|C5557119|[qnco]|["%/g"-tx-1-"g"-adj-0]|TX|3/1|
text_000N_47320|MMI|3.45|Strand breaks|C0301647|[moft]|["Strand breaks"-tx-1-"strand breaks"-noun-0]|TX|30/13|
text_000N_47320|MMI|3.43|Double Value Type|C1705765|[qlco]|["Double"-tx-1-"double"-noun-0]|TX|23/6|
text_000N_47320|MMI|3.43|Doubling|C1705764|[acty]|["Double"-tx-1-"double"-noun-0]|TX|23/6|
text_000N_47320|MMI|3.43|Duplicate|C0205173|[ftcn]|["Double"-tx-1-"double"-noun-0]|TX|23/6|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Atomic Bomb Survivors|C5197894|[popg]|["Atomic Bomb Survivors"-tx-1-"atomic bomb survivors"-noun-0]|TX|45/21|
text_000N_43386|MMI|3.79|Increased risk of meningioma|C2748455|[fndg]|["Increased risk of meningioma"-tx-1-"increased risk of meningiomas"-noun-0]|TX|12/29|
text_000N_43386|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43386|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|CPX-351|C2346682|[phsu]|["CPX-351"-tx-1-"CPX-351"-noun-0]|TX|4/7|
text_000N_40839|MMI|5.18|ETFA wt Allele|C4318614|[gngm]|["EMA"-tx-1-"EMA"-noun-0]|TX|45/3|
text_000N_40839|MMI|5.18|Ecological Momentary Assessment|C4277684|[diap]|["EMA"-tx-1-"EMA"-noun-0]|TX|45/3|
text_000N_40839|MMI|5.18|European Medicines Agency|C4553329|[orgt]|["EMA"-tx-1-"EMA"-noun-0]|TX|45/3|
text_000N_40839|MMI|5.18|human MUC1 protein|C1612111|[aapp,imft,irda]|["EMA"-tx-1-"EMA"-noun-0]|TX|45/3|
text_000N_40839|MMI|3.57|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|17/8|
text_000N_40839|MMI|3.57|United States Food and Drug Administration|C0041714|[hcro]|["FDA"-tx-1-"FDA"-noun-0]|TX|33/3|
<<<<< MMI
>>>>> MMI
text_000N_40886|AA|d-TC|Does d-tubocurarine|3|4|5|19|21:4
text_000N_40886|AA|nAChR|nicotinic acetylcholine receptor|1|5|5|32|96:5
text_000N_40886|MMI|5.18|Induce (action)|C0205263|[ftcn]|["Induce"-tx-1-"induces"-verb-0]|TX|27/7|
text_000N_40886|MMI|5.18|Neuromuscular Junction|C0027869|[celc]|["Neuromuscular Junction"-tx-1-"neuromuscular junction"-noun-0]|TX|110/22|
text_000N_40886|MMI|3.63|Do (activity)|C2828361|[acty]|["Does"-tx-1-"Does"-aux-0]|TX|0/4|
text_000N_40886|MMI|3.63|Does - Ability interpretation value|C1272751|[fndg]|["Does"-tx-1-"Does"-aux-0]|TX|0/4|
text_000N_40886|MMI|3.63|tubocurarine|C0041345|[orch,phsu]|["TUBOCURARINE"-tx-1-"tubocurarine"-noun-0]|TX|7/12|
text_000N_40886|MMI|3.55|Inhibition|C3463820|[acty]|["Inhibition"-tx-1-"inhibition"-noun-0]|TX|48/10|
text_000N_40886|MMI|3.55|Metabolic Inhibition|C0021469|[moft]|["Inhibition"-tx-1-"inhibition"-noun-0]|TX|48/10|
text_000N_40886|MMI|3.55|Percent inhibition|C1628982|[qnco]|["% INHIBITION"-tx-1-"inhibition"-noun-0]|TX|48/10|
text_000N_40886|MMI|3.55|Psychological inhibition|C0021467|[menp]|["INHIBITION"-tx-1-"inhibition"-noun-0]|TX|48/10|
text_000N_40886|MMI|3.48|Nicotinic Receptors|C0034830|[aapp,rcpt]|["Nicotinic acetylcholine receptor"-tx-1-"nicotinic acetylcholine receptor"-noun-0]|TX|62/32|
text_000N_40886|MMI|3.48|nicotinic acetylcholine receptor location|C1749487|[celc]|["nicotinic acetylcholine receptor"-tx-1-"nicotinic acetylcholine receptor"-noun-0]|TX|62/32|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|7.19|Therapeutic radiology procedure|C1522449|[topp]|["Cancer Radiotherapy"-tx-1-"radiotherapy cancer"-noun-0,"RADIOTHERAPY"-tx-1-"radiotherapy"-noun-0]|TX|5/12,31/6;5/12|
text_000N_47349|MMI|3.71|Malignant tumor of colon|C0007102|[neop]|["Cancer of Colon"-tx-1-"of colon cancer"-noun-0]|TX|53/15|
text_000N_47349|MMI|3.60|cancer radiation therapy|C0920418|[topp]|["radiotherapy cancer"-tx-1-"radiotherapy cancer"-noun-0]|TX|5/12,31/6|
text_000N_47349|MMI|3.57|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-verb-0]|TX|48/4|
text_000N_47349|MMI|3.57|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-verb-0]|TX|48/4|
text_000N_47349|MMI|3.56|Radiation Oncology specialty|C0243005|[bmod]|["Radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|5/12|
text_000N_47349|MMI|3.56|radiotherapeutic|C0034619|[inpr]|["radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|5/12|
text_000N_47349|MMI|3.46|Cervix carcinoma|C0302592|[neop]|["CERVICAL CANCER"-tx-1-"cervical cancer"-noun-0]|TX|22/15|
text_000N_47349|MMI|3.46|Malignant tumor of cervix|C0007847|[neop]|["Cervical cancer"-tx-1-"cervical cancer"-noun-0]|TX|22/15|
text_000N_47349|MMI|3.46|NCI CTEP SDC Cervical Cancer Sub-Category Terminology|C3539064|[inpr]|["Cervical Cancer"-tx-1-"cervical cancer"-noun-0]|TX|22/15|
text_000N_47349|MMI|3.46|cervical cancer|C4048328|[neop]|["Cervical Cancer"-tx-1-"cervical cancer"-noun-0]|TX|22/15|
text_000N_47349|MMI|3.43|Cervical|C0205064|[spco]|["Cervical"-tx-1-"cervical"-noun-0]|TX|22/8|
text_000N_47349|MMI|3.43|Increase|C0442805|[ftcn]|["increases"-tx-1-"increases"-noun-0]|TX|38/9|
text_000N_47349|MMI|3.43|Increased|C0205217|[qnco]|["Increases"-tx-1-"increases"-noun-0]|TX|38/9|
text_000N_47349|MMI|3.43|Neck|C0027530|[blor]|["Cervical"-tx-1-"cervical"-noun-0]|TX|22/8|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.60|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|34/4|
text_000N_40913|MMI|3.60|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|34/4|
text_000N_40913|MMI|3.51|Head Neoplasms|C0018675|[neop]|["head Tumour"-tx-1-"head tumor"-noun-0]|TX|5/4,28/5|
text_000N_40913|MMI|3.48|CAT scan of brain|C0412585|[diap]|["ct brain"-tx-1-"ct brain"-noun-0]|TX|10/2,22/5|
text_000N_40913|MMI|3.48|Brain Neoplasms|C0006118|[neop]|["Brain tumour"-tx-1-"brain tumor"-noun-0]|TX|22/11|
text_000N_40913|MMI|3.48|CAT scan of head|C0202691|[diap]|["Head CT"-tx-1-"head ct"-noun-0]|TX|5/7|
text_000N_40913|MMI|3.46|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|13/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|AZD9668|C3489797|[orch]|["AZD9668"-tx-1-"AZD9668"-noun-0]|TX|3/7|
text_000N_40941|MMI|3.63|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|23/4|
text_000N_40941|MMI|3.63|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|23/4|
text_000N_40941|MMI|3.48|RNA, Messenger|C0035696|[bacs,nnon]|["mRNA"-tx-1-"mRNA"-noun-0]|TX|18/4|
text_000N_40941|MMI|3.48|Vascular Endothelial Growth Factors|C1256770|[aapp,bacs]|["VEGF"-tx-1-"VEGF"-noun-0]|TX|13/4|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Rheumatoid Arthritis|C0003873|[dsyn]|["RHEUMATOID ARTHRITIS"-tx-1-"Rheumatoid Arthritis"-noun-0]|TX|3/20|
text_000N_40972|MMI|3.59|Myopathy|C0026848|[dsyn]|["MYOPATHY"-tx-1-"myopathy"-noun-0]|TX|35/8|
text_000N_40972|MMI|3.59|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|24/7|
text_000N_40972|MMI|3.59|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|24/7|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.59|TRANSCRIPTION FACTOR|C0040648|[aapp,bacs]|["Transcription Factors"-tx-1-"transcription factors"-noun-0]|TX|35/21|
text_000N_40999|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40999|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40999|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_40999|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_40999|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_40999|MMI|3.44|DLX1 gene|C1414075|[gngm]|["DLX1"-tx-1-"Dlx1"-noun-0]|TX|21/4|
text_000N_40999|MMI|3.44|Homeobox Protein DLX-1|C4522156|[aapp,bacs]|["DLX1"-tx-1-"Dlx1"-noun-0]|TX|21/4|
text_000N_40999|MMI|3.43|Adrenal Cortex|C0001613|[bpoc]|["Cortical"-tx-1-"cortical"-adj-0]|TX|60/8|
text_000N_40999|MMI|3.43|Cerebral cortex|C0007776|[bpoc]|["Cortical"-tx-1-"cortical"-adj-0]|TX|60/8|
text_000N_40999|MMI|3.43|DLX2 gene|C1414076|[gngm]|["DLX2"-tx-1-"Dlx2"-noun-0]|TX|30/4|
text_000N_40999|MMI|3.43|Interneurons|C0021792|[cell]|["Interneurons"-tx-1-"interneurons"-noun-0]|TX|69/12|
text_000N_40999|MMI|3.43|Structure of cortex of kidney|C0022655|[bpoc]|["Cortical"-tx-1-"cortical"-adj-0]|TX|60/8|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|23/15|
text_000N_173087|MMI|3.68|Deficiency|C0011155|[ftcn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|12/10|
text_000N_173087|MMI|3.68|Malnutrition|C0162429|[dsyn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|12/10|
text_000N_173087|MMI|3.68|deficiency aspects|C1623416|[qlco]|["deficiency"-tx-1-"deficiency"-noun-0]|TX|12/10|
text_000N_173087|MMI|3.59|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|39/6|
text_000N_173087|MMI|3.59|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|39/6|
text_000N_173087|MMI|3.59|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|39/6|
text_000N_173087|MMI|3.50|ADAMTS18 gene|C1424749|[gngm]|["ADAMTS18"-tx-1-"Adamts18"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|ozanezumab|C3885499|[aapp,imft,phsu]|["OZANEZUMAB"-tx-1-"ozanezumab"-noun-0]|TX|3/10|
text_000N_173104|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173104|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173104|MMI|3.50|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|28/29|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|28/5|
text_000N_173120|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|28/5|
text_000N_173120|MMI|5.18|Ventricular Fibrillation|C0042510|[dsyn]|["Fibrillation, Ventricular"-tx-1-"ventricular fibrillation"-noun-0]|TX|34/24|
text_000N_173120|MMI|5.18|Ventricular Fibrillation by ECG Finding|C0344435|[lbtr]|["Ventricular Fibrillation"-tx-1-"ventricular fibrillation"-noun-0]|TX|34/24|
text_000N_173120|MMI|5.18|Ventricular Fibrillation, CTCAE 3.0|C1962976|[fndg]|["Ventricular fibrillation"-tx-1-"ventricular fibrillation"-noun-0]|TX|34/24|
text_000N_173120|MMI|5.18|Ventricular Fibrillation, CTCAE 5.0|C4554001|[fndg]|["Ventricular Fibrillation"-tx-1-"ventricular fibrillation"-noun-0]|TX|34/24|
text_000N_173120|MMI|3.59|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|4/9|
text_000N_173120|MMI|3.59|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|4/9|
text_000N_173120|MMI|3.45|Calmodulin|C0006772|[aapp,bacs]|["Calmodulin"-tx-1-"Calmodulin"-noun-0]|TX|17/10|
text_000N_173120|MMI|3.45|Calmodulin 1|C1366910|[aapp,bacs]|["Calmodulin"-tx-1-"Calmodulin"-noun-0]|TX|17/10|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|TTN gene|C1421222|[gngm]|["TITIN"-tx-1-"Titin"-noun-0]|TX|3/5|
text_000N_173136|MMI|5.18|TTN protein, human|C3711784|[aapp,enzy]|["Titin"-tx-1-"Titin"-noun-0]|TX|3/5|
text_000N_173136|MMI|5.18|Titin Kinase|C0283134|[aapp,enzy]|["Titin"-tx-1-"Titin"-noun-0]|TX|3/5|
text_000N_173136|MMI|5.18|connectin|C0056248|[aapp,enzy]|["Titin"-tx-1-"Titin"-noun-0]|TX|3/5|
text_000N_173136|MMI|3.70|single molecule|C0872367|[sbst]|["single molecule"-tx-1-"single molecule"-noun-0]|TX|21/6,36/8|
text_000N_173136|MMI|3.59|Nature|C0349590|[idcn]|["Nature"-tx-1-"Nature"-noun-0]|TX|54/6|
text_000N_173136|MMI|3.59|Natures|C1262865|[ftcn]|["Nature"-tx-1-"Nature"-noun-0]|TX|54/6|
text_000N_173136|MMI|3.59|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|45/5|
text_000N_173136|MMI|3.47|Largest|C0443228|[qnco]|["Largest"-tx-1-"largest"-adj-0]|TX|13/7|
text_000N_173136|MMI|3.47|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|28/7|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|cohesins|C0907709|[aapp,bacs]|["cohesin"-tx-1-"cohesin"-noun-0]|TX|40/7|
text_000N_173151|MMI|3.57|ERCC1 gene|C1333355|[gngm]|["ERCC1"-tx-1-"ERCC1"-noun-0]|TX|26/5|
text_000N_173151|MMI|3.57|ERCC4 gene|C1333358|[gngm]|["XPF"-tx-1-"XPF"-noun-0]|TX|32/3|
text_000N_173151|MMI|3.57|ERCC4 protein, human|C1568501|[aapp,enzy]|["XPF"-tx-1-"XPF"-noun-0]|TX|32/3|
text_000N_173151|MMI|3.57|ERCC4 wt Allele|C1705469|[gngm]|["XPF"-tx-1-"XPF"-noun-0]|TX|32/3|
text_000N_173151|MMI|3.57|Excision Repair Cross-Complementing 1|C1333483|[aapp,enzy]|["ERCC1"-tx-1-"ERCC1"-noun-0]|TX|26/5|
text_000N_173151|MMI|3.57|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_173151|MMI|3.57|Links List|C1517892|[inpr]|["Link"-tx-1-"link"-verb-0]|TX|13/4|
text_000N_173151|MMI|3.57|Xeroderma pigmentosum, group F|C0268140|[cgab]|["XPF"-tx-1-"XPF"-noun-0]|TX|32/3|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Diazepam measurement|C0202368|[lbpr]|["Diazepam"-tx-1-"Diazepam"-noun-0]|TX|4/8|
text_000N_173167|MMI|5.18|diazepam|C0012010|[orch,phsu]|["DIAZEPAM"-tx-1-"Diazepam"-noun-0]|TX|4/8|
text_000N_173167|MMI|3.46|Traumatic Brain Injury|C0876926|[inpo]|["Traumatic Brain Injury"-tx-1-"traumatic brain injury"-noun-0]|TX|49/22|
text_000N_173167|MMI|3.42|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_173167|MMI|3.42|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|BAX protein, human|C1528509|[aapp,bacs]|["Apoptosis Regulator BAX"-tx-1-"apoptosis regulator BAX"-noun-0]|TX|8/23|
text_000N_173183|MMI|5.18|Precipitating Factors|C0032930|[clna]|["Trigger"-tx-1-"trigger"-verb-0]|TX|32/7|
text_000N_173183|MMI|5.18|Triggered by|C1444748|[qlco]|["Trigger"-tx-1-"trigger"-verb-0]|TX|32/7|
text_000N_173183|MMI|3.56|% release (qualifier value)|C0439180|[qnco]|["% release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Discharge (release)|C0680255|[hlca]|["release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Patient Discharge|C0030685|[hlca]|["Release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Release (procedure)|C1963578|[topp]|["Release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Release - action (qualifier value)|C1283071|[ftcn]|["Release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Release Determination|C4521542|[resa]|["Release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.56|Released (action)|C0391871|[ftcn]|["Release"-tx-1-"release"-noun-0]|TX|44/7|
text_000N_173183|MMI|3.46|CYCS gene|C1426584|[gngm]|["CYTOCHROME C"-tx-1-"cytochrome c"-noun-0]|TX|55/12|
text_000N_173183|MMI|3.46|Cytochrome C, human|C4318401|[aapp,bacs]|["Cytochrome C"-tx-1-"cytochrome c"-noun-0]|TX|55/12|
text_000N_173183|MMI|3.46|Cytochromes c|C0010749|[aapp,enzy]|["Cytochrome c"-tx-1-"cytochrome c"-noun-0]|TX|55/12|
text_000N_173183|MMI|3.46|Cytochromes c'|C0010754|[aapp,bacs]|["Cytochrome c'"-tx-1-"cytochrome c"-noun-0]|TX|55/12|
text_000N_173183|MMI|3.46|cytochrome c''|C0653778|[aapp]|["Cytochrome c''"-tx-1-"cytochrome c"-noun-0]|TX|55/12|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|3/15|
text_000N_173199|MMI|5.18|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|3/15|
text_000N_173199|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|86/3|
text_000N_173199|MMI|3.65|CEP-26401|C3254381|[orch,phsu]|["CEP-26401"-tx-1-"CEP-26401"-noun-0]|TX|40/9|
text_000N_173199|MMI|3.60|Antagonist muscle action|C0231491|[ortf]|["Antagonist"-tx-1-"antagonist"-noun-0]|TX|29/10|
text_000N_173199|MMI|3.60|Substance with receptor antagonist mechanism of action (substance)|C4721408|[phsu]|["Antagonist"-tx-1-"antagonist"-noun-0]|TX|29/10|
text_000N_173199|MMI|3.60|influenza A virus H3 subtype|C2959654|[virs]|["H3"-tx-1-"H3"-noun-0]|TX|24/2|
text_000N_173199|MMI|3.56|Effect|C1280500|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|65/6|
text_000N_173199|MMI|3.56|Effect, Appearance|C2348382|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|65/6|
text_000N_173199|MMI|3.56|Outcome of Therapy|C1518681|[fndg]|["effect"-tx-1-"effect"-noun-0]|TX|65/6|
text_000N_173199|MMI|3.43|BRAF Gene Rearrangement|C4727483|[comd]|["Positive"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|Cognition|C0009240|[menp]|["Cognition"-tx-1-"cognition"-noun-0]|TX|75/9|
text_000N_173199|MMI|3.43|Positive|C1446409|[fndg]|["Positive"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|Positive Charge|C2825490|[qlco]|["Positive"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|Positive Finding|C1514241|[fndg]|["POSITIVE"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|Positive Lymph Node|C0746319|[fndg]|["Positive"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|Positive Number|C3812269|[qnco]|["Positive"-tx-1-"positive"-adj-0]|TX|56/8|
text_000N_173199|MMI|3.43|percent positive cells|C0439178|[qnco]|["% Positive"-tx-1-"positive"-adj-0]|TX|56/8|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|RG7112|C3659783|[orch,phsu]|["RG7112"-tx-1-"RG7112"-noun-0]|TX|6/6|
text_000N_173214|MMI|3.64|Cancer Therapeutic Procedure|C0920425|[topp]|["Cancer Therapy"-tx-1-"cancer therapy"-noun-0]|TX|24/14|
text_000N_173214|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|16/4|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Myasthenia Gravis|C0026896|[dsyn]|["MYASTHENIA GRAVIS"-tx-1-"myasthenia gravis"-noun-0]|TX|3/17|
text_000N_173230|MMI|5.18|Myasthenia Gravis, CTCAE|C4552647|[fndg]|["Myasthenia gravis"-tx-1-"myasthenia gravis"-noun-0]|TX|3/17|
text_000N_173230|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|21/15|
text_000N_173230|MMI|3.59|Osteoporosis|C0029456|[dsyn]|["OSTEOPOROSIS"-tx-1-"osteoporosis"-noun-0]|TX|37/12|
text_000N_173230|MMI|3.59|Osteoporosis, CTCAE 5.0|C4554622|[fndg]|["Osteoporosis"-tx-1-"osteoporosis"-noun-0]|TX|37/12|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Whole Exome Sequencing|C3640077|[mbrt]|["Exome Sequencing"-tx-1-"exome sequencing"-noun-0]|TX|3/16|
text_000N_173245|MMI|3.55|Efficient|C0442799|[qlco]|["Efficient"-tx-1-"efficient"-adj-0]|TX|20/9|
text_000N_173245|MMI|3.44|Germ-Line Mutation|C0206530|[genf]|["Mutations, Germline"-tx-1-"germline mutations"-noun-0]|TX|51/18|
text_000N_173245|MMI|3.42|Biological Detection Test|C5401329|[lbpr]|["DETECTION"-tx-1-"detection"-noun-0]|TX|38/9|
text_000N_173245|MMI|3.42|Detection|C1511790|[topp]|["Detection"-tx-1-"detection"-noun-0]|TX|38/9|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|7.49|CD99 gene|C1417157|[gngm]|["CD99"-tx-1-"CD99"-noun-0,"MIC2"-tx-1-"MIC2"-noun-0]|TX|3/4;19/4|
text_000N_173260|MMI|5.18|CD99 protein, human|C3887573|[aapp,imft]|["CD99"-tx-1-"CD99"-noun-0]|TX|3/4|
text_000N_173260|MMI|3.57|CD99 wt Allele|C3539707|[gngm]|["MIC2"-tx-1-"MIC2"-noun-0]|TX|19/4|
text_000N_173260|MMI|3.57|Encode (action)|C2700640|[acty]|["Encoded"-tx-1-"encoded"-verb-0]|TX|8/7|
text_000N_173260|MMI|3.57|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|24/4|
text_000N_173260|MMI|3.57|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|24/4|
text_000N_173260|MMI|3.57|encoding mental process|C0679058|[menp]|["encoded"-tx-1-"encoded"-verb-0]|TX|8/7|
<<<<< MMI
>>>>> MMI
text_000N_173276|AA|CNV|copy number variant|1|3|5|19|65:3
text_000N_173276|AA|CNVs|copy number variants|1|4|5|20|65:4
text_000N_173276|MMI|3.68|Copy Number Polymorphism|C1511518|[nusq]|["Copy Number variants"-tx-1-"copy number variants"-noun-0]|TX|43/20|
text_000N_173276|MMI|3.68|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|19/8|
text_000N_173276|MMI|3.56|Depletion|C0333668|[ftcn]|["Depleted"-tx-1-"depleted"-verb-0]|TX|28/8|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"autophagy"-noun-0]|TX|3/9|
text_000N_173291|MMI|3.56|Modulated|C0443264|[spco]|["Modulated"-tx-1-"modulated"-verb-0]|TX|13/9|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Corpus Callosum|C0010090|[bpoc]|["CORPUS CALLOSUM"-tx-1-"corpus callosum"-noun-0]|TX|3/15|
text_000N_97283|MMI|3.64|Mowat-Wilson syndrome|C1856113|[dsyn]|["MOWAT-WILSON SYNDROME"-tx-1-[77,111,119,97,116,8211,87,105,108,115,111,110,32,115,121,110,100,114,111,109,101]-noun-0]|TX|35/21|
text_000N_97283|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|19/8|
text_000N_97283|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|19/8|
<<<<< MMI
>>>>> MMI
text_000N_97301|AA|T-ALL|T-cell Acute Lymphoblastic Leukemia|3|5|9|35|68:5
text_000N_97301|MMI|3.74|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|C1961099|[neop]|["T-cell acute lymphoblastic leukaemia"-tx-1-"T-cell Acute Lymphoblastic Leukemia"-noun-0]|TX|31/35|
text_000N_97301|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|10/9|
text_000N_97301|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|10/9|
text_000N_97301|MMI|3.55|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|20/7|
text_000N_97301|MMI|3.55|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|20/7|
text_000N_97301|MMI|3.50|Notch|C1235660|[bsoj]|["Notch"-tx-1-"Notch"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|pazopanib|C1831796|[orch,phsu]|["PAZOPANIB"-tx-1-"pazopanib"-noun-0]|TX|4/9|
text_000N_97316|MMI|3.67|Von Hippel-Lindau Syndrome|C0019562|[dsyn]|["VON HIPPEL-LINDAU DISEASE"-tx-1-"von Hippel-Lindau disease"-noun-0]|TX|36/25|
text_000N_97316|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|17/4|
text_000N_97316|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_97316|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
<<<<< MMI
>>>>> MMI
text_000N_97331|AA|HDAC|histone deacetylase|1|4|3|19|25:4
text_000N_97331|MMI|5.18|Control function|C2587213|[ftcn]|["Control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|5.18|Scientific Control|C1882979|[cnce]|["Control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|5.18|Study Control|C4553389|[cnce]|["control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|58/2|
text_000N_97331|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|58/2|
text_000N_97331|MMI|5.18|True Control Status|C3274648|[qlco]|["Control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|5.18|control aspects|C0243148|[qlco]|["control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|5.18|control substance|C1550141|[sbst]|["Control"-tx-1-"control"-verb-0]|TX|61/7|
text_000N_97331|MMI|3.63|Metastatic Malignant Solid Neoplasm|C4287832|[neop]|["Metastatic Solid Tumor"-tx-1-"metastasis solid tumors"-noun-0]|TX|69/10,83/12|
text_000N_97331|MMI|3.57|Candidate|C4527371|[cnce]|["Candidate"-tx-1-"candidates"-noun-0]|TX|47/10|
text_000N_97331|MMI|3.52|Histone Deacetylase Inhibitors [MoA]|C2266853|[moft]|["Histone Deacetylase Inhibitors"-tx-1-"histone deacetylase inhibitors"-noun-0]|TX|4/19,31/10|
text_000N_97331|MMI|3.52|Histone deacetylase inhibitor|C1512474|[aapp,enzy,phsu]|["Histone Deacetylase Inhibitors"-tx-1-"histone deacetylase inhibitors"-noun-0]|TX|4/19,31/10|
text_000N_97331|MMI|3.46|Good|C0205170|[qlco]|["Good"-tx-1-"good"-adj-0]|TX|42/4|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|Blood Products Laboratory Testing|C3831328|[lbpr]|["Test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|5.18|Consent Type - Lumbar Puncture|C1548878|[hlca]|["Lumbar Puncture"-tx-1-"lumbar puncture"-noun-0]|TX|3/15|
text_000N_97347|MMI|5.18|Diagnostic lumbar puncture|C0553794|[diap]|["Lumbar puncture, NOS"-tx-1-"lumbar puncture"-noun-0]|TX|3/15|
text_000N_97347|MMI|5.18|First (number)|C0205435|[qnco]|["First"-tx-1-"first"-adj-0]|TX|23/5|
text_000N_97347|MMI|5.18|Firstly|C1279901|[qlco]|["First"-tx-1-"first"-adj-0]|TX|23/5|
text_000N_97347|MMI|5.18|Intracranial Hypertension|C0151740|[fndg]|["INTRACRANIAL PRESSURE, INCREASED"-tx-1-"increased intracranial pressure"-noun-0]|TX|77/31|
text_000N_97347|MMI|5.18|Laboratory Procedures|C0022885|[lbpr]|["Test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|5.18|Spinal Puncture|C0037943|[hlca]|["Lumbar Puncture"-tx-1-"lumbar puncture"-noun-0]|TX|3/15|
text_000N_97347|MMI|5.18|Test - temporal region|C4318744|[blor]|["Test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|5.18|Test Result|C0456984|[lbtr]|["Test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|5.18|Testing|C0039593|[ftcn]|["Test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|5.18|Tests (qualifier value)|C0392366|[inpr]|["test"-tx-1-"test"-verb-0]|TX|29/4|
text_000N_97347|MMI|3.57|Patients|C0030705|[podg]|["*^patient"-tx-1-"patient"-noun-0]|TX|64/7|
text_000N_97347|MMI|3.57|Performed|C0884358|[ftcn]|["PERFORMED"-tx-1-"performed"-verb-0]|TX|49/9|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|3.81|Adult Stem Cells|C1171322|[cell]|["adult Progenitor Cells"-tx-1-"adult progenitor cells"-noun-0]|TX|16/22|
text_000N_97362|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|39/9,53/9|
text_000N_97362|MMI|3.43|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|66/6|
text_000N_97362|MMI|3.43|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|66/6|
text_000N_97362|MMI|3.43|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|66/6|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.67|Clinical Trial, Phase II|C1096779|[inpr]|["Clinical Trial, Phase II"-tx-1-"phase II clinical trial"-noun-0]|TX|28/23|
text_000N_97378|MMI|3.67|Phase 2 Clinical Trials|C0282460|[resa]|["Phase II Clinical Trial"-tx-1-"phase II clinical trial"-noun-0]|TX|28/23|
text_000N_97378|MMI|3.55|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|16/6|
text_000N_97378|MMI|3.55|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|16/6|
text_000N_97378|MMI|3.50|HEPHL1 gene|C1539663|[gngm]|["ZP"-tx-1-"ZP"-noun-0]|TX|4/2|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Tivantinib|C2987651|[orch,phsu]|["TIVANTINIB"-tx-1-"tivantinib"-noun-0]|TX|3/10|
text_000N_47289|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47289|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47289|MMI|3.45|Liver carcinoma|C2239176|[neop]|["HEPATOCELLULAR CARCINOMA"-tx-1-"hepatocellular carcinoma"-noun-0]|TX|37/24|
text_000N_47289|MMI|3.43|Abnormally high|C1299351|[qlco]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|Fulfill|C1550543|[phpr]|["Met"-tx-1-"MET"-adj-0]|TX|28/3|
text_000N_47289|MMI|3.43|High|C0205250|[qlco]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|High (finding)|C5200928|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|High Level|C4321237|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|High Mitosis-Karyorrhexis Index|C3889660|[inpr]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|IPSS Risk Category High|C4522209|[inpr]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|IPSS-R Risk Category High|C5202936|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|MET - answer|C4760039|[ftcn]|["MET"-tx-1-"MET"-adj-0]|TX|28/3|
text_000N_47289|MMI|3.43|Met|C5551868|[fndg]|["Met"-tx-1-"MET"-adj-0]|TX|28/3|
text_000N_47289|MMI|3.43|Metabolic Equivalent of Task Unit|C4317104|[qnco]|["MET"-tx-1-"MET"-adj-0]|TX|28/3|
text_000N_47289|MMI|3.43|Methionine measurement|C0428210|[lbpr]|["MET"-tx-1-"MET"-adj-0]|TX|28/3|
text_000N_47289|MMI|3.43|Value Above Reference Range|C2700149|[inpr]|["HIGH"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_47289|MMI|3.43|high - ActExposureLevelCode|C3887512|[idcn]|["high"-tx-1-"high"-adj-0]|TX|32/4|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97394|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97394|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97394|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-adj-0]|TX|32/2|
text_000N_97394|MMI|3.55|Present|C0150312|[fndg]|["In"-tx-1-"in"-adj-0]|TX|32/2|
text_000N_97394|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|Within|C0332285|[spco]|["In"-tx-1-"in"-adj-0]|TX|32/2|
text_000N_97394|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-adj-0]|TX|35/9|
text_000N_97394|MMI|3.48|Obsessive compulsive disorder drugs|C4760315|[phsu]|["Obsessive compulsive disorder"-tx-1-"Obsessive-Compulsive Disorder"-noun-0]|TX|48/29|
text_000N_97394|MMI|3.48|Obsessive-Compulsive Disorder|C0028768|[mobd]|["OBSESSIVE COMPULSIVE DISORDER"-tx-1-"Obsessive-Compulsive Disorder"-noun-0]|TX|48/29|
text_000N_97394|MMI|3.46|Gamma Knife|C0182639|[medd]|["Gamma Knife"-tx-1-"gamma knife"-noun-0]|TX|20/11|
text_000N_97394|MMI|3.46|Gamma Knife Radiosurgery|C0086330|[topp]|["Gamma Knife"-tx-1-"gamma knife"-noun-0]|TX|20/11|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Contribution|C1880177|[acty]|["Contribute"-tx-1-"contribute"-verb-0]|TX|37/10|
text_000N_47274|MMI|5.18|Genus Homo|C1300203|[mamm]|["humans"-tx-1-"humans"-noun-0]|TX|87/6|
text_000N_47274|MMI|5.18|Homo sapiens|C0086418|[humn]|["Humans"-tx-1-"humans"-noun-0]|TX|87/6|
text_000N_47274|MMI|3.64|Variation (Genetics)|C0042333|[npop]|["Genetic Diversity"-tx-1-"genetic diversity"-noun-0]|TX|66/17|
text_000N_47274|MMI|3.60|Gene Expression|C0017262|[genf]|["expression gene"-tx-1-"genes expression"-noun-0]|TX|3/5,26/10|
text_000N_47274|MMI|3.60|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"genes expression"-noun-0]|TX|3/5,26/10|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.63|Approach (spatial)|C0449445|[spco]|["Approaches"-tx-1-"approaches"-noun-0]|TX|15/10|
text_000N_47334|MMI|3.63|Procedural approach|C1292724|[ftcn]|["Approaches"-tx-1-"approaches"-noun-0]|TX|15/10|
text_000N_47334|MMI|3.60|Injury of kidney|C0160420|[inpo]|["Injury of kidney"-tx-1-"of kidney injury"-noun-0]|TX|55/16|
text_000N_47334|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|26/10|
text_000N_47334|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.48|RNA Interference|C1136031|[genf]|["RNAi"-tx-1-"RNAi"-noun-0]|TX|10/4|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Entire fetus|C1305737|[anst]|["Foetus"-tx-1-"fetus"-noun-0]|TX|52/5|
text_000N_47363|MMI|5.18|Fetal Tissue|C0242291|[tisu]|["FETUS"-tx-1-"fetus"-noun-0]|TX|52/5|
text_000N_47363|MMI|5.18|Fetus|C0015965|[emst]|["Foetus"-tx-1-"fetus"-noun-0]|TX|52/5|
text_000N_47363|MMI|3.55|Poisoning|C0032343|[inpo]|["Poisoning"-tx-1-"poisoning"-noun-0]|TX|13/9|
text_000N_47363|MMI|3.55|Poisoning aspects|C0032344|[ftcn]|["poisoning"-tx-1-"poisoning"-noun-0]|TX|13/9|
text_000N_47363|MMI|3.45|Pregnant Women|C0033011|[popg]|["Pregnant woman"-tx-1-"pregnant woman"-noun-0]|TX|28/14|
text_000N_47363|MMI|3.43|Botulism|C0006057|[inpo]|["BOTULISM"-tx-1-"botulism"-noun-0]|TX|4/8|
text_000N_47363|MMI|3.43|Poisoning caused by Clostridium botulinum toxin|C5547149|[inpo]|["Botulism"-tx-1-"botulism"-noun-0]|TX|4/8|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|5.18|Acute Myeloid Leukemia Pathway|C2984331|[cnce]|["Acute myeloid leukemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|49/22|
text_000N_97409|MMI|5.18|Leukemia, Myelocytic, Acute|C0023467|[neop]|["Acute myeloid leukaemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|49/22|
text_000N_97409|MMI|5.18|NCI CTEP SDC Acute Myeloid Leukemia Sub-Category Terminology|C3541370|[inpr]|["Acute Myeloid Leukemia"-tx-1-"acute myeloid leukemia"-noun-0]|TX|49/22|
text_000N_97409|MMI|5.18|United States Food and Drug Administration|C0041714|[hcro]|["FDA"-tx-1-"FDA"-noun-0]|TX|20/3|
text_000N_97409|MMI|5.18|ivosidenib|C4682397|[orch,phsu]|["IVOSIDENIB"-tx-1-"ivosidenib"-noun-0]|TX|4/10|
text_000N_97409|MMI|3.59|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|24/8|
text_000N_97409|MMI|3.59|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-noun-0]|TX|37/3|
text_000N_97409|MMI|3.59|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-noun-0]|TX|37/3|
text_000N_97409|MMI|3.59|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-noun-0]|TX|37/3|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Chronic graft-versus-host disease|C0867389|[dsyn]|["Chronic"-tx-1-"chronic"-adj-0]|TX|49/7|
text_000N_47377|MMI|5.18|Fatigue|C0015672|[sosy]|["fatigues"-tx-1-"fatigues"-verb-0]|TX|57/8|
text_000N_47377|MMI|5.18|Fatigue Subordinate Domain|C4050243|[inpr]|["Fatigue"-tx-1-"fatigues"-verb-0]|TX|57/8|
text_000N_47377|MMI|5.18|Fatigue, CTCAE 5.0|C4554645|[fndg]|["Fatigue"-tx-1-"fatigues"-verb-0]|TX|57/8|
text_000N_47377|MMI|5.18|Feel Fatigue|C3463815|[inpr]|["Fatigue"-tx-1-"fatigues"-verb-0]|TX|57/8|
text_000N_47377|MMI|5.18|Genetic Syndrome Associated with Congenital Heart Defect|C5238705|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|66/8|
text_000N_47377|MMI|5.18|Syndrome|C0039082|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|66/8|
text_000N_47377|MMI|5.18|chronic|C0205191|[tmco]|["CHRONIC"-tx-1-"chronic"-adj-0]|TX|49/7|
text_000N_47377|MMI|5.18|rituximab|C0393022|[aapp,imft,phsu]|["RITUXIMAB"-tx-1-"rituximab"-noun-0]|TX|4/9|
text_000N_47377|MMI|3.68|November|C3828767|[tmco]|["November"-tx-2-"November"-noun-0]|TX|77/8|
text_000N_47377|MMI|3.57|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|19/10|
text_000N_47377|MMI|3.57|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.57|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|23/8|
text_000N_47304|MMI|5.18|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|23/8|
text_000N_47304|MMI|3.75|cell motility|C0007608|[celf]|["Cell Motility"-tx-1-"cell motility"-noun-0]|TX|35/13|
text_000N_47304|MMI|3.68|Acetylation|C0001038|[moft]|["Acetylation"-tx-1-"acetylation"-noun-0]|TX|11/11|
text_000N_47304|MMI|3.68|Protein Acetylation|C1521754|[moft]|["Acetylation"-tx-1-"acetylation"-noun-0]|TX|11/11|
text_000N_47304|MMI|3.50|Tubulin|C0041348|[aapp,bacs]|["Tubulin"-tx-1-"tubulin"-noun-0]|TX|3/7|
text_000N_47304|MMI|3.50|tubulin location|C2937342|[celc]|["tubulin"-tx-1-"tubulin"-noun-0]|TX|3/7|
text_000N_47304|MMI|3.48|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-adj-0]|TX|32/2|
text_000N_47304|MMI|3.48|Present|C0150312|[fndg]|["In"-tx-1-"in"-adj-0]|TX|32/2|
text_000N_47304|MMI|3.48|Within|C0332285|[spco]|["In"-tx-1-"in"-adj-0]|TX|32/2|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.98|Anatomical segmentation|C0441635|[spco]|["SEGMENT"-tx-1-"segmented"-verb-0]|TX|29/9|
text_000N_47450|MMI|3.63|Esthesia|C0036658|[ortf]|["sense"-tx-1-"sense"-noun-0]|TX|49/5|
text_000N_47450|MMI|3.63|Expression Negative|C5237010|[lbtr]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative|C0205160|[fndg]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative - answer|C3853545|[qlco]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative Charge|C2825491|[qlco]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative Finding|C1513916|[fndg]|["NEGATIVE"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative Lymph Node|C0678034|[fndg]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|Negative Number|C2825415|[qnco]|["Negative"-tx-1-"negative"-noun-0]|TX|40/8|
text_000N_47450|MMI|3.63|RNA|C0035668|[nnon]|["RNA"-tx-1-"RNA"-noun-0]|TX|55/3|
text_000N_47450|MMI|3.63|Ribonucleic Acid Measurement|C4319105|[lbpr]|["RNA"-tx-1-"RNA"-noun-0]|TX|55/3|
text_000N_47450|MMI|3.50|Paramyxovirus, NOS|C0318798|[virs]|["Paramyxovirus"-tx-1-"Paramyxovirus"-noun-0]|TX|7/13|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|minocycline|C0026187|[antb,orch]|["Minocyclin"-tx-1-"minocycline"-noun-0]|TX|7/11|
text_000N_43235|MMI|3.61|APP gene|C1364818|[gngm]|["Alzheimer disease"-tx-1-"Alzheimer disease"-noun-0]|TX|36/17|
text_000N_43235|MMI|3.61|Alzheimer's Disease|C0002395|[dsyn]|["ALZHEIMER DISEASE"-tx-1-"Alzheimer disease"-noun-0]|TX|36/17|
text_000N_43235|MMI|3.56|Epidermal cGVHD Score 2|C4761314|[fndg]|["Mild"-tx-1-"mild"-adj-0]|TX|31/4|
text_000N_43235|MMI|3.56|Mild (qualifier value)|C2945599|[qlco]|["MILD"-tx-1-"mild"-adj-0]|TX|31/4|
text_000N_43235|MMI|3.56|Mild Hallucination|C4722210|[fndg]|["Mild"-tx-1-"mild"-adj-0]|TX|31/4|
text_000N_43235|MMI|3.56|Mild dysplasia|C0334046|[comd]|["Mild"-tx-1-"mild"-adj-0]|TX|31/4|
text_000N_43235|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|22/4|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.59|Blood Glucose|C0005802|[orch]|["Blood sugar"-tx-1-"blood sugar"-noun-0]|TX|20/11|
text_000N_47392|MMI|3.59|Blood glucose measurement|C0392201|[lbpr]|["Blood Sugar"-tx-1-"blood sugar"-noun-0]|TX|20/11|
text_000N_47392|MMI|3.43|Body Site Modifier - Lower|C1548802|[blor]|["Lower"-tx-1-"lower"-adj-0]|TX|14/5|
text_000N_47392|MMI|3.43|Cucumber (Vegetable)|C0973457|[food]|["CUCUMBER"-tx-1-"cucumber"-noun-0]|TX|5/8|
text_000N_47392|MMI|3.43|Genus Cucumis|C0936045|[plnt]|["Cucumber, NOS"-tx-1-"cucumber"-noun-0]|TX|5/8|
text_000N_47392|MMI|3.43|Lower (action)|C2003888|[acty]|["Lower"-tx-1-"lower"-adj-0]|TX|14/5|
text_000N_47392|MMI|3.43|Lower - spatial qualifier|C0441994|[spco]|["LOWER"-tx-1-"lower"-adj-0]|TX|14/5|
text_000N_47392|MMI|3.43|cucumber extract|C3257523|[orch]|["cucumber"-tx-1-"cucumber"-noun-0]|TX|5/8|
text_000N_47392|MMI|3.43|diabetic|C0241863|[fndg]|["diabetics"-tx-1-"diabetics"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|POLD3 gene|C1427199|[gngm]|["POLD3"-tx-1-"POLD3"-noun-0]|TX|3/5|
text_000N_43303|MMI|5.18|POLD3 protein, human|C1448128|[aapp,enzy]|["POLD3"-tx-1-"POLD3"-noun-0]|TX|3/5|
text_000N_43303|MMI|3.57|Essential|C0205224|[qlco]|["Essential"-tx-1-"essential"-adj-0]|TX|9/9|
text_000N_43303|MMI|3.44|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|29/11|
text_000N_43303|MMI|3.44|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|29/11|
text_000N_43303|MMI|3.44|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|29/11|
text_000N_43303|MMI|3.44|House mice|C0025914|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|23/5|
text_000N_43303|MMI|3.44|Laboratory mice|C0025929|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|23/5|
text_000N_43303|MMI|3.44|Mus|C0026809|[mamm]|["MOUSE"-tx-1-"mouse"-noun-0]|TX|23/5|
text_000N_43303|MMI|3.44|Mus sp.|C1331371|[mamm]|["Mouse, NOS"-tx-1-"mouse"-noun-0]|TX|23/5|
text_000N_43303|MMI|3.44|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|29/11|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.78|Telomere Shortening|C1515263|[comd]|["Telomere Shortening"-tx-1-"telomere shortening"-noun-0]|TX|4/8,20/10|
text_000N_43331|MMI|3.63|Surgical shortening - action|C0441636|[topp]|["Shortening"-tx-1-"shortening"-noun-0]|TX|20/10|
text_000N_43331|MMI|3.59|Telomerase|C0087071|[aapp,enzy]|["Telomerase"-tx-1-"telomerase"-noun-0]|TX|46/10|
text_000N_43331|MMI|3.53|Telomere Length|C4331397|[qnco]|["Telomere Length"-tx-1-"telomere length"-noun-0]|TX|4/15|
text_000N_43331|MMI|3.48|Length|C1444754|[qnco]|["Length"-tx-1-"length"-noun-0]|TX|13/6|
text_000N_43331|MMI|3.48|Length of Trial|C1706316|[resa]|["LENGTH"-tx-1-"length"-noun-0]|TX|13/6|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Cardiolipins|C0007188|[orch]|["Cardiolipin"-tx-1-"cardiolipin"-noun-0]|TX|27/11|
text_000N_47320|MMI|5.18|Diphosphatidylglycerols|C0086164|[orch]|["Diphosphatidylglycerol"-tx-1-"diphosphatidylglycerol"-noun-0]|TX|3/22|
text_000N_47320|MMI|3.55|Phospholipid measurement|C0202177|[lbpr]|["Phospholipid"-tx-1-"phospholipid"-noun-0]|TX|42/12|
text_000N_47320|MMI|3.55|phospholipids|C0031676|[bacs,orch]|["Phospholipid"-tx-1-"phospholipid"-noun-0]|TX|42/12|
text_000N_47320|MMI|3.45|Mitochondrial Membranes|C0596952|[celc]|["Mitochondrial Membranes"-tx-1-"mitochondrial membranes"-noun-0]|TX|62/23|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Metabolic Syndrome X|C0524620|[dsyn]|["METABOLIC SYNDROME"-tx-1-"metabolic syndrome"-noun-0]|TX|3/18|
text_000N_47406|MMI|3.64|Cardiovascular Diseases|C0007222|[dsyn]|["Cardiovascular Disease"-tx-1-"cardiovascular disease"-noun-0]|TX|35/22|
text_000N_47406|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|22/7|
text_000N_47406|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|22/7|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|Valproate Measurement|C5553952|[lbpr]|["Valproic Acid"-tx-1-"valproic acid"-noun-0]|TX|4/13|
text_000N_47420|MMI|5.18|valproic acid|C0042291|[orch,phsu]|["VALPROIC ACID"-tx-1-"valproic acid"-noun-0]|TX|4/13|
text_000N_47420|MMI|3.55|ACTG1 wt Allele|C4723674|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|18/3|
text_000N_47420|MMI|3.55|ACTG2 wt Allele|C1704930|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|18/3|
text_000N_47420|MMI|3.55|Activator|C4743777|[bacs]|["ACTIVATOR"-tx-1-"activator"-noun-0]|TX|28/9|
text_000N_47420|MMI|3.55|Asthma Control Test Questionnaire|C4048375|[inpr]|["ACT"-tx-1-"act"-verb-0]|TX|18/3|
text_000N_47420|MMI|3.55|PRKAA1 wt Allele|C3890397|[gngm]|["AMPK"-tx-1-"AMPK"-noun-0]|TX|41/4|
text_000N_47420|MMI|3.55|SERPINA3 protein, human|C1869853|[aapp,bacs]|["ACT"-tx-1-"act"-verb-0]|TX|18/3|
text_000N_47420|MMI|3.55|SERPINA3 wt Allele|C3890007|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|18/3|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|3.68|FBP1 gene|C1414544|[gngm]|["FBP1"-tx-1-"fbp1"-noun-0]|TX|9/4|
text_000N_43275|MMI|3.68|Fructose-1,6-Bisphosphatase 1|C3889472|[aapp,enzy]|["FBP1"-tx-1-"fbp1"-noun-0]|TX|9/4|
text_000N_43275|MMI|3.56|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|14/8|
text_000N_43275|MMI|3.56|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|14/8|
text_000N_43275|MMI|3.56|Starvation|C0038187|[fndg]|["STARVATION"-tx-1-"starvation"-noun-0]|TX|34/10|
text_000N_43275|MMI|3.56|Stress|C0038435|[fndg]|["Stress"-tx-1-"stress"-noun-0]|TX|45/6|
text_000N_43275|MMI|3.56|W stress|C1718621|[clna]|["Stress"-tx-1-"stress"-noun-0]|TX|45/6|
text_000N_43275|MMI|3.56|glucose|C0017725|[bacs,orch,phsu]|["GLUCOSE"-tx-1-"glucose"-noun-0]|TX|26/7|
text_000N_43275|MMI|3.50|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.50|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.50|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.50|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.50|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|3/5|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|GPX4 gene|C1415278|[gngm]|["PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE"-tx-1-"phospholipid hydroperoxide glutathione peroxidase"-noun-0]|TX|3/49|
text_000N_43386|MMI|5.18|Selenoproteins|C0074302|[aapp,bacs]|["Selenoprotein"-tx-1-"selenoprotein"-noun-0]|TX|55/13|
text_000N_43386|MMI|5.18|phospholipid-hydroperoxide glutathione peroxidase|C0084035|[aapp,enzy]|["Phospholipid-hydroperoxide glutathione peroxidase"-tx-1-"phospholipid hydroperoxide glutathione peroxidase"-noun-0]|TX|3/49|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|3.64|European Medicines Agency|C4553329|[orgt]|["European Medicines Agency"-tx-1-"European Medicines Agency"-noun-0]|TX|36/25|
text_000N_40839|MMI|3.55|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|20/8|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Glioblastoma Multiforme Pathway|C2984291|[ftcn]|["Glioma"-tx-1-"glioma"-noun-0]|TX|59/6|
text_000N_43358|MMI|5.18|Glioma|C0017638|[neop]|["GLIOMA"-tx-1-"glioma"-noun-0]|TX|59/6|
text_000N_43358|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.47|Histone H3.3|C0086412|[aapp,bacs]|["Histone H3.3"-tx-1-"Histone H3.3"-noun-0]|TX|32/12|
text_000N_43358|MMI|3.47|Histone H3.3, human|C5441588|[aapp,bacs]|["Histone H3.3"-tx-1-"Histone H3.3"-noun-0]|TX|32/12|
text_000N_43358|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43358|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43358|MMI|3.42|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|45/9|
text_000N_43358|MMI|3.42|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|45/9|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_47349|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_47349|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_47349|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|12/7|
text_000N_47349|MMI|3.68|Urban Cluster|C5552707|[geoa]|["UC"-tx-1-"Uc"-noun-0]|TX|5/2|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Small Molecule|C1328819|[orch]|["Small Molecule"-tx-1-"small molecule"-noun-0]|TX|17/14|
text_000N_40913|MMI|5.18|eptinezumab|C4694272|[aapp,imft,phsu]|["EPTINEZUMAB"-tx-1-"eptinezumab"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_40941|AA|CRC|colorectal cancer|1|3|3|17|58:3
text_000N_40941|MMI|3.58|Tumor Progression|C0178874|[neop]|["Tumour progression"-tx-1-"tumor progression"-noun-0]|TX|18/17|
text_000N_40941|MMI|3.44|Colorectal Cancer Pathway|C2984278|[cnce]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|39/17|
text_000N_40941|MMI|3.44|Colorectal Carcinoma|C0009402|[neop]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|39/17|
text_000N_40941|MMI|3.44|Malignant neoplasm of colon and/or rectum|C4722085|[neop]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|39/17|
text_000N_40941|MMI|3.44|NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|C3542412|[inpr]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|39/17|
text_000N_40941|MMI|3.42|TIAM1 gene|C0812248|[gngm]|["TIAM1"-tx-1-"TIAM1"-noun-0]|TX|3/5|
text_000N_40941|MMI|3.42|TIAM1 protein, human|C1679363|[aapp,bacs]|["TIAM1"-tx-1-"TIAM1"-noun-0]|TX|3/5|
text_000N_40941|MMI|3.42|favor|C0309049|[orch,phsu,vita]|["favoring"-tx-1-"favoring"-adj-0]|TX|9/8|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Gene Therapy Agent|C1517496|[phsu]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|4/12|
text_000N_40972|MMI|5.18|Hearing|C0018767|[phsf]|["Auditory function"-tx-1-"auditory function"-noun-0]|TX|25/17|
text_000N_40972|MMI|5.18|gene therapy|C0017296|[topp]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.58|Growth Phase|C4484175|[fndg]|["Growth Phase"-tx-1-"growth phase"-noun-0]|TX|57/12|
text_000N_40999|MMI|3.56|Regulation|C0851285|[gora]|["Regulation"-tx-1-"regulation"-noun-0]|TX|7/10|
text_000N_40999|MMI|3.56|Regulation of biological process|C1327622|[biof]|["Regulation"-tx-1-"regulation"-noun-0]|TX|7/10|
text_000N_40999|MMI|3.46|vsr endonuclease|C0148622|[aapp,enzy]|["vsr endonuclease"-tx-1-"Vsr endonuclease"-noun-0]|TX|21/16|
text_000N_40999|MMI|3.44|Independent of|C0332291|[ftcn]|["Independent of"-tx-1-"independent of"-prep-0]|TX|38/14|
text_000N_40999|MMI|3.42|Bacteria|C0004611|[bact]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|73/8|
text_000N_40999|MMI|3.42|Bacteria present|C4038931|[fndg]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|73/8|
text_000N_40999|MMI|3.42|Percent of Bacteria|C2347473|[qnco]|["% Bacteria"-tx-1-"bacteria"-noun-0]|TX|73/8|
text_000N_40999|MMI|3.42|bacteria aspects|C1510439|[ftcn]|["bacteria"-tx-1-"bacteria"-noun-0]|TX|73/8|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.68|AQP1 gene|C1412491|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|18/2|
text_000N_173104|MMI|3.68|AQP1 wt Allele|C5551158|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|18/2|
text_000N_173104|MMI|3.68|Colombia|C3245499|[geoa]|["CO"-tx-1-"co"-verb-0]|TX|18/2|
text_000N_173104|MMI|3.68|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|12/5|
text_000N_173104|MMI|3.68|Regulation|C0851285|[gora]|["Regulated"-tx-1-"regulated"-verb-0]|TX|21/9|
text_000N_173104|MMI|3.50|Paralogous Gene|C1709461|[gngm]|["Paralog"-tx-1-"paralog"-noun-0]|TX|4/7|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Proteomics|C0872252|[bmod]|["Proteomics"-tx-1-"proteomics"-noun-0]|TX|4/10|
text_000N_173087|MMI|3.58|Pick Disease of the Brain|C0236642|[dsyn]|["Picks Disease"-tx-1-"Pick's disease"-noun-0]|TX|41/14|
text_000N_173087|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|20/4,38/2|
text_000N_173087|MMI|3.55|Off Study|C1518546|[qlco]|["Study"-tx-1-"study"-noun-0]|TX|32/5|
text_000N_173087|MMI|3.55|Room of building - Study|C0557651|[mnob]|["Study"-tx-1-"study"-noun-0]|TX|32/5|
text_000N_173087|MMI|3.55|Study|C2603343|[resa]|["Study"-tx-1-"study"-noun-0]|TX|32/5|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Activation action|C1879547|[acty]|["Activate"-tx-1-"activate"-verb-0]|TX|17/8|
text_000N_40886|MMI|5.18|activate - Data Operation|C3853838|[ftcn]|["activate"-tx-1-"activate"-verb-0]|TX|17/8|
text_000N_40886|MMI|5.18|activate biological process|C1515877|[ftcn]|["Activate"-tx-1-"activate"-verb-0]|TX|17/8|
text_000N_40886|MMI|5.18|gepotidacin|C4309999|[orch,phsu]|["GEPOTIDACIN"-tx-1-"gepotidacin"-noun-0]|TX|5/11|
text_000N_40886|MMI|3.68|Topoisomerase|C1336767|[aapp,enzy]|["Topoisomerase"-tx-1-"topoisomerase"-noun-0]|TX|36/13|
text_000N_40886|MMI|3.68|topoisomerase activity|C2257142|[genf]|["topoisomerase"-tx-1-"topoisomerase"-noun-0]|TX|36/13|
text_000N_40886|MMI|3.50|Bacterial|C0521009|[qlco]|["Bacterial"-tx-1-"bacterial"-adj-0]|TX|26/9|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Somatic mutation|C0544886|[comd]|["somatic mutations"-tx-1-"somatic mutations"-noun-0]|TX|4/17|
text_000N_173120|MMI|3.61|nuclear periphery|C2612504|[celc]|["nuclear periphery"-tx-1-"nuclear periphery"-noun-0]|TX|45/17|
text_000N_173120|MMI|3.53|Gene Physical Location|C1517493|[spco]|["position"-tx-1-"positioned"-verb-0]|TX|22/10|
text_000N_173120|MMI|3.53|Position of phenotypic abnormality|C4019252|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|22/10|
text_000N_173120|MMI|3.53|Positioning Attribute|C0733755|[spco]|["Position"-tx-1-"positioned"-verb-0]|TX|22/10|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|5.18|Changing|C0392747|[ftcn]|["Altered"-tx-1-"altered"-verb-0]|TX|48/7|
text_000N_97424|MMI|5.18|Coronary Arteriosclerosis|C0010054|[dsyn]|["coronary artery disease"-tx-1-"coronary artery disease"-noun-0]|TX|71/23|
text_000N_97424|MMI|5.18|Coronary Artery Disease|C1956346|[dsyn]|["CORONARY ARTERY DISEASE"-tx-1-"coronary artery disease"-noun-0]|TX|71/23|
text_000N_97424|MMI|5.18|Metabolism|C0025519|[orgf]|["Metabolism"-tx-1-"metabolism"-noun-0]|TX|56/10|
text_000N_97424|MMI|5.18|metabolic aspects|C0025520|[ftcn]|["metabolism"-tx-1-"metabolism"-noun-0]|TX|56/10|
text_000N_97424|MMI|3.56|CDISC Relationship Class|C3540605|[inpr]|["RELATIONSHIP"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97424|MMI|3.56|Concept Relationship|C1705630|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97424|MMI|3.56|Object Relationship|C1706279|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97424|MMI|3.56|Relationships|C0439849|[qlco]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97424|MMI|3.46|Thyroid Hormones|C0040135|[horm]|["Thyroid Hormone"-tx-1-"thyroid hormone"-noun-0]|TX|32/15|
text_000N_97424|MMI|3.46|Thyroid hormone (disposition)|C4522017|[qlco]|["Thyroid hormone"-tx-1-"thyroid hormone"-noun-0]|TX|32/15|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|saracatinib|C2828242|[orch,phsu]|["SARACATINIB"-tx-1-"saracatinib"-noun-0]|TX|4/11|
text_000N_173230|MMI|3.59|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|52/19|
text_000N_173230|MMI|3.59|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|52/19|
text_000N_173230|MMI|3.57|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|22/10|
text_000N_173230|MMI|3.57|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.57|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|38/9|
text_000N_173230|MMI|3.43|November|C3828767|[tmco]|["November"-tx-1-"November"-noun-0]|TX|75/8|
text_000N_173230|MMI|3.43|Preposition For|C0521125|[qlco]|["For"-tx-1-"for"-prep-0]|TX|48/3|
text_000N_173230|MMI|3.43|WWOX wt Allele|C4321252|[gngm]|["FOR"-tx-1-"for"-prep-0]|TX|48/3|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Vivotif|C0731026|[imft,phsu]|["Vivotif"-tx-1-"vivotif"-noun-0]|TX|4/7|
text_000N_173151|MMI|3.59|Europe|C0015176|[geoa]|["Europe"-tx-1-"Europe"-noun-0]|TX|24/6|
text_000N_173151|MMI|3.59|License|C0023636|[rnlw]|["Licensed"-tx-1-"licensed"-verb-0]|TX|12/8|
text_000N_173151|MMI|3.59|Licensed - Location characteristic ID|C1548573|[inpr]|["Licensed"-tx-1-"licensed"-verb-0]|TX|12/8|
text_000N_173151|MMI|3.59|Licensed as Wholesale Drug Distributor or Third Party Logistics Provider|C3889832|[qlco]|["Licensed"-tx-1-"licensed"-verb-0]|TX|12/8|
text_000N_173151|MMI|3.59|Licensing|C0242373|[gora]|["licensed"-tx-1-"licensed"-verb-0]|TX|12/8|
text_000N_173151|MMI|3.55|Duration (temporal concept)|C0449238|[tmco]|["TIME"-tx-1-"time"-noun-0]|TX|54/4|
text_000N_173151|MMI|3.55|Male external urethral sphincter|C0815353|[bpoc]|["US"-tx-1-"US"-pron-0]|TX|39/2|
text_000N_173151|MMI|3.55|Microsiemens|C4722409|[qnco]|["uS"-tx-1-"US"-pron-0]|TX|39/2|
text_000N_173151|MMI|3.55|S-Adenosylmethionine Measurement|C5400560|[lbpr]|["SAMe"-tx-1-"same"-adj-0]|TX|49/4|
text_000N_173151|MMI|3.55|Same|C0445247|[qlco]|["SAME"-tx-1-"same"-adj-0]|TX|49/4|
text_000N_173151|MMI|3.55|Time|C0040223|[tmco]|["TIME"-tx-1-"time"-noun-0]|TX|54/4|
text_000N_173151|MMI|3.55|Time (foundation metadata concept)|C3541383|[inpr]|["Time"-tx-1-"time"-noun-0]|TX|54/4|
text_000N_173151|MMI|3.55|Ultrasound Study File|C3889164|[inpr]|["US"-tx-1-"US"-pron-0]|TX|39/2|
<<<<< MMI
>>>>> MMI
text_000N_97440|MMI|5.18|nimotuzumab|C1570308|[aapp,imft,phsu]|["NIMOTUZUMAB"-tx-1-"nimotuzumab"-noun-0]|TX|5/11|
text_000N_97440|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_97440|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_97440|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97440|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97440|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97440|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97440|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|50/8|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|ALPHA-N-ACETYLGALACTOSAMINIDASE|C0051436|[aapp,enzy]|["ALPHA-N-ACETYLGALACTOSAMINIDASE"-tx-1-"alpha-N-acetylgalactosaminidase"-noun-0]|TX|49/31|
text_000N_173167|MMI|5.18|Alpha-N-acetylgalactosaminidase deficiency type 2|C1836522|[dsyn]|["KANZAKI DISEASE"-tx-1-"Kanzaki disease"-noun-0]|TX|3/15|
text_000N_173167|MMI|5.18|NAGA gene|C1417592|[gngm]|["N-acetylgalactosaminidase, alpha-"-tx-1-"alpha-N-acetylgalactosaminidase"-noun-0]|TX|49/31|
text_000N_173167|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|19/15|
text_000N_173167|MMI|3.59|Deficiency|C0011155|[ftcn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.59|Malnutrition|C0162429|[dsyn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.59|deficiency aspects|C1623416|[qlco]|["deficiency"-tx-1-"deficiency"-noun-0]|TX|35/10|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|gabapentin|C0060926|[orch,phsu]|["GABAPENTIN"-tx-1-"gabapentin"-noun-0]|TX|3/10|
text_000N_47435|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47435|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47435|MMI|3.50|Chronic pelvic pain of female|C0404484|[sosy]|["Chronic pelvic pain"-tx-1-"chronic pelvic pain"-noun-0]|TX|28/19|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Tuberous Sclerosis|C0041341|[neop]|["Sclerosis, Tuberous"-tx-1-"Tuberous Sclerosis"-noun-0]|TX|43/18|
text_000N_173214|MMI|3.56|Evidence|C3887511|[idcn]|["Evidence"-tx-1-"evidence"-noun-0]|TX|9/8|
text_000N_173214|MMI|3.46|Somatic mosaicism|C1866227|[fndg]|["Somatic mosaicism"-tx-1-"somatic mosaicism"-noun-0]|TX|22/17|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|3.81|Increased risk for lymphoma|C5542895|[fndg]|["Increased risk for lymphoma"-tx-1-"increased risk for lymphoma"-noun-0]|TX|38/27|
text_000N_173183|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|4/8|
text_000N_173183|MMI|3.48|Sjogren's Syndrome|C1527336|[dsyn]|["Sj√∂gren's syndrome"-tx-1-"Sjogren syndrome"-noun-0]|TX|18/16|
text_000N_173183|MMI|3.43|AT genotype|C4554368|[fndg]|["AT"-tx-1-"at"-prep-0]|TX|35/2|
text_000N_173183|MMI|3.43|Apnea Time|C4764186|[qnco]|["AT"-tx-1-"at"-prep-0]|TX|35/2|
text_000N_173183|MMI|3.43|At|C1516077|[spco]|["At"-tx-1-"at"-prep-0]|TX|35/2|
text_000N_173183|MMI|3.43|GATM wt Allele|C4049625|[gngm]|["AT"-tx-1-"at"-prep-0]|TX|35/2|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.57|Disease|C0012634|[dsyn]|["Diseases"-tx-1-"diseases"-noun-0]|TX|57/8|
text_000N_173245|MMI|3.57|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|51/5|
text_000N_173245|MMI|3.57|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|42/5|
text_000N_173245|MMI|3.56|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|5/9|
text_000N_173245|MMI|3.56|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|5/9|
text_000N_173245|MMI|3.46|Polycomb-Group Proteins|C1623167|[aapp,bacs]|["Polycomb-Group"-tx-1-"Polycomb group"-noun-0]|TX|22/14|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|Bypass|C0741847|[topp]|["Bypass"-tx-1-"bypass"-verb-0]|TX|14/6|
text_000N_173136|MMI|5.18|Codon (nucleotide sequence)|C0009221|[nusq]|["Codon"-tx-1-"codon"-noun-0]|TX|8/5|
text_000N_173136|MMI|5.18|Codon Genus|C1095825|[plnt]|["Codon"-tx-1-"codon"-noun-0]|TX|8/5|
text_000N_173136|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|21/8|
text_000N_173136|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|21/8|
text_000N_173136|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|21/8|
text_000N_173136|MMI|5.18|Stop (Instruction Imperative)|C1947925|[acty]|["Stop"-tx-1-"stop"-verb-0]|TX|3/4|
text_000N_173136|MMI|5.18|Stop (qualifier value)|C2746065|[tmco]|["Stop"-tx-1-"stop"-verb-0]|TX|3/4|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.58|Crystal Structure|C0444626|[chvs]|["Crystal Structure"-tx-1-"crystal structure"-noun-0]|TX|7/17|
text_000N_173260|MMI|3.42|PIM1 gene|C0812214|[gngm]|["PIM"-tx-1-"Pim"-noun-0]|TX|28/3|
text_000N_173260|MMI|3.42|PIM1 wt Allele|C1709403|[gngm]|["PIM"-tx-1-"Pim"-noun-0]|TX|28/3|
text_000N_173260|MMI|3.42|Availability of|C0470187|[ftcn]|["Availability of"-tx-1-"of available"-adj-0]|TX|25/2,34/9|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|25/2|
text_000N_173276|MMI|5.18|Thinking, function|C0039869|[menp]|["Thought"-tx-1-"thought"-verb-0]|TX|17/7|
text_000N_173276|MMI|5.18|Thought|C4319827|[idcn]|["Thought"-tx-1-"thought"-verb-0]|TX|17/7|
text_000N_173276|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|25/2|
text_000N_173276|MMI|3.68|AS virus|C0319157|[virs]|["virus"-tx-1-"virus"-noun-0]|TX|11/5|
text_000N_173276|MMI|3.68|Virus|C0042776|[virs]|["VIRUS"-tx-1-"virus"-noun-0]|TX|11/5|
text_000N_173276|MMI|3.54|Emotional Strain|C2987481|[menp]|["Strain"-tx-1-"strain"-noun-0]|TX|41/6|
text_000N_173276|MMI|3.54|Microbiology subtype strains|C0456178|[qlco]|["strain"-tx-1-"strain"-noun-0]|TX|41/6|
text_000N_173276|MMI|3.54|Muscle strain|C0080194|[inpo]|["Strain"-tx-1-"strain"-noun-0]|TX|41/6|
text_000N_173276|MMI|3.54|Organism Strain|C1518614|[orgm]|["STRAIN"-tx-1-"strain"-noun-0]|TX|41/6|
text_000N_173276|MMI|3.46|Coronavirus, Feline|C0936087|[virs]|["Feline Enteric Coronavirus"-tx-1-"Feline enteric Coronavirus"-noun-0]|TX|56/26|
text_000N_173276|MMI|3.42|Gene Variant Negative|C5444830|[lbtr]|["Mutated"-tx-1-"mutated"-adj-0]|TX|33/7|
text_000N_173276|MMI|3.42|Gene Variant Positive|C5444829|[lbtr]|["Mutated"-tx-1-"mutated"-adj-0]|TX|33/7|
text_000N_173276|MMI|3.42|Mutation Abnormality|C1705285|[comd]|["Mutated"-tx-1-"mutated"-adj-0]|TX|33/7|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"autophagy"-noun-0]|TX|31/9|
text_000N_173291|MMI|3.68|FRAP1 protein, human|C1307407|[aapp,enzy]|["mTOR"-tx-1-"mTOR"-noun-0]|TX|17/4|
text_000N_173291|MMI|3.68|MTOR gene|C1414805|[gngm]|["MTOR"-tx-1-"mTOR"-noun-0]|TX|17/4|
text_000N_173291|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|9/7|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Blood - brain barrier anatomy|C0005854|[bpoc]|["Blood-Brain Barrier"-tx-1-"blood-brain barrier"-noun-0]|TX|38/19|
text_000N_97283|MMI|5.18|Blood - brain barrier function|C1305865|[ortf]|["Blood-brain barrier"-tx-1-"blood-brain barrier"-noun-0]|TX|38/19|
text_000N_97283|MMI|5.18|Loosening|C0333050|[ftcn]|["loosen"-tx-1-"loosen"-verb-0]|TX|27/6|
text_000N_97283|MMI|3.59|Extract (substance)|C2828366|[sbst]|["Extract"-tx-1-"extracts"-noun-0]|TX|18/8|
text_000N_97283|MMI|3.53|Crocus sativus|C0946614|[plnt]|["Crocus sativus"-tx-1-"Crocus sativus"-noun-0]|TX|3/14|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|3.68|Afrezza|C3834216|[aapp,phsu]|["Afrezza"-tx-1-"Afrezza"-noun-0]|TX|13/7|
text_000N_97316|MMI|3.57|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|26/8|
text_000N_97316|MMI|3.57|United States Food and Drug Administration|C0041714|[hcro]|["FDA"-tx-1-"FDA"-noun-0]|TX|42/3|
text_000N_97316|MMI|3.50|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|8/4|
text_000N_97316|MMI|3.50|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|8/4|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|Assisted (qualifier value)|C1269765|[qlco]|["Help"-tx-1-"help"-verb-0]|TX|32/4|
text_000N_97362|MMI|5.18|BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20|C4759928|[fndg]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|44/7|
text_000N_97362|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Help document|C1552861|[inpr]|["help"-tx-1-"help"-verb-0]|TX|32/4|
text_000N_97362|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Obesity|C0028754|[dsyn]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|44/7|
text_000N_97362|MMI|5.18|Obesity, CTCAE|C1963185|[fndg]|["Obesity"-tx-1-"obesity"-noun-0]|TX|44/7|
text_000N_97362|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|54/3|
text_000N_97362|MMI|3.59|glucoraphanin|C0768176|[orch]|["Glucoraphanin"-tx-1-"Glucoraphanin"-noun-0]|TX|0/13|
text_000N_97362|MMI|3.45|Brassica oleracea|C0330498|[plnt]|["Broccoli"-tx-1-"broccoli"-noun-0]|TX|19/8|
text_000N_97362|MMI|3.45|Broccoli - dietary|C0330499|[food]|["BROCCOLI"-tx-1-"broccoli"-noun-0]|TX|19/8|
text_000N_97362|MMI|3.45|broccoli preparation|C1095887|[orch,phsu]|["broccoli"-tx-1-"broccoli"-noun-0]|TX|19/8|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Low T3 Syndrome|C0024043|[dsyn]|["Low T3 Syndrome"-tx-1-"low T3 syndrome"-noun-0]|TX|3/15|
text_000N_173199|MMI|5.18|cardiac patient|C0741926|[podg]|["cardiac patients"-tx-1-"cardiac patients"-noun-0]|TX|44/16|
text_000N_173199|MMI|3.57|Abnormally high|C1299351|[qlco]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|Brain natriuretic peptide measurement|C1095989|[lbpr]|["BNP"-tx-1-"BNP"-noun-0]|TX|37/3|
text_000N_173199|MMI|3.57|High|C0205250|[qlco]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|High (finding)|C5200928|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|High Level|C4321237|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|High Mitosis-Karyorrhexis Index|C3889660|[inpr]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|IPSS Risk Category High|C4522209|[inpr]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|IPSS-R Risk Category High|C5202936|[fndg]|["High"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|NPPB gene|C1417808|[gngm]|["BNP"-tx-1-"BNP"-noun-0]|TX|37/3|
text_000N_173199|MMI|3.57|NPPB wt Allele|C2982014|[gngm]|["BNP"-tx-1-"BNP"-noun-0]|TX|37/3|
text_000N_173199|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|19/7|
text_000N_173199|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|19/7|
text_000N_173199|MMI|3.57|Value Above Reference Range|C2700149|[inpr]|["HIGH"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|high - ActExposureLevelCode|C3887512|[idcn]|["high"-tx-1-"high"-adj-0]|TX|32/4|
text_000N_173199|MMI|3.57|nesiritide|C0054015|[aapp,horm,phsu]|["BNP"-tx-1-"BNP"-noun-0]|TX|37/3|
<<<<< MMI
>>>>> MMI
text_000N_97456|MMI|3.60|Therapeutic|C0302350|[ftcn]|["Therapeutic"-tx-1-"therapeutic"-noun-0]|TX|25/11|
text_000N_97456|MMI|3.60|Therapeutic procedure|C0087111|[topp]|["Therapeutic"-tx-1-"therapeutic"-noun-0]|TX|25/11|
text_000N_97456|MMI|3.57|Target|C1521840|[ftcn]|["Target"-tx-1-"targets"-noun-0]|TX|37/7|
text_000N_97456|MMI|3.57|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"targets"-noun-0]|TX|37/7|
text_000N_97456|MMI|3.46|Good|C0205170|[qlco]|["Good"-tx-1-"good"-adj-0]|TX|9/4|
text_000N_97456|MMI|3.46|Immunoreceptor Tyrosine-Based Activation Motif|C1521889|[amas]|["TAM"-tx-1-"TAMs"-noun-0]|TX|4/4|
text_000N_97456|MMI|3.46|MYELOPROLIFERATIVE SYNDROME, TRANSIENT|C1834582|[neop]|["TAM"-tx-1-"TAMs"-noun-0]|TX|4/4|
text_000N_97456|MMI|3.46|Tamil language|C0039285|[lang]|["TAM"-tx-1-"TAMs"-noun-0]|TX|4/4|
text_000N_97456|MMI|3.46|Tubular Aggregate Myopathy|C0410207|[dsyn]|["TAM"-tx-1-"TAMs"-noun-0]|TX|4/4|
text_000N_97456|MMI|3.46|tamoxifen|C0039286|[orch,phsu]|["TAM"-tx-1-"TAMs"-noun-0]|TX|4/4|
<<<<< MMI
>>>>> MMI
text_000N_97471|MMI|5.18|dupilumab|C3660996|[aapp,imft,phsu]|["DUPILUMAB"-tx-1-"Dupilumab"-noun-0]|TX|3/9|
text_000N_97471|MMI|3.59|Dermatitis, Atopic|C0011615|[dsyn]|["ATOPIC DERMATITIS"-tx-1-"atopic dermatitis"-noun-0]|TX|35/17|
text_000N_97471|MMI|3.59|Eczema|C0013595|[dsyn]|["Atopic Dermatitis"-tx-1-"atopic dermatitis"-noun-0]|TX|35/17|
text_000N_97471|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|13/4,32/2|
text_000N_97471|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
text_000N_97471|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|22/9|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.68|Biological Markers|C0005516|[clna]|["marker"-tx-1-"marker"-noun-0]|TX|20/6|
text_000N_97378|MMI|3.68|Marker|C5445211|[qlco]|["Marker"-tx-1-"marker"-noun-0]|TX|20/6|
<<<<< MMI
>>>>> MMI
text_000N_47334|AA|TAD|topologically associated domain|1|3|5|31|96:3
text_000N_47334|AA|TADs|topologically associated domains|1|4|5|32|96:4
text_000N_47334|MMI|10.42|Saccharomyces cerevisiae|C0036025|[fngs]|["Saccharomyces cerevisae"-tx-1-"Saccharomyces cerevisiae"-noun-0,"yeast"-tx-1-"yeast"-noun-0]|TX|14/24;7/5|
text_000N_47334|MMI|5.18|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_47334|MMI|5.18|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|40/6|
text_000N_47334|MMI|5.18|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|40/6|
text_000N_47334|MMI|5.18|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_47334|MMI|5.18|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_47334|MMI|5.18|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|7/5|
text_000N_47334|MMI|3.56|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-noun-0]|TX|76/10|
text_000N_47334|MMI|3.56|Organized|C1300196|[ftcn]|["Organized"-tx-1-"organized"-verb-0]|TX|47/9|
text_000N_47334|MMI|3.53|Concept model domain|C3541951|[inpr]|["Domain"-tx-1-"domains"-noun-0]|TX|87/7|
text_000N_47334|MMI|3.53|Domain (area of knowledge)|C1880389|[ftcn]|["Domain"-tx-1-"domains"-noun-0]|TX|87/7|
text_000N_47334|MMI|3.53|Superkingdom (taxonomic category)|C1883221|[cnce]|["Domain"-tx-1-"domains"-noun-0]|TX|87/7|
<<<<< MMI
>>>>> MMI
text_000N_97487|MMI|5.18|hesperidin|C0019392|[orch,phsu,vita]|["HESPERIDIN"-tx-1-"Hesperidin"-noun-0]|TX|4/10|
text_000N_97487|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_97487|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_97487|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|19/4|
text_000N_97487|MMI|3.45|Neuroprotective Agents|C0242912|[phsu]|["Neuroprotective Agent"-tx-1-"Neuroprotective Agent"-noun-0]|TX|29/21|
text_000N_97487|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|15/3|
text_000N_97487|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|15/3|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|CTCF gene|C1422163|[gngm]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|3/4|
text_000N_43235|MMI|5.18|CTCF protein, human|C1456335|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|3/4|
text_000N_43235|MMI|5.18|CTGF protein, human|C1137457|[aapp,bacs]|["CTCF"-tx-1-"CTCF"-noun-0]|TX|3/4|
text_000N_43235|MMI|3.56|% bound (qualifier value)|C1689898|[qnco]|["% bound"-tx-1-"bound"-verb-0]|TX|8/5|
text_000N_43235|MMI|3.56|Binding action|C1145667|[acty]|["Bound"-tx-1-"bound"-verb-0]|TX|8/5|
text_000N_43235|MMI|3.56|Bound (value)|C2349209|[cnce]|["Bound"-tx-1-"bound"-verb-0]|TX|8/5|
text_000N_43235|MMI|3.56|Bounded by|C0332297|[spco]|["bound"-tx-1-"bound"-verb-0]|TX|8/5|
text_000N_43235|MMI|3.56|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"free"-adj-0]|TX|28/4|
text_000N_43235|MMI|3.56|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"free"-adj-0]|TX|28/4|
text_000N_43235|MMI|3.56|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosome"-tx-1-"nucleosome"-noun-0]|TX|17/10|
text_000N_43235|MMI|3.56|nucleosome location|C1166675|[celc]|["nucleosome"-tx-1-"nucleosome"-noun-0]|TX|17/10|
text_000N_43235|MMI|3.53|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|33/7|
text_000N_43235|MMI|3.53|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|33/7|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Gene Fusion|C0178648|[mbrt]|["Gene Fusion"-tx-1-"gene fusion"-noun-0]|TX|42/11|
text_000N_47274|MMI|5.18|Gene Fusion Abnormality|C1705736|[comd]|["Gene Fusion"-tx-1-"gene fusion"-noun-0]|TX|42/11|
text_000N_47274|MMI|3.65|Difference in rate|C3258806|[qnco]|["Difference in rate"-tx-1-"difference in rate"-noun-0]|TX|11/13,29/4|
text_000N_47274|MMI|3.50|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|58/4|
text_000N_47274|MMI|3.50|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|58/4|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|DNA-Binding Protein SATB1|C2699550|[aapp,rcpt]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|5/5|
text_000N_47363|MMI|5.18|RAG1 gene|C0085218|[gngm]|["RAG1"-tx-1-"RAG1"-noun-0]|TX|24/4|
text_000N_47363|MMI|5.18|Rag1 Mouse|C1514714|[mamm]|["Rag1"-tx-1-"RAG1"-noun-0]|TX|24/4|
text_000N_47363|MMI|5.18|SATB1 gene|C1419822|[gngm]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|5/5|
text_000N_47363|MMI|5.18|V(D)J Recombination-Activating Protein 1|C3887674|[aapp,imft]|["RAG-1"-tx-1-"RAG1"-noun-0]|TX|24/4|
text_000N_47363|MMI|3.98|RAG2 gene|C1419248|[gngm]|["RAG2 Gene"-tx-1-"RAG2 genes"-noun-0]|TX|33/10|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|SLC6A4 gene|C1420214|[gngm]|["SERT"-tx-1-"SERT"-noun-0]|TX|30/4|
text_000N_47377|MMI|5.18|SLC6A4 wt Allele|C3814032|[gngm]|["SERT"-tx-1-"SERT"-noun-0]|TX|30/4|
text_000N_47377|MMI|5.18|Selective External Radiation Therapy|C1882994|[topp]|["SERT"-tx-1-"SERT"-noun-0]|TX|30/4|
text_000N_47377|MMI|3.63|Ephrin Type-B Receptor 1, human|C3853572|[aapp,enzy,rcpt]|["NET"-tx-1-"NET"-noun-0]|TX|22/3|
text_000N_47377|MMI|3.63|Net (qualifier)|C3887809|[qlco]|["Net"-tx-1-"NET"-noun-0]|TX|22/3|
text_000N_47377|MMI|3.63|Neutrophil Extracellular Traps|C3850088|[celc]|["NET"-tx-1-"NET"-noun-0]|TX|22/3|
text_000N_47377|MMI|3.63|SLC6A2 protein, human|C1456447|[aapp,bacs]|["NET"-tx-1-"NET"-noun-0]|TX|22/3|
text_000N_47377|MMI|3.63|SLC6A2 wt Allele|C3890893|[gngm]|["NET"-tx-1-"NET"-noun-0]|TX|22/3|
text_000N_47377|MMI|3.48|(City) Block|C1706084|[geoa]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Block Specimens|C1533157|[bdsu]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Blocking|C0332206|[ftcn]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Obstruction|C0028778|[patf]|["Block"-tx-1-"block"-noun-0]|TX|16/5|
text_000N_47377|MMI|3.48|Venlafaxine measurement|C1266786|[lbpr]|["Venlafaxine"-tx-1-"venlafaxine"-noun-0]|TX|4/11|
text_000N_47377|MMI|3.48|venlafaxine|C0078569|[orch,phsu]|["VENLAFAXINE"-tx-1-"venlafaxine"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|mogamulizumab|C2987603|[aapp,imft,phsu]|["MOGAMULIZUMAB"-tx-1-"mogamulizumab"-noun-0]|TX|4/13|
text_000N_47289|MMI|3.62|Lymphoma, T-Cell, Cutaneous|C0079773|[neop]|["CUTANEOUS T CELL LYMPHOMA"-tx-1-"cutaneous T-cell lymphoma"-noun-0]|TX|47/25|
text_000N_47289|MMI|3.54|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|21/4,44/2|
text_000N_47289|MMI|3.54|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
text_000N_47289|MMI|3.54|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|34/9|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Nerinetide|C5418474|[orch,phsu]|["NERINETIDE"-tx-1-"nerinetide"-noun-0]|TX|7/10|
text_000N_47304|MMI|3.59|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischaemic stroke"-noun-0]|TX|43/16|
text_000N_47304|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|21/4,40/2|
text_000N_47304|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
text_000N_47304|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|30/9|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|Dexmecamylamine|C4519222|[orch,phsu]|["DEXMECAMYLAMINE"-tx-1-"Dexmecamylamine"-noun-0]|TX|3/15|
text_000N_47450|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|19/9|
text_000N_47450|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|19/9|
text_000N_47450|MMI|3.45|Depressed mood|C0344315|[mobd]|["depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depression - recess|C4085311|[qlco]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depression Scale (BASC-2)|C4049644|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depression Subordinate Domain|C4084909|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depression Visual Analogue Scale|C4553827|[inpr]|["Depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depression motion|C0460137|[ftcn]|["Depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Depressive disorder|C0011581|[mobd]|["Depression"-tx-1-"depression"-noun-0]|TX|33/10|
text_000N_47450|MMI|3.45|Mental Depression|C0011570|[mobd]|["DEPRESSION"-tx-1-"depression"-noun-0]|TX|33/10|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Adenovirus Vector|C1510800|[nnon]|["Adenoviral Vector"-tx-1-"adenoviral vector"-noun-0]|TX|19/17|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Genomic Instability|C0919532|[comd]|["Genomic Instability"-tx-1-"genomic instability"-noun-0]|TX|53/19|
text_000N_47406|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|45/7|
text_000N_47406|MMI|3.60|Stress|C0038435|[fndg]|["Stress"-tx-1-"stress"-noun-0]|TX|38/6|
text_000N_47406|MMI|3.60|W stress|C1718621|[clna]|["Stress"-tx-1-"stress"-noun-0]|TX|38/6|
text_000N_47406|MMI|3.49|DNA Replication|C0598312|[genf]|["DNA Replication"-tx-1-"DNA replication"-noun-0]|TX|22/15|
text_000N_47406|MMI|3.49|DNA Replication Pathway|C2984261|[ftcn]|["DNA replication"-tx-1-"DNA replication"-noun-0]|TX|22/15|
text_000N_47406|MMI|3.46|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-adj-0]|TX|14/7|
text_000N_47406|MMI|3.46|Oncogenes|C0029016|[gngm]|["Oncogene"-tx-1-"oncogene"-noun-0]|TX|5/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|10/9|
text_000N_47349|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|10/9|
text_000N_47349|MMI|3.58|HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1|C3888239|[fndg]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|51/20|
text_000N_47349|MMI|3.58|Hirschsprung Disease|C0019569|[dsyn]|["HIRSCHSPRUNG DISEASE"-tx-1-"Hirschsprung disease"-noun-0]|TX|51/20|
text_000N_47349|MMI|3.55|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|36/11|
text_000N_47349|MMI|3.55|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|36/11|
text_000N_47349|MMI|3.55|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|36/11|
text_000N_47349|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
text_000N_47349|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|20/8|
text_000N_47349|MMI|3.55|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|36/11|
text_000N_47349|MMI|3.50|EDNRB gene|C1414263|[gngm]|["EDNRB"-tx-1-"EDNRB"-noun-0]|TX|4/5|
text_000N_47349|MMI|3.50|EDNRB protein, human|C3852390|[aapp,rcpt]|["EDNRB"-tx-1-"EDNRB"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|golimumab|C2353893|[aapp,imft,phsu]|["GOLIMUMAB"-tx-1-"golimumab"-noun-0]|TX|3/9|
text_000N_43275|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43275|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_43275|MMI|3.45|SARCOIDOSIS, SUSCEPTIBILITY TO, 1 (finding)|C2697310|[fndg]|["SARCOIDOSIS"-tx-1-"sarcoidosis"-noun-0]|TX|27/11|
text_000N_43275|MMI|3.45|Sarcoidosis|C0036202|[dsyn]|["SARCOIDOSIS"-tx-1-"sarcoidosis"-noun-0]|TX|27/11|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.98|Adeno-Associated Virus Vector|C5553018|[nnon]|["AAV Vector"-tx-1-"AAV vectors"-noun-0]|TX|4/11|
text_000N_47420|MMI|3.58|Retinal Dystrophies|C0854723|[dsyn]|["Retinal Dystrophies"-tx-1-"retinal dystrophies"-noun-0]|TX|48/19|
text_000N_47420|MMI|3.57|Retinal therapeutic procedures|C0947830|[topp]|["Retinal Treatment"-tx-1-"treatment retinal"-noun-0]|TX|35/9,48/7|
text_000N_47420|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|Dystrophy|C0333606|[patf]|["DYSTROPHIES"-tx-1-"dystrophies"-noun-0]|TX|56/11|
text_000N_47420|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|16/10|
text_000N_47420|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
text_000N_47420|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|EZH2 gene|C1333368|[gngm]|["EZH2"-tx-1-"EZH2"-noun-0]|TX|3/4|
text_000N_47320|MMI|5.18|EZH2 protein, human|C1172384|[aapp,bacs]|["EZH2"-tx-1-"EZH2"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|8/15|
text_000N_47320|MMI|3.64|Malignant neoplasm of prostate|C0376358|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|24/15|
text_000N_47320|MMI|3.64|NCI CTEP SDC Prostate Cancer Sub-Category Terminology|C3541264|[inpr]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|24/15|
text_000N_47320|MMI|3.64|Prostate Cancer Pathway|C2984325|[cnce]|["Prostate cancer"-tx-1-"prostate cancer"-noun-0]|TX|24/15|
text_000N_47320|MMI|3.64|Prostate carcinoma|C0600139|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|24/15|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|4.12|Selenium supplement|C0521939|[inch,phsu]|["Selenium supplement"-tx-1-"selenium supplements"-noun-0]|TX|4/20|
text_000N_43331|MMI|3.68|Prevention of Prostate Cancer|C0281413|[topp]|["Prostate Cancer Prevention"-tx-1-"prostate cancer prevention"-noun-0]|TX|41/26|
text_000N_43331|MMI|3.56|Recommendation|C0034866|[idcn]|["Recommended"-tx-1-"recommended"-verb-0]|TX|25/11|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.68|Intercellular matrix component|C0932050|[celc]|["Part of extracellular matrix"-tx-1-"part of extracellular matrix"-noun-0]|TX|14/7,26/20|
text_000N_47392|MMI|3.43|Integrins|C0021701|[aapp,imft,rcpt]|["Integrins"-tx-1-"integrins"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.57|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|52/7|
text_000N_43358|MMI|3.57|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|46/5|
text_000N_43358|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|34/8|
text_000N_43358|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|34/8|
text_000N_43358|MMI|3.55|Length|C1444754|[qnco]|["Length"-tx-1-"length"-noun-0]|TX|7/6|
text_000N_43358|MMI|3.55|Length of Trial|C1706316|[resa]|["LENGTH"-tx-1-"length"-noun-0]|TX|7/6|
text_000N_43358|MMI|3.47|Poly(A) Tail|C0242494|[bacs,nnon]|["POLY A TAIL"-tx-1-"poly(A tail"-noun-0]|TX|21/6,29/4|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Triticum aestivum|C1123020|[plnt]|["Wheat"-tx-1-"wheat"-noun-0]|TX|5/5|
text_000N_43386|MMI|5.18|Wheat (Dietary)|C0043137|[food]|["WHEAT"-tx-1-"wheat"-noun-0]|TX|5/5|
text_000N_43386|MMI|5.18|Wheat - grass (plant)|C1510495|[plnt]|["Wheat"-tx-1-"wheat"-noun-0]|TX|5/5|
text_000N_43386|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|39/3|
text_000N_43386|MMI|5.18|wheat preparation|C1095911|[orch,phsu]|["WHEAT"-tx-1-"wheat"-noun-0]|TX|5/5|
text_000N_43386|MMI|3.56|Avena (plant)|C0331496|[plnt]|["Avena"-tx-1-"Avena"-noun-0]|TX|32/5|
text_000N_43386|MMI|3.56|Genus|C1708235|[clas]|["Genus"-tx-1-"genus"-noun-0]|TX|26/5|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|figitumumab|C2713009|[aapp,imft,phsu]|["FIGITUMUMAB"-tx-1-"Figitumumab"-noun-0]|TX|3/11|
text_000N_40839|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40839|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_40839|MMI|3.53|NCI CTEP SDC Non-Small Cell Lung Cancer Sub-Category Terminology|C3539721|[inpr]|["Non-Small Cell Lung Cancer"-tx-1-"non-small cell lung cancer"-noun-0]|TX|29/26|
text_000N_40839|MMI|3.53|Non-Small Cell Lung Cancer Pathway|C2984258|[cnce]|["Non-small cell lung cancer"-tx-1-"non-small cell lung cancer"-noun-0]|TX|29/26|
text_000N_40839|MMI|3.53|Non-Small Cell Lung Carcinoma|C0007131|[neop]|["NONSMALL CELL LUNG CANCER"-tx-1-"non-small cell lung cancer"-noun-0]|TX|29/26|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.55|Biological Markers|C0005516|[clna]|["Biomarkers"-tx-1-"biomarkers"-noun-0]|TX|20/10|
text_000N_40913|MMI|3.47|Chronic Kidney Disease, CTCAE|C4553188|[fndg]|["Chronic Kidney Disease"-tx-1-"chronic kidney disease"-noun-0]|TX|35/22|
text_000N_40913|MMI|3.47|Chronic Kidney Diseases|C1561643|[dsyn]|["Chronic Kidney Disease"-tx-1-"chronic kidney disease"-noun-0]|TX|35/22|
text_000N_40913|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_40913|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_40913|MMI|3.42|In Urine|C0042037|[ftcn]|["URINE"-tx-1-"urine"-noun-0]|TX|14/5|
text_000N_40913|MMI|3.42|Portion of urine|C2963137|[bdsu]|["Urine"-tx-1-"urine"-noun-0]|TX|14/5|
text_000N_40913|MMI|3.42|Urine|C0042036|[bdsu]|["URINE"-tx-1-"urine"-noun-0]|TX|14/5|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Alpha-Taxilin|C2698064|[aapp]|["Taxilin"-tx-1-"taxilin"-noun-0]|TX|3/7|
text_000N_40972|MMI|3.68|Biological Markers|C0005516|[clna]|["marker"-tx-1-"marker"-noun-0]|TX|20/6|
text_000N_40972|MMI|3.68|Marker|C5445211|[qlco]|["Marker"-tx-1-"marker"-noun-0]|TX|20/6|
text_000N_40972|MMI|3.50|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|13/6|
text_000N_40972|MMI|3.50|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|13/6|
text_000N_40972|MMI|3.50|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|13/6|
<<<<< MMI
>>>>> MMI
text_000N_173104|AA|CD44v|CD44 variants|1|5|3|13|19:5
text_000N_173104|MMI|3.68|Variant|C0205419|[qlco]|["variants"-tx-1-"variants"-noun-0]|TX|9/8|
text_000N_173104|MMI|3.59|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|26/15|
text_000N_173104|MMI|3.59|Prognosis bad|C0278252|[fndg]|["Poor prognosis"-tx-1-"poor prognosis"-noun-0]|TX|42/14|
text_000N_173104|MMI|3.55|Metastasis|C4255448|[patf]|["Metastasis"-tx-1-"metastasis"-noun-0]|TX|60/10|
text_000N_173104|MMI|3.55|Metastatic Neoplasm|C2939420|[neop]|["metastasis"-tx-1-"metastasis"-noun-0]|TX|60/10|
text_000N_173104|MMI|3.55|Neoplasm Metastasis|C0027627|[neop]|["Metastasis"-tx-1-"metastasis"-noun-0]|TX|60/10|
text_000N_173104|MMI|3.55|Secondary Neoplasm|C2939419|[neop]|["Metastasis"-tx-1-"metastasis"-noun-0]|TX|60/10|
text_000N_173104|MMI|3.50|CD44 protein, human|C1097299|[aapp,imft]|["CD44"-tx-1-"CD44"-noun-0]|TX|4/4|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|57/19|
text_000N_40886|MMI|5.18|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|57/19|
text_000N_40886|MMI|5.18|bapineuzumab|C2698328|[aapp,imft,phsu]|["BAPINEUZUMAB"-tx-1-"bapineuzumab"-noun-0]|TX|3/12|
text_000N_40886|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|16/9,30/9|
text_000N_40886|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|tocilizumab|C1609165|[aapp,imft,phsu]|["TOCILIZUMAB"-tx-1-"tocilizumab"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|HAVCR2 gene|C1425514|[gngm]|["Tim-3"-tx-1-"TIM-3"-noun-0]|TX|3/5|
text_000N_97301|MMI|5.18|HAVCR2 protein, human|C1120826|[aapp,rcpt]|["TIM-3"-tx-1-"TIM-3"-noun-0]|TX|3/5|
text_000N_97301|MMI|5.18|HAVCR2 wt Allele|C3541254|[gngm]|["Tim-3"-tx-1-"TIM-3"-noun-0]|TX|3/5|
text_000N_97301|MMI|5.18|Non-Small Cell Lung Carcinoma|C0007131|[neop]|["NSCLC"-tx-1-"NSCLC"-noun-0]|TX|46/5|
text_000N_97301|MMI|3.56|Target|C1521840|[ftcn]|["Target"-tx-1-"target"-noun-0]|TX|11/6|
text_000N_97301|MMI|3.56|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"target"-noun-0]|TX|11/6|
text_000N_97301|MMI|3.49|Immunotherapy for cancer|C0278348|[topp]|["Immunotherapy for cancer"-tx-1-"for cancer immunotherapy"-noun-0]|TX|18/24|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|3.56|Effect|C1280500|[qlco]|["Effects"-tx-1-"effects"-noun-0]|TX|18/7|
text_000N_97331|MMI|3.46|Adipose tissue|C0001527|[tisu]|["Fat Tissue"-tx-1-"fat tissue"-noun-0]|TX|29/10|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|Hepatocyte Growth Factor Receptor Measurement|C5399850|[lbpr]|["c-Met"-tx-1-"c-met"-noun-0]|TX|3/5|
text_000N_173120|MMI|5.18|MET protein, human|C1456828|[aapp,rcpt]|["C-MET"-tx-1-"c-met"-noun-0]|TX|3/5|
text_000N_173120|MMI|5.18|MET wt Allele|C1704823|[gngm]|["C-MET"-tx-1-"c-met"-noun-0]|TX|3/5|
text_000N_173120|MMI|3.54|AKT1 gene|C0812228|[gngm]|["AKT"-tx-1-"Akt"-noun-0]|TX|43/3|
text_000N_173120|MMI|3.54|Activation action|C1879547|[acty]|["Activation"-tx-1-"activation"-noun-0]|TX|25/10|
text_000N_173120|MMI|3.54|Biochemical Pathway|C1704259|[moft]|["Pathway"-tx-1-"pathway"-noun-0]|TX|47/7|
text_000N_173120|MMI|3.54|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_173120|MMI|3.54|Pathway (interactions)|C1705987|[cnce]|["Pathway"-tx-1-"pathway"-noun-0]|TX|47/7|
text_000N_173120|MMI|3.54|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_173120|MMI|3.54|Proto-Oncogene Proteins c-akt|C0164786|[aapp,enzy]|["AKT"-tx-1-"Akt"-noun-0]|TX|43/3|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|lenvatinib|C2986924|[orch,phsu]|["LENVATINIB"-tx-1-"lenvatinib"-noun-0]|TX|3/10|
text_000N_173230|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173230|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173230|MMI|3.50|Conventional (Clear Cell) Renal Cell Carcinoma|C0279702|[neop]|["renal cell carcinoma"-tx-1-"renal cell carcinoma"-noun-0]|TX|28/20|
text_000N_173230|MMI|3.50|NCI CTEP SDC Renal Cell Carcinoma Sub-Category Terminology|C3540608|[inpr]|["Renal Cell Carcinoma"-tx-1-"renal cell carcinoma"-noun-0]|TX|28/20|
text_000N_173230|MMI|3.50|Renal Cell Carcinoma|C0007134|[neop]|["RENAL CELL CARCINOMA"-tx-1-"renal cell carcinoma"-noun-0]|TX|28/20|
text_000N_173230|MMI|3.50|Renal Cell Carcinoma Pathway|C2984311|[cnce]|["Renal cell carcinoma"-tx-1-"renal cell carcinoma"-noun-0]|TX|28/20|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|NERVOUS SYSTEM DRUGS|C3542961|[phsu]|["NERVOUS SYSTEM"-tx-1-"nervous system"-noun-0]|TX|59/14|
text_000N_97347|MMI|5.18|Nervous system structure|C0027763|[bdsy]|["Nervous System"-tx-1-"nervous system"-noun-0]|TX|59/14|
text_000N_97347|MMI|5.18|Neurological observations|C0422837|[fndg]|["NERVOUS SYSTEM"-tx-1-"nervous system"-noun-0]|TX|59/14|
text_000N_97347|MMI|5.18|PLK2 gene|C1426344|[gngm]|["PLK2"-tx-1-"PLK2"-noun-0]|TX|3/4|
text_000N_97347|MMI|3.61|SNCA gene|C1420276|[gngm]|[[945,45,115,121,110,117,99,108,101,105,110]-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_97347|MMI|3.61|SNCA protein, human|C1311196|[aapp,bacs]|["Alpha-Synuclein"-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_97347|MMI|3.61|alpha-Synuclein|C0285890|[aapp,bacs]|["Alpha synuclein"-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_97347|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_97347|MMI|3.56|Phosphorylation|C0031715|[moft]|["Phosphorylation"-tx-1-"phosphorylation"-noun-0]|TX|36/15|
text_000N_97347|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_97347|MMI|3.56|Protein phosphorylation|C1158886|[moft]|["Phosphorylation"-tx-1-"phosphorylation"-noun-0]|TX|36/15|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|24/6|
text_000N_173087|MMI|5.18|DNA Replication Timing|C1257780|[genf]|["Replication Timing"-tx-1-"replication timing"-noun-0]|TX|5/18|
text_000N_173087|MMI|3.56|Rate|C1521828|[qnco]|["Rate"-tx-1-"rate"-noun-0]|TX|35/4|
text_000N_173087|MMI|3.56|Rating (action)|C0871208|[acty]|["Rate"-tx-1-"rate"-noun-0]|TX|35/4|
text_000N_173087|MMI|3.46|Somatic mutation|C0544886|[comd]|["somatic mutations"-tx-1-"somatic mutations"-noun-0]|TX|43/17|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|5.18|Tumor Necrosis Factor Inhibitors|C3537192|[phsu]|["Tumor Necrosis Factor Inhibitor"-tx-1-"tumor necrosis factor inhibitor"-noun-0]|TX|17/31|
text_000N_97394|MMI|5.18|tocilizumab|C1609165|[aapp,imft,phsu]|["TOCILIZUMAB"-tx-1-"tocilizumab"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|5.18|Possible|C0332149|[fndg]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97409|MMI|5.18|Possible diagnosis|C2362652|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97409|MMI|5.18|Possibly Related to Intervention|C1705910|[qlco]|["Possible"-tx-1-"possible"-adj-0]|TX|6/8|
text_000N_97409|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_97409|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_97409|MMI|5.18|Use of|C1524063|[ftcn]|["Using"-tx-1-"using"-verb-0]|TX|52/5|
text_000N_97409|MMI|3.68|Ultrasonic|C0220934|[ftcn]|["ultrasound"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.68|Ultrasonic Shockwave|C0041621|[npop]|["ultrasound"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.68|Ultrasonics (sound)|C1456803|[npop]|["Ultrasound"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.68|Ultrasonography|C0041618|[diap]|["ULTRASOUND"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.68|Urological ultrasound|C1315081|[diap]|["Ultrasound"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.68|ultrasound device|C1875843|[medd]|["ULTRASOUND"-tx-1-"ultrasound"-noun-0]|TX|71/10|
text_000N_97409|MMI|3.59|Atomic Nucleus|C4724279|[elii]|["Nucleus"-tx-1-"nucleus"-noun-0]|TX|41/7|
text_000N_97409|MMI|3.59|Cell Nucleus|C0007610|[celc]|["NUCLEUS"-tx-1-"nucleus"-noun-0]|TX|41/7|
text_000N_97409|MMI|3.50|Transcranial approach|C0442348|[spco]|["Transcranial"-tx-1-"transcranial"-adj-0]|TX|58/12|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|5.18|enzastaurin|C1327830|[orch,phsu]|["ENZASTAURIN"-tx-1-"Enzastaurin"-noun-0]|TX|5/11|
text_000N_97424|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_97424|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|25/8|
text_000N_97424|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97424|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97424|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97424|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|37/12|
text_000N_97424|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|50/8|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.55|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|27/4|
text_000N_47435|MMI|3.55|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|27/4|
text_000N_47435|MMI|3.47|Pyloric Stenosis, Hypertrophic|C0700639|[cgab]|["Hypertrophic Pyloric Stenosis"-tx-1-"hypertrophic pyloric stenosis"-noun-0]|TX|35/29|
text_000N_47435|MMI|3.42|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-noun-0]|TX|18/8|
text_000N_47435|MMI|3.42|erythromycin|C0014806|[antb,orch]|["ERYTHROMYCIN"-tx-1-"erythromycin"-noun-0]|TX|5/12|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Cytoplasm|C0010834|[celc]|["Cytoplasm"-tx-1-"cytoplasm"-noun-0]|TX|58/9|
text_000N_173151|MMI|5.18|SGOT - Glutamate oxaloacetate transaminase|C0242192|[aapp,enzy]|["GOT"-tx-1-"got"-verb-0]|TX|31/3|
text_000N_173151|MMI|5.18|Sharing (Social Behavior)|C0237876|[socb]|["Share"-tx-1-"share"-verb-0]|TX|52/5|
text_000N_173151|MMI|3.98|Atomic Nucleus|C4724279|[elii]|["Nucleus"-tx-1-"nuclei"-noun-0]|TX|40/6|
text_000N_173151|MMI|3.98|Cell Nucleus|C0007610|[celc]|["NUCLEUS"-tx-1-"nuclei"-noun-0]|TX|40/6|
text_000N_173151|MMI|3.75|Eremothecium gossypii|C1004375|[fngs]|["Ashbya gossypii"-tx-1-"Ashbya gossypii"-noun-0]|TX|15/15|
text_000N_173151|MMI|3.48|Fungi|C0016832|[fngs]|["FUNGUS"-tx-1-"fungus"-noun-0]|TX|8/6|
text_000N_173151|MMI|3.48|Fungi Measurement|C4759686|[lbpr]|["Fungus"-tx-1-"fungus"-noun-0]|TX|8/6|
text_000N_173151|MMI|3.48|Fungus (lab result)|C2939457|[lbtr]|["FUNGUS"-tx-1-"fungus"-noun-0]|TX|8/6|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Homeobox Protein Meis1, Human|C1334040|[aapp,bacs]|["MEIS1"-tx-1-"Meis1"-noun-0]|TX|3/5|
text_000N_40999|MMI|5.18|MEIS1 gene|C1334501|[gngm]|["MEIS1"-tx-1-"Meis1"-noun-0]|TX|3/5|
text_000N_40999|MMI|3.59|Microphthalmos|C0026010|[cgab]|["MICROPHTHALMIA"-tx-1-"microphthalmia"-noun-0]|TX|23/14|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|avanafil|C2698280|[orch,phsu]|["AVANAFIL"-tx-1-"avanafil"-noun-0]|TX|3/8|
text_000N_173167|MMI|3.59|Erectile Dysfunction, CTCAE|C1961100|[fndg]|["Erectile Dysfunction"-tx-1-"erectile dysfunction"-noun-0]|TX|39/20|
text_000N_173167|MMI|3.59|Erectile dysfunction|C0242350|[dsyn]|["Erectile Dysfunction"-tx-1-"erectile dysfunction"-noun-0]|TX|39/20|
text_000N_173167|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|Indicated|C1444656|[fndg]|["Indicated"-tx-1-"indicated"-verb-0]|TX|12/9|
text_000N_173167|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
text_000N_173167|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|26/9|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|DNA Helicases|C0920283|[aapp,enzy]|["DNA Helicases"-tx-1-"DNA helicases"-noun-0]|TX|4/13|
text_000N_173136|MMI|3.60|Cockayne Syndrome|C0009207|[dsyn]|["progeroid syndrome"-tx-1-"progeroid syndromes"-noun-0]|TX|30/19|
text_000N_173136|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|18/8|
text_000N_173136|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|18/8|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|3.56|Sex Characteristics|C0036866|[orga]|["Sex Differences"-tx-1-"sex differences"-noun-0]|TX|10/15|
text_000N_173214|MMI|3.43|CNS - Brain - Hippocampus (MMHCC)|C1523990|[tisu]|["Mouse Hippocampus"-tx-1-"mouse hippocampus"-noun-0]|TX|54/17|
text_000N_173214|MMI|3.42|Transcriptome|C3178810|[nusq]|["Transcriptome"-tx-1-"transcriptome"-noun-0]|TX|33/13|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|obeticholic acid|C1143018|[orch,phsu]|["OBETICHOLIC ACID"-tx-1-"Obeticholic Acid"-noun-0]|TX|3/16|
text_000N_173183|MMI|3.62|Primary Biliary Cholangitis|C0008312|[dsyn]|["Primary Biliary Cholangitis"-tx-1-"Primary Biliary Cholangitis"-noun-0]|TX|42/27|
text_000N_173183|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|20/4,39/2|
text_000N_173183|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_173183|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|10.42|MicroRNAs|C1101610|[bacs,nnon]|["MicroRNA"-tx-1-"microRNA"-noun-0,"miRNA"-tx-1-"miRNA"-noun-0]|TX|3/8;12/5|
text_000N_173291|MMI|5.18|30%|C3842588|[qnco]|["30%"-tx-1-"30"-integer-0]|TX|19/2|
text_000N_173291|MMI|3.55|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173291|MMI|3.55|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173291|MMI|3.55|DESI1 gene|C3470073|[gngm]|["POST"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173291|MMI|3.55|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|48/7|
text_000N_173291|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
text_000N_173291|MMI|3.55|Ischemic|C0475224|[ftcn]|["Ischemic"-tx-1-"ischemic"-adj-0]|TX|39/8|
text_000N_173291|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|22/8|
text_000N_173291|MMI|3.55|Post|C0687676|[tmco]|["Post"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173291|MMI|3.55|Post Device|C1704687|[mnob]|["Post"-tx-1-"post"-adj-0]|TX|34/4|
text_000N_173291|MMI|3.55|SLC35G1 gene|C3469826|[gngm]|["POST"-tx-1-"post"-adj-0]|TX|34/4|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|NGB gene|C1422393|[gngm]|["NEUROGLOBIN"-tx-1-"neuroglobin"-noun-0]|TX|5/11|
text_000N_97316|MMI|5.18|neuroglobin|C0971087|[aapp]|["Neuroglobin"-tx-1-"neuroglobin"-noun-0]|TX|5/11|
text_000N_97316|MMI|3.54|Has property|C1292721|[ftcn]|["properties"-tx-1-"properties"-noun-0]|TX|37/10|
text_000N_97316|MMI|3.54|Property (attribute)|C0871161|[qlco]|["properties"-tx-1-"properties"-noun-0]|TX|37/10|
text_000N_97316|MMI|3.45|Traumatic Brain Injury|C0876926|[inpo]|["Traumatic Brain Injury"-tx-1-"traumatic brain injury"-noun-0]|TX|66/22|
text_000N_97316|MMI|3.42|Parameterized Data Type - Set|C1552652|[idcn]|["SETTING"-tx-1-"setting"-noun-0]|TX|55/7|
text_000N_97316|MMI|3.42|Settings (qualitative concept)|C4533435|[qlco]|["Setting"-tx-1-"setting"-noun-0]|TX|55/7|
text_000N_97316|MMI|3.42|contextual factors|C0542559|[menp]|["setting"-tx-1-"setting"-noun-0]|TX|55/7|
text_000N_97316|MMI|3.42|{Setting}|C1318139|[qnco]|["{Setting}"-tx-1-"setting"-noun-0]|TX|55/7|
text_000N_97316|MMI|3.38|Neuroprotection|C0598958|[celf]|["Neuroprotection"-tx-1-"neuroprotective"-adj-0]|TX|21/15|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Acid reflux|C4317146|[fndg]|["reflux"-tx-1-"reflux"-noun-0]|TX|44/6|
text_000N_97283|MMI|5.18|Reflux|C0232483|[patf]|["Reflux"-tx-1-"reflux"-noun-0]|TX|44/6|
text_000N_97283|MMI|3.57|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_97283|MMI|3.57|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_97283|MMI|3.57|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_97283|MMI|3.57|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_97283|MMI|3.44|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_97283|MMI|3.44|Bruxism|C0006325|[mobd]|["BRUXISM"-tx-1-"bruxism"-noun-0]|TX|32/7|
text_000N_97283|MMI|3.44|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.55|member|C0680022|[popg]|["members"-tx-1-"members"-noun-0]|TX|22/7|
text_000N_173245|MMI|3.43|Protein antibody|C1445860|[aapp,imft]|["Protein Immunoglobulin"-tx-1-"proteins immunoglobulin"-noun-0]|TX|13/8,37/14|
text_000N_173245|MMI|3.42|Superfamily|C1883220|[cnce]|["Superfamily"-tx-1-"superfamily"-noun-0]|TX|52/11|
<<<<< MMI
>>>>> MMI
text_000N_97362|AA|DKK1|Dickkopf-1|1|4|3|10|32:4
text_000N_97362|MMI|5.18|Malignant neoplasm of prostate|C0376358|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|41/15|
text_000N_97362|MMI|5.18|NCI CTEP SDC Prostate Cancer Sub-Category Terminology|C3541264|[inpr]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|41/15|
text_000N_97362|MMI|5.18|Prostate Cancer Pathway|C2984325|[cnce]|["Prostate cancer"-tx-1-"prostate cancer"-noun-0]|TX|41/15|
text_000N_97362|MMI|5.18|Prostate carcinoma|C0600139|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|41/15|
text_000N_97362|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97362|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97362|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|11/4|
text_000N_97362|MMI|3.46|Dickkopf-Related Protein 1|C2987134|[aapp]|["Dickkopf-1"-tx-1-"Dickkopf-1"-noun-0]|TX|20/10|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Prevnar 13|C2756364|[imft,orch,phsu]|["Prevnar 13"-tx-1-"prevnar 13"-noun-0]|TX|4/10|
text_000N_43235|MMI|3.59|Child|C0008059|[aggp]|["Children"-tx-1-"children"-noun-0]|TX|26/8|
text_000N_43235|MMI|3.59|Offspring|C0680063|[famg]|["Children"-tx-1-"children"-noun-0]|TX|26/8|
text_000N_43235|MMI|3.59|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|18/4|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.68|Environment|C0014406|[spco]|["Environment"-tx-1-"environment"-noun-0]|TX|99/11|
text_000N_47334|MMI|3.60|Effect|C1280500|[qlco]|["Effects"-tx-1-"effects"-noun-0]|TX|46/7|
text_000N_47334|MMI|3.50|S-Adenosylmethionine Measurement|C5400560|[lbpr]|["SAMe"-tx-1-"same"-adj-0]|TX|94/4|
text_000N_47334|MMI|3.50|Same|C0445247|[qlco]|["SAME"-tx-1-"same"-adj-0]|TX|94/4|
text_000N_47334|MMI|3.46|Entity Name Part Type - given|C1550718|[idcn]|["given"-tx-1-"given"-adj-0]|TX|6/5|
text_000N_47334|MMI|3.46|Exhibitions|C0600649|[inpr]|["Exhibit"-tx-1-"exhibit"-noun-0]|TX|21/7|
text_000N_47334|MMI|3.46|Exhibits as Topic|C0015272|[inpr]|["Exhibit"-tx-1-"exhibit"-noun-0]|TX|21/7|
text_000N_47334|MMI|3.46|Fitness|C1456706|[dora]|["Fitness"-tx-1-"fitness"-noun-0]|TX|38/7|
text_000N_47334|MMI|3.46|GIVEN|C1442162|[ftcn]|["GIVEN"-tx-1-"given"-adj-0]|TX|6/5|
text_000N_47334|MMI|3.46|Genotype|C0017431|[orga]|["Genotype"-tx-1-"genotype"-noun-0]|TX|12/8|
text_000N_47334|MMI|3.46|Give - dosing instruction imperative|C1947971|[ftcn]|["Given"-tx-1-"given"-adj-0]|TX|6/5|
text_000N_47334|MMI|3.46|Given name|C3244317|[inpr]|["given"-tx-1-"given"-adj-0]|TX|6/5|
text_000N_47334|MMI|3.46|Opposite|C1521805|[spco]|["Opposite"-tx-1-"opposite"-adj-0]|TX|29/8|
text_000N_47334|MMI|3.46|Organism by Genotype|C5552680|[clas]|["GENOTYPE"-tx-1-"genotype"-noun-0]|TX|12/8|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Cilengitide|C0971473|[aapp,phsu]|["CILENGITIDE"-tx-1-"cilengitide"-noun-0]|TX|3/11|
text_000N_47363|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|15/9,29/9|
text_000N_47363|MMI|3.43|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|42/12|
text_000N_47363|MMI|3.43|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|42/12|
text_000N_47363|MMI|3.43|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|42/12|
text_000N_47363|MMI|3.43|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|42/12|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|7.62|Ewings sarcoma-primitive neuroectodermal tumor (PNET)|C0684337|[neop]|["Peripheral Neuroepithelioma"-tx-1-"peripheral neuroepithelioma"-noun-0,"sarcoma, Ewing's"-tx-1-"Ewing sarcoma"-noun-0]|TX|3/27;42/13|
text_000N_43303|MMI|5.18|Neuroepithelioma, Peripheral|C3489398|[neop]|["NEUROEPITHELIOMA, PERIPHERAL"-tx-1-"peripheral neuroepithelioma"-noun-0]|TX|3/27|
text_000N_43303|MMI|3.64|Ewings sarcoma|C0553580|[neop]|["Ewings Sarcoma"-tx-1-"Ewing sarcoma"-noun-0]|TX|42/13|
text_000N_43303|MMI|3.64|NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology|C3541889|[inpr]|["Ewing Sarcoma"-tx-1-"Ewing sarcoma"-noun-0]|TX|42/13|
text_000N_43303|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|31/7|
text_000N_43303|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|31/7|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|tofacitinib|C2930696|[orch,phsu]|["TOFACITINIB"-tx-1-"Tofacitinib"-noun-0]|TX|3/11|
text_000N_47304|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47304|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_47304|MMI|3.48|Ulcerative Colitis|C0009324|[dsyn]|["COLITIS, ULCERATIVE"-tx-1-"Ulcerative Colitis"-noun-0]|TX|29/18|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Thrombophilia|C0398623|[dsyn]|["Thrombophilia"-tx-1-"thrombophilia"-noun-0]|TX|3/13|
text_000N_173199|MMI|3.59|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|28/14|
text_000N_173199|MMI|3.55|Miscarriage|C4552766|[dsyn]|["MISCARRIAGE"-tx-1-"miscarriage"-noun-0]|TX|46/11|
text_000N_173199|MMI|3.55|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|17/7|
text_000N_173199|MMI|3.55|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|17/7|
text_000N_173199|MMI|3.55|Spontaneous abortion|C0000786|[patf]|["Miscarriage"-tx-1-"miscarriage"-noun-0]|TX|46/11|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|PTEN gene|C0694888|[gngm]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_47450|MMI|5.18|PTEN protein, human|C1430988|[aapp,enzy]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_47450|MMI|5.18|Phosphatase and Tensin Homolog Measurement|C4553405|[lbpr]|["PTEN"-tx-1-"PTEN"-noun-0]|TX|3/4|
text_000N_47450|MMI|3.68|Follicular thyroid carcinoma|C0206682|[neop]|["Follicular Thyroid Carcinoma"-tx-1-"follicular thyroid carcinoma"-noun-0]|TX|20/28|
text_000N_47450|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_47450|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
<<<<< MMI
>>>>> MMI
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|HDAC1 gene|C1333891|[gngm]|["HDAC1"-tx-1-"HDAC1"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.59|GATA1 gene|C1333663|[gngm]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|22/6|
text_000N_43275|MMI|3.59|GATA1 protein, human|C1530719|[aapp,bacs]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|22/6|
text_000N_43275|MMI|3.59|GATA1 wt Allele|C1706325|[gngm]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|22/6|
text_000N_43275|MMI|3.55|*Activity (kind of quantity)|C1561536|[idcn]|["*Activity"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Active|C0205177|[qlco]|["Activity"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Activities|C0441655|[acty]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Activity (animal life circumstance)|C3668946|[fndg]|["Activity"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Biochemical Activity|C3897134|[qnco]|["Activity"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|FDA Establishment Activity Terminology|C4049939|[inpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Percent Activity|C0439167|[qnco]|["% Activity"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Physical Activity Measurement|C4049938|[lbpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|45/8|
text_000N_43275|MMI|3.55|Requirement|C1514873|[ftcn]|["Required"-tx-1-"required"-verb-0]|TX|9/8|
text_000N_43275|MMI|3.55|Transcription, Genetic|C0040649|[genf]|["Transcriptional"-tx-1-"transcriptional"-adj-0]|TX|29/15|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Phytochemicals|C0577749|[bacs,orch]|["Phytochemical"-tx-1-"phytochemical"-adj-0]|TX|14/13|
text_000N_47406|MMI|5.18|curcumin|C0010467|[irda,orch,phsu]|["CURCUMIN"-tx-1-"curcumin"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Breast Carcinoma|C0678222|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|57/13|
text_000N_47320|MMI|5.18|Childhood Breast Carcinoma|C3897071|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|57/13|
text_000N_47320|MMI|5.18|Malignant neoplasm of breast|C0006142|[neop]|["BREAST CANCER"-tx-1-"breast cancer"-noun-0]|TX|57/13|
text_000N_47320|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47320|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47320|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47320|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47320|MMI|3.46|Klinefelter Syndrome|C0022735|[dsyn]|["KLINEFELTER'S SYNDROME"-tx-1-"Klinefelter syndrome"-noun-0]|TX|32/20|
text_000N_47320|MMI|3.46|Klinefelter's syndrome - male with more than two X chromosomes|C0432474|[cgab]|["Klinefelter's syndrome"-tx-1-"Klinefelter syndrome"-noun-0]|TX|32/20|
text_000N_47320|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47320|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Developmental Disabilities|C0008073|[mobd]|["DEVELOPMENTAL DISORDERS"-tx-1-"developmental disorders"-noun-0]|TX|49/23|
text_000N_47349|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|43/5|
text_000N_47349|MMI|5.18|Only - dosing instruction fragment|C1720467|[inpr]|["Only"-tx-1-"only"-adv-0]|TX|3/4|
text_000N_47349|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|43/5|
text_000N_47349|MMI|5.18|Singular|C0205171|[qnco]|["Only"-tx-1-"only"-adv-0]|TX|3/4|
text_000N_47349|MMI|3.55|Open Reading Frames|C0079941|[gngm]|["Coding Region"-tx-1-"coding regions"-noun-0]|TX|19/14|
text_000N_47349|MMI|3.55|Change -- procedure|C4319952|[topp]|["Change"-tx-1-"changes"-verb-0]|TX|8/7|
text_000N_47349|MMI|3.55|Changed status|C0443172|[qnco]|["changes"-tx-1-"changes"-verb-0]|TX|8/7|
text_000N_47349|MMI|3.55|Changing|C0392747|[ftcn]|["changes"-tx-1-"changes"-verb-0]|TX|8/7|
text_000N_47349|MMI|3.55|Delta (difference)|C1705241|[qnco]|["Change"-tx-1-"changes"-verb-0]|TX|8/7|
text_000N_47349|MMI|3.55|MEF2C gene|C1417102|[gngm]|["MEF2C"-tx-1-"MEF2C"-noun-0]|TX|37/5|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.59|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|19/9|
text_000N_47377|MMI|3.48|Expression Negative|C5237010|[lbtr]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative|C0205160|[fndg]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative - answer|C3853545|[qlco]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative Charge|C2825491|[qlco]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative Finding|C1513916|[fndg]|["NEGATIVE"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative Lymph Node|C0678034|[fndg]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
text_000N_47377|MMI|3.48|Negative Number|C2825415|[qnco]|["Negative"-tx-1-"negative"-adj-0]|TX|10/8|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Multiple Sclerosis|C0026769|[dsyn]|["MULTIPLE SCLEROSIS"-tx-1-"multiple sclerosis"-noun-0]|TX|43/18|
text_000N_47289|MMI|3.59|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|10/15|
text_000N_47289|MMI|3.59|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|10/15|
text_000N_47289|MMI|3.45|Stem cells|C0038250|[cell]|["Stem Cells"-tx-1-"stem cells"-noun-0]|TX|29/10|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Phosphoproteins|C0031689|[aapp,bacs]|["Phosphoprotein"-tx-1-"phosphoprotein"-noun-0]|TX|14/14|
text_000N_43331|MMI|5.18|Synapsins|C0085252|[aapp,bacs]|["Synapsin"-tx-1-"synapsin"-noun-0]|TX|3/8|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.63|Intellectual scale|C0349674|[inpr]|["Scale"-tx-1-"Scale"-noun-0]|TX|22/5|
text_000N_47420|MMI|3.63|SCALE:*|C5444316|[fndg]|["SCALE:*"-tx-1-"Scale"-noun-0]|TX|22/5|
text_000N_47420|MMI|3.63|Scaling|C1947916|[acty]|["Scale"-tx-1-"Scale"-noun-0]|TX|22/5|
text_000N_47420|MMI|3.63|Weight measurement scales|C0175659|[medd]|["Scale"-tx-1-"Scale"-noun-0]|TX|22/5|
text_000N_47420|MMI|3.59|Postoperative delirium|C4721772|[mobd]|["Postoperative delirium"-tx-1-"postoperative delirium"-noun-0]|TX|54/22|
text_000N_47420|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|31/4,51/2|
text_000N_47420|MMI|3.55|Evaluation|C0220825|[hlca]|["Evaluation"-tx-1-"evaluation"-noun-0]|TX|40/10|
text_000N_47420|MMI|3.55|Evaluation procedure|C1261322|[hlca]|["Evaluation"-tx-1-"evaluation"-noun-0]|TX|40/10|
text_000N_47420|MMI|3.48|Clouded consciousness|C0683369|[fndg]|["Confusion"-tx-1-"Confusion"-noun-0]|TX|12/9|
text_000N_47420|MMI|3.48|Confusion|C0009676|[mobd]|["CONFUSION"-tx-1-"Confusion"-noun-0]|TX|12/9|
text_000N_47420|MMI|3.48|Confusion, CTCAE 3.0|C1963086|[fndg]|["Confusion"-tx-1-"Confusion"-noun-0]|TX|12/9|
text_000N_47420|MMI|3.48|Confusion, CTCAE 5.0|C4555211|[fndg]|["Confusion"-tx-1-"Confusion"-noun-0]|TX|12/9|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|7.37|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|[12/9],[50/9]|
text_000N_47392|MMI|5.18|Stretching exercises|C0600080|[topp]|["stretch"-tx-1-"stretch"-verb-0]|TX|4/7|
text_000N_47392|MMI|3.57|More|C0205172|[qnco]|["More"-tx-1-"more"-adv-0]|TX|34/4|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Gavestinel|C0907380|[orch,phsu]|["GAVESTINEL"-tx-1-"gavestinel"-noun-0]|TX|5/10|
text_000N_40886|MMI|3.58|Patient Outcome|C1547647|[idcn]|["Patient Outcome"-tx-1-"outcomes patients"-noun-0]|TX|24/8,43/8|
text_000N_40886|MMI|3.44|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|36/6|
text_000N_40886|MMI|3.44|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|36/6|
text_000N_40886|MMI|3.44|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|36/6|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|SLEEP APNEA (device)|C3496180|[medd]|["SLEEP APNEA"-tx-1-"sleep apnea"-noun-0]|TX|4/11|
text_000N_43386|MMI|5.18|Sleep Apnea Syndromes|C0037315|[dsyn]|["Sleep apnoea"-tx-1-"sleep apnea"-noun-0]|TX|4/11|
text_000N_43386|MMI|5.18|Sleep Apnea, CTCAE|C4555214|[fndg]|["Sleep Apnea"-tx-1-"sleep apnea"-noun-0]|TX|4/11|
text_000N_43386|MMI|5.18|Snoring|C0037384|[sosy]|["SNORING"-tx-1-"snoring"-noun-0]|TX|20/7|
text_000N_43386|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|28/15|
text_000N_43386|MMI|3.64|Cardiac Arrhythmia|C0003811|[dsyn]|["Cardiac Arrhythmias"-tx-1-"cardiac arrhythmias"-noun-0]|TX|44/19|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.68|Mutation|C0026882|[genf]|["Mutation"-tx-1-"mutation"-noun-0]|TX|19/8|
text_000N_40913|MMI|3.68|Mutation Abnormality|C1705285|[comd]|["Mutation"-tx-1-"mutation"-noun-0]|TX|19/8|
text_000N_40913|MMI|3.56|Outcome of Therapy|C1518681|[fndg]|["Therapy Effect"-tx-1-"effect therapy"-noun-0]|TX|36/6,79/7|
text_000N_40913|MMI|3.44|Clinical Response|C4055223|[fndg]|["Clinical Response"-tx-1-"clinical response"-noun-0]|TX|46/17|
text_000N_40913|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|33/2|
text_000N_40913|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|33/2|
text_000N_40913|MMI|3.42|iodide ion I-131|C2828294|[elii,irda]|["Radioiodine"-tx-1-"radioiodine"-noun-0]|TX|67/11|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|3.58|Family member|C0086282|[famg]|["FAMILY MEMBER"-tx-1-"member family"-noun-0]|TX|11/6,30/6|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|19/7|
text_000N_40972|MMI|3.68|Juice|C1268568|[food]|["Juice"-tx-1-"juice"-noun-0]|TX|13/5|
text_000N_40972|MMI|3.63|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.63|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.63|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|38/6|
text_000N_40972|MMI|3.50|Annona x atemoya|C1079976|[plnt]|["atemoya"-tx-1-"atemoya"-noun-0]|TX|5/7|
text_000N_40972|MMI|3.48|Cytochrome P-450 CYP3A4|C3714798|[aapp,enzy]|["CYP3A4"-tx-1-"CYP3A4"-noun-0]|TX|31/6|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|davunetide|C0966140|[aapp,bacs]|["DAVUNETIDE"-tx-1-"davunetide"-noun-0]|TX|3/10|
text_000N_173104|MMI|3.60|Progressive supranuclear palsy|C0038868|[dsyn]|["Progressive Supranuclear Palsy"-tx-1-"progressive supranuclear palsy"-noun-0]|TX|52/30|
text_000N_173104|MMI|3.54|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|consider|C0750591|[idcn]|["considered"-tx-1-"considered"-verb-0]|TX|20/10|
text_000N_173104|MMI|3.54|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173104|MMI|3.54|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.61|Nerve Degeneration|C0027746|[comd]|["Neurodegeneration"-tx-1-"neurodegeneration"-noun-0]|TX|26/17|
text_000N_173260|MMI|3.47|Deletion (action)|C1880274|[acty]|["Deletion"-tx-1-"deletion"-noun-0]|TX|11/8|
text_000N_173260|MMI|3.47|Deletion Mutation|C1511760|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|11/8|
text_000N_173260|MMI|3.47|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|20/5|
text_000N_173260|MMI|3.47|Gene Deletion Abnormality|C1442161|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|11/8|
text_000N_173260|MMI|3.47|SARM1 gene|C1424724|[gngm]|["SARM1"-tx-1-"SARM1"-noun-0]|TX|5/5|
text_000N_173260|MMI|3.47|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|20/5|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|Cognitive Therapy|C0009244|[topp]|["cognitive behavioural therapy"-tx-1-"cognitive behavioral therapy"-noun-0]|TX|4/28|
text_000N_173276|MMI|3.62|Cancer-related fatigue|C4274302|[sosy]|["Cancer Fatigue"-tx-1-"fatigue cancer"-noun-0]|TX|41/7,52/6|
text_000N_173276|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|59/8|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|59/8|
text_000N_43358|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|59/8|
text_000N_43358|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_43358|MMI|3.48|TERT Promoter Mutation|C5205374|[comd]|["TERT Promoter Mutation"-tx-1-"TERT promoter mutation"-noun-0]|TX|32/22|
text_000N_43358|MMI|3.44|Glioblastoma Multiforme Pathway|C2984291|[ftcn]|["Glioma"-tx-1-"glioma"-noun-0]|TX|71/6|
text_000N_43358|MMI|3.44|Glioma|C0017638|[neop]|["GLIOMA"-tx-1-"glioma"-noun-0]|TX|71/6|
text_000N_43358|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|78/8|
text_000N_43358|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43358|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|10.42|Hyperthermic Intraperitoneal Chemotherapy|C1868801|[topp]|["HIPEC"-tx-1-"HIPEC"-noun-0,"Hyperthermic Intraperitoneal Chemotherapy"-tx-1-"Hyperthermic intraperitoneal chemotherapy"-noun-0]|TX|49/5;6/41|
text_000N_40839|MMI|3.54|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|59/9|
text_000N_40839|MMI|3.54|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|59/9|
text_000N_40839|MMI|3.46|Recurrent ovarian cancer|C0278689|[neop]|["Recurrent Carcinoma of the Ovary"-tx-1-"the of recurrent ovarian cancer"-noun-0]|TX|73/3,87/27|
text_000N_40839|MMI|3.42|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
text_000N_40839|MMI|3.42|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|77/9|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.57|Patient Condition Code - Stable|C1547311|[inpr]|["Stable"-tx-1-"stable"-adj-0]|TX|44/6|
text_000N_173120|MMI|3.57|Stable status|C0205360|[qlco]|["STABLE"-tx-1-"stable"-adj-0]|TX|44/6|
text_000N_173120|MMI|3.55|3 Days|C1442459|[tmco]|["3D"-tx-1-"3D"-noun-0]|TX|9/2|
text_000N_173120|MMI|3.52|Structural Genomics|C1171366|[bmod]|["Structural genomic"-tx-1-"structure genome"-noun-0]|TX|12/9,30/6|
text_000N_173120|MMI|3.48|Cell Differentiation process|C0007589|[celf]|["Cell Differentiation"-tx-1-"cell differentiation"-noun-0]|TX|58/20|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|3.62|Skin fibroblast|C1272578|[cell]|["fibroblasts skin"-tx-1-"skin fibroblasts"-noun-0]|TX|35/16|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.68|mimetics|C0920591|[bmod]|["mimetics"-tx-1-"mimetics"-noun-0]|TX|20/8|
text_000N_40999|MMI|3.64|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|42/15|
text_000N_40999|MMI|3.64|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|42/15|
text_000N_40999|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|34/4|
text_000N_40999|MMI|3.50|Apolipoproteins|C0003591|[aapp,bacs]|["Apolipoprotein"-tx-1-"apolipoprotein"-noun-0]|TX|5/14|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Create data operation|C3244320|[ftcn]|["create"-tx-1-"create"-verb-0]|TX|7/6|
text_000N_173087|MMI|5.18|Creation|C1706214|[acty]|["Create"-tx-1-"create"-verb-0]|TX|7/6|
text_000N_173087|MMI|3.56|Effect|C1280500|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173087|MMI|3.56|Effect, Appearance|C2348382|[qlco]|["Effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173087|MMI|3.56|Outcome of Therapy|C1518681|[fndg]|["effect"-tx-1-"effect"-noun-0]|TX|23/6|
text_000N_173087|MMI|3.43|Data Transcription|C4554264|[acty]|["transcription"-tx-1-"transcription"-noun-0]|TX|33/13|
text_000N_173087|MMI|3.43|Transcription, Genetic|C0040649|[genf]|["Transcription"-tx-1-"transcription"-noun-0]|TX|33/13|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|3.57|de novo Mutation|C2985439|[comd]|["de novo Mutation"-tx-1-"de novo mutations"-noun-0]|TX|3/7,22/9|
text_000N_97301|MMI|3.44|Cancer Etiology|C1516195|[bmod]|["Cancer Cause"-tx-1-"cause cancer"-noun-0]|TX|41/12|
text_000N_97301|MMI|3.42|WASF1 gene|C1421479|[gngm]|["WASF1"-tx-1-"WASF1"-noun-0]|TX|35/5|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|EREG gene|C1366644|[gngm]|["EPIREGULIN"-tx-1-"epiregulin"-noun-0]|TX|39/10|
text_000N_97331|MMI|5.18|EREG protein, human|C3884279|[aapp,bacs]|["Epiregulin"-tx-1-"epiregulin"-noun-0]|TX|39/10|
text_000N_97331|MMI|5.18|Epiregulin|C0296263|[aapp,bacs]|["Epiregulin"-tx-1-"epiregulin"-noun-0]|TX|39/10|
text_000N_97331|MMI|5.18|Proepiregulin, human|C3888282|[aapp,bacs]|["Epiregulin"-tx-1-"epiregulin"-noun-0]|TX|39/10|
text_000N_97331|MMI|5.18|Suppressed|C1260953|[ftcn]|["suppress"-tx-1-"suppress"-verb-0]|TX|30/8|
text_000N_97331|MMI|3.48|Sphingosine|C0037907|[bacs,orch]|["Sphingosine"-tx-1-"sphingosine"-noun-0]|TX|5/11|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|COL18A1 gene|C1332771|[gngm]|["ENDOSTATIN"-tx-1-"endostatin"-noun-0]|TX|3/10|
text_000N_173136|MMI|5.18|Endostatin Measurement|C5401187|[lbpr]|["Endostatin"-tx-1-"endostatin"-noun-0]|TX|3/10|
text_000N_173136|MMI|5.18|Endostatin, human|C3887702|[aapp,bacs]|["Endostatin"-tx-1-"endostatin"-noun-0]|TX|3/10|
text_000N_173136|MMI|5.18|Endostatins|C0534628|[aapp,phsu]|["Endostatin"-tx-1-"endostatin"-noun-0]|TX|3/10|
text_000N_173136|MMI|5.18|Recombinant Human Endostatin|C1705207|[aapp,phsu]|["Endostatin"-tx-1-"endostatin"-noun-0]|TX|3/10|
text_000N_173136|MMI|3.68|Factor|C1521761|[ftcn]|["Factor"-tx-1-"factor"-noun-0]|TX|30/6|
text_000N_173136|MMI|3.68|Feelings about Genomic Testing Results|C5400797|[inpr]|["FACToR"-tx-1-"factor"-noun-0]|TX|30/6|
text_000N_173136|MMI|3.68|Mathematical Factor|C2827422|[cnce]|["Factor"-tx-1-"factor"-noun-0]|TX|30/6|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|5.18|Revlimid|C1135145|[orch,phsu]|["Revlimid"-tx-1-"Revlimid"-noun-0]|TX|4/8|
text_000N_97378|MMI|5.18|United States Food and Drug Administration|C0041714|[hcro]|["food drug administration"-tx-1-"Food and Drug Administration"-noun-0]|TX|37/28|
text_000N_97378|MMI|3.59|Approved|C0205540|[qlco]|["Approved"-tx-1-"approved"-verb-0]|TX|18/8|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|3.64|Huntington Disease|C0020179|[dsyn]|["huntingtons disease"-tx-1-"Huntington's disease"-noun-0]|TX|34/20|
text_000N_97394|MMI|3.64|Huntington's Disease Pathway|C2919056|[ftcn]|["Huntington's Disease"-tx-1-"Huntington's disease"-noun-0]|TX|34/20|
text_000N_97394|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|25/4|
text_000N_97394|MMI|3.50|Antisense Therapy|C0935882|[topp]|["Antisense"-tx-1-"antisense"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Dimerization|C0376525|[npop]|["Dimerize"-tx-1-"dimerizes"-verb-0]|TX|28/9|
text_000N_97283|MMI|3.63|ERBB2 gene|C0242957|[gngm]|["HER-2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.63|ERBB2 protein, human|C1702024|[aapp,enzy,rcpt]|["HER2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.63|HER-2-neu peptide vaccine|C0879250|[aapp,imft,phsu]|["HER-2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.63|Human Epidermal Growth Factor Receptor 2 Measurement|C3810543|[lbpr]|["HER2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.63|Oncogene ErbB2|C3853888|[gngm]|["HER -2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.63|erbB-2 Receptor|C0069515|[aapp,enzy,rcpt]|["her-2"-tx-1-"HER2"-noun-0]|TX|3/4|
text_000N_97283|MMI|3.48|Active|C0205177|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|8/6|
text_000N_97283|MMI|3.48|Active License|C3888249|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|8/6|
text_000N_97283|MMI|3.48|Active State|C0679217|[idcn]|["Active"-tx-1-"active"-adj-0]|TX|8/6|
text_000N_97283|MMI|3.48|Only - dosing instruction fragment|C1720467|[inpr]|["Only"-tx-1-"only"-adv-0]|TX|15/4|
text_000N_97283|MMI|3.48|Pet is as Active as it Has Been|C5238549|[inpr]|["active"-tx-1-"active"-adj-0]|TX|8/6|
text_000N_97283|MMI|3.48|Singular|C0205171|[qnco]|["Only"-tx-1-"only"-adv-0]|TX|15/4|
text_000N_97283|MMI|3.48|active (HL7 RoleLink)|C3853793|[idcn]|["active"-tx-1-"active"-adj-0]|TX|8/6|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Chromosomes, Human, Pair 21|C0008664|[celc]|["Chromosome 21"-tx-1-"chromosome 21"-noun-0]|TX|95/13|
text_000N_47435|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|110/3|
text_000N_47435|MMI|3.68|DiGeorge Syndrome|C0012236|[dsyn]|["DiGeorge's Syndrome"-tx-1-"Di George syndrome"-noun-0]|TX|48/18|
text_000N_47435|MMI|3.63|Genetic Syndrome Associated with Congenital Heart Defect|C5238705|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|19/8|
text_000N_47435|MMI|3.63|Syndrome|C0039082|[dsyn]|["Syndrome"-tx-1-"syndrome"-noun-0]|TX|19/8|
text_000N_47435|MMI|3.57|Deletion (action)|C1880274|[acty]|["Deletion"-tx-1-"deletion"-noun-0]|TX|83/8|
text_000N_47435|MMI|3.57|Deletion Mutation|C1511760|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|83/8|
text_000N_47435|MMI|3.57|Gene Deletion Abnormality|C1442161|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|83/8|
text_000N_47435|MMI|3.56|Known|C0205309|[qlco]|["Known"-tx-1-"known"-verb-0]|TX|39/5|
text_000N_47435|MMI|3.54|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|71/6|
text_000N_47435|MMI|3.54|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|71/6|
text_000N_47435|MMI|3.48|Face|C0015450|[blor]|["Facial"-tx-1-"facial"-adj-0]|TX|12/6|
text_000N_47435|MMI|3.48|Facial|C5202986|[spco]|["FACIAL"-tx-1-"facial"-adj-0]|TX|12/6|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|3.61|Hormone replacement therapy|C0282402|[topp]|["therapy, replacement"-tx-1-"replacement therapy"-noun-0]|TX|32/19|
text_000N_97409|MMI|3.61|Replacement therapy|C0279033|[topp]|["Replacement Therapy"-tx-1-"replacement therapy"-noun-0]|TX|32/19|
text_000N_97409|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|11/4|
text_000N_97409|MMI|3.56|antidiuretic|C0596110|[phsu]|["antidiuretic"-tx-1-"antidiuretic"-adj-0]|TX|19/12|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Recombinant Tumor Necrosis Factor-Alpha|C1522669|[aapp,imft,phsu]|["TNF-Alpha"-tx-1-[84,78,70,45,945]-noun-0]|TX|3/5|
text_000N_43235|MMI|5.18|TNF protein, human|C1448177|[aapp,bacs]|["TNF Alpha"-tx-1-[84,78,70,45,945]-noun-0]|TX|3/5|
text_000N_43235|MMI|5.18|Tumor Necrosis Factor-alpha|C1456820|[aapp,imft]|["TNFalpha"-tx-1-[84,78,70,45,945]-noun-0]|TX|3/5|
text_000N_43235|MMI|3.55|Activator|C4743777|[bacs]|["ACTIVATOR"-tx-1-"activator"-noun-0]|TX|12/9|
text_000N_43235|MMI|3.48|Pancreatic Stellate Cells|C2936598|[cell]|["Pancreatic Stellate Cells"-tx-1-"pancreatic stellate cells"-noun-0]|TX|25/25|
text_000N_43235|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_43235|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Paramyxovirus, NOS|C0318798|[virs]|["Paramyxovirus"-tx-1-"paramyxovirus"-noun-0]|TX|3/13|
text_000N_173167|MMI|3.61|Subacute thyroiditis|C0040149|[dsyn]|["Subacute Thyroiditis"-tx-1-"subacute thyroiditis"-noun-0]|TX|35/20|
text_000N_173167|MMI|3.56|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|29/5|
text_000N_173167|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|17/8|
text_000N_173167|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|17/8|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|liraglutide|C1456408|[aapp,horm,phsu]|["LIRAGLUTIDE"-tx-1-"liraglutide"-noun-0]|TX|3/11|
text_000N_173214|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173214|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173214|MMI|3.48|Weight decreased|C1262477|[fndg]|["Weight Reduction"-tx-1-"weight reduction"-noun-0]|TX|29/16|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.65|Protein phosphatase|C0031686|[aapp,enzy]|["Protein Phosphatase"-tx-1-"protein phosphatase"-noun-0]|TX|11/19|
text_000N_173291|MMI|3.46|PIM1 gene|C0812214|[gngm]|["PIM"-tx-1-"Pim"-noun-0]|TX|3/3|
text_000N_173291|MMI|3.46|PIM1 wt Allele|C1709403|[gngm]|["PIM"-tx-1-"Pim"-noun-0]|TX|3/3|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|Ryanodine Receptor Calcium Release Channel|C0054493|[aapp,rcpt]|["Ryanodine--Receptors"-tx-1-"ryanodine receptors"-noun-0]|TX|44/19|
text_000N_97347|MMI|5.18|Ryanodine Receptors|C0917729|[aapp,rcpt]|["Ryanodine Receptors"-tx-1-"ryanodine receptors"-noun-0]|TX|44/19|
text_000N_97347|MMI|3.57|CDISC Relationship Class|C3540605|[inpr]|["RELATIONSHIP"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97347|MMI|3.57|Concept Relationship|C1705630|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97347|MMI|3.57|Object Relationship|C1706279|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97347|MMI|3.57|Relationships|C0439849|[qlco]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_97347|MMI|3.44|ASPH gene|C1412592|[gngm]|["JUNCTIN"-tx-1-"junctin"-noun-0]|TX|32/7|
text_000N_97347|MMI|3.44|Junctin-2|C5235419|[aapp,bacs]|["Junctin"-tx-1-"junctin"-noun-0]|TX|32/7|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|3.61|Non-invasive|C0205303|[ftcn]|["Non-invasive"-tx-1-"non-invasive"-adj-0]|TX|23/12|
text_000N_97362|MMI|3.56|Testing|C0039593|[ftcn]|["Testing"-tx-1-"testing"-noun-0]|TX|36/7|
text_000N_97362|MMI|3.56|Tests (qualifier value)|C0392366|[inpr]|["testing"-tx-1-"testing"-noun-0]|TX|36/7|
text_000N_97362|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-1]|TX|14/4|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|GARS1 wt Allele|C4318453|[gngm]|["Glycyl-tRNA Synthetase Gene"-tx-1-"glycyl-tRNA synthetase gene"-noun-0]|TX|3/27|
text_000N_47274|MMI|3.62|Charcot-Marie-Tooth Disease|C0007959|[dsyn]|["Charcot Marie Tooth Disease"-tx-1-"Charcot-Marie-Tooth disease"-noun-0]|TX|62/27|
text_000N_47274|MMI|3.54|Biologic Development|C0678723|[orgf]|["Development"-tx-1-"development"-noun-0]|TX|47/11|
text_000N_47274|MMI|3.54|Development|C1527148|[ftcn]|["Development"-tx-1-"development"-noun-0]|TX|47/11|
text_000N_47274|MMI|3.54|Development Batch|C4521286|[mnob]|["Development"-tx-1-"development"-noun-0]|TX|47/11|
text_000N_47274|MMI|3.54|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|31/8|
text_000N_47274|MMI|3.54|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|31/8|
text_000N_47274|MMI|3.54|development aspects|C0243107|[ftcn]|["development"-tx-1-"development"-noun-0]|TX|47/11|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Arimidex|C0878174|[orch,phsu]|["Arimidex"-tx-1-"Arimidex"-noun-0]|TX|6/8|
text_000N_47304|MMI|5.18|Bothered by Hot Flashes|C4085327|[inpr]|["Hot flashes"-tx-1-"hot flashes"-noun-0]|TX|35/11|
text_000N_47304|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|29/5|
text_000N_47304|MMI|5.18|Hot Flashes, CTCAE|C4551747|[fndg]|["Hot Flashes"-tx-1-"hot flashes"-noun-0]|TX|35/11|
text_000N_47304|MMI|5.18|Hot flushes|C0600142|[sosy]|["HOT FLASHES"-tx-1-"hot flashes"-noun-0]|TX|35/11|
text_000N_47304|MMI|5.18|How Big a Problem Are Hot Flashes|C4085328|[inpr]|["Hot flashes"-tx-1-"hot flashes"-noun-0]|TX|35/11|
text_000N_47304|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|29/5|
text_000N_47304|MMI|5.18|anastrozole|C0290883|[orch,phsu]|["ANASTROZOLE"-tx-1-"anastrozole"-noun-0]|TX|16/11|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|3.64|Pulmonary toxicity|C0919924|[inpo]|["Pulmonary Toxicity"-tx-1-"lung toxicity"-noun-0]|TX|21/13|
text_000N_47363|MMI|3.47|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|15/5|
text_000N_47363|MMI|3.47|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|15/5|
text_000N_47363|MMI|3.47|bleomycin|C0005740|[aapp,antb]|["BLEOMYCIN"-tx-1-"bleomycin"-noun-0]|TX|5/9|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|oleuropein aglycone|C4547446|[orch,phsu]|["oleuropein aglycone"-tx-1-"oleuropein aglycone"-noun-0]|TX|4/19|
text_000N_43303|MMI|3.57|APP protein, human|C0611285|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-noun-0]|TX|39/7|
text_000N_43303|MMI|3.57|Aggregation|C0332621|[ftcn]|["Aggregation"-tx-1-"aggregation"-noun-0]|TX|47/11|
text_000N_43303|MMI|3.57|Amyloid|C0002716|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-noun-0]|TX|39/7|
text_000N_43303|MMI|3.57|Amyloid Proteins|C1456454|[aapp,bacs]|["Amyloid"-tx-1-"amyloid"-noun-0]|TX|39/7|
text_000N_43303|MMI|3.57|Amyloid deposition|C0011560|[patf]|["Amyloid"-tx-1-"amyloid"-noun-0]|TX|39/7|
text_000N_43303|MMI|3.57|Amyloidosis|C0002726|[dsyn]|["AMYLOID"-tx-1-"amyloid"-noun-0]|TX|39/7|
text_000N_43303|MMI|3.57|Interferes with|C0521102|[ftcn]|["Interfere"-tx-1-"interfere"-verb-0]|TX|24/9|
text_000N_43303|MMI|3.57|Percentage aggregation|C0439168|[qnco]|["% aggregation"-tx-1-"aggregation"-noun-0]|TX|47/11|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|MicroRNAs|C1101610|[bacs,nnon]|["MicroRNAs"-tx-1-"microRNAs"-noun-0]|TX|5/9|
text_000N_47406|MMI|3.59|Pharmacogenomics|C1138555|[bmod]|["Pharmacogenomics"-tx-1-"pharmacogenomics"-noun-0]|TX|34/16|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.98|Piwi-Interacting RNA|C1956352|[bacs,nnon]|["piRNA"-tx-1-"piRNAs"-noun-0]|TX|4/6|
text_000N_47334|MMI|3.64|Gene Silencing|C0598496|[genf]|["Gene Silencing"-tx-1-"gene silencing"-noun-0]|TX|23/14|
text_000N_47334|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
text_000N_47334|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.98|Harbor|C0475311|[mnob]|["Harbor"-tx-1-"harboring"-verb-0]|TX|51/9|
text_000N_47377|MMI|3.60|ITIH3 gene|C1416508|[gngm]|["ITIH3 gene"-tx-1-"gene ITIH3"-noun-0]|TX|65/10|
text_000N_47377|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|13/11|
text_000N_47377|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|13/11|
text_000N_47377|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|13/11|
text_000N_47377|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|13/11|
text_000N_47377|MMI|3.45|Region of chromosome|C1953345|[celc]|["Region of chromosome"-tx-1-"of chromosomal region"-noun-0]|TX|25/2,32/18|
text_000N_47377|MMI|3.43|Schizophrenia|C0036341|[mobd]|["SCHIZOPHRENIA"-tx-1-"schizophrenia"-noun-0]|TX|81/13|
text_000N_47377|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_47377|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.63|Factor|C1521761|[ftcn]|["Factor"-tx-1-"factor"-noun-0]|TX|41/6|
text_000N_47450|MMI|3.63|Feelings about Genomic Testing Results|C5400797|[inpr]|["FACToR"-tx-1-"factor"-noun-0]|TX|41/6|
text_000N_47450|MMI|3.63|Mathematical Factor|C2827422|[cnce]|["Factor"-tx-1-"factor"-noun-0]|TX|41/6|
text_000N_47450|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
text_000N_47450|MMI|3.48|Ribosomes|C0035553|[celc]|["Ribosomal"-tx-1-"ribosomal"-adj-0]|TX|24/9|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|22/2|
text_000N_43275|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|22/2|
text_000N_43275|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|17/4|
text_000N_43275|MMI|5.18|clonidine|C0009014|[orch,phsu]|["CLONIDINE"-tx-1-"clonidine"-noun-0]|TX|4/9|
text_000N_43275|MMI|3.61|Agitated child|C0850738|[sosy]|["Agitated child"-tx-1-"agitation children"-noun-0]|TX|32/9,45/8|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|7.20|Cell Invasion|C2699153|[patf]|["Cell Invasion"-tx-1-"cell invasion"-noun-0,"Invasion"-tx-1-"invasion"-noun-0]|TX|27/13;32/8|
text_000N_43331|MMI|5.18|RAC1 gene|C1419227|[gngm]|["Rac-1"-tx-1-"Rac1"-noun-0]|TX|3/4|
text_000N_43331|MMI|5.18|RAC1 wt Allele|C3274857|[gngm]|["Rac-1"-tx-1-"Rac1"-noun-0]|TX|3/4|
text_000N_43331|MMI|5.18|RNASE1 gene|C1419407|[gngm]|["RAC1"-tx-1-"Rac1"-noun-0]|TX|3/4|
text_000N_43331|MMI|3.61|Tumor cells, malignant|C0334227|[cell]|["Cancer Cell"-tx-1-"cancer cell"-noun-0]|TX|20/11|
text_000N_43331|MMI|3.56|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_43331|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_43331|MMI|3.56|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_43331|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_43331|MMI|3.56|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|20/6|
text_000N_43331|MMI|3.56|Tumor Cell Invasion|C1269955|[neop]|["Invasion"-tx-1-"invasion"-noun-0]|TX|32/8|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|GDF15 gene|C1335222|[gngm]|["GDF15"-tx-1-"GDF15"-noun-0]|TX|4/5|
text_000N_173151|MMI|5.18|GDF15 protein, human|C1431343|[aapp,bacs]|["GDF15"-tx-1-"GDF15"-noun-0]|TX|4/5|
text_000N_173151|MMI|5.18|GDF15 wt Allele|C1705016|[gngm]|["GDF-15"-tx-1-"GDF15"-noun-0]|TX|4/5|
text_000N_173151|MMI|5.18|Growth Differentiation Factor 15|C0668195|[aapp,imft]|["GDF-15"-tx-1-"GDF15"-noun-0]|TX|4/5|
text_000N_173151|MMI|5.18|Growth Differentiation Factor 15 Measurement|C5553895|[lbpr]|["GDF15"-tx-1-"GDF15"-noun-0]|TX|4/5|
text_000N_173151|MMI|3.56|Biological Markers|C0005516|[clna]|["Biomarker"-tx-1-"biomarker"-noun-0]|TX|15/9|
text_000N_173151|MMI|3.43|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|metformin|C0025598|[orch,phsu]|["METFORMIN"-tx-1-"metformin"-noun-0]|TX|29/9|
text_000N_173151|MMI|3.43|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
text_000N_173151|MMI|3.43|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|39/9|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Change -- procedure|C4319952|[topp]|["Change"-tx-1-"change"-verb-0]|TX|32/6|
text_000N_173183|MMI|5.18|Changed status|C0443172|[qnco]|["change"-tx-1-"change"-verb-0]|TX|32/6|
text_000N_173183|MMI|5.18|Changing|C0392747|[ftcn]|["Change"-tx-1-"change"-verb-0]|TX|32/6|
text_000N_173183|MMI|5.18|Delta (difference)|C1705241|[qnco]|["Change"-tx-1-"change"-verb-0]|TX|32/6|
text_000N_173183|MMI|3.61|Intake|C1512806|[ftcn]|["Intake"-tx-1-"intake"-noun-0]|TX|25/6|
text_000N_173183|MMI|3.56|Drug Kinetics|C0031327|[phsf]|["Pharmacokinetics"-tx-1-"pharmacokinetics"-noun-0]|TX|43/16|
text_000N_173183|MMI|3.56|Pharmacokinetic aspects|C0031328|[ftcn]|["pharmacokinetics"-tx-1-"pharmacokinetics"-noun-0]|TX|43/16|
text_000N_173183|MMI|3.47|Annona x atemoya|C1079976|[plnt]|["atemoya"-tx-1-"atemoya"-noun-0]|TX|11/7|
text_000N_173183|MMI|3.47|Chief Complaint is Present Daily|C5238668|[fndg]|["Daily"-tx-1-"daily"-adv-0]|TX|5/5|
text_000N_173183|MMI|3.47|Daily|C0332173|[tmco]|["Daily"-tx-1-"daily"-adv-0]|TX|5/5|
text_000N_173183|MMI|3.47|Juice|C1268568|[food]|["Juice"-tx-1-"juice"-noun-0]|TX|19/5|
text_000N_173183|MMI|3.45|CYP1A2 Substrate|C3899737|[sbst]|["CYP1A2 Substrate"-tx-1-"CYP1A2 substrates"-noun-0]|TX|63/17|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|3.56|Proteome|C0751973|[aapp,bacs]|["Proteome"-tx-1-"proteome"-noun-0]|TX|8/8|
text_000N_173199|MMI|3.45|CNS - Brain - Hippocampus (MMHCC)|C1523990|[tisu]|["Mouse Hippocampus"-tx-1-"mice hippocampus"-noun-0]|TX|20/16|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|77/3|
text_000N_40886|MMI|5.18|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|77/3|
text_000N_40886|MMI|5.18|Does play|C0600138|[fndg]|["playing"-tx-1-"playing"-verb-0]|TX|43/7|
text_000N_40886|MMI|5.18|Mitochondrial Damage|C1096176|[patf]|["Mitochondrial Damage"-tx-1-"mitochondrial damage"-noun-0]|TX|84/20|
text_000N_40886|MMI|5.18|Play|C0032214|[dora]|["playing"-tx-1-"playing"-verb-0]|TX|43/7|
text_000N_40886|MMI|3.61|Alternative Splicing|C0002345|[genf]|["Alternative Splicing"-tx-1-"alternative splicing"-noun-0]|TX|3/20|
text_000N_40886|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|53/4|
text_000N_40886|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|53/4|
text_000N_40886|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|53/4|
text_000N_40886|MMI|3.43|Apoptotic|C1516044|[qlco]|["APOPTOTIC"-tx-1-"apoptotic"-adj-0]|TX|27/9|
text_000N_40886|MMI|3.43|Disease Response|C1704632|[fndg]|["RESPONSE"-tx-1-"response"-noun-0]|TX|65/8|
text_000N_40886|MMI|3.43|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|37/5|
text_000N_40886|MMI|3.43|Response (communication)|C2911692|[menp]|["Response"-tx-1-"response"-noun-0]|TX|65/8|
text_000N_40886|MMI|3.43|Response (statement)|C1706817|[inpr]|["Response"-tx-1-"response"-noun-0]|TX|65/8|
text_000N_40886|MMI|3.43|Response process|C0871261|[orga]|["Response"-tx-1-"response"-noun-0]|TX|65/8|
text_000N_40886|MMI|3.43|Responsive Disease|C5236984|[fndg]|["response"-tx-1-"response"-noun-0]|TX|65/8|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|NOD1 gene|C1826448|[gngm]|["NOD1"-tx-1-"NOD1"-noun-0]|TX|3/4|
text_000N_47320|MMI|3.59|Activation action|C1879547|[acty]|["ACTIVATED"-tx-1-"activated"-verb-0]|TX|8/9|
text_000N_47320|MMI|3.59|Inflammation|C0021368|[patf]|["INFLAMMATION"-tx-1-"inflammation"-noun-0]|TX|21/12|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|tirilazad|C0245179|[orch,phsu]|["TIRILAZAD"-tx-1-"tirilazad"-noun-0]|TX|7/9|
text_000N_47349|MMI|3.59|Ischemic stroke|C0948008|[dsyn]|["Ischaemic stroke"-tx-1-"ischemic stroke"-noun-0]|TX|42/15|
text_000N_47349|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|20/4,39/2|
text_000N_47349|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
text_000N_47349|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|29/9|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|PLK2 gene|C1426344|[gngm]|["PLK2"-tx-1-"PLK2"-noun-0]|TX|3/4|
text_000N_47289|MMI|5.18|Parkinson Disease|C0030567|[dsyn]|["PARKINSON DISEASE"-tx-1-"Parkinson disease"-noun-0]|TX|55/17|
text_000N_47289|MMI|3.61|SNCA gene|C1420276|[gngm]|[[945,45,115,121,110,117,99,108,101,105,110]-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_47289|MMI|3.61|SNCA protein, human|C1311196|[aapp,bacs]|["Alpha-Synuclein"-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_47289|MMI|3.61|alpha-Synuclein|C0285890|[aapp,bacs]|["Alpha synuclein"-tx-1-"alpha-synuclein"-noun-0]|TX|20/15|
text_000N_47289|MMI|3.56|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_47289|MMI|3.56|Phosphorylation|C0031715|[moft]|["Phosphorylation"-tx-1-"phosphorylation"-noun-0]|TX|36/15|
text_000N_47289|MMI|3.56|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_47289|MMI|3.56|Protein phosphorylation|C1158886|[moft]|["Phosphorylation"-tx-1-"phosphorylation"-noun-0]|TX|36/15|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|siltuximab|C1609931|[aapp,imft,phsu]|["SILTUXIMAB"-tx-1-"siltuximab"-noun-0]|TX|3/10|
text_000N_47392|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47392|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47392|MMI|3.48|Angiolymphoid hyperplasia|C0017531|[dsyn]|["Castleman Disease"-tx-1-"Castleman disease"-noun-0]|TX|28/17|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|SMOC2 gene|C1426859|[gngm]|["SMOC2"-tx-1-"SMOC2"-noun-0]|TX|3/5|
text_000N_43358|MMI|3.64|Wound Healing|C0043240|[orgf]|["Wound Healing"-tx-1-"wound healing"-noun-0]|TX|26/13|
text_000N_43358|MMI|3.64|Wound healed (finding)|C0574776|[fndg]|["Wound healing"-tx-1-"wound healing"-noun-0]|TX|26/13|
text_000N_43358|MMI|3.57|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|9/9|
text_000N_43358|MMI|3.57|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|9/9|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|37/6|
text_000N_43386|MMI|5.18|Insulin Secretion|C1256369|[celf]|["Insulin Secretion"-tx-1-"insulin secretion"-noun-0]|TX|44/17|
text_000N_43386|MMI|3.55|Thyroid Hormone Receptor|C0034843|[aapp,rcpt]|["Thyroid Hormone Receptor"-tx-1-"thyroid hormone receptor"-noun-0]|TX|6/24|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Optic Atrophy|C0029124|[dsyn]|["OPTIC ATROPHY"-tx-1-"optic atrophy"-noun-0]|TX|67/13|
text_000N_40913|MMI|3.68|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|14/9|
text_000N_40913|MMI|3.68|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|14/9|
text_000N_40913|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|29/15|
text_000N_40913|MMI|3.64|Axonal neuropathy|C0270921|[dsyn]|["Axonal Neuropathy"-tx-1-"axonal neuropathy"-noun-0]|TX|45/17|
text_000N_40913|MMI|3.50|MTRFR gene|C2240303|[gngm]|["C12ORF65"-tx-1-"C12orf65"-noun-0]|TX|5/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Breast Carcinoma|C0678222|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|46/13|
text_000N_40941|MMI|5.18|Childhood Breast Carcinoma|C3897071|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|46/13|
text_000N_40941|MMI|5.18|Malignant neoplasm of breast|C0006142|[neop]|["BREAST CANCER"-tx-1-"breast cancer"-noun-0]|TX|46/13|
text_000N_40941|MMI|3.56|Survivors|C0206194|[podg]|["Survivors"-tx-1-"survivors"-noun-0]|TX|14/9|
text_000N_40941|MMI|3.46|Increased risk|C4699158|[fndg]|["Increased risk"-tx-1-"increased risk"-noun-0]|TX|27/14|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|3.55|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|24/8|
text_000N_40972|MMI|3.45|royal jelly|C0073603|[orch,phsu]|["ROYAL JELLY"-tx-1-"royal jelly"-noun-0]|TX|36/11|
text_000N_40972|MMI|3.43|Antibiotics|C0003232|[antb]|["Antimicrobial"-tx-1-"antimicrobial"-adj-0]|TX|10/13|
text_000N_40972|MMI|3.43|Antimicrobial [APC]|C5399717|[phsu]|["Antimicrobial"-tx-1-"antimicrobial"-adj-0]|TX|10/13|
text_000N_40972|MMI|3.43|Microbicides|C1136254|[phsu]|["Antimicrobial"-tx-1-"antimicrobial"-adj-0]|TX|10/13|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"process"-noun-0]|TX|21/7|
text_000N_47420|MMI|5.18|Polyadenylation|C0949765|[moft]|["Polyadenylation"-tx-1-"polyadenylation"-noun-0]|TX|3/15|
text_000N_47420|MMI|5.18|Process|C1522240|[phpr]|["Process"-tx-1-"process"-noun-0]|TX|21/7|
text_000N_47420|MMI|5.18|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"process"-noun-0]|TX|21/7|
text_000N_47420|MMI|5.18|Stabilized (qualifier value)|C0184512|[fndg]|["stabilizes"-tx-1-"stabilizes"-verb-0]|TX|34/10|
text_000N_47420|MMI|5.18|bony process|C1184743|[bpoc]|["Process"-tx-1-"process"-noun-0]|TX|21/7|
text_000N_47420|MMI|3.64|Staphylococcal Protein A|C0038164|[aapp,imft,irda]|["a protein"-tx-1-"a protein"-noun-0]|TX|45/9|
text_000N_47420|MMI|3.56|Data types - String|C1547402|[inpr]|["String"-tx-1-"string"-noun-0]|TX|67/6|
text_000N_47420|MMI|3.56|String (device)|C0183652|[medd]|["string"-tx-1-"string"-noun-0]|TX|67/6|
text_000N_47420|MMI|3.56|String (foundation metadata concept)|C3540771|[inpr]|["String"-tx-1-"string"-noun-0]|TX|67/6|
text_000N_47420|MMI|3.55|End|C0444930|[spco]|["End"-tx-1-"end"-noun-0]|TX|103/3|
text_000N_47420|MMI|3.55|Stop (qualifier value)|C2746065|[tmco]|["End"-tx-1-"end"-noun-0]|TX|103/3|
text_000N_47420|MMI|3.43|adenosine|C0001443|[bacs,nnon,phsu]|["ADENOSINE"-tx-1-"Adenosine"-noun-0]|TX|77/9|
text_000N_47420|MMI|3.43|Molecule|C0567416|[sbst]|["Molecule"-tx-1-"molecule"-noun-0]|TX|114/8|
text_000N_47420|MMI|3.43|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-prep-0]|TX|96/2|
text_000N_47420|MMI|3.43|To|C1883351|[qlco]|["To"-tx-1-"to"-prep-0]|TX|96/2|
text_000N_47420|MMI|3.42|Add|C5401128|[fndg]|["Add"-tx-1-"adding"-noun-0]|TX|58/6|
text_000N_47420|MMI|3.42|Add - instruction imperative|C1883712|[ftcn]|["Add"-tx-1-"adding"-noun-0]|TX|58/6|
text_000N_47420|MMI|3.41|Residue|C1709915|[cnce]|["Residue"-tx-1-"residues"-noun-0]|TX|87/8|
<<<<< MMI
>>>>> MMI
text_000N_40999|AA|HRQOL|Health-Related Quality-of-Life|1|5|9|30|107:5
text_000N_40999|AA|CR|chronic rhinosinusiti|1|2|3|21|154:2
text_000N_40999|AA|CRS|chronic rhinosinusitis|1|3|3|22|154:3
text_000N_40999|MMI|5.18|Sino-Nasal Outcome Test-22|C5197690|[inpr]|["SNOT-22"-tx-1-"SNOT-22"-noun-0]|TX|40/7|
text_000N_40999|MMI|3.75|Sino-Nasal Outcome Test|C5197689|[inpr]|["Sino-Nasal Outcome Test"-tx-1-"sino-nasal outcome test"-noun-0]|TX|15/23|
text_000N_40999|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|114/15|
text_000N_40999|MMI|3.64|Chronic sinusitis|C0149516|[dsyn]|["Chronic rhinosinusitis"-tx-1-"chronic rhinosinusitis"-noun-0]|TX|130/22|
text_000N_40999|MMI|3.54|Measurement|C0242485|[ftcn]|["Measure"-tx-1-"measure"-noun-0]|TX|63/7|
text_000N_40999|MMI|3.54|Measures|C0079809|[qnco]|["Measure"-tx-1-"measure"-noun-0]|TX|63/7|
text_000N_40999|MMI|3.48|Health-Related Quality Of Life|C4279947|[idcn]|["Health-Related Quality Of Life"-tx-1-"Health-Related Quality-of-Life"-adj-0]|TX|75/30|
text_000N_40999|MMI|3.46|Clinical Item|C4554251|[inpr]|["item"-tx-1-"item"-noun-0]|TX|10/4|
text_000N_40999|MMI|3.46|Entity|C1551338|[enty]|["Item"-tx-1-"item"-noun-0]|TX|10/4|
text_000N_40999|MMI|3.42|Used by|C1273517|[fndg]|["used"-tx-1-"used"-adj-0]|TX|58/4|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|armodafinil|C1701455|[orch,phsu]|["ARMODAFINIL"-tx-1-"armodafinil"-noun-0]|TX|3/11|
text_000N_173245|MMI|3.58|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|15/4,34/2|
text_000N_173245|MMI|3.56|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|Insomnia, CTCAE 3.0|C1963237|[fndg]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|37/8|
text_000N_173245|MMI|3.56|Insomnia, CTCAE 5.0|C4554626|[fndg]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|37/8|
text_000N_173245|MMI|3.56|Sleep Quality Question|C4082202|[inpr]|["Insomnia"-tx-1-"insomnia"-noun-0]|TX|37/8|
text_000N_173245|MMI|3.56|Sleeplessness|C0917801|[sosy]|["INSOMNIA"-tx-1-"insomnia"-noun-0]|TX|37/8|
text_000N_173245|MMI|3.56|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
text_000N_173245|MMI|3.56|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|24/9|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|Contain (action)|C2700400|[acty]|["Contain"-tx-1-"contain"-verb-0]|TX|19/7|
text_000N_173260|MMI|5.18|Containing (qualifier)|C0332256|[ftcn]|["contain"-tx-1-"contain"-verb-0]|TX|19/7|
text_000N_173260|MMI|4.12|Armadillo Repeat|C1510939|[amas]|["Armadillo Repeat"-tx-1-"armadillo repeats"-noun-0]|TX|27/17|
text_000N_173260|MMI|3.68|ARMCX1 gene|C1538939|[gngm]|["ALEX1"-tx-1-"ALEX1"-noun-0]|TX|13/5|
text_000N_173260|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|5/7|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|3.59|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|3/9|
text_000N_97316|MMI|3.59|Meningioma|C0025286|[neop]|["MENINGIOMAS"-tx-1-"meningiomas"-noun-0]|TX|30/11|
text_000N_97316|MMI|3.59|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|3/9|
text_000N_97316|MMI|3.59|Occur (action)|C1709305|[acty]|["Occur"-tx-1-"occur"-verb-0]|TX|21/5|
text_000N_97316|MMI|3.59|Occurrence Indicator|C4284875|[ftcn]|["OCCUR"-tx-1-"occur"-verb-0]|TX|21/5|
text_000N_97316|MMI|3.45|AKT1 gene|C0812228|[gngm]|["AKT1"-tx-1-"AKT1"-noun-0]|TX|16/4|
text_000N_97316|MMI|3.45|AKT1 protein, human|C0668624|[aapp,enzy]|["AKT1"-tx-1-"AKT1"-noun-0]|TX|16/4|
<<<<< MMI
>>>>> MMI
text_000N_173104|AA|PAC|periampullary carcinoma|1|3|3|23|28:3
text_000N_173104|MMI|5.18|Periampullary carcinoma|C0861830|[neop]|["Periampullary carcinoma"-tx-1-"periampullary carcinoma"-noun-0]|TX|3/23|
text_000N_173104|MMI|3.68|Genitourinary Cancer|C0751569|[neop]|["Genitourinary Malignancy"-tx-1-"genitourinary malignancy"-noun-0]|TX|51/24|
text_000N_173104|MMI|3.47|Infrequent|C0521114|[tmco]|["Rare"-tx-1-"rare"-adj-0]|TX|46/4|
text_000N_173104|MMI|3.47|Rare|C0522498|[qlco]|["Rare"-tx-1-"rare"-adj-0]|TX|46/4|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Estimated Potential Vessel Value|C2348043|[qlco]|["Reconstructed"-tx-1-"reconstructed"-verb-0]|TX|31/13|
text_000N_40839|MMI|3.63|AS virus|C0319157|[virs]|["virus"-tx-1-"virus"-noun-0]|TX|20/5|
text_000N_40839|MMI|3.63|Virus|C0042776|[virs]|["VIRUS"-tx-1-"virus"-noun-0]|TX|20/5|
text_000N_40839|MMI|3.48|Influenza|C0021400|[dsyn]|["FLU"-tx-1-"flu"-noun-0]|TX|16/3|
text_000N_40839|MMI|3.48|ZMYND10 wt Allele|C3811318|[gngm]|["FLU"-tx-1-"flu"-noun-0]|TX|16/3|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|17/6|
text_000N_173276|MMI|5.18|Tetracycline Antibiotics|C1744619|[antb,orch]|["tetracycline"-tx-1-"tetracycline"-noun-0]|TX|4/12|
text_000N_173276|MMI|5.18|tetracycline|C0039644|[antb,orch]|["Tetracyclin"-tx-1-"tetracycline"-noun-0]|TX|4/12|
text_000N_173276|MMI|3.91|Dentin formation|C0232509|[ortf]|["Dentin Formation"-tx-1-"tooth formation"-noun-0]|TX|24/15|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|5.18|tremelimumab|C2351038|[aapp,imft,phsu]|["TREMELIMUMAB"-tx-1-"tremelimumab"-noun-0]|TX|5/12|
text_000N_97424|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_97424|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_97424|MMI|3.44|Malignant mesothelioma|C0345967|[neop]|["Mesothelioma"-tx-1-"mesothelioma"-noun-0]|TX|38/12|
text_000N_97424|MMI|3.44|Mesothelioma|C0025500|[neop]|["MESOTHELIOMA"-tx-1-"mesothelioma"-noun-0]|TX|38/12|
text_000N_97424|MMI|3.44|NCI CTEP SDC Mesothelioma Sub-Category Terminology|C3538785|[inpr]|["Mesothelioma"-tx-1-"mesothelioma"-noun-0]|TX|38/12|
text_000N_97424|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|51/8|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|3.68|ERAP2 gene|C1836110|[gngm]|["ERAP2"-tx-1-"ERAP2"-noun-0]|TX|14/5|
text_000N_173136|MMI|3.59|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|20/15|
text_000N_173136|MMI|3.59|Birdshot Chorioretinopathy|C1853959|[dsyn]|["BIRDSHOT CHORIORETINOPATHY"-tx-1-"birdshot chorioretinopathy"-noun-0]|TX|48/26|
text_000N_173136|MMI|3.55|Disease|C0012634|[dsyn]|["Disease"-tx-1-"disease"-noun-0]|TX|40/7|
text_000N_173136|MMI|3.50|Enzyme (disposition)|C4521602|[qlco]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
text_000N_173136|MMI|3.50|Enzyme [APC]|C5399708|[enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
text_000N_173136|MMI|3.50|Enzymes|C0014442|[aapp,enzy]|["Enzyme"-tx-1-"enzyme"-noun-0]|TX|7/6|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|Proteomics|C0872252|[bmod]|["Proteomics"-tx-1-"proteomics"-noun-0]|TX|4/10|
text_000N_173087|MMI|3.59|Dry Eye Syndrome, CTCAE|C1962953|[fndg]|["Dry eye syndrome"-tx-1-"dry eye syndrome"-noun-0]|TX|45/16|
text_000N_173087|MMI|3.59|Dry Eye Syndromes|C0013238|[dsyn]|["Dry Eye Syndrome"-tx-1-"dry eye syndrome"-noun-0]|TX|45/16|
text_000N_173087|MMI|3.54|use studies|C0869040|[resa]|["study use"-tx-1-"used study"-noun-0]|TX|20/4,32/5|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|3.72|Phase 3 Clinical Trials|C0282461|[resa]|["Clinical Trials, Phase III"-tx-1-"phase III clinical trials"-noun-0]|TX|27/25|
text_000N_173230|MMI|3.55|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|17/6|
text_000N_173230|MMI|3.55|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|17/6|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Scientific Equipment|C2827396|[mnob]|["Tool"-tx-1-"tool"-noun-0]|TX|13/4|
text_000N_97283|MMI|5.18|Tool, device (physical object)|C0336791|[mnob]|["Tool"-tx-1-"tool"-noun-0]|TX|13/4|
text_000N_97283|MMI|5.18|Zebrafish|C0043457|[fish]|["Zebrafish"-tx-1-"zebrafish"-noun-0]|TX|88/9|
text_000N_97283|MMI|3.58|Functional behavioral assessment|C0558024|[hlca]|["Functional analysis"-tx-1-"functional analysis"-noun-0]|TX|39/19|
text_000N_97283|MMI|3.44|Regulatory Sequences, Nucleic Acid|C0034987|[bacs,nnon]|["Regulatory Regions"-tx-1-"regulatory regions"-noun-0]|TX|66/18|
text_000N_97283|MMI|3.42|CISH protein, human|C1742862|[aapp,bacs]|["CIS"-tx-1-"cis"-adj-0]|TX|62/3|
text_000N_97283|MMI|3.42|Genus Cis|C1504308|[euka]|["Cis"-tx-1-"cis"-adj-0]|TX|62/3|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Anti-BCMA/PBD ADC MEDI2228|C4725626|[aapp,imft,phsu]|["MEDI2228"-tx-1-"MEDI2228"-noun-0]|TX|3/8|
text_000N_97301|MMI|5.18|Antibodies, Bispecific|C0206492|[aapp,imft,phsu]|["Bispecific Antibody"-tx-1-"bispecific antibody"-noun-0]|TX|14/19|
<<<<< MMI
>>>>> MMI
text_000N_97331|AA|CNV|Copy Number Variant|1|3|5|19|26:3
text_000N_97331|AA|CNVs|Copy Number Variants|1|4|5|20|26:4
text_000N_97331|MMI|5.18|Copy Number Polymorphism|C1511518|[nusq]|["Copy Number variants"-tx-1-"Copy Number Variants"-noun-0]|TX|4/20|
text_000N_97331|MMI|3.55|Depletion|C0333668|[ftcn]|["Depleted"-tx-1-"depleted"-verb-0]|TX|32/8|
text_000N_97331|MMI|3.55|IPSS Risk Category Low|C4522223|[inpr]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|IPSS-R Risk Category Low|C5203106|[fndg]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|Low Level|C4321351|[fndg]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|Low Mitosis-Karyorrhexis Index|C3890211|[qnco]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|Malignant Germ Cell International Collaborative Risk Classification, Low|C5444026|[clas]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|low|C0205251|[qlco]|["Low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|low confidentiality|C1550472|[inpr]|["low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.55|low exposure|C4048187|[qlco]|["low"-tx-1-"low"-adj-0]|TX|55/3|
text_000N_97331|MMI|3.52|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|44/7|
text_000N_97331|MMI|3.52|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|44/7|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|5.18|5-methoxypsoralen|C0049289|[orch,phsu]|["Bergapten"-tx-1-"bergapten"-noun-0]|TX|4/9|
text_000N_97378|MMI|5.18|Dermatitis, Phototoxic|C0162830|[dsyn]|["phototoxicity"-tx-1-"phototoxicity"-noun-0]|TX|20/13|
text_000N_97378|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|14/5|
text_000N_97378|MMI|5.18|Phototoxicity|C1527358|[dsyn]|["Phototoxicity"-tx-1-"phototoxicity"-noun-0]|TX|20/13|
text_000N_97378|MMI|5.18|Phototoxicity Study|C3892046|[resa]|["PHOTOTOXICITY"-tx-1-"phototoxicity"-noun-0]|TX|20/13|
text_000N_97378|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|14/5|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|12.00|calmodulin-dependent protein kinase II|C0248868|[aapp,enzy]|["CaM KII"-tx-1-"CaMKII"-noun-0,"Calcium-Calmodulin Protein Kinase II"-tx-1-"Calcium/Calmodulin protein kinase II"-noun-0,"Calmodulin-Dependent Protein Kinase II"-tx-1-"Calmodulin dependent protein kinase II"-noun-0]|TX|51/6;3/18,32/17;11/38|
text_000N_97394|MMI|5.18|Congestive heart failure|C0018802|[dsyn]|["Heart failure"-tx-1-"heart failure"-noun-0]|TX|95/13|
text_000N_97394|MMI|5.18|Heart Failure, CTCAE|C4554158|[fndg]|["Heart Failure"-tx-1-"heart failure"-noun-0]|TX|95/13|
text_000N_97394|MMI|5.18|Heart failure|C0018801|[dsyn]|["HEART FAILURE"-tx-1-"heart failure"-noun-0]|TX|95/13|
text_000N_97394|MMI|3.88|Calcium/calmodulin-dependent protein kinase|C0769224|[aapp,enzy]|["Calcium/calmodulin-dependent protein kinase"-tx-1-"Calcium/Calmodulin dependent protein kinase"-noun-0]|TX|3/43|
text_000N_97394|MMI|3.64|Cardiac Arrhythmia|C0003811|[dsyn]|["Cardiac Arrhythmias"-tx-1-"cardiac arrhythmias"-noun-0]|TX|71/19|
text_000N_97394|MMI|3.60|CALCIUM SUPPLEMENTS|C3540037|[phsu,vita]|["CALCIUM"-tx-1-"Calcium"-noun-0]|TX|3/7|
text_000N_97394|MMI|3.60|Calcium Drug Class|C3714611|[phsu]|["CALCIUM"-tx-1-"Calcium"-noun-0]|TX|3/7|
text_000N_97394|MMI|3.60|Calcium [EPC]|C2936886|[phsu]|["Calcium"-tx-1-"Calcium"-noun-0]|TX|3/7|
text_000N_97394|MMI|3.60|Calcium, Dietary|C0006726|[inch]|["Calcium"-tx-1-"Calcium"-noun-0]|TX|3/7|
text_000N_97394|MMI|3.60|Conditional|C1701901|[qlco]|["Dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.60|Dependent - ability|C0851827|[qlco]|["Dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.60|Dependent for Toilet Use|C4321395|[inpr]|["dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.60|Dependent for bathing|C0429986|[fndg]|["dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.60|Dependent for dressing|C0429964|[fndg]|["dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.60|GCNT2 gene|C1415022|[gngm]|["II"-tx-1-"II"-noun-0]|TX|47/2|
text_000N_97394|MMI|3.60|HLA Class II Histocompatibility Antigen Gamma Chain, human|C4082587|[aapp,imft]|["Ii"-tx-1-"II"-noun-0]|TX|47/2|
text_000N_97394|MMI|3.60|ISS Stage II Plasma Cell Myeloma|C2346457|[neop]|["II"-tx-1-"II"-noun-0]|TX|47/2|
text_000N_97394|MMI|3.60|VIPR1 wt Allele|C1710602|[gngm]|["II"-tx-1-"II"-noun-0]|TX|47/2|
text_000N_97394|MMI|3.60|calcium|C0006675|[bacs,elii,phsu]|["CALCIUM"-tx-1-"Calcium"-noun-0]|TX|3/7|
text_000N_97394|MMI|3.60|dependent|C3244310|[ftcn]|["dependent"-tx-1-"dependent"-noun-0]|TX|22/9|
text_000N_97394|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|59/8|
text_000N_97394|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|59/8|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|B-Cell Lymphoma/Leukemia 11B|C2984595|[aapp]|["BCL11B"-tx-1-"BCL11B"-noun-0]|TX|3/6|
text_000N_43235|MMI|5.18|BCL11B gene|C1421887|[gngm]|["BCL11B"-tx-1-"BCL11B"-noun-0]|TX|3/6|
text_000N_43235|MMI|3.59|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|10/8|
text_000N_43235|MMI|3.59|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|10/8|
text_000N_43235|MMI|3.59|Schizophrenia|C0036341|[mobd]|["SCHIZOPHRENIA"-tx-1-"schizophrenia"-noun-0]|TX|22/13|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|FN1 protein, human|C1570610|[aapp,bacs]|["Fibronectin"-tx-1-"fibronectin"-noun-0]|TX|5/11|
text_000N_173214|MMI|5.18|Fibronectins|C0016055|[aapp,bacs]|["Fibronectin"-tx-1-"fibronectin"-noun-0]|TX|5/11|
text_000N_173214|MMI|3.58|Serum Markers|C0162491|[qlco]|["Serum biomarker"-tx-1-"serum biomarker"-noun-0]|TX|30/15|
text_000N_173214|MMI|3.47|Muscular Dystrophy, Duchenne|C0013264|[dsyn]|["DUCHENNE MUSCULAR DYSTROPHY"-tx-1-"Duchenne muscular dystrophy"-noun-0]|TX|50/27|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|AS virus|C0319157|[virs]|["virus"-tx-1-"virus"-noun-0]|TX|33/5|
text_000N_173291|MMI|5.18|Acquisition (action)|C1706701|[acty]|["Obtain"-tx-1-"obtains"-verb-0]|TX|39/7|
text_000N_173291|MMI|5.18|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"Autophagy"-noun-0]|TX|0/9|
text_000N_173291|MMI|5.18|Obtain|C1301820|[ftcn]|["Obtain"-tx-1-"obtains"-verb-0]|TX|39/7|
text_000N_173291|MMI|5.18|Virus|C0042776|[virs]|["VIRUS"-tx-1-"virus"-noun-0]|TX|33/5|
text_000N_173291|MMI|3.78|Yes or No Response|C1512698|[inpr]|["yes/no"-tx-1-"yes no"-noun-0]|TX|73/3,80/2|
text_000N_173291|MMI|3.68|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"process"-noun-0]|TX|17/7|
text_000N_173291|MMI|3.68|Process|C1522240|[phpr]|["Process"-tx-1-"process"-noun-0]|TX|17/7|
text_000N_173291|MMI|3.68|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"process"-noun-0]|TX|17/7|
text_000N_173291|MMI|3.68|bony process|C1184743|[bpoc]|["Process"-tx-1-"process"-noun-0]|TX|17/7|
text_000N_173291|MMI|3.57|Nutrients|C0678695|[food]|["Nutrients"-tx-1-"nutrients"-noun-0]|TX|47/9|
text_000N_173291|MMI|3.44|Host (organism)|C1167395|[orgm]|["Host"-tx-1-"host"-noun-0]|TX|67/4|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_97347|MMI|5.18|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_97347|MMI|5.18|TLE5 gene|C1412268|[gngm]|["GRG5"-tx-1-"GRG5"-noun-0]|TX|3/4|
text_000N_97347|MMI|3.58|Embryonic Development|C0013936|[ortf]|["Embryonic Development"-tx-1-"embryonic development"-noun-0]|TX|30/9,46/11|
text_000N_97347|MMI|3.58|Embryonic development aspects|C0243100|[ftcn]|["embryonic development"-tx-1-"embryonic development"-noun-0]|TX|30/9,46/11|
text_000N_97347|MMI|3.55|House mice|C0025914|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|40/5|
text_000N_97347|MMI|3.55|Laboratory mice|C0025929|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|40/5|
text_000N_97347|MMI|3.55|Late|C0205087|[tmco]|["Late"-tx-1-"late"-adj-0]|TX|25/4|
text_000N_97347|MMI|3.55|Mus|C0026809|[mamm]|["MOUSE"-tx-1-"mouse"-noun-0]|TX|40/5|
text_000N_97347|MMI|3.55|Mus sp.|C1331371|[mamm]|["Mouse, NOS"-tx-1-"mouse"-noun-0]|TX|40/5|
text_000N_97347|MMI|3.55|Only - dosing instruction fragment|C1720467|[inpr]|["Only"-tx-1-"only"-adv-0]|TX|17/4|
text_000N_97347|MMI|3.55|Singular|C0205171|[qnco]|["Only"-tx-1-"only"-adv-0]|TX|17/4|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|COL5A2 gene|C1413588|[gngm]|["COL5A2 Gene"-tx-1-"COL5A2 gene"-noun-0]|TX|3/11|
text_000N_43303|MMI|3.68|Coronary Arteriosclerosis|C0010054|[dsyn]|["ischaemic heart disease"-tx-1-"ischemic heart disease"-noun-0]|TX|29/22|
text_000N_43303|MMI|3.68|Myocardial Ischemia|C0151744|[dsyn]|["Ischaemic heart disease, NOS"-tx-1-"ischemic heart disease"-noun-0]|TX|29/22|
text_000N_43303|MMI|3.56|Associated with|C0332281|[qlco]|["Associated"-tx-1-"associated"-verb-0]|TX|15/10|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|23/6|
text_000N_47435|MMI|5.18|Cardiac Surgery procedures|C0018821|[topp]|["Cardiac Surgery"-tx-1-"cardiac surgery"-noun-0]|TX|58/15|
text_000N_47435|MMI|5.18|Decreased triiodothyronine level|C1295669|[fndg]|["Low T3"-tx-1-"low T3"-noun-0]|TX|5/6|
text_000N_47435|MMI|5.18|Discipline of Heart Surgery|C0524727|[bmod]|["Cardiac surgery"-tx-1-"cardiac surgery"-noun-0]|TX|58/15|
text_000N_47435|MMI|3.59|Forecast of outcome|C0033325|[hlca]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|30/9|
text_000N_47435|MMI|3.59|Prognosis:Find:Pt:^Patient:Nom|C3854082|[clna]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|30/9|
text_000N_47435|MMI|3.45|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|simvastatin|C0074554|[orch,phsu]|["SIMVASTATIN"-tx-1-"simvastatin"-noun-0]|TX|5/11|
text_000N_47406|MMI|3.53|Result|C1274040|[ftcn]|["Outcome"-tx-1-"outcomes"-noun-0]|TX|25/8|
text_000N_47406|MMI|3.50|Subarachnoid Hemorrhage, Aneurysmal|C0751530|[patf]|["Subarachnoid Hemorrhage, Aneurysmal"-tx-1-"aneurysmal subarachnoid hemorrhage"-noun-0]|TX|37/34|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|5.18|galcanezumab|C4694273|[aapp,imft,phsu]|["GALCANEZUMAB"-tx-1-"galcanezumab"-noun-0]|TX|3/12|
text_000N_173120|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|16/9,30/9|
text_000N_173120|MMI|3.43|Migraine Disorders|C0149931|[dsyn]|["MIGRAINE"-tx-1-"migraine"-noun-0]|TX|43/8|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.68|KCNQ2 gene|C1416614|[gngm]|["KCNQ2"-tx-1-"KCNQ2"-noun-0]|TX|15/5|
text_000N_47304|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|21/15|
text_000N_47304|MMI|3.64|idiopathic epilepsy|C0391957|[dsyn]|["Idiopathic epilepsy"-tx-1-"idiopathic epilepsy"-noun-0]|TX|37/19|
text_000N_47304|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|CCCTC-binding factor|C0669443|[aapp,bacs]|["CTCF Protein"-tx-1-"CTCF protein"-noun-0]|TX|9/12|
text_000N_47363|MMI|3.57|AQP1 gene|C1412491|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|22/2|
text_000N_47363|MMI|3.57|AQP1 wt Allele|C5551158|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|22/2|
text_000N_47363|MMI|3.57|Colombia|C3245499|[geoa]|["CO"-tx-1-"co"-verb-0]|TX|22/2|
text_000N_47363|MMI|3.57|Localized|C0392752|[spco]|["localize"-tx-1-"localize"-verb-0]|TX|25/8|
text_000N_47363|MMI|3.57|cohesins|C0907709|[aapp,bacs]|["cohesin"-tx-1-"cohesin"-noun-0]|TX|39/7|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Carpal Tunnel Syndrome|C0007286|[dsyn]|["CARPAL TUNNEL SYNDROME"-tx-1-"carpal tunnel syndrome"-noun-0]|TX|26/22|
text_000N_43275|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|20/5|
text_000N_43275|MMI|5.18|Radius Fractures|C0034628|[inpo]|["Fracture, Radius"-tx-1-"radius fracture"-noun-0]|TX|4/15|
text_000N_43275|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|20/5|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|3.68|Histones|C0019652|[aapp,bacs]|["Histone"-tx-1-"histone"-noun-0]|TX|14/7|
text_000N_47274|MMI|3.56|Candida albicans allergenic extract|C0717551|[imft,phsu]|["YEAST"-tx-1-"yeast"-noun-0]|TX|35/5|
text_000N_47274|MMI|3.56|Exist|C2987476|[qlco]|["Exist"-tx-1-"exist"-verb-0]|TX|22/5|
text_000N_47274|MMI|3.56|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|41/6|
text_000N_47274|MMI|3.56|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|41/6|
text_000N_47274|MMI|3.56|Saccharomyces cerevisiae|C0036025|[fngs]|["yeast"-tx-1-"yeast"-noun-0]|TX|35/5|
text_000N_47274|MMI|3.56|Yeast Present|C4049929|[lbtr]|["YEAST"-tx-1-"yeast"-noun-0]|TX|35/5|
text_000N_47274|MMI|3.56|Yeast, Dried|C0043392|[food]|["Yeast"-tx-1-"yeast"-noun-0]|TX|35/5|
text_000N_47274|MMI|3.56|Yeasts|C0043393|[fngs]|["YEAST"-tx-1-"yeast"-noun-0]|TX|35/5|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|3.68|Phase 3 Clinical Trials|C0282461|[resa]|["Phase III Trials"-tx-1-"phase III trials"-noun-0]|TX|32/16|
text_000N_47334|MMI|3.46|Clinical|C0205210|[qlco]|["Clinical"-tx-1-"clinical"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.46|Clinical Batch|C4523057|[mnob]|["Clinical"-tx-1-"clinical"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.46|Clinical Data|C1516606|[inpr]|["Clinical"-tx-1-"clinical"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.46|Clinical NEC (not elsewhere classified in LNC)|C1315013|[inpr]|["Clinical"-tx-1-"clinical"-adj-0]|TX|23/8|
text_000N_47334|MMI|3.46|Entered|C1521975|[qlco]|["Entered"-tx-1-"entered"-adj-0]|TX|15/7|
text_000N_47334|MMI|3.46|ubrogepant|C4505936|[orch,phsu]|["UBROGEPANT"-tx-1-"ubrogepant"-noun-0]|TX|4/10|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.63|Escape (mental process)|C0870509|[menp]|["escape"-tx-1-"escape"-noun-0]|TX|59/6|
text_000N_43331|MMI|3.57|Relations|C0869014|[socb]|["relation"-tx-1-"relation"-noun-0]|TX|11/8|
text_000N_43331|MMI|3.57|Relative (related person)|C0080103|[famg]|["Relation"-tx-1-"relation"-noun-0]|TX|11/8|
text_000N_43331|MMI|3.48|Albumins|C0001924|[aapp,bacs]|["Albumen"-tx-1-"albumin"-noun-0]|TX|51/7|
text_000N_43331|MMI|3.47|NPR1 protein, human|C1529723|[aapp,enzy,rcpt]|["ANP-A"-tx-1-"a ANP"-noun-0]|TX|9/1,28/3|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|arimoclomol|C1451975|[orch,phsu]|["ARIMOCLOMOL"-tx-1-"arimoclomol"-noun-0]|TX|3/11|
text_000N_47450|MMI|3.54|Inducer|C3898767|[sbst]|["Inducer"-tx-1-"inducer"-noun-0]|TX|20/7|
text_000N_47450|MMI|3.46|Heat-Shock Response|C0282498|[phsf]|["Heat-Shock Response"-tx-1-"heat shock response"-noun-0]|TX|35/19|
text_000N_47450|MMI|3.44|Co^a|C2361996|[imft]|["Co^a"-tx-1-"a co"-noun-0]|TX|15/4|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|3.60|Ubiquitination|C1519751|[moft]|["Ubiquitination"-tx-1-"ubiquitination"-noun-0]|TX|23/14|
text_000N_173151|MMI|3.60|proteasome complex disassembly|C3824143|[moft]|["proteasome degradation"-tx-1-"proteasomal degradation"-noun-0]|TX|49/23|
text_000N_173151|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|38/7|
text_000N_173151|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|38/7|
text_000N_173151|MMI|3.49|link protein|C0065011|[aapp,bacs]|["linked protein"-tx-1-"linked protein"-noun-0]|TX|8/14|
text_000N_173151|MMI|3.46|63|C4319614|[qnco]|["63"-tx-1-"63"-integer-0]|TX|5/2|
text_000N_173151|MMI|3.46|K Prime|C1708601|[qnco]|["K'"-tx-1-"K"-noun-0]|TX|3/1|
text_000N_173151|MMI|3.46|potassium ion|C0597277|[elii,phsu]|["K+"-tx-1-"K"-noun-0]|TX|3/1|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.55|Controlled Clinical Trial [Publication Type]|C0936233|[inpr]|["Controlled Trial"-tx-1-"controlled trials"-noun-0]|TX|21/17|
text_000N_47320|MMI|3.55|Controlled Clinical Trials as Topic|C0009933|[resa]|["Controlled Trial"-tx-1-"controlled trials"-noun-0]|TX|21/17|
text_000N_47320|MMI|3.43|sevoflurane|C0074414|[orch,phsu]|["SEVOFLURANE"-tx-1-"sevoflurane"-noun-0]|TX|42/11|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|3.61|Cancer Prognosis|C1516221|[clna]|["Cancer Prognosis"-tx-1-"cancer prognosis"-noun-0]|TX|53/16|
text_000N_47349|MMI|3.61|Colorectal Cancer Pathway|C2984278|[cnce]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_47349|MMI|3.61|Colorectal Carcinoma|C0009402|[neop]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_47349|MMI|3.61|Malignant neoplasm of colon and/or rectum|C4722085|[neop]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_47349|MMI|3.61|NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|C3542412|[inpr]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|42/17|
text_000N_47349|MMI|3.59|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["lncRNA"-tx-1-"lncRNAs"-noun-0]|TX|22/7|
text_000N_47349|MMI|3.59|RNA, Long Untranslated|C3494264|[bacs,nnon]|["lncRNA"-tx-1-"lncRNAs"-noun-0]|TX|22/7|
text_000N_47349|MMI|3.56|Colorectal|C0555952|[spco]|["Colorectal"-tx-1-"colorectal"-noun-0]|TX|42/10|
text_000N_47349|MMI|3.56|Forecast of outcome|C0033325|[hlca]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|60/9|
text_000N_47349|MMI|3.56|Prognosis:Find:Pt:^Patient:Nom|C3854082|[clna]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|60/9|
text_000N_47349|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|33/4|
text_000N_47349|MMI|3.48|Autophagy|C0004391|[celf]|["Autophagy"-tx-1-"autophagy"-adj-0]|TX|4/9|
text_000N_47349|MMI|3.48|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-adj-0]|TX|14/7|
text_000N_47349|MMI|3.48|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-adj-0]|TX|14/7|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Restless Legs Syndrome|C0035258|[dsyn]|["Restless Legs Syndrome"-tx-1-"restless leg syndrome"-noun-0]|TX|55/21|
text_000N_47377|MMI|5.18|pregabalin|C0657912|[aapp,phsu]|["PREGABALIN"-tx-1-"pregabalin"-noun-0]|TX|3/10|
text_000N_47377|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|14/9,28/9|
text_000N_47377|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|41/8|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.63|Photosensitivity of skin|C0349506|[patf]|["PHOTOSENSITIVITY"-tx-1-"photosensitivity"-noun-0]|TX|22/16|
text_000N_47392|MMI|3.63|Photosensitivity, CTCAE|C2362621|[fndg]|["Photosensitivity"-tx-1-"photosensitivity"-noun-0]|TX|22/16|
text_000N_47392|MMI|3.48|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|16/5|
text_000N_47392|MMI|3.48|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|16/5|
text_000N_47392|MMI|3.48|doxycycline|C0013090|[antb,orch]|["Doxycyclin"-tx-1-"doxycycline"-noun-0]|TX|4/11|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|dexamethasone|C0011777|[orch,phsu]|["DEXAMETHASONE"-tx-1-"dexamethasone"-noun-0]|TX|3/13|
text_000N_43358|MMI|3.59|Cerebral Hemorrhage|C2937358|[patf]|["Intracerebral haemorrhage"-tx-1-"intracerebral hemorrhage"-noun-0]|TX|46/24|
text_000N_43358|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|Recommendation|C0034866|[idcn]|["Recommended"-tx-1-"recommended"-verb-0]|TX|17/11|
text_000N_43358|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
text_000N_43358|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|33/9|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|3.63|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancers"-noun-0]|TX|10/9|
text_000N_40886|MMI|3.62|Chromatin Loop|C1516509|[celc]|["Chromatin Loop"-tx-1-"chromatin loops"-noun-0]|TX|46/15|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Cerebral Edema|C0006114|[patf]|["Cerebral oedema"-tx-1-"cerebral edema"-noun-0]|TX|21/14|
text_000N_40941|MMI|5.18|glyburide|C0017628|[orch,phsu]|["GLYBURIDE"-tx-1-"glyburide"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|3.64|Parkinson Disease|C0030567|[dsyn]|["Parkinsons disease"-tx-1-"Parkinson's disease"-noun-0]|TX|21/19|
text_000N_43386|MMI|3.64|Parkinson's Disease Pathway|C1521736|[ftcn]|["Parkinson's Disease"-tx-1-"Parkinson's disease"-noun-0]|TX|21/19|
text_000N_43386|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
text_000N_43386|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|9/8|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.63|Scientific Equipment|C2827396|[mnob]|["Tool"-tx-1-"tools"-noun-0]|TX|17/5|
text_000N_40913|MMI|3.63|Tool, device (physical object)|C0336791|[mnob]|["Tool"-tx-1-"tools"-noun-0]|TX|17/5|
text_000N_40913|MMI|3.60|use studies|C0869040|[resa]|["study use"-tx-1-"used study"-noun-0]|TX|23/4,35/5|
text_000N_40913|MMI|3.59|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.59|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|45/9|
text_000N_40913|MMI|3.50|Optogenetics|C3494301|[mbrt]|["Optogenetics"-tx-1-"optogenetics"-noun-0]|TX|4/12|
text_000N_40913|MMI|3.45|Epilepsy|C0014544|[dsyn]|["EPILEPSY"-tx-1-"epilepsy"-noun-0]|TX|58/8|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|6.88|Compleat Liquid Nutrition|C0725685|[food]|["COMPLEAT"-tx-2-"complete"-adj-0,"COMPLEAT"-tx-1-"complete"-adj-0]|TX|80/8;56/8|
text_000N_40972|MMI|6.88|Complete|C0205197|[qlco]|["COMPLETE"-tx-2-"complete"-adj-0,"COMPLETE"-tx-1-"complete"-adj-0]|TX|80/8;56/8|
text_000N_40972|MMI|6.88|Complete Pharyngeal Contraction|C4283785|[fndg]|["Complete"-tx-2-"complete"-adj-0,"Complete"-tx-1-"complete"-adj-0]|TX|80/8;56/8|
text_000N_40972|MMI|6.88|Data operation - complete|C3853530|[ftcn]|["complete"-tx-2-"complete"-adj-0,"complete"-tx-1-"complete"-adj-0]|TX|80/8;56/8|
text_000N_40972|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-2-"available"-adj-0]|TX|138/9|
text_000N_40972|MMI|5.18|Needs|C0027552|[qlco]|["Need"-tx-1-"need"-verb-0]|TX|19/4|
text_000N_40972|MMI|5.18|Patient need for (contextual qualifier)|C0686904|[ftcn]|["need"-tx-1-"need"-verb-0]|TX|19/4|
text_000N_40972|MMI|3.63|Analysis|C0936012|[resa]|["ANALYSIS"-tx-1-"analyses"-noun-0]|TX|10/8|
text_000N_40972|MMI|3.63|Analysis of substances|C0002778|[lbpr]|["Analysis"-tx-1-"analyses"-noun-0]|TX|10/8|
text_000N_40972|MMI|3.63|analysis aspect|C1524024|[ftcn]|["analysis"-tx-1-"analyses"-noun-0]|TX|10/8|
text_000N_40972|MMI|3.55|Knowledge|C0376554|[inpr]|["Knowledge"-tx-1-"knowledge"-noun-0]|TX|30/9|
text_000N_40972|MMI|3.52|Genome, Bacterial|C0085238|[gngm]|["Bacterial genome"-tx-2-"genome bacteria"-noun-0]|TX|89/6,103/8|
text_000N_40972|MMI|3.50|Proteomics|C0872252|[bmod]|["proteomic"-tx-1-"Proteomic"-adj-0]|TX|0/9|
text_000N_40972|MMI|3.43|Arthrobacter|C0003876|[bact]|["Genus Arthrobacter"-tx-2-"genus Arthrobacter"-noun-0]|TX|119/18|
text_000N_40972|MMI|3.42|Before|C0332152|[tmco]|["Prior"-tx-1-"prior"-adj-0]|TX|24/5|
text_000N_40972|MMI|3.42|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|65/6|
text_000N_40972|MMI|3.42|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|65/6|
text_000N_40972|MMI|3.42|Organism|C0029235|[orgm]|["Organism"-tx-1-"organism"-noun-0]|TX|47/8|
text_000N_40972|MMI|3.42|Prior Medication Usage|C2826257|[evnt]|["PRIOR"-tx-1-"prior"-adj-0]|TX|24/5|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.54|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_47289|MMI|3.54|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_47289|MMI|3.48|NCI CTEP SDC Non-Small Cell Lung Cancer Sub-Category Terminology|C3539721|[inpr]|["Non-Small Cell Lung Cancer"-tx-1-"non-small-cell lung cancer"-noun-0]|TX|43/26|
text_000N_47289|MMI|3.48|Non-Small Cell Lung Cancer Pathway|C2984258|[cnce]|["Non-small cell lung cancer"-tx-1-"non-small-cell lung cancer"-noun-0]|TX|43/26|
text_000N_47289|MMI|3.48|Non-Small Cell Lung Carcinoma|C0007131|[neop]|["NONSMALL CELL LUNG CANCER"-tx-1-"non-small-cell lung cancer"-noun-0]|TX|43/26|
text_000N_47289|MMI|3.43|MAGE-A3 Peptide Vaccine|C1541478|[aapp,imft,phsu]|["MAGE-A3"-tx-1-"MAGE-A3"-noun-0]|TX|3/7|
text_000N_47289|MMI|3.43|MAGEA3 protein, human|C0962473|[aapp,imft]|["MAGE-A3"-tx-1-"MAGE-A3"-noun-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|3.62|Rotavirus Vaccines|C0597418|[aapp,imft,phsu]|["Rotavirus Vaccine"-tx-1-"vaccine rotavirus"-noun-0]|TX|11/7,23/9|
text_000N_40839|MMI|3.62|Vaccine product containing only Rotavirus antigen (medicinal product)|C5397359|[phsu]|["Rotavirus vaccine"-tx-1-"vaccine rotavirus"-noun-0]|TX|11/7,23/9|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Cri du chat|C0234861|[fndg]|["Cri du chat"-tx-1-"Cri Du Chat"-noun-0]|TX|3/11|
text_000N_173167|MMI|3.64|Chromosomes, Human, Pair 5|C0008668|[celc]|["Chromosome 5"-tx-1-"chromosome 5"-noun-0]|TX|82/12|
text_000N_173167|MMI|3.58|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|15/15|
text_000N_173167|MMI|3.57|Repeat Expansion Disease|C5447383|[dsyn]|["Repeat expansion"-tx-1-"expansion repeat"-noun-0]|TX|34/9,49/6|
text_000N_173167|MMI|3.57|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|68/4|
text_000N_173167|MMI|3.57|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|68/4|
text_000N_173167|MMI|3.57|In addition to|C0332287|[ftcn]|["With"-tx-1-"with"-prep-0]|TX|56/4|
text_000N_173167|MMI|3.57|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|73/5|
text_000N_173167|MMI|3.57|With - dosing instruction fragment|C1705690|[inpr]|["With"-tx-1-"with"-prep-0]|TX|56/4|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_173183|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_173183|MMI|5.18|liothyronine|C0041014|[aapp,horm,phsu]|["Triiodothyronine"-tx-1-"triiodothyronine"-noun-0]|TX|34/16|
text_000N_173183|MMI|5.18|suggestion|C1705535|[idcn]|["Suggest"-tx-1-"suggest"-verb-0]|TX|21/7|
text_000N_173183|MMI|3.68|Evidence|C3887511|[idcn]|["Evidence"-tx-1-"evidence"-noun-0]|TX|9/8|
text_000N_173183|MMI|3.55|Has property|C1292721|[ftcn]|["properties"-tx-1-"properties"-noun-0]|TX|71/10|
text_000N_173183|MMI|3.55|Property (attribute)|C0871161|[qlco]|["properties"-tx-1-"properties"-noun-0]|TX|71/10|
text_000N_173183|MMI|3.48|Traumatic Brain Injury|C0876926|[inpo]|["Traumatic Brain Injury"-tx-1-"traumatic brain injury"-noun-0]|TX|85/22|
text_000N_173183|MMI|3.38|Neuroprotection|C0598958|[celf]|["Neuroprotection"-tx-1-"neuroprotective"-adj-0]|TX|55/15|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|3.68|Signal Transduction|C0037083|[celf]|["Signaling"-tx-1-"signalling"-noun-0]|TX|35/10|
text_000N_173199|MMI|3.68|biological signaling|C3537152|[biof]|["signalling"-tx-1-"signalling"-noun-0]|TX|35/10|
text_000N_173199|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173199|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173199|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173199|MMI|3.50|MYC protein, human|C1454487|[aapp,bacs]|["MYC"-tx-1-"MYC"-noun-0]|TX|31/3|
text_000N_173199|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173199|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173199|MMI|3.44|HUWE1 gene|C1537395|[gngm]|["HUWE1"-tx-1-"HUWE1"-noun-0]|TX|22/5|
text_000N_173199|MMI|3.44|HUWE1 protein, human|C1619903|[aapp,enzy]|["HUWE1"-tx-1-"HUWE1"-noun-0]|TX|22/5|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Major Depressive Disorder|C1269683|[mobd]|["MDD"-tx-1-"MDD"-noun-0]|TX|93/3|
text_000N_173245|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|40/2|
text_000N_173245|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|40/2|
text_000N_173245|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|35/4|
text_000N_173245|MMI|3.63|Severe major depression|C3472470|[mobd]|["Severe major Depressive disorder"-tx-1-"severity major depressive disorder"-noun-0]|TX|55/8,67/25|
text_000N_173245|MMI|3.63|Methods|C0025663|[ftcn]|["Methods"-tx-1-"methods"-noun-0]|TX|22/7|
text_000N_173245|MMI|3.63|Methods aspects|C0025664|[ftcn]|["METHODS"-tx-1-"methods"-noun-0]|TX|22/7|
text_000N_173245|MMI|3.63|Techniques|C0449851|[ftcn]|["Methods"-tx-1-"methods"-noun-0]|TX|22/7|
text_000N_173245|MMI|3.53|Machine Learning|C0376284|[mcha]|["Machine Learning"-tx-1-"machine learning"-noun-0]|TX|5/16|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|Cessation of smoking|C0085134|[inbe]|["Smoking Cessation"-tx-1-"smoking cessation"-noun-0]|TX|57/17|
text_000N_173104|MMI|5.18|Smoking cessation therapy|C1095963|[topp]|["smoking cessation"-tx-1-"smoking cessation"-noun-0]|TX|57/17|
text_000N_173104|MMI|5.18|cytisine|C0056913|[orch,phsu]|["CYTISINE"-tx-1-"cytisine"-noun-0]|TX|3/8|
text_000N_173104|MMI|3.56|Upper|C1282910|[spco]|["SUPERIOR"-tx-1-"superior"-adj-0]|TX|12/8|
text_000N_173104|MMI|3.50|Nicotine replacement therapy|C1278444|[topp]|["Nicotine Replacement Therapy"-tx-1-"nicotine replacement therapy"-noun-0]|TX|24/28|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|3.68|Chromosomes|C0008633|[celc]|["Chromosomes"-tx-1-"chromosomes"-noun-0]|TX|10/11|
text_000N_47274|MMI|3.50|House mice|C0025914|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|4/5|
text_000N_47274|MMI|3.50|Laboratory mice|C0025929|[mamm]|["mouse"-tx-1-"mouse"-noun-0]|TX|4/5|
text_000N_47274|MMI|3.50|Mus|C0026809|[mamm]|["MOUSE"-tx-1-"mouse"-noun-0]|TX|4/5|
text_000N_47274|MMI|3.50|Mus sp.|C1331371|[mamm]|["Mouse, NOS"-tx-1-"mouse"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|17/4|
text_000N_47304|MMI|5.18|silicon|C0037107|[elii]|["SILICON"-tx-1-"silicon"-noun-0]|TX|4/7|
text_000N_47304|MMI|3.57|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-adj-0]|TX|22/2|
text_000N_47304|MMI|3.57|Present|C0150312|[fndg]|["In"-tx-1-"in"-adj-0]|TX|22/2|
text_000N_47304|MMI|3.57|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|Within|C0332285|[spco]|["In"-tx-1-"in"-adj-0]|TX|22/2|
text_000N_47304|MMI|3.57|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.57|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-adj-0]|TX|25/9|
text_000N_47304|MMI|3.44|Incontinence|C0021167|[dsyn]|["INCONTINENCE"-tx-1-"incontinence"-noun-0]|TX|39/12|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|Eucommia ulmoides leaf extract|C4306727|[orch]|["Eucommia ulmoides leaf extract"-tx-1-"Eucommia ulmoides leaf extract"-noun-0]|TX|5/30|
text_000N_47320|MMI|3.78|Fatty Liver|C0015695|[dsyn]|["Steatosis liver"-tx-1-"steatosis liver"-noun-0]|TX|48/9,64/5|
text_000N_47320|MMI|3.68|Diet, High-Fat|C0521974|[topp]|["Diet, High-Fat"-tx-1-"high-fat diet"-noun-0]|TX|81/13|
text_000N_47320|MMI|3.68|High fat diet (finding)|C5441638|[fndg]|["High fat diet NOS"-tx-1-"high-fat diet"-noun-0]|TX|81/13|
text_000N_47320|MMI|3.56|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-verb-0]|TX|70/7|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|TRDN gene|C1421109|[gngm]|["TRIADIN"-tx-1-"triadin"-noun-0]|TX|3/7|
text_000N_47334|MMI|5.18|triadin|C0146619|[aapp,bacs]|["triadin"-tx-1-"triadin"-noun-0]|TX|3/7|
text_000N_47334|MMI|3.64|Cardiac function|C0232164|[ortf]|["Cardiac function"-tx-1-"cardiac function"-noun-0]|TX|23/16|
text_000N_47334|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
text_000N_47334|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_47349|AA|GFI1B|Growth factor independence 1b|1|5|7|29|34:5
text_000N_47349|MMI|5.18|GFI1B protein, human|C1333880|[aapp,bacs]|["Growth Factor Independence-1B"-tx-1-"Growth factor independence 1b"-noun-0]|TX|3/29|
text_000N_47349|MMI|3.59|Importance Rating Score 0|C4084912|[inpr]|["Important"-tx-1-"important"-adj-0]|TX|41/9|
text_000N_47349|MMI|3.59|Important|C3898777|[qlco]|["Important"-tx-1-"important"-adj-0]|TX|41/9|
text_000N_47349|MMI|3.45|Hematopoiesis|C0018951|[ortf]|["Hematopoiesis"-tx-1-"hematopoiesis"-noun-0]|TX|55/13|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Cognition|C0009240|[menp]|["Cognitive function"-tx-1-"cognitive function"-noun-0]|TX|24/18|
text_000N_47363|MMI|5.18|Cognitive Function Subordinate Domain|C4050130|[inpr]|["Cognitive Function"-tx-1-"cognitive function"-noun-0]|TX|24/18|
text_000N_47363|MMI|5.18|Cognitive functions|C0392335|[menp]|["Cognitive function"-tx-1-"cognitive function"-noun-0]|TX|24/18|
text_000N_47363|MMI|5.18|evolocumab|C3529352|[aapp,imft,phsu]|["EVOLOCUMAB"-tx-1-"Evolocumab"-noun-0]|TX|5/10|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Asthma|C0004096|[dsyn]|["ASTHMA"-tx-1-"asthma"-noun-0]|TX|68/6|
text_000N_47377|MMI|5.18|Asthma Pathway|C2984299|[cnce]|["Asthma"-tx-1-"asthma"-noun-0]|TX|68/6|
text_000N_47377|MMI|5.18|PREVENT (product)|C0309872|[phsu]|["PREVENT"-tx-1-"prevent"-verb-0]|TX|49/7|
text_000N_47377|MMI|3.67|Schistosomiasis|C0036323|[dsyn]|["Infection by Schistosoma"-tx-1-"infections by Schistosoma"-noun-0]|TX|13/25|
text_000N_47377|MMI|3.43|Parasite Present|C4050301|[fndg]|["PARASITE"-tx-1-"parasite"-noun-0]|TX|4/8|
text_000N_47377|MMI|3.43|Parasites|C0030498|[euka]|["PARASITE"-tx-1-"parasite"-noun-0]|TX|4/8|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.81|Clinical stage II|C0205571|[qlco]|["Clinical Phase II"-tx-1-"clinical phase II"-noun-0]|TX|42/17|
text_000N_47392|MMI|3.68|November|C3828767|[tmco]|["November"-tx-1-"November"-noun-0]|TX|24/8|
text_000N_47392|MMI|3.68|patisiran|C3896714|[orch,phsu]|["PATISIRAN"-tx-1-"patisiran"-noun-0]|TX|3/9|
text_000N_47392|MMI|3.58|Clinical Trials|C0008976|[resa]|["Trial"-tx-1-"trials"-noun-0]|TX|60/6|
text_000N_47392|MMI|3.50|Current (present time)|C0521116|[tmco]|["Currently"-tx-1-"currently"-adv-0]|TX|13/9|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|4.25|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["LONG NON-CODING RNA"-tx-1-"long non coding RNAs"-noun-0]|TX|4/20|
text_000N_47406|MMI|4.25|RNA, Long Untranslated|C3494264|[bacs,nnon]|["RNA, Long Non-Coding"-tx-1-"long non coding RNAs"-noun-0]|TX|4/20|
text_000N_47406|MMI|3.98|Splice-Site Mutation|C1519478|[genf]|["Splice"-tx-1-"spliced"-verb-0]|TX|25/7|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|Prochlorococcus|C0995582|[bact]|["Prochlorococcus"-tx-1-"Prochlorococcus"-noun-0]|TX|3/15|
text_000N_47420|MMI|3.61|Organism|C0029235|[orgm]|["Organism"-tx-1-"organism"-noun-0]|TX|52/8|
text_000N_47420|MMI|3.47|Abundance|C2346714|[qlco]|["Abundant"-tx-1-"abundant"-adj-0]|TX|28/8|
text_000N_47420|MMI|3.47|Most|C0205393|[qnco]|["Most"-tx-1-"most"-adv-0]|TX|23/4|
text_000N_47420|MMI|3.42|Photosynthesis|C0031764|[npop]|["Photosynthesis"-tx-1-"photosynthetic"-adj-0]|TX|37/14|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.68|Observation Method - algorithm|C1553907|[ftcn]|["algorithm"-tx-1-"algorithm"-noun-0]|TX|13/9|
text_000N_47435|MMI|3.68|algorithm|C0002045|[inpr]|["Algorithm"-tx-1-"algorithm"-noun-0]|TX|13/9|
text_000N_47435|MMI|3.58|CRISPR Loci|C3658268|[gngm]|["CRISPR Array"-tx-1-"arrayed CRISPR"-noun-0]|TX|32/14|
text_000N_47435|MMI|3.56|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|23/4|
text_000N_47435|MMI|3.53|Disease Screening|C1710031|[diap]|["screen"-tx-1-"screens"-noun-0]|TX|47/7|
text_000N_47435|MMI|3.53|Human Cells, Tissues, and Cellular and Tissue-Based Products Screening|C4521255|[lbpr]|["Screen"-tx-1-"screens"-noun-0]|TX|47/7|
text_000N_47435|MMI|3.53|Screening procedure|C0220908|[diap]|["screen"-tx-1-"screens"-noun-0]|TX|47/7|
text_000N_47435|MMI|3.53|Screening test|C0871311|[hlca]|["SCREEN"-tx-1-"screens"-noun-0]|TX|47/7|
text_000N_47435|MMI|3.53|Screens (device)|C0183185|[mnob]|["Screen"-tx-1-"screens"-noun-0]|TX|47/7|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|G3BP1 gene|C1825325|[gngm]|["G3BP1"-tx-1-"G3BP1"-noun-0]|TX|3/5|
text_000N_47450|MMI|3.64|Stress Granules|C5442023|[celc]|["Stress Granules"-tx-1-"stress granules"-noun-0]|TX|18/15|
text_000N_47450|MMI|3.57|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|9/5|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Estrogen [EPC]|C2936882|[phsu]|["Estrogen"-tx-1-"Estrogen"-noun-0]|TX|5/8|
text_000N_43235|MMI|5.18|estrogens|C0014939|[horm,orch,phsu]|["Oestrogen, NOS"-tx-1-"Estrogen"-noun-0]|TX|5/8|
text_000N_43235|MMI|3.56|Activation action|C1879547|[acty]|["Activation"-tx-1-"activation"-noun-0]|TX|37/10|
text_000N_43235|MMI|3.56|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|14/4|
text_000N_43235|MMI|3.56|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|14/4|
text_000N_43235|MMI|3.56|FOXA1 gene|C1415626|[gngm]|["FOXA1"-tx-1-"FoxA1"-noun-0]|TX|31/5|
text_000N_43235|MMI|3.56|FOXA1 protein, human|C1506537|[aapp,bacs]|["FoxA1"-tx-1-"FoxA1"-noun-0]|TX|31/5|
text_000N_43235|MMI|3.56|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|14/4|
text_000N_43235|MMI|3.56|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|14/4|
text_000N_43235|MMI|3.56|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|14/4|
text_000N_43235|MMI|3.56|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|14/4|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|serotonin|C0036751|[bacs,orch]|["SEROTONIN"-tx-1-"serotonin"-noun-0]|TX|3/9|
text_000N_43275|MMI|3.59|Blood Platelets|C0005821|[cell]|["Platelets"-tx-1-"platelets"-noun-0]|TX|28/9|
text_000N_43275|MMI|3.59|Platelets Product|C0443116|[phsu]|["Platelets"-tx-1-"platelets"-noun-0]|TX|28/9|
text_000N_43275|MMI|3.59|Platelets, CTCAE|C1963076|[fndg]|["Platelets"-tx-1-"platelets"-noun-0]|TX|28/9|
text_000N_43275|MMI|3.55|Biological Transport|C0005528|[celf]|["Transport, NOS"-tx-1-"transported"-verb-0]|TX|13/11|
text_000N_43275|MMI|3.55|Mobility aid|C3495449|[medd]|["transport"-tx-1-"transported"-verb-0]|TX|13/11|
text_000N_43275|MMI|3.55|transport (device)|C1317949|[mnob]|["Transport"-tx-1-"transported"-verb-0]|TX|13/11|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|15/6|
text_000N_43303|MMI|5.18|Amblyopia|C0002418|[dsyn]|["AMBLYOPIA"-tx-1-"Amblyopia"-noun-0]|TX|5/9|
text_000N_43303|MMI|5.18|Eye|C0015392|[bpoc]|["?Eye"-tx-1-"eye"-noun-0]|TX|26/3|
text_000N_43303|MMI|5.18|Head>Eye|C4266572|[bpoc]|["Eye"-tx-1-"eye"-noun-0]|TX|26/3|
text_000N_43303|MMI|5.18|Orbital region|C0700042|[blor]|["Eye"-tx-1-"eye"-noun-0]|TX|26/3|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.68|Hypomethylation|C2613367|[genf]|["Hypomethylation"-tx-1-"hypomethylation"-noun-0]|TX|7/15|
text_000N_43331|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|23/15|
text_000N_43331|MMI|3.64|Breast Carcinoma|C0678222|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|39/13|
text_000N_43331|MMI|3.64|Childhood Breast Carcinoma|C3897071|[neop]|["Breast Cancer"-tx-1-"breast cancer"-noun-0]|TX|39/13|
text_000N_43331|MMI|3.64|Malignant neoplasm of breast|C0006142|[neop]|["BREAST CANCER"-tx-1-"breast cancer"-noun-0]|TX|39/13|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.59|Introns|C0021920|[bacs,nnon]|["Introns"-tx-1-"introns"-noun-0]|TX|43/7|
text_000N_43358|MMI|3.45|Common (qualifier value)|C0205214|[qnco]|["Common"-tx-1-"common"-adj-0]|TX|27/6|
text_000N_43358|MMI|3.45|Common Specifications in HL7 V3 Publishing|C3245511|[inpr]|["common"-tx-1-"common"-adj-0]|TX|27/6|
text_000N_43358|MMI|3.45|RNA Splicing|C0035687|[genf]|["Splicing"-tx-1-"splicing"-noun-0]|TX|13/8|
text_000N_43358|MMI|3.45|Recursive|C1554127|[idcn]|["Recursive"-tx-1-"recursive"-adj-0]|TX|3/9|
text_000N_43358|MMI|3.45|Short|C1806781|[qnco]|["SHORT"-tx-1-"short"-adv-0]|TX|37/5|
text_000N_43358|MMI|3.45|Short Heart Murmur|C5238699|[fndg]|["Short"-tx-1-"short"-adv-0]|TX|37/5|
text_000N_43358|MMI|3.45|Short Value|C2350002|[qnco]|["Short"-tx-1-"short"-adv-0]|TX|37/5|
text_000N_43358|MMI|3.45|Shortened|C1282927|[qlco]|["short"-tx-1-"short"-adv-0]|TX|37/5|
text_000N_43358|MMI|3.45|nuclear mRNA cis splicing, via spliceosome|C2610186|[genf]|["splicing"-tx-1-"splicing"-noun-0]|TX|13/8|
text_000N_43358|MMI|3.45|shared attribute|C1522138|[ftcn]|["Common"-tx-1-"common"-adj-0]|TX|27/6|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|SAFE-Biopharma Standard|C4684764|[inpr]|["SAFE"-tx-1-"safe"-adj-0]|TX|6/4|
text_000N_43386|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|11/2|
text_000N_43386|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|11/2|
text_000N_43386|MMI|5.18|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-verb-0]|TX|14/3|
text_000N_43386|MMI|5.18|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-verb-0]|TX|14/3|
text_000N_43386|MMI|5.18|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-verb-0]|TX|14/3|
text_000N_43386|MMI|3.59|abatacept|C1619966|[aapp,phsu]|["ABATACEPT"-tx-1-"Abatacept"-noun-0]|TX|18/9|
text_000N_43386|MMI|3.45|Patient currently pregnant|C0549206|[fndg]|["Pregnancy"-tx-1-"pregnancy"-noun-0]|TX|35/9|
text_000N_43386|MMI|3.45|Pregnancy|C0032961|[orgf]|["PREGNANCY"-tx-1-"pregnancy"-noun-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1|C3888239|[fndg]|["AGANGLIONIC MEGACOLON"-tx-1-"aganglionic megacolon"-noun-0]|TX|3/21|
text_000N_40839|MMI|5.18|Hirschsprung Disease|C0019569|[dsyn]|["Aganglionic Megacolon"-tx-1-"aganglionic megacolon"-noun-0]|TX|3/21|
text_000N_40839|MMI|3.56|Array Feature|C1706388|[cnce]|["Feature"-tx-1-"feature"-noun-0]|TX|27/7|
text_000N_40839|MMI|3.56|Characteristics|C1521970|[qlco]|["Feature"-tx-1-"feature"-noun-0]|TX|27/7|
text_000N_40839|MMI|3.56|Feature|C2348519|[qlco]|["Feature"-tx-1-"feature"-noun-0]|TX|27/7|
text_000N_40839|MMI|3.56|Image Feature|C2346469|[qlco]|["Feature"-tx-1-"feature"-noun-0]|TX|27/7|
text_000N_40839|MMI|3.46|Complete Trisomy 21 Syndrome|C4521042|[dsyn]|["Down Syndrome"-tx-1-"Down syndrome"-noun-0]|TX|38/13|
text_000N_40839|MMI|3.46|Down Syndrome|C0013080|[dsyn]|["Downs Syndrome"-tx-1-"Down syndrome"-noun-0]|TX|38/13|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|Subarachnoid Hemorrhage, Aneurysmal|C0751530|[patf]|["Subarachnoid Hemorrhage, Aneurysmal"-tx-1-"aneurysmal subarachnoid hemorrhage"-noun-0]|TX|54/34|
text_000N_40886|MMI|3.68|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-noun-0]|TX|10/3|
text_000N_40886|MMI|3.68|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-noun-0]|TX|10/3|
text_000N_40886|MMI|3.68|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-noun-0]|TX|10/3|
text_000N_40886|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|14/15|
text_000N_40886|MMI|3.57|Admission Level of Care Code - Improved|C1561611|[inpr]|["Improved"-tx-1-"improved"-adj-0]|TX|30/8|
text_000N_40886|MMI|3.57|Better|C0332272|[qlco]|["Improved"-tx-1-"improved"-adj-0]|TX|30/8|
text_000N_40886|MMI|3.57|Improved|C0184511|[fndg]|["Improved"-tx-1-"improved"-adj-0]|TX|30/8|
text_000N_40886|MMI|3.57|Improved - answer to question|C4084203|[fndg]|["IMPROVED"-tx-1-"improved"-adj-0]|TX|30/8|
text_000N_40886|MMI|3.54|Result|C1274040|[ftcn]|["Outcome"-tx-1-"outcomes"-noun-0]|TX|39/8|
text_000N_40886|MMI|3.50|3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (disposition)|C4521898|[qlco]|["Statin"-tx-1-"statin"-noun-0]|TX|3/6|
text_000N_40886|MMI|3.50|EEF1A2 gene|C1414273|[gngm]|["statin"-tx-1-"statin"-noun-0]|TX|3/6|
text_000N_40886|MMI|3.50|Hydroxymethylglutaryl-CoA Reductase Inhibitors|C0360714|[orch,phsu]|["Statin"-tx-1-"statin"-noun-0]|TX|3/6|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|3.73|Antimalarials|C0003374|[phsu]|["Anti-Malarial Drug"-tx-1-"anti-malaria drugs"-noun-0]|TX|52/18|
text_000N_40913|MMI|3.59|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|21/4|
text_000N_40913|MMI|3.55|Target|C1521840|[ftcn]|["Target"-tx-1-"targets"-noun-0]|TX|29/7|
text_000N_40913|MMI|3.55|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"targets"-noun-0]|TX|29/7|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|HYDIN gene|C1426196|[gngm]|["HYDIN"-tx-1-"HYDIN"-noun-0]|TX|3/5|
text_000N_40941|MMI|3.68|Homologous Protein|C1512488|[aapp]|["Protein Homolog"-tx-1-"protein homolog"-noun-0]|TX|33/15|
text_000N_40941|MMI|3.68|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|62/7|
text_000N_40941|MMI|3.47|Hydrocephalus|C0020255|[dsyn]|["HYDROCEPHALUS"-tx-1-"Hydrocephalus"-noun-0]|TX|10/13|
text_000N_40941|MMI|3.47|Hydrocephalus, CTCAE|C1963137|[fndg]|["Hydrocephalus"-tx-1-"Hydrocephalus"-noun-0]|TX|10/13|
text_000N_40941|MMI|3.47|Induce (action)|C0205263|[ftcn]|["Inducing"-tx-1-"inducing"-adj-0]|TX|24/8|
text_000N_40941|MMI|3.45|Axoneme|C0230750|[celc]|["Axonemes"-tx-1-"axonemal"-adj-0]|TX|53/8|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Acute Kidney Injury, CTCAE|C4552597|[fndg]|["Acute Kidney Injury"-tx-1-"acute kidney injury"-noun-0]|TX|40/19|
text_000N_40999|MMI|5.18|Acute kidney injury|C2609414|[inpo]|["Acute kidney injury"-tx-1-"acute kidney injury"-noun-0]|TX|40/19|
text_000N_40999|MMI|5.18|Kidney Failure, Acute|C0022660|[dsyn]|["Acute Kidney Injury"-tx-1-"acute kidney injury"-noun-0]|TX|40/19|
text_000N_40999|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|31/2|
text_000N_40999|MMI|5.18|Therapeutic procedure|C0087111|[topp]|["TREAT"-tx-1-"treat"-verb-0]|TX|34/5|
text_000N_40999|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|31/2|
text_000N_40999|MMI|5.18|Treating|C1522326|[ftcn]|["Treat"-tx-1-"treat"-verb-0]|TX|34/5|
text_000N_40999|MMI|5.18|Treatment intent|C1292734|[ftcn]|["treat"-tx-1-"treat"-verb-0]|TX|34/5|
text_000N_40999|MMI|5.18|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|26/4|
text_000N_40999|MMI|4.12|ALL Stem Cell Transplant Table|C5552991|[inpr]|["Stem Cell Transplant"-tx-1-"stem cell transplants"-noun-0]|TX|4/21|
text_000N_40999|MMI|4.12|Hemopoietic stem cell transplant|C0472699|[topp]|["Stem Cell Transplant"-tx-1-"stem cell transplants"-noun-0]|TX|4/21|
text_000N_40999|MMI|4.12|Stem cell transplant|C1504389|[topp]|["Stem Cell Transplant"-tx-1-"stem cell transplants"-noun-0]|TX|4/21|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.56|Classification|C0008902|[clas]|["Classification"-tx-1-"classification"-noun-0]|TX|41/14|
text_000N_173087|MMI|3.56|Classification of information|C0678229|[ocac]|["classification"-tx-1-"classification"-noun-0]|TX|41/14|
text_000N_173087|MMI|3.56|Drug Packaging|C0013194|[medd]|["Package"-tx-1-"package"-noun-0]|TX|11/7|
text_000N_173087|MMI|3.56|Human Cells, Tissues, and Cellular and Tissue-Based Products Packing|C4521539|[lbpr]|["Package"-tx-1-"package"-noun-0]|TX|11/7|
text_000N_173087|MMI|3.56|Package|C2700580|[mnob]|["Package"-tx-1-"package"-noun-0]|TX|11/7|
text_000N_173087|MMI|3.56|Package Dosing Unit|C1704710|[qnco]|["{Package}"-tx-1-"package"-noun-0]|TX|11/7|
text_000N_173087|MMI|3.56|Taxonomic|C0008903|[ftcn]|["classification"-tx-1-"classification"-noun-0]|TX|41/14|
text_000N_173087|MMI|3.46|Alternative Splicing|C0002345|[genf]|["Alternative Splicing"-tx-1-"alternative splicing"-noun-0]|TX|59/20|
text_000N_173087|MMI|3.43|Preposition For|C0521125|[qlco]|["For"-tx-1-"for"-prep-0]|TX|37/3|
text_000N_173087|MMI|3.43|WWOX wt Allele|C4321252|[gngm]|["FOR"-tx-1-"for"-prep-0]|TX|37/3|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.68|Assessed|C1516048|[acty]|["Assessment"-tx-1-"assessment"-noun-0]|TX|14/10|
text_000N_47289|MMI|3.68|Evaluation procedure|C1261322|[hlca]|["Assessment"-tx-1-"assessment"-noun-0]|TX|14/10|
text_000N_47289|MMI|3.61|Model for end-stage liver disease score|C1718072|[fndg]|["MELD - Score"-tx-1-"MELD score"-noun-0]|TX|41/10|
text_000N_47289|MMI|3.61|Model for end-stage liver disease score:Score:Pt:^Patient:Qn|C1715987|[clna]|["MELD score"-tx-1-"MELD score"-noun-0]|TX|41/10|
text_000N_47289|MMI|3.56|Including (qualifier)|C0332257|[ftcn]|["included"-tx-1-"included"-verb-0]|TX|25/8|
text_000N_47289|MMI|3.50|Creatinine, CTCAE|C1561535|[fndg]|["Creatinine"-tx-1-"creatinine"-noun-0]|TX|3/10|
text_000N_47289|MMI|3.50|creatinine|C0010294|[bacs,orch]|["CREATININE"-tx-1-"creatinine"-noun-0]|TX|3/10|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|7.19|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0,"gene mutations"-tx-1-"mutations gene"-noun-0]|TX|4/9;4/9,30/4|
text_000N_173104|MMI|6.93|C9orf72 gene|C1428691|[gngm]|["C9ORF72"-tx-1-"C9orf72"-noun-0,"C9orf72 Gene"-tx-1-"C9orf72 gene"-noun-0]|TX|21/7;21/7,30/4|
text_000N_173104|MMI|3.64|Age related macular degeneration|C0242383|[dsyn]|["Macular Degeneration"-tx-1-"macular degeneration"-noun-0]|TX|51/20|
text_000N_173104|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|35/15|
text_000N_173104|MMI|3.64|Macular degeneration|C0024437|[dsyn]|["MACULAR DEGENERATION"-tx-1-"macular degeneration"-noun-0]|TX|51/20|
text_000N_173104|MMI|3.56|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|4/9|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|RUNX1T1 gene|C1539715|[gngm]|["RUNX1T1"-tx-1-"RUNX1T1"-noun-0]|TX|3/7|
text_000N_40972|MMI|5.18|RUNX1T1 wt Allele|C1706326|[gngm]|["RUNX1T1"-tx-1-"RUNX1T1"-noun-0]|TX|3/7|
text_000N_40972|MMI|3.59|Associate - assistant|C1706221|[prog]|["Associate"-tx-1-"associate"-verb-0]|TX|11/9|
text_000N_40972|MMI|3.59|Associate - relationship|C0750490|[idcn]|["Associate"-tx-1-"associate"-verb-0]|TX|11/9|
text_000N_40972|MMI|3.59|BODY MASS INDEX QUANTITATIVE TRAIT LOCUS 20|C4759928|[fndg]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|26/7|
text_000N_40972|MMI|3.59|Obesity|C0028754|[dsyn]|["OBESITY"-tx-1-"obesity"-noun-0]|TX|26/7|
text_000N_40972|MMI|3.59|Obesity, CTCAE|C1963185|[fndg]|["Obesity"-tx-1-"obesity"-noun-0]|TX|26/7|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.63|Expression (foundation metadata concept)|C3854321|[idcn]|["Expression"-tx-1-"expression"-noun-0]|TX|16/10|
text_000N_173120|MMI|3.63|Expression procedure|C0185117|[topp]|["Expression"-tx-1-"expression"-noun-0]|TX|16/10|
text_000N_173120|MMI|3.59|Cardiac Lead Procedure|C3275067|[topp]|["LEAD"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.59|Dietary Lead|C2348269|[elii]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.59|ITK protein, human|C1567665|[aapp,enzy]|["EMT"-tx-1-"EMT"-noun-0]|TX|35/3|
text_000N_173120|MMI|3.59|Leading|C1522538|[ftcn]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.59|Leads (device)|C0181586|[mnob]|["Lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.59|Plumbum metallicum, homeopathic preparation|C1442948|[inch,phsu]|["lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.59|SLC22A3 wt Allele|C3812262|[gngm]|["EMT"-tx-1-"EMT"-noun-0]|TX|35/3|
text_000N_173120|MMI|3.59|Solute Carrier Family 22 Member 3, human|C3811688|[aapp,bacs]|["EMT"-tx-1-"EMT"-noun-0]|TX|35/3|
text_000N_173120|MMI|3.59|lead|C0023175|[elii,hops]|["???lead"-tx-1-"lead"-verb-0]|TX|27/4|
text_000N_173120|MMI|3.48|GRHL2 gene|C1837820|[gngm]|["GRHL2"-tx-1-"GRHL2"-noun-0]|TX|5/5|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|liothyronine|C0041014|[aapp,horm,phsu]|["Triiodothyronine"-tx-1-"triiodothyronine"-noun-0]|TX|5/16|
text_000N_173136|MMI|3.75|Angiogenesis Effect|C3179307|[phsf]|["Angiogenic Effects"-tx-1-"angiogenic effects"-noun-0]|TX|39/18|
text_000N_173136|MMI|3.48|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|31/7|
text_000N_173136|MMI|3.48|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|31/7|
text_000N_173136|MMI|3.48|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|31/7|
<<<<< MMI
>>>>> MMI
text_000N_173151|AA|UTR|untranslated region|1|3|3|19|43:3
text_000N_173151|AA|UTRs|untranslated regions|1|4|3|20|43:4
text_000N_173151|MMI|5.18|ELAVL1 gene|C1414371|[gngm]|["HuR"-tx-1-"HuR"-noun-0]|TX|5/3|
text_000N_173151|MMI|5.18|ELAVL1 wt Allele|C3812730|[gngm]|["HUR"-tx-1-"HuR"-noun-0]|TX|5/3|
text_000N_173151|MMI|3.65|Untranslated Regions|C0600680|[nnon]|["untranslated regions of mRNA"-tx-1-"untranslated regions of mRNAs"-noun-0]|TX|21/20,49/8|
text_000N_173151|MMI|3.55|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|9/4|
text_000N_173151|MMI|3.55|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|9/4|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|10.42|Multisystem inflammatory syndrome in children|C5389369|[dsyn]|["MIS-C"-tx-1-"MIS-C"-noun-0,"Multisystem inflammatory syndrome in children"-tx-1-"Multisystem Inflammatory syndrome in children"-noun-0]|TX|3/5;12/11,25/33|
text_000N_173167|MMI|5.18|multisystem inflammatory syndrome in children with COVID-19 infection|C5391534|[dsyn]|["Multisystem inflammatory syndrome in children"-tx-1-"Multisystem Inflammatory syndrome in children"-noun-0]|TX|12/11,25/33|
text_000N_173167|MMI|3.56|Complication|C0009566|[patf]|["Complication"-tx-1-"complication"-noun-0]|TX|61/12|
text_000N_173167|MMI|3.56|Complication (attribute)|C2362589|[idcn]|["Complication"-tx-1-"complication"-noun-0]|TX|61/12|
text_000N_173167|MMI|3.46|COVID-19|C5203670|[dsyn]|["COVID 19"-tx-1-"Covid-19"-noun-0]|TX|77/8|
text_000N_173167|MMI|3.46|COVID19 (document)|C5243469|[inpr]|["COVID-19"-tx-1-"Covid-19"-noun-0]|TX|77/8|
text_000N_173167|MMI|3.46|A 19|C0619485|[antb]|["A 19"-tx-1-"a 19"-noun-0]|TX|59/1,83/2|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Genus Fusobacterium|C0016878|[bact]|["FUSOBACTERIUM"-tx-1-"fusobacterium"-noun-0]|TX|3/13|
text_000N_173183|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|17/15|
text_000N_173183|MMI|3.64|Lemierre Syndrome|C0343525|[dsyn]|["Lemierre's syndrome"-tx-1-"Lemierre's syndrome"-noun-0]|TX|33/19|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|MIR21 gene|C1537719|[gngm]|["MIR-21"-tx-1-"miR-21"-noun-0]|TX|3/6|
text_000N_173199|MMI|3.59|Carcinogenesis|C0596263|[neop]|["Carcinogenesis"-tx-1-"carcinogenesis"-noun-0]|TX|21/14|
text_000N_173199|MMI|3.59|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|10/7|
text_000N_173199|MMI|3.59|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|10/7|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Cardiac Surgery procedures|C0018821|[topp]|["Cardiac Surgery"-tx-1-"cardiac surgery"-noun-0]|TX|104/15|
text_000N_173214|MMI|5.18|Discipline of Heart Surgery|C0524727|[bmod]|["Cardiac surgery"-tx-1-"cardiac surgery"-noun-0]|TX|104/15|
text_000N_173214|MMI|5.18|Either|C3844638|[fndg]|["Either"-tx-1-"either"-adv-0]|TX|33/6|
text_000N_173214|MMI|5.18|Following|C0332282|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|94/9|
text_000N_173214|MMI|5.18|Status post|C0231290|[tmco]|["Following"-tx-1-"following"-verb-0]|TX|94/9|
text_000N_173214|MMI|5.18|Use of|C1524063|[ftcn]|["Using"-tx-1-"using"-verb-0]|TX|27/5|
text_000N_173214|MMI|3.68|EDQM-HC Closure Terminology|C4723635|[inpr]|["Closure"-tx-1-"closure"-noun-0]|TX|14/7|
text_000N_173214|MMI|3.68|Reparative closure|C0185003|[topp]|["Closure"-tx-1-"closure"-noun-0]|TX|14/7|
text_000N_173214|MMI|3.63|Administration via Implantation|C1711357|[ftcn]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Bone Wires|C0005978|[medd]|["Wire"-tx-1-"wire"-noun-0]|TX|89/4|
text_000N_173214|MMI|3.63|Implant (unit of presentation)|C4319676|[qnco]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implant - dosing instruction imperative|C4721997|[inpr]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implant Dosage Form Category|C4722468|[bodm]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implant Dosing Unit|C1705604|[qnco]|["{Implant}"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implant component:Find:Pt:^Patient:Nom|C5444783|[clna]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implantation procedure|C0021107|[topp]|["Implant, NOS"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Implants|C0021102|[medd]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Traumatic implants|C0332837|[inpo]|["Implant"-tx-1-"implant"-noun-0]|TX|58/7|
text_000N_173214|MMI|3.63|Wire -- device|C4522306|[mnob]|["Wire"-tx-1-"wire"-noun-0]|TX|89/4|
text_000N_173214|MMI|3.50|Sternotomy (procedure)|C0185792|[topp]|["Sternotomy"-tx-1-"sternotomy"-noun-0]|TX|3/10|
text_000N_173214|MMI|3.48|Conventional|C0439858|[qlco]|["Conventional"-tx-1-"conventional"-adj-0]|TX|70/12|
text_000N_173214|MMI|3.48|Conventional Release Mechanism of Action|C4724243|[ftcn]|["Conventional"-tx-1-"conventional"-adj-0]|TX|70/12|
text_000N_173214|MMI|3.48|Steel|C0038239|[bodm]|["Steel"-tx-1-"steel"-noun-0]|TX|83/5|
text_000N_173214|MMI|3.48|Sternum|C0038293|[bpoc]|["Sternal"-tx-1-"sternal"-adj-0]|TX|42/7|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|Butterfly rash|C0277942|[fndg]|["Butterfly rash"-tx-1-"butterfly rash"-noun-0]|TX|3/14|
text_000N_173230|MMI|3.55|Symptom:Find:Pt:^Patient:Nom|C3854129|[clna]|["Symptom"-tx-1-"symptom"-noun-0]|TX|20/7|
text_000N_173230|MMI|3.55|Symptoms|C1457887|[sosy]|["Symptom"-tx-1-"symptom"-noun-0]|TX|20/7|
text_000N_173230|MMI|3.48|Lupus Erythematosus, Systemic|C0024141|[dsyn]|["SYSTEMIC LUPUS ERYTHEMATOSIS"-tx-1-"Systemic lupus erythematosus"-noun-0]|TX|31/28|
text_000N_173230|MMI|3.48|Systemic Lupus Erythematosus Pathway|C2984317|[cnce]|["Systemic lupus erythematosus"-tx-1-"Systemic lupus erythematosus"-noun-0]|TX|31/28|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Crohn Disease|C0010346|[dsyn]|["Crohns Disease"-tx-1-"Crohn's disease"-noun-0]|TX|59/15|
text_000N_173245|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173245|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173245|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173245|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_173245|MMI|3.46|Pyostomatitis vegetans|C0267000|[dsyn]|["Pyostomatitis vegetans"-tx-1-"pyostomatitis vegetans"-noun-0]|TX|32/22|
text_000N_173245|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_173245|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.78|Traumatic spondylopathy|C0152088|[dsyn]|["K√ºmmell disease"-tx-1-"Kummell disease"-noun-0]|TX|3/7,13/7|
text_000N_173260|MMI|3.58|Avascular Necrosis, CTCAE|C4553018|[fndg]|["Avascular Necrosis"-tx-1-"avascular necrosis"-noun-0]|TX|24/18|
text_000N_173260|MMI|3.58|Avascular necrosis|C3887513|[patf]|["AVASCULAR NECROSIS"-tx-1-"avascular necrosis"-noun-0]|TX|24/18|
text_000N_173260|MMI|3.58|Avascular necrosis of bone|C0027543|[dsyn]|["Avascular necrosis"-tx-1-"avascular necrosis"-noun-0]|TX|24/18|
text_000N_173260|MMI|3.44|Body of vertebra|C0223084|[bpoc]|["Vertebral Body"-tx-1-"vertebral body"-noun-0]|TX|50/14|
text_000N_173260|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|21/2|
text_000N_173260|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|21/2|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|PXN gene|C1419150|[gngm]|["PAXILLIN"-tx-1-"paxillin"-noun-0]|TX|3/8|
text_000N_173276|MMI|5.18|PXN protein, human|C1565440|[aapp,bacs]|["Paxillin"-tx-1-"paxillin"-noun-0]|TX|3/8|
text_000N_173276|MMI|5.18|paxillin|C0135575|[aapp,bacs]|["Paxillin"-tx-1-"paxillin"-noun-0]|TX|3/8|
text_000N_173276|MMI|3.59|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|12/8|
text_000N_173276|MMI|3.59|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|12/8|
text_000N_173276|MMI|3.59|Receptor Activator Nuclear KappaB Ligand Measurement|C3890560|[lbpr]|["RANKL"-tx-1-"RANKL"-noun-0]|TX|24/5|
text_000N_173276|MMI|3.59|TNFSF11 gene|C1367028|[gngm]|["RANKL"-tx-1-"RANKL"-noun-0]|TX|24/5|
text_000N_173276|MMI|3.59|TNFSF11 protein, human|C0666361|[aapp,bacs]|["RANKL"-tx-1-"RANKL"-noun-0]|TX|24/5|
text_000N_173276|MMI|3.59|TNFSF11 wt Allele|C1704863|[gngm]|["RANKL"-tx-1-"RANKL"-noun-0]|TX|24/5|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|DNA Methylation|C0376452|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_173291|MMI|5.18|DNA Methylation Analysis|C1880239|[mbrt]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_173291|MMI|5.18|DNA Methylation [PE]|C3536933|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|3/15|
text_000N_173291|MMI|3.57|Correlation|C1707520|[qlco]|["Correlated"-tx-1-"correlated"-verb-0]|TX|19/10|
text_000N_173291|MMI|3.57|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosome"-tx-1-"nucleosome"-noun-0]|TX|35/10|
text_000N_173291|MMI|3.57|Occupancy|C2827063|[qlco]|["Occupancy"-tx-1-"occupancy"-noun-0]|TX|46/9|
text_000N_173291|MMI|3.57|nucleosome location|C1166675|[celc]|["nucleosome"-tx-1-"nucleosome"-noun-0]|TX|35/10|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Indicated|C1444656|[fndg]|["Indicated"-tx-1-"indicated"-verb-0]|TX|3/9|
text_000N_97283|MMI|3.68|CDISC SDTM Coronary Artery Disease Risk Terminology|C3640263|[inpr]|["Coronary Artery Disease Risk"-tx-1-"risk coronary artery disease"-noun-0]|TX|63/4,72/23|
text_000N_97283|MMI|3.64|Use of|C1524063|[ftcn]|["Use of"-tx-1-"use of"-noun-0]|TX|17/6|
text_000N_97283|MMI|3.59|Dietary Supplements|C0242295|[food]|["Supplement"-tx-1-"supplements"-verb-0]|TX|36/11|
text_000N_97283|MMI|3.59|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|51/8|
text_000N_97283|MMI|3.59|Supplement|C2348609|[ftcn]|["Supplement"-tx-1-"supplements"-verb-0]|TX|36/11|
text_000N_97283|MMI|3.59|Supplement (document)|C1947943|[inpr]|["Supplement"-tx-1-"supplements"-verb-0]|TX|36/11|
text_000N_97283|MMI|3.55|AT genotype|C4554368|[fndg]|["AT"-tx-1-"at"-adj-0]|TX|60/2|
text_000N_97283|MMI|3.55|Apnea Time|C4764186|[qnco]|["AT"-tx-1-"at"-adj-0]|TX|60/2|
text_000N_97283|MMI|3.55|At|C1516077|[spco]|["At"-tx-1-"at"-adj-0]|TX|60/2|
text_000N_97283|MMI|3.55|GATM wt Allele|C4049625|[gngm]|["AT"-tx-1-"at"-adj-0]|TX|60/2|
text_000N_97283|MMI|3.44|Antioxidants|C0003402|[phsu]|["Antioxidant"-tx-1-"antioxidant"-noun-0]|TX|24/11|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|axitinib|C1700874|[orch,phsu]|["AXITINIB"-tx-1-"Axitinib"-noun-0]|TX|5/8|
text_000N_47274|MMI|3.56|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.56|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|22/8|
text_000N_47274|MMI|3.47|Malignant neoplasm of pancreas|C0346647|[neop]|["Cancer of Pancreas"-tx-1-"of Pancreatic Cancer"-noun-0]|TX|31/20|
text_000N_47274|MMI|3.47|Pancreatic carcinoma|C0235974|[neop]|["Cancer of Pancreas"-tx-1-"of Pancreatic Cancer"-noun-0]|TX|31/20|
text_000N_47274|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|52/8|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Diabetes|C0011847|[dsyn]|["Diabetes"-tx-1-"Diabetes"-noun-0]|TX|4/8|
text_000N_97301|MMI|5.18|Diabetes Mellitus|C0011849|[dsyn]|["Diabetes"-tx-1-"Diabetes"-noun-0]|TX|4/8|
text_000N_97301|MMI|3.57|Defect|C1457869|[ftcn]|["Defect"-tx-1-"defect"-noun-0]|TX|28/6|
text_000N_97301|MMI|3.54|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|16/6|
text_000N_97301|MMI|3.54|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|16/6|
text_000N_97301|MMI|3.50|Potassium Drug Class|C3714637|[phsu]|["POTASSIUM"-tx-1-"potassium"-noun-0]|TX|40/9|
text_000N_97301|MMI|3.50|Potassium supplement|C0304475|[inch,phsu]|["POTASSIUM"-tx-1-"potassium"-noun-0]|TX|40/9|
text_000N_97301|MMI|3.50|potassium|C0032821|[bacs,elii,phsu]|["POTASSIUM"-tx-1-"potassium"-noun-0]|TX|40/9|
text_000N_97301|MMI|3.50|potassium ion|C0597277|[elii,phsu]|["Potassium+"-tx-1-"potassium"-noun-0]|TX|40/9|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|inositol|C0021547|[orch,phsu,vita]|["INOSITOL"-tx-1-"inositol"-noun-0]|TX|3/8|
text_000N_47304|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_47304|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_47304|MMI|3.45|Trichotillomania|C0040953|[mobd]|["TRICHOTILLOMANIA"-tx-1-"trichotillomania"-noun-0]|TX|26/16|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|macroautophagy|C1155604|[celf]|["Macroautophagy"-tx-1-"macroautophagy"-noun-0]|TX|3/14|
text_000N_97316|MMI|3.63|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"process"-noun-0]|TX|42/7|
text_000N_97316|MMI|3.63|Process|C1522240|[phpr]|["Process"-tx-1-"process"-noun-0]|TX|42/7|
text_000N_97316|MMI|3.63|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"process"-noun-0]|TX|42/7|
text_000N_97316|MMI|3.63|bony process|C1184743|[bpoc]|["Process"-tx-1-"process"-noun-0]|TX|42/7|
text_000N_97316|MMI|3.48|Catabolism|C0699900|[orgf]|["Degradation"-tx-1-"degradation"-noun-0]|TX|30/11|
text_000N_97316|MMI|3.48|Material Degradation|C1881707|[fndg]|["Degradation"-tx-1-"degradation"-noun-0]|TX|30/11|
text_000N_97316|MMI|3.48|degradation aspects|C0243125|[orgf]|["degradation"-tx-1-"degradation"-noun-0]|TX|30/11|
text_000N_97316|MMI|3.43|Choose (action)|C1707391|[acty]|["Selection"-tx-1-"selective"-adj-0]|TX|20/9|
text_000N_97316|MMI|3.43|Genetic Selection|C0036576|[genf]|["selection"-tx-1-"selective"-adj-0]|TX|20/9|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|Craniosynostosis|C0010278|[dsyn]|["CRANIOSYNOSTOSIS"-tx-1-"craniosynostosis"-noun-0]|TX|37/16|
text_000N_47334|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|31/5|
text_000N_47334|MMI|5.18|Familial Hypophosphatemic Rickets|C3536983|[dsyn]|["hypophosphatemic rickets"-tx-1-"hypophosphatemic rickets"-noun-0]|TX|6/24|
text_000N_47334|MMI|5.18|Hypophosphatemic Rickets|C1704375|[dsyn]|["Hypophosphatemic Rickets"-tx-1-"hypophosphatemic rickets"-noun-0]|TX|6/24|
text_000N_47334|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|31/5|
text_000N_47334|MMI|5.18|TWIST1 gene|C1421244|[gngm]|["craniosynostosis"-tx-1-"craniosynostosis"-noun-0]|TX|37/16|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|3.61|Blood Clot|C0302148|[patf]|["Thrombosis"-tx-1-"thrombosis"-noun-0]|TX|26/10|
text_000N_47363|MMI|3.61|Thrombosis|C0040053|[patf]|["THROMBOSIS"-tx-1-"thrombosis"-noun-0]|TX|26/10|
text_000N_47363|MMI|3.61|Thrombosis of blood vessel|C2586211|[patf]|["thrombosis"-tx-1-"thrombosis"-noun-0]|TX|26/10|
text_000N_47363|MMI|3.47|Complement Decay-Accelerating Factor, human|C4721410|[aapp,imft]|["CD55"-tx-1-"CD55"-noun-0]|TX|4/4|
text_000N_47363|MMI|3.47|Deficiency|C0011155|[ftcn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|9/10|
text_000N_47363|MMI|3.47|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|20/5|
text_000N_47363|MMI|3.47|Malnutrition|C0162429|[dsyn]|["Deficiency"-tx-1-"deficiency"-noun-0]|TX|9/10|
text_000N_47363|MMI|3.47|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|20/5|
text_000N_47363|MMI|3.47|deficiency aspects|C1623416|[qlco]|["deficiency"-tx-1-"deficiency"-noun-0]|TX|9/10|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Mycobacterium abscessus|C0445910|[bact]|["MYCOBACTERIUM ABSCESSUS"-tx-1-"Mycobacterium abscessus"-noun-0]|TX|3/23|
text_000N_47349|MMI|5.18|Mycobacterium abscessus Measurement|C5401032|[lbpr]|["Mycobacterium abscessus"-tx-1-"Mycobacterium abscessus"-noun-0]|TX|3/23|
text_000N_47349|MMI|3.68|Pathogenic organism|C0450254|[orgm]|["Pathogen"-tx-1-"pathogen"-noun-0]|TX|35/8|
text_000N_47349|MMI|3.50|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|29/5|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.98|teleost|C0599050|[fish]|["teleost"-tx-1-"teleosts"-noun-0]|TX|79/8|
text_000N_47420|MMI|3.61|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|30/8|
text_000N_47420|MMI|3.60|Genome, Human|C0017429|[gngm]|["Human Genomes"-tx-1-"genomes human"-noun-0]|TX|58/7,69/5|
text_000N_47420|MMI|3.56|Container status - Identified|C1550043|[fndg]|["Identified"-tx-1-"identified"-verb-0]|TX|39/10|
text_000N_47420|MMI|3.56|Identified|C0205396|[qlco]|["Identified"-tx-1-"identified"-verb-0]|TX|39/10|
text_000N_47420|MMI|3.56|Microfilaria sp identified|C0552545|[lbtr]|["Identified"-tx-1-"identified"-verb-0]|TX|39/10|
text_000N_47420|MMI|3.56|Treponema identified|C0370079|[lbtr]|["Identified"-tx-1-"identified"-verb-0]|TX|39/10|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|Beta plus thalassemia|C3841475|[dsyn]|["Beta + thalassemia"-tx-1-"Beta-Thalassemia"-noun-0]|TX|3/16|
text_000N_97331|MMI|5.18|beta Thalassemia|C0005283|[dsyn]|["beta Thalassaemia"-tx-1-"Beta-Thalassemia"-noun-0]|TX|3/16|
text_000N_97331|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|23/15|
text_000N_97331|MMI|3.62|Gene Deletion|C0017260|[genf]|["Gene Deletion"-tx-1-"deletion gene"-noun-0]|TX|53/8,69/4|
text_000N_97331|MMI|3.57|Mutation|C0026882|[genf]|["Mutation"-tx-1-"mutation"-noun-0]|TX|41/8|
text_000N_97331|MMI|3.57|Mutation Abnormality|C1705285|[comd]|["Mutation"-tx-1-"mutation"-noun-0]|TX|41/8|
text_000N_97331|MMI|3.56|A Codes|C0919279|[inpr]|["codes"-tx-1-"codes"-noun-0]|TX|79/5|
text_000N_97331|MMI|3.46|Hemoglobin Subunit Alpha|C0544482|[aapp]|["Alpha-Globin"-tx-1-"alpha globin"-noun-0]|TX|89/12|
text_000N_97331|MMI|3.46|alpha-Globins|C0002270|[aapp,bacs]|["alpha globin"-tx-1-"alpha globin"-noun-0]|TX|89/12|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_47392|MMI|5.18|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_47392|MMI|5.18|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_47392|MMI|3.55|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47392|MMI|3.55|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47392|MMI|3.55|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_47392|MMI|3.44|Escherichia coli|C0014834|[bact]|["E coli"-tx-1-"E coli"-noun-0]|TX|37/1,40/4|
text_000N_47392|MMI|3.42|ARAF protein, human|C3853563|[aapp,enzy]|["PKS"-tx-1-"pks"-noun-0]|TX|31/3|
text_000N_47392|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_47392|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_47392|MMI|3.38|genotoxicity|C0598309|[comd]|["genotoxicity"-tx-1-"genotoxic"-adj-0]|TX|21/9|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|7.80|Malignant Peripheral Nerve Sheath Tumor|C0751690|[neop]|["MPNST"-tx-1-"MPNST"-noun-0,"Malignant peripheral nerve sheath tumors"-tx-1-"Malignant Peripheral Nerve Sheath Tumors"-noun-0]|TX|71/5;30/40|
text_000N_47406|MMI|3.73|Primary malignant neoplasm of peripheral nerve|C1827888|[neop]|["Primary malignant Peripheral Nerve Tumors"-tx-1-"Primary Malignant Peripheral Nerve Tumors"-noun-0]|TX|22/34,64/6|
text_000N_47406|MMI|3.59|Foreskin of penis|C0227952|[bpoc]|["Sheath"-tx-1-"Sheath"-noun-0]|TX|57/6|
text_000N_47406|MMI|3.57|Infrequent|C0521114|[tmco]|["Rare"-tx-1-"rare"-adj-0]|TX|78/4|
text_000N_47406|MMI|3.57|Rare|C0522498|[qlco]|["Rare"-tx-1-"rare"-adj-0]|TX|78/4|
text_000N_47406|MMI|3.45|Intradural Route of Administration|C1512939|[ftcn]|["INTRADURAL"-tx-1-"Intradural"-adj-0]|TX|11/10|
text_000N_47406|MMI|3.45|Primary|C0205225|[qlco]|["Primary"-tx-1-"Primary"-adj-0]|TX|22/7|
text_000N_47406|MMI|3.45|Primary Cause of Death|C3262229|[fndg]|["Primary"-tx-1-"Primary"-adj-0]|TX|22/7|
text_000N_47406|MMI|3.45|Primary Neoplasm|C0677930|[neop]|["Primary"-tx-1-"Primary"-adj-0]|TX|22/7|
text_000N_47406|MMI|3.45|Spinal|C0521329|[spco]|["Spinal"-tx-1-"Spinal"-adj-0]|TX|4/6|
text_000N_47406|MMI|3.45|True primary (qualifier value)|C0439612|[tmco]|["Primary"-tx-1-"Primary"-adj-0]|TX|22/7|
text_000N_47406|MMI|3.44|NCI CTEP SDC Neurofibromatosis Sub-Category Terminology|C3540584|[inpr]|["Neurofibromatosis"-tx-1-"neurofibromatosis"-noun-0]|TX|86/17|
text_000N_47406|MMI|3.44|NF1 gene|C0085113|[gngm]|["neurofibromatosis"-tx-1-"neurofibromatosis"-noun-0]|TX|86/17|
text_000N_47406|MMI|3.44|Neurofibromatoses|C0162678|[neop]|["NEUROFIBROMATOSIS"-tx-1-"neurofibromatosis"-noun-0]|TX|86/17|
text_000N_47406|MMI|3.44|Neurofibromatosis 1|C0027831|[neop]|["Neurofibromatosis"-tx-1-"neurofibromatosis"-noun-0]|TX|86/17|
text_000N_47406|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|104/8|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|SLCO1B1 gene|C1420131|[gngm]|["OATP1B1"-tx-1-"OATP1B1"-noun-0]|TX|4/7|
text_000N_47435|MMI|5.18|SLCO1B1 wt Allele|C3812257|[gngm]|["OATP1B1"-tx-1-"OATP1B1"-noun-0]|TX|4/7|
text_000N_47435|MMI|5.18|SLCO1B3 gene|C1420132|[gngm]|["OATP1B3"-tx-1-"OATP1B3"-noun-0]|TX|16/7|
text_000N_47435|MMI|5.18|SLCO1B3 wt Allele|C3812258|[gngm]|["OATP1B3"-tx-1-"OATP1B3"-noun-0]|TX|16/7|
text_000N_47435|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|24/15|
text_000N_47435|MMI|3.64|bilirubin transport|C1159622|[celf]|["bilirubin transport"-tx-1-"bilirubin transport"-noun-0]|TX|40/19|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|FDA Approval|C2700205|[inpr]|["FDA Approval"-tx-1-"FDA approval"-noun-0]|TX|49/12|
text_000N_43235|MMI|5.18|Receive|C1514756|[qlco]|["RECEIVED"-tx-1-"received"-verb-0]|TX|40/8|
text_000N_43235|MMI|3.63|HercepTest|C1512416|[lbpr]|["HercepTest"-tx-1-"HercepTest"-noun-0]|TX|29/10|
text_000N_43235|MMI|3.48|Companions|C0335343|[popg]|["Companion"-tx-1-"companion"-noun-0]|TX|8/9|
text_000N_43235|MMI|3.48|Diagnosis|C0011900|[diap]|["Diagnostic"-tx-1-"diagnostic"-adj-0]|TX|18/10|
text_000N_43235|MMI|3.48|Diagnostic|C0348026|[ftcn]|["Diagnostic"-tx-1-"diagnostic"-adj-0]|TX|18/10|
text_000N_43235|MMI|3.48|Pet Animal|C0031268|[anim]|["Companion"-tx-1-"companion"-noun-0]|TX|8/9|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|verubecestat|C4307343|[orch,phsu]|["VERUBECESTAT"-tx-1-"Verubecestat"-noun-0]|TX|3/12|
text_000N_47450|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_47450|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_47450|MMI|3.48|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|30/19|
text_000N_47450|MMI|3.48|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's Disease"-noun-0]|TX|30/19|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|38/6|
text_000N_47377|MMI|3.61|Ratio|C0456603|[qnco]|["RATIO"-tx-1-"ratio"-noun-0]|TX|32/5|
text_000N_47377|MMI|3.61|Ratio Result Type|C5552836|[ftcn]|["RATIO"-tx-1-"ratio"-noun-0]|TX|32/5|
text_000N_47377|MMI|3.56|Disease Response|C1704632|[fndg]|["RESPONSE"-tx-1-"response"-noun-0]|TX|49/8|
text_000N_47377|MMI|3.56|Response (communication)|C2911692|[menp]|["Response"-tx-1-"response"-noun-0]|TX|49/8|
text_000N_47377|MMI|3.56|Response (statement)|C1706817|[inpr]|["Response"-tx-1-"response"-noun-0]|TX|49/8|
text_000N_47377|MMI|3.56|Response process|C0871261|[orga]|["Response"-tx-1-"response"-noun-0]|TX|49/8|
text_000N_47377|MMI|3.56|Responsive Disease|C5236984|[fndg]|["response"-tx-1-"response"-noun-0]|TX|49/8|
text_000N_47377|MMI|3.47|Expression (foundation metadata concept)|C3854321|[idcn]|["Expression"-tx-1-"expression"-noun-0]|TX|21/10|
text_000N_47377|MMI|3.47|Expression procedure|C0185117|[topp]|["Expression"-tx-1-"expression"-noun-0]|TX|21/10|
text_000N_47377|MMI|3.47|TOP2A gene|C1336657|[gngm]|["TOP2A"-tx-1-"TOP2A"-noun-0]|TX|15/5|
text_000N_47377|MMI|3.47|TOP2A protein, human|C4549282|[aapp,enzy]|["TOP2A"-tx-1-"TOP2A"-noun-0]|TX|15/5|
text_000N_47377|MMI|3.47|TOP2B gene|C1336658|[gngm]|["TOP2B"-tx-1-"TOP2B"-noun-0]|TX|9/5|
text_000N_47377|MMI|3.47|TOP2B protein, human|C1504636|[aapp,enzy]|["TOP2B"-tx-1-"TOP2B"-noun-0]|TX|9/5|
text_000N_47377|MMI|3.43|Chemotherapy|C3665472|[topp]|["CHEMOTHERAPY"-tx-1-"chemotherapy"-noun-0]|TX|65/12|
text_000N_47377|MMI|3.43|Chemotherapy Regimen|C0392920|[topp]|["Chemotherapy, NOS"-tx-1-"chemotherapy"-noun-0]|TX|65/12|
text_000N_47377|MMI|3.43|Leukemia, Myelocytic, Acute|C0023467|[neop]|["AML"-tx-1-"AML"-noun-0]|TX|61/3|
text_000N_47377|MMI|3.43|Pharmacotherapy|C0013216|[topp]|["Chemotherapy"-tx-1-"chemotherapy"-noun-0]|TX|65/12|
text_000N_47377|MMI|3.43|pharmacotherapeutic|C0013217|[ftcn]|["chemotherapy"-tx-1-"chemotherapy"-noun-0]|TX|65/12|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|ospemifene|C1313616|[orch,phsu]|["OSPEMIFENE"-tx-1-"ospemifene"-noun-0]|TX|3/10|
text_000N_43303|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|14/9,28/9|
text_000N_43303|MMI|3.43|Dyspareunia|C1384606|[fndg]|["DYSPAREUNIA"-tx-1-"dyspareunia"-noun-0]|TX|41/11|
text_000N_43303|MMI|3.43|Dyspareunia (female)|C0013394|[dsyn]|["DYSPAREUNIA"-tx-1-"dyspareunia"-noun-0]|TX|41/11|
text_000N_43303|MMI|3.43|Dyspareunia, CTCAE|C4553423|[fndg]|["Dyspareunia"-tx-1-"dyspareunia"-noun-0]|TX|41/11|
text_000N_43303|MMI|3.43|Painful intercourse female|C0423742|[fndg]|["Dyspareunia"-tx-1-"dyspareunia"-noun-0]|TX|41/11|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|dupilumab|C3660996|[aapp,imft,phsu]|["DUPILUMAB"-tx-1-"dupilumab"-noun-0]|TX|3/9|
text_000N_47320|MMI|3.60|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|13/9,27/9|
text_000N_47320|MMI|3.43|Asthma|C0004096|[dsyn]|["ASTHMA"-tx-1-"asthma"-noun-0]|TX|40/6|
text_000N_47320|MMI|3.43|Asthma Pathway|C2984299|[cnce]|["Asthma"-tx-1-"asthma"-noun-0]|TX|40/6|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.98|Off Study|C1518546|[qlco]|["Study"-tx-1-"studied"-verb-0]|TX|40/7|
text_000N_43358|MMI|3.98|Room of building - Study|C0557651|[mnob]|["Study"-tx-1-"studied"-verb-0]|TX|40/7|
text_000N_43358|MMI|3.98|Study|C2603343|[resa]|["Study"-tx-1-"studied"-verb-0]|TX|40/7|
text_000N_43358|MMI|3.61|Proteome|C0751973|[aapp,bacs]|["Proteome"-tx-1-"proteome"-noun-0]|TX|26/8|
text_000N_43358|MMI|3.51|Olive pollen|C0440390|[plnt]|["Olive pollen"-tx-1-"olive pollen"-noun-0]|TX|8/5,19/6|
text_000N_43358|MMI|3.50|Olea (plant)|C0996956|[plnt]|["Olive Tree"-tx-1-"olive tree"-noun-0]|TX|8/10|
text_000N_43358|MMI|3.50|tree pollen allergenic extracts|C3541399|[phsu]|["Tree pollen"-tx-1-"tree pollen"-noun-0]|TX|14/11|
text_000N_43358|MMI|3.47|Hierarchy|C0699032|[ftcn]|["Tree"-tx-1-"tree"-noun-0]|TX|14/4|
text_000N_43358|MMI|3.47|Olea europaea|C1122969|[plnt]|["Olive"-tx-1-"olive"-noun-0]|TX|8/5|
text_000N_43358|MMI|3.47|Olivary Nucleus|C0228539|[bpoc]|["Olive"-tx-1-"olive"-noun-0]|TX|8/5|
text_000N_43358|MMI|3.47|Olives - dietary|C0349382|[food]|["Olive"-tx-1-"olive"-noun-0]|TX|8/5|
text_000N_43358|MMI|3.47|Pollen|C0032385|[plnt]|["Pollen"-tx-1-"pollen"-noun-0]|TX|19/6|
text_000N_43358|MMI|3.47|Trees (plant)|C0040811|[plnt]|["Tree"-tx-1-"tree"-noun-0]|TX|14/4|
text_000N_43358|MMI|3.47|bee pollen|C0795585|[orch,phsu]|["POLLEN"-tx-1-"pollen"-noun-0]|TX|19/6|
text_000N_43358|MMI|3.47|inferior olivary eminence|C0262254|[bpoc]|["olive"-tx-1-"olive"-noun-0]|TX|8/5|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|15/6|
text_000N_43275|MMI|5.18|Body Weight|C0005910|[orga]|["Body Weight"-tx-1-"body weight"-noun-0]|TX|22/11|
text_000N_43275|MMI|5.18|Molindone measurement (procedure)|C1266630|[lbpr]|["Molindone"-tx-1-"molindone"-noun-0]|TX|5/9|
text_000N_43275|MMI|5.18|Weighing patient|C1305866|[hlca]|["body weight"-tx-1-"body weight"-noun-0]|TX|22/11|
text_000N_43275|MMI|5.18|molindone|C0026388|[orch,phsu]|["MOLINDONE"-tx-1-"molindone"-noun-0]|TX|5/9|
<<<<< MMI
>>>>> MMI
text_000N_43331|AA|MTI|medical text indexer|1|3|5|20|33:3
text_000N_43331|MMI|5.18|Relevance|C2347946|[qlco]|["Relevant"-tx-1-"relevant"-adj-0]|TX|55/8|
text_000N_43331|MMI|3.68|Useful|C3827682|[qlco]|["Useful"-tx-1-"useful"-adj-0]|TX|44/6|
text_000N_43331|MMI|3.61|Indexer Device|C1708497|[mnob]|["Indexer"-tx-1-"indexer"-noun-0]|TX|24/7|
text_000N_43331|MMI|3.47|Medical|C0205476|[ftcn]|["Medical"-tx-1-"medical"-adj-0]|TX|11/7|
text_000N_43331|MMI|3.47|Medical service|C0199168|[hlca]|["Medical"-tx-1-"medical"-adj-0]|TX|11/7|
text_000N_43331|MMI|3.47|Text|C1527021|[inpr]|["Text"-tx-1-"text"-noun-0]|TX|19/4|
text_000N_43331|MMI|3.47|Text (foundation metadata concept)|C3541382|[inpr]|["Text"-tx-1-"text"-noun-0]|TX|19/4|
text_000N_43331|MMI|3.47|Text - MDFAttributeType|C1554111|[inpr]|["Text"-tx-1-"text"-noun-0]|TX|19/4|
text_000N_43331|MMI|3.47|Text Line|C1705606|[inpr]|["Text"-tx-1-"text"-noun-0]|TX|19/4|
text_000N_43331|MMI|3.47|Text Messages|C3178910|[inpr]|["Text"-tx-1-"text"-noun-0]|TX|19/4|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Colorectal Cancer Pathway|C2984278|[cnce]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|21/17|
text_000N_43386|MMI|5.18|Colorectal Carcinoma|C0009402|[neop]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|21/17|
text_000N_43386|MMI|5.18|Malignant neoplasm of colon and/or rectum|C4722085|[neop]|["Colorectal cancer"-tx-1-"colorectal cancer"-noun-0]|TX|21/17|
text_000N_43386|MMI|5.18|NCI CTEP SDC Colorectal Cancer Sub-Category Terminology|C3542412|[inpr]|["Colorectal Cancer"-tx-1-"colorectal cancer"-noun-0]|TX|21/17|
text_000N_43386|MMI|5.18|PCBP2-OT1 gene|C3812534|[gngm]|["TUC.338"-tx-1-"TUC.338"-noun-0]|TX|5/7|
text_000N_43386|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|13/7|
text_000N_43386|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|13/7|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Tumor-Associated Macrophage|C3891660|[cell]|["Tumor-Associated Macrophages"-tx-1-"tumour-associated macrophages"-noun-0]|TX|3/29|
text_000N_40839|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|51/4|
text_000N_40839|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|51/4|
text_000N_40839|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|51/4|
text_000N_40839|MMI|3.43|Glioma|C0017638|[neop]|["GLIOMAS"-tx-1-"gliomas"-noun-0]|TX|59/7|
text_000N_40839|MMI|3.43|prognostic|C0220901|[inpr]|["Prognostic"-tx-1-"prognostic"-adj-0]|TX|40/10|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|3.63|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|24/8|
text_000N_40886|MMI|3.57|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|33/15|
text_000N_40886|MMI|3.54|Adult human body|C4082212|[anst]|["Body"-tx-1-"body"-noun-0]|TX|73/4|
text_000N_40886|MMI|3.54|Animal allergens|C1979620|[imft]|["Animal"-tx-1-"animal"-noun-0]|TX|66/6|
text_000N_40886|MMI|3.54|Animals|C0003062|[anim]|["ANIMAL"-tx-1-"animal"-noun-0]|TX|66/6|
text_000N_40886|MMI|3.54|Biological Evolution|C0015219|[genf]|["Evolution"-tx-1-"evolution"-noun-0]|TX|53/9|
text_000N_40886|MMI|3.54|Body structure|C1268086|[anst]|["Body"-tx-1-"body"-noun-0]|TX|73/4|
text_000N_40886|MMI|3.54|Human body|C0242821|[humn]|["body"-tx-1-"body"-noun-0]|TX|73/4|
text_000N_40886|MMI|3.54|Human body structure|C0460148|[anst]|["Body"-tx-1-"body"-noun-0]|TX|73/4|
text_000N_40886|MMI|3.54|Whole body|C0444584|[anst]|["BODY"-tx-1-"body"-noun-0]|TX|73/4|
text_000N_40886|MMI|3.51|Infantile Neuroaxonal Dystrophy|C0270724|[dsyn]|["PLAN"-tx-1-"plans"-noun-0]|TX|78/5|
text_000N_40886|MMI|3.51|Planned|C1301732|[ftcn]|["Plan"-tx-1-"plans"-noun-0]|TX|78/5|
text_000N_40886|MMI|3.51|Treatment Plan|C0599880|[inpr]|["Plan"-tx-1-"plans"-noun-0]|TX|78/5|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Physical performance|C2607857|[orgf]|["Performance, Physical"-tx-1-"physical performance"-noun-0]|TX|3/20|
text_000N_40941|MMI|3.68|thyroid hormone metabolism|C1156937|[moft]|["thyroid hormone metabolism"-tx-1-"thyroid hormone metabolism"-noun-0]|TX|38/26|
text_000N_40941|MMI|3.53|Influence|C4054723|[cnce]|["Influence"-tx-1-"influenced"-verb-0]|TX|24/10|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|7.16|SLC24A5 gene|C1427030|[gngm]|["SLC24A5"-tx-1-"SLC24A5"-noun-0,"SLC24A5 Gene"-tx-1-"SLC24A5 gene"-noun-0]|TX|44/7;44/12|
text_000N_40972|MMI|5.18|Observation of color of skin|C0475704|[fndg]|["skin colour"-tx-1-"skin color"-noun-0]|TX|3/10|
text_000N_40972|MMI|5.18|Skin Pigmentation|C0037290|[ortf]|["Skin Color"-tx-1-"skin color"-noun-0]|TX|3/10|
text_000N_40972|MMI|5.18|skin color|C0599910|[orga]|["skin colour"-tx-1-"skin color"-noun-0]|TX|3/10|
text_000N_40972|MMI|3.57|Gene Mutant|C0678941|[gngm]|["Gene variations"-tx-1-"variations gene"-noun-0]|TX|26/10,52/4|
text_000N_40972|MMI|3.55|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|14/8|
text_000N_40972|MMI|3.55|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|14/8|
text_000N_40972|MMI|3.55|Sodium/Potassium/Calcium Exchanger 5, Human|C5444669|[aapp,bacs]|["SLC24A5"-tx-1-"SLC24A5"-noun-0]|TX|44/7|
text_000N_40972|MMI|3.55|Variant|C0205419|[qlco]|["variations"-tx-1-"variations"-noun-0]|TX|26/10|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|18/6|
text_000N_40913|MMI|5.18|dronedarone|C0766326|[orch,phsu]|["DRONEDARONE"-tx-1-"dronedarone"-noun-0]|TX|5/11|
text_000N_40913|MMI|3.98|Level of the fourth thoracic vertebra|C0505385|[blor]|["T4 level"-tx-1-"T4 levels"-noun-0]|TX|33/9|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|3.55|Biological Markers|C0005516|[clna]|["Biomarker"-tx-1-"biomarker"-noun-0]|TX|18/9|
text_000N_97347|MMI|3.44|Well controlled|C3853142|[ftcn]|["Well controlled"-tx-1-"well-controlled"-adj-0]|TX|31/15|
text_000N_97347|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_97347|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_97347|MMI|3.42|Diabetes|C0011847|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|47/8|
text_000N_97347|MMI|3.42|Diabetes Mellitus|C0011849|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|47/8|
text_000N_97347|MMI|3.42|Ideal|C1512612|[qlco]|["Ideal"-tx-1-"ideal"-adj-0]|TX|12/5|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|3.59|Left|C0205091|[spco]|["LEFT"-tx-1-"lefty"-noun-0]|TX|15/5|
text_000N_97362|MMI|3.59|Left sided|C0443246|[spco]|["Left"-tx-1-"lefty"-noun-0]|TX|15/5|
text_000N_97362|MMI|3.59|Table Cell Horizontal Align - left|C1552822|[ftcn]|["left"-tx-1-"lefty"-noun-0]|TX|15/5|
text_000N_97362|MMI|3.57|Inhibitor|C1999216|[bacs]|["INHIBITOR"-tx-1-"inhibitor"-noun-0]|TX|24/9|
text_000N_97362|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
text_000N_97362|MMI|3.44|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|21/2|
text_000N_97362|MMI|3.44|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|21/2|
text_000N_97362|MMI|3.44|NODAL gene|C1417752|[gngm]|["NODAL"-tx-1-"nodal"-adj-0]|TX|37/5|
text_000N_97362|MMI|3.44|Nodal Homolog|C3272515|[aapp]|["NODAL"-tx-1-"nodal"-adj-0]|TX|37/5|
text_000N_97362|MMI|3.44|nodal (pertaining to a node)|C0443268|[spco]|["Nodal"-tx-1-"nodal"-adj-0]|TX|37/5|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Anti-BCMA/CD3 BiTE Antibody REGN5458|C4764258|[aapp,bacs]|["REGN5458"-tx-1-"REGN5458"-noun-0]|TX|3/8|
text_000N_47289|MMI|3.63|Antibodies|C0003241|[aapp,imft,phsu]|["Antibody"-tx-1-"antibody"-noun-0]|TX|30/8|
text_000N_47289|MMI|3.63|Immunoglobulin complex location, circulating|C3665580|[celc]|["antibody"-tx-1-"antibody"-noun-0]|TX|30/8|
text_000N_47289|MMI|3.63|Immunoglobulins|C0021027|[aapp,imft]|["Antibody"-tx-1-"antibody"-noun-0]|TX|30/8|
text_000N_47289|MMI|3.63|immunoglobulin complex location|C1167408|[celc]|["antibody"-tx-1-"antibody"-noun-0]|TX|30/8|
text_000N_47289|MMI|3.48|Singular|C0205171|[qnco]|["SINGLE"-tx-1-"single"-adj-0]|TX|14/6|
text_000N_47289|MMI|3.48|Target|C1521840|[ftcn]|["Targeted"-tx-1-"targeted"-adj-0]|TX|21/8|
text_000N_47289|MMI|3.48|Unmarried|C0087136|[fndg]|["single"-tx-1-"single"-adj-0]|TX|14/6|
text_000N_47289|MMI|3.48|Unmarried person|C0037179|[popg]|["Single"-tx-1-"single"-adj-0]|TX|14/6|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.64|Matrix Attachment Regions|C1257994|[bacs,nnon]|["Matrix Attachment Regions"-tx-1-"matrix-attachment regions"-noun-0]|TX|46/25|
text_000N_40999|MMI|3.63|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|23/8|
text_000N_40999|MMI|3.55|AQP1 gene|C1412491|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|32/2|
text_000N_40999|MMI|3.55|AQP1 wt Allele|C5551158|[gngm]|["CO"-tx-1-"co"-verb-0]|TX|32/2|
text_000N_40999|MMI|3.55|Colombia|C3245499|[geoa]|["CO"-tx-1-"co"-verb-0]|TX|32/2|
text_000N_40999|MMI|3.55|Occur (action)|C1709305|[acty]|["Occur"-tx-1-"occur"-verb-0]|TX|35/5|
text_000N_40999|MMI|3.55|Occurrence Indicator|C4284875|[ftcn]|["OCCUR"-tx-1-"occur"-verb-0]|TX|35/5|
<<<<< MMI
>>>>> MMI
text_000N_173087|AA|miR-1|micro RNA 1|3|5|5|11|16:5
text_000N_173087|MMI|3.75|MicroRNAs|C1101610|[bacs,nnon]|["MicroRNA"-tx-1-"micro RNA"-noun-0]|TX|3/9|
text_000N_173087|MMI|3.64|Cardiac Arrhythmia|C0003811|[dsyn]|["Cardiac Arrhythmias"-tx-1-"cardiac arrhythmias"-noun-0]|TX|37/19|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.68|C-X-C motif chemokine 12 receptor activity|C3539513|[moft]|["CXCR4"-tx-1-"CXCR4"-noun-0]|TX|11/5|
text_000N_97378|MMI|3.68|CXCR4 gene|C1332823|[gngm]|["CXCR4"-tx-1-"CXCR4"-noun-0]|TX|11/5|
text_000N_97378|MMI|3.68|CXCR4 protein, human|C2352110|[aapp,rcpt]|["CXCR4"-tx-1-"CXCR4"-noun-0]|TX|11/5|
text_000N_97378|MMI|3.68|CXCR4 wt Allele|C1707171|[gngm]|["CXCR-4"-tx-1-"CXCR4"-noun-0]|TX|11/5|
text_000N_97378|MMI|3.58|Prognostic Marker|C1514475|[qlco]|["Prognostic Marker"-tx-1-"prognostic marker"-noun-0]|TX|27/17|
text_000N_97378|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|17/4,45/2|
text_000N_97378|MMI|3.55|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_97378|MMI|3.55|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_97378|MMI|3.55|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|48/6|
text_000N_97378|MMI|3.50|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_173104|AA|PGD|Preimplantation Genetic Diagnosis|1|3|5|33|39:3
text_000N_173104|MMI|5.18|Preimplantation Diagnosis|C0086142|[diap]|["Preimplantation Genetic Diagnosis"-tx-1-"Preimplantation Genetic Diagnosis"-noun-0]|TX|4/33|
text_000N_173104|MMI|3.57|Choose (action)|C1707391|[acty]|["Selection"-tx-1-"selection"-noun-0]|TX|63/9|
text_000N_173104|MMI|3.57|GDC Gender Terminology|C5203051|[inpr]|["gender"-tx-1-"gender"-noun-0]|TX|56/6|
text_000N_173104|MMI|3.57|Gender|C0079399|[orga]|["Gender"-tx-1-"gender"-noun-0]|TX|56/6|
text_000N_173104|MMI|3.57|Genetic Selection|C0036576|[genf]|["selection"-tx-1-"selection"-noun-0]|TX|63/9|
text_000N_173104|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|47/4|
text_000N_173104|MMI|3.57|sex|C1522384|[orga]|["Gender"-tx-1-"gender"-noun-0]|TX|56/6|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.61|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|15/19|
text_000N_173120|MMI|3.43|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173120|MMI|3.43|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173120|MMI|3.43|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173120|MMI|3.43|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173120|MMI|3.43|enzastaurin|C1327830|[orch,phsu]|["ENZASTAURIN"-tx-1-"enzastaurin"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Valproate Measurement|C5553952|[lbpr]|["Valproic Acid"-tx-1-"valproic acid"-noun-0]|TX|3/13|
text_000N_173199|MMI|5.18|valproic acid|C0042291|[orch,phsu]|["VALPROIC ACID"-tx-1-"valproic acid"-noun-0]|TX|3/13|
text_000N_173199|MMI|3.62|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|17/9,44/9|
text_000N_173199|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_173199|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_173199|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
text_000N_173199|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|31/12|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|KRR1 gene|C1825740|[gngm]|["RIP-1"-tx-1-"RIP-1"-noun-0]|TX|9/5|
text_000N_173183|MMI|5.18|RALBP1 wt Allele|C3539807|[gngm]|["RIP1"-tx-1-"RIP1"-noun-0]|TX|3/4|
text_000N_173183|MMI|5.18|RIPK1 protein, human|C0297981|[aapp,enzy]|["RIP-1"-tx-1-"RIP-1"-noun-0]|TX|9/5|
text_000N_173183|MMI|3.64|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|16/7|
text_000N_173183|MMI|3.44|necrosome|C3821058|[celc]|["necrosome"-tx-1-"necrosome"-noun-0]|TX|28/9|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|42/7|
text_000N_173136|MMI|3.68|Retrotransposition|C1514925|[genf]|["Retrotransposition"-tx-1-"retrotransposition"-noun-0]|TX|53/18|
text_000N_173136|MMI|3.57|Interaction|C1704675|[ftcn]|["Interaction"-tx-1-"interaction"-noun-0]|TX|9/11|
text_000N_173136|MMI|3.50|CYRIB protein, human|C5196828|[aapp,bacs]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|FAM49B wt Allele|C3812159|[gngm]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|IGKV1-16 gene|C1416177|[gngm]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|INRG Stage L1|C4524638|[fndg]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|L1 innervation|C1179698|[blor]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|L1 level|C0446432|[blor]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.50|Long Interspersed Nucleotide Element-1|C0600472|[bacs,nnon]|["L1"-tx-1-"L1"-noun-0]|TX|50/2|
text_000N_173136|MMI|3.44|MOV10 gene|C1417230|[gngm]|["MOV10"-tx-1-"MOV10"-noun-0]|TX|24/5|
<<<<< MMI
>>>>> MMI
text_000N_173151|AA|ANE|Acute Necrotizing Encephalopathy|1|3|5|32|37:3
text_000N_173151|MMI|5.18|Acute necrotizing encephalopathy|C1855020|[dsyn]|["Acute necrotizing encephalopathy"-tx-1-"Acute Necrotizing Encephalopathy"-noun-0]|TX|3/32|
text_000N_173151|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affects"-tx-1-"affects"-verb-0]|TX|58/7|
text_000N_173151|MMI|5.18|Air Pollution|C0001873|[eehu]|["Air Pollution"-tx-1-"air pollution"-noun-0]|TX|123/13|
text_000N_173151|MMI|5.18|Usual|C3538928|[qlco]|["Usually"-tx-1-"usually"-adv-0]|TX|90/7|
text_000N_173151|MMI|5.18|Usually|C3888388|[fndg]|["Usually"-tx-1-"usually"-adv-0]|TX|90/7|
text_000N_173151|MMI|3.74|young child|C0728836|[aggp]|["young child"-tx-1-"young children"-noun-0]|TX|66/5,81/8|
text_000N_173151|MMI|3.72|Triggered by|C1444748|[qlco]|["Triggered by"-tx-1-"triggered by"-verb-0]|TX|98/12|
text_000N_173151|MMI|3.63|Healthy|C3898900|[qlco]|["Healthy"-tx-1-"healthy"-noun-0]|TX|73/7|
text_000N_173151|MMI|3.59|Exposure to|C0332157|[qlco]|["Exposure"-tx-1-"exposure"-noun-0]|TX|111/8|
text_000N_173151|MMI|3.59|Injury due to exposure to external cause|C0274281|[inpo]|["Exposure NOS"-tx-1-"exposure"-noun-0]|TX|111/8|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.55|Application procedure|C0185125|[topp]|["applications"-tx-1-"applications"-noun-0]|TX|23/12|
text_000N_173245|MMI|3.47|pain chronic management|C0747141|[topp]|["chronic pain management"-tx-1-"chronic pain management"-noun-0]|TX|40/23|
text_000N_173245|MMI|3.42|Telemedicine|C0162648|[hlca]|["Telemedicine"-tx-1-"telemedicine"-noun-0]|TX|10/12|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|DNA-Directed RNA Polymerase|C0035681|[aapp,enzy]|["RNA Polymerase"-tx-1-"RNA polymerase"-noun-0]|TX|101/14|
text_000N_173276|MMI|5.18|RNA Polymerase Assembly Pathway|C2984241|[ftcn]|["RNA polymerase"-tx-1-"RNA polymerase"-noun-0]|TX|101/14|
text_000N_173276|MMI|3.98|depend|C0725813|[medd]|["depend"-tx-1-"depended"-verb-0]|TX|92/8|
text_000N_173276|MMI|3.75|RNA, Viral|C0035736|[nnon]|["RNA, Viral"-tx-1-"viral RNA"-noun-0]|TX|82/9|
text_000N_173276|MMI|3.68|DNA Helicases|C0920283|[aapp,enzy]|["Helicase"-tx-1-"helicase"-noun-0]|TX|126/8|
text_000N_173276|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|24/11|
text_000N_173276|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|24/11|
text_000N_173276|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|24/11|
text_000N_173276|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|24/11|
text_000N_173276|MMI|3.50|Viral|C0521026|[ftcn]|["Viral"-tx-1-"viral"-adj-0]|TX|120/5|
text_000N_173276|MMI|3.48|Flaviviridae|C0206510|[virs]|["Flaviviridae"-tx-1-"flaviviridae"-noun-0]|TX|69/12|
text_000N_173276|MMI|3.45|Virus Replication|C0042774|[celf]|["Viral Replication"-tx-1-"viral replication"-noun-0]|TX|43/17|
text_000N_173276|MMI|3.43|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173276|MMI|3.43|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173276|MMI|3.43|Function (attribute)|C0542341|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|13/10|
text_000N_173276|MMI|3.43|Functional|C0205245|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|13/10|
text_000N_173276|MMI|3.43|Functional Relationship|C2700217|[cnce]|["Functional"-tx-1-"functional"-adj-0]|TX|13/10|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|verubecestat|C4307343|[orch,phsu]|["VERUBECESTAT"-tx-1-"verubecestat"-noun-0]|TX|3/12|
text_000N_173230|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_173230|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_173230|MMI|3.46|APP gene|C1364818|[gngm]|["Alzheimer disease"-tx-1-"Alzheimer Disease"-noun-0]|TX|30/9,42/7|
text_000N_173230|MMI|3.46|Alzheimer's Disease|C0002395|[dsyn]|["ALZHEIMER DISEASE"-tx-1-"Alzheimer Disease"-noun-0]|TX|30/9,42/7|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|22/15|
text_000N_173291|MMI|3.68|Exposure to|C0332157|[qlco]|["Exposure"-tx-1-"exposure"-noun-0]|TX|13/8|
text_000N_173291|MMI|3.68|Injury due to exposure to external cause|C0274281|[inpo]|["Exposure NOS"-tx-1-"exposure"-noun-0]|TX|13/8|
text_000N_173291|MMI|3.59|Polyneuropathy|C0152025|[dsyn]|["POLYNEUROPATHY"-tx-1-"polyneuropathy"-noun-0]|TX|38/14|
text_000N_173291|MMI|3.50|Pesticides|C0031253|[hops]|["Pesticide"-tx-1-"pesticide"-noun-0]|TX|3/9|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|Lennox-Gastaut syndrome|C0238111|[dsyn]|["LENNOX-GASTAUT SYNDROME"-tx-1-"Lennox-Gastaut Syndrome"-noun-0]|TX|3/23|
text_000N_97301|MMI|5.18|Usual|C3538928|[qlco]|["Usually"-tx-1-"usually"-adv-0]|TX|27/7|
text_000N_97301|MMI|5.18|Usually|C3888388|[fndg]|["Usually"-tx-1-"usually"-adv-0]|TX|27/7|
text_000N_97301|MMI|3.64|Elderly (population group)|C0001792|[popg]|["Older Adults"-tx-1-"older adults"-noun-0]|TX|48/12|
text_000N_97301|MMI|3.57|Diagnosis|C0011900|[diap]|["Diagnosed"-tx-1-"diagnosed"-verb-0]|TX|35/9|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|3.64|Phase 4 Clinical Trials|C0282462|[resa]|["Clinical Trials, Phase IV"-tx-1-"phase IV clinical trials"-noun-0]|TX|23/24|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|5.18|LYZ gene|C1416945|[gngm]|["LYSOZYME"-tx-1-"Lysozyme"-noun-0]|TX|3/8|
text_000N_97394|MMI|5.18|lysozyme|C3541379|[aapp,enzy,phsu]|["LYSOZYME"-tx-1-"Lysozyme"-noun-0]|TX|3/8|
text_000N_97394|MMI|5.18|lysozyme, chicken egg white|C0964782|[aapp,enzy,imft]|["LYSOZYME"-tx-1-"Lysozyme"-noun-0]|TX|3/8|
text_000N_97394|MMI|5.18|muramidase|C0026794|[aapp,enzy,phsu]|["Lysozyme"-tx-1-"Lysozyme"-noun-0]|TX|3/8|
text_000N_97394|MMI|3.57|Abundance|C2346714|[qlco]|["Abundant"-tx-1-"abundant"-adj-0]|TX|12/8|
text_000N_97394|MMI|3.44|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|24/5|
text_000N_97394|MMI|3.44|Specimen Source Codes - Tears|C1547924|[inpr]|["Tears"-tx-1-"tears"-noun-0]|TX|30/5|
text_000N_97394|MMI|3.44|Tears - SpecimenType|C1611838|[bdsu]|["Tears"-tx-1-"tears"-noun-0]|TX|30/5|
text_000N_97394|MMI|3.44|Tears body substance|C0039409|[bdsu]|["Tears"-tx-1-"tears"-noun-0]|TX|30/5|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|olaparib|C2316164|[orch,phsu]|["OLAPARIB"-tx-1-"Olaparib"-noun-0]|TX|3/8|
text_000N_173167|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_173167|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_173167|MMI|3.48|Malignant neoplasm of prostate|C0376358|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|26/15|
text_000N_173167|MMI|3.48|NCI CTEP SDC Prostate Cancer Sub-Category Terminology|C3541264|[inpr]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|26/15|
text_000N_173167|MMI|3.48|Prostate Cancer Pathway|C2984325|[cnce]|["Prostate cancer"-tx-1-"prostate cancer"-noun-0]|TX|26/15|
text_000N_173167|MMI|3.48|Prostate carcinoma|C0600139|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|26/15|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Base - General Qualifier|C1705938|[idcn]|["Based"-tx-1-"based"-verb-0]|TX|14/5|
text_000N_47274|MMI|5.18|Basis - conceptual entity|C1527178|[ftcn]|["Based"-tx-1-"based"-verb-0]|TX|14/5|
text_000N_47274|MMI|3.68|Internet|C0282111|[mnob]|["Web"-tx-1-"web"-noun-0]|TX|10/3|
text_000N_47274|MMI|3.55|Strategy|C0679199|[menp]|["strategies"-tx-1-"strategies"-noun-0]|TX|36/10|
text_000N_47274|MMI|3.47|pain chronic management|C0747141|[topp]|["chronic pain management"-tx-1-"management chronic pain"-noun-0]|TX|25/10,51/12|
text_000N_47274|MMI|3.43|Self|C0036588|[idcn]|["Self"-tx-1-"self"-noun-0]|TX|20/4|
text_000N_47274|MMI|3.43|subscriber - self|C1551994|[inpr]|["self"-tx-1-"self"-noun-0]|TX|20/4|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|3.58|Gene Deletion|C0017260|[genf]|["Gene Deletion"-tx-1-"deletion gene"-noun-0]|TX|5/8,32/4|
text_000N_47304|MMI|3.55|Deletion (action)|C1880274|[acty]|["Deletion"-tx-1-"deletion"-noun-0]|TX|5/8|
text_000N_47304|MMI|3.55|Deletion Mutation|C1511760|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|5/8|
text_000N_47304|MMI|3.55|Gene Deletion Abnormality|C1442161|[comd]|["Deletion"-tx-1-"deletion"-noun-0]|TX|5/8|
text_000N_47304|MMI|3.45|Gene Expression|C0017262|[genf]|["Gene Expression"-tx-1-"gene expression"-noun-0]|TX|32/15|
text_000N_47304|MMI|3.45|Gene Expression Process|C1517486|[genf]|["Gene expression"-tx-1-"gene expression"-noun-0]|TX|32/15|
text_000N_47304|MMI|3.43|Change -- procedure|C4319952|[topp]|["Change"-tx-1-"change"-noun-0]|TX|25/6|
text_000N_47304|MMI|3.43|Changed status|C0443172|[qnco]|["change"-tx-1-"change"-noun-0]|TX|25/6|
text_000N_47304|MMI|3.43|Changing|C0392747|[ftcn]|["Change"-tx-1-"change"-noun-0]|TX|25/6|
text_000N_47304|MMI|3.43|Delta (difference)|C1705241|[qnco]|["Change"-tx-1-"change"-noun-0]|TX|25/6|
text_000N_47304|MMI|3.43|Expression (foundation metadata concept)|C3854321|[idcn]|["Expression"-tx-1-"expression"-noun-0]|TX|37/10|
text_000N_47304|MMI|3.43|Expression procedure|C0185117|[topp]|["Expression"-tx-1-"expression"-noun-0]|TX|37/10|
text_000N_47304|MMI|3.43|cohesins|C0907709|[aapp,bacs]|["cohesin"-tx-1-"cohesin"-noun-0]|TX|17/7|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|AFM gene|C1412275|[gngm]|["AFAMIN"-tx-1-"Afamin"-noun-0]|TX|3/6|
text_000N_173260|MMI|5.18|Binding (Molecular Function)|C1167622|[moft]|["bind"-tx-1-"bind"-verb-0]|TX|10/4|
text_000N_173260|MMI|5.18|Binding action|C1145667|[acty]|["Bind"-tx-1-"bind"-verb-0]|TX|10/4|
text_000N_173260|MMI|5.18|Vitamin E Drug Class|C3714803|[phsu,vita]|["VITAMIN E"-tx-1-"Vitamin E"-noun-0]|TX|15/9|
text_000N_173260|MMI|5.18|vitamin E|C0042874|[orch,phsu,vita]|["VITAMIN E"-tx-1-"Vitamin E"-noun-0]|TX|15/9|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|10.42|SPI1 gene|C0919490|[gngm]|["PU.1"-tx-1-"PU.1"-noun-0,"SPI-1"-tx-1-"SPI1"-noun-0]|TX|5/4;11/4|
text_000N_47334|MMI|10.42|SPI1 wt Allele|C1705644|[gngm]|["PU.1"-tx-1-"PU.1"-noun-0,"SPI-1"-tx-1-"SPI1"-noun-0]|TX|5/4;11/4|
text_000N_47334|MMI|5.18|Affect (mental function)|C0001721|[menp]|["Affect"-tx-1-"affect"-verb-0]|TX|17/6|
text_000N_47334|MMI|5.18|SPI1 protein, human|C1452130|[aapp,bacs]|["SPI1"-tx-1-"SPI1"-noun-0]|TX|11/4|
text_000N_47334|MMI|5.18|lambda Spi-1|C0253464|[aapp,phsu]|["Spi-1"-tx-1-"SPI1"-noun-0]|TX|11/4|
text_000N_47334|MMI|3.63|Binding (Molecular Function)|C1167622|[moft]|["Binding"-tx-1-"binding"-noun-0]|TX|30/7|
text_000N_47334|MMI|3.63|Binding action|C1145667|[acty]|["Binding"-tx-1-"binding"-noun-0]|TX|30/7|
text_000N_47334|MMI|3.53|NF-kappa B|C0079904|[aapp,imft]|["NF kB"-tx-1-"NF-kB"-noun-0]|TX|24/5|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Encode (action)|C2700640|[acty]|["Encoded"-tx-1-"encoded"-verb-0]|TX|36/7|
text_000N_173214|MMI|5.18|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|44/7|
text_000N_173214|MMI|5.18|encoding mental process|C0679058|[menp]|["encoded"-tx-1-"encoded"-verb-0]|TX|36/7|
text_000N_173214|MMI|3.46|SARS coronavirus|C1175743|[virs]|["SARS Virus"-tx-1-"SARS virus"-noun-0]|TX|3/10|
text_000N_173214|MMI|3.43|ACE2 gene|C1422064|[gngm]|["ACE2"-tx-1-"ACE2"-noun-0]|TX|31/4|
text_000N_173214|MMI|3.43|ACE2 protein, human|C5433525|[aapp,enzy]|["ACE2"-tx-1-"ACE2"-noun-0]|TX|31/4|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|40/2|
text_000N_47349|MMI|5.18|Therapeutic procedure|C0087111|[topp]|["TREAT"-tx-1-"treat"-verb-0]|TX|43/5|
text_000N_47349|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|40/2|
text_000N_47349|MMI|5.18|Treating|C1522326|[ftcn]|["Treat"-tx-1-"treat"-verb-0]|TX|43/5|
text_000N_47349|MMI|5.18|Treatment intent|C1292734|[ftcn]|["treat"-tx-1-"treat"-verb-0]|TX|43/5|
text_000N_47349|MMI|5.18|Urge Incontinence|C0150045|[fndg]|["Urge Incontinence"-tx-1-"urge incontinence"-noun-0]|TX|50/17|
text_000N_47349|MMI|5.18|Urinary bladder training|C0150474|[hlca]|["Bladder training"-tx-1-"Bladder training"-noun-0]|TX|3/16|
text_000N_47349|MMI|3.68|METHOD:*|C5445274|[fndg]|["METHOD:*"-tx-1-"method"-noun-0]|TX|33/6|
text_000N_47349|MMI|3.68|Methods|C0025663|[ftcn]|["Method"-tx-1-"method"-noun-0]|TX|33/6|
text_000N_47349|MMI|3.68|Techniques|C0449851|[ftcn]|["Method"-tx-1-"method"-noun-0]|TX|33/6|
text_000N_47349|MMI|3.68|Test Method|C0871511|[lbpr]|["METHOD"-tx-1-"method"-noun-0]|TX|33/6|
text_000N_47349|MMI|3.50|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|23/9|
text_000N_47349|MMI|3.50|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|23/9|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|3.56|Patient Outcome|C1547647|[idcn]|["Patient Outcome"-tx-1-"outcomes patients"-noun-0]|TX|70/8,106/8|
text_000N_47363|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47363|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47363|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47363|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47363|MMI|3.47|C-Reactive Protein, human|C4048285|[aapp,imft]|["C-Reactive Protein"-tx-1-"c-reactive protein"-noun-0]|TX|32/18|
text_000N_47363|MMI|3.47|C-reactive protein|C0006560|[aapp,imft]|["C Reactive Protein"-tx-1-"c-reactive protein"-noun-0]|TX|32/18|
text_000N_47363|MMI|3.47|CRP gene|C1413716|[gngm]|["C-REACTIVE PROTEIN"-tx-1-"c-reactive protein"-noun-0]|TX|32/18|
text_000N_47363|MMI|3.46|Subarachnoid Hemorrhage|C0038525|[dsyn]|["SUBARACHNOID HEMORRHAGE"-tx-1-"subarachnoid hemorrhage"-noun-0]|TX|82/23|
text_000N_47363|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47363|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47363|MMI|3.42|Mental concentration|C0086045|[menp]|["concentrations"-tx-1-"concentrations"-noun-0]|TX|51/14|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|3.55|Biological Markers|C0005516|[clna]|["Biomarkers"-tx-1-"biomarkers"-noun-0]|TX|20/10|
text_000N_97283|MMI|3.44|Carcinoma of bladder|C0699885|[neop]|["Urinary Bladder Cancer"-tx-1-"urine bladder cancer"-noun-0]|TX|14/5,35/14|
text_000N_97283|MMI|3.44|Malignant neoplasm of urinary bladder|C0005684|[neop]|["Cancer, Urinary Bladder"-tx-1-"urine bladder cancer"-noun-0]|TX|14/5,35/14|
text_000N_97283|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|10/3|
text_000N_97283|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|10/3|
text_000N_97283|MMI|3.42|Date of diagnosis|C2316983|[tmco]|["Diagnosis"-tx-1-"diagnosis"-noun-0]|TX|50/9|
text_000N_97283|MMI|3.42|Diagnosis|C0011900|[diap]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|50/9|
text_000N_97283|MMI|3.42|Diagnosis Code|C1550350|[inpr]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|50/9|
text_000N_97283|MMI|3.42|Diagnosis Study|C1704656|[resa]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|50/9|
text_000N_97283|MMI|3.42|Disease|C0012634|[dsyn]|["Diagnosis"-tx-1-"diagnosis"-noun-0]|TX|50/9|
text_000N_97283|MMI|3.42|diagnosis aspect|C1704338|[ftcn]|["diagnosis"-tx-1-"diagnosis"-noun-0]|TX|50/9|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|3.59|A Mouse|C1522424|[mamm]|["A Mouse"-tx-1-"a mouse"-noun-0]|TX|9/7|
text_000N_43235|MMI|3.55|Digital Model Attachment|C3853906|[inpr]|["model"-tx-1-"model"-noun-0]|TX|17/5|
text_000N_43235|MMI|3.55|Model|C3161035|[inpr]|["Model"-tx-1-"model"-noun-0]|TX|17/5|
text_000N_43235|MMI|3.55|Model - style/design|C3714583|[cnce]|["Model"-tx-1-"model"-noun-0]|TX|17/5|
text_000N_43235|MMI|3.55|Model Number|C3274659|[inpr]|["MODEL"-tx-1-"model"-noun-0]|TX|17/5|
text_000N_43235|MMI|3.55|Vendor model number:ID:Pt:{Device}:Nom|C3833412|[clna]|["Model #"-tx-1-"model"-noun-0]|TX|17/5|
text_000N_43235|MMI|3.45|FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)|C3469521|[dsyn]|["FANCONI ANEMIA"-tx-1-"Fanconi anemia"-noun-0]|TX|27/14|
text_000N_43235|MMI|3.45|Fanconi Anemia|C0015625|[dsyn]|["Fanconi anaemia"-tx-1-"Fanconi anemia"-noun-0]|TX|27/14|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|5.18|ANXA2 protein, human|C1175494|[aapp,bacs]|["Protein I"-tx-1-"protein 1"-noun-0]|TX|14/9|
text_000N_97409|MMI|5.18|Apoptosis Inducing Proteins|C1565115|[aapp,bacs]|["Protein, Pro-Apoptotic"-tx-1-"pro apoptotic protein"-noun-0]|TX|27/21|
text_000N_97409|MMI|5.18|BCL2 gene|C0376515|[gngm]|["Bcl-2"-tx-1-"Bcl-2"-noun-0]|TX|3/5|
text_000N_97409|MMI|5.18|BCL2 protein, human|C4042483|[aapp]|["BCL2"-tx-1-"Bcl-2"-noun-0]|TX|3/5|
text_000N_97409|MMI|5.18|Synapsin I|C0087044|[aapp,bacs]|["protein i"-tx-1-"protein 1"-noun-0]|TX|14/9|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|DNA-Binding Protein SATB1|C2699550|[aapp,rcpt]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_47435|MMI|5.18|SATB1 gene|C1419822|[gngm]|["SATB1"-tx-1-"SATB1"-noun-0]|TX|3/5|
text_000N_47435|MMI|3.59|Expression Positive|C5444885|[lbtr]|["Expressed"-tx-1-"expressed"-verb-0]|TX|9/9|
text_000N_47435|MMI|3.59|Positive Finding|C1514241|[fndg]|["EXPRESSED"-tx-1-"expressed"-verb-0]|TX|9/9|
text_000N_47435|MMI|3.59|thymocyte|C0814999|[cell]|["Thymocytes"-tx-1-"thymocytes"-noun-0]|TX|22/10|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.68|Nasal Cannula|C0179574|[medd]|["Nasal Cannulae"-tx-1-"nasal cannulae"-noun-0]|TX|14/14|
text_000N_47320|MMI|3.61|Abnormally high|C1299351|[qlco]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|Flow|C0806140|[npop]|["Flow"-tx-1-"flow"-noun-0]|TX|9/4|
text_000N_47320|MMI|3.61|High|C0205250|[qlco]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|High (finding)|C5200928|[fndg]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|High Level|C4321237|[fndg]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|High Mitosis-Karyorrhexis Index|C3889660|[inpr]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|IPSS Risk Category High|C4522209|[inpr]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|IPSS-R Risk Category High|C5202936|[fndg]|["High"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|Value Above Reference Range|C2700149|[inpr]|["HIGH"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.61|high - ActExposureLevelCode|C3887512|[idcn]|["high"-tx-1-"high"-noun-0]|TX|4/4|
text_000N_47320|MMI|3.58|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|29/9,43/9|
text_000N_47320|MMI|3.45|Preterm Infant|C4048294|[aggp]|["Preterm Infants"-tx-1-"preterm infants"-noun-0]|TX|56/15|
<<<<< MMI
>>>>> MMI
text_000N_47420|AA|GAPDH|Glyceraldehyde 3-phosphate dehydrogenase|1|5|7|40|46:5
text_000N_47420|MMI|5.18|GAPDH gene|C1414968|[gngm]|["GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE"-tx-1-"Glyceraldehyde 3-phosphate dehydrogenase"-noun-0]|TX|4/40|
text_000N_47420|MMI|5.18|GAPDH protein, human|C5433435|[aapp,enzy]|["Glyceraldehyde-3-Phosphate Dehydrogenase"-tx-1-"Glyceraldehyde 3-phosphate dehydrogenase"-noun-0]|TX|4/40|
text_000N_47420|MMI|5.18|Glyceraldehyde-3-Phosphate Dehydrogenases|C0017857|[aapp,enzy]|["Glyceraldehyde-3-Phosphate Dehydrogenase"-tx-1-"Glyceraldehyde 3-phosphate dehydrogenase"-noun-0]|TX|4/40|
text_000N_47420|MMI|5.18|Glyceraldehyde-3-phosphate dehydrogenase|C3536868|[aapp,enzy]|["Glyceraldehyde 3 phosphate dehydrogenase"-tx-1-"Glyceraldehyde 3-phosphate dehydrogenase"-noun-0]|TX|4/40|
text_000N_47420|MMI|5.18|Report (document)|C0684224|[inpr]|["Reported"-tx-1-"reported"-verb-0]|TX|58/8|
text_000N_47420|MMI|5.18|Reported|C4319718|[ftcn]|["Reported"-tx-1-"reported"-verb-0]|TX|58/8|
text_000N_47420|MMI|5.18|Reporting|C0700287|[hlca]|["Reported"-tx-1-"reported"-verb-0]|TX|58/8|
text_000N_47420|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|67/2|
text_000N_47420|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|67/2|
text_000N_47420|MMI|3.55|receptor|C0597357|[aapp,rcpt]|["Receptor"-tx-1-"receptor"-noun-0]|TX|87/8|
text_000N_47420|MMI|3.43|Bacteria|C0004611|[bact]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|110/8|
text_000N_47420|MMI|3.43|Bacteria present|C4038931|[fndg]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|110/8|
text_000N_47420|MMI|3.43|PLG gene|C1367553|[gngm]|["PLASMINOGEN"-tx-1-"plasminogen"-noun-0]|TX|75/11|
text_000N_47420|MMI|3.43|PLG protein, human|C5441720|[aapp,bacs]|["Plasminogen"-tx-1-"plasminogen"-noun-0]|TX|75/11|
text_000N_47420|MMI|3.43|Pathogenic Variant|C3816499|[nusq]|["Pathogenic"-tx-1-"pathogenic"-adj-0]|TX|99/10|
text_000N_47420|MMI|3.43|Pathogenic organism|C0450254|[orgm]|["Pathogenic"-tx-1-"pathogenic"-adj-0]|TX|99/10|
text_000N_47420|MMI|3.43|Percent of Bacteria|C2347473|[qnco]|["% Bacteria"-tx-1-"bacteria"-noun-0]|TX|110/8|
text_000N_47420|MMI|3.43|bacteria aspects|C1510439|[ftcn]|["bacteria"-tx-1-"bacteria"-noun-0]|TX|110/8|
text_000N_47420|MMI|3.43|plasminogen|C0032140|[aapp,bacs,phsu]|["Plasminogen"-tx-1-"plasminogen"-noun-0]|TX|75/11|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.54|Limits of Stability Test|C5401439|[inpr]|["LOS"-tx-1-"Loss"-noun-0]|TX|3/4|
text_000N_47450|MMI|3.54|Loss|C1517945|[qnco]|["Loss"-tx-1-"Loss"-noun-0]|TX|3/4|
text_000N_47450|MMI|3.42|1 (finding)|C5201140|[fndg]|["One"-tx-1-"one"-noun-0]|TX|20/3|
text_000N_47450|MMI|3.42|Argynnis pandora|C2700598|[euka]|["cardinal"-tx-1-"cardinal"-noun-0]|TX|31/8|
text_000N_47450|MMI|3.42|Aspects of signs|C0220912|[ftcn]|["signs"-tx-1-"signs"-noun-0]|TX|40/5|
text_000N_47450|MMI|3.42|Cardinalis cardinalis|C0326926|[bird]|["Cardinal"-tx-1-"cardinal"-noun-0]|TX|31/8|
text_000N_47450|MMI|3.42|Function (attribute)|C0542341|[ftcn]|["Function"-tx-1-"function"-noun-0]|TX|11/8|
text_000N_47450|MMI|3.42|Function Axis|C0700205|[orga]|["FUNCTION"-tx-1-"function"-noun-0]|TX|11/8|
text_000N_47450|MMI|3.42|Genus Cardinalis (organism)|C1320142|[bird]|["Cardinal"-tx-1-"cardinal"-noun-0]|TX|31/8|
text_000N_47450|MMI|3.42|Inflammation|C0021368|[patf]|["INFLAMMATION"-tx-1-"inflammation"-noun-0]|TX|49/12|
text_000N_47450|MMI|3.42|Manufactured sign|C0220913|[mnob]|["signs"-tx-1-"signs"-noun-0]|TX|40/5|
text_000N_47450|MMI|3.42|Mathematical Operator|C1705273|[inpr]|["Function"-tx-1-"function"-noun-0]|TX|11/8|
text_000N_47450|MMI|3.42|One|C0205447|[qnco]|["ONE"-tx-1-"one"-noun-0]|TX|20/3|
text_000N_47450|MMI|3.42|Physical findings|C0311392|[fndg]|["SIGNS"-tx-1-"signs"-noun-0]|TX|40/5|
text_000N_47450|MMI|3.42|physiological aspects|C0031843|[phsf]|["function"-tx-1-"function"-noun-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.58|Patient Outcome|C1547647|[idcn]|["Patient Outcome"-tx-1-"outcomes patients"-noun-0]|TX|71/8,90/8|
text_000N_47392|MMI|3.55|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47392|MMI|3.55|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47392|MMI|3.55|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47392|MMI|3.55|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47392|MMI|3.44|IL6 protein, human|C1698754|[aapp,bacs]|["Interleukin-6"-tx-1-"interleukin-6"-noun-0]|TX|38/13|
text_000N_47392|MMI|3.44|Recombinant Interleukin-6|C1527132|[aapp,imft,phsu]|["Interleukin-6"-tx-1-"interleukin-6"-noun-0]|TX|38/13|
text_000N_47392|MMI|3.44|interleukin-6|C0021760|[aapp,imft]|["Interleukin 6"-tx-1-"interleukin-6"-noun-0]|TX|38/13|
text_000N_47392|MMI|3.44|serum concentration|C0683149|[qnco]|["concentrations serum"-tx-1-"serum concentrations"-noun-0]|TX|32/5,52/14|
text_000N_47392|MMI|3.44|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|83/6|
text_000N_47392|MMI|3.44|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|83/6|
text_000N_47392|MMI|3.44|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|83/6|
text_000N_47392|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47392|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|3.68|Borg Scale Rating of Perceived Exertion Score 11|C4050248|[fndg]|["Light"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|Hypersensitivity|C0020517|[patf]|["Sensitive"-tx-1-"sensitive"-adj-0]|TX|36/9|
text_000N_43275|MMI|3.68|Light|C0023693|[npop]|["Light"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|Light (qualifier)|C1881376|[qlco]|["Light"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|Light - subjective measurement|C3842678|[fndg]|["Light"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|Light color|C1306462|[ftcn]|["Light"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|Sensitive|C0332324|[ftcn]|["Sensitive"-tx-1-"sensitive"-adj-0]|TX|36/9|
text_000N_43275|MMI|3.68|TNFSF14 protein, human|C1570446|[aapp,bacs]|["LIGHT"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|TNFSF14 wt Allele|C4521367|[gngm]|["LIGHT"-tx-1-"light"-adj-0]|TX|30/5|
text_000N_43275|MMI|3.68|stimulus sensitivity|C1522640|[qlco]|["Sensitive"-tx-1-"sensitive"-adj-0]|TX|36/9|
text_000N_43275|MMI|3.63|Chromosomes, Human, Pair 2|C0008662|[celc]|["chr2"-tx-1-"ChR2"-noun-0]|TX|25/4|
text_000N_43275|MMI|3.48|Optogenetics|C3494301|[mbrt]|["Optogenetics"-tx-1-"optogenetics"-noun-0]|TX|7/12|
text_000N_43275|MMI|3.48|Scientific Equipment|C2827396|[mnob]|["Tool"-tx-1-"tool"-noun-0]|TX|20/4|
text_000N_43275|MMI|3.48|Tool, device (physical object)|C0336791|[mnob]|["Tool"-tx-1-"tool"-noun-0]|TX|20/4|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|3.68|TIPIN gene|C1823281|[gngm]|["TIPIN"-tx-1-"TIPIN"-noun-0]|TX|14/5|
text_000N_47377|MMI|3.57|Disassembly (action)|C1707798|[acty]|["Disassembly"-tx-1-"disassembly"-noun-0]|TX|45/11|
text_000N_47377|MMI|3.57|replisome|C1325592|[celc]|["replisome"-tx-1-"replisome"-noun-0]|TX|35/9|
text_000N_47377|MMI|3.50|TIMELESS gene|C1420737|[gngm]|["TIMELESS"-tx-1-"TIMELESS"-noun-0]|TX|5/8|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Schizophrenia|C0036341|[mobd]|["SCHIZOPHRENIA"-tx-1-"schizophrenia"-noun-1]|TX|62/13|
text_000N_43303|MMI|3.54|Involvement with|C1314939|[ftcn]|["Involvement"-tx-1-"involvement"-noun-0]|TX|13/11|
text_000N_43303|MMI|3.47|Long Intergenic Non-Protein Coding RNA|C2982391|[bacs,nnon]|["LONG NON-CODING RNA"-tx-1-"long non-coding RNA"-noun-0]|TX|32/19|
text_000N_43303|MMI|3.47|RNA, Long Untranslated|C3494264|[bacs,nnon]|["RNA, Long Non-Coding"-tx-1-"long non-coding RNA"-noun-0]|TX|32/19|
text_000N_43303|MMI|3.42|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_43303|MMI|3.42|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_43303|MMI|3.42|MIAT gene|C1970205|[gngm]|["gomafu"-tx-1-"Gomafu"-noun-0]|TX|52/6|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Craniosynostosis|C0010278|[dsyn]|["CRANIOSYNOSTOSIS"-tx-1-"craniosynostosis"-noun-0]|TX|25/16|
text_000N_43358|MMI|5.18|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0]|TX|19/5|
text_000N_43358|MMI|5.18|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0]|TX|19/5|
text_000N_43358|MMI|5.18|TWIST1 gene|C1421244|[gngm]|["craniosynostosis"-tx-1-"craniosynostosis"-noun-0]|TX|25/16|
text_000N_43358|MMI|3.68|Variant|C0205419|[qlco]|["variants"-tx-1-"variants"-noun-0]|TX|10/8|
text_000N_43358|MMI|3.50|SMAD6 gene|C1334469|[gngm]|["SMAD6"-tx-1-"SMAD6"-noun-0]|TX|4/5|
text_000N_43358|MMI|3.50|SMAD6 protein, human|C0540682|[aapp,bacs]|["SMAD6"-tx-1-"SMAD6"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Domestic Sheep|C1123019|[mamm]|["Ovine"-tx-1-"ovine"-adj-0]|TX|14/5|
text_000N_43386|MMI|5.18|Sheep|C0036945|[mamm]|["Ovine"-tx-1-"ovine"-adj-0]|TX|14/5|
text_000N_43386|MMI|5.18|Term (lexical)|C1705313|[idcn]|["Word"-tx-1-"word"-noun-0]|TX|9/4|
text_000N_43386|MMI|3.59|Capra hircus|C0018019|[mamm]|["goats"-tx-1-"goats"-noun-0]|TX|30/5|
text_000N_43386|MMI|3.59|Goat|C1510458|[mamm]|["Goats"-tx-1-"goats"-noun-0]|TX|30/5|
text_000N_43386|MMI|3.59|Referring|C0205543|[ftcn]|["refers"-tx-1-"refers"-verb-0]|TX|20/6|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Malignant mesothelioma|C0345967|[neop]|["Mesothelioma"-tx-1-"mesothelioma"-noun-0]|TX|3/12|
text_000N_40839|MMI|5.18|Mesothelioma|C0025500|[neop]|["MESOTHELIOMA"-tx-1-"mesothelioma"-noun-0]|TX|3/12|
text_000N_40839|MMI|5.18|NCI CTEP SDC Mesothelioma Sub-Category Terminology|C3538785|[inpr]|["Mesothelioma"-tx-1-"mesothelioma"-noun-0]|TX|3/12|
text_000N_40839|MMI|3.64|Exposure to asbestos|C0003948|[fndg]|["ASBESTOS EXPOSURE"-tx-1-"asbestos exposure"-noun-0]|TX|26/17|
text_000N_40839|MMI|3.54|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|16/6|
text_000N_40839|MMI|3.54|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|16/6|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|Adenocarcinoma Of Esophagus|C0279628|[neop]|["Oesophageal Adenocarcinoma NOS"-tx-1-"esophageal adenocarcinoma"-noun-0]|TX|3/25|
text_000N_43331|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|29/15|
text_000N_43331|MMI|3.57|Aberrant|C0443127|[qlco]|["Aberrant"-tx-1-"aberrant"-adj-0]|TX|45/8|
text_000N_43331|MMI|3.57|Protein Glycosylation|C0376322|[moft]|["Glycosylation"-tx-1-"glycosylation"-noun-0]|TX|54/13|
text_000N_43331|MMI|3.57|glycosylation|C0017982|[npop]|["Glycosylation"-tx-1-"glycosylation"-noun-0]|TX|54/13|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|7.06|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|[26/8],[57/8]|
text_000N_40886|MMI|3.56|Similarity|C2348205|[qlco]|["Similar"-tx-1-"similar"-adj-0]|TX|35/7|
text_000N_40886|MMI|3.50|royal jelly|C0073603|[orch,phsu]|["ROYAL JELLY"-tx-1-"royal jelly"-noun-0]|TX|14/11|
text_000N_40886|MMI|3.47|Major|C0205164|[qlco]|["Major"-tx-1-"major"-adj-0]|TX|8/5|
text_000N_40886|MMI|3.47|Major <insect>|C4318856|[euka]|["Major"-tx-1-"major"-adj-0]|TX|8/5|
text_000N_40886|MMI|3.47|Severe (severity modifier)|C0205082|[fndg]|["Major"-tx-1-"major"-adj-0]|TX|8/5|
text_000N_40886|MMI|3.47|US Military Commissioned Officer O4|C4521762|[clas]|["Major"-tx-1-"major"-adj-0]|TX|8/5|
text_000N_40886|MMI|3.43|Yellow color|C0221205|[qlco]|["YELLOW"-tx-1-"yellow"-adj-0]|TX|50/6|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|Dyskeratosis Congenita|C0265965|[dsyn]|["Dyskeratosis Congenita"-tx-1-"Dyskeratosis Congenita"-noun-0]|TX|41/22|
text_000N_40913|MMI|3.81|Increased risk for cancer|C3553618|[fndg]|["Increased risk for cancer"-tx-1-"increased risk for cancer"-noun-0]|TX|12/25|
text_000N_40913|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_40913|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|5.18|Availability of|C0470187|[ftcn]|["Available"-tx-1-"available"-adj-0]|TX|43/9|
text_000N_40941|MMI|3.68|Hydranencephaly with Renal Aplasia-Dysplasia|C1856053|[dsyn]|["MARCH"-tx-1-"March"-noun-0]|TX|31/5|
text_000N_40941|MMI|3.68|March (month)|C3829202|[tmco]|["March"-tx-1-"March"-noun-0]|TX|31/5|
text_000N_40941|MMI|3.63|Exubera|C1176237|[aapp,horm,phsu]|["EXUBERA"-tx-1-"Exubera"-noun-0]|TX|12/7|
text_000N_40941|MMI|3.48|Current (present time)|C0521116|[tmco]|["Currently"-tx-1-"currently"-adv-0]|TX|20/9|
text_000N_40941|MMI|3.48|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|7/4|
text_000N_40941|MMI|3.48|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|7/4|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|3.55|Promoter|C0086860|[bacs,nnon]|["promoters"-tx-1-"promoters"-noun-0]|TX|20/9|
text_000N_47289|MMI|3.42|Daily Living|C4552744|[dora]|["functions"-tx-1-"functions"-noun-0]|TX|51/9|
text_000N_47289|MMI|3.42|Distal (qualifier value)|C0205108|[spco]|["DISTAL"-tx-1-"distal"-adj-0]|TX|35/6|
text_000N_47289|MMI|3.42|Distal Resection Margin|C4522154|[clna]|["Distal"-tx-1-"distal"-adj-0]|TX|35/6|
text_000N_47289|MMI|3.42|Enhancer of transcription|C0086222|[nnon]|["Enhancer"-tx-1-"enhancer"-noun-0]|TX|42/8|
text_000N_47289|MMI|3.42|Function (attribute)|C0542341|[ftcn]|["Functions"-tx-1-"functions"-noun-0]|TX|51/9|
text_000N_47289|MMI|3.42|Mammals|C0024660|[mamm]|["Mammalian"-tx-1-"mammalian"-adj-0]|TX|10/9|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|PRDM9 gene|C1422331|[gngm]|["PRDM9"-tx-1-"PRDM9"-noun-0]|TX|3/5|
text_000N_40972|MMI|3.59|Essential|C0205224|[qlco]|["Essential"-tx-1-"essential"-adj-0]|TX|9/9|
text_000N_40972|MMI|3.45|Meiosis|C0025186|[celf]|["Meiosis"-tx-1-"meiosis"-noun-0]|TX|23/7|
text_000N_40972|MMI|3.45|meiotic cell cycle|C1657605|[celf]|["meiosis"-tx-1-"meiosis"-noun-0]|TX|23/7|
text_000N_40972|MMI|3.45|meiotic nuclear division|C4325600|[celf]|["meiosis"-tx-1-"meiosis"-noun-0]|TX|23/7|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|Longevity|C0023980|[tmco]|["Longevity"-tx-1-"longevity"-noun-0]|TX|19/9|
text_000N_40999|MMI|5.18|Modulated|C0443264|[spco]|["modulate"-tx-1-"modulate"-verb-0]|TX|10/8|
text_000N_40999|MMI|3.98|FOXO Family|C3899164|[aapp]|["FoxO"-tx-1-"FOXOs"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|3.63|Bacteria|C0004611|[bact]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|17/8|
text_000N_97331|MMI|3.63|Bacteria present|C4038931|[fndg]|["Bacterium"-tx-1-"bacteria"-noun-0]|TX|17/8|
text_000N_97331|MMI|3.63|Percent of Bacteria|C2347473|[qnco]|["% Bacteria"-tx-1-"bacteria"-noun-0]|TX|17/8|
text_000N_97331|MMI|3.63|bacteria aspects|C1510439|[ftcn]|["bacteria"-tx-1-"bacteria"-noun-0]|TX|17/8|
text_000N_97331|MMI|3.59|Brain|C0006104|[bpoc]|["BRAIN"-tx-1-"brain"-noun-0]|TX|35/5|
text_000N_97331|MMI|3.59|Head>Brain|C4266577|[bpoc]|["Brain"-tx-1-"brain"-noun-0]|TX|35/5|
text_000N_97331|MMI|3.59|Present|C0150312|[fndg]|["Found"-tx-1-"found"-verb-0]|TX|26/5|
text_000N_97331|MMI|3.48|P Blood group antibodies|C0369773|[aapp,imft]|["P NOS"-tx-1-"P"-noun-0]|TX|3/1|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|macitentan|C2606556|[orch,phsu]|["MACITENTAN"-tx-1-"macitentan"-noun-0]|TX|3/10|
text_000N_97347|MMI|3.68|Agonist|C2987634|[bacs]|["Agonist"-tx-1-"agonist"-noun-0]|TX|20/7|
text_000N_97347|MMI|3.50|Thrombocythemia, Essential|C0040028|[dsyn]|["ET"-tx-1-"ET"-adj-0]|TX|17/2|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|3.59|Profiling (action)|C2003903|[ftcn]|["Profile"-tx-1-"profiles"-noun-0]|TX|19/8|
text_000N_173120|MMI|3.59|Changing|C0392747|[ftcn]|["Altered"-tx-1-"altered"-verb-0]|TX|28/7|
text_000N_173120|MMI|3.59|Irradiation (physical force)|C1282930|[npop]|["Irradiation"-tx-1-"irradiation"-noun-0]|TX|39/11|
text_000N_173120|MMI|3.59|Therapeutic radiology procedure|C1522449|[topp]|["Irradiation"-tx-1-"irradiation"-noun-0]|TX|39/11|
text_000N_173120|MMI|3.53|Gastrointestinal Microbiome|C4018878|[orgm]|["Microbiota, Gut"-tx-1-"gut microbiota"-noun-0]|TX|4/14|
text_000N_173120|MMI|3.53|Intestinal Microbiome|C2985398|[orgm]|["Gut Microbiota"-tx-1-"gut microbiota"-noun-0]|TX|4/14|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|apremilast|C1678805|[orch,phsu]|["APREMILAST"-tx-1-"apremilast"-noun-0]|TX|3/10|
text_000N_173136|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173136|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_173136|MMI|3.45|Psoriasis|C0033860|[dsyn]|["PSORIASIS"-tx-1-"psoriasis"-noun-0]|TX|28/9|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|10.42|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-verb-0,"causes"-tx-1-"causes"-verb-0]|TX|66/5;38/6|
text_000N_97362|MMI|10.42|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-verb-0,"Cause"-tx-1-"causes"-verb-0]|TX|66/5;38/6|
text_000N_97362|MMI|5.18|Brucella abortus|C0006304|[bact]|["BRUCELLA ABORTUS"-tx-1-"Brucella abortus"-noun-0]|TX|3/16|
text_000N_97362|MMI|5.18|Etiology|C1314792|[ftcn]|["Causes"-tx-1-"causes"-verb-0]|TX|38/6|
text_000N_97362|MMI|5.18|Known|C0205309|[qlco]|["Known"-tx-1-"known"-verb-0]|TX|57/5|
text_000N_97362|MMI|5.18|Organism|C0029235|[orgm]|["Organism"-tx-1-"organism"-noun-0]|TX|24/8|
text_000N_97362|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|63/2|
text_000N_97362|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|63/2|
text_000N_97362|MMI|3.64|Spontaneous abortion|C0000786|[patf]|["Spontaneous Abortions"-tx-1-"spontaneous abortions"-noun-0]|TX|72/21|
text_000N_97362|MMI|3.44|Genus Homo|C1300203|[mamm]|["humans"-tx-1-"humans"-noun-0]|TX|97/6|
text_000N_97362|MMI|3.44|Homo sapiens|C0086418|[humn]|["Humans"-tx-1-"humans"-noun-0]|TX|97/6|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|Huntington Disease|C0020179|[dsyn]|["huntingtons disease"-tx-1-"Huntington's disease"-noun-0]|TX|3/20|
text_000N_173199|MMI|5.18|Huntington's Disease Pathway|C2919056|[ftcn]|["Huntington's Disease"-tx-1-"Huntington's disease"-noun-0]|TX|3/20|
text_000N_173199|MMI|3.58|HTT gene|C1415504|[gngm]|["HTT Gene"-tx-1-"HTT gene"-noun-0]|TX|70/8|
text_000N_173199|MMI|3.57|Repeat Expansion Disease|C5447383|[dsyn]|["Repeat expansion"-tx-1-"expansion repeat"-noun-0]|TX|37/9,56/6|
text_000N_173199|MMI|3.52|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"caused"-verb-0]|TX|27/6|
text_000N_173199|MMI|3.52|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"caused"-verb-0]|TX|27/6|
text_000N_173199|MMI|3.44|Chromosomes, Human, Pair 4|C0008667|[celc]|["Chromosome 4"-tx-1-"Chromosome 4"-noun-0]|TX|82/12|
text_000N_173199|MMI|3.42|CD44 wt Allele|C1707101|[gngm]|["IN"-tx-1-"in"-prep-0]|TX|63/2|
text_000N_173199|MMI|3.42|Present|C0150312|[fndg]|["In"-tx-1-"in"-prep-0]|TX|63/2|
text_000N_173199|MMI|3.42|Within|C0332285|[spco]|["In"-tx-1-"in"-prep-0]|TX|63/2|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.75|Malignant neoplasm of prostate|C0376358|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|61/15|
text_000N_97378|MMI|3.75|NCI CTEP SDC Prostate Cancer Sub-Category Terminology|C3541264|[inpr]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|61/15|
text_000N_97378|MMI|3.75|Prostate Cancer Pathway|C2984325|[cnce]|["Prostate cancer"-tx-1-"prostate cancer"-noun-0]|TX|61/15|
text_000N_97378|MMI|3.75|Prostate carcinoma|C0600139|[neop]|["Prostate Cancer"-tx-1-"prostate cancer"-noun-0]|TX|61/15|
text_000N_97378|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|24/15|
text_000N_97378|MMI|3.63|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|77/8|
text_000N_97378|MMI|3.60|RB1 Negative|C4331208|[lbtr]|["RB1 Loss"-tx-1-"loss RB1"-noun-0]|TX|6/4,20/3|
text_000N_97378|MMI|3.57|Better|C0332272|[qlco]|["Better"-tx-1-"better"-adj-0]|TX|40/6|
text_000N_97378|MMI|3.57|Better than Others|C4522046|[fndg]|["Better"-tx-1-"better"-adj-0]|TX|40/6|
text_000N_97378|MMI|3.57|Forecast of outcome|C0033325|[hlca]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|47/9|
text_000N_97378|MMI|3.57|Improved - answer to question|C4084203|[fndg]|["Better"-tx-1-"better"-adj-0]|TX|40/6|
text_000N_97378|MMI|3.57|Prognosis:Find:Pt:^Patient:Nom|C3854082|[clna]|["Prognosis"-tx-1-"prognosis"-noun-0]|TX|47/9|
text_000N_97378|MMI|3.43|AQP1 gene|C1412491|[gngm]|["CO"-tx-1-"co"-noun-0]|TX|3/2|
text_000N_97378|MMI|3.43|AQP1 wt Allele|C5551158|[gngm]|["CO"-tx-1-"co"-noun-0]|TX|3/2|
text_000N_97378|MMI|3.43|BRCA2 gene|C0598034|[gngm]|["BRCA2"-tx-1-"BRCA2"-noun-0]|TX|14/5|
text_000N_97378|MMI|3.43|BRCA2 protein, human|C2973986|[aapp,bacs]|["BRCA2"-tx-1-"BRCA2"-noun-0]|TX|14/5|
text_000N_97378|MMI|3.43|Colombia|C3245499|[geoa]|["CO"-tx-1-"co"-noun-0]|TX|3/2|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.64|Vitamin D Deficiency|C0042870|[dsyn]|["Deficient in vitamin D"-tx-1-"Vitamin D deficiency in"-noun-0]|TX|3/23|
text_000N_173087|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|42/15|
text_000N_173087|MMI|3.64|Gestational Diabetes|C0085207|[dsyn]|["Gestational Diabetes"-tx-1-"gestational diabetes"-noun-0]|TX|58/20|
text_000N_173087|MMI|3.45|Pregnant Women|C0033011|[popg]|["Pregnant Women"-tx-1-"pregnant women"-noun-0]|TX|27/14|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Valproate Measurement|C5553952|[lbpr]|["Valproic Acid"-tx-1-"valproic acid"-noun-0]|TX|4/13|
text_000N_173183|MMI|5.18|valproic acid|C0042291|[orch,phsu]|["VALPROIC ACID"-tx-1-"valproic acid"-noun-0]|TX|4/13|
text_000N_173183|MMI|3.57|Continuance of life|C0038952|[acty]|["Survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_173183|MMI|3.57|survival aspects|C0220921|[ftcn]|["survival"-tx-1-"survival"-noun-0]|TX|26/8|
text_000N_173183|MMI|3.44|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173183|MMI|3.44|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173183|MMI|3.44|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173183|MMI|3.44|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|38/12|
text_000N_173183|MMI|3.44|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|51/8|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.58|gene synthesis|C0598991|[mbrt]|["gene Biosynthesis"-tx-1-"genes biosynthesis"-noun-0]|TX|8/5,27/12|
text_000N_173104|MMI|3.55|Genome|C0017428|[gngm]|["Genome"-tx-1-"genome"-noun-0]|TX|57/6|
text_000N_173104|MMI|3.55|Genome - anatomical entity|C2338314|[cnce]|["Genome"-tx-1-"genome"-noun-0]|TX|57/6|
text_000N_173104|MMI|3.55|Scattered|C0439742|[spco]|["Scattered"-tx-1-"scattered"-verb-0]|TX|40/9|
text_000N_173104|MMI|3.43|marneral|C2603901|[orch]|["marneral"-tx-1-"marneral"-noun-0]|TX|18/8|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|SLN gene|C1420247|[gngm]|["SARCOLIPIN"-tx-1-"Sarcolipin"-noun-0]|TX|3/10|
text_000N_47406|MMI|5.18|sarcolipin|C0654533|[aapp,bacs]|["Sarcolipin"-tx-1-"Sarcolipin"-noun-0]|TX|3/10|
text_000N_47406|MMI|3.56|Staphylococcal Protein A|C0038164|[aapp,imft,irda]|["a protein"-tx-1-"a protein"-noun-0]|TX|14/1,38/7|
text_000N_47406|MMI|3.45|Sarcoplasmic Reticulum Calcium-Transporting ATPases|C0916181|[aapp,enzy]|["SERCA Calcium ATPase"-tx-1-"Calcium ATPase SERCA"-noun-0]|TX|53/20|
text_000N_47406|MMI|3.42|Inhibition|C3463820|[acty]|["Inhibitory"-tx-1-"inhibitory"-adj-0]|TX|27/10|
text_000N_47406|MMI|3.42|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-adj-0]|TX|16/10|
text_000N_47406|MMI|3.42|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-adj-0]|TX|16/10|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|ORMD-0801|C3712707|[aapp,horm]|["ORMD-0801"-tx-1-"ORMD-0801"-noun-0]|TX|4/9|
text_000N_173230|MMI|3.59|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|29/8|
text_000N_173230|MMI|3.59|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|19/6|
text_000N_173230|MMI|3.59|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|19/6|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|3.54|Bound (value)|C2349209|[cnce]|["Limit"-tx-1-"limit"-noun-0]|TX|18/5|
text_000N_173291|MMI|3.54|Limit - Amount class|C1549649|[idcn]|["Limit"-tx-1-"limit"-noun-0]|TX|18/5|
text_000N_173291|MMI|3.54|Limited (extensiveness)|C0439801|[ftcn]|["Limit"-tx-1-"limit"-noun-0]|TX|18/5|
text_000N_173291|MMI|3.54|Upper|C1282910|[spco]|["UPPER"-tx-1-"upper"-noun-0]|TX|12/5|
text_000N_173291|MMI|3.43|Fraction of|C1264633|[qnco]|["Fraction of"-tx-1-"fraction of"-noun-0]|TX|42/11|
text_000N_173291|MMI|3.43|Genome, Human|C0017429|[gngm]|["Genome, Human"-tx-1-"human genome"-noun-0]|TX|58/12|
text_000N_173291|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_173291|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_173291|MMI|3.42|Function (attribute)|C0542341|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|31/10|
text_000N_173291|MMI|3.42|Functional|C0205245|[ftcn]|["Functional"-tx-1-"functional"-adj-0]|TX|31/10|
text_000N_173291|MMI|3.42|Functional Relationship|C2700217|[cnce]|["Functional"-tx-1-"functional"-adj-0]|TX|31/10|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|HRC gene|C1415718|[gngm]|["HRC"-tx-1-"HRC"-noun-0]|TX|44/3|
text_000N_97301|MMI|3.78|histidine-binding protein|C0062750|[aapp,bacs]|["histidine-binding protein"-tx-1-"histidine binding protein"-noun-0]|TX|9/9,27/15|
text_000N_97301|MMI|3.59|TRDN gene|C1421109|[gngm]|["TRIADIN"-tx-1-"triadin"-noun-0]|TX|63/7|
text_000N_97301|MMI|3.59|triadin|C0146619|[aapp,bacs]|["triadin"-tx-1-"triadin"-noun-0]|TX|63/7|
text_000N_97301|MMI|3.46|Wealthy|C0699759|[qlco]|["Rich"-tx-1-"rich"-adj-0]|TX|19/4|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|5.18|Pseudouridine|C0033846|[bacs,nnon]|["Pseudouridine"-tx-1-"pseudouridine"-noun-0]|TX|3/13|
text_000N_97316|MMI|5.18|RNA modification|C1158744|[genf]|["RNA modification"-tx-1-"RNA modification"-noun-0]|TX|19/16|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|3.63|Variant|C0205419|[qlco]|["variants"-tx-1-"variants"-noun-0]|TX|21/8|
text_000N_173245|MMI|3.55|Responsible to (attribute)|C1273518|[fndg]|["Responsible Individual"-tx-1-"responsible individuals"-noun-0]|TX|30/11,92/11|
text_000N_173245|MMI|3.48|Coding|C0009219|[ocac]|["Coding"-tx-1-"coding"-adj-0]|TX|14/6|
text_000N_173245|MMI|3.48|Coding Subtest (WAIS-IV)|C4050311|[inpr]|["Coding"-tx-1-"coding"-adj-0]|TX|14/6|
text_000N_173245|MMI|3.48|Coding Subtest (WISC-V)|C4050310|[inpr]|["Coding"-tx-1-"coding"-adj-0]|TX|14/6|
text_000N_173245|MMI|3.48|Encode (action)|C2700640|[acty]|["coding"-tx-1-"coding"-adj-0]|TX|14/6|
text_000N_173245|MMI|3.42|Undiagnosed|C1408353|[fndg]|["Undiagnosed"-tx-1-"undiagnosed"-adj-0]|TX|62/11|
text_000N_173245|MMI|3.42|majority|C0680220|[socb]|["majority"-tx-1-"majority"-noun-0]|TX|50/8|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|WDHD1 gene|C1427963|[gngm]|["CTF4"-tx-1-"Ctf4"-noun-0]|TX|3/4|
text_000N_173276|MMI|3.64|sister chromatid cohesion|C1155633|[celf]|["sister chromatid cohesion"-tx-1-"sister chromatid cohesion"-noun-0]|TX|20/25|
text_000N_173276|MMI|3.55|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
text_000N_173276|MMI|3.55|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|8/8|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|F11 gene|C1414498|[gngm]|["FACTOR XI"-tx-1-"factor XI"-noun-0]|TX|3/9|
text_000N_173167|MMI|5.18|Factor XI|C0015522|[aapp,bacs]|["Factor XI"-tx-1-"factor XI"-noun-0]|TX|3/9|
text_000N_173167|MMI|5.18|Factor XI Measurement|C5235469|[lbpr]|["Factor XI"-tx-1-"factor XI"-noun-0]|TX|3/9|
text_000N_173167|MMI|3.57|Deficiency|C0011155|[ftcn]|["Deficient"-tx-1-"deficient"-adj-0]|TX|13/9|
text_000N_173167|MMI|3.57|Percentage deficient|C1636779|[qnco]|["% deficient"-tx-1-"deficient"-adj-0]|TX|13/9|
text_000N_173167|MMI|3.48|Hereditary Factor XI Deficiency|C0015523|[dsyn]|["Haemophilia C"-tx-1-"Hemophilia C"-noun-0]|TX|26/12|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-verb-0]|TX|23/8|
text_000N_47304|MMI|5.18|Variation (Genetics)|C0042333|[npop]|["Genetic Variation"-tx-1-"genetic variation"-noun-0]|TX|32/17|
text_000N_47304|MMI|3.68|Sweep|C2348625|[hlca]|["Sweep"-tx-1-"sweep"-noun-0]|TX|17/5|
text_000N_47304|MMI|3.45|Choose (action)|C1707391|[acty]|["Selection"-tx-1-"selective"-adj-0]|TX|7/9|
text_000N_47304|MMI|3.45|Genetic Selection|C0036576|[genf]|["selection"-tx-1-"selective"-adj-0]|TX|7/9|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|5.18|Opdivo|C3872108|[aapp,phsu]|["Opdivo"-tx-1-"Opdivo"-noun-0]|TX|14/6|
text_000N_97424|MMI|5.18|PD-L1 Inhibitors|C5392068|[phsu]|["PD-L1 Inhibitor"-tx-1-"PD-L1 inhibitor"-noun-0]|TX|24/15|
text_000N_97424|MMI|5.18|nivolumab|C3657270|[aapp,imft,phsu]|["NIVOLUMAB"-tx-1-"Nivolumab"-noun-0]|TX|3/9|
<<<<< MMI
>>>>> MMI
text_000N_97440|MMI|5.18|ACE2 gene|C1422064|[gngm]|["ACE2"-tx-1-"ACE2"-noun-0]|TX|3/4|
text_000N_97440|MMI|5.18|ACE2 protein, human|C5433525|[aapp,enzy]|["ACE2"-tx-1-"ACE2"-noun-0]|TX|3/4|
text_000N_97440|MMI|3.69|Cell surface|C0699040|[celc]|["Cell Surface"-tx-1-"cell surfaces"-noun-0]|TX|21/13|
text_000N_97440|MMI|3.48|On (qualifier value)|C1720294|[inpr]|["On"-tx-1-"on"-noun-0]|TX|18/2|
text_000N_97440|MMI|3.48|SPARC protein, human|C3530142|[aapp,bacs]|["ON"-tx-1-"on"-noun-0]|TX|18/2|
text_000N_97440|MMI|3.48|Upon - dosing instruction fragment|C1720176|[ftcn]|["On"-tx-1-"on"-noun-0]|TX|18/2|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|enlimomab|C1258935|[imft]|["enlimomab"-tx-1-"Enlimomab"-noun-0]|TX|4/9|
text_000N_47274|MMI|3.63|Result|C1274040|[ftcn]|["Outcome"-tx-1-"outcomes"-noun-0]|TX|29/8|
text_000N_47274|MMI|3.50|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|22/6|
text_000N_47274|MMI|3.50|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|22/6|
text_000N_47274|MMI|3.50|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|22/6|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|10.42|Polycomb-Group Proteins|C1623167|[aapp,bacs]|["PcG"-tx-1-"PcG"-noun-0,"Polycomb-Group Proteins"-tx-1-"polycomb group proteins"-noun-0]|TX|28/3;3/23|
text_000N_47334|MMI|5.18|Mediate|C0086597|[socb]|["Mediate"-tx-1-"mediate"-verb-0]|TX|33/7|
text_000N_47334|MMI|5.18|penicillin G|C0030827|[antb,orch]|["PCG"-tx-1-"PcG"-noun-0]|TX|28/3|
text_000N_47334|MMI|3.56|Anabolism|C0220781|[biof]|["formation"-tx-1-"formation"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.56|Formation|C1522492|[ftcn]|["Formation"-tx-1-"formation"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.56|Formations|C0439634|[spco]|["formation"-tx-1-"formation"-noun-0]|TX|45/9|
text_000N_47334|MMI|3.45|Chromatin Loop|C1516509|[celc]|["Chromatin Loop"-tx-1-"chromatin loops"-noun-0]|TX|58/15|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|5.18|ZYX gene|C1421874|[gngm]|["ZYXIN"-tx-1-"zyxin"-noun-0]|TX|3/5|
text_000N_47435|MMI|5.18|ZYX protein, human|C1430219|[aapp,horm]|["Zyxin"-tx-1-"zyxin"-noun-0]|TX|3/5|
text_000N_47435|MMI|5.18|Zyxin|C3202972|[aapp,horm]|["Zyxin"-tx-1-"zyxin"-noun-0]|TX|3/5|
text_000N_47435|MMI|3.75|Adhesion protein|C3872829|[aapp,bacs]|["Adhesion protein"-tx-1-"adhesion protein"-noun-0]|TX|17/16|
text_000N_47435|MMI|3.75|Focal Adhesions|C0887870|[celc]|["Focal Adhesion"-tx-1-"focal adhesion"-noun-0]|TX|11/14|
text_000N_47435|MMI|3.75|Focal adhesion pathway|C1512810|[celf]|["Focal Adhesion"-tx-1-"focal adhesion"-noun-0]|TX|11/14|
text_000N_47435|MMI|3.63|Focal|C0205234|[spco]|["FOCAL"-tx-1-"focal"-noun-0]|TX|11/5|
text_000N_47435|MMI|3.63|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|26/7|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|L-Type Calcium Channels|C0288263|[aapp,bacs]|["L-Type Calcium Channels"-tx-1-"L-type calcium channels"-noun-0]|TX|24/23|
text_000N_173151|MMI|5.18|nifedipine|C0028066|[orch,phsu]|["NIFEDIPINE"-tx-1-"nifedipine"-noun-0]|TX|5/10|
text_000N_173151|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_173151|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|16/7|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|4.12|FANCA gene|C1414527|[gngm]|["FANCONI ANEMIA gene"-tx-1-"Fanconi anemia genes"-noun-0]|TX|8/20|
text_000N_173214|MMI|4.12|FANCA gene (procedure)|C2237024|[lbpr]|["FANCONI ANEMIA gene"-tx-1-"Fanconi anemia genes"-noun-0]|TX|8/20|
text_000N_173214|MMI|3.58|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|31/7|
text_000N_173214|MMI|3.44|Signal Transduction|C0037083|[celf]|["signalling pathway"-tx-1-"signalling pathway"-noun-0]|TX|48/18|
text_000N_173214|MMI|3.44|Signal Transduction Pathways|C0086982|[moft]|["Signaling Pathway"-tx-1-"signalling pathway"-noun-0]|TX|48/18|
text_000N_173214|MMI|3.42|S-Adenosylmethionine Measurement|C5400560|[lbpr]|["SAMe"-tx-1-"same"-adj-0]|TX|43/4|
text_000N_173214|MMI|3.42|Same|C0445247|[qlco]|["SAME"-tx-1-"same"-adj-0]|TX|43/4|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|34/19|
text_000N_43235|MMI|5.18|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|34/19|
text_000N_43235|MMI|5.18|CHI3L1 protein, human|C0528649|[aapp,bacs]|["YKL-40"-tx-1-"YKL-40"-noun-0]|TX|3/6|
text_000N_43235|MMI|5.18|CHI3L1 wt Allele|C4084754|[gngm]|["YKL-40"-tx-1-"YKL-40"-noun-0]|TX|3/6|
text_000N_43235|MMI|5.18|Chitinase-3-Like Protein 1|C3872855|[aapp,bacs]|["YKL-40"-tx-1-"YKL-40"-noun-0]|TX|3/6|
text_000N_43235|MMI|3.57|Biological Markers|C0005516|[clna]|["Biomarker"-tx-1-"biomarker"-noun-0]|TX|20/9|
text_000N_43235|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|10/4|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|3.57|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173260|MMI|3.57|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173260|MMI|3.57|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|13/4|
text_000N_173260|MMI|3.50|cohesion|C0597767|[npop]|["cohesion"-tx-1-"cohesion"-noun-0]|TX|31/8|
text_000N_173260|MMI|3.44|Any|C1552551|[qlco]|["Any"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173260|MMI|3.44|Any Data Type|C3272371|[inpr]|["ANY"-tx-1-"any"-det-0]|TX|9/3|
text_000N_173260|MMI|3.44|PDS5B gene|C1332105|[gngm]|["PDS5B"-tx-1-"Pds5b"-noun-0]|TX|22/5|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|5.18|Contain (action)|C2700400|[acty]|["Contain"-tx-1-"contain"-verb-0]|TX|13/7|
text_000N_43358|MMI|5.18|Containing (qualifier)|C0332256|[ftcn]|["contain"-tx-1-"contain"-verb-0]|TX|13/7|
text_000N_43358|MMI|5.18|Nematodes|C1704319|[euka]|["Nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
text_000N_43358|MMI|5.18|Nematodes <beetle>|C1947962|[euka]|["Nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
text_000N_43358|MMI|5.18|Phylum Nematoda|C0027581|[euka]|["nematodes"-tx-1-"nematodes"-noun-0]|TX|3/9|
text_000N_43358|MMI|3.67|CTCFL protein, human|C1136749|[aapp,bacs]|["CTCF-Like Protein"-tx-1-"proteins like CTCF"-noun-0]|TX|35/18|
text_000N_43358|MMI|3.39|Architecture|C0003737|[ocdi]|["Architecture"-tx-1-"architectural"-adj-0]|TX|21/13|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|Multiple Sclerosis|C0026769|[dsyn]|["MULTIPLE SCLEROSIS"-tx-1-"Multiple Sclerosis"-noun-0]|TX|44/18|
text_000N_47349|MMI|3.56|CDISC Relationship Class|C3540605|[inpr]|["RELATIONSHIP"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_47349|MMI|3.56|Concept Relationship|C1705630|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_47349|MMI|3.56|Object Relationship|C1706279|[idcn]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_47349|MMI|3.56|Relationships|C0439849|[qlco]|["Relationship"-tx-1-"relationship"-noun-0]|TX|11/12|
text_000N_47349|MMI|3.46|A & B|C3845933|[fndg]|["A & B"-tx-1-"a B"-noun-0]|TX|9/1,32/1|
text_000N_47349|MMI|3.46|A,B|C1440044|[imft]|["A,B"-tx-1-"a B"-noun-0]|TX|9/1,32/1|
text_000N_47349|MMI|3.43|Cell Count|C0007584|[lbpr]|["CELLS"-tx-1-"cells"-noun-0]|TX|34/5|
text_000N_47349|MMI|3.43|Cells|C0007634|[cell]|["Cells"-tx-1-"cells"-noun-0]|TX|34/5|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Genus Homo|C1300203|[mamm]|["humans"-tx-1-"humans"-noun-0]|TX|48/6|
text_000N_43275|MMI|5.18|Homo sapiens|C0086418|[humn]|["Humans"-tx-1-"humans"-noun-0]|TX|48/6|
text_000N_43275|MMI|5.18|TREM2 gene|C1425067|[gngm]|["TREM2"-tx-1-"TREM2"-noun-0]|TX|3/5|
text_000N_43275|MMI|5.18|TREM2 protein, human|C1143976|[aapp,rcpt]|["TREM2"-tx-1-"TREM2"-noun-0]|TX|3/5|
text_000N_43275|MMI|5.18|TREM2 wt Allele|C4085570|[gngm]|["TREM-2"-tx-1-"TREM2"-noun-0]|TX|3/5|
text_000N_43275|MMI|3.64|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|25/19|
text_000N_43275|MMI|3.64|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|25/19|
text_000N_43275|MMI|3.64|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|9/15|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Angiogenic Process|C0302600|[ortf]|["Angiogenesis"-tx-1-"angiogenesis"-noun-0]|TX|24/12|
text_000N_97283|MMI|5.18|Tumor Angiogenesis|C1519670|[neop]|["angiogenesis"-tx-1-"angiogenesis"-noun-0]|TX|24/12|
text_000N_97283|MMI|5.18|midostaurin|C0526371|[orch,phsu]|["MIDOSTAURIN"-tx-1-"midostaurin"-noun-0]|TX|4/11|
text_000N_97283|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|16/7|
text_000N_97283|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|16/7|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|3.68|Pharmaceutical Preparations|C0013227|[phsu]|["Drug"-tx-1-"drug"-noun-0]|TX|36/4|
text_000N_47320|MMI|3.68|Pharmacologic Substance|C1254351|[phsu]|["DRUG"-tx-1-"drug"-noun-0]|TX|36/4|
text_000N_47320|MMI|3.68|thalidomide|C0039736|[hops,orch,phsu]|["THALIDOMIDE"-tx-1-"Thalidomide"-noun-0]|TX|3/11|
text_000N_47320|MMI|3.50|Current (present time)|C0521116|[tmco]|["Currently"-tx-1-"currently"-adv-0]|TX|15/9|
text_000N_47320|MMI|3.48|Market|C1318228|[geoa]|["Market"-tx-1-"marketed"-adj-0]|TX|27/8|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|3.98|RNA, Long Untranslated|C3494264|[bacs,nnon]|["RNA, Long Noncoding"-tx-1-"long noncoding RNAs"-noun-0]|TX|41/19|
text_000N_43331|MMI|3.54|Interaction|C1704675|[ftcn]|["Interaction"-tx-1-"interactions"-noun-0]|TX|10/12|
text_000N_43331|MMI|3.44|Short|C1806781|[qnco]|["SHORT"-tx-1-"short"-adj-0]|TX|31/5|
text_000N_43331|MMI|3.44|Short Heart Murmur|C5238699|[fndg]|["Short"-tx-1-"short"-adj-0]|TX|31/5|
text_000N_43331|MMI|3.44|Short Value|C2350002|[qnco]|["Short"-tx-1-"short"-adj-0]|TX|31/5|
text_000N_43331|MMI|3.44|Shortened|C1282927|[qlco]|["short"-tx-1-"short"-adj-0]|TX|31/5|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|marimastat|C0338344|[orch,phsu]|["MARIMASTAT"-tx-1-"marimastat"-noun-0]|TX|3/10|
text_000N_47363|MMI|3.55|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47363|MMI|3.55|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|14/9|
text_000N_47363|MMI|3.52|NCI CTEP SDC Small Cell Lung Cancer Sub-Category Terminology|C3540630|[inpr]|["Small Cell Lung Cancer"-tx-1-"small-cell lung cancer"-noun-0]|TX|28/22|
text_000N_47363|MMI|3.52|Small Cell Lung Cancer Pathway|C2984312|[cnce]|["Small cell lung cancer"-tx-1-"small-cell lung cancer"-noun-0]|TX|28/22|
text_000N_47363|MMI|3.52|Small cell carcinoma of lung|C0149925|[neop]|["Lung cancer, small cell"-tx-1-"small-cell lung cancer"-noun-0]|TX|28/22|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Known|C0205309|[qlco]|["Known"-tx-1-"known"-verb-0]|TX|41/5|
text_000N_47377|MMI|3.63|Proteome|C0751973|[aapp,bacs]|["Proteome"-tx-1-"proteome"-noun-0]|TX|32/8|
text_000N_47377|MMI|3.53|Dictyostelium discoideum|C0086149|[euka]|["Dictyostelium discoideum"-tx-1-"Dictyostelium discoideum"-noun-0]|TX|7/24|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|5.18|Congenital deafness|C0339789|[cgab]|["Congenital deafness"-tx-1-"congenital deafness"-noun-0]|TX|42/19|
text_000N_47392|MMI|5.18|Present|C0150312|[fndg]|["PRESENT"-tx-1-"present"-verb-0]|TX|34/7|
text_000N_47392|MMI|5.18|Presentation|C0449450|[idcn]|["Present"-tx-1-"present"-verb-0]|TX|34/7|
text_000N_47392|MMI|5.18|Radial-Femoral Lag Present|C5238858|[fndg]|["Present"-tx-1-"present"-verb-0]|TX|34/7|
text_000N_47392|MMI|3.57|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|3/8|
text_000N_47392|MMI|3.48|Pendred's syndrome|C0271829|[dsyn]|["Pendred's Syndrome"-tx-1-"Pendred syndrome"-noun-0]|TX|17/16|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|5.18|3,5-diiodothyropropionic acid|C0218166|[orch]|["DITPA"-tx-1-"DITPA"-noun-0]|TX|3/5|
text_000N_47450|MMI|5.18|Clinical Research|C0008972|[resa]|["Clinical Studies"-tx-1-"clinical studies"-noun-0]|TX|63/16|
text_000N_47450|MMI|3.75|hormone analog|C0019935|[horm,phsu]|["hormone analog"-tx-1-"hormone analog"-noun-0]|TX|19/14|
text_000N_47450|MMI|3.63|Analog|C0243071|[chvs]|["Analogue"-tx-1-"analog"-noun-0]|TX|27/6|
text_000N_47450|MMI|3.59|Experimentally Determined Chemical Structure|C4522251|[inpr]|["Experimental"-tx-1-"experimental"-adj-0]|TX|46/12|
text_000N_47450|MMI|3.59|Investigational|C1517586|[qlco]|["Experimental"-tx-1-"experimental"-adj-0]|TX|46/12|
text_000N_47450|MMI|3.53|Thyroid Hormones|C0040135|[horm]|["Thyroid Hormone"-tx-1-"thyroid hormone"-noun-0]|TX|11/15|
text_000N_47450|MMI|3.53|Thyroid hormone (disposition)|C4522017|[qlco]|["Thyroid hormone"-tx-1-"thyroid hormone"-noun-0]|TX|11/15|
text_000N_47450|MMI|3.48|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|C3540038|[irda]|["THYROID"-tx-1-"thyroid"-noun-0]|TX|11/7|
text_000N_47450|MMI|3.48|Thyroid Gland|C0040132|[bpoc]|["Thyroid, NOS"-tx-1-"thyroid"-noun-0]|TX|11/7|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|RNA, Circular|C0073432|[nnon]|["RNAs, Circular"-tx-1-"circular RNAs"-noun-0]|TX|4/13|
text_000N_43303|MMI|3.72|Disorder of eye|C0015397|[dsyn]|["DISEASES OF THE EYE"-tx-1-"diseases of the eye"-noun-0]|TX|32/19|
<<<<< MMI
>>>>> MMI
text_000N_43386|MMI|5.18|Epistaxis|C0014591|[patf]|["EPISTAXIS"-tx-1-"Epistaxis"-noun-0]|TX|3/9|
text_000N_43386|MMI|5.18|Epistaxis, CTCAE|C4554627|[fndg]|["Epistaxis"-tx-1-"Epistaxis"-noun-0]|TX|3/9|
text_000N_43386|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|13/15|
text_000N_43386|MMI|3.61|Implantable dental prosthesis, device|C0011373|[medd]|["Dental Implant"-tx-1-"dental implant"-noun-0]|TX|29/14|
text_000N_43386|MMI|3.56|Clinical act of insertion|C0441587|[hlca]|["Placement"-tx-1-"placement"-noun-0]|TX|44/9|
text_000N_43386|MMI|3.56|Implantation procedure|C0021107|[topp]|["Placement"-tx-1-"placement"-noun-0]|TX|44/9|
text_000N_43386|MMI|3.56|Placement|C1524072|[qlco]|["Placement"-tx-1-"placement"-noun-0]|TX|44/9|
text_000N_43386|MMI|3.56|Placement action|C1533810|[hlca]|["Placement"-tx-1-"placement"-noun-0]|TX|44/9|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Arthritis|C0003864|[dsyn]|["ARTHRITIS"-tx-1-"arthritis"-noun-0]|TX|38/9|
text_000N_40839|MMI|5.18|Arthritis, CTCAE|C4552845|[fndg]|["Arthritis"-tx-1-"arthritis"-noun-0]|TX|38/9|
text_000N_40839|MMI|5.18|Freund's Adjuvant|C0016712|[imft,phsu]|["Freund's Complete Adjuvant"-tx-1-"Freund's complete adjuvant"-noun-0]|TX|4/26|
text_000N_40839|MMI|5.18|Induce (action)|C0205263|[ftcn]|["Induce"-tx-1-"induce"-verb-0]|TX|31/6|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|5.18|pembrolizumab|C3658706|[aapp,imft,phsu]|["PEMBROLIZUMAB"-tx-1-"pembrolizumab"-noun-0]|TX|3/13|
text_000N_40886|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|17/9|
text_000N_40886|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|17/9|
text_000N_40886|MMI|3.48|Ewings sarcoma|C0553580|[neop]|["Ewings Sarcoma"-tx-1-"Ewing's sarcoma"-noun-0]|TX|35/15|
text_000N_40886|MMI|3.48|Ewings sarcoma-primitive neuroectodermal tumor (PNET)|C0684337|[neop]|["sarcoma, Ewing's"-tx-1-"Ewing's sarcoma"-noun-0]|TX|35/15|
text_000N_40886|MMI|3.48|NCI CTEP SDC Ewing Sarcoma Sub-Category Terminology|C3541889|[inpr]|["Ewing Sarcoma"-tx-1-"Ewing's sarcoma"-noun-0]|TX|35/15|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|Alzheimer's Disease|C0002395|[dsyn]|["Alzheimers Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|40/19|
text_000N_47289|MMI|5.18|Alzheimer's Disease Pathway KEGG|C1521724|[cnce]|["Alzheimer's Disease"-tx-1-"Alzheimer's disease"-noun-0]|TX|40/19|
text_000N_47289|MMI|5.18|Off Study|C1518546|[qlco]|["Study"-tx-1-"study"-verb-0]|TX|34/5|
text_000N_47289|MMI|5.18|Room of building - Study|C0557651|[mnob]|["Study"-tx-1-"study"-verb-0]|TX|34/5|
text_000N_47289|MMI|5.18|Study|C2603343|[resa]|["Study"-tx-1-"study"-verb-0]|TX|34/5|
text_000N_47289|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|31/2|
text_000N_47289|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|31/2|
text_000N_47289|MMI|5.18|Usage|C0457083|[ftcn]|["Use"-tx-1-"use"-verb-0]|TX|7/3|
text_000N_47289|MMI|5.18|Use - dosing instruction imperative|C1947944|[inpr]|["Use"-tx-1-"use"-verb-0]|TX|7/3|
text_000N_47289|MMI|5.18|utilization qualifier|C0042153|[ftcn]|["use"-tx-1-"use"-verb-0]|TX|7/3|
text_000N_47289|MMI|3.68|Biological Markers|C0005516|[clna]|["Biomarkers"-tx-1-"biomarkers"-noun-0]|TX|20/10|
text_000N_47289|MMI|3.50|Blood Platelets|C0005821|[cell]|["PLATELET"-tx-1-"platelet"-noun-0]|TX|11/8|
<<<<< MMI
>>>>> MMI
text_000N_40913|MMI|5.18|TNNI3K gene|C1426311|[gngm]|["TNNI3K"-tx-1-"TNNI3K"-noun-0]|TX|3/6|
text_000N_40913|MMI|3.63|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|29/7|
text_000N_40913|MMI|3.48|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|12/7|
text_000N_40913|MMI|3.48|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|12/7|
text_000N_40913|MMI|3.48|Entity Determiner - specific|C1552740|[inpr]|["specific"-tx-1-"specific"-adj-0]|TX|20/8|
text_000N_40913|MMI|3.48|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|12/7|
text_000N_40913|MMI|3.48|Specific qualifier value|C0205369|[qlco]|["Specific"-tx-1-"specific"-adj-0]|TX|20/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|3.68|Cluster|C1704332|[qnco]|["Cluster"-tx-1-"cluster"-noun-0]|TX|16/7|
text_000N_40941|MMI|3.68|entry - cluster|C1555715|[inpr]|["Cluster"-tx-1-"cluster"-noun-0]|TX|16/7|
text_000N_40941|MMI|3.64|Prader-Willi Syndrome|C0032897|[dsyn]|["PRADER-WILLI SYNDROME"-tx-1-"Prader-Willi syndrome"-noun-0]|TX|44/21|
text_000N_40941|MMI|3.59|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|24/15|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|Activation action|C1879547|[acty]|["Activate"-tx-1-"activate"-verb-0]|TX|18/8|
text_000N_40972|MMI|5.18|BACE1 gene|C1412727|[gngm]|["BACE"-tx-1-"BACE"-noun-0]|TX|27/4|
text_000N_40972|MMI|5.18|BACE1 wt Allele|C3815269|[gngm]|["BACE"-tx-1-"BACE"-noun-0]|TX|27/4|
text_000N_40972|MMI|5.18|activate - Data Operation|C3853838|[ftcn]|["activate"-tx-1-"activate"-verb-0]|TX|18/8|
text_000N_40972|MMI|5.18|activate biological process|C1515877|[ftcn]|["Activate"-tx-1-"activate"-verb-0]|TX|18/8|
text_000N_40972|MMI|5.18|verubecestat|C4307343|[orch,phsu]|["VERUBECESTAT"-tx-1-"verubecestat"-noun-0]|TX|5/12|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|5.18|FGFR3 Gene Mutation|C1517091|[comd]|["FGFR3 Gene Mutation"-tx-1-"FGFR3 gene mutation"-noun-0]|TX|52/19|
text_000N_47420|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47420|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47420|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47420|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|12/11|
text_000N_47420|MMI|3.46|Muenke Syndrome|C1864436|[dsyn]|["MUENKE SYNDROME"-tx-1-"Muenke Syndrome"-noun-0]|TX|32/15|
text_000N_47420|MMI|3.43|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|9/2|
text_000N_47420|MMI|3.43|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|9/2|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|3.75|Renal Elimination|C1373187|[ortf]|["Renal Excretion"-tx-1-"renal excretion"-noun-0]|TX|11/15|
text_000N_40999|MMI|3.64|Bariatric Surgery|C1456587|[topp]|["Bariatric Surgery"-tx-1-"bariatric surgery"-noun-0]|TX|43/17|
text_000N_40999|MMI|3.57|Increase|C0442805|[ftcn]|["INCREASED"-tx-1-"increased"-verb-0]|TX|27/9|
text_000N_40999|MMI|3.57|Increased|C0205217|[qnco]|["Increased"-tx-1-"increased"-verb-0]|TX|27/9|
text_000N_40999|MMI|3.57|Increased (finding)|C5236002|[fndg]|["Increased"-tx-1-"increased"-verb-0]|TX|27/9|
text_000N_40999|MMI|3.48|Oxalates|C0029988|[orch]|["Oxalate"-tx-1-"oxalate"-noun-0]|TX|3/7|
text_000N_40999|MMI|3.48|oxalate|C3669135|[orch]|["Oxalate"-tx-1-"oxalate"-noun-0]|TX|3/7|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|6.96|Therapeutic radiology procedure|C1522449|[topp]|["RADIATION"-tx-1-"radiation"-adj-0,"RADIOTHERAPY"-tx-1-"radiotherapy"-noun-0]|TX|23/9;4/12|
text_000N_173120|MMI|3.60|Childhood Osteosarcoma|C1332986|[neop]|["Osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|41/12|
text_000N_173120|MMI|3.60|NCI CTEP SDC Osteosarcoma Sub-Category Terminology|C3541899|[inpr]|["Osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|41/12|
text_000N_173120|MMI|3.60|Osteosarcoma|C0029463|[neop]|["OSTEOSARCOMA"-tx-1-"osteosarcoma"-noun-0]|TX|41/12|
text_000N_173120|MMI|3.60|Osteosarcoma of bone|C0585442|[neop]|["osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|41/12|
text_000N_173120|MMI|3.60|RB1 gene|C0694889|[gngm]|["osteosarcoma"-tx-1-"osteosarcoma"-noun-0]|TX|41/12|
text_000N_173120|MMI|3.46|Electromagnetic Radiation|C0034519|[npop]|["Radiation"-tx-1-"radiation"-adj-0]|TX|23/9|
text_000N_173120|MMI|3.46|Etiology aspects|C0015127|[ftcn]|["cause"-tx-1-"cause"-noun-0]|TX|17/5|
text_000N_173120|MMI|3.46|Induce (action)|C0205263|[ftcn]|["Induced"-tx-1-"induced"-adj-0]|TX|33/7|
text_000N_173120|MMI|3.46|Radiation|C0851346|[npop]|["Radiation"-tx-1-"radiation"-adj-0]|TX|23/9|
text_000N_173120|MMI|3.46|Radiation Ionizing Radiotherapy|C1524020|[topp]|["Radiation"-tx-1-"radiation"-adj-0]|TX|23/9|
text_000N_173120|MMI|3.46|Radiation Oncology specialty|C0243005|[bmod]|["Radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|4/12|
text_000N_173120|MMI|3.46|Radiotherapy Research|C1524021|[resa]|["Radiation"-tx-1-"radiation"-adj-0]|TX|23/9|
text_000N_173120|MMI|3.46|Science of Etiology|C1524003|[cnce]|["Cause"-tx-1-"cause"-noun-0]|TX|17/5|
text_000N_173120|MMI|3.46|Unit of radiation dose|C0560559|[qnco]|["Radiation"-tx-1-"radiation"-adj-0]|TX|23/9|
text_000N_173120|MMI|3.46|radiotherapeutic|C0034619|[inpr]|["radiotherapy"-tx-1-"radiotherapy"-noun-0]|TX|4/12|
<<<<< MMI
>>>>> MMI
text_000N_173136|AA|NFR|nucleosome-free regions|1|3|5|23|49:3
text_000N_173136|MMI|5.18|Gaga|C3606286|[plnt]|["Gaga"-tx-1-"GAGA"-adj-0]|TX|3/4|
text_000N_173136|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|8/15|
text_000N_173136|MMI|3.56|Empty (qualifier)|C1880497|[qlco]|["Free"-tx-1-"free"-adj-0]|TX|35/4|
text_000N_173136|MMI|3.56|Free of (attribute)|C0332296|[ftcn]|["free"-tx-1-"free"-adj-0]|TX|35/4|
text_000N_173136|MMI|3.56|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosome"-tx-1-"nucleosome"-noun-0]|TX|24/10|
text_000N_173136|MMI|3.56|nucleosome location|C1166675|[celc]|["nucleosome"-tx-1-"nucleosome"-noun-0]|TX|24/10|
text_000N_173136|MMI|3.53|Geographic Locations|C0017446|[geoa]|["Region"-tx-1-"regions"-noun-0]|TX|40/7|
text_000N_173136|MMI|3.53|regional|C0205147|[spco]|["Region"-tx-1-"regions"-noun-0]|TX|40/7|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|10.42|Thyrotropin-Releasing Hormone, human|C4521441|[aapp,horm]|["TRH"-tx-1-"TRH"-noun-0,"Thyrotropin-Releasing Hormone"-tx-1-"thyrotropin releasing hormone"-noun-0]|TX|34/3;39/29|
text_000N_97331|MMI|5.18|Administration occupational activities|C0001554|[ocac]|["Administration"-tx-1-"administration"-noun-0]|TX|70/14|
text_000N_97331|MMI|5.18|Administration procedure|C1533734|[topp]|["Administration"-tx-1-"administration"-noun-0]|TX|70/14|
text_000N_97331|MMI|5.18|Agent Administration|C2348003|[hlca]|["Administration"-tx-1-"administration"-noun-0]|TX|70/14|
text_000N_97331|MMI|5.18|Data|C1511726|[idcn]|["Data"-tx-1-"data"-noun-0]|TX|13/4|
text_000N_97331|MMI|5.18|Data (eukaryote)|C3714741|[euka]|["Data"-tx-1-"data"-noun-0]|TX|13/4|
text_000N_97331|MMI|5.18|Data call receiving device|C3245479|[medd]|["data"-tx-1-"data"-noun-0]|TX|13/4|
text_000N_97331|MMI|5.18|Pro-Thyrotropin-Releasing Hormone, human|C4520836|[aapp,horm]|["TRH"-tx-1-"TRH"-noun-0]|TX|34/3|
text_000N_97331|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_97331|MMI|5.18|TRH gene|C1421143|[gngm]|["THYROTROPIN-RELEASING HORMONE"-tx-1-"thyrotropin releasing hormone"-noun-0]|TX|39/29|
text_000N_97331|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|18/2|
text_000N_97331|MMI|5.18|suggestion|C1705535|[idcn]|["Suggest"-tx-1-"suggest"-verb-0]|TX|21/7|
text_000N_97331|MMI|5.18|thyrotropin-releasing hormone|C0040162|[aapp,horm,phsu]|["Thyrotropin releasing hormone"-tx-1-"thyrotropin releasing hormone"-noun-0]|TX|39/29|
text_000N_97331|MMI|3.58|Severity of symptoms:Finding:Point in time:^Patient:Ordinal|C3174773|[clna]|["Symptom severity"-tx-1-"symptom severity"-noun-0]|TX|97/16|
text_000N_97331|MMI|3.58|Symptom severity (finding)|C1319166|[fndg]|["Symptom severity NOS"-tx-1-"symptom severity"-noun-0]|TX|97/16|
text_000N_97331|MMI|3.47|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|117/29|
text_000N_97331|MMI|3.42|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|147/8|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Ocular melanosis|C0025210|[cgab]|["Ocular melanosis"-tx-1-"ocular melanosis"-noun-0]|TX|3/16|
text_000N_173183|MMI|3.62|Melanoma Risk Factor|C4745040|[fndg]|["Melanoma Risk Factor"-tx-1-"risk factor melanoma"-noun-0]|TX|22/11,44/8|
text_000N_173183|MMI|3.43|Uvea|C0042160|[bpoc]|["Uveal"-tx-1-"uveal"-noun-0]|TX|38/5|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|5.18|ozanimod|C4278675|[aapp,phsu]|["OZANIMOD"-tx-1-"Ozanimod"-noun-0]|TX|3/8|
text_000N_97347|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_97347|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|12/9|
text_000N_97347|MMI|3.48|Ulcerative Colitis|C0009324|[dsyn]|["COLITIS, ULCERATIVE"-tx-1-"Ulcerative Colitis"-noun-0]|TX|26/18|
<<<<< MMI
>>>>> MMI
text_000N_97394|MMI|3.75|Animal Model|C0599779|[anim]|["Animal models"-tx-1-"animal models"-noun-0]|TX|17/13|
text_000N_97394|MMI|3.58|Intestinal Diseases|C0021831|[dsyn]|["bowel disease"-tx-1-"bowel disease"-noun-0]|TX|58/13|
text_000N_97394|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|36/4,55/2|
text_000N_97394|MMI|3.55|Off Study|C1518546|[qlco]|["Study"-tx-1-"study"-noun-0]|TX|49/5|
text_000N_97394|MMI|3.55|Room of building - Study|C0557651|[mnob]|["Study"-tx-1-"study"-noun-0]|TX|49/5|
text_000N_97394|MMI|3.55|Study|C2603343|[resa]|["Study"-tx-1-"study"-noun-0]|TX|49/5|
text_000N_97394|MMI|3.48|Gnotobiotics|C0018014|[ocdi]|["Gnotobiotic"-tx-1-"gnotobiotic"-adj-0]|TX|5/11|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|3.63|Exons|C0015295|[bacs,nnon]|["Exons"-tx-1-"exons"-noun-0]|TX|19/5|
text_000N_173230|MMI|3.57|DNA Sequence|C0162326|[nusq]|["Sequences"-tx-1-"sequences"-noun-0]|TX|44/9|
text_000N_173230|MMI|3.48|Coding|C0009219|[ocac]|["Coding"-tx-1-"coding"-noun-0]|TX|12/6|
text_000N_173230|MMI|3.48|Coding Subtest (WAIS-IV)|C4050311|[inpr]|["Coding"-tx-1-"coding"-noun-0]|TX|12/6|
text_000N_173230|MMI|3.48|Coding Subtest (WISC-V)|C4050310|[inpr]|["Coding"-tx-1-"coding"-noun-0]|TX|12/6|
text_000N_173230|MMI|3.48|Encode (action)|C2700640|[acty]|["coding"-tx-1-"coding"-noun-0]|TX|12/6|
text_000N_173230|MMI|3.48|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|4/7|
<<<<< MMI
>>>>> MMI
text_000N_97316|MMI|3.54|Rate|C1521828|[qnco]|["Rate"-tx-1-"rate"-noun-0]|TX|33/4|
text_000N_97316|MMI|3.54|Rating (action)|C0871208|[acty]|["Rate"-tx-1-"rate"-noun-0]|TX|33/4|
text_000N_97316|MMI|3.42|Homo sapiens|C0086418|[humn]|["Human"-tx-1-"human"-noun-0]|TX|41/5|
text_000N_97316|MMI|3.42|Increase|C0442805|[ftcn]|["INCREASED"-tx-1-"increased"-adj-0]|TX|9/9|
text_000N_97316|MMI|3.42|Increased|C0205217|[qnco]|["Increased"-tx-1-"increased"-adj-0]|TX|9/9|
text_000N_97316|MMI|3.42|Increased (finding)|C5236002|[fndg]|["Increased"-tx-1-"increased"-adj-0]|TX|9/9|
text_000N_97316|MMI|3.42|Recombination, Genetic|C0034865|[genf]|["Recombination"-tx-1-"recombination"-noun-0]|TX|19/13|
text_000N_97316|MMI|3.42|Regulator|C1704735|[cnce]|["Regulatory"-tx-1-"regulatory"-noun-0]|TX|47/10|
text_000N_97316|MMI|3.42|regulatory|C0220905|[rnlw]|["regulatory"-tx-1-"regulatory"-noun-0]|TX|47/10|
text_000N_97316|MMI|3.40|Concept model domain|C3541951|[inpr]|["Domain"-tx-1-"domains"-noun-0]|TX|58/7|
text_000N_97316|MMI|3.40|Domain (area of knowledge)|C1880389|[ftcn]|["Domain"-tx-1-"domains"-noun-0]|TX|58/7|
text_000N_97316|MMI|3.40|Superkingdom (taxonomic category)|C1883221|[cnce]|["Domain"-tx-1-"domains"-noun-0]|TX|58/7|
<<<<< MMI
>>>>> MMI
text_000N_97378|MMI|3.68|Machine|C0336779|[mnob]|["Machine"-tx-1-"machine"-noun-0]|TX|8/7|
text_000N_97378|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_97378|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|16/9|
text_000N_97378|MMI|3.48|Ten|C0205456|[qnco]|["Ten"-tx-1-"TENS"-noun-0]|TX|3/4|
text_000N_97378|MMI|3.48|Toxic Epidermal Necrolysis|C0014518|[dsyn]|["TEN"-tx-1-"TENS"-noun-0]|TX|3/4|
text_000N_97378|MMI|3.48|pentaerythritol tetranitrate|C0030858|[orch,phsu]|["TEN"-tx-1-"TENS"-noun-0]|TX|3/4|
text_000N_97378|MMI|3.45|Feel Pain|C4554132|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Frequency of Pain Question|C0518090|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Have Pain|C2984058|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|How Much Distress Pain|C4085212|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Pain|C0030193|[sosy]|["PAIN"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Pain Distress Question|C4085211|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Pain NOS, CTCAE|C1962977|[fndg]|["Pain NOS"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Pain, CTCAE|C4553004|[fndg]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
text_000N_97378|MMI|3.45|Usual Severity Pain|C4085210|[inpr]|["Pain"-tx-1-"pain"-noun-0]|TX|29/4|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|3.68|DUX4 gene|C1414197|[gngm]|["DUX4"-tx-1-"DUX4"-noun-0]|TX|12/4|
text_000N_173087|MMI|3.68|DUX4 protein, human|C1317909|[aapp,bacs]|["DUX4"-tx-1-"DUX4"-noun-0]|TX|12/4|
text_000N_173087|MMI|3.68|DUX4L1 gene|C3890878|[gngm]|["DUX4"-tx-1-"DUX4"-noun-0]|TX|12/4|
text_000N_173087|MMI|3.68|DUX4L2 wt Allele|C4553518|[gngm]|["DUX4"-tx-1-"DUX4"-noun-0]|TX|12/4|
text_000N_173087|MMI|3.64|Diploid Cell|C1257909|[cell]|["Somatic Cells"-tx-1-"somatic cells"-noun-0]|TX|45/13|
text_000N_173087|MMI|3.57|Regulation|C0851285|[gora]|["Regulated"-tx-1-"regulated"-verb-0]|TX|32/9|
text_000N_173087|MMI|3.50|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|7/4|
text_000N_173087|MMI|3.50|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|7/4|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|5.18|CPX-351|C2346682|[phsu]|["CPX-351"-tx-1-"CPX-351"-noun-0]|TX|4/7|
text_000N_97301|MMI|3.58|tuberculosis treatment|C0749724|[topp]|["tuberculosis treatment"-tx-1-"treatment tuberculosis"-noun-0]|TX|28/9,41/12|
text_000N_97301|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|15/4,38/2|
text_000N_97301|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|Tuberculosis|C0041296|[dsyn]|["TUBERCULOSIS"-tx-1-"tuberculosis"-noun-0]|TX|41/12|
text_000N_97301|MMI|3.55|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|15/4|
text_000N_97301|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
text_000N_97301|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|28/9|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|5.18|EPO protein, human|C2976467|[aapp,bacs]|["Erythropoietin"-tx-1-"erythropoietin"-noun-0]|TX|3/14|
text_000N_173199|MMI|5.18|Erythropoietin|C0014822|[aapp,horm,phsu]|["Erythropoietin"-tx-1-"erythropoietin"-noun-0]|TX|3/14|
text_000N_173199|MMI|5.18|Recombinant Erythropoietin|C0376541|[aapp,phsu]|["ERYTHROPOIETIN"-tx-1-"erythropoietin"-noun-0]|TX|3/14|
text_000N_173199|MMI|5.18|epoetin alfa|C0357126|[aapp,phsu]|["ERYTHROPOIETIN"-tx-1-"erythropoietin"-noun-0]|TX|3/14|
text_000N_173199|MMI|5.18|erythropoietin activity|C1755594|[moft]|["erythropoietin"-tx-1-"erythropoietin"-noun-0]|TX|3/14|
text_000N_173199|MMI|3.57|Treatment Effectiveness|C0087113|[qlco]|["effective treatment"-tx-1-"effective treatment"-noun-0]|TX|18/9,32/9|
text_000N_173199|MMI|3.47|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"amyotrophic lateral sclerosis"-noun-0]|TX|45/29|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|5.18|vesatolimod|C4519174|[orch,phsu]|["VESATOLIMOD"-tx-1-"vesatolimod"-noun-0]|TX|5/11|
text_000N_97362|MMI|3.87|(City) Block|C1706084|[geoa]|["Block"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Arrested progression|C0237477|[tmco]|["Arresting"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Block (unit of measure)|C2828370|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Block (unit of presentation)|C4319518|[qnco]|["Block"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Block Specimens|C1533157|[bdsu]|["Blocks"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Block Unit of Distance|C3811660|[qnco]|["BLOCKS"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Blocking|C0332206|[ftcn]|["blocks"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Cardiac Arrest|C0018790|[dsyn]|["arrested"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Law enforcement arrest|C0392351|[gora]|["arrests"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Mental blocking|C0233660|[mobd]|["Blocking"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Obstruction|C0028778|[patf]|["blocks"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Restrained|C5453175|[qlco]|["Restrained"-tx-1-"inhibit"-verb-0]|TX|17/7|
text_000N_97362|MMI|3.87|Retarded|C0521111|[qlco]|["retards"-tx-1-"inhibit"-verb-0]|TX|17/7|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|3.64|Tumor cells, malignant|C0334227|[cell]|["cancer cells"-tx-1-"cancer cells"-noun-0]|TX|64/12|
text_000N_173104|MMI|3.55|Cumulative Dose|C2986497|[cnce]|["dosage"-tx-1-"dosage"-noun-0]|TX|16/6|
text_000N_173104|MMI|3.55|Dosage|C0178602|[qnco]|["Dosage"-tx-1-"dosage"-noun-0]|TX|16/6|
text_000N_173104|MMI|3.43|Abnormal|C0205161|[fndg]|["ABNORMAL"-tx-1-"abnormal"-adj-0]|TX|7/8|
text_000N_173104|MMI|3.43|Abnormal Reference Range|C2699333|[inpr]|["ABNORMAL"-tx-1-"abnormal"-adj-0]|TX|7/8|
text_000N_173104|MMI|3.43|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|41/8|
text_000N_173104|MMI|3.43|Laboratory test result abnormal|C0438215|[lbtr]|["Abnormal, NOS"-tx-1-"abnormal"-adj-0]|TX|7/8|
text_000N_173104|MMI|3.43|Percent of Abnormal Cells|C2347472|[qnco]|["% Abnormal"-tx-1-"abnormal"-adj-0]|TX|7/8|
<<<<< MMI
>>>>> MMI
text_000N_173276|AA|PE|preeclampsia|1|2|1|12|114:2
text_000N_173276|MMI|5.18|Including (qualifier)|C0332257|[ftcn]|["Including"-tx-1-"including"-verb-0]|TX|90/9|
text_000N_173276|MMI|5.18|Pre-Eclampsia|C0032914|[patf]|["Pre-Eclampsia"-tx-1-"preeclampsia"-noun-0]|TX|100/12|
text_000N_173276|MMI|3.61|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|46/15|
text_000N_173276|MMI|3.61|Pregnancy Outcome|C0032972|[fndg]|["Pregnancy Outcomes"-tx-1-"pregnancy outcomes"-noun-0]|TX|70/18|
text_000N_173276|MMI|3.56|Disruption|C0332453|[ftcn]|["Disruption"-tx-1-"disruption"-noun-0]|TX|3/10|
text_000N_173276|MMI|3.43|Immune|C0439662|[fndg]|["Immune"-tx-1-"immune"-adj-0]|TX|17/6|
text_000N_173276|MMI|3.43|Mechanism (attribute)|C0441712|[ftcn]|["Mechanisms"-tx-1-"mechanisms"-noun-0]|TX|35/10|
text_000N_173276|MMI|3.43|Regulation|C0851285|[gora]|["Regulation"-tx-1-"regulation"-noun-0]|TX|24/10|
text_000N_173276|MMI|3.43|Regulation of biological process|C1327622|[biof]|["Regulation"-tx-1-"regulation"-noun-0]|TX|24/10|
<<<<< MMI
>>>>> MMI
text_000N_97409|MMI|5.18|Adipokines|C1955907|[aapp,bacs]|["Adipokine"-tx-1-"adipokine"-noun-0]|TX|32/9|
text_000N_97409|MMI|5.18|RBP4 gene|C1419320|[gngm]|["RETINOL-BINDING PROTEIN 4"-tx-1-"retinol binding protein 4"-noun-0]|TX|3/25|
text_000N_97409|MMI|5.18|RBP4 protein, human|C1438309|[aapp,bacs]|["Retinol-Binding Protein 4"-tx-1-"retinol binding protein 4"-noun-0]|TX|3/25|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|Intepirdine|C4508906|[orch,phsu]|["INTEPIRDINE"-tx-1-"intepirdine"-noun-0]|TX|4/11|
text_000N_47274|MMI|3.68|November|C3828767|[tmco]|["November"-tx-2-"November"-noun-0]|TX|52/8|
text_000N_47274|MMI|3.64|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|34/15|
text_000N_47274|MMI|3.64|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|34/15|
text_000N_47274|MMI|3.57|Evaluation|C0220825|[hlca]|["Evaluated"-tx-1-"evaluated"-verb-0]|TX|21/9|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|Interferes with|C0521102|[ftcn]|["Interfere"-tx-1-"interfere"-verb-0]|TX|15/9|
text_000N_173167|MMI|5.18|metformin|C0025598|[orch,phsu]|["METFORMIN"-tx-1-"metformin"-noun-0]|TX|5/9|
text_000N_173167|MMI|3.68|Biological Absorption|C2347023|[orgf]|["Absorption"-tx-1-"absorption"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.68|Energy Absorption|C2825050|[phpr]|["Absorption"-tx-1-"absorption"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.68|Material Absorption|C2347080|[phpr]|["Absorption"-tx-1-"absorption"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.68|Pharmacokinetics: Absorption|C2698776|[bmod]|["ABSORPTION"-tx-1-"absorption"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.68|Process of absorption|C0000854|[npop]|["Absorption"-tx-1-"absorption"-noun-0]|TX|35/10|
text_000N_173167|MMI|3.50|levothyroxine|C0040165|[aapp,horm,phsu]|["Thyroxine"-tx-1-"thyroxine"-noun-0]|TX|25/9|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Athletes|C0238703|[prog]|["Athletes"-tx-1-"athletes"-noun-0]|TX|48/8|
text_000N_173245|MMI|5.18|Athletes <Butterfly>|C3714533|[euka]|["Athletes"-tx-1-"athletes"-noun-0]|TX|48/8|
text_000N_173245|MMI|3.56|Incidence|C0021149|[qnco]|["Incidence"-tx-1-"incidence"-noun-0]|TX|19/9|
text_000N_173245|MMI|3.56|incidence of cases|C0220856|[ftcn]|["incidence"-tx-1-"incidence"-noun-0]|TX|19/9|
text_000N_173245|MMI|3.43|Incontinence|C0021167|[dsyn]|["INCONTINENCE"-tx-1-"incontinence"-noun-0]|TX|32/12|
text_000N_173245|MMI|3.43|Increase|C0442805|[ftcn]|["INCREASED"-tx-1-"increased"-adj-0]|TX|9/9|
text_000N_173245|MMI|3.43|Increased|C0205217|[qnco]|["Increased"-tx-1-"increased"-adj-0]|TX|9/9|
text_000N_173245|MMI|3.43|Increased (finding)|C5236002|[fndg]|["Increased"-tx-1-"increased"-adj-0]|TX|9/9|
<<<<< MMI
>>>>> MMI
text_000N_97424|MMI|3.63|MSC gene|C1334531|[gngm]|["ABF1"-tx-1-"Abf1"-noun-0]|TX|22/4|
text_000N_97424|MMI|3.63|MSC wt Allele|C1708837|[gngm]|["ABF1"-tx-1-"Abf1"-noun-0]|TX|22/4|
text_000N_97424|MMI|3.59|ACTG1 wt Allele|C4723674|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|27/3|
text_000N_97424|MMI|3.59|ACTG2 wt Allele|C1704930|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|27/3|
text_000N_97424|MMI|3.59|Asthma Control Test Questionnaire|C4048375|[inpr]|["ACT"-tx-1-"act"-verb-0]|TX|27/3|
text_000N_97424|MMI|3.59|Insulator|C0221463|[prog]|["INSULATOR"-tx-1-"insulator"-noun-0]|TX|34/9|
text_000N_97424|MMI|3.59|SERPINA3 protein, human|C1869853|[aapp,bacs]|["ACT"-tx-1-"act"-verb-0]|TX|27/3|
text_000N_97424|MMI|3.59|SERPINA3 wt Allele|C3890007|[gngm]|["ACT"-tx-1-"act"-verb-0]|TX|27/3|
text_000N_97424|MMI|3.53|Yeast Proteins|C0872306|[aapp,bacs]|["Yeast Protein"-tx-1-"yeast protein"-noun-0]|TX|8/13|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|Chief Complaint Caused by Trauma|C5238665|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Chief Complaint was Witnessed|C5238682|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Has Response to Intervention for Kawasaki Disease|C5238715|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Has Sibling|C5238716|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Intercurrent Illness is Present at Onset of Chief Complaint|C5238753|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Intervention Given for Kawasaki Disease|C5238758|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Alcohol Use|C5238771|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Congenital Heart Disease|C5238774|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Gestational Complication|C5238775|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Illicit Drug Use|C5238776|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Kawasaki Disease|C5238777|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Neonatal Complication|C5238778|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Known History of Rheumatic Fever|C5238780|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Minor Criteria for Rheumatic Heart Disease Present|C5238793|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Patient was Previously Evaluated for Current Chief Complaint|C5238838|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|YES Portal|C5202962|[inpr]|["YES"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|YES1 wt Allele|C1710701|[gngm]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Yes|C5399964|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Yes (indicator)|C1705108|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|Yes - Yes/no indicator|C1549445|[idcn]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|taking medication (history)|C5235038|[fndg]|["Yes"-tx-1-"yes"-noun-0]|TX|65/3|
text_000N_47304|MMI|5.18|thymoquinone|C0076611|[orch]|["Thymoquinone"-tx-1-"Thymoquinone"-noun-0]|TX|0/12|
text_000N_47304|MMI|3.56|ineffective|C3242229|[idcn]|["ineffective"-tx-1-"ineffective"-adj-0]|TX|16/11|
text_000N_47304|MMI|3.50|Radiation enteritis of intestine|C0259795|[dsyn]|["Radiation induced enteritis"-tx-1-"radiation induced enteritis"-noun-0]|TX|36/27|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|5.18|Depressive Disorder, Treatment-Resistant|C2063866|[mobd]|["Resistant Depression, Treatment"-tx-1-"treatment resistant depression"-noun-0]|TX|3/30|
text_000N_43235|MMI|3.64|Folic acid measurement|C0523631|[lbpr]|["Vitamin B9"-tx-1-"vitamin B9"-noun-0]|TX|45/10|
text_000N_43235|MMI|3.64|folic acid|C0016410|[orch,phsu,vita]|["Vitamin B9"-tx-1-"vitamin B9"-noun-0]|TX|45/10|
text_000N_43235|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|34/7|
text_000N_43235|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|34/7|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.68|Proteins|C0033684|[aapp,bacs]|["PROTEINS"-tx-1-"proteins"-noun-0]|TX|20/8|
text_000N_47435|MMI|3.59|Plants|C0032098|[plnt]|["Plants"-tx-1-"plants"-noun-0]|TX|40/6|
text_000N_47435|MMI|3.59|Present|C0150312|[fndg]|["PRESENT"-tx-1-"present"-verb-0]|TX|29/7|
text_000N_47435|MMI|3.59|Presentation|C0449450|[idcn]|["Present"-tx-1-"present"-verb-0]|TX|29/7|
text_000N_47435|MMI|3.59|Radial-Femoral Lag Present|C5238858|[fndg]|["Present"-tx-1-"present"-verb-0]|TX|29/7|
text_000N_47435|MMI|3.50|DNMT3 Family|C4727141|[aapp,enzy]|["DNMT3"-tx-1-"DNMT3"-noun-0]|TX|14/5|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|5.18|dacomitinib|C2987430|[orch,phsu]|["DACOMITINIB"-tx-1-"dacomitinib"-noun-0]|TX|7/11|
text_000N_47334|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|22/4,41/2|
text_000N_47334|MMI|3.55|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|44/12|
text_000N_47334|MMI|3.55|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|44/12|
text_000N_47334|MMI|3.55|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|44/12|
text_000N_47334|MMI|3.55|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|44/12|
text_000N_47334|MMI|3.55|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|57/8|
text_000N_47334|MMI|3.55|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
text_000N_47334|MMI|3.55|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|31/9|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|Polyclonal antibody|C0312586|[aapp,imft]|["Polyclonal Antibody"-tx-1-"polyclonal antibody"-noun-0]|TX|17/19|
text_000N_47406|MMI|5.18|ustekinumab|C1608841|[aapp,imft,phsu]|["USTEKINUMAB"-tx-1-"ustekinumab"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|rivaroxaban|C1739768|[orch,phsu]|["RIVAROXABAN"-tx-1-"rivaroxaban"-noun-0]|TX|3/11|
text_000N_47320|MMI|3.59|Both kidneys|C0227665|[bpoc]|["kidneys"-tx-1-"kidneys"-noun-0]|TX|30/7|
text_000N_47320|MMI|3.59|Kidney|C0022646|[bpoc]|["KIDNEYS"-tx-1-"kidneys"-noun-0]|TX|30/7|
text_000N_47320|MMI|3.59|Metabolic Process, Cellular|C1524026|[celf]|["Metabolized"-tx-1-"metabolized"-verb-0]|TX|15/11|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Scuba diving|C0240984|[dora]|["SCUBA DIVING"-tx-1-"scuba diving"-noun-0]|TX|3/12|
text_000N_43275|MMI|3.59|SAFE-Biopharma Standard|C4684764|[inpr]|["SAFE"-tx-1-"safe"-adj-0]|TX|16/4|
text_000N_43275|MMI|3.45|Patient currently pregnant|C0549206|[fndg]|["Pregnancy"-tx-1-"pregnancy"-noun-0]|TX|28/9|
text_000N_43275|MMI|3.45|Pregnancy|C0032961|[orgf]|["PREGNANCY"-tx-1-"pregnancy"-noun-0]|TX|28/9|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|7.41|Gene Mutation|C0596611|[genf]|["Mutations"-tx-1-"mutations"-noun-0,"gene mutations"-tx-1-"gene mutations"-noun-0]|TX|20/9;15/14|
text_000N_43358|MMI|7.05|CEP290 gene|C1824725|[gngm]|["CEP290"-tx-1-"CEP290"-noun-0,"CEP290 gene"-tx-1-"CEP290 gene"-noun-0]|TX|8/6;8/11|
text_000N_43358|MMI|3.63|Mutation|C0026882|[genf]|["Mutations"-tx-1-"mutations"-noun-0]|TX|20/9|
text_000N_43358|MMI|3.59|Gene Therapy Agent|C1517496|[phsu]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|58/12|
text_000N_43358|MMI|3.59|gene therapy|C0017296|[topp]|["Gene Therapy"-tx-1-"gene therapy"-noun-0]|TX|58/12|
text_000N_43358|MMI|3.58|Targeted Therapy|C2985566|[topp]|["Targeted Therapy"-tx-1-"targeted therapy"-noun-0]|TX|33/8,63/7|
text_000N_43358|MMI|3.55|AAVS1 gene|C1412056|[gngm]|["AAV"-tx-1-"AAV"-noun-0]|TX|45/3|
text_000N_43358|MMI|3.55|Gene Symbol|C1706510|[inpr]|["gene"-tx-1-"gene"-noun-0]|TX|58/4|
text_000N_43358|MMI|3.55|Genes|C0017337|[gngm]|["Gene"-tx-1-"gene"-noun-0]|TX|58/4|
text_000N_43358|MMI|3.55|Mediate|C0086597|[socb]|["mediated"-tx-1-"mediated"-adj-0]|TX|49/8|
text_000N_43358|MMI|3.55|Mediator brand of benfluorex hydrochloride|C0127400|[orch,phsu]|["Mediated"-tx-1-"mediated"-adj-0]|TX|49/8|
text_000N_43358|MMI|3.55|Target|C1521840|[ftcn]|["Targeted"-tx-1-"targeted"-verb-0]|TX|33/8|
<<<<< MMI
>>>>> MMI
text_000N_173214|MMI|5.18|Gene Silencing|C0598496|[genf]|["Gene Silencing"-tx-1-"gene silencing"-noun-0]|TX|47/14|
text_000N_173214|MMI|5.18|Promotion (action)|C0033414|[acty]|["Promote"-tx-1-"promote"-verb-0]|TX|39/7|
text_000N_173214|MMI|3.56|Chemical Association|C0596306|[phpr]|["Association"-tx-1-"association"-noun-0]|TX|5/11|
text_000N_173214|MMI|3.56|Mental association|C0004083|[menp]|["Association"-tx-1-"association"-noun-0]|TX|5/11|
text_000N_173214|MMI|3.56|Relationship by association|C0699792|[socb]|["association"-tx-1-"association"-noun-0]|TX|5/11|
text_000N_173214|MMI|3.56|Relationships|C0439849|[qlco]|["Association"-tx-1-"association"-noun-0]|TX|5/11|
text_000N_173214|MMI|3.46|Nuclear Pore|C0028587|[celc]|["Nuclear Pore"-tx-1-"nuclear pore"-noun-0]|TX|26/12|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|RNA Polymerase II|C0035679|[aapp,enzy]|["RNA Polymerase II"-tx-1-"RNA polymerase II"-noun-0]|TX|5/17|
text_000N_43331|MMI|3.63|*Activity (kind of quantity)|C1561536|[idcn]|["*Activity"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Active|C0205177|[qlco]|["Activity"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Activities|C0441655|[acty]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Activity (animal life circumstance)|C3668946|[fndg]|["Activity"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Biochemical Activity|C3897134|[qnco]|["Activity"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|FDA Establishment Activity Terminology|C4049939|[inpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Percent Activity|C0439167|[qnco]|["% Activity"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.63|Physical Activity Measurement|C4049938|[lbpr]|["ACTIVITY"-tx-1-"activity"-noun-0]|TX|41/8|
text_000N_43331|MMI|3.53|RNA Cleavage|C3178791|[moft]|["RNA Cleavage"-tx-1-"RNA cleavage"-noun-0]|TX|28/12|
<<<<< MMI
>>>>> MMI
text_000N_173260|MMI|5.18|Psammoma Body Formation|C0391863|[bdsu]|["Psammoma bodies"-tx-1-"psammoma bodies"-noun-0]|TX|4/15|
text_000N_173260|MMI|3.59|Characteristics|C1521970|[qlco]|["Characteristic"-tx-1-"characteristic"-adj-0]|TX|20/14|
text_000N_173260|MMI|3.45|Meningioma|C0025286|[neop]|["MENINGIOMAS"-tx-1-"meningiomas"-noun-0]|TX|38/11|
<<<<< MMI
>>>>> MMI
text_000N_173291|MMI|5.18|MK-1602|C4505937|[orch,phsu]|["MK-1602"-tx-1-"MK-1602"-noun-0]|TX|3/7|
text_000N_173291|MMI|3.68|Antagonist muscle action|C0231491|[ortf]|["Antagonist"-tx-1-"antagonist"-noun-0]|TX|18/10|
text_000N_173291|MMI|3.68|Substance with receptor antagonist mechanism of action (substance)|C4721408|[phsu]|["Antagonist"-tx-1-"antagonist"-noun-0]|TX|18/10|
<<<<< MMI
>>>>> MMI
text_000N_97283|MMI|5.18|Turcot syndrome (disorder)|C0265325|[dsyn]|["Turcot's syndrome"-tx-1-"Turcot syndrome"-noun-0]|TX|3/15|
text_000N_97283|MMI|3.72|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|19/15|
text_000N_97283|MMI|3.59|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|35/12|
text_000N_97283|MMI|3.59|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|35/12|
text_000N_97283|MMI|3.59|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|35/12|
text_000N_97283|MMI|3.59|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|35/12|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|golimumab|C2353893|[aapp,imft,phsu]|["GOLIMUMAB"-tx-1-"golimumab"-noun-0]|TX|4/9|
text_000N_47349|MMI|3.59|Diabetes|C0011847|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|25/8|
text_000N_47349|MMI|3.59|Diabetes Mellitus|C0011849|[dsyn]|["Diabetes"-tx-1-"diabetes"-noun-0]|TX|25/8|
text_000N_47349|MMI|3.59|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|14/6|
text_000N_47349|MMI|3.59|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|14/6|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|5.18|Acquisition (action)|C1706701|[acty]|["Obtain"-tx-1-"obtain"-verb-0]|TX|18/6|
text_000N_43303|MMI|5.18|Obtain|C1301820|[ftcn]|["Obtain"-tx-1-"obtain"-verb-0]|TX|18/6|
text_000N_43303|MMI|5.18|TDO2 protein, human|C5441735|[aapp,enzy]|["TO"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_43303|MMI|5.18|To|C1883351|[qlco]|["To"-tx-1-"to"-adv-0]|TX|15/2|
text_000N_43303|MMI|3.82|Feasibility|C5235660|[qlco]|["Feasibility"-tx-1-"feasible"-adj-0]|TX|6/8|
text_000N_43303|MMI|3.72|Read Length|C4727198|[lbpr]|["Read Length"-tx-1-"read lengths"-noun-0]|TX|29/12|
text_000N_43303|MMI|3.50|30%|C3842588|[qnco]|["30%"-tx-1-"30"-integer-0]|TX|54/2|
text_000N_43303|MMI|3.48|DNA|C0012854|[bacs,nnon]|["DNA"-tx-1-"DNA"-noun-0]|TX|25/3|
text_000N_43303|MMI|3.48|Deoxyribonucleic Acid Measurement|C4521340|[lbpr]|["DNA"-tx-1-"DNA"-noun-0]|TX|25/3|
<<<<< MMI
>>>>> MMI
text_000N_47377|MMI|5.18|Desvenlafaxine Measurement|C4553828|[lbpr]|["Desvenlafaxine"-tx-1-"desvenlafaxine"-noun-0]|TX|4/14|
text_000N_47377|MMI|5.18|desvenlafaxine|C1880288|[orch,phsu]|["DESVENLAFAXINE"-tx-1-"desvenlafaxine"-noun-0]|TX|4/14|
text_000N_47377|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|22/4,37/2|
text_000N_47377|MMI|3.55|Daily|C0332173|[tmco]|["/day"-tx-1-"day"-noun-0]|TX|45/3|
text_000N_47377|MMI|3.55|Dosage|C0178602|[qnco]|["DOSE"-tx-1-"dose"-noun-0]|TX|32/4|
text_000N_47377|MMI|3.55|Dose number:Number:Point in time:^Patient:Quantitative|C1114758|[clna]|["Dose #"-tx-1-"dose"-noun-0]|TX|32/4|
text_000N_47377|MMI|3.55|Unit dose|C0869039|[qnco]|["Dose"-tx-1-"dose"-noun-0]|TX|32/4|
text_000N_47377|MMI|3.55|day|C0439228|[tmco]|["DAY"-tx-1-"day"-noun-0]|TX|45/3|
text_000N_47377|MMI|3.55|per day|C0439505|[tmco]|["/day"-tx-1-"day"-noun-0]|TX|45/3|
<<<<< MMI
>>>>> MMI
text_000N_47392|MMI|3.63|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|75/5|
text_000N_47392|MMI|3.55|Massive|C0522501|[qlco]|["marks"-tx-1-"marks"-noun-0]|TX|20/5|
text_000N_47392|MMI|3.48|Regulation|C0851285|[gora]|["Regulated"-tx-1-"regulated"-adj-0]|TX|65/9|
text_000N_47392|MMI|3.43|Active|C0205177|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|29/6|
text_000N_47392|MMI|3.43|Active License|C3888249|[qlco]|["Active"-tx-1-"active"-adj-0]|TX|29/6|
text_000N_47392|MMI|3.43|Active State|C0679217|[idcn]|["Active"-tx-1-"active"-adj-0]|TX|29/6|
text_000N_47392|MMI|3.43|Chromatin|C0008546|[aapp]|["Chromatin"-tx-1-"chromatin"-noun-0]|TX|36/9|
text_000N_47392|MMI|3.43|Pet is as Active as it Has Been|C5238549|[inpr]|["active"-tx-1-"active"-adj-0]|TX|29/6|
text_000N_47392|MMI|3.43|active (HL7 RoleLink)|C3853793|[idcn]|["active"-tx-1-"active"-adj-0]|TX|29/6|
text_000N_47392|MMI|3.43|chromatin location|C1325550|[celc]|["chromatin"-tx-1-"chromatin"-noun-0]|TX|36/9|
<<<<< MMI
>>>>> MMI
text_000N_47363|MMI|5.18|Does play|C0600138|[fndg]|["play"-tx-1-"play"-verb-0]|TX|14/4|
text_000N_47363|MMI|5.18|Electrocardiogram: myocardial infarction (finding)|C0428953|[lbtr]|["MYOCARDIAL INFARCTION"-tx-1-"myocardial infarction"-noun-0]|TX|56/21|
text_000N_47363|MMI|5.18|Myocardial Infarction|C0027051|[dsyn]|["Infarction, Myocardial"-tx-1-"myocardial infarction"-noun-0]|TX|56/21|
text_000N_47363|MMI|5.18|Myocardial Infarction ECG Assessment|C3810814|[diap]|["Myocardial Infarction"-tx-1-"myocardial infarction"-noun-0]|TX|56/21|
text_000N_47363|MMI|5.18|Myocardial Infarction, CTCAE|C4552959|[fndg]|["Myocardial Infarction"-tx-1-"myocardial infarction"-noun-0]|TX|56/21|
text_000N_47363|MMI|5.18|Myocardial infarction:Finding:Point in time:^Patient:Ordinal|C2926063|[clna]|["Myocardial infarction"-tx-1-"myocardial infarction"-noun-0]|TX|56/21|
text_000N_47363|MMI|5.18|Play|C0032214|[dora]|["Play"-tx-1-"play"-verb-0]|TX|14/4|
text_000N_47363|MMI|5.18|Recombinant Transforming Growth Factor-Beta|C1527196|[aapp,bacs]|["TGF-Beta"-tx-1-"TGF-beta"-noun-0]|TX|5/8|
text_000N_47363|MMI|5.18|TGFB1 gene|C1366557|[gngm]|["TGFbeta"-tx-1-"TGF-beta"-noun-0]|TX|5/8|
text_000N_47363|MMI|5.18|Transforming Growth Factor beta|C0040690|[aapp,bacs]|["TGFbeta"-tx-1-"TGF-beta"-noun-0]|TX|5/8|
text_000N_47363|MMI|3.56|Generic Role|C1705810|[qlco]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_47363|MMI|3.56|Role|C3871154|[inpr]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_47363|MMI|3.56|Social Role|C0035820|[socb]|["Role"-tx-1-"role"-noun-0]|TX|21/4|
text_000N_47363|MMI|3.43|Cardiac - anatomy qualifier|C1522601|[qlco]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|29/7|
text_000N_47363|MMI|3.43|Cardiac attachment|C1314974|[inpr]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|29/7|
text_000N_47363|MMI|3.43|Heart|C0018787|[bpoc]|["Cardiac"-tx-1-"cardiac"-adj-0]|TX|29/7|
text_000N_47363|MMI|3.43|Natural regeneration|C0034963|[ortf]|["REGENERATION"-tx-1-"regeneration"-noun-0]|TX|37/12|
<<<<< MMI
>>>>> MMI
text_000N_43386|AA|UCE|Ultra-conserved element|1|3|5|23|30:3
text_000N_43386|AA|UCEs|Ultra-conserved elements|1|4|5|24|30:4
text_000N_43386|MMI|3.64|Segmental Duplications, Genomic|C2717927|[nnon]|["Segmental Duplications"-tx-1-"segmental duplications"-noun-0]|TX|48/22|
text_000N_43386|MMI|3.63|Elements|C0013879|[elii]|["Elements"-tx-1-"elements"-noun-0]|TX|20/8|
text_000N_43386|MMI|3.57|Enrich (product)|C0359583|[food]|["enriched"-tx-1-"enriched"-verb-0]|TX|36/8|
text_000N_43386|MMI|3.48|ultra|C0728475|[medd]|["ultra"-tx-1-"Ultra"-noun-0]|TX|4/5|
<<<<< MMI
>>>>> MMI
text_000N_40839|MMI|5.18|Acupuncture and Oriental Medicine|C1515884|[topp]|["traditional Chinese medicine"-tx-1-"traditional Chinese medicine"-noun-0]|TX|3/28|
text_000N_40839|MMI|5.18|Receive|C1514756|[qlco]|["RECEIVING"-tx-1-"receiving"-verb-0]|TX|108/9|
text_000N_40839|MMI|5.18|Traditional Chinese Medicine|C0025124|[bmod]|["Traditional Chinese Medicine"-tx-1-"traditional Chinese medicine"-noun-0]|TX|3/28|
text_000N_40839|MMI|3.68|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.68|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|130/9|
text_000N_40839|MMI|3.56|Breast Carcinoma|C0678222|[neop]|["Cancer of Breast"-tx-1-"of breast cancer"-noun-0]|TX|65/2,85/13|
text_000N_40839|MMI|3.56|Malignant neoplasm of breast|C0006142|[neop]|["Cancer of Breast"-tx-1-"of breast cancer"-noun-0]|TX|65/2,85/13|
text_000N_40839|MMI|3.55|Associated with|C0332281|[qlco]|["Associated with"-tx-1-"associated with"-verb-0]|TX|32/15|
text_000N_40839|MMI|3.55|Congestive heart failure|C0018802|[dsyn]|["Heart failure"-tx-1-"heart failure"-noun-0]|TX|68/13|
text_000N_40839|MMI|3.55|Heart Failure, CTCAE|C4554158|[fndg]|["Heart Failure"-tx-1-"heart failure"-noun-0]|TX|68/13|
text_000N_40839|MMI|3.55|Heart failure|C0018801|[dsyn]|["HEART FAILURE"-tx-1-"heart failure"-noun-0]|TX|68/13|
text_000N_40839|MMI|3.54|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|99/8|
text_000N_40839|MMI|3.53|Risk Reduction|C1137094|[inbe]|["Risk Decrease"-tx-1-"decreased risk"-noun-0]|TX|50/14|
text_000N_40839|MMI|3.50|doxorubicin|C0013089|[antb,orch]|["Doxorubicine"-tx-1-"doxorubicin"-noun-0]|TX|118/11|
<<<<< MMI
>>>>> MMI
text_000N_47289|MMI|5.18|AZD9668|C3489797|[orch]|["AZD9668"-tx-1-"AZD9668"-noun-0]|TX|4/7|
text_000N_47289|MMI|3.64|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|27/15|
text_000N_47289|MMI|3.64|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|27/15|
text_000N_47289|MMI|3.57|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|17/6|
text_000N_47289|MMI|3.57|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|17/6|
<<<<< MMI
>>>>> MMI
text_000N_47420|MMI|3.57|Before|C0332152|[tmco]|["Pre"-tx-1-"pre"-noun-0]|TX|27/3|
text_000N_47420|MMI|3.57|Before values|C0740175|[qlco]|["Pre"-tx-1-"pre"-noun-0]|TX|27/3|
text_000N_47420|MMI|3.57|Focal|C0205234|[spco]|["Localized"-tx-1-"localized"-verb-0]|TX|14/9|
text_000N_47420|MMI|3.57|Localized|C0392752|[spco]|["LOCALIZED"-tx-1-"localized"-verb-0]|TX|14/9|
text_000N_47420|MMI|3.57|Pure Spanish horse breed (organism)|C3669034|[mamm]|["PRE"-tx-1-"pre"-noun-0]|TX|27/3|
text_000N_47420|MMI|3.57|Synapses|C0039062|[bsoj]|["Synapses"-tx-1-"synapses"-noun-0]|TX|31/8|
text_000N_47420|MMI|3.57|photoreactivating enzyme activity|C2257086|[genf]|["PRE"-tx-1-"pre"-noun-0]|TX|27/3|
<<<<< MMI
>>>>> MMI
text_000N_47450|MMI|3.60|Anastasis|C1512772|[celf]|["anti-apoptosis"-tx-1-"anti-apoptotic"-adj-0]|TX|21/14|
text_000N_47450|MMI|3.49|MCL1 gene|C1366587|[gngm]|["Mcl-1"-tx-1-"MCL-1"-noun-0]|TX|15/5|
text_000N_47450|MMI|3.46|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|7/7|
<<<<< MMI
>>>>> MMI
text_000N_40886|MMI|3.50|Hypoactive Sexual Desire Disorder|C0020594|[mobd]|["Hypoactive Sexual Desire Disorder"-tx-1-"Hypoactive Sexual Desire Disorder"-noun-0]|TX|28/33|
text_000N_40886|MMI|3.42|flibanserin|C0754280|[orch,phsu]|["FLIBANSERIN"-tx-1-"flibanserin"-noun-0]|TX|3/11|
<<<<< MMI
>>>>> MMI
text_000N_40913|AA|miR-132|microRNA 132|3|7|3|12|21:7
text_000N_40913|MMI|5.18|MIR132 gene|C1537781|[gngm]|["microRNA 132"-tx-1-"microRNA 132"-noun-0]|TX|7/12|
text_000N_40913|MMI|3.64|Brain Pathology|C0006119|[patf]|["brain pathologies"-tx-1-"brain pathologies"-noun-0]|TX|42/17|
text_000N_40913|MMI|3.57|Involvement with|C1314939|[ftcn]|["Involved"-tx-1-"involved"-verb-0]|TX|30/8|
text_000N_40913|MMI|3.57|Positive Surgical Margins|C1709603|[fndg]|["Involved"-tx-1-"involved"-verb-0]|TX|30/8|
<<<<< MMI
>>>>> MMI
text_000N_40941|MMI|3.68|Aptamer|C0599013|[nnon]|["Aptamer"-tx-1-"aptamer"-noun-0]|TX|14/7|
text_000N_40941|MMI|3.57|Inhibitor|C1999216|[bacs]|["INHIBITOR"-tx-1-"inhibitor"-noun-0]|TX|41/9|
text_000N_40941|MMI|3.57|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|33/7|
text_000N_40941|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|25/4|
text_000N_40941|MMI|3.50|Peptides|C0030956|[aapp,phsu]|["Peptide"-tx-1-"peptide"-noun-0]|TX|6/7|
<<<<< MMI
>>>>> MMI
text_000N_40972|MMI|5.18|niraparib|C2744440|[orch,phsu]|["NIRAPARIB"-tx-1-"Niraparib"-noun-0]|TX|3/9|
text_000N_40972|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_40972|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_40972|MMI|3.48|Carcinoma, Ovarian Epithelial|C4721610|[neop]|["Ovarian Cancer"-tx-1-"ovarian cancer"-noun-0]|TX|27/14|
text_000N_40972|MMI|3.48|Malignant neoplasm of ovary|C1140680|[neop]|["OVARIAN CANCER"-tx-1-"ovarian cancer"-noun-0]|TX|27/14|
text_000N_40972|MMI|3.48|ovarian neoplasm|C0919267|[neop]|["ovarian cancer"-tx-1-"ovarian cancer"-noun-0]|TX|27/14|
<<<<< MMI
>>>>> MMI
text_000N_40999|MMI|5.18|CADASIL Syndrome|C0751587|[dsyn]|["CADASIL Syndrome"-tx-1-"cadasil syndrome"-noun-0]|TX|3/16|
text_000N_40999|MMI|5.18|Hereditary Diseases|C0019247|[dsyn]|["Hereditary Disease"-tx-1-"hereditary disease"-noun-0]|TX|22/18|
<<<<< MMI
>>>>> MMI
text_000N_173120|MMI|6.91|citicoline|C0010725|[nnon,phsu]|["Cyticholine"-tx-1-"Citicoline"-noun-0,"Cyticholine"-tx-1-"citicoline"-noun-0]|TX|19/10;79/10|
text_000N_173120|MMI|5.18|Support, device|C0183683|[medd]|["Support, NOS"-tx-1-"supports"-verb-0]|TX|58/8|
text_000N_173120|MMI|5.18|Supportive assistance|C1521721|[cnce]|["Support"-tx-1-"supports"-verb-0]|TX|58/8|
text_000N_173120|MMI|3.68|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|Therapeutic procedure|C0087111|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|therapeutic aspects|C0039798|[ftcn]|["treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.68|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|101/9|
text_000N_173120|MMI|3.59|Effectiveness|C1280519|[qlco]|["Efficacy"-tx-1-"efficacy"-noun-0]|TX|67/8|
text_000N_173120|MMI|3.59|Efficacy Study|C1707887|[resa]|["EFFICACY"-tx-1-"efficacy"-noun-0]|TX|67/8|
text_000N_173120|MMI|3.50|Cerebrovascular accident|C0038454|[dsyn]|["STROKE"-tx-1-"stroke"-noun-0]|TX|94/6|
text_000N_173120|MMI|3.50|Family history of stroke|C1261367|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|94/6|
text_000N_173120|MMI|3.50|Stroke, CTCAE|C4554100|[fndg]|["Stroke"-tx-1-"stroke"-noun-0]|TX|94/6|
text_000N_173120|MMI|3.44|Acute Cerebrovascular Accidents|C0751956|[dsyn]|["Acute stroke"-tx-1-"acUte Stroke"-noun-0]|TX|39/12|
text_000N_173120|MMI|3.42|Clinical Trials|C0008976|[resa]|["Trial"-tx-1-"Trial"-noun-0]|TX|30/5|
text_000N_173120|MMI|3.42|International|C1512888|[idcn]|["International"-tx-1-"International"-adj-0]|TX|5/13|
<<<<< MMI
>>>>> MMI
text_000N_173136|MMI|5.18|Vocimagene amiretrorepvec|C2984522|[virs]|["VOCIMAGENE AMIRETROREPVEC"-tx-1-"vocimagene amiretrorepvec"-noun-0]|TX|3/25|
text_000N_173136|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_173136|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|29/9|
text_000N_173136|MMI|3.45|Adult Glioblastoma|C0278878|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|43/12|
text_000N_173136|MMI|3.45|Childhood Glioblastoma|C0280474|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|43/12|
text_000N_173136|MMI|3.45|Glioblastoma|C0017636|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|43/12|
text_000N_173136|MMI|3.45|Glioblastoma Multiforme|C1621958|[neop]|["Glioblastoma"-tx-1-"glioblastoma"-noun-0]|TX|43/12|
<<<<< MMI
>>>>> MMI
text_000N_173151|MMI|5.18|Escape (mental process)|C0870509|[menp]|["escape"-tx-1-"escape"-verb-0]|TX|15/6|
text_000N_173151|MMI|5.18|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|4/5|
text_000N_173151|MMI|5.18|X CHROMOSOME INACTIVATION|C1507147|[fndg]|["X CHROMOSOME INACTIVATION"-tx-1-"X-chromosome inactivation"-noun-0]|TX|22/25|
text_000N_173151|MMI|5.18|X Chromosome Inactivation function|C0043297|[genf]|["X Chromosome Inactivation"-tx-1-"X-chromosome inactivation"-noun-0]|TX|22/25|
text_000N_173151|MMI|3.64|Abnormal mental state|C0278061|[mobd]|["Mental impairment"-tx-1-"mental impairment"-noun-0]|TX|59/17|
text_000N_173151|MMI|3.64|Mental handicap|C1306341|[mobd]|["Mental impairment"-tx-1-"mental impairment"-noun-0]|TX|59/17|
text_000N_173151|MMI|3.64|Mental impairment|C0683322|[mobd]|["Mental impairment"-tx-1-"mental impairment"-noun-0]|TX|59/17|
text_000N_173151|MMI|3.57|Related personal status|C0445223|[fndg]|["Related"-tx-1-"related"-verb-0]|TX|48/7|
text_000N_173151|MMI|3.57|Relationships|C0439849|[qlco]|["Related"-tx-1-"related"-verb-0]|TX|48/7|
<<<<< MMI
>>>>> MMI
text_000N_173183|MMI|5.18|Chromatin Remodeling Factor|C1333030|[aapp,bacs]|["Chromatin Remodeling Complex"-tx-1-"chromatin remodeling complex"-noun-0]|TX|9/28|
text_000N_173183|MMI|3.60|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosomes"-tx-1-"nucleosomes"-noun-0]|TX|56/11|
text_000N_173183|MMI|3.49|H2AZ1 gene|C1415408|[gngm]|["H2A.Z"-tx-1-"H2A.Z"-noun-0]|TX|50/5|
text_000N_173183|MMI|3.49|H2AZ1 wt Allele|C4284461|[gngm]|["H2A.z"-tx-1-"H2A.Z"-noun-0]|TX|50/5|
text_000N_173183|MMI|3.49|Histone H2A.Z|C4284633|[aapp,bacs]|["H2A/z"-tx-1-"H2A.Z"-noun-0]|TX|50/5|
text_000N_173183|MMI|3.46|Remodels the Structure of Chromatin|C1335651|[aapp,bacs]|["RSC"-tx-1-"RSC"-noun-0]|TX|39/3|
text_000N_173183|MMI|3.46|Target|C1521840|[ftcn]|["Target"-tx-1-"target"-noun-0]|TX|43/6|
text_000N_173183|MMI|3.46|Target Lesion Identification|C2986546|[diap]|["TARGET"-tx-1-"target"-noun-0]|TX|43/6|
<<<<< MMI
>>>>> MMI
text_000N_173230|MMI|5.18|ATP8A2 protein, human|C2744579|[aapp,enzy]|["ATP"-tx-1-"ATP"-noun-0]|TX|52/3|
text_000N_173230|MMI|5.18|Adenosine Triphosphate Measurement|C4552600|[lbpr]|["ATP"-tx-1-"ATP"-noun-0]|TX|52/3|
text_000N_173230|MMI|3.55|Human Cells, Tissues, and Cellular and Tissue-Based Products Processing|C4521541|[hlca]|["Process"-tx-1-"process"-noun-0]|TX|7/7|
text_000N_173230|MMI|3.55|Process|C1522240|[phpr]|["Process"-tx-1-"process"-noun-0]|TX|7/7|
text_000N_173230|MMI|3.55|Process (qualifier value)|C4521054|[ftcn]|["Process"-tx-1-"process"-noun-0]|TX|7/7|
text_000N_173230|MMI|3.55|bony process|C1184743|[bpoc]|["Process"-tx-1-"process"-noun-0]|TX|7/7|
text_000N_173230|MMI|3.45|Chromatin Loop|C1516509|[celc]|["DNA Loop"-tx-1-"DNA loop"-noun-0]|TX|18/8|
text_000N_173230|MMI|3.43|Extrusion|C0443213|[fndg]|["Extrusion"-tx-1-"extrusion"-noun-0]|TX|27/9|
<<<<< MMI
>>>>> MMI
text_000N_97301|MMI|3.64|MECP2 gene|C1417098|[gngm]|["Rett syndrome"-tx-1-"Rett Syndrome"-noun-0]|TX|53/13|
text_000N_97301|MMI|3.64|Rett Syndrome|C0035372|[dsyn]|["Rett's syndrome"-tx-1-"Rett Syndrome"-noun-0]|TX|53/13|
text_000N_97301|MMI|3.59|CAGE Antibody|C4555210|[aapp,imft,phsu]|["CAGE"-tx-1-"CAGE"-noun-0]|TX|91/4|
text_000N_97301|MMI|3.59|CAP Analysis of Gene Expression|C5552712|[lbpr]|["CAGE"-tx-1-"CAGE"-noun-0]|TX|91/4|
text_000N_97301|MMI|3.59|Cage device|C0337189|[mnob]|["Cage"-tx-1-"CAGE"-noun-0]|TX|91/4|
text_000N_97301|MMI|3.59|Characterization|C1880022|[acty]|["Characterized"-tx-1-"characterized"-verb-0]|TX|72/13|
text_000N_97301|MMI|3.58|Promoter Regions, Genetic|C0033413|[bacs,nnon]|["Promoter Regions, Genetic"-tx-1-"promoter regions genes"-noun-0]|TX|9/16,33/5|
<<<<< MMI
>>>>> MMI
text_000N_97347|MMI|3.56|Use of|C1524063|[ftcn]|["Use of"-tx-1-"used of"-verb-0]|TX|29/4,53/2|
text_000N_97347|MMI|3.55|Coding|C0009219|[ocac]|["Coding"-tx-1-"coding"-adj-0]|TX|56/6|
text_000N_97347|MMI|3.55|Coding Subtest (WAIS-IV)|C4050311|[inpr]|["Coding"-tx-1-"coding"-adj-0]|TX|56/6|
text_000N_97347|MMI|3.55|Coding Subtest (WISC-V)|C4050310|[inpr]|["Coding"-tx-1-"coding"-adj-0]|TX|56/6|
text_000N_97347|MMI|3.55|Encode (action)|C2700640|[acty]|["coding"-tx-1-"coding"-adj-0]|TX|56/6|
text_000N_97347|MMI|3.55|Prediction|C0681842|[idcn]|["Prediction"-tx-1-"prediction"-noun-0]|TX|42/10|
text_000N_97347|MMI|3.55|Variant|C0205419|[qlco]|["variants"-tx-1-"variants"-noun-0]|TX|63/8|
text_000N_97347|MMI|3.50|Pine, Bach Flower Essence|C0885001|[phsu]|["pines"-tx-1-"PINES"-noun-0]|TX|7/5|
text_000N_97347|MMI|3.50|pine bark extract|C0872909|[orch,phsu]|["pines"-tx-1-"PINES"-noun-0]|TX|7/5|
<<<<< MMI
>>>>> MMI
text_000N_97362|MMI|3.61|Conditional|C1701901|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.61|Dependent - ability|C0851827|[qlco]|["Dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.61|Dependent for Toilet Use|C4321395|[inpr]|["dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.61|Dependent for bathing|C0429986|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.61|Dependent for dressing|C0429964|[fndg]|["dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.61|dependent|C3244310|[ftcn]|["dependent"-tx-1-"dependent"-adj-0]|TX|27/9|
text_000N_97362|MMI|3.47|ATP8A2 protein, human|C2744579|[aapp,enzy]|["ATP"-tx-1-"ATP"-noun-0]|TX|23/3|
text_000N_97362|MMI|3.47|Adenosine Triphosphate Measurement|C4552600|[lbpr]|["ATP"-tx-1-"ATP"-noun-0]|TX|23/3|
text_000N_97362|MMI|3.47|Nucleosomes|C0028623|[aapp,bacs]|["Nucleosome"-tx-1-"nucleosome"-noun-0]|TX|3/10|
text_000N_97362|MMI|3.47|nucleosome location|C1166675|[celc]|["nucleosome"-tx-1-"nucleosome"-noun-0]|TX|3/10|
<<<<< MMI
>>>>> MMI
text_000N_97331|MMI|5.18|Activating Transcription Factor 4|C0101379|[aapp,bacs]|["ATF4 Transcription Factor"-tx-1-"ATF4 transcription factor"-noun-0]|TX|4/25|
text_000N_97331|MMI|5.18|Neoplastic Cell Transformation|C0007621|[neop]|["neoplastic transformation"-tx-1-"neoplastic transformation"-noun-0]|TX|56/25|
text_000N_97331|MMI|3.59|Cancer Genus|C0998265|[euka]|["Cancer"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_97331|MMI|3.59|Malignant Neoplasms|C0006826|[neop]|["CANCER"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_97331|MMI|3.59|Primary malignant neoplasm|C1306459|[neop]|["Cancer"-tx-1-"cancer"-noun-0]|TX|45/6|
text_000N_97331|MMI|3.55|Hyperlink|C1704666|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|35/6|
text_000N_97331|MMI|3.55|Links List|C1517892|[inpr]|["Link"-tx-1-"linked"-verb-0]|TX|35/6|
<<<<< MMI
>>>>> MMI
text_000N_173199|MMI|3.68|Vaccine [APC]|C5399710|[phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|10/7|
text_000N_173199|MMI|3.68|Vaccines|C0042210|[aapp,imft,phsu]|["Vaccine"-tx-1-"vaccine"-noun-0]|TX|10/7|
text_000N_173199|MMI|3.57|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|18/9|
text_000N_173199|MMI|3.57|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|18/9|
text_000N_173199|MMI|3.50|NicVAX|C2981860|[imft,phsu]|["NicVAX"-tx-1-"NicVAX"-noun-0]|TX|3/6|
text_000N_173199|MMI|3.48|Cessation of smoking|C0085134|[inbe]|["Smoking Cessation"-tx-1-"smoking cessation"-noun-0]|TX|32/17|
text_000N_173199|MMI|3.48|Smoking cessation therapy|C1095963|[topp]|["smoking cessation"-tx-1-"smoking cessation"-noun-0]|TX|32/17|
<<<<< MMI
>>>>> MMI
text_000N_173167|MMI|5.18|PF-05190457|C4310563|[orch,phsu]|["PF-05190457"-tx-1-"PF-05190457"-noun-0]|TX|3/11|
text_000N_173167|MMI|3.60|Growth Hormone Secretagogue Receptor Agonist [EPC]|C4551437|[phsu]|["Ghrelin Receptor Agonist"-tx-1-"agonist ghrelin receptor"-noun-0]|TX|26/7,41/16|
text_000N_173167|MMI|3.60|Growth hormone secretagogue receptor agonist (disposition)|C4722116|[qlco]|["Ghrelin receptor agonist"-tx-1-"agonist ghrelin receptor"-noun-0]|TX|26/7,41/16|
text_000N_173167|MMI|3.60|Substance with growth hormone secretagogue receptor agonist mechanism of action (substance)|C4722152|[phsu]|["Ghrelin receptor agonist"-tx-1-"agonist ghrelin receptor"-noun-0]|TX|26/7,41/16|
text_000N_173167|MMI|3.60|Inverse Receptor Agonist|C4743780|[bacs]|["INVERSE RECEPTOR AGONIST"-tx-1-"inverse agonist receptor"-noun-0]|TX|18/15,49/8|
text_000N_173167|MMI|3.42|Aniridia type 1|C0344542|[cgab]|["AN"-tx-1-"an"-det-0]|TX|15/2|
text_000N_173167|MMI|3.42|DIAPH3 wt Allele|C4321249|[gngm]|["AN"-tx-1-"an"-det-0]|TX|15/2|
text_000N_173167|MMI|3.42|GHRL gene|C1825346|[gngm]|["GHRELIN"-tx-1-"ghrelin"-noun-0]|TX|41/7|
text_000N_173167|MMI|3.42|GHRL protein, human|C1870739|[aapp,horm]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|41/7|
text_000N_173167|MMI|3.42|Ghrelin Measurement|C3813179|[lbpr]|["GHRELIN"-tx-1-"ghrelin"-noun-0]|TX|41/7|
text_000N_173167|MMI|3.42|Inverse|C0439850|[qlco]|["Inverse"-tx-1-"inverse"-adj-0]|TX|18/7|
text_000N_173167|MMI|3.42|Lenomorelin|C4722442|[orch,phsu]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|41/7|
text_000N_173167|MMI|3.42|ghrelin|C0911014|[aapp,horm]|["Ghrelin"-tx-1-"ghrelin"-noun-0]|TX|41/7|
<<<<< MMI
>>>>> MMI
text_000N_173087|MMI|5.18|flotillins|C0539788|[aapp,rcpt]|["flotillin"-tx-1-"Flotillin"-noun-0]|TX|4/9|
text_000N_173087|MMI|3.57|Biological Markers|C0005516|[clna]|["marker"-tx-1-"marker"-noun-0]|TX|34/6|
text_000N_173087|MMI|3.57|Marker|C5445211|[qlco]|["Marker"-tx-1-"marker"-noun-0]|TX|34/6|
text_000N_173087|MMI|3.57|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|17/4|
<<<<< MMI
>>>>> MMI
text_000N_47274|MMI|5.18|DNA-Directed RNA Polymerase|C0035681|[aapp,enzy]|["RNA Polymerase"-tx-1-"RNA Polymerase"-noun-0]|TX|105/14|
text_000N_47274|MMI|5.18|RNA Polymerase Assembly Pathway|C2984241|[ftcn]|["RNA polymerase"-tx-1-"RNA Polymerase"-noun-0]|TX|105/14|
text_000N_47274|MMI|3.98|depend|C0725813|[medd]|["depend"-tx-1-"depended"-verb-0]|TX|96/8|
text_000N_47274|MMI|3.68|RNA|C0035668|[nnon]|["RNA"-tx-1-"RNA"-noun-0]|TX|92/3|
text_000N_47274|MMI|3.68|Ribonucleic Acid Measurement|C4319105|[lbpr]|["RNA"-tx-1-"RNA"-noun-0]|TX|92/3|
text_000N_47274|MMI|3.55|Crystal Structure|C0444626|[chvs]|["Crystal Structure"-tx-1-"crystal structure"-noun-0]|TX|11/17|
text_000N_47274|MMI|3.50|Methyltransferase|C0025831|[aapp,enzy]|["Methyltransferase"-tx-1-"Methyltransferase"-noun-0]|TX|72/17|
text_000N_47274|MMI|3.50|Methyltransferase (disposition)|C4521687|[qlco]|["Methyltransferase"-tx-1-"Methyltransferase"-noun-0]|TX|72/17|
text_000N_47274|MMI|3.42|Flaviviridae|C0206510|[virs]|["Flaviviridae"-tx-1-"flaviviridae"-noun-0]|TX|55/12|
text_000N_47274|MMI|3.42|Full|C0443225|[qlco]|["Full"-tx-1-"full"-adj-0]|TX|36/4|
text_000N_47274|MMI|3.42|Length|C1444754|[qnco]|["Length"-tx-1-"length"-adj-0]|TX|41/6|
text_000N_47274|MMI|3.42|Length of Trial|C1706316|[resa]|["LENGTH"-tx-1-"length"-adj-0]|TX|41/6|
text_000N_47274|MMI|3.42|NS 5|C0614427|[antb]|["NS 5"-tx-1-"NS5"-noun-0]|TX|68/3|
text_000N_47274|MMI|3.42|Noonan Syndrome 5|C1969057|[dsyn]|["NS5"-tx-1-"NS5"-noun-0]|TX|68/3|
text_000N_47274|MMI|3.42|RAF1 wt Allele|C1706586|[gngm]|["NS5"-tx-1-"NS5"-noun-0]|TX|68/3|
<<<<< MMI
>>>>> MMI
text_000N_43235|MMI|7.19|Proteins|C0033684|[aapp,bacs]|["PROTEIN"-tx-1-"protein"-noun-0]|TX|[8/7],[55/7]|
text_000N_43235|MMI|5.18|Diagnostic Imaging|C0011923|[diap]|["Imaging"-tx-1-"imaging"-verb-0]|TX|63/7|
text_000N_43235|MMI|5.18|Imaging Techniques|C0079595|[diap]|["Imaging"-tx-1-"imaging"-verb-0]|TX|63/7|
text_000N_43235|MMI|3.68|Green Fluorescent Proteins|C0120285|[aapp,irda]|["GFP"-tx-1-"GFP"-noun-0]|TX|16/3|
text_000N_43235|MMI|3.59|Gene Transfer Techniques|C0886519|[resa]|["Transgenesis"-tx-1-"transgenesis"-noun-0]|TX|33/12|
text_000N_43235|MMI|3.59|Used by|C1273517|[fndg]|["used"-tx-1-"used"-verb-0]|TX|25/4|
text_000N_43235|MMI|3.50|Live - Specimen Condition|C1548795|[qlco]|["Live"-tx-1-"live"-adj-0]|TX|50/4|
text_000N_43235|MMI|3.50|Live File|C5399957|[fndg]|["live"-tx-1-"live"-adj-0]|TX|50/4|
text_000N_43235|MMI|3.50|Percentage live|C1634625|[qnco]|["% live"-tx-1-"live"-adj-0]|TX|50/4|
text_000N_43235|MMI|3.50|Reside|C2982691|[acty]|["Live"-tx-1-"live"-adj-0]|TX|50/4|
<<<<< MMI
>>>>> MMI
text_000N_173245|MMI|5.18|Sotatercept|C2699571|[aapp,phsu]|["SOTATERCEPT"-tx-1-"Sotatercept"-noun-0]|TX|3/11|
text_000N_173245|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173245|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|15/9|
text_000N_173245|MMI|3.50|Idiopathic pulmonary arterial hypertension|C3203102|[dsyn]|["PULMONARY ARTERIAL HYPERTENSION"-tx-1-"Pulmonary Arterial Hypertension"-noun-0]|TX|29/31|
text_000N_173245|MMI|3.50|Pulmonary arterial hypertension|C2973725|[dsyn]|["Hypertension, Pulmonary Arterial"-tx-1-"Pulmonary Arterial Hypertension"-noun-0]|TX|29/31|
<<<<< MMI
>>>>> MMI
text_000N_43275|MMI|5.18|Echinacea <Asteraceae>|C1095869|[plnt]|["Echinacea"-tx-1-"echinacea"-noun-0]|TX|5/9|
text_000N_43275|MMI|5.18|Echinacea <Echinodermata>|C1017603|[euka]|["Echinacea"-tx-1-"echinacea"-noun-0]|TX|5/9|
text_000N_43275|MMI|5.18|Echinacea antigen|C5445960|[imft]|["Echinacea"-tx-1-"echinacea"-noun-0]|TX|5/9|
text_000N_43275|MMI|5.18|Echinacea preparation|C0752270|[orch,phsu]|["ECHINACEA"-tx-1-"echinacea"-noun-0]|TX|5/9|
text_000N_43275|MMI|5.18|Increase|C0442805|[ftcn]|["Increase"-tx-1-"increase"-verb-0]|TX|15/8|
text_000N_43275|MMI|3.68|Risk|C0035647|[idcn]|["Risk"-tx-1-"risk"-noun-0]|TX|36/4|
text_000N_43275|MMI|3.68|Subject Risk|C4552904|[cnce]|["risk"-tx-1-"risk"-noun-0]|TX|36/4|
text_000N_43275|MMI|3.50|Anaphylactic shock|C4316895|[patf]|["Anaphylaxis"-tx-1-"anaphylaxis"-noun-0]|TX|24/11|
text_000N_43275|MMI|3.50|Anaphylaxis, CTCAE|C4553015|[fndg]|["Anaphylaxis"-tx-1-"anaphylaxis"-noun-0]|TX|24/11|
text_000N_43275|MMI|3.50|anaphylaxis|C0002792|[dsyn]|["ANAPHYLAXIS"-tx-1-"anaphylaxis"-noun-0]|TX|24/11|
<<<<< MMI
>>>>> MMI
text_000N_173276|MMI|5.18|FXYD1 gene|C1414874|[gngm]|["PHOSPHOLEMMAN"-tx-1-"Phospholemman"-noun-0]|TX|3/13|
text_000N_173276|MMI|5.18|Membrane Proteins|C0025252|[aapp,bacs]|["Membrane Protein"-tx-1-"membrane protein"-noun-0]|TX|19/16|
text_000N_173276|MMI|5.18|phospholemman|C0136870|[aapp,rcpt]|["phospholemman"-tx-1-"Phospholemman"-noun-0]|TX|3/13|
<<<<< MMI
>>>>> MMI
text_000N_47334|MMI|7.01|Therapeutic procedure|C0087111|[topp]|["Therapy"-tx-1-"therapy"-noun-0,"Treatment"-tx-1-"treatment"-noun-0]|TX|71/7;40/9|
text_000N_47334|MMI|7.01|therapeutic aspects|C0039798|[ftcn]|["therapy"-tx-1-"therapy"-noun-0,"treatment"-tx-1-"treatment"-noun-0]|TX|71/7;40/9|
text_000N_47334|MMI|5.18|Coronary Artery Bypass Surgery|C0010055|[topp]|["Coronary Artery Bypass Grafting"-tx-1-"coronary artery bypass grafting"-noun-0]|TX|102/31|
text_000N_47334|MMI|5.18|Recommendation|C0034866|[idcn]|["Recommended"-tx-1-"recommended"-verb-0]|TX|3/11|
text_000N_47334|MMI|3.61|Use of|C1524063|[ftcn]|["Use of"-tx-1-"use of"-noun-0]|TX|19/6|
text_000N_47334|MMI|3.59|Hormone Therapy|C0279025|[topp]|["Hormone Therapy"-tx-1-"hormone therapy"-noun-0]|TX|63/15|
text_000N_47334|MMI|3.59|Hormone Therapy Agent|C4688302|[phsu]|["Hormone Therapy"-tx-1-"hormone therapy"-noun-0]|TX|63/15|
text_000N_47334|MMI|3.58|THYROID THERAPY DRUGS|C3540775|[phsu]|["THYROID THERAPY"-tx-1-"thyroid therapy"-noun-0]|TX|55/7,71/7|
text_000N_47334|MMI|3.58|Thyroid therapy|C1696944|[topp]|["Thyroid therapy"-tx-1-"thyroid therapy"-noun-0]|TX|55/7,71/7|
text_000N_47334|MMI|3.55|Therapy Object (animal model)|C1363945|[fndg]|["Therapy"-tx-1-"therapy"-noun-0]|TX|71/7|
text_000N_47334|MMI|3.45|Thyroid Hormones|C0040135|[horm]|["Thyroid Hormone"-tx-1-"thyroid hormone"-noun-0]|TX|55/15|
text_000N_47334|MMI|3.45|Thyroid hormone (disposition)|C4522017|[qlco]|["Thyroid hormone"-tx-1-"thyroid hormone"-noun-0]|TX|55/15|
text_000N_47334|MMI|3.43|Administration procedure|C1533734|[topp]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47334|MMI|3.43|Biomaterial Treatment|C1705169|[cnce]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47334|MMI|3.43|Treating|C1522326|[ftcn]|["Treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47334|MMI|3.43|Treatment Epoch|C3538994|[resa]|["TREATMENT"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47334|MMI|3.43|perioperative|C1518988|[tmco]|["Perioperative"-tx-1-"perioperative"-adj-0]|TX|26/13|
text_000N_47334|MMI|3.43|treatment - ActInformationManagementReason|C3887704|[hlca]|["treatment"-tx-1-"treatment"-noun-0]|TX|40/9|
text_000N_47334|MMI|3.43|Hormone (disposition)|C4521914|[qlco]|["Hormone"-tx-1-"hormone"-noun-0]|TX|63/7|
text_000N_47334|MMI|3.43|Hormone [APC]|C5399720|[phsu]|["Hormone"-tx-1-"hormone"-noun-0]|TX|63/7|
text_000N_47334|MMI|3.43|Hormones|C0019932|[horm]|["Hormone"-tx-1-"hormone"-noun-0]|TX|63/7|
text_000N_47334|MMI|3.43|In addition to|C0332287|[ftcn]|["With"-tx-1-"with"-prep-0]|TX|50/4|
text_000N_47334|MMI|3.43|Patients|C0030705|[podg]|["Patients"-tx-1-"patients"-noun-0]|TX|82/8|
text_000N_47334|MMI|3.43|THYROID DIAGNOSTIC RADIOPHARMACEUTICALS|C3540038|[irda]|["THYROID"-tx-1-"thyroid"-noun-0]|TX|55/7|
text_000N_47334|MMI|3.43|Thyroid Gland|C0040132|[bpoc]|["Thyroid, NOS"-tx-1-"thyroid"-noun-0]|TX|55/7|
text_000N_47334|MMI|3.43|With - dosing instruction fragment|C1705690|[inpr]|["With"-tx-1-"with"-prep-0]|TX|50/4|
<<<<< MMI
>>>>> MMI
text_000N_47304|MMI|5.18|C3orf62 gene|C1824157|[gngm]|["MAPS"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|5.18|DNA Methylation|C0376452|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|4/15|
text_000N_47304|MMI|5.18|DNA Methylation Analysis|C1880239|[mbrt]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|4/15|
text_000N_47304|MMI|5.18|DNA Methylation [PE]|C3536933|[moft]|["DNA Methylation"-tx-1-"DNA methylation"-noun-0]|TX|4/15|
text_000N_47304|MMI|5.18|Functional Map|C1706473|[cnce]|["Map"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|5.18|Map|C0024779|[inpr]|["Maps"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|5.18|Microtubule-Associated Proteins|C0026045|[aapp,bacs]|["MAPs"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|5.18|Myositis Activities Profile|C4050322|[lbpr]|["MAP"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|5.18|System Support Mapping|C4724148|[topp]|["MAP"-tx-1-"maps"-verb-0]|TX|20/4|
text_000N_47304|MMI|3.54|Applicable|C1706839|[qlco]|["Applicable"-tx-1-"applicable"-adj-0]|TX|25/10|
text_000N_47304|MMI|3.54|Not Applicable|C1272460|[qlco]|["applicable"-tx-1-"applicable"-adj-0]|TX|25/10|
text_000N_47304|MMI|3.49|Non-Small Cell Lung Carcinoma|C0007131|[neop]|["Non-Small Cell Carcinoma of the Lung"-tx-1-"the of non-small-cell lung carcinomas"-noun-0]|TX|39/3,53/33|
text_000N_47304|MMI|3.49|Non-small cell carcinoma|C1266002|[neop]|["non Small cell carcinoma of the lung"-tx-1-"the of non-small-cell lung carcinomas"-noun-0]|TX|39/3,53/33|
text_000N_47304|MMI|3.42|Date of diagnosis|C2316983|[tmco]|["Diagnosis"-tx-1-"diagnosis"-noun-0]|TX|43/9|
text_000N_47304|MMI|3.42|Diagnosis|C0011900|[diap]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|43/9|
text_000N_47304|MMI|3.42|Diagnosis Code|C1550350|[inpr]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|43/9|
text_000N_47304|MMI|3.42|Diagnosis Study|C1704656|[resa]|["DIAGNOSIS"-tx-1-"diagnosis"-noun-0]|TX|43/9|
text_000N_47304|MMI|3.42|Disease|C0012634|[dsyn]|["Diagnosis"-tx-1-"diagnosis"-noun-1]|TX|43/9|
text_000N_47304|MMI|3.42|diagnosis aspect|C1704338|[ftcn]|["diagnosis"-tx-1-"diagnosis"-noun-0]|TX|43/9|
<<<<< MMI
>>>>> MMI
text_000N_47320|MMI|5.18|belimumab|C1723401|[aapp,imft,phsu]|["BELIMUMAB"-tx-1-"belimumab"-noun-0]|TX|3/9|
text_000N_47320|MMI|3.56|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_47320|MMI|3.56|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_47320|MMI|3.46|Lupus Nephritis|C0024143|[dsyn]|["LUPUS NEPHRITIS"-tx-1-"lupus nephritis"-noun-0]|TX|31/15|
<<<<< MMI
>>>>> MMI
text_000N_47406|MMI|5.18|CALCIUM SUPPLEMENTS|C3540037|[phsu,vita]|["CALCIUM"-tx-1-"calcium"-noun-0]|TX|30/7|
text_000N_47406|MMI|5.18|Calcium Drug Class|C3714611|[phsu]|["CALCIUM"-tx-1-"calcium"-noun-0]|TX|30/7|
text_000N_47406|MMI|5.18|Calcium [EPC]|C2936886|[phsu]|["Calcium"-tx-1-"calcium"-noun-0]|TX|30/7|
text_000N_47406|MMI|5.18|Calcium, Dietary|C0006726|[inch]|["Calcium"-tx-1-"calcium"-noun-0]|TX|30/7|
text_000N_47406|MMI|5.18|Thyroid Hormones|C0040135|[horm]|["Thyroid Hormone"-tx-1-"thyroid hormone"-noun-0]|TX|5/15|
text_000N_47406|MMI|5.18|Thyroid hormone (disposition)|C4522017|[qlco]|["Thyroid hormone"-tx-1-"thyroid hormone"-noun-0]|TX|5/15|
text_000N_47406|MMI|5.18|calcium|C0006675|[bacs,elii,phsu]|["CALCIUM"-tx-1-"calcium"-noun-0]|TX|30/7|
text_000N_47406|MMI|3.57|Transient Population Group|C0040704|[popg]|["Transient"-tx-1-"transient"-adj-0]|TX|38/9|
text_000N_47406|MMI|3.57|Transitory|C0205374|[tmco]|["Transient"-tx-1-"transient"-adj-0]|TX|38/9|
text_000N_47406|MMI|3.44|Myocardium|C0027061|[tisu]|["Myocardium"-tx-1-"myocardium"-noun-0]|TX|55/10|
<<<<< MMI
>>>>> MMI
text_000N_47435|MMI|3.98|Immune Cell|C4330475|[cell]|["Immune Cell"-tx-1-"immune cells"-noun-0]|TX|4/12|
text_000N_47435|MMI|3.68|Amyotrophic Lateral Sclerosis|C0002736|[dsyn]|["AMYOTROPHIC LATERAL SCLEROSIS"-tx-1-"Amyotrophic Lateral Sclerosis"-noun-0]|TX|29/29|
text_000N_47435|MMI|3.56|Affecting|C0392760|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|17/8|
text_000N_47435|MMI|3.56|Involvement with|C1314939|[ftcn]|["Affected"-tx-1-"affected"-verb-0]|TX|17/8|
<<<<< MMI
>>>>> MMI
text_000N_43331|MMI|5.18|GATA1 gene|C1333663|[gngm]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|5/6|
text_000N_43331|MMI|5.18|GATA1 protein, human|C1530719|[aapp,bacs]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|5/6|
text_000N_43331|MMI|5.18|GATA1 wt Allele|C1706325|[gngm]|["GATA-1"-tx-1-"GATA-1"-noun-0]|TX|5/6|
text_000N_43331|MMI|3.75|Ribosomal Proteins|C0035552|[aapp,bacs]|["Ribosomal Protein"-tx-1-"ribosomal protein"-noun-0]|TX|21/17|
text_000N_43331|MMI|3.75|ribosomal protein activity|C1622856|[genf]|["ribosomal protein"-tx-1-"ribosomal protein"-noun-0]|TX|21/17|
text_000N_43331|MMI|3.63|Genes|C0017337|[gngm]|["Genes"-tx-1-"genes"-noun-0]|TX|39/5|
<<<<< MMI
>>>>> MMI
text_000N_43358|MMI|3.61|Phylogenetic Analysis|C1519068|[resa]|["Phylogenetic Analysis"-tx-1-"phylogenetic analysis"-noun-0]|TX|11/21|
text_000N_43358|MMI|3.43|HIV|C0019682|[virs]|["HIV"-tx-1-"HIV"-noun-0]|TX|37/3|
text_000N_43358|MMI|3.43|HIV Infections|C0019693|[dsyn]|["HIV"-tx-1-"HIV"-noun-0]|TX|37/3|
text_000N_43358|MMI|3.43|HIV Seropositivity|C0019699|[lbtr]|["HIV+"-tx-1-"HIV"-noun-0]|TX|37/3|
text_000N_43358|MMI|3.43|Human Immunodeficiency Virus Measurement|C5202935|[lbpr]|["HIV"-tx-1-"HIV"-noun-0]|TX|37/3|
<<<<< MMI
>>>>> MMI
text_000N_47349|MMI|5.18|tretinoin|C0040845|[hops,orch,phsu]|["TRETINOIN"-tx-1-"tretinoin"-noun-0]|TX|3/9|
text_000N_47349|MMI|3.59|Effective|C1704419|[qlco]|["Effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_47349|MMI|3.59|Effectiveness|C1280519|[qlco]|["effective"-tx-1-"effective"-adj-0]|TX|13/9|
text_000N_47349|MMI|3.45|Solar elastosis|C0263415|[inpo]|["Photoaging"-tx-1-"photoaging"-noun-0]|TX|27/10|
<<<<< MMI
>>>>> MMI
text_000N_43303|MMI|3.98|Intercellular Adhesion Molecule Measurement|C4085554|[lbpr]|["ICAM"-tx-1-"ICAMS"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.98|Intercellular Adhesion Molecules|C0242565|[aapp,bacs]|["ICAM"-tx-1-"ICAMS"-noun-0]|TX|4/5|
text_000N_43303|MMI|3.69|Cell Adhesion Molecules|C0007578|[aapp,bacs]|["Adhesion Molecule"-tx-1-"Adhesion Molecules"-noun-0]|TX|25/18|
text_000N_43303|MMI|3.61|part of|C1292711|[spco]|["part of"-tx-1-"part of"-noun-0]|TX|45/7|
text_000N_43303|MMI|3.48|Intracellular|C0178719|[spco]|["Intracellular"-tx-1-"Intracellular"-adj-0]|TX|11/13|
text_000N_43303|MMI|3.48|Protoplasm|C0175996|[celc]|["intracellular"-tx-1-"Intracellular"-adj-0]|TX|11/13|
text_000N_43303|MMI|3.43|Immunoglobulins|C0021027|[aapp,imft]|["Immunoglobulin"-tx-1-"immunoglobulin"-noun-0]|TX|57/14|
text_000N_43303|MMI|3.43|Superfamily|C1883220|[cnce]|["Superfamily"-tx-1-"superfamily"-noun-0]|TX|72/11|
text_000N_43303|MMI|3.43|immunoglobulin activity|C1621846|[moft]|["immunoglobulin"-tx-1-"immunoglobulin"-noun-0]|TX|57/14|
<<<<< MMI
>>>>> MMI
text_000N_173104|MMI|5.18|saracatinib|C2828242|[orch,phsu]|["SARACATINIB"-tx-1-"saracatinib"-noun-0]|TX|4/11|
text_000N_173104|MMI|3.64|Clinical Trial [Publication Type]|C1096775|[inpr]|["clinical trials"-tx-1-"clinical trials"-noun-0]|TX|31/15|
text_000N_173104|MMI|3.64|Clinical Trials|C0008976|[resa]|["CLINICAL TRIALS"-tx-1-"clinical trials"-noun-0]|TX|31/15|
text_000N_173104|MMI|3.57|Testing|C0039593|[ftcn]|["tested"-tx-1-"tested"-verb-0]|TX|21/6|
text_000N_173104|MMI|3.57|Tests (qualifier value)|C0392366|[inpr]|["tested"-tx-1-"tested"-verb-0]|TX|21/6|
<<<<< MMI
